data_2jvv_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2jvv _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.402 ' CE1' ' HB2' ' A' ' 180' ' ' LYS . 79.8 m-85 . . . . . 0 N--CA 1.489 1.514 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.478 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 1.2 mt-10 -138.65 159.29 68.03 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.202 -0.937 . . . . 0.0 109.457 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.478 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.1 Cg_endo -53.53 129.41 33.68 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.547 2.165 . . . . 0.0 111.82 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 90.47 -1.2 78.82 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.441 ' HG2' ' O ' ' A' ' 129' ' ' GLU . 77.0 mm-40 -86.45 135.51 33.45 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.168 -1.195 . . . . 0.0 109.475 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.452 ' HA ' ' HA ' ' A' ' 147' ' ' VAL . 44.2 ttm -79.58 146.91 32.32 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.16 -0.963 . . . . 0.0 109.49 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.453 HG11 ' O ' ' A' ' 179' ' ' GLU . 2.5 t -131.55 179.24 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.266 -0.896 . . . . 0.0 109.324 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.457 ' O ' ' HA ' ' A' ' 178' ' ' VAL . 40.4 ttt180 -130.29 138.34 50.43 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.226 -0.921 . . . . 0.0 109.49 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.453 HG11 ' CB ' ' A' ' 141' ' ' PHE . 45.4 t -106.63 132.79 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.271 -0.893 . . . . 0.0 109.451 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 56.1 p30 -135.64 20.44 3.33 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.263 -0.898 . . . . 0.0 109.495 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.422 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 59.0 t0 -140.88 148.17 40.07 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.209 -0.932 . . . . 0.0 109.481 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.422 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 70.23 177.23 20.76 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -55.01 -20.17 22.37 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.562 2.175 . . . . 0.0 111.791 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . 0.453 ' CB ' HG11 ' A' ' 136' ' ' VAL . 98.7 m-85 -85.6 6.73 26.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.217 -0.927 . . . . 0.0 109.504 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' ALA . . . . . 0.458 ' O ' ' HB3' ' A' ' 143' ' ' ASP . . . -66.19 148.91 51.13 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.287 -0.883 . . . . 0.0 109.462 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.458 ' HB3' ' O ' ' A' ' 142' ' ' ALA . 35.5 t0 73.06 29.97 1.69 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.222 -0.924 . . . . 0.0 109.51 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.516 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 84.7 m-85 -138.12 151.52 47.86 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.249 -0.907 . . . . 0.0 109.511 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 43.3 p-10 -118.04 164.09 15.63 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.25 -0.906 . . . . 0.0 109.427 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -172.16 -173.73 39.07 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.452 ' HA ' ' HA ' ' A' ' 133' ' ' MET . 57.9 t -120.29 151.64 23.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.227 -1.161 . . . . 0.0 109.491 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.497 ' CG2' HG21 ' A' ' 151' ' ' VAL . 2.1 p -94.39 98.85 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.274 -0.892 . . . . 0.0 109.466 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 76.2 mm-40 -69.37 -36.69 77.09 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.215 -0.928 . . . . 0.0 109.425 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -134.44 149.63 50.77 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.261 -0.9 . . . . 0.0 109.464 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.516 HG11 ' CD2' ' A' ' 158' ' ' LEU . 48.0 t -127.3 150.22 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.233 -0.917 . . . . 0.0 109.477 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' ASP . . . . . 0.416 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 93.5 m-20 -136.2 87.77 2.33 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.261 -0.9 . . . . 0.0 109.466 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -66.31 -37.05 84.5 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.274 -0.891 . . . . 0.0 109.463 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 48.3 tp10 -62.62 -44.28 96.69 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.248 -0.907 . . . . 0.0 109.484 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.463 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 21.5 mttt -88.62 0.61 56.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.289 -0.882 . . . . 0.0 109.602 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' SER . . . . . 0.404 ' O ' ' OG ' ' A' ' 156' ' ' SER . 7.5 p 52.51 51.98 15.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.188 -0.945 . . . . 0.0 109.437 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' ARG . . . . . 0.463 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 41.0 mmm-85 -145.32 140.46 27.76 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.259 -0.901 . . . . 0.0 109.472 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' LEU . . . . . 0.516 ' CD2' HG11 ' A' ' 151' ' ' VAL . 35.2 mt -108.53 134.28 51.52 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.254 -0.904 . . . . 0.0 109.542 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 15.1 tttp -92.47 93.09 8.39 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.224 -0.923 . . . . 0.0 109.374 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . 0.45 HG23 ' HA ' ' A' ' 148' ' ' VAL . 41.4 t -124.13 142.01 42.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.222 -0.923 . . . . 0.0 109.519 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' SER . . . . . 0.471 ' CA ' ' HA ' ' A' ' 170' ' ' PRO . 86.7 p -106.31 147.7 28.87 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.263 -0.898 . . . . 0.0 109.436 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' VAL . . . . . 0.516 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 18.1 t -108.49 132.66 55.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.231 -0.918 . . . . 0.0 109.523 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 71.6 m . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.205 -0.934 . . . . 0.0 109.433 179.988 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 82.0 mtp180 . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -69.17 142.13 54.39 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.261 -0.9 . . . . 0.0 109.443 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 15.4 m -124.37 75.81 61.59 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.271 -0.893 . . . . 0.0 109.475 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.471 ' HA ' ' CA ' ' A' ' 161' ' ' SER . 50.0 Cg_endo -47.95 106.45 0.11 Allowed 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.642 2.228 . . . . 0.0 111.784 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 21.2 m -128.74 155.12 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.293 -0.879 . . . . 0.0 109.478 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.456 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.0 mt-10 -95.04 123.33 38.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.924 . . . . 0.0 109.458 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . 0.456 HD23 ' O ' ' A' ' 172' ' ' GLU . 67.2 mt -125.98 147.91 49.41 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.231 -0.918 . . . . 0.0 109.477 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 174' ' ' ASP . . . . . 0.424 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 91.7 m-20 -75.84 164.87 25.78 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.216 -0.927 . . . . 0.0 109.441 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.56 ' N ' ' CD1' ' A' ' 175' ' ' PHE . 2.3 m-30 -60.69 -41.16 94.57 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.211 -0.931 . . . . 0.0 109.495 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 19.3 m -76.06 -26.28 56.38 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.258 -0.901 . . . . 0.0 109.384 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 177' ' ' GLN . . . . . 0.424 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 87.9 mt-30 -69.04 -25.8 64.65 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.31 -0.869 . . . . 0.0 109.465 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.457 ' HA ' ' O ' ' A' ' 135' ' ' ARG . 13.9 m -128.41 158.72 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.242 -0.911 . . . . 0.0 109.434 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 179' ' ' GLU . . . . . 0.453 ' O ' HG11 ' A' ' 134' ' ' VAL . 77.8 mt-10 -113.13 149.24 33.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.232 -0.917 . . . . 0.0 109.49 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 180' ' ' LYS . . . . . 0.402 ' HB2' ' CE1' ' A' ' 128' ' ' PHE . 30.6 tttm -69.94 135.79 49.85 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.241 -0.912 . . . . 0.0 109.479 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.587 0 O-C-N 121.266 -0.896 . . . . 0.0 109.454 -179.986 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.571 ' CE1' ' HG3' ' A' ' 180' ' ' LYS . 74.5 m-85 . . . . . 0 N--CA 1.49 1.525 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.436 ' HB2' ' HG3' ' A' ' 132' ' ' GLU . 28.9 mt-10 -131.55 153.85 81.68 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.252 -0.905 . . . . 0.0 109.508 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.407 ' HD2' ' HB3' ' A' ' 129' ' ' GLU . 50.9 Cg_endo -52.96 128.14 27.68 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 122.605 2.203 . . . . 0.0 111.776 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 86.5 10.16 74.15 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.436 ' HG3' ' HB2' ' A' ' 129' ' ' GLU . 72.7 mm-40 -96.13 127.26 41.98 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.304 -1.115 . . . . 0.0 109.432 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 5.8 ttm -63.71 134.71 55.84 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.263 -0.898 . . . . 0.0 109.501 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.433 HG12 ' HB ' ' A' ' 178' ' ' VAL . 2.5 t -123.5 179.03 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.228 -0.92 . . . . 0.0 109.394 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.512 ' N ' ' O ' ' A' ' 179' ' ' GLU . 55.1 ttt-85 -135.95 133.53 37.68 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.264 -0.898 . . . . 0.0 109.288 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.454 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 90.7 t -106.03 132.06 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.202 -0.937 . . . . 0.0 109.584 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . 0.438 ' HB3' ' NH1' ' A' ' 135' ' ' ARG . 32.3 p30 -130.34 18.8 5.35 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.227 -0.921 . . . . 0.0 109.45 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -134.53 143.77 47.62 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.248 -0.907 . . . . 0.0 109.4 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 72.15 177.16 29.01 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -51.14 -20.95 8.44 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.638 2.225 . . . . 0.0 111.757 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . 0.454 ' O ' ' HB ' ' A' ' 136' ' ' VAL . 93.8 m-85 -86.94 12.92 10.02 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.896 . . . . 0.0 109.45 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' ALA . . . . . 0.464 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -69.57 143.71 53.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.25 -0.907 . . . . 0.0 109.594 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.464 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 19.3 m-20 65.9 50.52 1.49 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.57 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.455 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 49.9 m-85 -144.11 146.26 32.67 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.238 -0.914 . . . . 0.0 109.455 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -99.64 141.35 32.56 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.266 -0.896 . . . . 0.0 109.548 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.44 -173.85 27.39 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.379 -1.488 . . . . 0.0 109.379 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.472 HG13 ' N ' ' A' ' 148' ' ' VAL . 40.1 t -132.19 152.34 36.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.256 -1.143 . . . . 0.0 109.463 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.472 ' N ' HG13 ' A' ' 147' ' ' VAL . 2.3 p -95.47 118.09 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.227 -0.921 . . . . 0.0 109.486 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 77.1 mm-40 -73.78 -42.18 61.38 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.331 -0.856 . . . . 0.0 109.364 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.444 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 95.3 mt-10 -147.21 162.56 38.64 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.298 -0.876 . . . . 0.0 109.431 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.501 ' CG1' ' CD2' ' A' ' 158' ' ' LEU . 49.1 t -129.03 153.2 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.216 -0.927 . . . . 0.0 109.459 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' ASP . . . . . 0.4 ' O ' ' N ' ' A' ' 156' ' ' SER . 91.4 m-20 -128.7 97.37 4.66 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.176 -0.953 . . . . 0.0 109.442 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 90.3 m-85 -66.51 -41.59 88.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.232 -0.917 . . . . 0.0 109.453 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -63.12 -40.41 97.54 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.283 -0.885 . . . . 0.0 109.504 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 82.7 mttt -93.36 -0.66 56.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.246 -0.909 . . . . 0.0 109.592 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' SER . . . . . 0.4 ' N ' ' O ' ' A' ' 152' ' ' ASP . 4.5 m 46.22 52.27 10.54 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.239 -0.913 . . . . 0.0 109.426 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 7.4 tpt180 -138.08 140.62 40.09 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.298 -0.876 . . . . 0.0 109.451 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' LEU . . . . . 0.501 ' CD2' ' CG1' ' A' ' 151' ' ' VAL . 41.1 mt -109.04 137.49 46.87 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.243 -0.911 . . . . 0.0 109.597 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . 0.444 ' HD2' ' HB2' ' A' ' 150' ' ' GLU . 21.3 mttp -99.78 96.7 7.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.259 -0.9 . . . . 0.0 109.377 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . 0.451 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 38.6 t -124.5 139.65 50.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.187 -0.946 . . . . 0.0 109.498 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 60.7 p -108.67 147.98 31.1 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.32 -0.862 . . . . 0.0 109.435 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' VAL . . . . . 0.447 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 4.2 t -117.69 133.01 65.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.158 -0.964 . . . . 0.0 109.472 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 31.0 t . . . . . 0 N--CA 1.49 1.564 0 O-C-N 121.306 -0.871 . . . . 0.0 109.457 -179.998 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 72.3 ttt180 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -68.03 138.73 56.07 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.279 -0.888 . . . . 0.0 109.491 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 169' ' ' THR . . . . . 0.421 ' O ' HG11 ' A' ' 171' ' ' VAL . 1.3 m -125.44 77.91 68.33 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.214 -0.929 . . . . 0.0 109.435 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -53.91 103.66 0.1 OUTLIER 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.668 2.245 . . . . 0.0 111.78 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.421 HG11 ' O ' ' A' ' 169' ' ' THR . 31.4 m -129.8 154.46 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.242 -0.912 . . . . 0.0 109.434 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.465 ' O ' HD12 ' A' ' 173' ' ' LEU . 94.9 mt-10 -108.17 130.18 55.14 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.243 -0.911 . . . . 0.0 109.529 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . 0.579 ' CD2' ' N ' ' A' ' 173' ' ' LEU . 2.5 mm? -126.96 157.59 39.1 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.284 -0.885 . . . . 0.0 109.477 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 174' ' ' ASP . . . . . 0.4 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 94.2 m-20 -77.04 176.19 8.89 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.261 -0.899 . . . . 0.0 109.394 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.421 ' N ' ' CD1' ' A' ' 175' ' ' PHE . 7.3 m-30 -65.87 -43.15 89.19 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.222 -0.924 . . . . 0.0 109.417 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 82.4 p -76.77 -26.04 54.07 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.214 -0.929 . . . . 0.0 109.518 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 177' ' ' GLN . . . . . 0.4 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 86.5 mt-30 -68.03 -18.95 64.85 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.264 -0.897 . . . . 0.0 109.538 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.456 HG11 ' HB3' ' A' ' 173' ' ' LEU . 27.2 m -138.48 162.13 30.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.232 -0.918 . . . . 0.0 109.51 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 179' ' ' GLU . . . . . 0.512 ' O ' ' N ' ' A' ' 135' ' ' ARG . 35.7 mt-10 -127.38 155.9 42.88 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.24 -0.912 . . . . 0.0 109.476 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 180' ' ' LYS . . . . . 0.571 ' HG3' ' CE1' ' A' ' 128' ' ' PHE . 9.5 mtmt -85.48 143.72 28.38 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.245 -0.91 . . . . 0.0 109.488 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.565 0 O-C-N 121.241 -0.912 . . . . 0.0 109.499 179.971 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.521 ' CE2' ' HD3' ' A' ' 180' ' ' LYS . 71.1 m-85 . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.464 ' HB2' ' HD2' ' A' ' 130' ' ' PRO . 2.6 pp20? -128.13 138.65 33.44 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.325 -0.859 . . . . 0.0 109.464 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.464 ' HD2' ' HB2' ' A' ' 129' ' ' GLU . 49.3 Cg_endo -39.0 128.9 1.35 Allowed 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.469 2.112 . . . . 0.0 111.749 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 89.65 10.08 65.66 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.448 ' OE2' ' HD2' ' A' ' 180' ' ' LYS . 84.8 tt0 -104.16 135.15 46.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.341 -1.094 . . . . 0.0 109.458 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.406 ' HG2' HG23 ' A' ' 147' ' ' VAL . 82.9 mtp -71.9 139.94 49.02 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.201 -0.937 . . . . 0.0 109.534 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.451 HG12 ' O ' ' A' ' 179' ' ' GLU . 2.5 t -127.03 178.59 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.183 -0.948 . . . . 0.0 109.372 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.488 ' N ' ' O ' ' A' ' 179' ' ' GLU . 75.2 ttt-85 -126.56 144.55 50.84 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.274 -0.891 . . . . 0.0 109.549 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.461 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 45.0 t -112.15 132.3 61.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.236 -0.915 . . . . 0.0 109.453 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . 0.411 ' C ' ' OD1' ' A' ' 137' ' ' ASN . 48.0 p30 -131.83 14.65 4.82 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.233 -0.917 . . . . 0.0 109.474 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 59.1 t0 -142.18 143.15 32.81 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.234 -0.916 . . . . 0.0 109.49 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 79.87 171.2 41.96 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -55.73 -21.96 34.51 Favored 'Trans proline' 0 C--O 1.216 -0.625 0 C-N-CA 122.601 2.201 . . . . 0.0 111.813 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . 0.461 ' O ' ' HB ' ' A' ' 136' ' ' VAL . 99.0 m-85 -85.21 5.67 29.2 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.13 -0.981 . . . . 0.0 109.54 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' ALA . . . . . 0.493 ' O ' ' CB ' ' A' ' 143' ' ' ASP . . . -69.15 149.01 49.11 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.272 -0.892 . . . . 0.0 109.416 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.493 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 30.3 t0 75.13 28.67 1.01 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.174 -0.954 . . . . 0.0 109.45 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.445 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 90.2 m-85 -135.77 145.0 46.1 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.263 -0.898 . . . . 0.0 109.456 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 74.0 m-20 -97.9 140.22 32.58 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.26 -0.9 . . . . 0.0 109.415 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -153.85 -173.06 22.53 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.478 HG11 ' N ' ' A' ' 148' ' ' VAL . 44.9 t -129.08 152.63 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.248 -1.148 . . . . 0.0 109.418 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.478 ' N ' HG11 ' A' ' 147' ' ' VAL . 2.5 p -92.52 107.97 19.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.294 -0.879 . . . . 0.0 109.398 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.449 ' HB2' ' HE3' ' A' ' 159' ' ' LYS . 75.1 mm-40 -70.63 -39.23 73.83 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.224 -0.923 . . . . 0.0 109.365 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.457 ' HB2' ' HE2' ' A' ' 159' ' ' LYS . 92.4 mt-10 -139.41 157.5 45.75 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.239 -0.913 . . . . 0.0 109.393 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.474 HG11 ' CD2' ' A' ' 158' ' ' LEU . 48.5 t -127.29 151.04 33.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.274 -0.891 . . . . 0.0 109.481 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' ASP . . . . . 0.401 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 88.1 m-20 -134.43 87.7 2.38 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.223 -0.923 . . . . 0.0 109.436 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -63.34 -39.45 94.59 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.259 -0.901 . . . . 0.0 109.461 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -62.27 -42.15 99.1 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.18 -0.95 . . . . 0.0 109.506 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.412 ' O ' ' C ' ' A' ' 156' ' ' SER . 43.5 mttp -91.19 5.17 50.14 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.186 -0.946 . . . . 0.0 109.61 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' SER . . . . . 0.51 ' HA ' ' CZ ' ' A' ' 175' ' ' PHE . 0.3 OUTLIER 43.91 51.8 6.8 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.187 -0.945 . . . . 0.0 109.472 -179.943 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' ARG . . . . . 0.45 ' HD2' ' OD1' ' A' ' 174' ' ' ASP . 9.3 tpt180 -145.44 137.14 25.32 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.257 -0.902 . . . . 0.0 109.402 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' LEU . . . . . 0.475 HD13 ' CD1' ' A' ' 128' ' ' PHE . 46.2 mt -108.34 136.2 48.37 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 109.53 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . 0.457 ' HE2' ' HB2' ' A' ' 150' ' ' GLU . 14.2 ttpt -95.19 109.2 21.33 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.327 -0.858 . . . . 0.0 109.442 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . 0.41 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 39.2 t -127.84 142.0 44.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -0.921 . . . . 0.0 109.464 -179.88 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' SER . . . . . 0.417 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 96.1 p -107.0 147.44 29.89 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.191 -0.943 . . . . 0.0 109.504 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' VAL . . . . . . . . . . . . . 26.1 t -119.21 132.05 70.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.31 -0.869 . . . . 0.0 109.565 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 32.0 t . . . . . 0 N--CA 1.489 1.521 0 O-C-N 121.217 -0.927 . . . . 0.0 109.433 179.921 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 39.0 mtm105 . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -72.08 137.29 46.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.208 -0.933 . . . . 0.0 109.497 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 59.3 m -129.82 77.02 77.55 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.244 -0.91 . . . . 0.0 109.44 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.417 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 50.6 Cg_endo -53.19 111.47 0.68 Allowed 'Trans proline' 0 C--O 1.214 -0.687 0 C-N-CA 122.579 2.186 . . . . 0.0 111.807 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 20.9 m -130.44 155.27 41.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.288 -0.883 . . . . 0.0 109.493 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.452 ' O ' HD21 ' A' ' 173' ' ' LEU . 95.2 mt-10 -104.57 135.81 45.28 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.268 -0.895 . . . . 0.0 109.528 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . 0.52 ' CB ' ' CG1' ' A' ' 178' ' ' VAL . 63.0 mt -133.91 148.28 51.2 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.316 -0.865 . . . . 0.0 109.576 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 174' ' ' ASP . . . . . 0.45 ' OD1' ' HD2' ' A' ' 157' ' ' ARG . 91.4 m-20 -68.91 171.16 8.42 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.283 -0.886 . . . . 0.0 109.4 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.548 ' N ' ' CD1' ' A' ' 175' ' ' PHE . 3.6 m-30 -65.29 -47.58 76.13 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.206 -0.934 . . . . 0.0 109.463 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 14.6 m -70.73 -28.03 64.41 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.315 -0.865 . . . . 0.0 109.498 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 177' ' ' GLN . . . . . 0.416 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 91.0 mt-30 -68.07 -20.64 64.97 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.306 -0.871 . . . . 0.0 109.473 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.52 ' CG1' ' CB ' ' A' ' 173' ' ' LEU . 13.7 m -131.23 160.29 42.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.278 -0.888 . . . . 0.0 109.484 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 179' ' ' GLU . . . . . 0.488 ' O ' ' N ' ' A' ' 135' ' ' ARG . 55.1 mt-10 -128.65 167.54 17.06 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.183 -0.948 . . . . 0.0 109.513 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 180' ' ' LYS . . . . . 0.521 ' HD3' ' CE2' ' A' ' 128' ' ' PHE . 29.0 mmtp -66.36 145.83 55.26 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.275 -0.89 . . . . 0.0 109.497 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.502 0 O-C-N 121.139 -0.975 . . . . 0.0 109.48 179.973 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.456 ' HA ' ' OE1' ' A' ' 132' ' ' GLU . 69.0 m-85 . . . . . 0 N--CA 1.489 1.513 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.515 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.9 OUTLIER -144.55 157.73 55.14 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.26 -0.9 . . . . 0.0 109.394 179.959 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.515 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.2 Cg_endo -49.51 128.18 20.1 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.625 2.217 . . . . 0.0 111.805 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 96.1 -3.89 64.74 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.456 ' OE1' ' HA ' ' A' ' 128' ' ' PHE . 88.2 mt-10 -92.38 129.88 38.2 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.14 -1.212 . . . . 0.0 109.5 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.4 ' HG2' ' CB ' ' A' ' 181' ' ' ALA . 43.5 ttm -77.13 145.7 37.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.237 -0.914 . . . . 0.0 109.353 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.454 HG12 ' HB ' ' A' ' 178' ' ' VAL . 2.5 t -129.76 178.66 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.198 -0.939 . . . . 0.0 109.404 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.458 ' O ' ' HB ' ' A' ' 178' ' ' VAL . 58.6 ttt180 -131.61 140.95 49.54 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.308 -0.87 . . . . 0.0 109.426 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.489 ' CG2' ' CD1' ' A' ' 173' ' ' LEU . 40.6 t -113.21 135.86 51.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.222 -0.923 . . . . 0.0 109.54 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . 0.446 ' O ' ' OD1' ' A' ' 138' ' ' ASP . 29.0 p30 -128.8 18.04 6.22 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.273 -0.892 . . . . 0.0 109.537 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.453 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 91.3 m-20 -139.43 164.37 30.03 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.208 -0.932 . . . . 0.0 109.497 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.435 ' O ' ' HB1' ' A' ' 142' ' ' ALA . . . 57.94 172.86 0.32 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -53.26 -21.1 16.32 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.581 2.187 . . . . 0.0 111.777 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . 0.451 ' O ' ' HB ' ' A' ' 136' ' ' VAL . 91.8 m-85 -82.18 6.36 16.83 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.216 -0.928 . . . . 0.0 109.458 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' ALA . . . . . 0.438 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -62.62 143.24 57.52 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.278 -0.889 . . . . 0.0 109.488 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.438 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 10.2 m-20 67.06 48.69 1.2 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.257 -0.902 . . . . 0.0 109.413 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.48 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 43.6 m-85 -146.39 129.08 16.16 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.239 -0.913 . . . . 0.0 109.465 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 68.5 m-20 -90.87 138.04 31.9 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.227 -0.921 . . . . 0.0 109.509 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -152.71 177.39 30.44 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.495 HG11 ' N ' ' A' ' 148' ' ' VAL . 38.9 t -118.95 156.52 20.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.273 -1.134 . . . . 0.0 109.447 179.87 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.495 ' N ' HG11 ' A' ' 147' ' ' VAL . 50.9 t -89.36 106.84 17.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.161 -0.962 . . . . 0.0 109.574 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -73.58 -31.84 63.81 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.247 -0.908 . . . . 0.0 109.392 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -144.42 148.63 34.87 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.282 -0.886 . . . . 0.0 109.25 179.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.446 HG21 ' CG1' ' A' ' 148' ' ' VAL . 37.1 t -125.55 146.43 31.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.157 -0.964 . . . . 0.0 109.644 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -132.28 87.89 2.48 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.279 -0.888 . . . . 0.0 109.412 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -61.1 -40.41 93.64 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.195 -0.941 . . . . 0.0 109.442 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -62.39 -40.53 96.76 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.21 -0.932 . . . . 0.0 109.51 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.401 ' O ' ' OG ' ' A' ' 156' ' ' SER . 94.9 mttt -91.52 2.45 56.43 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.217 -0.927 . . . . 0.0 109.649 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' SER . . . . . 0.401 ' OG ' ' O ' ' A' ' 155' ' ' LYS . 13.6 p 45.21 52.62 8.52 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.154 -0.966 . . . . 0.0 109.394 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' ARG . . . . . 0.455 ' CG ' ' HB3' ' A' ' 172' ' ' GLU . 0.0 OUTLIER -136.67 156.28 48.75 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.202 -0.937 . . . . 0.0 109.543 179.919 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' LEU . . . . . 0.616 ' CD1' ' CE1' ' A' ' 175' ' ' PHE . 7.4 mp -120.39 123.66 43.61 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.257 -0.902 . . . . 0.0 109.525 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 18.0 tttm -91.01 92.18 8.63 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.25 -0.906 . . . . 0.0 109.378 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . 0.495 ' CG2' HG23 ' A' ' 148' ' ' VAL . 21.7 t -116.22 150.27 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.199 -0.938 . . . . 0.0 109.359 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' SER . . . . . 0.467 ' OG ' ' N ' ' A' ' 170' ' ' PRO . 18.3 t -119.74 131.32 55.34 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.311 -0.868 . . . . 0.0 109.431 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' VAL . . . . . 0.48 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 11.7 t -102.16 131.98 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.243 -0.91 . . . . 0.0 109.387 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 40.5 t . . . . . 0 N--CA 1.489 1.515 0 O-C-N 121.273 -0.892 . . . . 0.0 109.43 -179.978 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 70.1 mtm180 . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -68.17 144.53 54.93 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 109.521 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 2.9 m -128.09 73.82 79.34 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.249 -0.907 . . . . 0.0 109.414 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.467 ' N ' ' OG ' ' A' ' 161' ' ' SER . 50.2 Cg_endo -49.09 105.98 0.1 Allowed 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.585 2.19 . . . . 0.0 111.794 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 19.3 m -133.67 153.94 37.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.295 -0.878 . . . . 0.0 109.359 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.455 ' HB3' ' CG ' ' A' ' 157' ' ' ARG . 95.2 mt-10 -97.23 135.81 38.63 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.259 -0.901 . . . . 0.0 109.489 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . 0.495 HD21 ' NE2' ' A' ' 177' ' ' GLN . 28.9 mt -124.97 160.06 29.8 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.256 -0.902 . . . . 0.0 109.421 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 174' ' ' ASP . . . . . 0.453 ' HB2' ' HB2' ' A' ' 177' ' ' GLN . 92.7 m-20 -83.54 160.78 21.4 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.184 -0.948 . . . . 0.0 109.521 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.616 ' CE1' ' CD1' ' A' ' 158' ' ' LEU . 4.5 m-85 -53.67 -49.95 66.86 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.321 -0.862 . . . . 0.0 109.561 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 15.5 m -74.67 -24.36 58.79 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.162 -0.961 . . . . 0.0 109.546 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 177' ' ' GLN . . . . . 0.495 ' NE2' HD21 ' A' ' 173' ' ' LEU . 61.9 tt0 -64.6 -27.21 68.79 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.231 -0.918 . . . . 0.0 109.425 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.494 ' CG1' ' CD1' ' A' ' 173' ' ' LEU . 13.7 m -127.97 161.83 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.334 -0.854 . . . . 0.0 109.482 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 179' ' ' GLU . . . . . 0.448 ' O ' HG11 ' A' ' 134' ' ' VAL . 61.6 mt-10 -118.32 148.19 42.73 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.207 -0.933 . . . . 0.0 109.489 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -66.95 130.91 44.67 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.32 -0.863 . . . . 0.0 109.427 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . 0.4 ' CB ' ' HG2' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.558 0 O-C-N 121.259 -0.901 . . . . 0.0 109.461 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.434 ' CE1' ' HB2' ' A' ' 180' ' ' LYS . 68.8 m-85 . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.462 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.0 OUTLIER -125.87 153.54 73.52 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.23 -0.919 . . . . 0.0 109.503 179.949 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.462 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 49.4 Cg_endo -47.88 134.59 23.13 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.636 2.224 . . . . 0.0 111.72 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 85.45 3.72 86.47 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 48.9 tp10 -89.9 136.11 33.24 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.168 -1.195 . . . . 0.0 109.474 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.516 ' SD ' ' CG2' ' A' ' 147' ' ' VAL . 92.9 mmm -74.82 148.55 40.19 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.253 -0.904 . . . . 0.0 109.48 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.527 HG21 ' CG2' ' A' ' 148' ' ' VAL . 2.5 t -139.06 179.18 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.285 -0.885 . . . . 0.0 109.373 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.478 ' CZ ' ' OE1' ' A' ' 179' ' ' GLU . 19.8 ttp85 -137.58 142.41 41.31 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.323 -0.861 . . . . 0.0 109.445 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.453 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 43.8 t -106.45 132.16 54.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.224 -0.923 . . . . 0.0 109.533 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 29.0 p30 -118.48 13.33 13.47 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.337 -0.852 . . . . 0.0 109.425 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 51.9 p30 -151.89 169.93 21.07 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.235 -0.916 . . . . 0.0 109.461 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 67.4 168.79 3.94 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -56.71 -18.11 25.45 Favored 'Trans proline' 0 C--O 1.214 -0.702 0 C-N-CA 122.565 2.177 . . . . 0.0 111.848 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . 0.453 ' O ' ' HB ' ' A' ' 136' ' ' VAL . 92.5 m-85 -88.12 8.1 28.46 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.28 -0.888 . . . . 0.0 109.48 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' ALA . . . . . 0.481 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -61.34 150.68 34.35 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.213 -0.929 . . . . 0.0 109.458 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.459 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 63.2 m-20 62.63 42.4 8.44 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.243 -0.911 . . . . 0.0 109.446 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.481 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 51.3 m-85 -146.9 134.52 21.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.165 -0.959 . . . . 0.0 109.516 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -87.68 141.98 28.18 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.898 . . . . 0.0 109.453 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -149.61 177.89 27.48 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.516 ' CG2' ' SD ' ' A' ' 133' ' ' MET . 35.6 t -119.92 156.34 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.306 -1.114 . . . . 0.0 109.462 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.527 ' CG2' HG21 ' A' ' 134' ' ' VAL . 61.3 t -87.54 103.18 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.22 -0.925 . . . . 0.0 109.457 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 75.2 mm-40 -67.63 -38.69 84.23 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.268 -0.895 . . . . 0.0 109.415 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -153.77 150.81 28.88 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.232 -0.918 . . . . 0.0 109.426 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.521 ' CG2' HG12 ' A' ' 148' ' ' VAL . 58.9 t -122.68 154.41 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.269 -0.895 . . . . 0.0 109.475 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -135.12 94.83 3.19 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.301 -0.875 . . . . 0.0 109.459 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 81.1 m-85 -67.32 -42.44 83.65 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.301 -0.874 . . . . 0.0 109.487 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -62.63 -36.67 83.56 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.212 -0.93 . . . . 0.0 109.412 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.464 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 57.0 tttm -95.59 1.4 53.73 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.202 -0.936 . . . . 0.0 109.617 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 41.1 t 46.6 52.4 11.09 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.171 -0.956 . . . . 0.0 109.486 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 7.7 tpt180 -141.28 138.25 33.07 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.256 -0.903 . . . . 0.0 109.417 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' LEU . . . . . 0.428 HD21 ' CE1' ' A' ' 175' ' ' PHE . 55.2 mt -107.25 131.66 53.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.221 -0.924 . . . . 0.0 109.496 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 60.3 tttm -96.52 105.78 17.93 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.874 . . . . 0.0 109.373 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . 0.453 HG11 ' O ' ' A' ' 147' ' ' VAL . 38.6 t -123.36 145.75 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.265 -0.897 . . . . 0.0 109.578 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' SER . . . . . 0.446 ' OG ' ' HA ' ' A' ' 170' ' ' PRO . 11.4 m -118.85 137.01 53.72 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.33 -0.856 . . . . 0.0 109.359 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' VAL . . . . . . . . . . . . . 25.2 t -107.85 133.68 51.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.292 -0.88 . . . . 0.0 109.634 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 33.8 t . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.233 -0.917 . . . . 0.0 109.193 179.82 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 51.1 mtt180 . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -74.29 140.94 45.26 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.194 -0.941 . . . . 0.0 109.568 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 169' ' ' THR . . . . . 0.417 ' CG2' ' CZ ' ' A' ' 141' ' ' PHE . 0.2 OUTLIER -127.03 73.99 76.76 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.317 -0.864 . . . . 0.0 109.443 179.953 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.446 ' HA ' ' OG ' ' A' ' 161' ' ' SER . 49.8 Cg_endo -54.17 100.28 0.06 OUTLIER 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.567 2.178 . . . . 0.0 111.81 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 26.9 m -126.96 153.4 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.278 -0.889 . . . . 0.0 109.489 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.459 ' O ' HD23 ' A' ' 173' ' ' LEU . 57.0 mp0 -102.02 134.8 44.66 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.292 -0.88 . . . . 0.0 109.563 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . 0.497 ' CB ' HG11 ' A' ' 178' ' ' VAL . 53.4 mt -132.95 147.8 52.28 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.245 -0.91 . . . . 0.0 109.455 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 174' ' ' ASP . . . . . 0.424 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 90.7 m-20 -70.89 174.32 6.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.262 -0.899 . . . . 0.0 109.458 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.529 ' N ' ' CD1' ' A' ' 175' ' ' PHE . 3.8 m-30 -65.13 -44.66 87.94 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.212 -0.93 . . . . 0.0 109.457 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 94.8 p -73.73 -28.81 61.9 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.205 -0.935 . . . . 0.0 109.463 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 177' ' ' GLN . . . . . 0.424 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 82.1 mt-30 -63.49 -25.71 68.38 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.283 -0.885 . . . . 0.0 109.49 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.497 HG11 ' CB ' ' A' ' 173' ' ' LEU . 6.1 m -130.02 160.79 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.266 -0.896 . . . . 0.0 109.485 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 179' ' ' GLU . . . . . 0.478 ' OE1' ' CZ ' ' A' ' 135' ' ' ARG . 79.6 mt-10 -112.14 147.61 35.75 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.278 -0.889 . . . . 0.0 109.465 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 180' ' ' LYS . . . . . 0.434 ' HB2' ' CE1' ' A' ' 128' ' ' PHE . 19.1 tttm -76.02 132.04 39.9 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.286 -0.884 . . . . 0.0 109.465 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.552 0 O-C-N 121.2 -0.937 . . . . 0.0 109.518 -179.957 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.435 ' CD2' HD11 ' A' ' 158' ' ' LEU . 72.8 m-85 . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.508 -0.552 . . . . 0.0 109.508 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.526 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.1 OUTLIER -143.62 156.69 59.72 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.328 -0.858 . . . . 0.0 109.412 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.526 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.4 Cg_endo -47.34 132.19 19.11 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.552 2.168 . . . . 0.0 111.737 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 93.59 0.67 66.74 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -103.68 139.99 38.19 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.234 -1.157 . . . . 0.0 109.435 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 87.7 mtp -83.78 152.69 24.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.317 -0.865 . . . . 0.0 109.491 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.552 ' CG2' ' CG2' ' A' ' 148' ' ' VAL . 2.5 t -136.82 179.21 3.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.258 -0.901 . . . . 0.0 109.345 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.447 ' O ' ' HA ' ' A' ' 178' ' ' VAL . 53.0 ttm-85 -135.08 139.02 44.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.232 -0.918 . . . . 0.0 109.456 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.56 ' CG2' ' CD1' ' A' ' 173' ' ' LEU . 50.0 t -107.1 131.23 57.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.266 -0.896 . . . . 0.0 109.494 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . 0.421 ' O ' ' OD1' ' A' ' 138' ' ' ASP . 11.4 p30 -122.54 16.32 10.39 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.279 -0.888 . . . . 0.0 109.43 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.421 ' OD1' ' O ' ' A' ' 137' ' ' ASN . 93.5 m-20 -135.67 160.16 39.39 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.229 -0.919 . . . . 0.0 109.489 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 60.35 173.08 0.82 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -53.53 -20.37 15.95 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.609 2.206 . . . . 0.0 111.803 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . 0.514 ' CD1' HG21 ' A' ' 162' ' ' VAL . 99.4 m-85 -80.57 4.07 19.71 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.222 -0.924 . . . . 0.0 109.481 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' ALA . . . . . 0.497 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -63.99 150.84 44.35 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.139 -0.976 . . . . 0.0 109.474 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.454 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 57.9 m-20 62.83 47.53 4.5 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.275 -0.89 . . . . 0.0 109.398 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.497 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 50.2 m-85 -149.34 144.56 26.51 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.308 -0.87 . . . . 0.0 109.493 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 19.8 m120 -97.9 145.52 26.36 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.27 -0.894 . . . . 0.0 109.497 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -154.21 174.68 32.62 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.513 HG11 ' N ' ' A' ' 148' ' ' VAL . 47.3 t -114.4 165.16 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.223 -1.163 . . . . 0.0 109.386 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.552 ' CG2' ' CG2' ' A' ' 134' ' ' VAL . 51.0 t -101.57 123.66 54.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.273 -0.892 . . . . 0.0 109.512 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 74.7 mm-40 -99.76 -44.55 6.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.256 -0.903 . . . . 0.0 109.435 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -133.24 155.61 49.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.237 -0.914 . . . . 0.0 109.348 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.427 HG13 ' CE2' ' A' ' 153' ' ' TYR . 38.7 t -122.79 151.15 26.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.29 -0.881 . . . . 0.0 109.565 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' ASP . . . . . 0.408 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 93.3 m-20 -135.3 78.93 1.76 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.292 -0.88 . . . . 0.0 109.373 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' TYR . . . . . 0.427 ' CE2' HG13 ' A' ' 151' ' ' VAL . 98.1 m-85 -62.68 -37.3 85.9 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.197 -0.939 . . . . 0.0 109.651 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -64.35 -40.95 96.88 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.277 -0.889 . . . . 0.0 109.593 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.456 ' O ' ' HG3' ' A' ' 157' ' ' ARG . 28.9 mttt -87.1 3.13 47.44 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.211 -0.93 . . . . 0.0 109.627 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' SER . . . . . 0.485 ' HA ' ' CZ ' ' A' ' 175' ' ' PHE . 58.1 m 52.83 52.59 13.63 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.224 -0.922 . . . . 0.0 109.469 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' ARG . . . . . 0.472 ' CG ' ' O ' ' A' ' 156' ' ' SER . 47.0 mtt180 -157.81 155.43 29.72 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.278 -0.889 . . . . 0.0 109.44 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' LEU . . . . . 0.568 HD23 ' CE1' ' A' ' 175' ' ' PHE . 12.0 mt -119.83 137.0 54.26 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.243 -0.911 . . . . 0.0 109.57 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 14.8 tttt -83.63 105.34 14.48 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.302 -0.874 . . . . 0.0 109.308 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . 0.455 HG23 HG21 ' A' ' 148' ' ' VAL . 57.8 t -123.11 145.27 30.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.205 -0.934 . . . . 0.0 109.596 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' SER . . . . . 0.45 ' OG ' ' HA ' ' A' ' 170' ' ' PRO . 14.9 m -111.86 140.85 46.17 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.257 -0.902 . . . . 0.0 109.444 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' VAL . . . . . 0.514 HG21 ' CD1' ' A' ' 141' ' ' PHE . 14.0 t -110.46 133.14 56.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.206 -0.934 . . . . 0.0 109.493 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 60.7 p . . . . . 0 N--CA 1.49 1.534 0 O-C-N 121.191 -0.943 . . . . 0.0 109.435 179.928 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.462 -0.569 . . . . 0.0 109.462 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -72.76 137.23 45.73 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.287 -0.883 . . . . 0.0 109.471 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 18.6 m -129.96 74.18 80.79 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.203 -0.936 . . . . 0.0 109.486 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.45 ' HA ' ' OG ' ' A' ' 161' ' ' SER . 49.5 Cg_endo -51.04 112.72 0.85 Allowed 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.607 2.205 . . . . 0.0 111.73 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 28.7 m -133.11 153.46 37.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.308 -0.87 . . . . 0.0 109.423 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -95.68 130.28 42.62 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.24 -0.913 . . . . 0.0 109.5 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . 0.56 ' CD1' ' CG2' ' A' ' 136' ' ' VAL . 51.6 mt -128.08 146.4 50.7 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.327 -0.858 . . . . 0.0 109.404 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 57.1 m-20 -67.77 171.06 6.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.268 -0.895 . . . . 0.0 109.451 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.568 ' CE1' HD23 ' A' ' 158' ' ' LEU . 6.2 m-30 -64.64 -49.19 71.99 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.248 -0.908 . . . . 0.0 109.386 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 87.0 p -74.94 -18.64 60.36 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.169 -0.957 . . . . 0.0 109.453 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 177' ' ' GLN . . . . . 0.506 ' NE2' HD21 ' A' ' 173' ' ' LEU . 63.8 tt0 -70.66 -20.85 62.67 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.296 -0.878 . . . . 0.0 109.483 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.54 ' CG1' ' CB ' ' A' ' 173' ' ' LEU . 4.7 m -130.2 159.2 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.285 -0.885 . . . . 0.0 109.403 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 179' ' ' GLU . . . . . 0.458 ' O ' HG12 ' A' ' 134' ' ' VAL . 73.0 mt-10 -115.6 151.96 33.98 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.189 -0.944 . . . . 0.0 109.525 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 21.1 tttt -75.7 136.42 40.36 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.249 -0.907 . . . . 0.0 109.511 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.516 0 O-C-N 121.292 -0.88 . . . . 0.0 109.527 179.978 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.45 ' CD2' HD23 ' A' ' 158' ' ' LEU . 83.9 m-85 . . . . . 0 N--CA 1.489 1.509 0 CA-C-O 121.246 0.546 . . . . 0.0 109.564 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.42 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.2 OUTLIER -123.02 155.03 64.71 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.287 -0.883 . . . . 0.0 109.464 179.979 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.42 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 49.5 Cg_endo -51.22 128.89 26.78 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.648 2.232 . . . . 0.0 111.815 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 91.52 2.93 69.58 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.443 ' OE2' ' HE3' ' A' ' 180' ' ' LYS . 65.7 tt0 -88.5 141.87 28.18 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.154 -1.204 . . . . 0.0 109.485 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.48 ' SD ' ' CG2' ' A' ' 147' ' ' VAL . 80.4 mmm -80.33 137.56 36.59 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.208 -0.932 . . . . 0.0 109.556 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.525 ' CG2' ' CG2' ' A' ' 148' ' ' VAL . 2.5 t -129.22 179.28 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.247 -0.908 . . . . 0.0 109.285 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.456 ' O ' ' HA ' ' A' ' 178' ' ' VAL . 37.4 ttm180 -137.83 142.6 40.77 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.123 -0.986 . . . . 0.0 109.48 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.462 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 59.3 t -110.95 133.02 57.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.302 -0.874 . . . . 0.0 109.512 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 40.7 p30 -124.75 19.86 8.55 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.176 -0.952 . . . . 0.0 109.384 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.44 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 55.9 t0 -143.13 153.77 43.23 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.289 -0.882 . . . . 0.0 109.481 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.44 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 69.84 172.07 9.52 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -52.88 -16.9 6.62 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.582 2.188 . . . . 0.0 111.71 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . 0.479 ' CD1' HG22 ' A' ' 162' ' ' VAL . 99.5 m-85 -88.15 10.83 18.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.299 -0.876 . . . . 0.0 109.426 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' ALA . . . . . 0.461 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -64.27 145.79 55.42 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.276 -0.89 . . . . 0.0 109.554 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.461 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 50.8 m-20 63.54 46.88 4.02 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.33 -0.856 . . . . 0.0 109.622 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.53 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 39.3 m-85 -143.38 140.86 30.68 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.176 -0.952 . . . . 0.0 109.599 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 73.5 m-20 -95.6 142.05 28.38 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.271 -0.893 . . . . 0.0 109.492 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -151.29 173.16 30.76 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.48 ' CG2' ' SD ' ' A' ' 133' ' ' MET . 22.6 t -117.9 153.04 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.154 -1.204 . . . . 0.0 109.401 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.525 ' CG2' ' CG2' ' A' ' 134' ' ' VAL . 57.5 t -88.87 109.67 20.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.234 -0.916 . . . . 0.0 109.521 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -68.13 -40.9 82.37 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.262 -0.899 . . . . 0.0 109.418 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.436 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 95.6 mt-10 -153.93 157.53 39.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.207 -0.933 . . . . 0.0 109.395 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 43.9 t -120.99 144.27 30.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.233 -0.917 . . . . 0.0 109.462 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -123.15 95.61 4.67 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.212 -0.93 . . . . 0.0 109.493 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -66.14 -42.24 89.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.183 -0.948 . . . . 0.0 109.51 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 76.2 mm-40 -59.58 -43.37 93.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.29 -0.881 . . . . 0.0 109.427 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 23.7 mttt -87.35 -10.25 52.69 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.29 -0.881 . . . . 0.0 109.495 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 1.6 m 55.62 53.28 9.81 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.23 -0.919 . . . . 0.0 109.432 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' ARG . . . . . 0.419 ' C ' HD13 ' A' ' 158' ' ' LEU . 88.5 mmt-85 -139.47 162.55 34.79 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.277 -0.889 . . . . 0.0 109.512 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' LEU . . . . . 0.651 ' CD1' ' CE1' ' A' ' 175' ' ' PHE . 7.0 mp -122.55 131.31 53.78 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.278 -0.889 . . . . 0.0 109.542 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . 0.436 ' HD2' ' HB2' ' A' ' 150' ' ' GLU . 23.8 mttm -97.14 98.6 10.17 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.198 -0.939 . . . . 0.0 109.233 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 30.0 t -123.17 145.68 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.236 -0.915 . . . . 0.0 109.662 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' SER . . . . . 0.494 ' CB ' ' HA ' ' A' ' 170' ' ' PRO . 88.1 p -112.71 148.29 35.02 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.277 -0.89 . . . . 0.0 109.333 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' VAL . . . . . 0.53 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 18.0 t -113.4 128.32 70.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.215 -0.928 . . . . 0.0 109.626 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 36.5 t . . . . . 0 N--CA 1.489 1.522 0 O-C-N 121.29 -0.881 . . . . 0.0 109.503 179.85 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 72.9 mtm180 . . . . . 0 N--CA 1.489 1.512 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -81.08 134.75 35.71 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.258 -0.901 . . . . 0.0 109.496 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 169' ' ' THR . . . . . 0.403 ' O ' HG21 ' A' ' 169' ' ' THR . 64.8 m -128.48 77.26 77.5 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.215 -0.928 . . . . 0.0 109.475 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.494 ' HA ' ' CB ' ' A' ' 161' ' ' SER . 48.9 Cg_endo -53.13 107.8 0.22 Allowed 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.631 2.22 . . . . 0.0 111.789 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 19.4 m -127.04 157.68 38.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.27 -0.893 . . . . 0.0 109.463 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.422 ' O ' HD11 ' A' ' 173' ' ' LEU . 95.8 mt-10 -91.05 128.46 36.88 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.311 -0.868 . . . . 0.0 109.503 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . 0.578 ' CD2' ' N ' ' A' ' 173' ' ' LEU . 2.2 mm? -122.33 156.08 34.64 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.289 -0.882 . . . . 0.0 109.497 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 174' ' ' ASP . . . . . 0.45 ' HB2' ' HB2' ' A' ' 177' ' ' GLN . 84.5 m-20 -83.34 168.13 16.92 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.217 -0.927 . . . . 0.0 109.596 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.651 ' CE1' ' CD1' ' A' ' 158' ' ' LEU . 8.2 m-85 -59.49 -49.44 77.77 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.255 -0.903 . . . . 0.0 109.584 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 84.0 p -78.09 -19.36 54.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.2 -0.937 . . . . 0.0 109.653 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 177' ' ' GLN . . . . . 0.507 ' NE2' HD13 ' A' ' 173' ' ' LEU . 64.9 tt0 -67.25 -25.26 65.99 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.116 -0.99 . . . . 0.0 109.483 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.515 HG12 ' CB ' ' A' ' 173' ' ' LEU . 4.5 m -127.08 157.57 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.264 -0.897 . . . . 0.0 109.592 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 179' ' ' GLU . . . . . 0.45 ' O ' HG13 ' A' ' 134' ' ' VAL . 56.4 mt-10 -111.29 152.74 26.86 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.258 -0.901 . . . . 0.0 109.438 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 180' ' ' LYS . . . . . 0.443 ' HE3' ' OE2' ' A' ' 132' ' ' GLU . 5.4 tttp -72.9 133.02 44.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.228 -0.92 . . . . 0.0 109.481 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . 0.448 ' HB2' ' O ' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.547 0 O-C-N 121.249 -0.907 . . . . 0.0 109.514 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.428 ' HA ' ' OE1' ' A' ' 132' ' ' GLU . 56.9 m-85 . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.483 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.1 OUTLIER -145.42 155.44 53.69 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.252 -0.905 . . . . 0.0 109.502 179.933 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.483 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.2 Cg_endo -48.58 128.52 18.3 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.633 2.222 . . . . 0.0 111.828 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 96.25 -9.57 67.41 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.428 ' OE1' ' HA ' ' A' ' 128' ' ' PHE . 92.2 mt-10 -86.95 140.24 29.8 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.155 -1.203 . . . . 0.0 109.496 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.423 ' HA ' ' HA ' ' A' ' 147' ' ' VAL . 87.9 mtp -84.76 152.25 23.82 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.333 -0.854 . . . . 0.0 109.456 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.475 ' CG2' ' CG2' ' A' ' 148' ' ' VAL . 2.5 t -133.45 179.21 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.236 -0.915 . . . . 0.0 109.308 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.452 ' O ' ' HB ' ' A' ' 178' ' ' VAL . 64.1 mtm180 -138.9 150.31 45.8 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.233 -0.917 . . . . 0.0 109.53 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.425 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 42.1 t -108.31 135.24 47.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.297 -0.877 . . . . 0.0 109.444 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 36.7 p30 -118.17 14.16 13.91 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.239 -0.913 . . . . 0.0 109.528 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 53.7 p30 -157.21 169.95 23.6 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.269 -0.894 . . . . 0.0 109.499 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 69.04 165.55 4.11 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -55.97 -18.61 23.0 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.629 2.219 . . . . 0.0 111.739 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . 0.627 ' CD1' ' CG2' ' A' ' 162' ' ' VAL . 94.1 m-85 -88.74 7.77 32.18 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.291 -0.881 . . . . 0.0 109.523 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' ALA . . . . . 0.497 ' O ' ' CB ' ' A' ' 143' ' ' ASP . . . -67.9 147.98 51.75 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.178 -0.951 . . . . 0.0 109.48 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.497 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 3.9 t70 76.29 27.47 0.86 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.281 -0.887 . . . . 0.0 109.56 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.482 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 96.5 m-85 -135.87 146.55 47.55 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -0.878 . . . . 0.0 109.47 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 75.6 m-20 -103.63 146.98 27.77 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.268 -0.895 . . . . 0.0 109.377 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . 0.435 ' HA3' ' O ' ' A' ' 161' ' ' SER . . . -151.24 -173.94 21.63 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.423 ' HA ' ' HA ' ' A' ' 133' ' ' MET . 48.7 t -123.99 156.68 31.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.302 -1.116 . . . . 0.0 109.487 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.475 ' CG2' ' CG2' ' A' ' 134' ' ' VAL . 98.7 t -86.59 96.07 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.246 -0.909 . . . . 0.0 109.519 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -68.31 -34.92 77.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.294 -0.879 . . . . 0.0 109.411 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -151.11 159.19 44.63 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.202 -0.936 . . . . 0.0 109.479 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.524 HG13 ' CZ ' ' A' ' 153' ' ' TYR . 43.6 t -129.02 148.22 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.459 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' ASP . . . . . 0.493 ' N ' HG12 ' A' ' 151' ' ' VAL . 92.6 m-20 -134.2 86.71 2.3 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.242 -0.911 . . . . 0.0 109.476 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' TYR . . . . . 0.524 ' CZ ' HG13 ' A' ' 151' ' ' VAL . 97.3 m-85 -67.34 -36.72 82.0 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.285 -0.884 . . . . 0.0 109.505 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -64.15 -41.45 97.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.202 -0.937 . . . . 0.0 109.442 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.415 ' O ' ' C ' ' A' ' 156' ' ' SER . 42.7 mttp -92.64 9.43 34.82 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.225 -0.922 . . . . 0.0 109.478 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' SER . . . . . 0.415 ' C ' ' O ' ' A' ' 155' ' ' LYS . 8.1 m 43.85 52.76 6.46 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.304 -0.872 . . . . 0.0 109.445 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' ARG . . . . . 0.434 ' CG ' ' HB3' ' A' ' 172' ' ' GLU . 7.7 tpt180 -144.45 140.0 28.68 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.243 -0.911 . . . . 0.0 109.43 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' LEU . . . . . 0.526 HD11 ' CD1' ' A' ' 175' ' ' PHE . 53.7 mt -107.35 134.54 50.26 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.198 -0.939 . . . . 0.0 109.454 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 13.6 tptt -92.74 95.9 9.83 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.247 -0.908 . . . . 0.0 109.463 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . 0.425 ' O ' ' O ' ' A' ' 171' ' ' VAL . 40.9 t -117.7 143.41 28.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.148 -0.97 . . . . 0.0 109.473 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' SER . . . . . 0.454 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 28.4 t -109.21 147.67 32.18 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.246 -0.909 . . . . 0.0 109.469 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' VAL . . . . . 0.627 ' CG2' ' CD1' ' A' ' 141' ' ' PHE . 21.1 t -88.43 134.39 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.258 -0.901 . . . . 0.0 109.615 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 5.7 m . . . . . 0 N--CA 1.49 1.541 0 O-C-N 121.319 -0.863 . . . . 0.0 109.231 179.765 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 17.3 ttt180 . . . . . 0 N--CA 1.492 1.656 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -67.28 147.57 52.83 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.206 -0.934 . . . . 0.0 109.382 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 5.3 m -124.58 88.95 52.89 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.221 -0.924 . . . . 0.0 109.541 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.454 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.4 Cg_endo -68.23 107.89 1.65 Allowed 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 122.592 2.194 . . . . 0.0 111.783 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.425 ' O ' ' O ' ' A' ' 160' ' ' VAL . 21.2 m -132.87 160.69 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.302 -0.874 . . . . 0.0 109.45 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.434 ' HB3' ' CG ' ' A' ' 157' ' ' ARG . 97.7 mt-10 -103.97 128.61 51.51 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.266 -0.896 . . . . 0.0 109.508 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . 0.509 ' HB2' ' CG1' ' A' ' 178' ' ' VAL . 55.7 mt -129.74 147.32 51.5 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.269 -0.895 . . . . 0.0 109.51 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 174' ' ' ASP . . . . . 0.432 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 88.9 m-20 -67.41 173.13 4.24 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.282 -0.886 . . . . 0.0 109.455 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.53 ' N ' ' CD1' ' A' ' 175' ' ' PHE . 2.7 m-30 -64.92 -41.46 95.55 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.191 -0.943 . . . . 0.0 109.403 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 19.4 m -75.11 -25.79 58.76 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.233 -0.917 . . . . 0.0 109.433 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 177' ' ' GLN . . . . . 0.432 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 83.2 mt-30 -68.29 -22.67 64.72 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.219 -0.926 . . . . 0.0 109.415 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.509 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 9.0 m -132.99 157.57 43.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.241 -0.912 . . . . 0.0 109.396 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 179' ' ' GLU . . . . . 0.421 ' O ' HG12 ' A' ' 134' ' ' VAL . 93.4 mt-10 -114.94 150.18 36.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.359 -0.838 . . . . 0.0 109.486 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 18.1 tttm -66.04 140.1 58.24 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.253 -0.904 . . . . 0.0 109.428 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.503 0 O-C-N 121.23 -0.919 . . . . 0.0 109.456 -179.971 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.49 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.6 OUTLIER -133.38 153.16 80.38 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.236 -0.915 . . . . 0.0 109.476 179.961 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.49 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 49.8 Cg_endo -45.79 132.79 13.77 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.591 2.194 . . . . 0.0 111.762 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 89.57 -1.28 81.42 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 49.0 tp10 -94.5 127.98 40.77 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.131 -1.217 . . . . 0.0 109.423 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.453 ' HA ' ' HA ' ' A' ' 147' ' ' VAL . 81.6 mtp -68.14 153.96 42.67 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.208 -0.932 . . . . 0.0 109.438 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.431 HG11 ' HB ' ' A' ' 178' ' ' VAL . 2.5 t -138.1 178.82 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.218 -0.927 . . . . 0.0 109.284 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.511 ' N ' ' O ' ' A' ' 179' ' ' GLU . 76.3 ttt180 -135.42 148.09 49.19 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.25 -0.906 . . . . 0.0 109.458 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.473 ' O ' ' N ' ' A' ' 143' ' ' ASP . 48.5 t -118.15 126.91 75.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.278 -0.889 . . . . 0.0 109.471 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . 0.403 ' O ' ' OD1' ' A' ' 138' ' ' ASP . 26.2 p30 -126.28 12.87 7.66 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.249 -0.907 . . . . 0.0 109.492 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.458 ' CB ' ' OE1' ' A' ' 177' ' ' GLN . 93.5 m-20 -137.78 163.07 32.28 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.21 -0.931 . . . . 0.0 109.506 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 63.86 176.48 4.2 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -58.14 -24.49 66.8 Favored 'Trans proline' 0 C--O 1.216 -0.613 0 C-N-CA 122.597 2.198 . . . . 0.0 111.745 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . 0.417 ' O ' ' HB ' ' A' ' 136' ' ' VAL . 98.8 m-85 -82.81 7.87 13.95 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.224 -0.922 . . . . 0.0 109.488 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' ALA . . . . . 0.458 ' HA ' HG12 ' A' ' 136' ' ' VAL . . . -61.03 150.87 32.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.215 -0.928 . . . . 0.0 109.499 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.473 ' N ' ' O ' ' A' ' 136' ' ' VAL . 37.8 m-20 62.66 52.58 2.8 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.271 -0.893 . . . . 0.0 109.579 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.487 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 35.6 m-85 -150.4 132.02 14.88 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.237 -0.914 . . . . 0.0 109.489 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 56.5 m-20 -92.98 138.72 31.23 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.209 -0.932 . . . . 0.0 109.402 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -156.67 -179.65 31.8 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.522 ' O ' ' CG1' ' A' ' 160' ' ' VAL . 40.9 t -121.48 159.52 23.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.243 -1.151 . . . . 0.0 109.349 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.477 ' N ' HG11 ' A' ' 147' ' ' VAL . 2.5 p -100.26 115.62 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.281 -0.887 . . . . 0.0 109.519 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 83.3 mt-10 -70.52 -36.59 73.82 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.279 -0.888 . . . . 0.0 109.294 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.465 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 93.7 mt-10 -152.32 162.45 41.15 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.283 -0.886 . . . . 0.0 109.459 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 48.0 t -132.27 151.75 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.19 -0.944 . . . . 0.0 109.51 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' ASP . . . . . 0.517 ' O ' ' N ' ' A' ' 156' ' ' SER . 84.3 m-20 -125.52 98.58 5.65 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.243 -0.91 . . . . 0.0 109.424 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 87.4 m-85 -66.33 -35.8 81.29 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.219 -0.926 . . . . 0.0 109.572 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -66.94 -45.3 78.24 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.286 -0.883 . . . . 0.0 109.551 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 19.3 mttt -91.07 -8.55 48.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.242 -0.911 . . . . 0.0 109.512 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' SER . . . . . 0.517 ' N ' ' O ' ' A' ' 152' ' ' ASP . 44.3 t 55.75 52.33 11.04 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.548 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 83.3 mmt-85 -133.2 151.1 51.95 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.896 . . . . 0.0 109.327 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' LEU . . . . . 0.588 HD12 ' CD1' ' A' ' 175' ' ' PHE . 4.3 mp -118.16 137.12 53.19 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.18 -0.95 . . . . 0.0 109.592 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . 0.465 ' HD2' ' HB2' ' A' ' 150' ' ' GLU . 34.1 mttt -99.15 90.55 4.63 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.243 -0.911 . . . . 0.0 109.347 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . 0.522 ' CG1' ' O ' ' A' ' 147' ' ' VAL . 46.5 t -118.52 142.99 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.224 -0.922 . . . . 0.0 109.533 -179.759 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 27.0 t -112.53 136.64 51.82 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.245 -0.909 . . . . 0.0 109.395 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' VAL . . . . . 0.487 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 21.5 t -107.47 132.35 55.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.176 -0.953 . . . . 0.0 109.511 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 33.1 t . . . . . 0 N--CA 1.491 1.576 0 O-C-N 121.292 -0.88 . . . . 0.0 109.48 -179.994 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 78.7 mtp180 . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -68.5 140.67 55.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.274 -0.891 . . . . 0.0 109.543 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 8.2 m -128.36 74.44 79.76 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.235 -0.916 . . . . 0.0 109.37 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -54.24 105.2 0.13 Allowed 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.579 2.186 . . . . 0.0 111.82 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 19.6 m -128.09 159.37 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.243 -0.911 . . . . 0.0 109.419 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.452 ' HA ' ' O ' ' A' ' 158' ' ' LEU . 95.9 mt-10 -102.91 130.93 50.13 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.213 -0.929 . . . . 0.0 109.45 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . 0.574 ' CD1' ' CG1' ' A' ' 178' ' ' VAL . 55.1 mt -125.02 160.84 28.07 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.276 -0.89 . . . . 0.0 109.527 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 174' ' ' ASP . . . . . 0.433 ' HB2' ' HG2' ' A' ' 177' ' ' GLN . 90.6 m-20 -82.82 176.78 9.04 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.3 -0.875 . . . . 0.0 109.558 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.588 ' CD1' HD12 ' A' ' 158' ' ' LEU . 3.2 m-85 -66.1 -39.77 90.24 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.333 -0.855 . . . . 0.0 109.613 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 15.4 m -79.81 -26.23 40.58 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.208 -0.933 . . . . 0.0 109.619 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 177' ' ' GLN . . . . . 0.458 ' OE1' ' CB ' ' A' ' 138' ' ' ASP . 96.6 mm-40 -67.08 -30.71 70.83 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.22 -0.925 . . . . 0.0 109.519 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.574 ' CG1' ' CD1' ' A' ' 173' ' ' LEU . 12.7 m -125.29 158.26 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.249 -0.907 . . . . 0.0 109.386 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 179' ' ' GLU . . . . . 0.511 ' O ' ' N ' ' A' ' 135' ' ' ARG . 70.6 tt0 -120.38 143.09 48.61 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.218 -0.926 . . . . 0.0 109.498 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 23.6 ttmt -59.71 140.15 56.69 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.309 -0.87 . . . . 0.0 109.434 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.527 0 O-C-N 121.174 -0.954 . . . . 0.0 109.452 -179.984 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 92.2 m-85 . . . . . 0 N--CA 1.489 1.477 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.462 ' HB2' ' HD2' ' A' ' 130' ' ' PRO . 16.5 pt-20 -133.01 134.98 25.06 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.921 . . . . 0.0 109.454 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.462 ' HD2' ' HB2' ' A' ' 129' ' ' GLU . 49.2 Cg_endo -35.28 131.36 0.24 Allowed 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.517 2.145 . . . . 0.0 111.738 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . 0.487 ' C ' ' CG1' ' A' ' 147' ' ' VAL . . . 90.89 -4.48 81.71 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.469 ' O ' ' CG1' ' A' ' 147' ' ' VAL . 49.2 tp10 -83.58 141.7 31.38 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.125 -1.221 . . . . 0.0 109.548 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.471 ' HG2' ' CG2' ' A' ' 147' ' ' VAL . 90.5 mtp -80.94 150.11 29.11 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.184 -0.948 . . . . 0.0 109.438 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.454 HG12 ' O ' ' A' ' 179' ' ' GLU . 2.5 t -135.65 179.06 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.168 -0.958 . . . . 0.0 109.375 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.455 ' O ' ' HB ' ' A' ' 178' ' ' VAL . 94.5 mtt180 -132.86 146.52 51.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.318 -0.864 . . . . 0.0 109.467 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 41.4 t -112.53 130.42 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.265 -0.897 . . . . 0.0 109.423 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 54.9 p30 -123.37 19.21 9.75 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.201 -0.937 . . . . 0.0 109.534 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -156.27 151.24 26.26 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.212 -0.93 . . . . 0.0 109.493 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 82.27 164.16 33.97 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -54.19 -23.66 30.54 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.606 2.204 . . . . 0.0 111.779 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . 0.569 ' CD1' HG23 ' A' ' 162' ' ' VAL . 98.9 m-85 -86.87 11.05 14.26 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.252 -0.905 . . . . 0.0 109.391 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' ALA . . . . . 0.471 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -70.09 151.09 45.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.491 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.471 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 25.0 t0 74.9 28.62 1.09 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.279 -0.888 . . . . 0.0 109.517 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.504 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 92.5 m-85 -135.03 140.3 45.5 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.164 -0.96 . . . . 0.0 109.608 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 21.2 m120 -95.95 141.07 29.81 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.32 -0.862 . . . . 0.0 109.418 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -151.3 -173.42 21.18 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.487 ' CG1' ' C ' ' A' ' 131' ' ' GLY . 54.8 t -132.01 144.26 37.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.362 -1.081 . . . . 0.0 109.454 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.525 ' CA ' HG21 ' A' ' 160' ' ' VAL . 2.1 p -83.03 106.11 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.281 -0.887 . . . . 0.0 109.443 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 56.5 mp0 -70.2 -46.8 63.83 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.231 -0.918 . . . . 0.0 109.461 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -131.8 153.24 50.34 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.186 -0.947 . . . . 0.0 109.36 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.517 HG11 ' CD2' ' A' ' 158' ' ' LEU . 47.9 t -120.18 153.53 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.174 -0.954 . . . . 0.0 109.579 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 92.2 m-20 -135.76 83.25 2.0 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.306 -0.871 . . . . 0.0 109.339 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -67.03 -34.84 78.59 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.244 -0.91 . . . . 0.0 109.555 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 76.0 mm-40 -62.21 -40.81 97.32 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.202 -0.936 . . . . 0.0 109.562 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.442 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 31.7 tttt -96.88 -4.3 40.44 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.289 -0.882 . . . . 0.0 109.655 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' SER . . . . . 0.442 ' HB2' ' O ' ' A' ' 155' ' ' LYS . 19.8 m 59.9 53.05 4.92 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.195 -0.941 . . . . 0.0 109.46 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 13.5 tpt180 -142.63 138.97 31.07 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.281 -0.887 . . . . 0.0 109.488 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' LEU . . . . . 0.517 ' CD2' HG11 ' A' ' 151' ' ' VAL . 41.9 mt -108.08 134.63 50.68 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.252 -0.905 . . . . 0.0 109.524 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 62.8 tttm -97.28 97.08 8.85 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.225 -0.922 . . . . 0.0 109.418 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . 0.525 HG21 ' CA ' ' A' ' 148' ' ' VAL . 42.9 t -123.27 138.37 53.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.258 -0.901 . . . . 0.0 109.615 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' SER . . . . . 0.454 ' CB ' ' HA ' ' A' ' 170' ' ' PRO . 83.6 p -100.75 155.24 18.02 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.299 -0.876 . . . . 0.0 109.508 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' VAL . . . . . 0.569 HG23 ' CD1' ' A' ' 141' ' ' PHE . 5.3 t -106.14 129.15 59.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.25 -0.906 . . . . 0.0 109.479 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 55.1 m . . . . . 0 N--CA 1.49 1.564 0 O-C-N 121.286 -0.884 . . . . 0.0 109.383 179.887 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 7.9 mtm180 . . . . . 0 N--CA 1.492 1.665 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -69.39 138.87 53.98 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.221 -0.924 . . . . 0.0 109.384 179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 29.7 m -123.04 87.85 51.0 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.172 -0.955 . . . . 0.0 109.526 -179.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.454 ' HA ' ' CB ' ' A' ' 161' ' ' SER . 50.2 Cg_endo -62.74 107.53 0.62 Allowed 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.558 2.172 . . . . 0.0 111.685 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' A' ' 160' ' ' VAL . 18.9 m -129.97 156.92 42.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.278 -0.889 . . . . 0.0 109.567 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.448 ' O ' HD22 ' A' ' 173' ' ' LEU . 94.5 mt-10 -103.97 129.38 51.54 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.281 -0.887 . . . . 0.0 109.371 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . 0.524 ' HB2' ' CG1' ' A' ' 178' ' ' VAL . 65.5 mt -126.25 147.89 49.6 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.268 -0.895 . . . . 0.0 109.471 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -68.5 173.35 5.07 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.25 -0.907 . . . . 0.0 109.407 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.492 ' N ' ' CD1' ' A' ' 175' ' ' PHE . 2.9 m-30 -66.51 -40.24 89.11 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.248 -0.907 . . . . 0.0 109.446 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 14.8 m -75.36 -24.41 57.29 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.231 -0.918 . . . . 0.0 109.406 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -70.32 -28.8 65.45 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.219 -0.926 . . . . 0.0 109.499 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.524 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 4.4 m -127.95 161.08 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.231 -0.918 . . . . 0.0 109.468 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 179' ' ' GLU . . . . . 0.454 ' O ' HG12 ' A' ' 134' ' ' VAL . 75.0 mm-40 -120.0 148.64 43.31 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.236 -0.915 . . . . 0.0 109.505 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 20.1 tttt -58.95 140.56 55.43 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.188 -0.945 . . . . 0.0 109.485 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.589 0 O-C-N 121.21 -0.932 . . . . 0.0 109.43 179.984 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.436 ' CD2' HD22 ' A' ' 158' ' ' LEU . 92.0 m-85 . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.475 ' HB2' ' HD2' ' A' ' 130' ' ' PRO . 2.2 pt-20 -142.35 147.31 42.91 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.231 -0.918 . . . . 0.0 109.418 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.475 ' HD2' ' HB2' ' A' ' 129' ' ' GLU . 48.8 Cg_endo -40.95 128.47 2.79 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.436 2.091 . . . . 0.0 111.84 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 100.28 -4.19 56.96 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.461 ' CG ' ' HG3' ' A' ' 129' ' ' GLU . 78.1 mm-40 -93.03 144.32 25.37 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.207 -1.172 . . . . 0.0 109.541 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.472 ' SD ' ' CG2' ' A' ' 147' ' ' VAL . 77.3 mmm -83.48 143.08 30.47 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.225 -0.922 . . . . 0.0 109.413 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.519 HG21 ' CG2' ' A' ' 148' ' ' VAL . 2.5 t -128.63 178.59 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.225 -0.922 . . . . 0.0 109.362 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.443 ' O ' ' HB ' ' A' ' 178' ' ' VAL . 40.0 ttt85 -141.88 145.8 35.04 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.343 -0.848 . . . . 0.0 109.405 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.472 HG21 ' CD1' ' A' ' 173' ' ' LEU . 43.5 t -112.48 135.29 52.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.235 -0.915 . . . . 0.0 109.495 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 34.6 p30 -126.67 10.41 7.17 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.279 -0.888 . . . . 0.0 109.411 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.451 ' HB3' ' HG3' ' A' ' 177' ' ' GLN . 49.9 t0 -150.58 159.04 44.78 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.229 -0.919 . . . . 0.0 109.541 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.416 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 77.52 165.33 24.63 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -50.45 -22.33 8.74 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 122.593 2.195 . . . . 0.0 111.721 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . 0.528 ' CZ ' HG13 ' A' ' 171' ' ' VAL . 93.9 m-85 -88.61 12.57 14.31 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.207 -0.933 . . . . 0.0 109.485 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' ALA . . . . . 0.451 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -62.83 149.2 44.86 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.339 -0.851 . . . . 0.0 109.529 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.446 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 44.7 m-20 63.28 45.31 5.07 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.472 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.52 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 46.0 m-85 -147.08 126.08 12.83 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.184 -0.947 . . . . 0.0 109.474 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 67.8 m-20 -88.42 145.24 25.89 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.224 -0.923 . . . . 0.0 109.605 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -157.1 177.26 34.06 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.495 HG13 ' N ' ' A' ' 148' ' ' VAL . 22.0 t -114.86 156.69 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.177 -1.19 . . . . 0.0 109.395 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.519 ' CG2' HG21 ' A' ' 134' ' ' VAL . 47.8 t -82.37 104.11 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.248 -0.907 . . . . 0.0 109.498 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.426 ' C ' ' HG2' ' A' ' 150' ' ' GLU . 97.2 mt-10 -69.86 -35.41 74.69 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.282 -0.886 . . . . 0.0 109.36 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.453 ' HB2' ' HD3' ' A' ' 159' ' ' LYS . 76.1 mm-40 -152.81 164.88 36.98 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.322 -0.861 . . . . 0.0 109.41 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 46.5 t -128.56 143.48 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.267 -0.896 . . . . 0.0 109.424 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 93.8 m-20 -124.91 78.31 1.69 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.19 -0.944 . . . . 0.0 109.542 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -59.87 -42.21 93.24 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.238 -0.914 . . . . 0.0 109.385 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -54.61 -45.08 73.6 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.244 -0.91 . . . . 0.0 109.366 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 44.2 mttp -86.23 -2.96 58.85 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.264 -0.897 . . . . 0.0 109.515 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 17.1 m 55.68 53.7 9.21 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.183 -0.948 . . . . 0.0 109.358 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 66.9 mtt180 -147.95 162.79 38.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 109.534 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' LEU . . . . . 0.638 ' CD1' ' CE1' ' A' ' 175' ' ' PHE . 6.7 mp -114.02 139.27 49.4 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.331 -0.856 . . . . 0.0 109.428 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . 0.453 ' HD3' ' HB2' ' A' ' 150' ' ' GLU . 41.1 tttt -104.56 100.22 9.9 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.158 -0.963 . . . . 0.0 109.312 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . 0.47 HG11 ' N ' ' A' ' 161' ' ' SER . 39.9 t -119.9 148.52 22.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.207 -0.933 . . . . 0.0 109.549 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 161' ' ' SER . . . . . 0.47 ' N ' HG11 ' A' ' 160' ' ' VAL . 22.7 t -117.95 138.85 51.88 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.245 -0.909 . . . . 0.0 109.333 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 162' ' ' VAL . . . . . 0.52 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 4.4 t -107.19 133.13 52.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.182 -0.949 . . . . 0.0 109.708 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 44.1 t . . . . . 0 N--CA 1.49 1.53 0 O-C-N 121.321 -0.862 . . . . 0.0 109.311 179.838 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 76.1 mtm180 . . . . . 0 N--CA 1.489 1.485 0 N-CA-C 109.441 -0.578 . . . . 0.0 109.441 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -80.12 134.6 36.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.2 -0.938 . . . . 0.0 109.413 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 169' ' ' THR . . . . . 0.458 HG21 ' CZ ' ' A' ' 141' ' ' PHE . 57.3 m -128.65 73.32 80.92 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.286 -0.884 . . . . 0.0 109.437 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.453 ' HA ' ' CB ' ' A' ' 161' ' ' SER . 49.6 Cg_endo -52.1 108.42 0.25 Allowed 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.69 2.26 . . . . 0.0 111.89 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.528 HG13 ' CZ ' ' A' ' 141' ' ' PHE . 20.5 m -126.04 155.12 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.264 -0.898 . . . . 0.0 109.417 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.439 ' O ' HD21 ' A' ' 173' ' ' LEU . 95.3 mt-10 -90.89 129.99 36.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.213 -0.929 . . . . 0.0 109.553 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . 0.48 ' HB3' ' CG1' ' A' ' 178' ' ' VAL . 61.9 mt -122.02 154.91 36.63 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.234 -0.916 . . . . 0.0 109.49 179.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 174' ' ' ASP . . . . . 0.456 ' HB2' ' HB2' ' A' ' 177' ' ' GLN . 85.1 m-20 -83.81 154.95 23.23 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.221 -0.925 . . . . 0.0 109.629 -179.867 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.638 ' CE1' ' CD1' ' A' ' 158' ' ' LEU . 25.4 m-85 -51.14 -50.24 59.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.38 -0.825 . . . . 0.0 109.615 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 72.4 p -74.8 -18.45 60.46 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.223 -0.923 . . . . 0.0 109.594 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 177' ' ' GLN . . . . . 0.456 ' HB2' ' HB2' ' A' ' 174' ' ' ASP . 65.7 tt0 -72.95 -25.15 60.92 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.301 -0.874 . . . . 0.0 109.448 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.48 ' CG1' ' HB3' ' A' ' 173' ' ' LEU . 5.2 m -125.34 161.81 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.154 -0.966 . . . . 0.0 109.487 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 179' ' ' GLU . . . . . . . . . . . . . 61.1 mt-10 -118.42 148.96 42.01 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.225 -0.922 . . . . 0.0 109.482 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 21.1 tttm -79.79 132.65 36.19 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.34 -0.85 . . . . 0.0 109.449 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.499 0 O-C-N 121.278 -0.889 . . . . 0.0 109.49 179.99 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.416 ' CG ' HD21 ' A' ' 158' ' ' LEU . 75.2 m-85 . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.455 ' HB3' ' HD2' ' A' ' 130' ' ' PRO . 0.6 OUTLIER -129.46 150.04 74.5 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.206 -0.934 . . . . 0.0 109.469 -179.99 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.455 ' HD2' ' HB3' ' A' ' 129' ' ' GLU . 50.0 Cg_endo -47.27 123.48 7.81 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.67 2.247 . . . . 0.0 111.771 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 99.29 2.17 56.78 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.626 -1.389 . . . . 0.0 109.626 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.448 ' HG2' ' O ' ' A' ' 129' ' ' GLU . 74.9 mm-40 -92.32 141.3 28.71 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.186 -1.185 . . . . 0.0 109.438 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.506 ' SD ' ' CG2' ' A' ' 147' ' ' VAL . 84.4 mmm -74.18 142.18 45.46 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.234 -0.916 . . . . 0.0 109.468 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.435 HG11 ' HB ' ' A' ' 178' ' ' VAL . 2.5 t -130.27 178.96 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.248 -0.908 . . . . 0.0 109.347 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.451 ' O ' ' HB ' ' A' ' 178' ' ' VAL . 45.7 ttt85 -142.44 135.75 28.8 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.333 -0.855 . . . . 0.0 109.429 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.494 HG22 ' CD1' ' A' ' 173' ' ' LEU . 66.3 t -106.29 133.56 50.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.264 -0.897 . . . . 0.0 109.444 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 11.4 p30 -132.06 22.11 4.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.302 -0.874 . . . . 0.0 109.431 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.457 ' HB3' ' HG3' ' A' ' 177' ' ' GLN . 51.7 t0 -143.23 156.42 44.74 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.243 -0.911 . . . . 0.0 109.447 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.452 ' O ' ' N ' ' A' ' 142' ' ' ALA . . . 62.98 167.17 0.74 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -44.28 -24.86 1.08 Allowed 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.585 2.19 . . . . 0.0 111.795 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . 0.444 ' O ' ' HB ' ' A' ' 136' ' ' VAL . 88.0 m-85 -86.57 14.96 6.04 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.255 -0.903 . . . . 0.0 109.468 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' ALA . . . . . 0.518 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -73.67 145.24 45.43 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.285 -0.885 . . . . 0.0 109.501 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.44 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 3.5 m-20 71.05 43.83 0.63 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.318 -0.864 . . . . 0.0 109.526 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.518 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 80.9 m-85 -142.25 139.98 32.12 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.25 -0.906 . . . . 0.0 109.522 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 78.9 m-20 -94.05 138.99 31.52 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.235 -0.916 . . . . 0.0 109.46 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -153.1 179.8 29.23 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.506 ' CG2' ' SD ' ' A' ' 133' ' ' MET . 22.8 t -124.18 151.38 29.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.256 -1.144 . . . . 0.0 109.449 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.501 ' CG2' HG23 ' A' ' 151' ' ' VAL . 3.1 p -87.28 95.23 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.219 -0.925 . . . . 0.0 109.552 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -65.75 -36.35 83.33 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.219 -0.925 . . . . 0.0 109.408 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.483 ' HG2' ' N ' ' A' ' 151' ' ' VAL . 84.7 tt0 -142.21 160.36 40.4 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.33 -0.856 . . . . 0.0 109.385 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.501 HG23 ' CG2' ' A' ' 148' ' ' VAL . 39.8 t -131.37 149.06 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.258 -0.901 . . . . 0.0 109.467 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -131.04 94.64 3.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.24 -0.912 . . . . 0.0 109.501 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -66.69 -32.9 74.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.257 -0.902 . . . . 0.0 109.487 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -61.81 -42.71 99.36 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -0.916 . . . . 0.0 109.368 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 29.9 mttm -90.03 -6.38 55.63 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.258 -0.901 . . . . 0.0 109.471 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 57.48 52.76 8.13 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.23 -0.919 . . . . 0.0 109.475 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 75.3 mtt180 -147.13 165.83 28.78 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.222 -0.924 . . . . 0.0 109.536 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' LEU . . . . . 0.638 ' CD1' ' CD1' ' A' ' 175' ' ' PHE . 3.5 mp -116.01 133.94 55.49 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.227 -0.921 . . . . 0.0 109.532 -179.736 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 80.8 tttt -91.53 85.77 5.83 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.183 -0.948 . . . . 0.0 109.298 179.765 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 61.1 t -110.4 144.28 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.264 -0.898 . . . . 0.0 109.603 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 60.0 p -107.76 140.51 40.71 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.282 -0.886 . . . . 0.0 109.348 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 162' ' ' VAL . . . . . 0.457 HG12 ' HB3' ' A' ' 144' ' ' PHE . 6.6 t -110.29 131.98 59.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.242 -0.911 . . . . 0.0 109.59 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 32.6 t . . . . . 0 N--CA 1.491 1.582 0 O-C-N 121.233 -0.917 . . . . 0.0 109.42 179.85 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 39.0 ptt180 . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -75.44 143.23 42.77 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.267 -0.895 . . . . 0.0 109.46 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 27.2 m -130.12 70.61 82.23 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.237 -0.914 . . . . 0.0 109.441 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -46.88 108.15 0.15 Allowed 'Trans proline' 0 C--O 1.214 -0.683 0 C-N-CA 122.613 2.209 . . . . 0.0 111.858 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 21.2 m -133.26 154.28 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.283 -0.886 . . . . 0.0 109.424 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.459 ' O ' HD23 ' A' ' 173' ' ' LEU . 94.5 mt-10 -100.08 136.36 40.1 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.18 -0.95 . . . . 0.0 109.451 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . 0.494 ' CD1' HG22 ' A' ' 136' ' ' VAL . 47.7 mt -131.01 152.47 50.29 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.285 -0.884 . . . . 0.0 109.513 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -69.54 156.34 39.05 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.245 -0.909 . . . . 0.0 109.515 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.638 ' CD1' ' CD1' ' A' ' 158' ' ' LEU . 51.0 m-85 -53.08 -44.48 67.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.547 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 82.5 p -75.3 -20.03 59.33 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.159 -0.963 . . . . 0.0 109.587 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 177' ' ' GLN . . . . . 0.457 ' HG3' ' HB3' ' A' ' 138' ' ' ASP . 50.6 tt0 -72.02 -24.55 61.57 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.283 -0.886 . . . . 0.0 109.503 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.462 ' CG1' HD12 ' A' ' 173' ' ' LEU . 17.7 m -127.26 163.55 30.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.26 -0.9 . . . . 0.0 109.516 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 179' ' ' GLU . . . . . 0.435 ' HB2' ' HB3' ' A' ' 135' ' ' ARG . 63.6 mm-40 -114.79 151.02 34.5 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.281 -0.887 . . . . 0.0 109.483 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 24.3 tttt -81.18 131.67 35.31 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.255 -0.903 . . . . 0.0 109.508 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . 0.455 ' HB2' ' O ' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.544 0 O-C-N 121.193 -0.942 . . . . 0.0 109.415 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.515 ' CD2' HD12 ' A' ' 158' ' ' LEU . 93.0 m-85 . . . . . 0 N--CA 1.489 1.501 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.433 ' O ' ' HB2' ' A' ' 132' ' ' GLU . 1.8 mm-40 -103.32 139.59 20.25 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.265 -0.897 . . . . 0.0 109.442 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.425 ' HD2' ' HB3' ' A' ' 129' ' ' GLU . 49.3 Cg_endo -43.25 135.82 5.82 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.623 2.215 . . . . 0.0 111.712 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 80.35 6.75 89.1 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.433 ' HB2' ' O ' ' A' ' 129' ' ' GLU . 85.0 tt0 -89.04 128.76 35.74 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.269 -1.136 . . . . 0.0 109.448 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.447 ' HA ' ' O ' ' A' ' 146' ' ' GLY . 42.2 ttm -68.19 144.57 54.9 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.235 -0.916 . . . . 0.0 109.44 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.423 HG13 ' O ' ' A' ' 179' ' ' GLU . 2.5 t -131.4 179.15 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.242 -0.911 . . . . 0.0 109.316 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.451 ' O ' ' HA ' ' A' ' 178' ' ' VAL . 28.4 ttt85 -129.99 135.98 48.9 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.196 -0.94 . . . . 0.0 109.42 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.427 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 60.7 t -107.71 133.87 51.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.213 -0.93 . . . . 0.0 109.498 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . 0.412 ' OD1' ' C ' ' A' ' 137' ' ' ASN . 44.0 p30 -132.59 23.39 4.34 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.239 -0.913 . . . . 0.0 109.462 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -142.85 144.08 32.36 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.269 -0.894 . . . . 0.0 109.531 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 75.49 172.85 32.58 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -52.1 -17.17 5.42 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.669 2.246 . . . . 0.0 111.756 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . 0.573 ' CD1' HG22 ' A' ' 162' ' ' VAL . 97.0 m-85 -92.68 17.51 10.17 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.28 -0.887 . . . . 0.0 109.495 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' ALA . . . . . 0.553 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -73.33 149.88 42.28 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.324 -0.86 . . . . 0.0 109.498 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.464 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 35.2 m-20 65.14 48.27 2.26 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.205 -0.935 . . . . 0.0 109.527 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.553 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 64.1 m-85 -147.22 146.89 29.96 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.218 -0.926 . . . . 0.0 109.404 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . 0.424 ' O ' ' OD1' ' A' ' 145' ' ' ASN . 44.0 p-10 -102.56 151.38 22.39 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.257 -0.902 . . . . 0.0 109.414 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . 0.447 ' O ' ' HA ' ' A' ' 133' ' ' MET . . . -164.95 -174.45 34.67 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.454 ' O ' HG13 ' A' ' 160' ' ' VAL . 96.7 t -130.29 150.75 34.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.18 -1.188 . . . . 0.0 109.427 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.468 HG13 ' O ' ' A' ' 148' ' ' VAL . 2.1 p -89.61 107.2 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.178 -0.951 . . . . 0.0 109.502 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -70.86 -37.4 73.09 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.182 -0.949 . . . . 0.0 109.396 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -138.64 157.5 46.02 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.355 -0.841 . . . . 0.0 109.338 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.408 HG23 HG23 ' A' ' 148' ' ' VAL . 57.1 t -130.81 149.79 33.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.179 -0.95 . . . . 0.0 109.417 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' ASP . . . . . 0.4 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 95.3 m-20 -136.43 90.17 2.54 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.273 -0.892 . . . . 0.0 109.484 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -67.56 -37.0 82.03 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.233 -0.917 . . . . 0.0 109.495 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -63.6 -42.61 98.24 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.257 -0.902 . . . . 0.0 109.411 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.401 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 58.2 mttt -89.44 -4.64 57.9 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.248 -0.908 . . . . 0.0 109.478 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 58.5 m 55.65 52.73 10.54 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.171 -0.956 . . . . 0.0 109.439 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' ARG . . . . . 0.425 ' HD3' ' OD1' ' A' ' 174' ' ' ASP . 15.6 mmt85 -144.64 141.97 29.77 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.213 -0.93 . . . . 0.0 109.427 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' LEU . . . . . 0.515 HD12 ' CD2' ' A' ' 128' ' ' PHE . 40.1 mt -111.74 132.34 54.71 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -0.901 . . . . 0.0 109.577 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 22.0 tttt -94.9 91.74 6.57 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.23 -0.919 . . . . 0.0 109.277 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . 0.454 HG13 ' O ' ' A' ' 147' ' ' VAL . 33.1 t -117.98 144.55 25.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.281 -0.887 . . . . 0.0 109.466 -179.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 161' ' ' SER . . . . . 0.448 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 61.8 m -99.84 148.62 24.23 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.241 -0.912 . . . . 0.0 109.45 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 162' ' ' VAL . . . . . 0.573 HG22 ' CD1' ' A' ' 141' ' ' PHE . 6.2 t -96.53 138.39 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.29 -0.881 . . . . 0.0 109.621 -179.873 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 19.7 m . . . . . 0 N--CA 1.489 1.501 0 O-C-N 121.266 -0.896 . . . . 0.0 109.254 179.737 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 17.8 ttp180 . . . . . 0 N--CA 1.494 1.765 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -61.18 143.67 55.11 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.243 -0.91 . . . . 0.0 109.33 179.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 169' ' ' THR . . . . . 0.458 HG22 ' CZ ' ' A' ' 141' ' ' PHE . 36.6 m -126.36 98.57 32.08 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.17 -0.956 . . . . 0.0 109.554 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 50.3 Cg_endo -70.26 103.89 1.32 Allowed 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.492 2.128 . . . . 0.0 111.707 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.407 ' CG2' ' CD2' ' A' ' 173' ' ' LEU . 14.6 m -129.25 161.08 39.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.246 -0.909 . . . . 0.0 109.523 -179.866 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.452 ' O ' HD11 ' A' ' 173' ' ' LEU . 96.5 mt-10 -99.03 129.15 45.29 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.277 -0.889 . . . . 0.0 109.4 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . 0.541 ' CD2' ' N ' ' A' ' 173' ' ' LEU . 2.8 mm? -125.41 146.3 49.67 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.192 -0.942 . . . . 0.0 109.529 -179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 174' ' ' ASP . . . . . 0.425 ' OD1' ' HD3' ' A' ' 157' ' ' ARG . 87.4 m-20 -69.35 170.36 10.52 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.228 -0.92 . . . . 0.0 109.489 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.538 ' N ' ' CD1' ' A' ' 175' ' ' PHE . 2.7 m-30 -65.74 -40.64 92.34 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.269 -0.895 . . . . 0.0 109.47 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 83.0 p -75.51 -28.66 59.23 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.362 -0.836 . . . . 0.0 109.499 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 177' ' ' GLN . . . . . 0.408 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 90.2 mt-30 -65.76 -23.55 66.75 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.293 -0.879 . . . . 0.0 109.435 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.452 HG13 ' HB2' ' A' ' 173' ' ' LEU . 12.3 m -130.23 164.42 33.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.259 -0.901 . . . . 0.0 109.452 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 179' ' ' GLU . . . . . 0.423 ' O ' HG13 ' A' ' 134' ' ' VAL . 76.3 mt-10 -119.41 142.49 48.16 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.259 -0.901 . . . . 0.0 109.542 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 31.4 ttmt -62.6 134.86 56.97 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.159 -0.963 . . . . 0.0 109.521 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . 0.445 ' CB ' ' HG2' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.128 -0.982 . . . . 0.0 109.391 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.563 ' CD2' HD21 ' A' ' 158' ' ' LEU . 89.6 m-85 . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 121.333 0.587 . . . . 0.0 109.446 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.45 ' HB3' ' HD2' ' A' ' 130' ' ' PRO . 3.5 mt-10 -139.41 150.04 62.54 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.241 -0.912 . . . . 0.0 109.354 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.457 ' HA ' ' O ' ' A' ' 148' ' ' VAL . 49.4 Cg_endo -46.33 128.88 12.74 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.418 2.079 . . . . 0.0 111.751 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 93.69 3.61 64.28 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.438 ' HG2' ' O ' ' A' ' 129' ' ' GLU . 76.7 mm-40 -98.57 138.57 35.57 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.168 -1.196 . . . . 0.0 109.455 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 78.5 mtp -76.12 148.78 37.61 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.23 -0.919 . . . . 0.0 109.468 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 2.5 t -137.21 179.38 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.26 -0.9 . . . . 0.0 109.375 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.447 ' O ' ' HB ' ' A' ' 178' ' ' VAL . 43.6 ttt180 -135.7 135.01 39.72 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.104 -0.997 . . . . 0.0 109.503 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.454 ' O ' ' N ' ' A' ' 143' ' ' ASP . 80.3 t -108.73 135.72 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.298 -0.877 . . . . 0.0 109.502 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 31.6 p30 -131.83 18.98 4.62 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.242 -0.911 . . . . 0.0 109.438 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -132.52 144.07 50.17 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.31 -0.869 . . . . 0.0 109.408 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 71.66 175.99 24.57 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -53.22 -19.49 12.51 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.608 2.205 . . . . 0.0 111.779 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . 0.428 ' O ' ' HB ' ' A' ' 136' ' ' VAL . 90.5 m-85 -88.61 12.65 14.08 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.279 -0.888 . . . . 0.0 109.415 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' ALA . . . . . 0.448 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -71.96 150.38 44.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.28 -0.888 . . . . 0.0 109.403 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.454 ' N ' ' O ' ' A' ' 136' ' ' VAL . 31.9 m-20 63.49 48.69 3.37 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.169 -0.957 . . . . 0.0 109.449 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.448 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 43.3 m-85 -145.06 143.05 30.24 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.147 -0.971 . . . . 0.0 109.524 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 73.6 m-20 -95.89 145.08 25.67 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.248 -0.908 . . . . 0.0 109.5 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -161.7 -178.42 35.6 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.439 HG13 ' N ' ' A' ' 148' ' ' VAL . 40.6 t -126.1 147.23 30.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.256 -1.143 . . . . 0.0 109.408 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 130' ' ' PRO . 2.5 p -82.95 99.37 5.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.179 -0.951 . . . . 0.0 109.467 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -66.59 -34.21 77.37 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.245 -0.91 . . . . 0.0 109.391 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.475 ' HB2' ' CD ' ' A' ' 159' ' ' LYS . 75.5 mm-40 -147.0 162.47 38.7 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.27 -0.894 . . . . 0.0 109.386 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 41.0 t -129.17 146.69 33.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.2 -0.937 . . . . 0.0 109.487 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -127.63 96.48 4.55 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.203 -0.936 . . . . 0.0 109.511 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -66.29 -40.3 89.94 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.305 -0.872 . . . . 0.0 109.475 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -62.37 -42.19 99.21 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.201 -0.937 . . . . 0.0 109.431 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.413 ' O ' ' OG ' ' A' ' 156' ' ' SER . 47.9 mttt -83.93 0.79 46.4 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.278 -0.889 . . . . 0.0 109.548 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' SER . . . . . 0.413 ' OG ' ' O ' ' A' ' 155' ' ' LYS . 24.3 p 45.62 57.04 5.28 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.216 -0.927 . . . . 0.0 109.465 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' ARG . . . . . 0.459 ' HG2' ' OD1' ' A' ' 174' ' ' ASP . 30.4 mtt180 -155.49 165.5 36.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.277 -0.89 . . . . 0.0 109.516 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' LEU . . . . . 0.641 ' CD1' ' CD1' ' A' ' 175' ' ' PHE . 4.3 mp -114.34 137.3 51.98 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.241 -0.912 . . . . 0.0 109.453 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . 0.475 ' CD ' ' HB2' ' A' ' 150' ' ' GLU . 40.4 tttp -92.97 94.88 9.15 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.184 -0.947 . . . . 0.0 109.339 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . 0.467 HG11 ' N ' ' A' ' 161' ' ' SER . 45.1 t -122.04 146.04 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.28 -0.888 . . . . 0.0 109.602 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 161' ' ' SER . . . . . 0.467 ' N ' HG11 ' A' ' 160' ' ' VAL . 29.3 t -111.82 141.64 45.19 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.329 -0.857 . . . . 0.0 109.28 179.868 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 162' ' ' VAL . . . . . . . . . . . . . 12.1 t -113.28 131.09 65.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.132 -0.98 . . . . 0.0 109.563 -179.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 35.5 t . . . . . 0 N--CA 1.489 1.511 0 O-C-N 121.291 -0.881 . . . . 0.0 109.403 179.928 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 42.1 mtp-105 . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -71.16 137.76 49.05 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.267 -0.896 . . . . 0.0 109.411 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 169' ' ' THR . . . . . 0.439 ' O ' HG12 ' A' ' 171' ' ' VAL . 1.9 m -133.01 75.96 71.07 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.292 -0.88 . . . . 0.0 109.458 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -56.69 104.2 0.14 Allowed 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.622 2.215 . . . . 0.0 111.836 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.439 HG12 ' O ' ' A' ' 169' ' ' THR . 18.2 m -129.34 155.56 41.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.305 -0.872 . . . . 0.0 109.419 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.447 ' O ' HD13 ' A' ' 173' ' ' LEU . 95.5 mt-10 -102.01 129.61 48.35 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.217 -0.927 . . . . 0.0 109.522 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . 0.578 ' CD2' ' N ' ' A' ' 173' ' ' LEU . 2.3 mm? -121.54 149.82 42.54 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.269 -0.895 . . . . 0.0 109.39 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 174' ' ' ASP . . . . . 0.459 ' OD1' ' HG2' ' A' ' 157' ' ' ARG . 82.1 m-20 -68.93 157.95 35.62 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.279 -0.888 . . . . 0.0 109.515 179.956 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.641 ' CD1' ' CD1' ' A' ' 158' ' ' LEU . 98.7 m-85 -61.25 -40.79 95.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.293 -0.879 . . . . 0.0 109.334 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 28.6 m -74.98 -19.7 59.98 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.222 -0.923 . . . . 0.0 109.313 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 89.9 mt-30 -82.16 -20.01 38.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.348 -0.845 . . . . 0.0 109.245 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.517 ' CG1' ' CB ' ' A' ' 173' ' ' LEU . 19.3 m -124.9 161.88 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.396 -0.815 . . . . 0.0 109.264 179.821 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 179' ' ' GLU . . . . . 0.402 ' HB2' ' HB3' ' A' ' 135' ' ' ARG . 61.8 mt-10 -121.31 153.26 37.95 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.133 -0.98 . . . . 0.0 109.695 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 17.8 tttm -74.14 135.52 42.87 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.322 -0.861 . . . . 0.0 109.451 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.309 -0.869 . . . . 0.0 109.494 179.989 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.434 ' O ' HG23 ' A' ' 151' ' ' VAL . 93.5 m-85 . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.484 ' HB2' ' HD2' ' A' ' 130' ' ' PRO . 22.3 pt-20 -142.07 138.75 17.13 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.234 -0.916 . . . . 0.0 109.3 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.484 ' HD2' ' HB2' ' A' ' 129' ' ' GLU . 47.7 Cg_endo -35.62 124.11 0.26 Allowed 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.107 1.872 . . . . 0.0 111.721 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 106.25 -0.47 37.83 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.44 ' HG3' ' O ' ' A' ' 129' ' ' GLU . 75.5 mt-10 -98.21 152.04 19.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.242 -1.152 . . . . 0.0 109.611 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.498 ' SD ' ' CG2' ' A' ' 147' ' ' VAL . 68.3 mmm -92.16 148.75 21.92 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.192 -0.943 . . . . 0.0 109.327 179.826 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.425 HG12 ' HB ' ' A' ' 178' ' ' VAL . 2.5 t -135.99 178.92 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.166 -0.959 . . . . 0.0 109.325 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.462 ' NH2' ' OD1' ' A' ' 145' ' ' ASN . 74.8 mtp85 -134.17 143.96 48.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.179 -0.951 . . . . 0.0 109.343 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.46 ' O ' ' N ' ' A' ' 143' ' ' ASP . 59.0 t -115.43 130.18 70.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.216 -0.927 . . . . 0.0 109.452 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 30.3 p30 -127.89 14.77 6.89 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.298 -0.876 . . . . 0.0 109.482 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.43 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 59.1 t0 -135.82 147.6 48.36 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.292 -0.88 . . . . 0.0 109.475 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.43 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 73.85 172.15 25.31 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -51.35 -21.96 10.98 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.602 2.201 . . . . 0.0 111.69 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . 0.406 ' CZ ' HG22 ' A' ' 169' ' ' THR . 98.3 m-85 -85.73 8.94 17.87 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.271 -0.893 . . . . 0.0 109.373 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' ALA . . . . . 0.454 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -64.02 145.27 56.19 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.241 -0.912 . . . . 0.0 109.558 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.46 ' N ' ' O ' ' A' ' 136' ' ' VAL . 31.6 m-20 64.96 46.82 2.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.259 -0.9 . . . . 0.0 109.593 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.427 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 44.9 m-85 -145.46 126.49 14.59 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.246 -0.909 . . . . 0.0 109.535 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . 0.462 ' OD1' ' NH2' ' A' ' 135' ' ' ARG . 69.9 m-20 -79.4 137.54 37.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.224 -0.923 . . . . 0.0 109.45 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -149.22 166.78 29.53 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.52 ' O ' ' CG1' ' A' ' 160' ' ' VAL . 15.1 t -108.79 154.87 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.255 -1.144 . . . . 0.0 109.406 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.466 ' O ' ' HA ' ' A' ' 130' ' ' PRO . 1.7 p -96.23 114.93 34.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.323 -0.861 . . . . 0.0 109.356 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.471 ' O ' ' CG ' ' A' ' 150' ' ' GLU . 74.9 mm-40 -75.94 -34.08 59.85 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.3 -0.875 . . . . 0.0 109.315 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.471 ' CG ' ' O ' ' A' ' 149' ' ' GLU . 94.7 mt-10 -158.11 159.15 35.93 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.36 -0.838 . . . . 0.0 109.415 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 128' ' ' PHE . 26.3 t -127.59 151.02 33.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.22 -0.925 . . . . 0.0 109.563 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' ASP . . . . . 0.477 ' O ' ' N ' ' A' ' 156' ' ' SER . 83.2 m-20 -120.71 84.46 2.23 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.339 -0.85 . . . . 0.0 109.342 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -57.4 -33.72 68.15 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.234 -0.916 . . . . 0.0 109.502 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -64.75 -41.48 95.88 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.167 -0.958 . . . . 0.0 109.529 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 29.5 mttt -97.09 -3.77 40.66 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.29 -0.881 . . . . 0.0 109.591 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' SER . . . . . 0.477 ' N ' ' O ' ' A' ' 152' ' ' ASP . 31.8 m 56.95 52.46 9.25 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.194 -0.941 . . . . 0.0 109.543 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 48.7 mmm-85 -137.06 155.82 49.17 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.258 -0.901 . . . . 0.0 109.355 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' LEU . . . . . 0.602 HD13 ' CD1' ' A' ' 175' ' ' PHE . 5.0 mp -115.87 139.26 50.38 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.201 -0.937 . . . . 0.0 109.643 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . 0.445 ' HD2' ' HB2' ' A' ' 150' ' ' GLU . 84.1 mttt -101.45 89.36 3.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.213 -0.929 . . . . 0.0 109.178 179.653 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . 0.52 ' CG1' ' O ' ' A' ' 147' ' ' VAL . 24.6 t -114.58 148.64 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.268 -0.895 . . . . 0.0 109.875 -179.617 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 161' ' ' SER . . . . . 0.458 ' HB2' ' HA ' ' A' ' 170' ' ' PRO . 43.9 t -119.37 131.17 55.65 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.378 -0.826 . . . . 0.0 109.242 179.769 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 162' ' ' VAL . . . . . 0.407 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 15.5 t -100.53 134.03 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.209 -0.932 . . . . 0.0 109.697 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 37.2 t . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.229 -0.919 . . . . 0.0 109.275 179.777 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 86.3 mtt-85 . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -72.16 141.84 49.09 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.352 -0.842 . . . . 0.0 109.463 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 169' ' ' THR . . . . . 0.406 HG22 ' CZ ' ' A' ' 141' ' ' PHE . 32.8 m -128.27 68.71 77.3 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.206 -0.934 . . . . 0.0 109.475 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.458 ' HA ' ' HB2' ' A' ' 161' ' ' SER . 49.4 Cg_endo -45.55 106.64 0.09 OUTLIER 'Trans proline' 0 C--O 1.214 -0.694 0 C-N-CA 122.703 2.269 . . . . 0.0 111.768 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 21.9 m -133.42 156.49 41.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.219 -0.926 . . . . 0.0 109.565 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.452 ' O ' HD12 ' A' ' 173' ' ' LEU . 94.6 mt-10 -105.39 129.97 53.59 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.301 -0.874 . . . . 0.0 109.334 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . 0.581 ' CD2' ' N ' ' A' ' 173' ' ' LEU . 1.9 mm? -119.46 157.81 27.5 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.189 -0.945 . . . . 0.0 109.618 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 174' ' ' ASP . . . . . 0.448 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 91.1 m-20 -79.64 157.89 27.17 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.352 -0.843 . . . . 0.0 109.573 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.602 ' CD1' HD13 ' A' ' 158' ' ' LEU . 3.6 m-85 -49.71 -49.39 48.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.305 -0.872 . . . . 0.0 109.785 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 11.2 m -71.15 -24.74 62.32 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.237 -0.914 . . . . 0.0 109.692 -179.754 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 177' ' ' GLN . . . . . 0.448 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 81.7 mt-30 -70.36 -24.72 63.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.218 -0.926 . . . . 0.0 109.722 -179.813 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.508 HG13 ' CB ' ' A' ' 173' ' ' LEU . 17.5 m -131.06 161.82 40.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.189 -0.945 . . . . 0.0 109.511 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 179' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -120.67 145.46 47.42 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.296 -0.878 . . . . 0.0 109.473 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 30.2 tttm -69.67 134.61 48.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.302 -0.874 . . . . 0.0 109.481 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.495 0 O-C-N 121.163 -0.96 . . . . 0.0 109.485 179.985 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.633 ' CD1' ' CD1' ' A' ' 158' ' ' LEU . 69.1 m-85 . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.462 ' HB3' ' HD2' ' A' ' 130' ' ' PRO . 1.2 mp0 -109.24 138.16 20.4 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.296 -0.878 . . . . 0.0 109.399 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.462 ' HD2' ' HB3' ' A' ' 129' ' ' GLU . 50.6 Cg_endo -39.68 133.99 1.57 Allowed 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.549 2.166 . . . . 0.0 111.765 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 84.69 8.45 82.83 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 45.7 tp10 -102.25 135.04 44.55 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.263 -1.14 . . . . 0.0 109.443 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 76.3 mtp -70.28 148.17 48.83 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.248 -0.908 . . . . 0.0 109.456 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.415 HG13 ' O ' ' A' ' 179' ' ' GLU . 2.5 t -136.72 179.08 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.26 -0.9 . . . . 0.0 109.353 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.502 ' N ' ' O ' ' A' ' 179' ' ' GLU . 70.3 ttt180 -136.51 143.12 43.59 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.263 -0.898 . . . . 0.0 109.43 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.453 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 60.3 t -111.16 124.86 68.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.258 -0.902 . . . . 0.0 109.524 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 26.4 p30 -124.77 22.31 8.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -0.905 . . . . 0.0 109.511 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -145.15 140.98 28.35 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.328 -0.858 . . . . 0.0 109.479 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 81.62 -179.82 53.26 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -58.67 -20.18 49.35 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.679 2.252 . . . . 0.0 111.764 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . 0.55 ' CZ ' HG13 ' A' ' 171' ' ' VAL . 99.2 m-85 -87.38 10.15 18.33 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.239 -0.913 . . . . 0.0 109.379 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' ALA . . . . . 0.505 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -64.17 152.99 39.21 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.282 -0.886 . . . . 0.0 109.59 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.465 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 58.8 m-20 63.65 42.57 6.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.3 -0.875 . . . . 0.0 109.676 179.746 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.536 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 58.8 m-85 -145.51 152.64 40.08 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.164 -0.96 . . . . 0.0 109.494 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 43.7 p-10 -113.63 167.06 10.92 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.238 -0.914 . . . . 0.0 109.395 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 179.35 -170.45 42.03 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.479 HG11 ' N ' ' A' ' 148' ' ' VAL . 43.0 t -129.11 150.43 34.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.225 -1.162 . . . . 0.0 109.517 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.479 ' N ' HG11 ' A' ' 147' ' ' VAL . 2.5 p -91.05 113.83 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.203 -0.936 . . . . 0.0 109.497 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 75.8 mm-40 -67.02 -37.1 83.54 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.222 -0.924 . . . . 0.0 109.445 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.406 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 94.9 mt-10 -153.97 163.38 40.15 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.223 -0.923 . . . . 0.0 109.501 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.506 ' CG1' ' CD2' ' A' ' 158' ' ' LEU . 45.7 t -127.27 146.32 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.247 -0.908 . . . . 0.0 109.535 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -133.02 90.88 2.8 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.277 -0.89 . . . . 0.0 109.5 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -62.93 -38.82 92.54 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.214 -0.929 . . . . 0.0 109.502 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -61.25 -41.7 97.35 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.48 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.441 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 60.2 mttm -92.23 -2.25 56.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -0.893 . . . . 0.0 109.601 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' SER . . . . . 0.465 ' HA ' ' CZ ' ' A' ' 175' ' ' PHE . 12.9 m 50.23 52.52 14.59 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.28 -0.887 . . . . 0.0 109.587 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' ARG . . . . . 0.441 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 13.7 mmt85 -146.15 142.77 28.79 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.295 -0.878 . . . . 0.0 109.468 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' LEU . . . . . 0.633 ' CD1' ' CD1' ' A' ' 128' ' ' PHE . 49.0 mt -116.34 133.19 56.29 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.196 -0.94 . . . . 0.0 109.497 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . 0.435 ' O ' ' HA ' ' A' ' 148' ' ' VAL . 65.5 mttm -87.39 100.64 12.88 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.282 -0.886 . . . . 0.0 109.346 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . 0.461 HG11 ' O ' ' A' ' 147' ' ' VAL . 57.6 t -128.34 138.75 53.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.176 -0.952 . . . . 0.0 109.524 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 161' ' ' SER . . . . . 0.407 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 88.3 p -107.2 148.13 29.28 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.272 -0.893 . . . . 0.0 109.431 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 162' ' ' VAL . . . . . 0.536 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 3.8 t -115.33 130.02 70.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.211 -0.931 . . . . 0.0 109.637 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 33.2 t . . . . . 0 N--CA 1.488 1.454 0 O-C-N 121.221 -0.924 . . . . 0.0 109.153 179.639 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 46.0 tpt85 . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 121.303 0.573 . . . . 0.0 109.546 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -72.76 138.89 46.76 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.206 -0.934 . . . . 0.0 109.477 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 169' ' ' THR . . . . . 0.447 ' O ' HG11 ' A' ' 171' ' ' VAL . 10.1 m -122.53 75.78 44.88 Favored Pre-proline 0 N--CA 1.488 1.465 0 O-C-N 121.128 -0.983 . . . . 0.0 109.484 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.4 Cg_endo -56.13 110.73 0.61 Allowed 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.572 2.181 . . . . 0.0 111.734 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.55 HG13 ' CZ ' ' A' ' 141' ' ' PHE . 16.5 m -129.6 154.87 40.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.26 -0.9 . . . . 0.0 109.502 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.417 ' O ' HD11 ' A' ' 173' ' ' LEU . 95.7 mt-10 -100.69 125.88 47.16 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.222 -0.923 . . . . 0.0 109.459 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . 0.569 ' CD2' ' N ' ' A' ' 173' ' ' LEU . 2.6 mm? -122.93 147.18 46.9 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.311 -0.868 . . . . 0.0 109.434 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 174' ' ' ASP . . . . . 0.435 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 90.3 m-20 -65.41 169.14 6.25 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.209 -0.932 . . . . 0.0 109.457 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.565 ' N ' ' CD1' ' A' ' 175' ' ' PHE . 2.3 m-30 -64.4 -36.83 85.44 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.178 -0.951 . . . . 0.0 109.462 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 86.1 p -80.07 -25.87 39.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.248 -0.907 . . . . 0.0 109.429 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 177' ' ' GLN . . . . . 0.435 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 86.2 mt-30 -66.57 -27.3 67.62 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.189 -0.945 . . . . 0.0 109.422 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.507 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 4.6 m -123.89 156.73 30.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.291 -0.881 . . . . 0.0 109.499 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 179' ' ' GLU . . . . . 0.502 ' O ' ' N ' ' A' ' 135' ' ' ARG . 83.6 tt0 -116.51 156.17 27.37 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.31 -0.869 . . . . 0.0 109.463 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 180' ' ' LYS . . . . . 0.432 ' HG2' ' CE2' ' A' ' 128' ' ' PHE . 54.4 mttt -69.89 142.88 52.93 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.233 -0.917 . . . . 0.0 109.481 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.578 0 O-C-N 121.267 -0.895 . . . . 0.0 109.472 179.999 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.428 ' CE1' ' HG2' ' A' ' 180' ' ' LYS . 50.8 m-85 . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.519 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.0 OUTLIER -134.57 156.91 78.36 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.312 -0.868 . . . . 0.0 109.454 179.99 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.519 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.2 Cg_endo -48.66 130.31 22.1 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.626 2.217 . . . . 0.0 111.819 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 90.15 10.26 64.48 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -113.42 138.9 49.42 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.243 -1.151 . . . . 0.0 109.51 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 87.1 mtp -79.77 149.25 31.16 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.294 -0.879 . . . . 0.0 109.527 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.52 ' CG2' HG21 ' A' ' 148' ' ' VAL . 2.5 t -131.93 179.08 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.314 -0.866 . . . . 0.0 109.387 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.504 ' N ' ' O ' ' A' ' 179' ' ' GLU . 24.4 tpt180 -130.88 138.92 50.03 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.284 -0.885 . . . . 0.0 109.365 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.44 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 28.7 t -103.98 130.56 54.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.24 -0.912 . . . . 0.0 109.539 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . 0.428 ' OD1' ' C ' ' A' ' 137' ' ' ASN . 22.2 p30 -132.03 18.08 4.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.324 -0.86 . . . . 0.0 109.403 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.473 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 59.7 t0 -140.66 148.67 41.19 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.204 -0.935 . . . . 0.0 109.499 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.473 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 73.0 172.85 23.57 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -52.99 -19.83 12.24 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.652 2.235 . . . . 0.0 111.786 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . 0.545 ' CE1' HG13 ' A' ' 162' ' ' VAL . 97.9 m-85 -87.43 10.31 17.96 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.183 -0.948 . . . . 0.0 109.444 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' ALA . . . . . 0.499 ' O ' ' CB ' ' A' ' 143' ' ' ASP . . . -66.29 147.77 52.83 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.256 -0.902 . . . . 0.0 109.485 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.499 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 24.9 t0 74.34 28.26 1.37 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.291 -0.881 . . . . 0.0 109.471 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -134.38 153.27 51.99 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.292 -0.88 . . . . 0.0 109.466 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 43.2 p-10 -113.77 165.54 12.45 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.258 -0.901 . . . . 0.0 109.425 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -174.07 -177.1 43.0 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.506 HG12 ' N ' ' A' ' 148' ' ' VAL . 44.2 t -117.27 161.28 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.213 -1.169 . . . . 0.0 109.477 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.52 HG21 ' CG2' ' A' ' 134' ' ' VAL . 79.4 t -93.4 96.25 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.213 -0.929 . . . . 0.0 109.524 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -66.02 -31.92 73.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.247 -0.908 . . . . 0.0 109.429 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -148.83 150.25 32.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.286 -0.884 . . . . 0.0 109.415 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.46 HG22 ' CG1' ' A' ' 148' ' ' VAL . 45.3 t -124.19 149.99 28.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.214 -0.929 . . . . 0.0 109.516 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 95.2 m-20 -136.48 79.88 1.79 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.216 -0.928 . . . . 0.0 109.502 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 98.9 m-85 -63.64 -37.46 87.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.227 -0.921 . . . . 0.0 109.518 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -59.42 -46.45 88.68 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.185 -0.947 . . . . 0.0 109.528 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.456 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 58.1 mttt -90.72 0.5 57.4 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.268 -0.895 . . . . 0.0 109.548 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 31.1 t 56.06 52.82 9.89 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.196 -0.94 . . . . 0.0 109.485 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' ARG . . . . . 0.456 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 22.9 mmt85 -140.29 140.51 35.72 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.275 -0.891 . . . . 0.0 109.367 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' LEU . . . . . 0.443 HD12 ' CD1' ' A' ' 175' ' ' PHE . 61.5 mt -110.06 129.47 55.68 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.162 -0.962 . . . . 0.0 109.522 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . 0.447 ' HG3' ' OE2' ' A' ' 172' ' ' GLU . 29.4 tttp -92.31 104.79 17.1 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.331 -0.856 . . . . 0.0 109.352 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . 0.421 HG11 ' O ' ' A' ' 147' ' ' VAL . 44.4 t -124.64 140.62 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.29 -0.881 . . . . 0.0 109.545 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 161' ' ' SER . . . . . 0.421 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 30.1 t -109.17 137.65 46.74 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.295 -0.878 . . . . 0.0 109.462 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 162' ' ' VAL . . . . . 0.545 HG13 ' CE1' ' A' ' 141' ' ' PHE . 9.4 p -104.9 138.86 27.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.185 -0.947 . . . . 0.0 109.636 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 163' ' ' SER . . . . . 0.43 ' HA ' ' O ' ' A' ' 167' ' ' ARG . 5.3 m . . . . . 0 N--CA 1.49 1.568 0 O-C-N 121.215 -0.928 . . . . 0.0 109.461 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 167' ' ' ARG . . . . . 0.43 ' O ' ' HA ' ' A' ' 163' ' ' SER . 62.2 mtt180 . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -98.19 139.12 34.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.232 -0.918 . . . . 0.0 109.497 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 169' ' ' THR . . . . . 0.512 ' HB ' ' CG1' ' A' ' 162' ' ' VAL . 6.0 m -129.81 74.04 80.98 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.287 -0.883 . . . . 0.0 109.453 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.421 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.7 Cg_endo -49.08 109.9 0.31 Allowed 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.603 2.202 . . . . 0.0 111.774 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 23.6 m -128.96 156.8 41.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.29 -0.881 . . . . 0.0 109.514 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.455 ' O ' HD21 ' A' ' 173' ' ' LEU . 75.7 mm-40 -101.6 130.65 47.97 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.293 -0.88 . . . . 0.0 109.465 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . 0.455 HD21 ' O ' ' A' ' 172' ' ' GLU . 51.8 mt -131.28 148.81 52.73 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.245 -0.91 . . . . 0.0 109.419 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -74.91 171.54 13.85 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.213 -0.93 . . . . 0.0 109.447 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.583 ' N ' ' CD1' ' A' ' 175' ' ' PHE . 2.7 m-30 -64.25 -36.81 85.29 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.318 -0.864 . . . . 0.0 109.439 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 83.4 p -79.58 -26.97 41.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.312 -0.867 . . . . 0.0 109.355 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 23.6 mt-30 -68.86 -19.69 64.25 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.26 -0.9 . . . . 0.0 109.381 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.457 ' HA ' ' O ' ' A' ' 135' ' ' ARG . 4.2 m -135.73 154.4 34.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.217 -0.927 . . . . 0.0 109.526 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 179' ' ' GLU . . . . . 0.504 ' O ' ' N ' ' A' ' 135' ' ' ARG . 37.7 mt-10 -120.07 166.53 13.27 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.278 -0.888 . . . . 0.0 109.427 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 180' ' ' LYS . . . . . 0.428 ' HG2' ' CE1' ' A' ' 128' ' ' PHE . 54.9 mttt -71.97 145.83 48.14 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.229 -0.919 . . . . 0.0 109.551 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.521 0 O-C-N 121.285 -0.884 . . . . 0.0 109.498 179.999 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 83.8 m-85 . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.452 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.0 OUTLIER -135.77 153.18 77.11 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.262 -0.899 . . . . 0.0 109.445 -179.968 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.452 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.4 Cg_endo -47.18 133.21 19.06 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.593 2.195 . . . . 0.0 111.793 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 86.51 3.1 84.42 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 50.2 tp10 -88.05 137.57 32.21 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.202 -1.175 . . . . 0.0 109.544 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' MET . . . . . 0.443 ' HA ' ' HA ' ' A' ' 147' ' ' VAL . 77.4 mtp -79.44 149.49 31.57 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.279 -0.888 . . . . 0.0 109.446 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.565 ' CG2' ' CG2' ' A' ' 148' ' ' VAL . 2.5 t -139.25 179.0 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.266 -0.896 . . . . 0.0 109.318 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.446 ' O ' ' HA ' ' A' ' 178' ' ' VAL . 18.5 mtp-105 -137.47 142.49 41.54 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.245 -0.91 . . . . 0.0 109.466 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.435 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 43.3 t -111.56 135.2 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.232 -0.917 . . . . 0.0 109.537 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 38.2 p30 -127.08 15.52 7.32 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.54 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.476 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 59.2 t0 -142.06 153.53 44.27 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.28 -0.888 . . . . 0.0 109.462 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.476 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 75.38 171.02 28.86 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -54.93 -18.47 16.73 Favored 'Trans proline' 0 C--O 1.214 -0.705 0 C-N-CA 122.578 2.185 . . . . 0.0 111.792 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . 0.557 ' CD1' HG13 ' A' ' 162' ' ' VAL . 90.5 m-85 -92.79 14.92 15.86 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.25 -0.906 . . . . 0.0 109.454 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' ALA . . . . . 0.461 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -66.23 149.51 50.23 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.301 -0.874 . . . . 0.0 109.523 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.461 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 43.7 m-20 64.03 46.85 3.58 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.232 -0.918 . . . . 0.0 109.473 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -140.79 142.01 34.73 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.295 -0.878 . . . . 0.0 109.531 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 73.0 m-20 -100.81 142.4 32.33 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.245 -0.909 . . . . 0.0 109.462 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.54 177.94 34.98 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.509 HG13 ' N ' ' A' ' 148' ' ' VAL . 49.0 t -114.29 164.2 10.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.184 -1.186 . . . . 0.0 109.438 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.565 ' CG2' ' CG2' ' A' ' 134' ' ' VAL . 98.6 t -93.16 95.54 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.257 -0.902 . . . . 0.0 109.553 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -67.42 -34.52 77.4 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.178 -0.951 . . . . 0.0 109.432 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.501 ' HB2' ' CD ' ' A' ' 159' ' ' LYS . 94.2 mt-10 -151.23 161.49 42.61 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.237 -0.915 . . . . 0.0 109.332 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 44.1 t -124.25 151.35 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.206 -0.934 . . . . 0.0 109.569 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -125.49 78.3 1.72 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.236 -0.915 . . . . 0.0 109.413 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 83.9 m-85 -63.68 -37.05 85.87 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.338 -0.851 . . . . 0.0 109.569 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -60.74 -42.83 98.15 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.247 -0.908 . . . . 0.0 109.532 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.458 ' O ' ' HG3' ' A' ' 157' ' ' ARG . 45.9 mttp -94.68 3.03 55.56 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.241 -0.912 . . . . 0.0 109.604 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 56.62 51.98 10.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.245 -0.909 . . . . 0.0 109.464 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' ARG . . . . . 0.458 ' HG3' ' O ' ' A' ' 155' ' ' LYS . 58.1 mtt180 -146.29 157.49 43.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.281 -0.887 . . . . 0.0 109.522 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' LEU . . . . . 0.432 ' CD2' ' CE1' ' A' ' 175' ' ' PHE . 18.2 mt -115.01 135.56 54.09 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.199 -0.938 . . . . 0.0 109.451 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . 0.501 ' CD ' ' HB2' ' A' ' 150' ' ' GLU . 31.0 tttp -87.99 105.92 17.78 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.269 -0.894 . . . . 0.0 109.318 179.855 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . 0.453 HG22 HG21 ' A' ' 148' ' ' VAL . 39.9 t -121.99 143.46 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.228 -0.92 . . . . 0.0 109.636 -179.833 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 93.5 p -110.31 145.24 37.79 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.263 -0.898 . . . . 0.0 109.41 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 162' ' ' VAL . . . . . 0.557 HG13 ' CD1' ' A' ' 141' ' ' PHE . 9.8 p -115.93 138.89 44.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.226 -0.921 . . . . 0.0 109.527 -179.899 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 37.8 t . . . . . 0 N--CA 1.489 1.511 0 O-C-N 121.256 -0.903 . . . . 0.0 109.408 179.892 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 65.7 mtt-85 . . . . . 0 N--CA 1.49 1.525 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -91.43 134.37 34.69 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.265 -0.897 . . . . 0.0 109.54 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 169' ' ' THR . . . . . 0.451 ' HB ' HG12 ' A' ' 162' ' ' VAL . 0.2 OUTLIER -128.3 74.11 79.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.312 -0.867 . . . . 0.0 109.458 -179.963 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -57.6 104.64 0.17 Allowed 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.598 2.198 . . . . 0.0 111.805 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.428 HG12 ' O ' ' A' ' 169' ' ' THR . 19.3 m -130.41 155.95 42.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.253 -0.905 . . . . 0.0 109.538 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.444 ' HG2' ' HA ' ' A' ' 159' ' ' LYS . 95.2 mt-10 -104.03 128.94 51.63 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.236 -0.915 . . . . 0.0 109.46 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . 0.572 ' CD2' ' N ' ' A' ' 173' ' ' LEU . 2.3 mm? -121.29 145.67 47.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.248 -0.907 . . . . 0.0 109.432 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 64.6 m-20 -65.63 173.48 2.76 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.263 -0.898 . . . . 0.0 109.38 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.492 ' N ' ' CD1' ' A' ' 175' ' ' PHE . 4.2 m-30 -66.65 -44.47 81.8 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.252 -0.905 . . . . 0.0 109.471 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 18.7 m -73.09 -23.62 60.55 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.201 -0.937 . . . . 0.0 109.384 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -70.78 -23.8 62.46 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.298 -0.876 . . . . 0.0 109.39 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.505 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 6.0 m -131.43 163.42 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.31 -0.869 . . . . 0.0 109.378 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 179' ' ' GLU . . . . . 0.457 ' O ' HG12 ' A' ' 134' ' ' VAL . 74.3 mm-40 -119.0 145.45 45.83 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.172 -0.955 . . . . 0.0 109.485 -179.895 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 18.3 tttm -64.87 140.0 58.82 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.202 -0.936 . . . . 0.0 109.463 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.542 0 O-C-N 121.207 -0.933 . . . . 0.0 109.44 -179.942 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.444 ' CE1' HG13 ' A' ' 134' ' ' VAL . 59.4 m-85 . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . 0.417 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 3.9 mt-10 -122.77 154.75 63.88 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.245 -0.909 . . . . 0.0 109.353 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.417 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.3 Cg_endo -51.15 129.05 27.15 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.597 2.198 . . . . 0.0 111.804 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 84.44 13.24 73.87 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.415 ' OE1' ' HA ' ' A' ' 128' ' ' PHE . 77.5 tt0 -104.13 133.83 48.4 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.236 -1.155 . . . . 0.0 109.443 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 85.7 mtp -69.36 144.97 53.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.316 -0.865 . . . . 0.0 109.545 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.518 HG21 ' CG2' ' A' ' 148' ' ' VAL . 2.5 t -133.11 178.87 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.344 -0.847 . . . . 0.0 109.363 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.507 ' N ' ' O ' ' A' ' 179' ' ' GLU . 40.9 ttm180 -129.15 136.08 49.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.275 -0.891 . . . . 0.0 109.326 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.454 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 39.5 t -106.34 130.34 58.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.215 -0.928 . . . . 0.0 109.529 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . 0.408 ' OD1' ' C ' ' A' ' 137' ' ' ASN . 43.0 p30 -127.61 17.4 6.93 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.282 -0.886 . . . . 0.0 109.443 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.462 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 60.1 t0 -136.98 147.17 46.13 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.306 -0.871 . . . . 0.0 109.468 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.462 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 74.58 173.62 30.93 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -57.2 -17.21 24.74 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.627 2.218 . . . . 0.0 111.883 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . 0.576 ' CD1' HG23 ' A' ' 162' ' ' VAL . 99.7 m-85 -90.23 12.68 17.35 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.13 -0.981 . . . . 0.0 109.452 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' ALA . . . . . 0.516 ' O ' ' CB ' ' A' ' 143' ' ' ASP . . . -72.5 147.15 46.3 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.276 -0.89 . . . . 0.0 109.509 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.516 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 24.9 t0 75.74 28.69 0.89 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.272 -0.893 . . . . 0.0 109.529 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.484 ' CD1' ' O ' ' A' ' 142' ' ' ALA . 91.8 m-85 -132.26 146.26 51.87 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.155 -0.966 . . . . 0.0 109.514 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -98.5 144.73 27.51 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.245 -0.909 . . . . 0.0 109.442 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -157.52 -178.77 31.89 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.519 HG12 ' N ' ' A' ' 148' ' ' VAL . 28.3 t -124.08 156.36 31.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.227 -1.161 . . . . 0.0 109.408 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.519 ' N ' HG12 ' A' ' 147' ' ' VAL . 87.5 t -89.25 100.54 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.206 -0.934 . . . . 0.0 109.388 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -65.47 -38.26 89.26 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.209 -0.932 . . . . 0.0 109.499 179.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -145.43 165.71 27.76 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.234 -0.916 . . . . 0.0 109.478 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.406 ' O ' ' OD1' ' A' ' 152' ' ' ASP . 41.2 t -129.45 150.82 34.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.3 -0.875 . . . . 0.0 109.497 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' ASP . . . . . 0.406 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 88.8 m-20 -134.45 83.2 2.02 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.268 -0.895 . . . . 0.0 109.413 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -64.77 -37.95 89.33 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.178 -0.951 . . . . 0.0 109.468 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . 0.412 ' OE1' ' HA ' ' A' ' 154' ' ' GLU . 72.8 mm-40 -60.53 -44.65 95.84 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.267 -0.896 . . . . 0.0 109.491 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.462 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 93.4 mttt -90.63 -1.0 57.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.306 -0.871 . . . . 0.0 109.559 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 48.9 m 54.32 53.09 11.41 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.146 -0.971 . . . . 0.0 109.495 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' ARG . . . . . 0.462 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 20.1 mmt85 -144.5 144.82 31.53 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.142 -0.973 . . . . 0.0 109.465 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' LEU . . . . . 0.456 ' HG ' ' CE1' ' A' ' 175' ' ' PHE . 55.6 mt -111.87 126.14 54.78 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.254 -0.904 . . . . 0.0 109.537 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 60.4 tttt -83.92 105.14 14.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.178 -0.952 . . . . 0.0 109.415 179.786 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 38.1 t -124.21 141.27 44.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.25 -0.906 . . . . 0.0 109.434 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.6 t -112.44 134.49 53.95 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.278 -0.889 . . . . 0.0 109.611 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 162' ' ' VAL . . . . . 0.576 HG23 ' CD1' ' A' ' 141' ' ' PHE . 3.7 t -88.84 130.32 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.234 -0.916 . . . . 0.0 109.47 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 59.3 m . . . . . 0 N--CA 1.489 1.525 0 O-C-N 121.228 -0.92 . . . . 0.0 109.387 179.939 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 30.5 ttp180 . . . . . 0 N--CA 1.493 1.717 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -63.16 136.71 57.91 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.243 -0.911 . . . . 0.0 109.292 179.841 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 169' ' ' THR . . . . . 0.419 HG23 ' CZ ' ' A' ' 141' ' ' PHE . 63.0 m -123.36 91.92 49.35 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.192 -0.943 . . . . 0.0 109.662 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -64.33 109.85 1.26 Allowed 'Trans proline' 0 C--O 1.216 -0.603 0 C-N-CA 122.502 2.134 . . . . 0.0 111.533 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.491 HG21 ' CD2' ' A' ' 173' ' ' LEU . 17.6 m -128.2 158.07 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.194 -0.942 . . . . 0.0 109.69 -179.806 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -100.04 125.07 46.05 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.383 -0.823 . . . . 0.0 109.348 179.843 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . 0.575 ' CD2' ' N ' ' A' ' 173' ' ' LEU . 1.7 mm? -120.48 145.63 47.07 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.203 -0.936 . . . . 0.0 109.493 -179.842 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 174' ' ' ASP . . . . . 0.434 ' OD1' ' HD3' ' A' ' 157' ' ' ARG . 88.3 m-20 -68.84 170.81 8.9 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.224 -0.923 . . . . 0.0 109.452 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.577 ' N ' ' CD1' ' A' ' 175' ' ' PHE . 2.5 m-30 -65.67 -44.21 86.95 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.217 -0.927 . . . . 0.0 109.436 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 11.1 m -76.0 -24.31 55.3 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.151 -0.968 . . . . 0.0 109.422 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 177' ' ' GLN . . . . . 0.433 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 86.5 mt-30 -69.68 -18.81 63.58 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.265 -0.897 . . . . 0.0 109.339 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.574 ' CG1' ' CB ' ' A' ' 173' ' ' LEU . 4.8 m -132.35 162.85 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.343 -0.848 . . . . 0.0 109.427 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 179' ' ' GLU . . . . . 0.507 ' O ' ' N ' ' A' ' 135' ' ' ARG . 60.7 mt-10 -126.38 161.73 27.18 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.29 -0.881 . . . . 0.0 109.554 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 84.5 mttt -67.36 144.28 55.91 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.204 -0.935 . . . . 0.0 109.447 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.566 0 O-C-N 121.202 -0.937 . . . . 0.0 109.481 179.959 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.428 ' CG ' HD13 ' A' ' 158' ' ' LEU . 85.8 m-85 . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -118.47 146.97 40.91 Favored Pre-proline 0 N--CA 1.489 1.488 0 O-C-N 121.296 -0.877 . . . . 0.0 109.47 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -48.09 126.63 13.66 Favored 'Trans proline' 0 C--O 1.214 -0.694 0 C-N-CA 122.576 2.184 . . . . 0.0 111.816 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . 0.44 ' C ' ' CG1' ' A' ' 147' ' ' VAL . . . 94.59 -5.25 70.04 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.528 ' O ' ' CG1' ' A' ' 147' ' ' VAL . 80.3 tt0 -79.21 148.42 32.25 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.124 -1.221 . . . . 0.0 109.467 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 64.1 mtp -82.08 146.49 29.62 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.26 -0.9 . . . . 0.0 109.545 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.454 HG13 ' O ' ' A' ' 179' ' ' GLU . 2.5 t -135.92 179.13 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.264 -0.898 . . . . 0.0 109.255 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' ARG . . . . . 0.461 ' O ' ' HB ' ' A' ' 178' ' ' VAL . 87.8 mtt180 -137.33 146.62 44.8 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.225 -0.922 . . . . 0.0 109.399 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . 0.474 HG11 ' CD1' ' A' ' 173' ' ' LEU . 39.3 t -117.01 134.73 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.212 -0.93 . . . . 0.0 109.558 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 30.7 p30 -128.45 14.7 6.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.233 -0.917 . . . . 0.0 109.48 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.452 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 57.8 t0 -147.17 153.4 39.83 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.253 -0.904 . . . . 0.0 109.396 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . 0.452 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 78.65 172.26 40.91 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -55.28 -19.1 20.41 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.571 2.181 . . . . 0.0 111.78 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . 0.569 ' CD1' HG11 ' A' ' 162' ' ' VAL . 86.3 m-85 -93.0 9.2 36.72 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.214 -0.929 . . . . 0.0 109.536 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' ALA . . . . . 0.464 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -61.79 146.38 49.66 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.217 -0.927 . . . . 0.0 109.562 -179.867 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' ASP . . . . . 0.464 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 18.0 m-20 65.86 47.83 1.97 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.296 -0.878 . . . . 0.0 109.592 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.46 ' HB3' HG21 ' A' ' 162' ' ' VAL . 43.9 m-85 -146.51 136.14 23.11 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.296 -0.877 . . . . 0.0 109.457 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 71.3 m-20 -94.03 141.02 29.01 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.236 -0.915 . . . . 0.0 109.419 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.14 -177.19 31.0 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' VAL . . . . . 0.528 ' CG1' ' O ' ' A' ' 132' ' ' GLU . 46.5 t -125.07 148.92 29.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.207 -1.172 . . . . 0.0 109.369 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.515 ' N ' HG13 ' A' ' 147' ' ' VAL . 2.5 p -85.67 102.2 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.192 -0.942 . . . . 0.0 109.552 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -68.33 -36.41 79.23 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.146 -0.971 . . . . 0.0 109.414 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -140.78 164.29 30.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.189 -0.944 . . . . 0.0 109.471 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . 0.44 HG13 ' N ' ' A' ' 152' ' ' ASP . 99.8 t -125.67 152.94 33.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.327 -0.858 . . . . 0.0 109.523 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' ASP . . . . . 0.44 ' N ' HG13 ' A' ' 151' ' ' VAL . 90.5 m-20 -130.53 88.43 2.63 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.319 -0.863 . . . . 0.0 109.386 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -69.58 -38.55 77.41 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.22 -0.925 . . . . 0.0 109.593 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -60.44 -46.64 89.29 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.213 -0.929 . . . . 0.0 109.45 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' LYS . . . . . 0.431 ' O ' ' HG3' ' A' ' 157' ' ' ARG . 32.0 mttt -89.32 -1.08 57.93 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.244 -0.91 . . . . 0.0 109.611 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 34.0 t 56.46 52.36 10.03 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.196 -0.94 . . . . 0.0 109.467 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' ARG . . . . . 0.44 ' O ' HD22 ' A' ' 158' ' ' LEU . 20.5 mtm180 -146.21 157.71 43.84 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.152 -0.967 . . . . 0.0 109.454 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' LEU . . . . . 0.53 ' CD2' ' CE1' ' A' ' 175' ' ' PHE . 13.9 mt -118.23 131.69 56.35 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.892 . . . . 0.0 109.531 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 20.9 tttp -84.37 106.77 16.23 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.295 -0.878 . . . . 0.0 109.443 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 47.5 t -124.86 140.72 47.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.162 -0.961 . . . . 0.0 109.56 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 161' ' ' SER . . . . . 0.403 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 23.0 t -104.3 141.88 35.53 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.439 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 162' ' ' VAL . . . . . 0.569 HG11 ' CD1' ' A' ' 141' ' ' PHE . 9.4 p -105.53 126.28 60.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.314 -0.867 . . . . 0.0 109.562 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 18.5 t . . . . . 0 N--CA 1.491 1.597 0 O-C-N 121.303 -0.873 . . . . 0.0 109.377 179.875 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 19.1 ttp180 . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -76.33 141.0 41.71 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.294 -0.879 . . . . 0.0 109.454 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 169' ' ' THR . . . . . 0.447 ' HB ' HG13 ' A' ' 162' ' ' VAL . 2.4 m -128.02 76.81 77.36 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.308 -0.87 . . . . 0.0 109.437 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.403 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.8 Cg_endo -55.27 106.51 0.19 Allowed 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.604 2.203 . . . . 0.0 111.852 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 18.9 m -129.61 157.84 42.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.461 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -102.1 128.54 48.53 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.24 -0.913 . . . . 0.0 109.477 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 173' ' ' LEU . . . . . 0.513 HD12 ' CG1' ' A' ' 178' ' ' VAL . 42.4 mt -124.86 144.13 50.47 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.29 -0.881 . . . . 0.0 109.513 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 24.6 m-20 -64.57 172.48 2.64 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.191 -0.943 . . . . 0.0 109.527 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 175' ' ' PHE . . . . . 0.53 ' CE1' ' CD2' ' A' ' 158' ' ' LEU . 4.5 m-30 -67.67 -44.41 77.89 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.166 -0.959 . . . . 0.0 109.501 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 15.0 m -71.33 -23.56 61.95 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.219 -0.925 . . . . 0.0 109.524 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 90.3 mt-30 -72.79 -23.53 60.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.177 -0.952 . . . . 0.0 109.431 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.513 ' CG1' HD12 ' A' ' 173' ' ' LEU . 4.5 m -128.16 161.26 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.253 -0.905 . . . . 0.0 109.401 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 179' ' ' GLU . . . . . 0.454 ' O ' HG13 ' A' ' 134' ' ' VAL . 95.0 mt-10 -116.74 149.97 39.02 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.179 -0.951 . . . . 0.0 109.559 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 180' ' ' LYS . . . . . 0.508 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 33.6 tttm -69.13 137.34 53.31 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.181 -0.949 . . . . 0.0 109.505 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.536 0 O-C-N 121.211 -0.931 . . . . 0.0 109.46 -179.972 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 6.3 ttm180 . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -56.6 145.93 78.51 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.62 2.213 . . . . 0.0 111.749 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 24.0 mttm -91.16 144.14 25.94 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.264 -0.898 . . . . 0.0 109.484 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.442 ' HA ' ' CE2' ' A' ' 128' ' ' PHE . 51.1 p -99.43 12.1 37.31 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.263 -0.898 . . . . 0.0 109.425 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.463 ' O ' ' HE3' ' A' ' 180' ' ' LYS . 64.6 mt -92.74 98.76 11.61 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.24 -0.912 . . . . 0.0 109.446 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.442 ' CE2' ' HA ' ' A' ' 126' ' ' THR . 79.8 m-85 -117.65 146.51 43.63 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.296 -0.878 . . . . 0.0 109.468 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.478 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 1.2 mt-10 -138.65 159.29 68.03 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.202 -0.937 . . . . 0.0 109.457 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.478 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.1 Cg_endo -53.53 129.41 33.68 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.547 2.165 . . . . 0.0 111.82 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 90.47 -1.2 78.82 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.441 ' HG2' ' O ' ' A' ' 129' ' ' GLU . 77.0 mm-40 -86.45 135.51 33.45 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.168 -1.195 . . . . 0.0 109.475 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.452 ' HA ' ' HA ' ' A' ' 147' ' ' VAL . 44.2 ttm -79.58 146.91 32.32 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.16 -0.963 . . . . 0.0 109.49 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.453 HG11 ' O ' ' A' ' 179' ' ' GLU . 2.5 t -131.55 179.24 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.266 -0.896 . . . . 0.0 109.324 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.457 ' O ' ' HA ' ' A' ' 178' ' ' VAL . 40.4 ttt180 -130.29 138.34 50.43 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.226 -0.921 . . . . 0.0 109.49 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.453 HG11 ' CB ' ' A' ' 141' ' ' PHE . 45.4 t -106.63 132.79 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.271 -0.893 . . . . 0.0 109.451 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 56.1 p30 -135.64 20.44 3.33 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.263 -0.898 . . . . 0.0 109.495 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.422 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 59.0 t0 -140.88 148.17 40.07 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.209 -0.932 . . . . 0.0 109.481 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.422 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 70.23 177.23 20.76 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -55.01 -20.17 22.37 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.562 2.175 . . . . 0.0 111.791 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . 0.453 ' CB ' HG11 ' A' ' 136' ' ' VAL . 98.7 m-85 -85.6 6.73 26.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.217 -0.927 . . . . 0.0 109.504 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' ALA . . . . . 0.458 ' O ' ' HB3' ' A' ' 143' ' ' ASP . . . -66.19 148.91 51.13 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.287 -0.883 . . . . 0.0 109.462 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.458 ' HB3' ' O ' ' A' ' 142' ' ' ALA . 35.5 t0 73.06 29.97 1.69 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.222 -0.924 . . . . 0.0 109.51 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.516 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 84.7 m-85 -138.12 151.52 47.86 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.249 -0.907 . . . . 0.0 109.511 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 43.3 p-10 -118.04 164.09 15.63 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.25 -0.906 . . . . 0.0 109.427 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -172.16 -173.73 39.07 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.452 ' HA ' ' HA ' ' A' ' 133' ' ' MET . 57.9 t -120.29 151.64 23.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.227 -1.161 . . . . 0.0 109.491 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.497 ' CG2' HG21 ' A' ' 151' ' ' VAL . 2.1 p -94.39 98.85 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.274 -0.892 . . . . 0.0 109.466 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 76.2 mm-40 -69.37 -36.69 77.09 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.215 -0.928 . . . . 0.0 109.425 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -134.44 149.63 50.77 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.261 -0.9 . . . . 0.0 109.464 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.516 HG11 ' CD2' ' A' ' 158' ' ' LEU . 48.0 t -127.3 150.22 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.233 -0.917 . . . . 0.0 109.477 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' ASP . . . . . 0.416 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 93.5 m-20 -136.2 87.77 2.33 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.261 -0.9 . . . . 0.0 109.466 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -66.31 -37.05 84.5 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.274 -0.891 . . . . 0.0 109.463 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 48.3 tp10 -62.62 -44.28 96.69 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.248 -0.907 . . . . 0.0 109.484 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.463 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 21.5 mttt -88.62 0.61 56.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.289 -0.882 . . . . 0.0 109.602 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' SER . . . . . 0.404 ' O ' ' OG ' ' A' ' 156' ' ' SER . 7.5 p 52.51 51.98 15.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.188 -0.945 . . . . 0.0 109.437 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . 0.463 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 41.0 mmm-85 -145.32 140.46 27.76 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.259 -0.901 . . . . 0.0 109.472 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' LEU . . . . . 0.516 ' CD2' HG11 ' A' ' 151' ' ' VAL . 35.2 mt -108.53 134.28 51.52 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.254 -0.904 . . . . 0.0 109.542 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 15.1 tttp -92.47 93.09 8.39 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.224 -0.923 . . . . 0.0 109.374 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . 0.45 HG23 ' HA ' ' A' ' 148' ' ' VAL . 41.4 t -124.13 142.01 42.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.222 -0.923 . . . . 0.0 109.519 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' SER . . . . . 0.471 ' CA ' ' HA ' ' A' ' 170' ' ' PRO . 86.7 p -106.31 147.7 28.87 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.263 -0.898 . . . . 0.0 109.436 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' VAL . . . . . 0.516 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 18.1 t -108.49 132.66 55.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.231 -0.918 . . . . 0.0 109.523 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 71.6 m -72.14 85.23 1.03 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.205 -0.934 . . . . 0.0 109.433 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.584 ' CG2' ' CD2' ' A' ' 165' ' ' PHE . 56.4 mt -108.32 139.89 28.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.265 -0.897 . . . . 0.0 109.485 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . 0.584 ' CD2' ' CG2' ' A' ' 164' ' ' ILE . 93.8 m-85 61.05 17.87 8.41 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.221 -0.925 . . . . 0.0 109.503 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 83.81 5.25 88.2 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 82.0 mtp180 -124.07 144.43 49.87 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.184 -1.186 . . . . 0.0 109.432 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -69.17 142.13 54.39 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.261 -0.9 . . . . 0.0 109.443 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 15.4 m -124.37 75.81 61.59 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.271 -0.893 . . . . 0.0 109.475 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.471 ' HA ' ' CA ' ' A' ' 161' ' ' SER . 50.0 Cg_endo -47.95 106.45 0.11 Allowed 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.642 2.228 . . . . 0.0 111.784 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 21.2 m -128.74 155.12 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.293 -0.879 . . . . 0.0 109.478 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.456 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.0 mt-10 -95.04 123.33 38.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.924 . . . . 0.0 109.458 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . 0.456 HD23 ' O ' ' A' ' 172' ' ' GLU . 67.2 mt -125.98 147.91 49.41 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.231 -0.918 . . . . 0.0 109.477 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' ASP . . . . . 0.424 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 91.7 m-20 -75.84 164.87 25.78 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.216 -0.927 . . . . 0.0 109.441 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.56 ' N ' ' CD1' ' A' ' 175' ' ' PHE . 2.3 m-30 -60.69 -41.16 94.57 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.211 -0.931 . . . . 0.0 109.495 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 19.3 m -76.06 -26.28 56.38 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.258 -0.901 . . . . 0.0 109.384 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' GLN . . . . . 0.424 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 87.9 mt-30 -69.04 -25.8 64.65 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.31 -0.869 . . . . 0.0 109.465 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.457 ' HA ' ' O ' ' A' ' 135' ' ' ARG . 13.9 m -128.41 158.72 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.242 -0.911 . . . . 0.0 109.434 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 179' ' ' GLU . . . . . 0.453 ' O ' HG11 ' A' ' 134' ' ' VAL . 77.8 mt-10 -113.13 149.24 33.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.232 -0.917 . . . . 0.0 109.49 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 180' ' ' LYS . . . . . 0.463 ' HE3' ' O ' ' A' ' 127' ' ' LEU . 30.6 tttm -69.94 135.79 49.85 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.241 -0.912 . . . . 0.0 109.479 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.587 0 O-C-N 121.266 -0.896 . . . . 0.0 109.454 -179.986 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 4.0 tmm_? . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -60.39 143.15 99.47 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.547 2.165 . . . . 0.0 111.829 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . 0.426 ' HG2' HD12 ' A' ' 127' ' ' LEU . 84.4 tttt -126.98 140.27 52.43 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.21 -0.931 . . . . 0.0 109.433 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.551 ' HB ' ' CE2' ' A' ' 128' ' ' PHE . 6.2 p -96.21 95.34 8.05 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.269 -0.895 . . . . 0.0 109.537 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.567 ' CD1' ' N ' ' A' ' 127' ' ' LEU . 3.7 mp -102.24 86.0 2.75 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.246 -0.909 . . . . 0.0 109.507 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.571 ' CE1' ' HG3' ' A' ' 180' ' ' LYS . 74.5 m-85 -81.71 130.51 35.08 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.17 -0.956 . . . . 0.0 109.464 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.436 ' HB2' ' HG3' ' A' ' 132' ' ' GLU . 28.9 mt-10 -131.55 153.85 81.68 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.252 -0.905 . . . . 0.0 109.508 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.407 ' HD2' ' HB3' ' A' ' 129' ' ' GLU . 50.9 Cg_endo -52.96 128.14 27.68 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 122.605 2.203 . . . . 0.0 111.776 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 86.5 10.16 74.15 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.436 ' HG3' ' HB2' ' A' ' 129' ' ' GLU . 72.7 mm-40 -96.13 127.26 41.98 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.304 -1.115 . . . . 0.0 109.432 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 5.8 ttm -63.71 134.71 55.84 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.263 -0.898 . . . . 0.0 109.501 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.433 HG12 ' HB ' ' A' ' 178' ' ' VAL . 2.5 t -123.5 179.03 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.228 -0.92 . . . . 0.0 109.394 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.512 ' N ' ' O ' ' A' ' 179' ' ' GLU . 55.1 ttt-85 -135.95 133.53 37.68 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.264 -0.898 . . . . 0.0 109.288 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.454 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 90.7 t -106.03 132.06 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.202 -0.937 . . . . 0.0 109.584 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . 0.438 ' HB3' ' NH1' ' A' ' 135' ' ' ARG . 32.3 p30 -130.34 18.8 5.35 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.227 -0.921 . . . . 0.0 109.45 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -134.53 143.77 47.62 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.248 -0.907 . . . . 0.0 109.4 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 72.15 177.16 29.01 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -51.14 -20.95 8.44 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.638 2.225 . . . . 0.0 111.757 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . 0.454 ' O ' ' HB ' ' A' ' 136' ' ' VAL . 93.8 m-85 -86.94 12.92 10.02 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.896 . . . . 0.0 109.45 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' ALA . . . . . 0.464 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -69.57 143.71 53.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.25 -0.907 . . . . 0.0 109.594 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.464 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 19.3 m-20 65.9 50.52 1.49 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.57 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.455 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 49.9 m-85 -144.11 146.26 32.67 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.238 -0.914 . . . . 0.0 109.455 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -99.64 141.35 32.56 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.266 -0.896 . . . . 0.0 109.548 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.44 -173.85 27.39 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.379 -1.488 . . . . 0.0 109.379 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.472 HG13 ' N ' ' A' ' 148' ' ' VAL . 40.1 t -132.19 152.34 36.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.256 -1.143 . . . . 0.0 109.463 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.472 ' N ' HG13 ' A' ' 147' ' ' VAL . 2.3 p -95.47 118.09 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.227 -0.921 . . . . 0.0 109.486 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 77.1 mm-40 -73.78 -42.18 61.38 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.331 -0.856 . . . . 0.0 109.364 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.444 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 95.3 mt-10 -147.21 162.56 38.64 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.298 -0.876 . . . . 0.0 109.431 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.501 ' CG1' ' CD2' ' A' ' 158' ' ' LEU . 49.1 t -129.03 153.2 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.216 -0.927 . . . . 0.0 109.459 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' ASP . . . . . 0.4 ' O ' ' N ' ' A' ' 156' ' ' SER . 91.4 m-20 -128.7 97.37 4.66 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.176 -0.953 . . . . 0.0 109.442 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 90.3 m-85 -66.51 -41.59 88.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.232 -0.917 . . . . 0.0 109.453 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -63.12 -40.41 97.54 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.283 -0.885 . . . . 0.0 109.504 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 82.7 mttt -93.36 -0.66 56.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.246 -0.909 . . . . 0.0 109.592 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' SER . . . . . 0.4 ' N ' ' O ' ' A' ' 152' ' ' ASP . 4.5 m 46.22 52.27 10.54 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.239 -0.913 . . . . 0.0 109.426 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 7.4 tpt180 -138.08 140.62 40.09 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.298 -0.876 . . . . 0.0 109.451 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' LEU . . . . . 0.501 ' CD2' ' CG1' ' A' ' 151' ' ' VAL . 41.1 mt -109.04 137.49 46.87 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.243 -0.911 . . . . 0.0 109.597 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . 0.444 ' HD2' ' HB2' ' A' ' 150' ' ' GLU . 21.3 mttp -99.78 96.7 7.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.259 -0.9 . . . . 0.0 109.377 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . 0.451 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 38.6 t -124.5 139.65 50.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.187 -0.946 . . . . 0.0 109.498 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 60.7 p -108.67 147.98 31.1 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.32 -0.862 . . . . 0.0 109.435 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' VAL . . . . . 0.447 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 4.2 t -117.69 133.01 65.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.158 -0.964 . . . . 0.0 109.472 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 31.0 t -83.73 83.04 8.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.306 -0.871 . . . . 0.0 109.457 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.514 HD11 HG21 ' A' ' 164' ' ' ILE . 44.2 mt -102.58 139.26 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.155 -0.966 . . . . 0.0 109.476 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . 0.506 ' CD2' ' O ' ' A' ' 165' ' ' PHE . 60.0 t80 63.65 11.91 6.14 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.289 -0.882 . . . . 0.0 109.515 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 85.81 4.11 85.23 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 72.3 ttt180 -116.63 139.07 50.94 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.214 -1.168 . . . . 0.0 109.448 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -68.03 138.73 56.07 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.279 -0.888 . . . . 0.0 109.491 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' THR . . . . . 0.421 ' O ' HG11 ' A' ' 171' ' ' VAL . 1.3 m -125.44 77.91 68.33 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.214 -0.929 . . . . 0.0 109.435 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -53.91 103.66 0.1 OUTLIER 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.668 2.245 . . . . 0.0 111.78 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.421 HG11 ' O ' ' A' ' 169' ' ' THR . 31.4 m -129.8 154.46 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.242 -0.912 . . . . 0.0 109.434 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.465 ' O ' HD12 ' A' ' 173' ' ' LEU . 94.9 mt-10 -108.17 130.18 55.14 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.243 -0.911 . . . . 0.0 109.529 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . 0.579 ' CD2' ' N ' ' A' ' 173' ' ' LEU . 2.5 mm? -126.96 157.59 39.1 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.284 -0.885 . . . . 0.0 109.477 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' ASP . . . . . 0.4 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 94.2 m-20 -77.04 176.19 8.89 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.261 -0.899 . . . . 0.0 109.394 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.421 ' N ' ' CD1' ' A' ' 175' ' ' PHE . 7.3 m-30 -65.87 -43.15 89.19 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.222 -0.924 . . . . 0.0 109.417 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 82.4 p -76.77 -26.04 54.07 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.214 -0.929 . . . . 0.0 109.518 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 177' ' ' GLN . . . . . 0.4 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 86.5 mt-30 -68.03 -18.95 64.85 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.264 -0.897 . . . . 0.0 109.538 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.456 HG11 ' HB3' ' A' ' 173' ' ' LEU . 27.2 m -138.48 162.13 30.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.232 -0.918 . . . . 0.0 109.51 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 179' ' ' GLU . . . . . 0.512 ' O ' ' N ' ' A' ' 135' ' ' ARG . 35.7 mt-10 -127.38 155.9 42.88 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.24 -0.912 . . . . 0.0 109.476 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 180' ' ' LYS . . . . . 0.571 ' HG3' ' CE1' ' A' ' 128' ' ' PHE . 9.5 mtmt -85.48 143.72 28.38 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.245 -0.91 . . . . 0.0 109.488 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.565 0 O-C-N 121.241 -0.912 . . . . 0.0 109.499 179.971 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.5 ' N ' ' CD ' ' A' ' 124' ' ' PRO . 5.4 mtt85 . . . . . 0 N--CA 1.491 1.607 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.5 ' CD ' ' N ' ' A' ' 123' ' ' ARG . 49.5 Cg_endo -56.06 143.99 81.43 Favored 'Trans proline' 0 C--O 1.216 -0.623 0 C-N-CA 122.516 2.144 . . . . 0.0 111.765 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . 0.429 ' O ' ' HG3' ' A' ' 180' ' ' LYS . 96.0 mttt -112.56 143.91 42.93 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.285 -0.885 . . . . 0.0 109.519 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.426 ' HA ' ' HE3' ' A' ' 180' ' ' LYS . 44.8 p -108.49 20.79 18.15 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.221 -0.924 . . . . 0.0 109.402 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 58.4 mt -83.37 99.66 10.19 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.271 -0.893 . . . . 0.0 109.532 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.521 ' CE2' ' HD3' ' A' ' 180' ' ' LYS . 71.1 m-85 -82.4 132.48 35.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.242 -0.911 . . . . 0.0 109.431 -179.867 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.464 ' HB2' ' HD2' ' A' ' 130' ' ' PRO . 2.6 pp20? -128.13 138.65 33.44 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.325 -0.859 . . . . 0.0 109.464 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.464 ' HD2' ' HB2' ' A' ' 129' ' ' GLU . 49.3 Cg_endo -39.0 128.9 1.35 Allowed 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.469 2.112 . . . . 0.0 111.749 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 89.65 10.08 65.66 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.448 ' OE2' ' HD2' ' A' ' 180' ' ' LYS . 84.8 tt0 -104.16 135.15 46.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.341 -1.094 . . . . 0.0 109.458 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.406 ' HG2' HG23 ' A' ' 147' ' ' VAL . 82.9 mtp -71.9 139.94 49.02 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.201 -0.937 . . . . 0.0 109.534 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.451 HG12 ' O ' ' A' ' 179' ' ' GLU . 2.5 t -127.03 178.59 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.183 -0.948 . . . . 0.0 109.372 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.488 ' N ' ' O ' ' A' ' 179' ' ' GLU . 75.2 ttt-85 -126.56 144.55 50.84 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.274 -0.891 . . . . 0.0 109.549 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.461 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 45.0 t -112.15 132.3 61.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.236 -0.915 . . . . 0.0 109.453 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . 0.411 ' C ' ' OD1' ' A' ' 137' ' ' ASN . 48.0 p30 -131.83 14.65 4.82 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.233 -0.917 . . . . 0.0 109.474 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 59.1 t0 -142.18 143.15 32.81 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.234 -0.916 . . . . 0.0 109.49 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 79.87 171.2 41.96 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -55.73 -21.96 34.51 Favored 'Trans proline' 0 C--O 1.216 -0.625 0 C-N-CA 122.601 2.201 . . . . 0.0 111.813 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . 0.461 ' O ' ' HB ' ' A' ' 136' ' ' VAL . 99.0 m-85 -85.21 5.67 29.2 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.13 -0.981 . . . . 0.0 109.54 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' ALA . . . . . 0.493 ' O ' ' CB ' ' A' ' 143' ' ' ASP . . . -69.15 149.01 49.11 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.272 -0.892 . . . . 0.0 109.416 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.493 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 30.3 t0 75.13 28.67 1.01 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.174 -0.954 . . . . 0.0 109.45 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.445 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 90.2 m-85 -135.77 145.0 46.1 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.263 -0.898 . . . . 0.0 109.456 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 74.0 m-20 -97.9 140.22 32.58 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.26 -0.9 . . . . 0.0 109.415 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -153.85 -173.06 22.53 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.478 HG11 ' N ' ' A' ' 148' ' ' VAL . 44.9 t -129.08 152.63 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.248 -1.148 . . . . 0.0 109.418 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.478 ' N ' HG11 ' A' ' 147' ' ' VAL . 2.5 p -92.52 107.97 19.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.294 -0.879 . . . . 0.0 109.398 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.449 ' HB2' ' HE3' ' A' ' 159' ' ' LYS . 75.1 mm-40 -70.63 -39.23 73.83 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.224 -0.923 . . . . 0.0 109.365 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.457 ' HB2' ' HE2' ' A' ' 159' ' ' LYS . 92.4 mt-10 -139.41 157.5 45.75 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.239 -0.913 . . . . 0.0 109.393 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.474 HG11 ' CD2' ' A' ' 158' ' ' LEU . 48.5 t -127.29 151.04 33.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.274 -0.891 . . . . 0.0 109.481 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' ASP . . . . . 0.401 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 88.1 m-20 -134.43 87.7 2.38 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.223 -0.923 . . . . 0.0 109.436 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -63.34 -39.45 94.59 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.259 -0.901 . . . . 0.0 109.461 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -62.27 -42.15 99.1 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.18 -0.95 . . . . 0.0 109.506 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.412 ' O ' ' C ' ' A' ' 156' ' ' SER . 43.5 mttp -91.19 5.17 50.14 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.186 -0.946 . . . . 0.0 109.61 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' SER . . . . . 0.51 ' HA ' ' CZ ' ' A' ' 175' ' ' PHE . 0.3 OUTLIER 43.91 51.8 6.8 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.187 -0.945 . . . . 0.0 109.472 -179.943 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . 0.45 ' HD2' ' OD1' ' A' ' 174' ' ' ASP . 9.3 tpt180 -145.44 137.14 25.32 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.257 -0.902 . . . . 0.0 109.402 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' LEU . . . . . 0.475 HD13 ' CD1' ' A' ' 128' ' ' PHE . 46.2 mt -108.34 136.2 48.37 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 109.53 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . 0.457 ' HE2' ' HB2' ' A' ' 150' ' ' GLU . 14.2 ttpt -95.19 109.2 21.33 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.327 -0.858 . . . . 0.0 109.442 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . 0.41 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 39.2 t -127.84 142.0 44.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -0.921 . . . . 0.0 109.464 -179.88 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' SER . . . . . 0.417 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 96.1 p -107.0 147.44 29.89 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.191 -0.943 . . . . 0.0 109.504 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' VAL . . . . . . . . . . . . . 26.1 t -119.21 132.05 70.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.31 -0.869 . . . . 0.0 109.565 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 32.0 t -83.31 83.0 8.03 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.217 -0.927 . . . . 0.0 109.433 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.537 ' CG2' ' CD2' ' A' ' 165' ' ' PHE . 43.9 mt -106.57 142.95 18.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.241 -0.912 . . . . 0.0 109.494 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . 0.537 ' CD2' ' CG2' ' A' ' 164' ' ' ILE . 93.1 m-85 62.38 13.92 6.45 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.272 -0.893 . . . . 0.0 109.5 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 81.59 10.12 84.79 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 39.0 mtm105 -122.85 140.84 52.52 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.225 -1.162 . . . . 0.0 109.453 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -72.08 137.29 46.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.208 -0.933 . . . . 0.0 109.497 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 59.3 m -129.82 77.02 77.55 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.244 -0.91 . . . . 0.0 109.44 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.417 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 50.6 Cg_endo -53.19 111.47 0.68 Allowed 'Trans proline' 0 C--O 1.214 -0.687 0 C-N-CA 122.579 2.186 . . . . 0.0 111.807 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 20.9 m -130.44 155.27 41.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.288 -0.883 . . . . 0.0 109.493 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.452 ' O ' HD21 ' A' ' 173' ' ' LEU . 95.2 mt-10 -104.57 135.81 45.28 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.268 -0.895 . . . . 0.0 109.528 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . 0.52 ' CB ' ' CG1' ' A' ' 178' ' ' VAL . 63.0 mt -133.91 148.28 51.2 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.316 -0.865 . . . . 0.0 109.576 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' ASP . . . . . 0.45 ' OD1' ' HD2' ' A' ' 157' ' ' ARG . 91.4 m-20 -68.91 171.16 8.42 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.283 -0.886 . . . . 0.0 109.4 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.548 ' N ' ' CD1' ' A' ' 175' ' ' PHE . 3.6 m-30 -65.29 -47.58 76.13 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.206 -0.934 . . . . 0.0 109.463 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 14.6 m -70.73 -28.03 64.41 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.315 -0.865 . . . . 0.0 109.498 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 177' ' ' GLN . . . . . 0.416 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 91.0 mt-30 -68.07 -20.64 64.97 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.306 -0.871 . . . . 0.0 109.473 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.52 ' CG1' ' CB ' ' A' ' 173' ' ' LEU . 13.7 m -131.23 160.29 42.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.278 -0.888 . . . . 0.0 109.484 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 179' ' ' GLU . . . . . 0.488 ' O ' ' N ' ' A' ' 135' ' ' ARG . 55.1 mt-10 -128.65 167.54 17.06 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.183 -0.948 . . . . 0.0 109.513 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 180' ' ' LYS . . . . . 0.521 ' HD3' ' CE2' ' A' ' 128' ' ' PHE . 29.0 mmtp -66.36 145.83 55.26 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.275 -0.89 . . . . 0.0 109.497 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.502 0 O-C-N 121.139 -0.975 . . . . 0.0 109.48 179.973 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 55.0 mtm-85 . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -56.36 145.09 80.27 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.578 2.185 . . . . 0.0 111.763 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 12.3 mtpt -90.56 151.27 21.4 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.242 -0.911 . . . . 0.0 109.462 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.48 ' HA ' ' CE2' ' A' ' 128' ' ' PHE . 28.8 p -88.15 15.1 7.95 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.218 -0.926 . . . . 0.0 109.458 -179.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 47.5 mt -94.41 92.38 7.12 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.247 -0.908 . . . . 0.0 109.488 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.48 ' CE2' ' HA ' ' A' ' 126' ' ' THR . 69.0 m-85 -106.27 141.09 38.19 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.222 -0.923 . . . . 0.0 109.473 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.515 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.9 OUTLIER -144.55 157.73 55.14 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.26 -0.9 . . . . 0.0 109.394 179.959 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.515 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.2 Cg_endo -49.51 128.18 20.1 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.625 2.217 . . . . 0.0 111.805 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 96.1 -3.89 64.74 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.456 ' OE1' ' HA ' ' A' ' 128' ' ' PHE . 88.2 mt-10 -92.38 129.88 38.2 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.14 -1.212 . . . . 0.0 109.5 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.4 ' HG2' ' CB ' ' A' ' 181' ' ' ALA . 43.5 ttm -77.13 145.7 37.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.237 -0.914 . . . . 0.0 109.353 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.454 HG12 ' HB ' ' A' ' 178' ' ' VAL . 2.5 t -129.76 178.66 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.198 -0.939 . . . . 0.0 109.404 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.458 ' O ' ' HB ' ' A' ' 178' ' ' VAL . 58.6 ttt180 -131.61 140.95 49.54 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.308 -0.87 . . . . 0.0 109.426 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.489 ' CG2' ' CD1' ' A' ' 173' ' ' LEU . 40.6 t -113.21 135.86 51.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.222 -0.923 . . . . 0.0 109.54 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . 0.446 ' O ' ' OD1' ' A' ' 138' ' ' ASP . 29.0 p30 -128.8 18.04 6.22 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.273 -0.892 . . . . 0.0 109.537 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.453 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 91.3 m-20 -139.43 164.37 30.03 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.208 -0.932 . . . . 0.0 109.497 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.435 ' O ' ' HB1' ' A' ' 142' ' ' ALA . . . 57.94 172.86 0.32 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -53.26 -21.1 16.32 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.581 2.187 . . . . 0.0 111.777 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . 0.538 ' CD1' HD13 ' A' ' 164' ' ' ILE . 91.8 m-85 -82.18 6.36 16.83 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.216 -0.928 . . . . 0.0 109.458 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' ALA . . . . . 0.438 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -62.62 143.24 57.52 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.278 -0.889 . . . . 0.0 109.488 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.438 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 10.2 m-20 67.06 48.69 1.2 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.257 -0.902 . . . . 0.0 109.413 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.48 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 43.6 m-85 -146.39 129.08 16.16 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.239 -0.913 . . . . 0.0 109.465 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 68.5 m-20 -90.87 138.04 31.9 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.227 -0.921 . . . . 0.0 109.509 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -152.71 177.39 30.44 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.495 HG11 ' N ' ' A' ' 148' ' ' VAL . 38.9 t -118.95 156.52 20.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.273 -1.134 . . . . 0.0 109.447 179.87 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.495 ' N ' HG11 ' A' ' 147' ' ' VAL . 50.9 t -89.36 106.84 17.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.161 -0.962 . . . . 0.0 109.574 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -73.58 -31.84 63.81 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.247 -0.908 . . . . 0.0 109.392 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -144.42 148.63 34.87 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.282 -0.886 . . . . 0.0 109.25 179.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.446 HG21 ' CG1' ' A' ' 148' ' ' VAL . 37.1 t -125.55 146.43 31.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.157 -0.964 . . . . 0.0 109.644 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -132.28 87.89 2.48 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.279 -0.888 . . . . 0.0 109.412 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -61.1 -40.41 93.64 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.195 -0.941 . . . . 0.0 109.442 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -62.39 -40.53 96.76 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.21 -0.932 . . . . 0.0 109.51 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.401 ' O ' ' OG ' ' A' ' 156' ' ' SER . 94.9 mttt -91.52 2.45 56.43 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.217 -0.927 . . . . 0.0 109.649 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' SER . . . . . 0.401 ' OG ' ' O ' ' A' ' 155' ' ' LYS . 13.6 p 45.21 52.62 8.52 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.154 -0.966 . . . . 0.0 109.394 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . 0.455 ' CG ' ' HB3' ' A' ' 172' ' ' GLU . 0.0 OUTLIER -136.67 156.28 48.75 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.202 -0.937 . . . . 0.0 109.543 179.919 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' LEU . . . . . 0.616 ' CD1' ' CE1' ' A' ' 175' ' ' PHE . 7.4 mp -120.39 123.66 43.61 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.257 -0.902 . . . . 0.0 109.525 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 18.0 tttm -91.01 92.18 8.63 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.25 -0.906 . . . . 0.0 109.378 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . 0.495 ' CG2' HG23 ' A' ' 148' ' ' VAL . 21.7 t -116.22 150.27 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.199 -0.938 . . . . 0.0 109.359 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' SER . . . . . 0.467 ' OG ' ' N ' ' A' ' 170' ' ' PRO . 18.3 t -119.74 131.32 55.34 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.311 -0.868 . . . . 0.0 109.431 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' VAL . . . . . 0.48 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 11.7 t -102.16 131.98 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.243 -0.91 . . . . 0.0 109.387 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 40.5 t -77.64 81.52 4.08 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.273 -0.892 . . . . 0.0 109.43 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.538 HD13 ' CD1' ' A' ' 141' ' ' PHE . 68.5 mt -100.18 142.18 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.305 -0.872 . . . . 0.0 109.483 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . 0.453 ' CD1' HG23 ' A' ' 164' ' ' ILE . 7.7 m-30 64.47 18.09 11.17 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.16 -0.963 . . . . 0.0 109.517 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 81.81 4.23 90.38 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 70.1 mtm180 -124.12 142.17 51.43 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.177 -1.19 . . . . 0.0 109.38 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -68.17 144.53 54.93 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 109.521 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 2.9 m -128.09 73.82 79.34 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.249 -0.907 . . . . 0.0 109.414 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.467 ' N ' ' OG ' ' A' ' 161' ' ' SER . 50.2 Cg_endo -49.09 105.98 0.1 Allowed 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.585 2.19 . . . . 0.0 111.794 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 19.3 m -133.67 153.94 37.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.295 -0.878 . . . . 0.0 109.359 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.455 ' HB3' ' CG ' ' A' ' 157' ' ' ARG . 95.2 mt-10 -97.23 135.81 38.63 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.259 -0.901 . . . . 0.0 109.489 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . 0.495 HD21 ' NE2' ' A' ' 177' ' ' GLN . 28.9 mt -124.97 160.06 29.8 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.256 -0.902 . . . . 0.0 109.421 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' ASP . . . . . 0.453 ' HB2' ' HB2' ' A' ' 177' ' ' GLN . 92.7 m-20 -83.54 160.78 21.4 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.184 -0.948 . . . . 0.0 109.521 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.616 ' CE1' ' CD1' ' A' ' 158' ' ' LEU . 4.5 m-85 -53.67 -49.95 66.86 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.321 -0.862 . . . . 0.0 109.561 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 15.5 m -74.67 -24.36 58.79 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.162 -0.961 . . . . 0.0 109.546 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 177' ' ' GLN . . . . . 0.495 ' NE2' HD21 ' A' ' 173' ' ' LEU . 61.9 tt0 -64.6 -27.21 68.79 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.231 -0.918 . . . . 0.0 109.425 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.494 ' CG1' ' CD1' ' A' ' 173' ' ' LEU . 13.7 m -127.97 161.83 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.334 -0.854 . . . . 0.0 109.482 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 179' ' ' GLU . . . . . 0.448 ' O ' HG11 ' A' ' 134' ' ' VAL . 61.6 mt-10 -118.32 148.19 42.73 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.207 -0.933 . . . . 0.0 109.489 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -66.95 130.91 44.67 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.32 -0.863 . . . . 0.0 109.427 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . 0.4 ' CB ' ' HG2' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.558 0 O-C-N 121.259 -0.901 . . . . 0.0 109.461 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.518 0 CA-C-O 121.248 0.547 . . . . 0.0 109.531 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -56.0 146.04 71.28 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.583 2.189 . . . . 0.0 111.748 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -92.28 144.63 25.2 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.27 -0.893 . . . . 0.0 109.485 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 46.6 p -93.26 11.29 28.55 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.316 -0.865 . . . . 0.0 109.435 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 47.8 mt -96.91 95.32 7.76 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.29 -0.881 . . . . 0.0 109.494 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.434 ' CE1' ' HB2' ' A' ' 180' ' ' LYS . 68.8 m-85 -99.48 135.67 40.55 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.299 -0.875 . . . . 0.0 109.463 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.462 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.0 OUTLIER -125.87 153.54 73.52 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.23 -0.919 . . . . 0.0 109.503 179.949 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.462 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 49.4 Cg_endo -47.88 134.59 23.13 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.636 2.224 . . . . 0.0 111.72 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 85.45 3.72 86.47 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 48.9 tp10 -89.9 136.11 33.24 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.168 -1.195 . . . . 0.0 109.474 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.516 ' SD ' ' CG2' ' A' ' 147' ' ' VAL . 92.9 mmm -74.82 148.55 40.19 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.253 -0.904 . . . . 0.0 109.48 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.527 HG21 ' CG2' ' A' ' 148' ' ' VAL . 2.5 t -139.06 179.18 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.285 -0.885 . . . . 0.0 109.373 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.478 ' CZ ' ' OE1' ' A' ' 179' ' ' GLU . 19.8 ttp85 -137.58 142.41 41.31 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.323 -0.861 . . . . 0.0 109.445 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.453 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 43.8 t -106.45 132.16 54.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.224 -0.923 . . . . 0.0 109.533 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 29.0 p30 -118.48 13.33 13.47 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.337 -0.852 . . . . 0.0 109.425 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 51.9 p30 -151.89 169.93 21.07 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.235 -0.916 . . . . 0.0 109.461 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 67.4 168.79 3.94 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -56.71 -18.11 25.45 Favored 'Trans proline' 0 C--O 1.214 -0.702 0 C-N-CA 122.565 2.177 . . . . 0.0 111.848 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . 0.453 ' O ' ' HB ' ' A' ' 136' ' ' VAL . 92.5 m-85 -88.12 8.1 28.46 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.28 -0.888 . . . . 0.0 109.48 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' ALA . . . . . 0.481 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -61.34 150.68 34.35 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.213 -0.929 . . . . 0.0 109.458 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.459 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 63.2 m-20 62.63 42.4 8.44 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.243 -0.911 . . . . 0.0 109.446 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.481 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 51.3 m-85 -146.9 134.52 21.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.165 -0.959 . . . . 0.0 109.516 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -87.68 141.98 28.18 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.898 . . . . 0.0 109.453 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -149.61 177.89 27.48 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.516 ' CG2' ' SD ' ' A' ' 133' ' ' MET . 35.6 t -119.92 156.34 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.306 -1.114 . . . . 0.0 109.462 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.527 ' CG2' HG21 ' A' ' 134' ' ' VAL . 61.3 t -87.54 103.18 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.22 -0.925 . . . . 0.0 109.457 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 75.2 mm-40 -67.63 -38.69 84.23 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.268 -0.895 . . . . 0.0 109.415 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -153.77 150.81 28.88 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.232 -0.918 . . . . 0.0 109.426 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.521 ' CG2' HG12 ' A' ' 148' ' ' VAL . 58.9 t -122.68 154.41 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.269 -0.895 . . . . 0.0 109.475 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -135.12 94.83 3.19 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.301 -0.875 . . . . 0.0 109.459 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 81.1 m-85 -67.32 -42.44 83.65 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.301 -0.874 . . . . 0.0 109.487 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -62.63 -36.67 83.56 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.212 -0.93 . . . . 0.0 109.412 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.464 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 57.0 tttm -95.59 1.4 53.73 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.202 -0.936 . . . . 0.0 109.617 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 41.1 t 46.6 52.4 11.09 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.171 -0.956 . . . . 0.0 109.486 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 7.7 tpt180 -141.28 138.25 33.07 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.256 -0.903 . . . . 0.0 109.417 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' LEU . . . . . 0.428 HD21 ' CE1' ' A' ' 175' ' ' PHE . 55.2 mt -107.25 131.66 53.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.221 -0.924 . . . . 0.0 109.496 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 60.3 tttm -96.52 105.78 17.93 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.874 . . . . 0.0 109.373 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . 0.453 HG11 ' O ' ' A' ' 147' ' ' VAL . 38.6 t -123.36 145.75 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.265 -0.897 . . . . 0.0 109.578 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' SER . . . . . 0.446 ' OG ' ' HA ' ' A' ' 170' ' ' PRO . 11.4 m -118.85 137.01 53.72 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.33 -0.856 . . . . 0.0 109.359 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' VAL . . . . . . . . . . . . . 25.2 t -107.85 133.68 51.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.292 -0.88 . . . . 0.0 109.634 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 33.8 t -87.31 83.49 7.35 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.233 -0.917 . . . . 0.0 109.193 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.567 ' CG2' ' CD2' ' A' ' 165' ' ' PHE . 31.7 mt -105.15 142.24 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.22 -0.925 . . . . 0.0 109.573 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . 0.567 ' CD2' ' CG2' ' A' ' 164' ' ' ILE . 98.5 m-85 60.57 19.8 9.66 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.263 -0.898 . . . . 0.0 109.523 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 76.18 12.39 84.16 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 51.1 mtt180 -121.68 139.54 53.42 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.259 -1.142 . . . . 0.0 109.433 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -74.29 140.94 45.26 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.194 -0.941 . . . . 0.0 109.568 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' THR . . . . . 0.417 ' CG2' ' CZ ' ' A' ' 141' ' ' PHE . 0.2 OUTLIER -127.03 73.99 76.76 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.317 -0.864 . . . . 0.0 109.443 179.953 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.446 ' HA ' ' OG ' ' A' ' 161' ' ' SER . 49.8 Cg_endo -54.17 100.28 0.06 OUTLIER 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.567 2.178 . . . . 0.0 111.81 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 26.9 m -126.96 153.4 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.278 -0.889 . . . . 0.0 109.489 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.459 ' O ' HD23 ' A' ' 173' ' ' LEU . 57.0 mp0 -102.02 134.8 44.66 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.292 -0.88 . . . . 0.0 109.563 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . 0.497 ' CB ' HG11 ' A' ' 178' ' ' VAL . 53.4 mt -132.95 147.8 52.28 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.245 -0.91 . . . . 0.0 109.455 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' ASP . . . . . 0.424 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 90.7 m-20 -70.89 174.32 6.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.262 -0.899 . . . . 0.0 109.458 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.529 ' N ' ' CD1' ' A' ' 175' ' ' PHE . 3.8 m-30 -65.13 -44.66 87.94 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.212 -0.93 . . . . 0.0 109.457 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 94.8 p -73.73 -28.81 61.9 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.205 -0.935 . . . . 0.0 109.463 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 177' ' ' GLN . . . . . 0.424 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 82.1 mt-30 -63.49 -25.71 68.38 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.283 -0.885 . . . . 0.0 109.49 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.497 HG11 ' CB ' ' A' ' 173' ' ' LEU . 6.1 m -130.02 160.79 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.266 -0.896 . . . . 0.0 109.485 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 179' ' ' GLU . . . . . 0.478 ' OE1' ' CZ ' ' A' ' 135' ' ' ARG . 79.6 mt-10 -112.14 147.61 35.75 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.278 -0.889 . . . . 0.0 109.465 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 180' ' ' LYS . . . . . 0.434 ' HB2' ' CE1' ' A' ' 128' ' ' PHE . 19.1 tttm -76.02 132.04 39.9 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.286 -0.884 . . . . 0.0 109.465 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.552 0 O-C-N 121.2 -0.937 . . . . 0.0 109.518 -179.957 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 12.8 mtp180 . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -55.75 146.71 64.8 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.606 2.204 . . . . 0.0 111.764 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . 0.441 ' HB2' ' CD ' ' A' ' 180' ' ' LYS . 67.2 mttt -95.18 146.69 24.15 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.889 . . . . 0.0 109.43 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 49.7 p -102.55 16.89 25.07 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -0.907 . . . . 0.0 109.426 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 44.6 mt -94.81 96.36 9.3 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.157 -0.964 . . . . 0.0 109.433 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.435 ' CD2' HD11 ' A' ' 158' ' ' LEU . 72.8 m-85 -98.43 132.51 43.82 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.277 -0.889 . . . . 0.0 109.508 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.526 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.1 OUTLIER -143.62 156.69 59.72 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.328 -0.858 . . . . 0.0 109.412 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.526 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.4 Cg_endo -47.34 132.19 19.11 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.552 2.168 . . . . 0.0 111.737 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 93.59 0.67 66.74 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -103.68 139.99 38.19 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.234 -1.157 . . . . 0.0 109.435 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 87.7 mtp -83.78 152.69 24.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.317 -0.865 . . . . 0.0 109.491 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.552 ' CG2' ' CG2' ' A' ' 148' ' ' VAL . 2.5 t -136.82 179.21 3.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.258 -0.901 . . . . 0.0 109.345 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.447 ' O ' ' HA ' ' A' ' 178' ' ' VAL . 53.0 ttm-85 -135.08 139.02 44.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.232 -0.918 . . . . 0.0 109.456 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.56 ' CG2' ' CD1' ' A' ' 173' ' ' LEU . 50.0 t -107.1 131.23 57.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.266 -0.896 . . . . 0.0 109.494 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . 0.421 ' O ' ' OD1' ' A' ' 138' ' ' ASP . 11.4 p30 -122.54 16.32 10.39 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.279 -0.888 . . . . 0.0 109.43 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.421 ' OD1' ' O ' ' A' ' 137' ' ' ASN . 93.5 m-20 -135.67 160.16 39.39 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.229 -0.919 . . . . 0.0 109.489 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 60.35 173.08 0.82 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -53.53 -20.37 15.95 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.609 2.206 . . . . 0.0 111.803 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . 0.514 ' CD1' HG21 ' A' ' 162' ' ' VAL . 99.4 m-85 -80.57 4.07 19.71 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.222 -0.924 . . . . 0.0 109.481 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' ALA . . . . . 0.497 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -63.99 150.84 44.35 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.139 -0.976 . . . . 0.0 109.474 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.454 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 57.9 m-20 62.83 47.53 4.5 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.275 -0.89 . . . . 0.0 109.398 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.497 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 50.2 m-85 -149.34 144.56 26.51 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.308 -0.87 . . . . 0.0 109.493 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 19.8 m120 -97.9 145.52 26.36 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.27 -0.894 . . . . 0.0 109.497 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -154.21 174.68 32.62 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.513 HG11 ' N ' ' A' ' 148' ' ' VAL . 47.3 t -114.4 165.16 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.223 -1.163 . . . . 0.0 109.386 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.552 ' CG2' ' CG2' ' A' ' 134' ' ' VAL . 51.0 t -101.57 123.66 54.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.273 -0.892 . . . . 0.0 109.512 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 74.7 mm-40 -99.76 -44.55 6.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.256 -0.903 . . . . 0.0 109.435 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -133.24 155.61 49.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.237 -0.914 . . . . 0.0 109.348 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.427 HG13 ' CE2' ' A' ' 153' ' ' TYR . 38.7 t -122.79 151.15 26.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.29 -0.881 . . . . 0.0 109.565 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' ASP . . . . . 0.408 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 93.3 m-20 -135.3 78.93 1.76 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.292 -0.88 . . . . 0.0 109.373 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' TYR . . . . . 0.427 ' CE2' HG13 ' A' ' 151' ' ' VAL . 98.1 m-85 -62.68 -37.3 85.9 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.197 -0.939 . . . . 0.0 109.651 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -64.35 -40.95 96.88 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.277 -0.889 . . . . 0.0 109.593 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.456 ' O ' ' HG3' ' A' ' 157' ' ' ARG . 28.9 mttt -87.1 3.13 47.44 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.211 -0.93 . . . . 0.0 109.627 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' SER . . . . . 0.485 ' HA ' ' CZ ' ' A' ' 175' ' ' PHE . 58.1 m 52.83 52.59 13.63 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.224 -0.922 . . . . 0.0 109.469 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . 0.472 ' CG ' ' O ' ' A' ' 156' ' ' SER . 47.0 mtt180 -157.81 155.43 29.72 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.278 -0.889 . . . . 0.0 109.44 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' LEU . . . . . 0.568 HD23 ' CE1' ' A' ' 175' ' ' PHE . 12.0 mt -119.83 137.0 54.26 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.243 -0.911 . . . . 0.0 109.57 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 14.8 tttt -83.63 105.34 14.48 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.302 -0.874 . . . . 0.0 109.308 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . 0.455 HG23 HG21 ' A' ' 148' ' ' VAL . 57.8 t -123.11 145.27 30.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.205 -0.934 . . . . 0.0 109.596 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' SER . . . . . 0.45 ' OG ' ' HA ' ' A' ' 170' ' ' PRO . 14.9 m -111.86 140.85 46.17 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.257 -0.902 . . . . 0.0 109.444 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' VAL . . . . . 0.514 HG21 ' CD1' ' A' ' 141' ' ' PHE . 14.0 t -110.46 133.14 56.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.206 -0.934 . . . . 0.0 109.493 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 60.7 p -83.36 82.56 8.23 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.191 -0.943 . . . . 0.0 109.435 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.536 HG23 ' CD1' ' A' ' 165' ' ' PHE . 54.5 mt -107.23 139.11 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.286 -0.884 . . . . 0.0 109.537 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . 0.536 ' CD1' HG23 ' A' ' 164' ' ' ILE . 9.4 m-85 66.2 18.55 10.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.282 -0.886 . . . . 0.0 109.454 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 74.4 12.07 82.22 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -123.85 142.42 51.14 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.207 -1.172 . . . . 0.0 109.462 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -72.76 137.23 45.73 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.287 -0.883 . . . . 0.0 109.471 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 18.6 m -129.96 74.18 80.79 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.203 -0.936 . . . . 0.0 109.486 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.45 ' HA ' ' OG ' ' A' ' 161' ' ' SER . 49.5 Cg_endo -51.04 112.72 0.85 Allowed 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.607 2.205 . . . . 0.0 111.73 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 28.7 m -133.11 153.46 37.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.308 -0.87 . . . . 0.0 109.423 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -95.68 130.28 42.62 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.24 -0.913 . . . . 0.0 109.5 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . 0.56 ' CD1' ' CG2' ' A' ' 136' ' ' VAL . 51.6 mt -128.08 146.4 50.7 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.327 -0.858 . . . . 0.0 109.404 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 57.1 m-20 -67.77 171.06 6.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.268 -0.895 . . . . 0.0 109.451 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.568 ' CE1' HD23 ' A' ' 158' ' ' LEU . 6.2 m-30 -64.64 -49.19 71.99 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.248 -0.908 . . . . 0.0 109.386 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 87.0 p -74.94 -18.64 60.36 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.169 -0.957 . . . . 0.0 109.453 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 177' ' ' GLN . . . . . 0.506 ' NE2' HD21 ' A' ' 173' ' ' LEU . 63.8 tt0 -70.66 -20.85 62.67 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.296 -0.878 . . . . 0.0 109.483 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.54 ' CG1' ' CB ' ' A' ' 173' ' ' LEU . 4.7 m -130.2 159.2 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.285 -0.885 . . . . 0.0 109.403 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 179' ' ' GLU . . . . . 0.458 ' O ' HG12 ' A' ' 134' ' ' VAL . 73.0 mt-10 -115.6 151.96 33.98 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.189 -0.944 . . . . 0.0 109.525 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 180' ' ' LYS . . . . . 0.441 ' CD ' ' HB2' ' A' ' 125' ' ' LYS . 21.1 tttt -75.7 136.42 40.36 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.249 -0.907 . . . . 0.0 109.511 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.516 0 O-C-N 121.292 -0.88 . . . . 0.0 109.527 179.978 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.522 ' CB ' ' CD ' ' A' ' 124' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 . . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.522 ' CD ' ' CB ' ' A' ' 123' ' ' ARG . 50.2 Cg_endo -55.52 143.86 76.37 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 C-N-CA 122.652 2.235 . . . . 0.0 111.784 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 59.8 mttp -104.53 154.02 20.43 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.297 -0.877 . . . . 0.0 109.478 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 52.1 p -99.63 28.83 4.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.276 -0.89 . . . . 0.0 109.471 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 58.7 mt -92.72 94.66 9.11 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.25 -0.906 . . . . 0.0 109.457 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.45 ' CD2' HD23 ' A' ' 158' ' ' LEU . 83.9 m-85 -91.77 129.78 37.67 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.232 -0.917 . . . . 0.0 109.564 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.42 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.2 OUTLIER -123.02 155.03 64.71 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.287 -0.883 . . . . 0.0 109.464 179.979 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.42 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 49.5 Cg_endo -51.22 128.89 26.78 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.648 2.232 . . . . 0.0 111.815 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 91.52 2.93 69.58 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.443 ' OE2' ' HE3' ' A' ' 180' ' ' LYS . 65.7 tt0 -88.5 141.87 28.18 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.154 -1.204 . . . . 0.0 109.485 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.48 ' SD ' ' CG2' ' A' ' 147' ' ' VAL . 80.4 mmm -80.33 137.56 36.59 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.208 -0.932 . . . . 0.0 109.556 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.525 ' CG2' ' CG2' ' A' ' 148' ' ' VAL . 2.5 t -129.22 179.28 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.247 -0.908 . . . . 0.0 109.285 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.456 ' O ' ' HA ' ' A' ' 178' ' ' VAL . 37.4 ttm180 -137.83 142.6 40.77 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.123 -0.986 . . . . 0.0 109.48 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.462 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 59.3 t -110.95 133.02 57.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.302 -0.874 . . . . 0.0 109.512 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 40.7 p30 -124.75 19.86 8.55 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.176 -0.952 . . . . 0.0 109.384 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.44 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 55.9 t0 -143.13 153.77 43.23 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.289 -0.882 . . . . 0.0 109.481 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.44 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 69.84 172.07 9.52 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -52.88 -16.9 6.62 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.582 2.188 . . . . 0.0 111.71 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . 0.479 ' CD1' HG22 ' A' ' 162' ' ' VAL . 99.5 m-85 -88.15 10.83 18.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.299 -0.876 . . . . 0.0 109.426 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' ALA . . . . . 0.461 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -64.27 145.79 55.42 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.276 -0.89 . . . . 0.0 109.554 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.461 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 50.8 m-20 63.54 46.88 4.02 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.33 -0.856 . . . . 0.0 109.622 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.53 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 39.3 m-85 -143.38 140.86 30.68 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.176 -0.952 . . . . 0.0 109.599 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 73.5 m-20 -95.6 142.05 28.38 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.271 -0.893 . . . . 0.0 109.492 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -151.29 173.16 30.76 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.48 ' CG2' ' SD ' ' A' ' 133' ' ' MET . 22.6 t -117.9 153.04 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.154 -1.204 . . . . 0.0 109.401 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.525 ' CG2' ' CG2' ' A' ' 134' ' ' VAL . 57.5 t -88.87 109.67 20.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.234 -0.916 . . . . 0.0 109.521 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -68.13 -40.9 82.37 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.262 -0.899 . . . . 0.0 109.418 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.436 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 95.6 mt-10 -153.93 157.53 39.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.207 -0.933 . . . . 0.0 109.395 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 43.9 t -120.99 144.27 30.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.233 -0.917 . . . . 0.0 109.462 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -123.15 95.61 4.67 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.212 -0.93 . . . . 0.0 109.493 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -66.14 -42.24 89.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.183 -0.948 . . . . 0.0 109.51 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 76.2 mm-40 -59.58 -43.37 93.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.29 -0.881 . . . . 0.0 109.427 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 23.7 mttt -87.35 -10.25 52.69 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.29 -0.881 . . . . 0.0 109.495 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 1.6 m 55.62 53.28 9.81 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.23 -0.919 . . . . 0.0 109.432 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . 0.419 ' C ' HD13 ' A' ' 158' ' ' LEU . 88.5 mmt-85 -139.47 162.55 34.79 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.277 -0.889 . . . . 0.0 109.512 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' LEU . . . . . 0.651 ' CD1' ' CE1' ' A' ' 175' ' ' PHE . 7.0 mp -122.55 131.31 53.78 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.278 -0.889 . . . . 0.0 109.542 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . 0.436 ' HD2' ' HB2' ' A' ' 150' ' ' GLU . 23.8 mttm -97.14 98.6 10.17 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.198 -0.939 . . . . 0.0 109.233 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 30.0 t -123.17 145.68 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.236 -0.915 . . . . 0.0 109.662 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' SER . . . . . 0.494 ' CB ' ' HA ' ' A' ' 170' ' ' PRO . 88.1 p -112.71 148.29 35.02 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.277 -0.89 . . . . 0.0 109.333 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' VAL . . . . . 0.53 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 18.0 t -113.4 128.32 70.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.215 -0.928 . . . . 0.0 109.626 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 36.5 t -80.75 80.76 7.16 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.29 -0.881 . . . . 0.0 109.503 179.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.469 HG23 HD11 ' A' ' 164' ' ' ILE . 57.9 mt -97.3 137.64 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.311 -0.868 . . . . 0.0 109.318 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . 0.508 ' CD2' ' O ' ' A' ' 165' ' ' PHE . 46.9 t80 63.87 14.25 8.19 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.215 -0.928 . . . . 0.0 109.363 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 84.72 9.62 80.78 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 72.9 mtm180 -117.83 142.41 47.33 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.24 -1.153 . . . . 0.0 109.403 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -81.08 134.75 35.71 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.258 -0.901 . . . . 0.0 109.496 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' THR . . . . . 0.403 ' O ' HG21 ' A' ' 169' ' ' THR . 64.8 m -128.48 77.26 77.5 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.215 -0.928 . . . . 0.0 109.475 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.494 ' HA ' ' CB ' ' A' ' 161' ' ' SER . 48.9 Cg_endo -53.13 107.8 0.22 Allowed 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.631 2.22 . . . . 0.0 111.789 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 19.4 m -127.04 157.68 38.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.27 -0.893 . . . . 0.0 109.463 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.422 ' O ' HD11 ' A' ' 173' ' ' LEU . 95.8 mt-10 -91.05 128.46 36.88 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.311 -0.868 . . . . 0.0 109.503 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . 0.578 ' CD2' ' N ' ' A' ' 173' ' ' LEU . 2.2 mm? -122.33 156.08 34.64 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.289 -0.882 . . . . 0.0 109.497 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' ASP . . . . . 0.45 ' HB2' ' HB2' ' A' ' 177' ' ' GLN . 84.5 m-20 -83.34 168.13 16.92 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.217 -0.927 . . . . 0.0 109.596 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.651 ' CE1' ' CD1' ' A' ' 158' ' ' LEU . 8.2 m-85 -59.49 -49.44 77.77 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.255 -0.903 . . . . 0.0 109.584 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 84.0 p -78.09 -19.36 54.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.2 -0.937 . . . . 0.0 109.653 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 177' ' ' GLN . . . . . 0.507 ' NE2' HD13 ' A' ' 173' ' ' LEU . 64.9 tt0 -67.25 -25.26 65.99 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.116 -0.99 . . . . 0.0 109.483 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.515 HG12 ' CB ' ' A' ' 173' ' ' LEU . 4.5 m -127.08 157.57 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.264 -0.897 . . . . 0.0 109.592 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 179' ' ' GLU . . . . . 0.45 ' O ' HG13 ' A' ' 134' ' ' VAL . 56.4 mt-10 -111.29 152.74 26.86 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.258 -0.901 . . . . 0.0 109.438 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 180' ' ' LYS . . . . . 0.443 ' HE3' ' OE2' ' A' ' 132' ' ' GLU . 5.4 tttp -72.9 133.02 44.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.228 -0.92 . . . . 0.0 109.481 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . 0.448 ' HB2' ' O ' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.547 0 O-C-N 121.249 -0.907 . . . . 0.0 109.514 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.579 ' CB ' ' CD ' ' A' ' 124' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.579 ' CD ' ' CB ' ' A' ' 123' ' ' ARG . 50.6 Cg_endo -55.91 146.8 66.18 Favored 'Trans proline' 0 C--O 1.213 -0.726 0 C-N-CA 122.621 2.214 . . . . 0.0 111.746 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 91.7 mttt -90.6 146.72 23.83 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.396 -0.815 . . . . 0.0 109.435 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 45.7 p -93.47 12.62 24.39 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.203 -0.936 . . . . 0.0 109.5 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.432 ' O ' ' HE3' ' A' ' 180' ' ' LYS . 44.4 mt -90.99 97.37 11.14 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.239 -0.913 . . . . 0.0 109.518 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.428 ' HA ' ' OE1' ' A' ' 132' ' ' GLU . 56.9 m-85 -109.14 145.49 35.65 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.191 -0.943 . . . . 0.0 109.442 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.483 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.1 OUTLIER -145.42 155.44 53.69 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.252 -0.905 . . . . 0.0 109.502 179.933 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.483 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.2 Cg_endo -48.58 128.52 18.3 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.633 2.222 . . . . 0.0 111.828 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 96.25 -9.57 67.41 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.428 ' OE1' ' HA ' ' A' ' 128' ' ' PHE . 92.2 mt-10 -86.95 140.24 29.8 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.155 -1.203 . . . . 0.0 109.496 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.423 ' HA ' ' HA ' ' A' ' 147' ' ' VAL . 87.9 mtp -84.76 152.25 23.82 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.333 -0.854 . . . . 0.0 109.456 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.475 ' CG2' ' CG2' ' A' ' 148' ' ' VAL . 2.5 t -133.45 179.21 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.236 -0.915 . . . . 0.0 109.308 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.452 ' O ' ' HB ' ' A' ' 178' ' ' VAL . 64.1 mtm180 -138.9 150.31 45.8 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.233 -0.917 . . . . 0.0 109.53 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.425 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 42.1 t -108.31 135.24 47.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.297 -0.877 . . . . 0.0 109.444 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 36.7 p30 -118.17 14.16 13.91 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.239 -0.913 . . . . 0.0 109.528 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 53.7 p30 -157.21 169.95 23.6 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.269 -0.894 . . . . 0.0 109.499 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 69.04 165.55 4.11 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -55.97 -18.61 23.0 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.629 2.219 . . . . 0.0 111.739 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . 0.627 ' CD1' ' CG2' ' A' ' 162' ' ' VAL . 94.1 m-85 -88.74 7.77 32.18 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.291 -0.881 . . . . 0.0 109.523 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' ALA . . . . . 0.497 ' O ' ' CB ' ' A' ' 143' ' ' ASP . . . -67.9 147.98 51.75 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.178 -0.951 . . . . 0.0 109.48 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.497 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 3.9 t70 76.29 27.47 0.86 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.281 -0.887 . . . . 0.0 109.56 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.482 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 96.5 m-85 -135.87 146.55 47.55 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -0.878 . . . . 0.0 109.47 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 75.6 m-20 -103.63 146.98 27.77 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.268 -0.895 . . . . 0.0 109.377 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . 0.435 ' HA3' ' O ' ' A' ' 161' ' ' SER . . . -151.24 -173.94 21.63 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.423 ' HA ' ' HA ' ' A' ' 133' ' ' MET . 48.7 t -123.99 156.68 31.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.302 -1.116 . . . . 0.0 109.487 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.475 ' CG2' ' CG2' ' A' ' 134' ' ' VAL . 98.7 t -86.59 96.07 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.246 -0.909 . . . . 0.0 109.519 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -68.31 -34.92 77.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.294 -0.879 . . . . 0.0 109.411 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -151.11 159.19 44.63 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.202 -0.936 . . . . 0.0 109.479 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.524 HG13 ' CZ ' ' A' ' 153' ' ' TYR . 43.6 t -129.02 148.22 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.459 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' ASP . . . . . 0.493 ' N ' HG12 ' A' ' 151' ' ' VAL . 92.6 m-20 -134.2 86.71 2.3 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.242 -0.911 . . . . 0.0 109.476 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' TYR . . . . . 0.524 ' CZ ' HG13 ' A' ' 151' ' ' VAL . 97.3 m-85 -67.34 -36.72 82.0 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.285 -0.884 . . . . 0.0 109.505 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -64.15 -41.45 97.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.202 -0.937 . . . . 0.0 109.442 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.415 ' O ' ' C ' ' A' ' 156' ' ' SER . 42.7 mttp -92.64 9.43 34.82 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.225 -0.922 . . . . 0.0 109.478 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' SER . . . . . 0.415 ' C ' ' O ' ' A' ' 155' ' ' LYS . 8.1 m 43.85 52.76 6.46 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.304 -0.872 . . . . 0.0 109.445 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . 0.434 ' CG ' ' HB3' ' A' ' 172' ' ' GLU . 7.7 tpt180 -144.45 140.0 28.68 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.243 -0.911 . . . . 0.0 109.43 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' LEU . . . . . 0.526 HD11 ' CD1' ' A' ' 175' ' ' PHE . 53.7 mt -107.35 134.54 50.26 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.198 -0.939 . . . . 0.0 109.454 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 13.6 tptt -92.74 95.9 9.83 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.247 -0.908 . . . . 0.0 109.463 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . 0.425 ' O ' ' O ' ' A' ' 171' ' ' VAL . 40.9 t -117.7 143.41 28.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.148 -0.97 . . . . 0.0 109.473 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' SER . . . . . 0.454 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 28.4 t -109.21 147.67 32.18 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.246 -0.909 . . . . 0.0 109.469 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' VAL . . . . . 0.627 ' CG2' ' CD1' ' A' ' 141' ' ' PHE . 21.1 t -88.43 134.39 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.258 -0.901 . . . . 0.0 109.615 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 5.7 m -85.97 82.42 8.13 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.319 -0.863 . . . . 0.0 109.231 179.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.47 ' HB ' ' O ' ' A' ' 167' ' ' ARG . 41.3 mt -98.31 139.96 19.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.256 -0.902 . . . . 0.0 109.442 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 71.6 t80 -56.7 -39.18 73.38 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.303 -0.873 . . . . 0.0 109.635 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.492 ' O ' ' HB2' ' A' ' 167' ' ' ARG . . . -63.37 -31.22 80.01 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' ARG . . . . . 0.492 ' HB2' ' O ' ' A' ' 166' ' ' GLY . 17.3 ttt180 165.13 154.22 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.336 -1.096 . . . . 0.0 109.226 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -67.28 147.57 52.83 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.206 -0.934 . . . . 0.0 109.382 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 5.3 m -124.58 88.95 52.89 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.221 -0.924 . . . . 0.0 109.541 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.454 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.4 Cg_endo -68.23 107.89 1.65 Allowed 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 122.592 2.194 . . . . 0.0 111.783 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.425 ' O ' ' O ' ' A' ' 160' ' ' VAL . 21.2 m -132.87 160.69 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.302 -0.874 . . . . 0.0 109.45 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.434 ' HB3' ' CG ' ' A' ' 157' ' ' ARG . 97.7 mt-10 -103.97 128.61 51.51 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.266 -0.896 . . . . 0.0 109.508 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . 0.509 ' HB2' ' CG1' ' A' ' 178' ' ' VAL . 55.7 mt -129.74 147.32 51.5 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.269 -0.895 . . . . 0.0 109.51 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' ASP . . . . . 0.432 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 88.9 m-20 -67.41 173.13 4.24 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.282 -0.886 . . . . 0.0 109.455 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.53 ' N ' ' CD1' ' A' ' 175' ' ' PHE . 2.7 m-30 -64.92 -41.46 95.55 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.191 -0.943 . . . . 0.0 109.403 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 19.4 m -75.11 -25.79 58.76 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.233 -0.917 . . . . 0.0 109.433 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 177' ' ' GLN . . . . . 0.432 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 83.2 mt-30 -68.29 -22.67 64.72 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.219 -0.926 . . . . 0.0 109.415 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.509 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 9.0 m -132.99 157.57 43.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.241 -0.912 . . . . 0.0 109.396 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 179' ' ' GLU . . . . . 0.421 ' O ' HG12 ' A' ' 134' ' ' VAL . 93.4 mt-10 -114.94 150.18 36.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.359 -0.838 . . . . 0.0 109.486 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 180' ' ' LYS . . . . . 0.432 ' HE3' ' O ' ' A' ' 127' ' ' LEU . 18.1 tttm -66.04 140.1 58.24 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.253 -0.904 . . . . 0.0 109.428 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.503 0 O-C-N 121.23 -0.919 . . . . 0.0 109.456 -179.971 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.489 1.484 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -55.9 144.24 78.73 Favored 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 122.608 2.205 . . . . 0.0 111.766 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . 0.513 ' HB2' ' CE ' ' A' ' 180' ' ' LYS . 35.4 mmtp -95.21 151.86 18.86 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.249 -0.907 . . . . 0.0 109.446 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 52.4 p -104.07 18.32 22.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.228 -0.92 . . . . 0.0 109.508 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 63.7 mt -97.12 95.39 7.74 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.246 -0.909 . . . . 0.0 109.461 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -103.37 132.58 49.51 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.3 -0.875 . . . . 0.0 109.457 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.49 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.6 OUTLIER -133.38 153.16 80.38 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.236 -0.915 . . . . 0.0 109.476 179.961 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.49 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 49.8 Cg_endo -45.79 132.79 13.77 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.591 2.194 . . . . 0.0 111.762 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 89.57 -1.28 81.42 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 49.0 tp10 -94.5 127.98 40.77 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.131 -1.217 . . . . 0.0 109.423 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.453 ' HA ' ' HA ' ' A' ' 147' ' ' VAL . 81.6 mtp -68.14 153.96 42.67 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.208 -0.932 . . . . 0.0 109.438 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.431 HG11 ' HB ' ' A' ' 178' ' ' VAL . 2.5 t -138.1 178.82 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.218 -0.927 . . . . 0.0 109.284 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.511 ' N ' ' O ' ' A' ' 179' ' ' GLU . 76.3 ttt180 -135.42 148.09 49.19 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.25 -0.906 . . . . 0.0 109.458 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.473 ' O ' ' N ' ' A' ' 143' ' ' ASP . 48.5 t -118.15 126.91 75.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.278 -0.889 . . . . 0.0 109.471 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . 0.403 ' O ' ' OD1' ' A' ' 138' ' ' ASP . 26.2 p30 -126.28 12.87 7.66 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.249 -0.907 . . . . 0.0 109.492 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.458 ' CB ' ' OE1' ' A' ' 177' ' ' GLN . 93.5 m-20 -137.78 163.07 32.28 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.21 -0.931 . . . . 0.0 109.506 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 63.86 176.48 4.2 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -58.14 -24.49 66.8 Favored 'Trans proline' 0 C--O 1.216 -0.613 0 C-N-CA 122.597 2.198 . . . . 0.0 111.745 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . 0.417 ' O ' ' HB ' ' A' ' 136' ' ' VAL . 98.8 m-85 -82.81 7.87 13.95 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.224 -0.922 . . . . 0.0 109.488 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' ALA . . . . . 0.458 ' HA ' HG12 ' A' ' 136' ' ' VAL . . . -61.03 150.87 32.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.215 -0.928 . . . . 0.0 109.499 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.473 ' N ' ' O ' ' A' ' 136' ' ' VAL . 37.8 m-20 62.66 52.58 2.8 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.271 -0.893 . . . . 0.0 109.579 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.487 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 35.6 m-85 -150.4 132.02 14.88 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.237 -0.914 . . . . 0.0 109.489 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 56.5 m-20 -92.98 138.72 31.23 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.209 -0.932 . . . . 0.0 109.402 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -156.67 -179.65 31.8 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.522 ' O ' ' CG1' ' A' ' 160' ' ' VAL . 40.9 t -121.48 159.52 23.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.243 -1.151 . . . . 0.0 109.349 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.477 ' N ' HG11 ' A' ' 147' ' ' VAL . 2.5 p -100.26 115.62 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.281 -0.887 . . . . 0.0 109.519 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 83.3 mt-10 -70.52 -36.59 73.82 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.279 -0.888 . . . . 0.0 109.294 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.465 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 93.7 mt-10 -152.32 162.45 41.15 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.283 -0.886 . . . . 0.0 109.459 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 48.0 t -132.27 151.75 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.19 -0.944 . . . . 0.0 109.51 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' ASP . . . . . 0.517 ' O ' ' N ' ' A' ' 156' ' ' SER . 84.3 m-20 -125.52 98.58 5.65 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.243 -0.91 . . . . 0.0 109.424 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 87.4 m-85 -66.33 -35.8 81.29 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.219 -0.926 . . . . 0.0 109.572 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -66.94 -45.3 78.24 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.286 -0.883 . . . . 0.0 109.551 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 19.3 mttt -91.07 -8.55 48.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.242 -0.911 . . . . 0.0 109.512 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' SER . . . . . 0.517 ' N ' ' O ' ' A' ' 152' ' ' ASP . 44.3 t 55.75 52.33 11.04 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.548 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 83.3 mmt-85 -133.2 151.1 51.95 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.896 . . . . 0.0 109.327 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' LEU . . . . . 0.588 HD12 ' CD1' ' A' ' 175' ' ' PHE . 4.3 mp -118.16 137.12 53.19 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.18 -0.95 . . . . 0.0 109.592 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . 0.465 ' HD2' ' HB2' ' A' ' 150' ' ' GLU . 34.1 mttt -99.15 90.55 4.63 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.243 -0.911 . . . . 0.0 109.347 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . 0.522 ' CG1' ' O ' ' A' ' 147' ' ' VAL . 46.5 t -118.52 142.99 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.224 -0.922 . . . . 0.0 109.533 -179.759 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 27.0 t -112.53 136.64 51.82 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.245 -0.909 . . . . 0.0 109.395 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' VAL . . . . . 0.487 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 21.5 t -107.47 132.35 55.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.176 -0.953 . . . . 0.0 109.511 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 33.1 t -78.62 82.42 4.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.292 -0.88 . . . . 0.0 109.48 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.516 HD11 HG21 ' A' ' 164' ' ' ILE . 47.0 mt -105.35 141.81 19.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.191 -0.943 . . . . 0.0 109.398 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . 0.475 ' CE1' HG23 ' A' ' 164' ' ' ILE . 8.0 m-30 64.88 16.2 10.35 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.289 -0.882 . . . . 0.0 109.429 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 80.08 7.64 88.35 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 78.7 mtp180 -125.43 139.15 53.9 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.275 -1.133 . . . . 0.0 109.455 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -68.5 140.67 55.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.274 -0.891 . . . . 0.0 109.543 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 8.2 m -128.36 74.44 79.76 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.235 -0.916 . . . . 0.0 109.37 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -54.24 105.2 0.13 Allowed 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.579 2.186 . . . . 0.0 111.82 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 19.6 m -128.09 159.37 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.243 -0.911 . . . . 0.0 109.419 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.452 ' HA ' ' O ' ' A' ' 158' ' ' LEU . 95.9 mt-10 -102.91 130.93 50.13 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.213 -0.929 . . . . 0.0 109.45 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . 0.574 ' CD1' ' CG1' ' A' ' 178' ' ' VAL . 55.1 mt -125.02 160.84 28.07 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.276 -0.89 . . . . 0.0 109.527 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' ASP . . . . . 0.433 ' HB2' ' HG2' ' A' ' 177' ' ' GLN . 90.6 m-20 -82.82 176.78 9.04 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.3 -0.875 . . . . 0.0 109.558 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.588 ' CD1' HD12 ' A' ' 158' ' ' LEU . 3.2 m-85 -66.1 -39.77 90.24 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.333 -0.855 . . . . 0.0 109.613 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 15.4 m -79.81 -26.23 40.58 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.208 -0.933 . . . . 0.0 109.619 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 177' ' ' GLN . . . . . 0.458 ' OE1' ' CB ' ' A' ' 138' ' ' ASP . 96.6 mm-40 -67.08 -30.71 70.83 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.22 -0.925 . . . . 0.0 109.519 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.574 ' CG1' ' CD1' ' A' ' 173' ' ' LEU . 12.7 m -125.29 158.26 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.249 -0.907 . . . . 0.0 109.386 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 179' ' ' GLU . . . . . 0.511 ' O ' ' N ' ' A' ' 135' ' ' ARG . 70.6 tt0 -120.38 143.09 48.61 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.218 -0.926 . . . . 0.0 109.498 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 180' ' ' LYS . . . . . 0.513 ' CE ' ' HB2' ' A' ' 125' ' ' LYS . 23.6 ttmt -59.71 140.15 56.69 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.309 -0.87 . . . . 0.0 109.434 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.527 0 O-C-N 121.174 -0.954 . . . . 0.0 109.452 -179.984 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.522 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -55.34 145.82 65.06 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.621 2.214 . . . . 0.0 111.789 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . 0.459 ' O ' ' HD2' ' A' ' 180' ' ' LYS . 58.9 mttt -94.7 150.72 19.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.175 -0.953 . . . . 0.0 109.504 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 52.2 p -89.64 9.4 27.1 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.276 -0.89 . . . . 0.0 109.447 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 49.6 mt -91.46 98.46 11.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.241 -0.912 . . . . 0.0 109.449 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 92.2 m-85 -103.12 136.51 42.79 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.259 -0.901 . . . . 0.0 109.491 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.462 ' HB2' ' HD2' ' A' ' 130' ' ' PRO . 16.5 pt-20 -133.01 134.98 25.06 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.921 . . . . 0.0 109.454 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.462 ' HD2' ' HB2' ' A' ' 129' ' ' GLU . 49.2 Cg_endo -35.28 131.36 0.24 Allowed 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.517 2.145 . . . . 0.0 111.738 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . 0.487 ' C ' ' CG1' ' A' ' 147' ' ' VAL . . . 90.89 -4.48 81.71 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.469 ' O ' ' CG1' ' A' ' 147' ' ' VAL . 49.2 tp10 -83.58 141.7 31.38 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.125 -1.221 . . . . 0.0 109.548 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.471 ' HG2' ' CG2' ' A' ' 147' ' ' VAL . 90.5 mtp -80.94 150.11 29.11 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.184 -0.948 . . . . 0.0 109.438 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.454 HG12 ' O ' ' A' ' 179' ' ' GLU . 2.5 t -135.65 179.06 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.168 -0.958 . . . . 0.0 109.375 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.455 ' O ' ' HB ' ' A' ' 178' ' ' VAL . 94.5 mtt180 -132.86 146.52 51.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.318 -0.864 . . . . 0.0 109.467 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 41.4 t -112.53 130.42 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.265 -0.897 . . . . 0.0 109.423 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 54.9 p30 -123.37 19.21 9.75 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.201 -0.937 . . . . 0.0 109.534 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -156.27 151.24 26.26 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.212 -0.93 . . . . 0.0 109.493 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 82.27 164.16 33.97 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -54.19 -23.66 30.54 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.606 2.204 . . . . 0.0 111.779 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . 0.569 ' CD1' HG23 ' A' ' 162' ' ' VAL . 98.9 m-85 -86.87 11.05 14.26 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.252 -0.905 . . . . 0.0 109.391 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' ALA . . . . . 0.471 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -70.09 151.09 45.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.491 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.471 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 25.0 t0 74.9 28.62 1.09 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.279 -0.888 . . . . 0.0 109.517 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.504 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 92.5 m-85 -135.03 140.3 45.5 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.164 -0.96 . . . . 0.0 109.608 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 21.2 m120 -95.95 141.07 29.81 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.32 -0.862 . . . . 0.0 109.418 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -151.3 -173.42 21.18 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.487 ' CG1' ' C ' ' A' ' 131' ' ' GLY . 54.8 t -132.01 144.26 37.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.362 -1.081 . . . . 0.0 109.454 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.525 ' CA ' HG21 ' A' ' 160' ' ' VAL . 2.1 p -83.03 106.11 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.281 -0.887 . . . . 0.0 109.443 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 56.5 mp0 -70.2 -46.8 63.83 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.231 -0.918 . . . . 0.0 109.461 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -131.8 153.24 50.34 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.186 -0.947 . . . . 0.0 109.36 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.517 HG11 ' CD2' ' A' ' 158' ' ' LEU . 47.9 t -120.18 153.53 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.174 -0.954 . . . . 0.0 109.579 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 92.2 m-20 -135.76 83.25 2.0 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.306 -0.871 . . . . 0.0 109.339 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -67.03 -34.84 78.59 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.244 -0.91 . . . . 0.0 109.555 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 76.0 mm-40 -62.21 -40.81 97.32 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.202 -0.936 . . . . 0.0 109.562 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.442 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 31.7 tttt -96.88 -4.3 40.44 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.289 -0.882 . . . . 0.0 109.655 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' SER . . . . . 0.442 ' HB2' ' O ' ' A' ' 155' ' ' LYS . 19.8 m 59.9 53.05 4.92 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.195 -0.941 . . . . 0.0 109.46 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 13.5 tpt180 -142.63 138.97 31.07 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.281 -0.887 . . . . 0.0 109.488 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' LEU . . . . . 0.517 ' CD2' HG11 ' A' ' 151' ' ' VAL . 41.9 mt -108.08 134.63 50.68 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.252 -0.905 . . . . 0.0 109.524 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 62.8 tttm -97.28 97.08 8.85 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.225 -0.922 . . . . 0.0 109.418 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . 0.525 HG21 ' CA ' ' A' ' 148' ' ' VAL . 42.9 t -123.27 138.37 53.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.258 -0.901 . . . . 0.0 109.615 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' SER . . . . . 0.454 ' CB ' ' HA ' ' A' ' 170' ' ' PRO . 83.6 p -100.75 155.24 18.02 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.299 -0.876 . . . . 0.0 109.508 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' VAL . . . . . 0.569 HG23 ' CD1' ' A' ' 141' ' ' PHE . 5.3 t -106.14 129.15 59.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.25 -0.906 . . . . 0.0 109.479 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 55.1 m -75.78 81.5 2.72 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.286 -0.884 . . . . 0.0 109.383 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 75.1 mt -91.45 146.78 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.231 -0.918 . . . . 0.0 109.421 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -55.05 -47.65 74.52 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.248 -0.908 . . . . 0.0 109.75 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.526 ' O ' ' CB ' ' A' ' 167' ' ' ARG . . . -54.54 -34.22 55.14 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.788 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' ARG . . . . . 0.526 ' CB ' ' O ' ' A' ' 166' ' ' GLY . 7.9 mtm180 161.26 167.14 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.315 -1.109 . . . . 0.0 109.423 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -69.39 138.87 53.98 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.221 -0.924 . . . . 0.0 109.384 179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 29.7 m -123.04 87.85 51.0 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.172 -0.955 . . . . 0.0 109.526 -179.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.454 ' HA ' ' CB ' ' A' ' 161' ' ' SER . 50.2 Cg_endo -62.74 107.53 0.62 Allowed 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.558 2.172 . . . . 0.0 111.685 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' A' ' 160' ' ' VAL . 18.9 m -129.97 156.92 42.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.278 -0.889 . . . . 0.0 109.567 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.448 ' O ' HD22 ' A' ' 173' ' ' LEU . 94.5 mt-10 -103.97 129.38 51.54 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.281 -0.887 . . . . 0.0 109.371 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . 0.524 ' HB2' ' CG1' ' A' ' 178' ' ' VAL . 65.5 mt -126.25 147.89 49.6 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.268 -0.895 . . . . 0.0 109.471 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -68.5 173.35 5.07 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.25 -0.907 . . . . 0.0 109.407 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.492 ' N ' ' CD1' ' A' ' 175' ' ' PHE . 2.9 m-30 -66.51 -40.24 89.11 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.248 -0.907 . . . . 0.0 109.446 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 14.8 m -75.36 -24.41 57.29 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.231 -0.918 . . . . 0.0 109.406 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -70.32 -28.8 65.45 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.219 -0.926 . . . . 0.0 109.499 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.524 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 4.4 m -127.95 161.08 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.231 -0.918 . . . . 0.0 109.468 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 179' ' ' GLU . . . . . 0.454 ' O ' HG12 ' A' ' 134' ' ' VAL . 75.0 mm-40 -120.0 148.64 43.31 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.236 -0.915 . . . . 0.0 109.505 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 180' ' ' LYS . . . . . 0.459 ' HD2' ' O ' ' A' ' 125' ' ' LYS . 20.1 tttt -58.95 140.56 55.43 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.188 -0.945 . . . . 0.0 109.485 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.589 0 O-C-N 121.21 -0.932 . . . . 0.0 109.43 179.984 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.436 ' N ' ' CD ' ' A' ' 124' ' ' PRO . 2.5 ttp85 . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.436 ' CD ' ' N ' ' A' ' 123' ' ' ARG . 49.2 Cg_endo -55.87 142.79 83.63 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.608 2.206 . . . . 0.0 111.847 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . 0.43 ' HB2' ' HD3' ' A' ' 180' ' ' LYS . 22.0 mttp -116.87 143.67 45.42 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -0.89 . . . . 0.0 109.497 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 48.7 p -113.41 21.46 15.16 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.224 -0.922 . . . . 0.0 109.478 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 56.2 mt -98.55 95.23 7.15 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.206 -0.934 . . . . 0.0 109.463 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.436 ' CD2' HD22 ' A' ' 158' ' ' LEU . 92.0 m-85 -96.84 131.4 43.62 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.368 -0.833 . . . . 0.0 109.455 179.861 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.475 ' HB2' ' HD2' ' A' ' 130' ' ' PRO . 2.2 pt-20 -142.35 147.31 42.91 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.231 -0.918 . . . . 0.0 109.418 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.475 ' HD2' ' HB2' ' A' ' 129' ' ' GLU . 48.8 Cg_endo -40.95 128.47 2.79 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.436 2.091 . . . . 0.0 111.84 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 100.28 -4.19 56.96 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.461 ' CG ' ' HG3' ' A' ' 129' ' ' GLU . 78.1 mm-40 -93.03 144.32 25.37 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.207 -1.172 . . . . 0.0 109.541 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.472 ' SD ' ' CG2' ' A' ' 147' ' ' VAL . 77.3 mmm -83.48 143.08 30.47 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.225 -0.922 . . . . 0.0 109.413 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.519 HG21 ' CG2' ' A' ' 148' ' ' VAL . 2.5 t -128.63 178.59 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.225 -0.922 . . . . 0.0 109.362 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.443 ' O ' ' HB ' ' A' ' 178' ' ' VAL . 40.0 ttt85 -141.88 145.8 35.04 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.343 -0.848 . . . . 0.0 109.405 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.472 HG21 ' CD1' ' A' ' 173' ' ' LEU . 43.5 t -112.48 135.29 52.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.235 -0.915 . . . . 0.0 109.495 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 34.6 p30 -126.67 10.41 7.17 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.279 -0.888 . . . . 0.0 109.411 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.451 ' HB3' ' HG3' ' A' ' 177' ' ' GLN . 49.9 t0 -150.58 159.04 44.78 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.229 -0.919 . . . . 0.0 109.541 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.416 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 77.52 165.33 24.63 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -50.45 -22.33 8.74 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 122.593 2.195 . . . . 0.0 111.721 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . 0.528 ' CZ ' HG13 ' A' ' 171' ' ' VAL . 93.9 m-85 -88.61 12.57 14.31 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.207 -0.933 . . . . 0.0 109.485 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' ALA . . . . . 0.451 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -62.83 149.2 44.86 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.339 -0.851 . . . . 0.0 109.529 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.446 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 44.7 m-20 63.28 45.31 5.07 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.472 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.52 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 46.0 m-85 -147.08 126.08 12.83 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.184 -0.947 . . . . 0.0 109.474 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 67.8 m-20 -88.42 145.24 25.89 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.224 -0.923 . . . . 0.0 109.605 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -157.1 177.26 34.06 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.495 HG13 ' N ' ' A' ' 148' ' ' VAL . 22.0 t -114.86 156.69 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.177 -1.19 . . . . 0.0 109.395 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.519 ' CG2' HG21 ' A' ' 134' ' ' VAL . 47.8 t -82.37 104.11 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.248 -0.907 . . . . 0.0 109.498 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.426 ' C ' ' HG2' ' A' ' 150' ' ' GLU . 97.2 mt-10 -69.86 -35.41 74.69 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.282 -0.886 . . . . 0.0 109.36 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.453 ' HB2' ' HD3' ' A' ' 159' ' ' LYS . 76.1 mm-40 -152.81 164.88 36.98 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.322 -0.861 . . . . 0.0 109.41 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 46.5 t -128.56 143.48 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.267 -0.896 . . . . 0.0 109.424 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 93.8 m-20 -124.91 78.31 1.69 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.19 -0.944 . . . . 0.0 109.542 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -59.87 -42.21 93.24 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.238 -0.914 . . . . 0.0 109.385 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -54.61 -45.08 73.6 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.244 -0.91 . . . . 0.0 109.366 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 44.2 mttp -86.23 -2.96 58.85 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.264 -0.897 . . . . 0.0 109.515 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 17.1 m 55.68 53.7 9.21 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.183 -0.948 . . . . 0.0 109.358 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 66.9 mtt180 -147.95 162.79 38.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 109.534 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' LEU . . . . . 0.638 ' CD1' ' CE1' ' A' ' 175' ' ' PHE . 6.7 mp -114.02 139.27 49.4 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.331 -0.856 . . . . 0.0 109.428 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . 0.453 ' HD3' ' HB2' ' A' ' 150' ' ' GLU . 41.1 tttt -104.56 100.22 9.9 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.158 -0.963 . . . . 0.0 109.312 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . 0.47 HG11 ' N ' ' A' ' 161' ' ' SER . 39.9 t -119.9 148.52 22.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.207 -0.933 . . . . 0.0 109.549 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' SER . . . . . 0.47 ' N ' HG11 ' A' ' 160' ' ' VAL . 22.7 t -117.95 138.85 51.88 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.245 -0.909 . . . . 0.0 109.333 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' VAL . . . . . 0.52 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 4.4 t -107.19 133.13 52.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.182 -0.949 . . . . 0.0 109.708 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 44.1 t -82.93 81.84 8.45 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.321 -0.862 . . . . 0.0 109.311 179.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.547 HG23 ' CE2' ' A' ' 165' ' ' PHE . 59.5 mt -97.19 134.91 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.142 -0.974 . . . . 0.0 109.469 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . 0.547 ' CE2' HG23 ' A' ' 164' ' ' ILE . 79.4 m-85 62.14 27.69 16.67 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.296 -0.878 . . . . 0.0 109.474 -179.903 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 70.13 13.09 69.63 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.792 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 76.1 mtm180 -119.35 141.1 49.33 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.252 -1.146 . . . . 0.0 109.441 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -80.12 134.6 36.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.2 -0.938 . . . . 0.0 109.413 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 169' ' ' THR . . . . . 0.458 HG21 ' CZ ' ' A' ' 141' ' ' PHE . 57.3 m -128.65 73.32 80.92 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.286 -0.884 . . . . 0.0 109.437 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.453 ' HA ' ' CB ' ' A' ' 161' ' ' SER . 49.6 Cg_endo -52.1 108.42 0.25 Allowed 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.69 2.26 . . . . 0.0 111.89 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.528 HG13 ' CZ ' ' A' ' 141' ' ' PHE . 20.5 m -126.04 155.12 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.264 -0.898 . . . . 0.0 109.417 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.439 ' O ' HD21 ' A' ' 173' ' ' LEU . 95.3 mt-10 -90.89 129.99 36.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.213 -0.929 . . . . 0.0 109.553 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . 0.48 ' HB3' ' CG1' ' A' ' 178' ' ' VAL . 61.9 mt -122.02 154.91 36.63 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.234 -0.916 . . . . 0.0 109.49 179.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 174' ' ' ASP . . . . . 0.456 ' HB2' ' HB2' ' A' ' 177' ' ' GLN . 85.1 m-20 -83.81 154.95 23.23 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.221 -0.925 . . . . 0.0 109.629 -179.867 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.638 ' CE1' ' CD1' ' A' ' 158' ' ' LEU . 25.4 m-85 -51.14 -50.24 59.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.38 -0.825 . . . . 0.0 109.615 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 72.4 p -74.8 -18.45 60.46 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.223 -0.923 . . . . 0.0 109.594 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 177' ' ' GLN . . . . . 0.456 ' HB2' ' HB2' ' A' ' 174' ' ' ASP . 65.7 tt0 -72.95 -25.15 60.92 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.301 -0.874 . . . . 0.0 109.448 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.48 ' CG1' ' HB3' ' A' ' 173' ' ' LEU . 5.2 m -125.34 161.81 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.154 -0.966 . . . . 0.0 109.487 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 179' ' ' GLU . . . . . . . . . . . . . 61.1 mt-10 -118.42 148.96 42.01 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.225 -0.922 . . . . 0.0 109.482 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 180' ' ' LYS . . . . . 0.43 ' HD3' ' HB2' ' A' ' 125' ' ' LYS . 21.1 tttm -79.79 132.65 36.19 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.34 -0.85 . . . . 0.0 109.449 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.499 0 O-C-N 121.278 -0.889 . . . . 0.0 109.49 179.99 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 9.5 mmt180 . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -54.47 147.33 48.1 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.606 2.204 . . . . 0.0 111.819 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 49.6 mttp -101.54 140.63 35.56 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.139 -0.976 . . . . 0.0 109.553 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 47.6 p -113.58 26.59 10.26 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.242 -0.911 . . . . 0.0 109.438 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 66.4 mt -95.01 91.98 6.63 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.254 -0.903 . . . . 0.0 109.431 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.416 ' CG ' HD21 ' A' ' 158' ' ' LEU . 75.2 m-85 -79.13 131.61 36.29 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.295 -0.878 . . . . 0.0 109.386 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.455 ' HB3' ' HD2' ' A' ' 130' ' ' PRO . 0.6 OUTLIER -129.46 150.04 74.5 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.206 -0.934 . . . . 0.0 109.469 -179.99 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.455 ' HD2' ' HB3' ' A' ' 129' ' ' GLU . 50.0 Cg_endo -47.27 123.48 7.81 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.67 2.247 . . . . 0.0 111.771 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 99.29 2.17 56.78 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.626 -1.389 . . . . 0.0 109.626 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.448 ' HG2' ' O ' ' A' ' 129' ' ' GLU . 74.9 mm-40 -92.32 141.3 28.71 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.186 -1.185 . . . . 0.0 109.438 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.506 ' SD ' ' CG2' ' A' ' 147' ' ' VAL . 84.4 mmm -74.18 142.18 45.46 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.234 -0.916 . . . . 0.0 109.468 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.435 HG11 ' HB ' ' A' ' 178' ' ' VAL . 2.5 t -130.27 178.96 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.248 -0.908 . . . . 0.0 109.347 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.451 ' O ' ' HB ' ' A' ' 178' ' ' VAL . 45.7 ttt85 -142.44 135.75 28.8 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.333 -0.855 . . . . 0.0 109.429 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.494 HG22 ' CD1' ' A' ' 173' ' ' LEU . 66.3 t -106.29 133.56 50.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.264 -0.897 . . . . 0.0 109.444 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 11.4 p30 -132.06 22.11 4.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.302 -0.874 . . . . 0.0 109.431 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.457 ' HB3' ' HG3' ' A' ' 177' ' ' GLN . 51.7 t0 -143.23 156.42 44.74 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.243 -0.911 . . . . 0.0 109.447 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.452 ' O ' ' N ' ' A' ' 142' ' ' ALA . . . 62.98 167.17 0.74 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -44.28 -24.86 1.08 Allowed 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.585 2.19 . . . . 0.0 111.795 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . 0.546 ' CE1' HD11 ' A' ' 164' ' ' ILE . 88.0 m-85 -86.57 14.96 6.04 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.255 -0.903 . . . . 0.0 109.468 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' ALA . . . . . 0.518 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -73.67 145.24 45.43 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.285 -0.885 . . . . 0.0 109.501 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.44 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 3.5 m-20 71.05 43.83 0.63 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.318 -0.864 . . . . 0.0 109.526 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.518 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 80.9 m-85 -142.25 139.98 32.12 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.25 -0.906 . . . . 0.0 109.522 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 78.9 m-20 -94.05 138.99 31.52 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.235 -0.916 . . . . 0.0 109.46 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -153.1 179.8 29.23 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.506 ' CG2' ' SD ' ' A' ' 133' ' ' MET . 22.8 t -124.18 151.38 29.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.256 -1.144 . . . . 0.0 109.449 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.501 ' CG2' HG23 ' A' ' 151' ' ' VAL . 3.1 p -87.28 95.23 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.219 -0.925 . . . . 0.0 109.552 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -65.75 -36.35 83.33 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.219 -0.925 . . . . 0.0 109.408 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.483 ' HG2' ' N ' ' A' ' 151' ' ' VAL . 84.7 tt0 -142.21 160.36 40.4 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.33 -0.856 . . . . 0.0 109.385 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.501 HG23 ' CG2' ' A' ' 148' ' ' VAL . 39.8 t -131.37 149.06 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.258 -0.901 . . . . 0.0 109.467 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -131.04 94.64 3.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.24 -0.912 . . . . 0.0 109.501 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -66.69 -32.9 74.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.257 -0.902 . . . . 0.0 109.487 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -61.81 -42.71 99.36 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -0.916 . . . . 0.0 109.368 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 29.9 mttm -90.03 -6.38 55.63 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.258 -0.901 . . . . 0.0 109.471 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 57.48 52.76 8.13 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.23 -0.919 . . . . 0.0 109.475 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 75.3 mtt180 -147.13 165.83 28.78 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.222 -0.924 . . . . 0.0 109.536 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' LEU . . . . . 0.638 ' CD1' ' CD1' ' A' ' 175' ' ' PHE . 3.5 mp -116.01 133.94 55.49 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.227 -0.921 . . . . 0.0 109.532 -179.736 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 80.8 tttt -91.53 85.77 5.83 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.183 -0.948 . . . . 0.0 109.298 179.765 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 147' ' ' VAL . 61.1 t -110.4 144.28 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.264 -0.898 . . . . 0.0 109.603 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 60.0 p -107.76 140.51 40.71 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.282 -0.886 . . . . 0.0 109.348 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' VAL . . . . . 0.457 HG12 ' HB3' ' A' ' 144' ' ' PHE . 6.6 t -110.29 131.98 59.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.242 -0.911 . . . . 0.0 109.59 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 32.6 t -78.63 82.12 4.9 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.233 -0.917 . . . . 0.0 109.42 179.85 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.546 HD11 ' CE1' ' A' ' 141' ' ' PHE . 68.9 mt -112.59 146.87 16.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.26 -0.9 . . . . 0.0 109.535 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . 0.523 ' CE2' ' CG2' ' A' ' 164' ' ' ILE . 28.2 m-85 68.84 13.73 8.87 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.246 -0.909 . . . . 0.0 109.408 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 80.09 22.71 62.76 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 167' ' ' ARG . . . . . 0.436 ' HG2' ' O ' ' A' ' 164' ' ' ILE . 39.0 ptt180 -148.44 155.42 41.18 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.245 -1.15 . . . . 0.0 109.413 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -75.44 143.23 42.77 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.267 -0.895 . . . . 0.0 109.46 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 27.2 m -130.12 70.61 82.23 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.237 -0.914 . . . . 0.0 109.441 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -46.88 108.15 0.15 Allowed 'Trans proline' 0 C--O 1.214 -0.683 0 C-N-CA 122.613 2.209 . . . . 0.0 111.858 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 21.2 m -133.26 154.28 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.283 -0.886 . . . . 0.0 109.424 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.459 ' O ' HD23 ' A' ' 173' ' ' LEU . 94.5 mt-10 -100.08 136.36 40.1 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.18 -0.95 . . . . 0.0 109.451 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . 0.494 ' CD1' HG22 ' A' ' 136' ' ' VAL . 47.7 mt -131.01 152.47 50.29 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.285 -0.884 . . . . 0.0 109.513 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -69.54 156.34 39.05 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.245 -0.909 . . . . 0.0 109.515 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.638 ' CD1' ' CD1' ' A' ' 158' ' ' LEU . 51.0 m-85 -53.08 -44.48 67.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.547 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 82.5 p -75.3 -20.03 59.33 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.159 -0.963 . . . . 0.0 109.587 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 177' ' ' GLN . . . . . 0.457 ' HG3' ' HB3' ' A' ' 138' ' ' ASP . 50.6 tt0 -72.02 -24.55 61.57 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.283 -0.886 . . . . 0.0 109.503 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.462 ' CG1' HD12 ' A' ' 173' ' ' LEU . 17.7 m -127.26 163.55 30.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.26 -0.9 . . . . 0.0 109.516 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 179' ' ' GLU . . . . . 0.435 ' HB2' ' HB3' ' A' ' 135' ' ' ARG . 63.6 mm-40 -114.79 151.02 34.5 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.281 -0.887 . . . . 0.0 109.483 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 24.3 tttt -81.18 131.67 35.31 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.255 -0.903 . . . . 0.0 109.508 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . 0.455 ' HB2' ' O ' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.544 0 O-C-N 121.193 -0.942 . . . . 0.0 109.415 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -55.62 151.1 40.46 Favored 'Trans proline' 0 C--O 1.214 -0.707 0 C-N-CA 122.642 2.228 . . . . 0.0 111.732 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . 0.466 ' HB3' ' CD2' ' A' ' 127' ' ' LEU . 71.2 mttt -82.34 142.17 32.25 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.265 -0.897 . . . . 0.0 109.397 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.526 ' O ' ' CD2' ' A' ' 128' ' ' PHE . 72.9 p -104.02 15.87 27.55 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.316 -0.865 . . . . 0.0 109.49 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.519 ' O ' ' CG ' ' A' ' 127' ' ' LEU . 1.3 pp -74.91 99.66 3.88 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.239 -0.913 . . . . 0.0 109.426 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.526 ' CD2' ' O ' ' A' ' 126' ' ' THR . 93.0 m-85 -102.53 129.1 48.97 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.163 -0.96 . . . . 0.0 109.423 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.433 ' O ' ' HB2' ' A' ' 132' ' ' GLU . 1.8 mm-40 -103.32 139.59 20.25 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.265 -0.897 . . . . 0.0 109.442 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.425 ' HD2' ' HB3' ' A' ' 129' ' ' GLU . 49.3 Cg_endo -43.25 135.82 5.82 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.623 2.215 . . . . 0.0 111.712 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 80.35 6.75 89.1 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.433 ' HB2' ' O ' ' A' ' 129' ' ' GLU . 85.0 tt0 -89.04 128.76 35.74 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.269 -1.136 . . . . 0.0 109.448 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.447 ' HA ' ' O ' ' A' ' 146' ' ' GLY . 42.2 ttm -68.19 144.57 54.9 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.235 -0.916 . . . . 0.0 109.44 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.423 HG13 ' O ' ' A' ' 179' ' ' GLU . 2.5 t -131.4 179.15 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.242 -0.911 . . . . 0.0 109.316 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.451 ' O ' ' HA ' ' A' ' 178' ' ' VAL . 28.4 ttt85 -129.99 135.98 48.9 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.196 -0.94 . . . . 0.0 109.42 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.427 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 60.7 t -107.71 133.87 51.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.213 -0.93 . . . . 0.0 109.498 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . 0.412 ' OD1' ' C ' ' A' ' 137' ' ' ASN . 44.0 p30 -132.59 23.39 4.34 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.239 -0.913 . . . . 0.0 109.462 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -142.85 144.08 32.36 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.269 -0.894 . . . . 0.0 109.531 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 75.49 172.85 32.58 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -52.1 -17.17 5.42 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.669 2.246 . . . . 0.0 111.756 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . 0.573 ' CD1' HG22 ' A' ' 162' ' ' VAL . 97.0 m-85 -92.68 17.51 10.17 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.28 -0.887 . . . . 0.0 109.495 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' ALA . . . . . 0.553 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -73.33 149.88 42.28 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.324 -0.86 . . . . 0.0 109.498 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.464 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 35.2 m-20 65.14 48.27 2.26 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.205 -0.935 . . . . 0.0 109.527 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.553 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 64.1 m-85 -147.22 146.89 29.96 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.218 -0.926 . . . . 0.0 109.404 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . 0.424 ' O ' ' OD1' ' A' ' 145' ' ' ASN . 44.0 p-10 -102.56 151.38 22.39 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.257 -0.902 . . . . 0.0 109.414 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . 0.447 ' O ' ' HA ' ' A' ' 133' ' ' MET . . . -164.95 -174.45 34.67 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.454 ' O ' HG13 ' A' ' 160' ' ' VAL . 96.7 t -130.29 150.75 34.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.18 -1.188 . . . . 0.0 109.427 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.468 HG13 ' O ' ' A' ' 148' ' ' VAL . 2.1 p -89.61 107.2 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.178 -0.951 . . . . 0.0 109.502 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -70.86 -37.4 73.09 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.182 -0.949 . . . . 0.0 109.396 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -138.64 157.5 46.02 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.355 -0.841 . . . . 0.0 109.338 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.408 HG23 HG23 ' A' ' 148' ' ' VAL . 57.1 t -130.81 149.79 33.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.179 -0.95 . . . . 0.0 109.417 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' ASP . . . . . 0.4 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 95.3 m-20 -136.43 90.17 2.54 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.273 -0.892 . . . . 0.0 109.484 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -67.56 -37.0 82.03 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.233 -0.917 . . . . 0.0 109.495 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -63.6 -42.61 98.24 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.257 -0.902 . . . . 0.0 109.411 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.401 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 58.2 mttt -89.44 -4.64 57.9 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.248 -0.908 . . . . 0.0 109.478 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 58.5 m 55.65 52.73 10.54 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.171 -0.956 . . . . 0.0 109.439 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . 0.425 ' HD3' ' OD1' ' A' ' 174' ' ' ASP . 15.6 mmt85 -144.64 141.97 29.77 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.213 -0.93 . . . . 0.0 109.427 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' LEU . . . . . 0.515 HD12 ' CD2' ' A' ' 128' ' ' PHE . 40.1 mt -111.74 132.34 54.71 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -0.901 . . . . 0.0 109.577 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 22.0 tttt -94.9 91.74 6.57 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.23 -0.919 . . . . 0.0 109.277 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . 0.454 HG13 ' O ' ' A' ' 147' ' ' VAL . 33.1 t -117.98 144.55 25.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.281 -0.887 . . . . 0.0 109.466 -179.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' SER . . . . . 0.448 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 61.8 m -99.84 148.62 24.23 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.241 -0.912 . . . . 0.0 109.45 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' VAL . . . . . 0.573 HG22 ' CD1' ' A' ' 141' ' ' PHE . 6.2 t -96.53 138.39 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.29 -0.881 . . . . 0.0 109.621 -179.873 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 19.7 m -86.58 83.39 7.63 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.266 -0.896 . . . . 0.0 109.254 179.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.468 HD11 HG22 ' A' ' 164' ' ' ILE . 43.8 mt -98.96 139.28 21.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.254 -0.904 . . . . 0.0 109.537 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -53.79 -41.5 67.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.35 -0.844 . . . . 0.0 109.743 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.526 ' O ' ' CB ' ' A' ' 167' ' ' ARG . . . -60.61 -34.01 84.4 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.646 -1.381 . . . . 0.0 109.646 -179.741 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 167' ' ' ARG . . . . . 0.526 ' CB ' ' O ' ' A' ' 166' ' ' GLY . 17.8 ttp180 161.78 148.49 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.461 -1.023 . . . . 0.0 109.151 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -61.18 143.67 55.11 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.243 -0.91 . . . . 0.0 109.33 179.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 169' ' ' THR . . . . . 0.458 HG22 ' CZ ' ' A' ' 141' ' ' PHE . 36.6 m -126.36 98.57 32.08 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.17 -0.956 . . . . 0.0 109.554 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 50.3 Cg_endo -70.26 103.89 1.32 Allowed 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.492 2.128 . . . . 0.0 111.707 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.407 ' CG2' ' CD2' ' A' ' 173' ' ' LEU . 14.6 m -129.25 161.08 39.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.246 -0.909 . . . . 0.0 109.523 -179.866 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.452 ' O ' HD11 ' A' ' 173' ' ' LEU . 96.5 mt-10 -99.03 129.15 45.29 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.277 -0.889 . . . . 0.0 109.4 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . 0.541 ' CD2' ' N ' ' A' ' 173' ' ' LEU . 2.8 mm? -125.41 146.3 49.67 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.192 -0.942 . . . . 0.0 109.529 -179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 174' ' ' ASP . . . . . 0.425 ' OD1' ' HD3' ' A' ' 157' ' ' ARG . 87.4 m-20 -69.35 170.36 10.52 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.228 -0.92 . . . . 0.0 109.489 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.538 ' N ' ' CD1' ' A' ' 175' ' ' PHE . 2.7 m-30 -65.74 -40.64 92.34 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.269 -0.895 . . . . 0.0 109.47 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 83.0 p -75.51 -28.66 59.23 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.362 -0.836 . . . . 0.0 109.499 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 177' ' ' GLN . . . . . 0.408 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 90.2 mt-30 -65.76 -23.55 66.75 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.293 -0.879 . . . . 0.0 109.435 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.452 HG13 ' HB2' ' A' ' 173' ' ' LEU . 12.3 m -130.23 164.42 33.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.259 -0.901 . . . . 0.0 109.452 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 179' ' ' GLU . . . . . 0.423 ' O ' HG13 ' A' ' 134' ' ' VAL . 76.3 mt-10 -119.41 142.49 48.16 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.259 -0.901 . . . . 0.0 109.542 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 180' ' ' LYS . . . . . 0.404 ' NZ ' ' HG ' ' A' ' 127' ' ' LEU . 31.4 ttmt -62.6 134.86 56.97 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.159 -0.963 . . . . 0.0 109.521 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . 0.445 ' CB ' ' HG2' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.128 -0.982 . . . . 0.0 109.391 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 4.5 mmt180 . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -58.32 143.01 97.93 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.576 2.184 . . . . 0.0 111.76 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 11.1 mtmt -102.12 150.4 23.3 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.3 -0.875 . . . . 0.0 109.514 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 61.8 p -92.62 14.2 17.7 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.289 -0.882 . . . . 0.0 109.466 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.458 ' O ' ' HE3' ' A' ' 180' ' ' LYS . 47.6 mt -89.81 97.67 11.32 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.208 -0.933 . . . . 0.0 109.529 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.563 ' CD2' HD21 ' A' ' 158' ' ' LEU . 89.6 m-85 -106.5 134.43 49.65 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.33 -0.856 . . . . 0.0 109.446 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.45 ' HB3' ' HD2' ' A' ' 130' ' ' PRO . 3.5 mt-10 -139.41 150.04 62.54 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.241 -0.912 . . . . 0.0 109.354 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.457 ' HA ' ' O ' ' A' ' 148' ' ' VAL . 49.4 Cg_endo -46.33 128.88 12.74 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.418 2.079 . . . . 0.0 111.751 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 93.69 3.61 64.28 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.438 ' HG2' ' O ' ' A' ' 129' ' ' GLU . 76.7 mm-40 -98.57 138.57 35.57 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.168 -1.196 . . . . 0.0 109.455 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 78.5 mtp -76.12 148.78 37.61 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.23 -0.919 . . . . 0.0 109.468 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 2.5 t -137.21 179.38 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.26 -0.9 . . . . 0.0 109.375 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.447 ' O ' ' HB ' ' A' ' 178' ' ' VAL . 43.6 ttt180 -135.7 135.01 39.72 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.104 -0.997 . . . . 0.0 109.503 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.454 ' O ' ' N ' ' A' ' 143' ' ' ASP . 80.3 t -108.73 135.72 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.298 -0.877 . . . . 0.0 109.502 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 31.6 p30 -131.83 18.98 4.62 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.242 -0.911 . . . . 0.0 109.438 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -132.52 144.07 50.17 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.31 -0.869 . . . . 0.0 109.408 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 71.66 175.99 24.57 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -53.22 -19.49 12.51 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.608 2.205 . . . . 0.0 111.779 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . 0.428 ' O ' ' HB ' ' A' ' 136' ' ' VAL . 90.5 m-85 -88.61 12.65 14.08 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.279 -0.888 . . . . 0.0 109.415 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' ALA . . . . . 0.448 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -71.96 150.38 44.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.28 -0.888 . . . . 0.0 109.403 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.454 ' N ' ' O ' ' A' ' 136' ' ' VAL . 31.9 m-20 63.49 48.69 3.37 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.169 -0.957 . . . . 0.0 109.449 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.448 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 43.3 m-85 -145.06 143.05 30.24 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.147 -0.971 . . . . 0.0 109.524 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 73.6 m-20 -95.89 145.08 25.67 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.248 -0.908 . . . . 0.0 109.5 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -161.7 -178.42 35.6 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.439 HG13 ' N ' ' A' ' 148' ' ' VAL . 40.6 t -126.1 147.23 30.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.256 -1.143 . . . . 0.0 109.408 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 130' ' ' PRO . 2.5 p -82.95 99.37 5.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.179 -0.951 . . . . 0.0 109.467 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -66.59 -34.21 77.37 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.245 -0.91 . . . . 0.0 109.391 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.475 ' HB2' ' CD ' ' A' ' 159' ' ' LYS . 75.5 mm-40 -147.0 162.47 38.7 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.27 -0.894 . . . . 0.0 109.386 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 41.0 t -129.17 146.69 33.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.2 -0.937 . . . . 0.0 109.487 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -127.63 96.48 4.55 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.203 -0.936 . . . . 0.0 109.511 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -66.29 -40.3 89.94 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.305 -0.872 . . . . 0.0 109.475 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -62.37 -42.19 99.21 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.201 -0.937 . . . . 0.0 109.431 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.413 ' O ' ' OG ' ' A' ' 156' ' ' SER . 47.9 mttt -83.93 0.79 46.4 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.278 -0.889 . . . . 0.0 109.548 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' SER . . . . . 0.413 ' OG ' ' O ' ' A' ' 155' ' ' LYS . 24.3 p 45.62 57.04 5.28 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.216 -0.927 . . . . 0.0 109.465 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . 0.459 ' HG2' ' OD1' ' A' ' 174' ' ' ASP . 30.4 mtt180 -155.49 165.5 36.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.277 -0.89 . . . . 0.0 109.516 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' LEU . . . . . 0.641 ' CD1' ' CD1' ' A' ' 175' ' ' PHE . 4.3 mp -114.34 137.3 51.98 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.241 -0.912 . . . . 0.0 109.453 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . 0.475 ' CD ' ' HB2' ' A' ' 150' ' ' GLU . 40.4 tttp -92.97 94.88 9.15 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.184 -0.947 . . . . 0.0 109.339 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . 0.467 HG11 ' N ' ' A' ' 161' ' ' SER . 45.1 t -122.04 146.04 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.28 -0.888 . . . . 0.0 109.602 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' SER . . . . . 0.467 ' N ' HG11 ' A' ' 160' ' ' VAL . 29.3 t -111.82 141.64 45.19 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.329 -0.857 . . . . 0.0 109.28 179.868 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' VAL . . . . . . . . . . . . . 12.1 t -113.28 131.09 65.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.132 -0.98 . . . . 0.0 109.563 -179.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 35.5 t -83.24 81.53 8.66 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.291 -0.881 . . . . 0.0 109.403 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.42 ' O ' ' HB3' ' A' ' 165' ' ' PHE . 45.2 mt -102.27 139.03 24.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.288 -0.882 . . . . 0.0 109.321 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . 0.522 ' CD2' ' O ' ' A' ' 165' ' ' PHE . 45.7 t80 65.42 12.11 7.88 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.281 -0.887 . . . . 0.0 109.404 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 80.75 11.56 83.81 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 42.1 mtp-105 -120.2 138.25 53.73 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.239 -1.154 . . . . 0.0 109.443 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -71.16 137.76 49.05 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.267 -0.896 . . . . 0.0 109.411 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 169' ' ' THR . . . . . 0.439 ' O ' HG12 ' A' ' 171' ' ' VAL . 1.9 m -133.01 75.96 71.07 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.292 -0.88 . . . . 0.0 109.458 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -56.69 104.2 0.14 Allowed 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.622 2.215 . . . . 0.0 111.836 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.439 HG12 ' O ' ' A' ' 169' ' ' THR . 18.2 m -129.34 155.56 41.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.305 -0.872 . . . . 0.0 109.419 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.447 ' O ' HD13 ' A' ' 173' ' ' LEU . 95.5 mt-10 -102.01 129.61 48.35 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.217 -0.927 . . . . 0.0 109.522 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . 0.578 ' CD2' ' N ' ' A' ' 173' ' ' LEU . 2.3 mm? -121.54 149.82 42.54 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.269 -0.895 . . . . 0.0 109.39 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 174' ' ' ASP . . . . . 0.459 ' OD1' ' HG2' ' A' ' 157' ' ' ARG . 82.1 m-20 -68.93 157.95 35.62 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.279 -0.888 . . . . 0.0 109.515 179.956 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.641 ' CD1' ' CD1' ' A' ' 158' ' ' LEU . 98.7 m-85 -61.25 -40.79 95.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.293 -0.879 . . . . 0.0 109.334 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 28.6 m -74.98 -19.7 59.98 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.222 -0.923 . . . . 0.0 109.313 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 89.9 mt-30 -82.16 -20.01 38.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.348 -0.845 . . . . 0.0 109.245 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.517 ' CG1' ' CB ' ' A' ' 173' ' ' LEU . 19.3 m -124.9 161.88 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.396 -0.815 . . . . 0.0 109.264 179.821 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 179' ' ' GLU . . . . . 0.402 ' HB2' ' HB3' ' A' ' 135' ' ' ARG . 61.8 mt-10 -121.31 153.26 37.95 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.133 -0.98 . . . . 0.0 109.695 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 180' ' ' LYS . . . . . 0.458 ' HE3' ' O ' ' A' ' 127' ' ' LEU . 17.8 tttm -74.14 135.52 42.87 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.322 -0.861 . . . . 0.0 109.451 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.309 -0.869 . . . . 0.0 109.494 179.989 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 6.8 mmt85 . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -56.35 148.64 60.46 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.587 2.191 . . . . 0.0 111.738 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 33.9 tptt -83.41 133.66 34.92 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.237 -0.915 . . . . 0.0 109.529 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.568 HG23 ' CE2' ' A' ' 128' ' ' PHE . 95.0 m -73.25 125.44 27.78 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.256 -0.903 . . . . 0.0 109.444 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.438 ' O ' ' HE3' ' A' ' 180' ' ' LYS . 48.3 mt -140.5 81.57 1.81 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.162 -0.961 . . . . 0.0 109.695 -179.825 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.568 ' CE2' HG23 ' A' ' 126' ' ' THR . 93.5 m-85 -101.55 120.92 41.05 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.313 -0.867 . . . . 0.0 109.352 179.73 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.484 ' HB2' ' HD2' ' A' ' 130' ' ' PRO . 22.3 pt-20 -142.07 138.75 17.13 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.234 -0.916 . . . . 0.0 109.3 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.484 ' HD2' ' HB2' ' A' ' 129' ' ' GLU . 47.7 Cg_endo -35.62 124.11 0.26 Allowed 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.107 1.872 . . . . 0.0 111.721 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 106.25 -0.47 37.83 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.44 ' HG3' ' O ' ' A' ' 129' ' ' GLU . 75.5 mt-10 -98.21 152.04 19.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.242 -1.152 . . . . 0.0 109.611 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.498 ' SD ' ' CG2' ' A' ' 147' ' ' VAL . 68.3 mmm -92.16 148.75 21.92 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.192 -0.943 . . . . 0.0 109.327 179.826 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.425 HG12 ' HB ' ' A' ' 178' ' ' VAL . 2.5 t -135.99 178.92 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.166 -0.959 . . . . 0.0 109.325 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.462 ' NH2' ' OD1' ' A' ' 145' ' ' ASN . 74.8 mtp85 -134.17 143.96 48.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.179 -0.951 . . . . 0.0 109.343 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.46 ' O ' ' N ' ' A' ' 143' ' ' ASP . 59.0 t -115.43 130.18 70.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.216 -0.927 . . . . 0.0 109.452 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 30.3 p30 -127.89 14.77 6.89 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.298 -0.876 . . . . 0.0 109.482 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.43 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 59.1 t0 -135.82 147.6 48.36 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.292 -0.88 . . . . 0.0 109.475 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.43 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 73.85 172.15 25.31 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -51.35 -21.96 10.98 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.602 2.201 . . . . 0.0 111.69 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . 0.502 ' CE1' HD11 ' A' ' 164' ' ' ILE . 98.3 m-85 -85.73 8.94 17.87 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.271 -0.893 . . . . 0.0 109.373 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' ALA . . . . . 0.454 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -64.02 145.27 56.19 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.241 -0.912 . . . . 0.0 109.558 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.46 ' N ' ' O ' ' A' ' 136' ' ' VAL . 31.6 m-20 64.96 46.82 2.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.259 -0.9 . . . . 0.0 109.593 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.427 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 44.9 m-85 -145.46 126.49 14.59 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.246 -0.909 . . . . 0.0 109.535 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . 0.462 ' OD1' ' NH2' ' A' ' 135' ' ' ARG . 69.9 m-20 -79.4 137.54 37.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.224 -0.923 . . . . 0.0 109.45 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -149.22 166.78 29.53 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.52 ' O ' ' CG1' ' A' ' 160' ' ' VAL . 15.1 t -108.79 154.87 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.255 -1.144 . . . . 0.0 109.406 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.466 ' O ' ' HA ' ' A' ' 130' ' ' PRO . 1.7 p -96.23 114.93 34.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.323 -0.861 . . . . 0.0 109.356 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.471 ' O ' ' CG ' ' A' ' 150' ' ' GLU . 74.9 mm-40 -75.94 -34.08 59.85 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.3 -0.875 . . . . 0.0 109.315 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.471 ' CG ' ' O ' ' A' ' 149' ' ' GLU . 94.7 mt-10 -158.11 159.15 35.93 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.36 -0.838 . . . . 0.0 109.415 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 128' ' ' PHE . 26.3 t -127.59 151.02 33.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.22 -0.925 . . . . 0.0 109.563 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' ASP . . . . . 0.477 ' O ' ' N ' ' A' ' 156' ' ' SER . 83.2 m-20 -120.71 84.46 2.23 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.339 -0.85 . . . . 0.0 109.342 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -57.4 -33.72 68.15 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.234 -0.916 . . . . 0.0 109.502 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -64.75 -41.48 95.88 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.167 -0.958 . . . . 0.0 109.529 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 29.5 mttt -97.09 -3.77 40.66 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.29 -0.881 . . . . 0.0 109.591 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' SER . . . . . 0.477 ' N ' ' O ' ' A' ' 152' ' ' ASP . 31.8 m 56.95 52.46 9.25 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.194 -0.941 . . . . 0.0 109.543 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 48.7 mmm-85 -137.06 155.82 49.17 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.258 -0.901 . . . . 0.0 109.355 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' LEU . . . . . 0.602 HD13 ' CD1' ' A' ' 175' ' ' PHE . 5.0 mp -115.87 139.26 50.38 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.201 -0.937 . . . . 0.0 109.643 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . 0.445 ' HD2' ' HB2' ' A' ' 150' ' ' GLU . 84.1 mttt -101.45 89.36 3.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.213 -0.929 . . . . 0.0 109.178 179.653 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . 0.52 ' CG1' ' O ' ' A' ' 147' ' ' VAL . 24.6 t -114.58 148.64 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.268 -0.895 . . . . 0.0 109.875 -179.617 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' SER . . . . . 0.458 ' HB2' ' HA ' ' A' ' 170' ' ' PRO . 43.9 t -119.37 131.17 55.65 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.378 -0.826 . . . . 0.0 109.242 179.769 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' VAL . . . . . 0.407 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 15.5 t -100.53 134.03 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.209 -0.932 . . . . 0.0 109.697 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 37.2 t -84.53 82.49 8.39 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.229 -0.919 . . . . 0.0 109.275 179.777 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.502 HD11 ' CE1' ' A' ' 141' ' ' PHE . 37.5 mt -101.86 141.71 17.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.203 -0.936 . . . . 0.0 109.526 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . 0.512 ' CD2' ' O ' ' A' ' 165' ' ' PHE . 54.4 t80 63.3 14.04 7.5 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.293 -0.879 . . . . 0.0 109.365 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 83.2 4.06 89.9 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 86.3 mtt-85 -117.85 139.13 51.55 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -1.149 . . . . 0.0 109.422 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -72.16 141.84 49.09 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.352 -0.842 . . . . 0.0 109.463 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 169' ' ' THR . . . . . 0.406 HG22 ' CZ ' ' A' ' 141' ' ' PHE . 32.8 m -128.27 68.71 77.3 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.206 -0.934 . . . . 0.0 109.475 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.458 ' HA ' ' HB2' ' A' ' 161' ' ' SER . 49.4 Cg_endo -45.55 106.64 0.09 OUTLIER 'Trans proline' 0 C--O 1.214 -0.694 0 C-N-CA 122.703 2.269 . . . . 0.0 111.768 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 21.9 m -133.42 156.49 41.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.219 -0.926 . . . . 0.0 109.565 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.452 ' O ' HD12 ' A' ' 173' ' ' LEU . 94.6 mt-10 -105.39 129.97 53.59 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.301 -0.874 . . . . 0.0 109.334 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . 0.581 ' CD2' ' N ' ' A' ' 173' ' ' LEU . 1.9 mm? -119.46 157.81 27.5 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.189 -0.945 . . . . 0.0 109.618 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 174' ' ' ASP . . . . . 0.448 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 91.1 m-20 -79.64 157.89 27.17 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.352 -0.843 . . . . 0.0 109.573 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.602 ' CD1' HD13 ' A' ' 158' ' ' LEU . 3.6 m-85 -49.71 -49.39 48.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.305 -0.872 . . . . 0.0 109.785 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 11.2 m -71.15 -24.74 62.32 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.237 -0.914 . . . . 0.0 109.692 -179.754 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 177' ' ' GLN . . . . . 0.448 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 81.7 mt-30 -70.36 -24.72 63.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.218 -0.926 . . . . 0.0 109.722 -179.813 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.508 HG13 ' CB ' ' A' ' 173' ' ' LEU . 17.5 m -131.06 161.82 40.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.189 -0.945 . . . . 0.0 109.511 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 179' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -120.67 145.46 47.42 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.296 -0.878 . . . . 0.0 109.473 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 180' ' ' LYS . . . . . 0.438 ' HE3' ' O ' ' A' ' 127' ' ' LEU . 30.2 tttm -69.67 134.61 48.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.302 -0.874 . . . . 0.0 109.481 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.495 0 O-C-N 121.163 -0.96 . . . . 0.0 109.485 179.985 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.561 ' CB ' ' CD ' ' A' ' 124' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 . . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.561 ' CD ' ' CB ' ' A' ' 123' ' ' ARG . 51.1 Cg_endo -54.42 150.34 34.46 Favored 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 122.626 2.217 . . . . 0.0 111.862 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . 0.458 ' O ' ' HE3' ' A' ' 180' ' ' LYS . 11.4 pttt -131.35 156.69 45.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.285 -0.884 . . . . 0.0 109.483 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 63.2 p -114.22 30.72 7.09 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.321 -0.862 . . . . 0.0 109.485 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 56.2 mt -80.63 99.45 8.15 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.183 -0.948 . . . . 0.0 109.554 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.633 ' CD1' ' CD1' ' A' ' 158' ' ' LEU . 69.1 m-85 -86.34 132.29 34.0 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.324 -0.86 . . . . 0.0 109.453 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.462 ' HB3' ' HD2' ' A' ' 130' ' ' PRO . 1.2 mp0 -109.24 138.16 20.4 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.296 -0.878 . . . . 0.0 109.399 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.462 ' HD2' ' HB3' ' A' ' 129' ' ' GLU . 50.6 Cg_endo -39.68 133.99 1.57 Allowed 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.549 2.166 . . . . 0.0 111.765 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 84.69 8.45 82.83 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 45.7 tp10 -102.25 135.04 44.55 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.263 -1.14 . . . . 0.0 109.443 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 76.3 mtp -70.28 148.17 48.83 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.248 -0.908 . . . . 0.0 109.456 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.415 HG13 ' O ' ' A' ' 179' ' ' GLU . 2.5 t -136.72 179.08 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.26 -0.9 . . . . 0.0 109.353 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.502 ' N ' ' O ' ' A' ' 179' ' ' GLU . 70.3 ttt180 -136.51 143.12 43.59 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.263 -0.898 . . . . 0.0 109.43 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.453 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 60.3 t -111.16 124.86 68.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.258 -0.902 . . . . 0.0 109.524 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 26.4 p30 -124.77 22.31 8.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -0.905 . . . . 0.0 109.511 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -145.15 140.98 28.35 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.328 -0.858 . . . . 0.0 109.479 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 81.62 -179.82 53.26 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -58.67 -20.18 49.35 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.679 2.252 . . . . 0.0 111.764 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . 0.55 ' CZ ' HG13 ' A' ' 171' ' ' VAL . 99.2 m-85 -87.38 10.15 18.33 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.239 -0.913 . . . . 0.0 109.379 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' ALA . . . . . 0.505 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -64.17 152.99 39.21 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.282 -0.886 . . . . 0.0 109.59 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.465 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 58.8 m-20 63.65 42.57 6.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.3 -0.875 . . . . 0.0 109.676 179.746 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.536 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 58.8 m-85 -145.51 152.64 40.08 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.164 -0.96 . . . . 0.0 109.494 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 43.7 p-10 -113.63 167.06 10.92 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.238 -0.914 . . . . 0.0 109.395 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 179.35 -170.45 42.03 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.479 HG11 ' N ' ' A' ' 148' ' ' VAL . 43.0 t -129.11 150.43 34.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.225 -1.162 . . . . 0.0 109.517 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.479 ' N ' HG11 ' A' ' 147' ' ' VAL . 2.5 p -91.05 113.83 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.203 -0.936 . . . . 0.0 109.497 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 75.8 mm-40 -67.02 -37.1 83.54 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.222 -0.924 . . . . 0.0 109.445 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.406 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 94.9 mt-10 -153.97 163.38 40.15 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.223 -0.923 . . . . 0.0 109.501 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.506 ' CG1' ' CD2' ' A' ' 158' ' ' LEU . 45.7 t -127.27 146.32 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.247 -0.908 . . . . 0.0 109.535 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -133.02 90.88 2.8 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.277 -0.89 . . . . 0.0 109.5 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -62.93 -38.82 92.54 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.214 -0.929 . . . . 0.0 109.502 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -61.25 -41.7 97.35 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.48 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.441 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 60.2 mttm -92.23 -2.25 56.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -0.893 . . . . 0.0 109.601 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' SER . . . . . 0.465 ' HA ' ' CZ ' ' A' ' 175' ' ' PHE . 12.9 m 50.23 52.52 14.59 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.28 -0.887 . . . . 0.0 109.587 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . 0.441 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 13.7 mmt85 -146.15 142.77 28.79 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.295 -0.878 . . . . 0.0 109.468 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' LEU . . . . . 0.633 ' CD1' ' CD1' ' A' ' 128' ' ' PHE . 49.0 mt -116.34 133.19 56.29 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.196 -0.94 . . . . 0.0 109.497 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . 0.435 ' O ' ' HA ' ' A' ' 148' ' ' VAL . 65.5 mttm -87.39 100.64 12.88 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.282 -0.886 . . . . 0.0 109.346 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . 0.461 HG11 ' O ' ' A' ' 147' ' ' VAL . 57.6 t -128.34 138.75 53.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.176 -0.952 . . . . 0.0 109.524 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' SER . . . . . 0.407 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 88.3 p -107.2 148.13 29.28 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.272 -0.893 . . . . 0.0 109.431 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' VAL . . . . . 0.536 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 3.8 t -115.33 130.02 70.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.211 -0.931 . . . . 0.0 109.637 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 33.2 t -75.58 90.59 2.78 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.221 -0.924 . . . . 0.0 109.153 179.639 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.567 HG22 ' CD2' ' A' ' 165' ' ' PHE . 38.2 mt -106.53 137.35 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.307 -0.871 . . . . 0.0 109.42 -179.735 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . 0.567 ' CD2' HG22 ' A' ' 164' ' ' ILE . 91.1 m-85 48.46 -126.2 1.92 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.276 -0.89 . . . . 0.0 109.15 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -119.34 31.46 5.42 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 46.0 tpt85 -145.0 132.98 21.3 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.089 -1.242 . . . . 0.0 109.546 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -72.76 138.89 46.76 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.206 -0.934 . . . . 0.0 109.477 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 169' ' ' THR . . . . . 0.447 ' O ' HG11 ' A' ' 171' ' ' VAL . 10.1 m -122.53 75.78 44.88 Favored Pre-proline 0 N--CA 1.488 1.465 0 O-C-N 121.128 -0.983 . . . . 0.0 109.484 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.4 Cg_endo -56.13 110.73 0.61 Allowed 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.572 2.181 . . . . 0.0 111.734 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.55 HG13 ' CZ ' ' A' ' 141' ' ' PHE . 16.5 m -129.6 154.87 40.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.26 -0.9 . . . . 0.0 109.502 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.417 ' O ' HD11 ' A' ' 173' ' ' LEU . 95.7 mt-10 -100.69 125.88 47.16 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.222 -0.923 . . . . 0.0 109.459 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . 0.569 ' CD2' ' N ' ' A' ' 173' ' ' LEU . 2.6 mm? -122.93 147.18 46.9 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.311 -0.868 . . . . 0.0 109.434 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 174' ' ' ASP . . . . . 0.435 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 90.3 m-20 -65.41 169.14 6.25 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.209 -0.932 . . . . 0.0 109.457 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.565 ' N ' ' CD1' ' A' ' 175' ' ' PHE . 2.3 m-30 -64.4 -36.83 85.44 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.178 -0.951 . . . . 0.0 109.462 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 86.1 p -80.07 -25.87 39.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.248 -0.907 . . . . 0.0 109.429 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 177' ' ' GLN . . . . . 0.435 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 86.2 mt-30 -66.57 -27.3 67.62 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.189 -0.945 . . . . 0.0 109.422 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.507 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 4.6 m -123.89 156.73 30.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.291 -0.881 . . . . 0.0 109.499 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 179' ' ' GLU . . . . . 0.502 ' O ' ' N ' ' A' ' 135' ' ' ARG . 83.6 tt0 -116.51 156.17 27.37 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.31 -0.869 . . . . 0.0 109.463 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 180' ' ' LYS . . . . . 0.458 ' HE3' ' O ' ' A' ' 125' ' ' LYS . 54.4 mttt -69.89 142.88 52.93 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.233 -0.917 . . . . 0.0 109.481 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.578 0 O-C-N 121.267 -0.895 . . . . 0.0 109.472 179.999 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 1.4 mmt85 . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -56.48 144.93 82.35 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.575 2.183 . . . . 0.0 111.789 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . 0.461 ' O ' ' HG ' ' A' ' 127' ' ' LEU . 53.9 mttp -97.8 25.88 5.56 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.211 -0.931 . . . . 0.0 109.42 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.43 ' OG1' ' O ' ' A' ' 125' ' ' LYS . 61.2 p 48.17 23.3 0.51 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.34 -0.85 . . . . 0.0 109.631 179.915 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.461 ' HG ' ' O ' ' A' ' 125' ' ' LYS . 26.2 mt -94.5 99.75 11.86 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.232 -0.917 . . . . 0.0 109.496 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.428 ' CE1' ' HG2' ' A' ' 180' ' ' LYS . 50.8 m-85 -92.43 138.31 31.63 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.256 -0.903 . . . . 0.0 109.489 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.519 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.0 OUTLIER -134.57 156.91 78.36 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.312 -0.868 . . . . 0.0 109.454 179.99 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.519 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.2 Cg_endo -48.66 130.31 22.1 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.626 2.217 . . . . 0.0 111.819 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 90.15 10.26 64.48 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -113.42 138.9 49.42 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.243 -1.151 . . . . 0.0 109.51 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 87.1 mtp -79.77 149.25 31.16 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.294 -0.879 . . . . 0.0 109.527 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.52 ' CG2' HG21 ' A' ' 148' ' ' VAL . 2.5 t -131.93 179.08 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.314 -0.866 . . . . 0.0 109.387 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.504 ' N ' ' O ' ' A' ' 179' ' ' GLU . 24.4 tpt180 -130.88 138.92 50.03 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.284 -0.885 . . . . 0.0 109.365 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.44 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 28.7 t -103.98 130.56 54.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.24 -0.912 . . . . 0.0 109.539 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . 0.428 ' OD1' ' C ' ' A' ' 137' ' ' ASN . 22.2 p30 -132.03 18.08 4.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.324 -0.86 . . . . 0.0 109.403 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.473 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 59.7 t0 -140.66 148.67 41.19 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.204 -0.935 . . . . 0.0 109.499 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.473 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 73.0 172.85 23.57 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -52.99 -19.83 12.24 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.652 2.235 . . . . 0.0 111.786 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . 0.545 ' CE1' HG13 ' A' ' 162' ' ' VAL . 97.9 m-85 -87.43 10.31 17.96 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.183 -0.948 . . . . 0.0 109.444 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' ALA . . . . . 0.499 ' O ' ' CB ' ' A' ' 143' ' ' ASP . . . -66.29 147.77 52.83 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.256 -0.902 . . . . 0.0 109.485 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.499 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 24.9 t0 74.34 28.26 1.37 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.291 -0.881 . . . . 0.0 109.471 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -134.38 153.27 51.99 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.292 -0.88 . . . . 0.0 109.466 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 43.2 p-10 -113.77 165.54 12.45 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.258 -0.901 . . . . 0.0 109.425 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -174.07 -177.1 43.0 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.506 HG12 ' N ' ' A' ' 148' ' ' VAL . 44.2 t -117.27 161.28 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.213 -1.169 . . . . 0.0 109.477 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.52 HG21 ' CG2' ' A' ' 134' ' ' VAL . 79.4 t -93.4 96.25 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.213 -0.929 . . . . 0.0 109.524 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -66.02 -31.92 73.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.247 -0.908 . . . . 0.0 109.429 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -148.83 150.25 32.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.286 -0.884 . . . . 0.0 109.415 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.46 HG22 ' CG1' ' A' ' 148' ' ' VAL . 45.3 t -124.19 149.99 28.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.214 -0.929 . . . . 0.0 109.516 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 95.2 m-20 -136.48 79.88 1.79 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.216 -0.928 . . . . 0.0 109.502 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 98.9 m-85 -63.64 -37.46 87.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.227 -0.921 . . . . 0.0 109.518 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -59.42 -46.45 88.68 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.185 -0.947 . . . . 0.0 109.528 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.456 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 58.1 mttt -90.72 0.5 57.4 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.268 -0.895 . . . . 0.0 109.548 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 31.1 t 56.06 52.82 9.89 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.196 -0.94 . . . . 0.0 109.485 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . 0.456 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 22.9 mmt85 -140.29 140.51 35.72 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.275 -0.891 . . . . 0.0 109.367 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' LEU . . . . . 0.443 HD12 ' CD1' ' A' ' 175' ' ' PHE . 61.5 mt -110.06 129.47 55.68 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.162 -0.962 . . . . 0.0 109.522 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . 0.447 ' HG3' ' OE2' ' A' ' 172' ' ' GLU . 29.4 tttp -92.31 104.79 17.1 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.331 -0.856 . . . . 0.0 109.352 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . 0.421 HG11 ' O ' ' A' ' 147' ' ' VAL . 44.4 t -124.64 140.62 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.29 -0.881 . . . . 0.0 109.545 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' SER . . . . . 0.421 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 30.1 t -109.17 137.65 46.74 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.295 -0.878 . . . . 0.0 109.462 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' VAL . . . . . 0.545 HG13 ' CE1' ' A' ' 141' ' ' PHE . 9.4 p -104.9 138.86 27.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.185 -0.947 . . . . 0.0 109.636 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 163' ' ' SER . . . . . 0.43 ' HA ' ' O ' ' A' ' 167' ' ' ARG . 5.3 m -102.7 95.2 6.05 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.215 -0.928 . . . . 0.0 109.461 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.577 ' CG2' ' CD2' ' A' ' 165' ' ' PHE . 37.4 mt -114.52 134.77 56.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.226 -0.921 . . . . 0.0 109.545 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . 0.577 ' CD2' ' CG2' ' A' ' 164' ' ' ILE . 94.3 m-85 59.4 23.97 12.54 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.271 -0.893 . . . . 0.0 109.485 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 78.64 14.3 82.24 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 167' ' ' ARG . . . . . 0.43 ' O ' ' HA ' ' A' ' 163' ' ' SER . 62.2 mtt180 -117.95 148.34 42.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.197 -1.178 . . . . 0.0 109.516 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -98.19 139.12 34.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.232 -0.918 . . . . 0.0 109.497 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 169' ' ' THR . . . . . 0.512 ' HB ' ' CG1' ' A' ' 162' ' ' VAL . 6.0 m -129.81 74.04 80.98 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.287 -0.883 . . . . 0.0 109.453 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.421 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.7 Cg_endo -49.08 109.9 0.31 Allowed 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.603 2.202 . . . . 0.0 111.774 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 23.6 m -128.96 156.8 41.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.29 -0.881 . . . . 0.0 109.514 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.455 ' O ' HD21 ' A' ' 173' ' ' LEU . 75.7 mm-40 -101.6 130.65 47.97 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.293 -0.88 . . . . 0.0 109.465 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . 0.455 HD21 ' O ' ' A' ' 172' ' ' GLU . 51.8 mt -131.28 148.81 52.73 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.245 -0.91 . . . . 0.0 109.419 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -74.91 171.54 13.85 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.213 -0.93 . . . . 0.0 109.447 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.583 ' N ' ' CD1' ' A' ' 175' ' ' PHE . 2.7 m-30 -64.25 -36.81 85.29 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.318 -0.864 . . . . 0.0 109.439 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 83.4 p -79.58 -26.97 41.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.312 -0.867 . . . . 0.0 109.355 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 23.6 mt-30 -68.86 -19.69 64.25 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.26 -0.9 . . . . 0.0 109.381 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.457 ' HA ' ' O ' ' A' ' 135' ' ' ARG . 4.2 m -135.73 154.4 34.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.217 -0.927 . . . . 0.0 109.526 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 179' ' ' GLU . . . . . 0.504 ' O ' ' N ' ' A' ' 135' ' ' ARG . 37.7 mt-10 -120.07 166.53 13.27 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.278 -0.888 . . . . 0.0 109.427 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 180' ' ' LYS . . . . . 0.428 ' HG2' ' CE1' ' A' ' 128' ' ' PHE . 54.9 mttt -71.97 145.83 48.14 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.229 -0.919 . . . . 0.0 109.551 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.521 0 O-C-N 121.285 -0.884 . . . . 0.0 109.498 179.999 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -56.13 148.69 57.96 Favored 'Trans proline' 0 C--O 1.214 -0.689 0 C-N-CA 122.596 2.197 . . . . 0.0 111.717 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 23.6 mttm -85.56 148.73 25.79 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.249 -0.907 . . . . 0.0 109.536 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 69.3 p -98.08 15.87 22.9 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.268 -0.895 . . . . 0.0 109.482 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.435 ' O ' ' HE3' ' A' ' 180' ' ' LYS . 52.5 mt -88.11 98.26 11.44 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.235 -0.915 . . . . 0.0 109.456 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 83.8 m-85 -109.2 139.83 43.61 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.17 -0.956 . . . . 0.0 109.482 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.452 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.0 OUTLIER -135.77 153.18 77.11 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.262 -0.899 . . . . 0.0 109.445 -179.968 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.452 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.4 Cg_endo -47.18 133.21 19.06 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.593 2.195 . . . . 0.0 111.793 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 86.51 3.1 84.42 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 50.2 tp10 -88.05 137.57 32.21 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.202 -1.175 . . . . 0.0 109.544 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' MET . . . . . 0.443 ' HA ' ' HA ' ' A' ' 147' ' ' VAL . 77.4 mtp -79.44 149.49 31.57 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.279 -0.888 . . . . 0.0 109.446 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.565 ' CG2' ' CG2' ' A' ' 148' ' ' VAL . 2.5 t -139.25 179.0 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.266 -0.896 . . . . 0.0 109.318 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.446 ' O ' ' HA ' ' A' ' 178' ' ' VAL . 18.5 mtp-105 -137.47 142.49 41.54 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.245 -0.91 . . . . 0.0 109.466 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.435 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 43.3 t -111.56 135.2 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.232 -0.917 . . . . 0.0 109.537 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 38.2 p30 -127.08 15.52 7.32 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.54 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.476 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 59.2 t0 -142.06 153.53 44.27 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.28 -0.888 . . . . 0.0 109.462 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.476 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 75.38 171.02 28.86 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -54.93 -18.47 16.73 Favored 'Trans proline' 0 C--O 1.214 -0.705 0 C-N-CA 122.578 2.185 . . . . 0.0 111.792 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . 0.557 ' CD1' HG13 ' A' ' 162' ' ' VAL . 90.5 m-85 -92.79 14.92 15.86 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.25 -0.906 . . . . 0.0 109.454 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' ALA . . . . . 0.461 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -66.23 149.51 50.23 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.301 -0.874 . . . . 0.0 109.523 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.461 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 43.7 m-20 64.03 46.85 3.58 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.232 -0.918 . . . . 0.0 109.473 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -140.79 142.01 34.73 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.295 -0.878 . . . . 0.0 109.531 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 73.0 m-20 -100.81 142.4 32.33 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.245 -0.909 . . . . 0.0 109.462 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.54 177.94 34.98 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.509 HG13 ' N ' ' A' ' 148' ' ' VAL . 49.0 t -114.29 164.2 10.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.184 -1.186 . . . . 0.0 109.438 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.565 ' CG2' ' CG2' ' A' ' 134' ' ' VAL . 98.6 t -93.16 95.54 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.257 -0.902 . . . . 0.0 109.553 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -67.42 -34.52 77.4 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.178 -0.951 . . . . 0.0 109.432 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.501 ' HB2' ' CD ' ' A' ' 159' ' ' LYS . 94.2 mt-10 -151.23 161.49 42.61 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.237 -0.915 . . . . 0.0 109.332 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 44.1 t -124.25 151.35 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.206 -0.934 . . . . 0.0 109.569 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -125.49 78.3 1.72 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.236 -0.915 . . . . 0.0 109.413 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 83.9 m-85 -63.68 -37.05 85.87 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.338 -0.851 . . . . 0.0 109.569 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -60.74 -42.83 98.15 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.247 -0.908 . . . . 0.0 109.532 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.458 ' O ' ' HG3' ' A' ' 157' ' ' ARG . 45.9 mttp -94.68 3.03 55.56 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.241 -0.912 . . . . 0.0 109.604 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 56.62 51.98 10.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.245 -0.909 . . . . 0.0 109.464 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . 0.458 ' HG3' ' O ' ' A' ' 155' ' ' LYS . 58.1 mtt180 -146.29 157.49 43.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.281 -0.887 . . . . 0.0 109.522 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' LEU . . . . . 0.432 ' CD2' ' CE1' ' A' ' 175' ' ' PHE . 18.2 mt -115.01 135.56 54.09 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.199 -0.938 . . . . 0.0 109.451 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . 0.501 ' CD ' ' HB2' ' A' ' 150' ' ' GLU . 31.0 tttp -87.99 105.92 17.78 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.269 -0.894 . . . . 0.0 109.318 179.855 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . 0.453 HG22 HG21 ' A' ' 148' ' ' VAL . 39.9 t -121.99 143.46 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.228 -0.92 . . . . 0.0 109.636 -179.833 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 93.5 p -110.31 145.24 37.79 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.263 -0.898 . . . . 0.0 109.41 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' VAL . . . . . 0.557 HG13 ' CD1' ' A' ' 141' ' ' PHE . 9.8 p -115.93 138.89 44.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.226 -0.921 . . . . 0.0 109.527 -179.899 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 37.8 t -102.82 97.55 7.68 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.256 -0.903 . . . . 0.0 109.408 179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.464 HD12 HG11 ' A' ' 162' ' ' VAL . 29.9 mt -116.04 135.88 54.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.28 -0.887 . . . . 0.0 109.498 -179.848 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 9.0 m-30 57.91 28.12 15.65 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.211 -0.931 . . . . 0.0 109.494 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 72.03 21.19 79.2 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 65.7 mtt-85 -119.18 143.79 47.04 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.279 -1.13 . . . . 0.0 109.463 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -91.43 134.37 34.69 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.265 -0.897 . . . . 0.0 109.54 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 169' ' ' THR . . . . . 0.451 ' HB ' HG12 ' A' ' 162' ' ' VAL . 0.2 OUTLIER -128.3 74.11 79.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.312 -0.867 . . . . 0.0 109.458 -179.963 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -57.6 104.64 0.17 Allowed 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.598 2.198 . . . . 0.0 111.805 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.428 HG12 ' O ' ' A' ' 169' ' ' THR . 19.3 m -130.41 155.95 42.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.253 -0.905 . . . . 0.0 109.538 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.444 ' HG2' ' HA ' ' A' ' 159' ' ' LYS . 95.2 mt-10 -104.03 128.94 51.63 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.236 -0.915 . . . . 0.0 109.46 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . 0.572 ' CD2' ' N ' ' A' ' 173' ' ' LEU . 2.3 mm? -121.29 145.67 47.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.248 -0.907 . . . . 0.0 109.432 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 64.6 m-20 -65.63 173.48 2.76 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.263 -0.898 . . . . 0.0 109.38 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.492 ' N ' ' CD1' ' A' ' 175' ' ' PHE . 4.2 m-30 -66.65 -44.47 81.8 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.252 -0.905 . . . . 0.0 109.471 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 18.7 m -73.09 -23.62 60.55 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.201 -0.937 . . . . 0.0 109.384 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -70.78 -23.8 62.46 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.298 -0.876 . . . . 0.0 109.39 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.505 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 6.0 m -131.43 163.42 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.31 -0.869 . . . . 0.0 109.378 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 179' ' ' GLU . . . . . 0.457 ' O ' HG12 ' A' ' 134' ' ' VAL . 74.3 mm-40 -119.0 145.45 45.83 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.172 -0.955 . . . . 0.0 109.485 -179.895 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 180' ' ' LYS . . . . . 0.435 ' HE3' ' O ' ' A' ' 127' ' ' LEU . 18.3 tttm -64.87 140.0 58.82 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.202 -0.936 . . . . 0.0 109.463 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.542 0 O-C-N 121.207 -0.933 . . . . 0.0 109.44 -179.942 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.43 ' HA ' ' HD2' ' A' ' 124' ' ' PRO . 7.1 ttt180 . . . . . 0 N--CA 1.489 1.519 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.43 ' HD2' ' HA ' ' A' ' 123' ' ' ARG . 50.8 Cg_endo -50.67 143.23 29.47 Favored 'Trans proline' 0 C--O 1.216 -0.596 0 C-N-CA 122.441 2.094 . . . . 0.0 111.787 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . 0.519 ' CB ' ' HG ' ' A' ' 127' ' ' LEU . 20.8 mttt -99.5 20.01 14.63 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.186 -0.946 . . . . 0.0 109.527 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' THR . . . . . 0.42 ' C ' ' O ' ' A' ' 125' ' ' LYS . 0.0 OUTLIER 40.16 33.1 0.14 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.665 -0.647 . . . . 0.0 109.829 179.795 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.519 ' HG ' ' CB ' ' A' ' 125' ' ' LYS . 39.4 mt -89.62 100.23 13.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.236 -0.915 . . . . 0.0 109.658 -179.88 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.444 ' CE1' HG13 ' A' ' 134' ' ' VAL . 59.4 m-85 -93.98 140.63 29.47 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.296 -0.877 . . . . 0.0 109.424 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . 0.417 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 3.9 mt-10 -122.77 154.75 63.88 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.245 -0.909 . . . . 0.0 109.353 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.417 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.3 Cg_endo -51.15 129.05 27.15 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.597 2.198 . . . . 0.0 111.804 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 84.44 13.24 73.87 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.415 ' OE1' ' HA ' ' A' ' 128' ' ' PHE . 77.5 tt0 -104.13 133.83 48.4 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.236 -1.155 . . . . 0.0 109.443 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 85.7 mtp -69.36 144.97 53.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.316 -0.865 . . . . 0.0 109.545 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.518 HG21 ' CG2' ' A' ' 148' ' ' VAL . 2.5 t -133.11 178.87 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.344 -0.847 . . . . 0.0 109.363 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.507 ' N ' ' O ' ' A' ' 179' ' ' GLU . 40.9 ttm180 -129.15 136.08 49.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.275 -0.891 . . . . 0.0 109.326 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.454 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 39.5 t -106.34 130.34 58.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.215 -0.928 . . . . 0.0 109.529 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . 0.408 ' OD1' ' C ' ' A' ' 137' ' ' ASN . 43.0 p30 -127.61 17.4 6.93 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.282 -0.886 . . . . 0.0 109.443 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.462 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 60.1 t0 -136.98 147.17 46.13 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.306 -0.871 . . . . 0.0 109.468 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.462 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 74.58 173.62 30.93 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -57.2 -17.21 24.74 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.627 2.218 . . . . 0.0 111.883 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . 0.576 ' CD1' HG23 ' A' ' 162' ' ' VAL . 99.7 m-85 -90.23 12.68 17.35 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.13 -0.981 . . . . 0.0 109.452 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' ALA . . . . . 0.516 ' O ' ' CB ' ' A' ' 143' ' ' ASP . . . -72.5 147.15 46.3 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.276 -0.89 . . . . 0.0 109.509 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.516 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 24.9 t0 75.74 28.69 0.89 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.272 -0.893 . . . . 0.0 109.529 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.484 ' CD1' ' O ' ' A' ' 142' ' ' ALA . 91.8 m-85 -132.26 146.26 51.87 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.155 -0.966 . . . . 0.0 109.514 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -98.5 144.73 27.51 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.245 -0.909 . . . . 0.0 109.442 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -157.52 -178.77 31.89 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.519 HG12 ' N ' ' A' ' 148' ' ' VAL . 28.3 t -124.08 156.36 31.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.227 -1.161 . . . . 0.0 109.408 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.519 ' N ' HG12 ' A' ' 147' ' ' VAL . 87.5 t -89.25 100.54 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.206 -0.934 . . . . 0.0 109.388 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -65.47 -38.26 89.26 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.209 -0.932 . . . . 0.0 109.499 179.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -145.43 165.71 27.76 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.234 -0.916 . . . . 0.0 109.478 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.406 ' O ' ' OD1' ' A' ' 152' ' ' ASP . 41.2 t -129.45 150.82 34.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.3 -0.875 . . . . 0.0 109.497 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' ASP . . . . . 0.406 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 88.8 m-20 -134.45 83.2 2.02 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.268 -0.895 . . . . 0.0 109.413 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -64.77 -37.95 89.33 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.178 -0.951 . . . . 0.0 109.468 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . 0.412 ' OE1' ' HA ' ' A' ' 154' ' ' GLU . 72.8 mm-40 -60.53 -44.65 95.84 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.267 -0.896 . . . . 0.0 109.491 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.462 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 93.4 mttt -90.63 -1.0 57.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.306 -0.871 . . . . 0.0 109.559 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 48.9 m 54.32 53.09 11.41 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.146 -0.971 . . . . 0.0 109.495 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . 0.462 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 20.1 mmt85 -144.5 144.82 31.53 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.142 -0.973 . . . . 0.0 109.465 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' LEU . . . . . 0.456 ' HG ' ' CE1' ' A' ' 175' ' ' PHE . 55.6 mt -111.87 126.14 54.78 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.254 -0.904 . . . . 0.0 109.537 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 60.4 tttt -83.92 105.14 14.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.178 -0.952 . . . . 0.0 109.415 179.786 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 38.1 t -124.21 141.27 44.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.25 -0.906 . . . . 0.0 109.434 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 23.6 t -112.44 134.49 53.95 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.278 -0.889 . . . . 0.0 109.611 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' VAL . . . . . 0.576 HG23 ' CD1' ' A' ' 141' ' ' PHE . 3.7 t -88.84 130.32 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.234 -0.916 . . . . 0.0 109.47 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 59.3 m -81.15 82.11 7.16 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.228 -0.92 . . . . 0.0 109.387 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.463 HG22 HD11 ' A' ' 164' ' ' ILE . 54.8 mt -96.1 139.46 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.278 -0.889 . . . . 0.0 109.453 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 20.6 m-85 -51.87 -44.8 63.84 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.298 -0.876 . . . . 0.0 109.665 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . 0.533 ' O ' ' CB ' ' A' ' 167' ' ' ARG . . . -53.96 -35.61 54.09 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.656 -1.377 . . . . 0.0 109.656 -179.684 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 167' ' ' ARG . . . . . 0.533 ' CB ' ' O ' ' A' ' 166' ' ' GLY . 30.5 ttp180 160.48 146.86 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.376 -1.073 . . . . 0.0 109.006 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -63.16 136.71 57.91 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.243 -0.911 . . . . 0.0 109.292 179.841 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 169' ' ' THR . . . . . 0.419 HG23 ' CZ ' ' A' ' 141' ' ' PHE . 63.0 m -123.36 91.92 49.35 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.192 -0.943 . . . . 0.0 109.662 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -64.33 109.85 1.26 Allowed 'Trans proline' 0 C--O 1.216 -0.603 0 C-N-CA 122.502 2.134 . . . . 0.0 111.533 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.491 HG21 ' CD2' ' A' ' 173' ' ' LEU . 17.6 m -128.2 158.07 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.194 -0.942 . . . . 0.0 109.69 -179.806 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -100.04 125.07 46.05 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.383 -0.823 . . . . 0.0 109.348 179.843 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . 0.575 ' CD2' ' N ' ' A' ' 173' ' ' LEU . 1.7 mm? -120.48 145.63 47.07 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.203 -0.936 . . . . 0.0 109.493 -179.842 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 174' ' ' ASP . . . . . 0.434 ' OD1' ' HD3' ' A' ' 157' ' ' ARG . 88.3 m-20 -68.84 170.81 8.9 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.224 -0.923 . . . . 0.0 109.452 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.577 ' N ' ' CD1' ' A' ' 175' ' ' PHE . 2.5 m-30 -65.67 -44.21 86.95 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.217 -0.927 . . . . 0.0 109.436 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 11.1 m -76.0 -24.31 55.3 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.151 -0.968 . . . . 0.0 109.422 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 177' ' ' GLN . . . . . 0.433 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 86.5 mt-30 -69.68 -18.81 63.58 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.265 -0.897 . . . . 0.0 109.339 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.574 ' CG1' ' CB ' ' A' ' 173' ' ' LEU . 4.8 m -132.35 162.85 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.343 -0.848 . . . . 0.0 109.427 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 179' ' ' GLU . . . . . 0.507 ' O ' ' N ' ' A' ' 135' ' ' ARG . 60.7 mt-10 -126.38 161.73 27.18 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.29 -0.881 . . . . 0.0 109.554 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 84.5 mttt -67.36 144.28 55.91 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.204 -0.935 . . . . 0.0 109.447 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.566 0 O-C-N 121.202 -0.937 . . . . 0.0 109.481 179.959 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.513 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -53.48 147.0 39.71 Favored 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.527 2.151 . . . . 0.0 111.827 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . 0.43 ' O ' ' HD2' ' A' ' 180' ' ' LYS . 23.3 mttm -94.66 149.68 21.0 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.225 -0.922 . . . . 0.0 109.464 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 42.6 p -107.74 26.44 10.3 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.226 -0.921 . . . . 0.0 109.457 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 60.0 mt -101.2 95.53 6.6 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.278 -0.889 . . . . 0.0 109.518 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.428 ' CG ' HD13 ' A' ' 158' ' ' LEU . 85.8 m-85 -99.17 128.3 45.28 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.218 -0.927 . . . . 0.0 109.449 -179.852 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -118.47 146.97 40.91 Favored Pre-proline 0 N--CA 1.489 1.488 0 O-C-N 121.296 -0.877 . . . . 0.0 109.47 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -48.09 126.63 13.66 Favored 'Trans proline' 0 C--O 1.214 -0.694 0 C-N-CA 122.576 2.184 . . . . 0.0 111.816 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . 0.44 ' C ' ' CG1' ' A' ' 147' ' ' VAL . . . 94.59 -5.25 70.04 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.528 ' O ' ' CG1' ' A' ' 147' ' ' VAL . 80.3 tt0 -79.21 148.42 32.25 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.124 -1.221 . . . . 0.0 109.467 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 64.1 mtp -82.08 146.49 29.62 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.26 -0.9 . . . . 0.0 109.545 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.454 HG13 ' O ' ' A' ' 179' ' ' GLU . 2.5 t -135.92 179.13 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.264 -0.898 . . . . 0.0 109.255 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' ARG . . . . . 0.461 ' O ' ' HB ' ' A' ' 178' ' ' VAL . 87.8 mtt180 -137.33 146.62 44.8 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.225 -0.922 . . . . 0.0 109.399 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . 0.474 HG11 ' CD1' ' A' ' 173' ' ' LEU . 39.3 t -117.01 134.73 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.212 -0.93 . . . . 0.0 109.558 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 30.7 p30 -128.45 14.7 6.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.233 -0.917 . . . . 0.0 109.48 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.452 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 57.8 t0 -147.17 153.4 39.83 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.253 -0.904 . . . . 0.0 109.396 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . 0.452 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 78.65 172.26 40.91 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -55.28 -19.1 20.41 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.571 2.181 . . . . 0.0 111.78 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . 0.569 ' CD1' HG11 ' A' ' 162' ' ' VAL . 86.3 m-85 -93.0 9.2 36.72 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.214 -0.929 . . . . 0.0 109.536 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' ALA . . . . . 0.464 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -61.79 146.38 49.66 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.217 -0.927 . . . . 0.0 109.562 -179.867 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' ASP . . . . . 0.464 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 18.0 m-20 65.86 47.83 1.97 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.296 -0.878 . . . . 0.0 109.592 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.46 ' HB3' HG21 ' A' ' 162' ' ' VAL . 43.9 m-85 -146.51 136.14 23.11 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.296 -0.877 . . . . 0.0 109.457 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 71.3 m-20 -94.03 141.02 29.01 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.236 -0.915 . . . . 0.0 109.419 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.14 -177.19 31.0 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' VAL . . . . . 0.528 ' CG1' ' O ' ' A' ' 132' ' ' GLU . 46.5 t -125.07 148.92 29.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.207 -1.172 . . . . 0.0 109.369 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.515 ' N ' HG13 ' A' ' 147' ' ' VAL . 2.5 p -85.67 102.2 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.192 -0.942 . . . . 0.0 109.552 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -68.33 -36.41 79.23 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.146 -0.971 . . . . 0.0 109.414 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -140.78 164.29 30.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.189 -0.944 . . . . 0.0 109.471 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.44 HG13 ' N ' ' A' ' 152' ' ' ASP . 99.8 t -125.67 152.94 33.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.327 -0.858 . . . . 0.0 109.523 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' ASP . . . . . 0.44 ' N ' HG13 ' A' ' 151' ' ' VAL . 90.5 m-20 -130.53 88.43 2.63 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.319 -0.863 . . . . 0.0 109.386 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -69.58 -38.55 77.41 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.22 -0.925 . . . . 0.0 109.593 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -60.44 -46.64 89.29 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.213 -0.929 . . . . 0.0 109.45 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' LYS . . . . . 0.431 ' O ' ' HG3' ' A' ' 157' ' ' ARG . 32.0 mttt -89.32 -1.08 57.93 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.244 -0.91 . . . . 0.0 109.611 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 34.0 t 56.46 52.36 10.03 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.196 -0.94 . . . . 0.0 109.467 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' ARG . . . . . 0.44 ' O ' HD22 ' A' ' 158' ' ' LEU . 20.5 mtm180 -146.21 157.71 43.84 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.152 -0.967 . . . . 0.0 109.454 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' LEU . . . . . 0.53 ' CD2' ' CE1' ' A' ' 175' ' ' PHE . 13.9 mt -118.23 131.69 56.35 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.892 . . . . 0.0 109.531 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 20.9 tttp -84.37 106.77 16.23 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.295 -0.878 . . . . 0.0 109.443 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' VAL . . . . . . . . . . . . . 47.5 t -124.86 140.72 47.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.162 -0.961 . . . . 0.0 109.56 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' SER . . . . . 0.403 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 23.0 t -104.3 141.88 35.53 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.439 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' VAL . . . . . 0.569 HG11 ' CD1' ' A' ' 141' ' ' PHE . 9.4 p -105.53 126.28 60.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.314 -0.867 . . . . 0.0 109.562 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 18.5 t -91.05 85.14 5.84 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.303 -0.873 . . . . 0.0 109.377 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 164' ' ' ILE . . . . . 0.449 HD12 HG12 ' A' ' 162' ' ' VAL . 7.3 pt -130.22 158.07 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.241 -0.912 . . . . 0.0 109.564 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 7.7 m-30 61.74 13.54 5.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.225 -0.922 . . . . 0.0 109.429 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 75.59 11.34 84.48 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 19.1 ttp180 -132.12 135.67 46.57 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.245 -1.15 . . . . 0.0 109.454 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -76.33 141.0 41.71 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.294 -0.879 . . . . 0.0 109.454 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 169' ' ' THR . . . . . 0.447 ' HB ' HG13 ' A' ' 162' ' ' VAL . 2.4 m -128.02 76.81 77.36 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.308 -0.87 . . . . 0.0 109.437 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.403 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.8 Cg_endo -55.27 106.51 0.19 Allowed 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.604 2.203 . . . . 0.0 111.852 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 18.9 m -129.61 157.84 42.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.461 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -102.1 128.54 48.53 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.24 -0.913 . . . . 0.0 109.477 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 173' ' ' LEU . . . . . 0.513 HD12 ' CG1' ' A' ' 178' ' ' VAL . 42.4 mt -124.86 144.13 50.47 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.29 -0.881 . . . . 0.0 109.513 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 24.6 m-20 -64.57 172.48 2.64 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.191 -0.943 . . . . 0.0 109.527 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 175' ' ' PHE . . . . . 0.53 ' CE1' ' CD2' ' A' ' 158' ' ' LEU . 4.5 m-30 -67.67 -44.41 77.89 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.166 -0.959 . . . . 0.0 109.501 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 15.0 m -71.33 -23.56 61.95 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.219 -0.925 . . . . 0.0 109.524 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 90.3 mt-30 -72.79 -23.53 60.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.177 -0.952 . . . . 0.0 109.431 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.513 ' CG1' HD12 ' A' ' 173' ' ' LEU . 4.5 m -128.16 161.26 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.253 -0.905 . . . . 0.0 109.401 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 179' ' ' GLU . . . . . 0.454 ' O ' HG13 ' A' ' 134' ' ' VAL . 95.0 mt-10 -116.74 149.97 39.02 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.179 -0.951 . . . . 0.0 109.559 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 180' ' ' LYS . . . . . 0.508 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 33.6 tttm -69.13 137.34 53.31 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.181 -0.949 . . . . 0.0 109.505 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.536 0 O-C-N 121.211 -0.931 . . . . 0.0 109.46 -179.972 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 . . . . . 0 N--CA 1.489 1.514 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.493 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 1.2 mt-10 -138.65 159.29 68.03 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.202 -0.937 . . . . 0.0 109.457 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.493 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.1 Cg_endo -53.53 129.41 33.68 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.547 2.165 . . . . 0.0 111.82 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 90.47 -1.2 78.82 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.489 ' O ' HG12 ' A' ' 148' ' ' VAL . 77.0 mm-40 -86.45 135.51 33.45 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.168 -1.195 . . . . 0.0 109.475 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.469 ' HA ' ' HA ' ' A' ' 147' ' ' VAL . 44.2 ttm -79.58 146.91 32.32 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.16 -0.963 . . . . 0.0 109.49 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.694 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -131.55 179.24 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.266 -0.896 . . . . 0.0 109.324 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.694 ' H ' HG12 ' A' ' 134' ' ' VAL . 40.4 ttt180 -130.29 138.34 50.43 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.226 -0.921 . . . . 0.0 109.49 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.493 HG22 ' CD1' ' A' ' 173' ' ' LEU . 45.4 t -106.63 132.79 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.271 -0.893 . . . . 0.0 109.451 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 56.1 p30 -135.64 20.44 3.33 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.263 -0.898 . . . . 0.0 109.495 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.422 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 59.0 t0 -140.88 148.17 40.07 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.209 -0.932 . . . . 0.0 109.481 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.422 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 70.23 177.23 20.76 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -55.01 -20.17 22.37 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.562 2.175 . . . . 0.0 111.791 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 141' ' ' PHE . . . . . 0.491 ' HB2' HG11 ' A' ' 136' ' ' VAL . 98.7 m-85 -85.6 6.73 26.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.217 -0.927 . . . . 0.0 109.504 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 142' ' ' ALA . . . . . 0.469 ' O ' ' HB3' ' A' ' 143' ' ' ASP . . . -66.19 148.91 51.13 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.287 -0.883 . . . . 0.0 109.462 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.469 ' HB3' ' O ' ' A' ' 142' ' ' ALA . 35.5 t0 73.06 29.97 1.69 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.222 -0.924 . . . . 0.0 109.51 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.533 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 84.7 m-85 -138.12 151.52 47.86 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.249 -0.907 . . . . 0.0 109.511 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 43.3 p-10 -118.04 164.09 15.63 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.25 -0.906 . . . . 0.0 109.427 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -172.16 -173.73 39.07 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.849 ' O ' HG13 ' A' ' 160' ' ' VAL . 57.9 t -120.29 151.64 23.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.227 -1.161 . . . . 0.0 109.491 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.856 HG21 HG22 ' A' ' 151' ' ' VAL . 2.1 p -94.39 98.85 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.274 -0.892 . . . . 0.0 109.466 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 76.2 mm-40 -69.37 -36.69 77.09 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.215 -0.928 . . . . 0.0 109.425 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -134.44 149.63 50.77 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.261 -0.9 . . . . 0.0 109.464 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.856 HG22 HG21 ' A' ' 148' ' ' VAL . 48.0 t -127.3 150.22 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.233 -0.917 . . . . 0.0 109.477 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 152' ' ' ASP . . . . . 0.416 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 93.5 m-20 -136.2 87.77 2.33 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.261 -0.9 . . . . 0.0 109.466 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -66.31 -37.05 84.5 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.274 -0.891 . . . . 0.0 109.463 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 48.3 tp10 -62.62 -44.28 96.69 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.248 -0.907 . . . . 0.0 109.484 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.48 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 21.5 mttt -88.62 0.61 56.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.289 -0.882 . . . . 0.0 109.602 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 156' ' ' SER . . . . . 0.404 ' O ' ' OG ' ' A' ' 156' ' ' SER . 7.5 p 52.51 51.98 15.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.188 -0.945 . . . . 0.0 109.437 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 157' ' ' ARG . . . . . 0.48 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 41.0 mmm-85 -145.32 140.46 27.76 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.259 -0.901 . . . . 0.0 109.472 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 158' ' ' LEU . . . . . 0.599 ' CD2' HG13 ' A' ' 151' ' ' VAL . 35.2 mt -108.53 134.28 51.52 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.254 -0.904 . . . . 0.0 109.542 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 15.1 tttp -92.47 93.09 8.39 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.224 -0.923 . . . . 0.0 109.374 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.849 HG13 ' O ' ' A' ' 147' ' ' VAL . 41.4 t -124.13 142.01 42.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.222 -0.923 . . . . 0.0 109.519 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 161' ' ' SER . . . . . 0.512 ' CA ' ' HA ' ' A' ' 170' ' ' PRO . 86.7 p -106.31 147.7 28.87 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.263 -0.898 . . . . 0.0 109.436 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 162' ' ' VAL . . . . . 0.533 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 18.1 t -108.49 132.66 55.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.231 -0.918 . . . . 0.0 109.523 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 71.6 m . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.205 -0.934 . . . . 0.0 109.433 179.988 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 82.0 mtp180 . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -69.17 142.13 54.39 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.261 -0.9 . . . . 0.0 109.443 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 169' ' ' THR . . . . . 0.829 ' O ' HG13 ' A' ' 171' ' ' VAL . 15.4 m -124.37 75.81 61.59 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.271 -0.893 . . . . 0.0 109.475 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.512 ' HA ' ' CA ' ' A' ' 161' ' ' SER . 50.0 Cg_endo -47.95 106.45 0.11 Allowed 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.642 2.228 . . . . 0.0 111.784 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.829 HG13 ' O ' ' A' ' 169' ' ' THR . 21.2 m -128.74 155.12 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.293 -0.879 . . . . 0.0 109.478 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.497 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.0 mt-10 -95.04 123.33 38.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.924 . . . . 0.0 109.458 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 173' ' ' LEU . . . . . 0.554 ' HB3' HG13 ' A' ' 178' ' ' VAL . 67.2 mt -125.98 147.91 49.41 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.231 -0.918 . . . . 0.0 109.477 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 174' ' ' ASP . . . . . 0.422 ' OD1' ' HD2' ' A' ' 157' ' ' ARG . 91.7 m-20 -75.84 164.87 25.78 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.216 -0.927 . . . . 0.0 109.441 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.56 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.3 m-30 -60.69 -41.16 94.57 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.211 -0.931 . . . . 0.0 109.495 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 19.3 m -76.06 -26.28 56.38 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.258 -0.901 . . . . 0.0 109.384 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 177' ' ' GLN . . . . . 0.419 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 87.9 mt-30 -69.04 -25.8 64.65 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.31 -0.869 . . . . 0.0 109.465 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.554 HG13 ' HB3' ' A' ' 173' ' ' LEU . 13.9 m -128.41 158.72 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.242 -0.911 . . . . 0.0 109.434 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 179' ' ' GLU . . . . . 0.434 ' HB2' ' HB3' ' A' ' 135' ' ' ARG . 77.8 mt-10 -113.13 149.24 33.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.232 -0.917 . . . . 0.0 109.49 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 30.6 tttm -69.94 135.79 49.85 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.241 -0.912 . . . . 0.0 109.479 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.587 0 O-C-N 121.266 -0.896 . . . . 0.0 109.454 -179.986 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.596 ' CE1' ' HG3' ' A' ' 180' ' ' LYS . 74.5 m-85 . . . . . 0 N--CA 1.49 1.525 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.472 ' HB2' ' HG3' ' A' ' 132' ' ' GLU . 28.9 mt-10 -131.55 153.85 81.68 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.252 -0.905 . . . . 0.0 109.508 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -52.96 128.14 27.68 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 122.605 2.203 . . . . 0.0 111.776 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 86.5 10.16 74.15 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.472 ' HG3' ' HB2' ' A' ' 129' ' ' GLU . 72.7 mm-40 -96.13 127.26 41.98 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.304 -1.115 . . . . 0.0 109.432 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 5.8 ttm -63.71 134.71 55.84 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.263 -0.898 . . . . 0.0 109.501 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.678 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -123.5 179.03 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.228 -0.92 . . . . 0.0 109.394 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.678 ' H ' HG12 ' A' ' 134' ' ' VAL . 55.1 ttt-85 -135.95 133.53 37.68 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.264 -0.898 . . . . 0.0 109.288 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.598 HG11 ' HB2' ' A' ' 141' ' ' PHE . 90.7 t -106.03 132.06 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.202 -0.937 . . . . 0.0 109.584 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 137' ' ' ASN . . . . . 0.455 ' HB3' ' NH1' ' A' ' 135' ' ' ARG . 32.3 p30 -130.34 18.8 5.35 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.227 -0.921 . . . . 0.0 109.45 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -134.53 143.77 47.62 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.248 -0.907 . . . . 0.0 109.4 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 72.15 177.16 29.01 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -51.14 -20.95 8.44 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.638 2.225 . . . . 0.0 111.757 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 141' ' ' PHE . . . . . 0.598 ' HB2' HG11 ' A' ' 136' ' ' VAL . 93.8 m-85 -86.94 12.92 10.02 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.896 . . . . 0.0 109.45 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 142' ' ' ALA . . . . . 0.455 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -69.57 143.71 53.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.25 -0.907 . . . . 0.0 109.594 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.45 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 19.3 m-20 65.9 50.52 1.49 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.57 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.465 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 49.9 m-85 -144.11 146.26 32.67 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.238 -0.914 . . . . 0.0 109.455 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -99.64 141.35 32.56 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.266 -0.896 . . . . 0.0 109.548 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.44 -173.85 27.39 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.379 -1.488 . . . . 0.0 109.379 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.809 ' O ' HG13 ' A' ' 160' ' ' VAL . 40.1 t -132.19 152.34 36.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.256 -1.143 . . . . 0.0 109.463 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.664 ' CA ' HG22 ' A' ' 160' ' ' VAL . 2.3 p -95.47 118.09 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.227 -0.921 . . . . 0.0 109.486 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 77.1 mm-40 -73.78 -42.18 61.38 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.331 -0.856 . . . . 0.0 109.364 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.459 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 95.3 mt-10 -147.21 162.56 38.64 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.298 -0.876 . . . . 0.0 109.431 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.983 HG13 ' CD2' ' A' ' 158' ' ' LEU . 49.1 t -129.03 153.2 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.216 -0.927 . . . . 0.0 109.459 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 152' ' ' ASP . . . . . 0.4 ' O ' ' N ' ' A' ' 156' ' ' SER . 91.4 m-20 -128.7 97.37 4.66 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.176 -0.953 . . . . 0.0 109.442 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 90.3 m-85 -66.51 -41.59 88.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.232 -0.917 . . . . 0.0 109.453 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -63.12 -40.41 97.54 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.283 -0.885 . . . . 0.0 109.504 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 82.7 mttt -93.36 -0.66 56.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.246 -0.909 . . . . 0.0 109.592 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 156' ' ' SER . . . . . 0.4 ' N ' ' O ' ' A' ' 152' ' ' ASP . 4.5 m 46.22 52.27 10.54 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.239 -0.913 . . . . 0.0 109.426 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 157' ' ' ARG . . . . . 0.412 ' CG ' ' HB3' ' A' ' 172' ' ' GLU . 7.4 tpt180 -138.08 140.62 40.09 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.298 -0.876 . . . . 0.0 109.451 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 158' ' ' LEU . . . . . 0.983 ' CD2' HG13 ' A' ' 151' ' ' VAL . 41.1 mt -109.04 137.49 46.87 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.243 -0.911 . . . . 0.0 109.597 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 159' ' ' LYS . . . . . 0.459 ' HD2' ' HB2' ' A' ' 150' ' ' GLU . 21.3 mttp -99.78 96.7 7.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.259 -0.9 . . . . 0.0 109.377 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.809 HG13 ' O ' ' A' ' 147' ' ' VAL . 38.6 t -124.5 139.65 50.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.187 -0.946 . . . . 0.0 109.498 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 60.7 p -108.67 147.98 31.1 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.32 -0.862 . . . . 0.0 109.435 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 162' ' ' VAL . . . . . 0.465 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 4.2 t -117.69 133.01 65.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.158 -0.964 . . . . 0.0 109.472 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 31.0 t . . . . . 0 N--CA 1.49 1.564 0 O-C-N 121.306 -0.871 . . . . 0.0 109.457 -179.998 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 72.3 ttt180 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -68.03 138.73 56.07 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.279 -0.888 . . . . 0.0 109.491 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 169' ' ' THR . . . . . 0.548 ' O ' HG13 ' A' ' 171' ' ' VAL . 1.3 m -125.44 77.91 68.33 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.214 -0.929 . . . . 0.0 109.435 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.402 ' HD2' ' HA ' ' A' ' 169' ' ' THR . 50.0 Cg_endo -53.91 103.66 0.1 OUTLIER 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.668 2.245 . . . . 0.0 111.78 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.873 HG23 HD21 ' A' ' 173' ' ' LEU . 31.4 m -129.8 154.46 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.242 -0.912 . . . . 0.0 109.434 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.879 ' C ' HD22 ' A' ' 173' ' ' LEU . 94.9 mt-10 -108.17 130.18 55.14 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.243 -0.911 . . . . 0.0 109.529 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 173' ' ' LEU . . . . . 0.879 HD22 ' C ' ' A' ' 172' ' ' GLU . 2.5 mm? -126.96 157.59 39.1 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.284 -0.885 . . . . 0.0 109.477 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 174' ' ' ASP . . . . . 0.545 ' O ' HG22 ' A' ' 178' ' ' VAL . 94.2 m-20 -77.04 176.19 8.89 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.261 -0.899 . . . . 0.0 109.394 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.422 ' CE1' HD21 ' A' ' 158' ' ' LEU . 7.3 m-30 -65.87 -43.15 89.19 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.222 -0.924 . . . . 0.0 109.417 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 82.4 p -76.77 -26.04 54.07 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.214 -0.929 . . . . 0.0 109.518 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -68.03 -18.95 64.85 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.264 -0.897 . . . . 0.0 109.538 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.545 HG22 ' O ' ' A' ' 174' ' ' ASP . 27.2 m -138.48 162.13 30.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.232 -0.918 . . . . 0.0 109.51 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 179' ' ' GLU . . . . . 0.512 ' O ' ' N ' ' A' ' 135' ' ' ARG . 35.7 mt-10 -127.38 155.9 42.88 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.24 -0.912 . . . . 0.0 109.476 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 180' ' ' LYS . . . . . 0.596 ' HG3' ' CE1' ' A' ' 128' ' ' PHE . 9.5 mtmt -85.48 143.72 28.38 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.245 -0.91 . . . . 0.0 109.488 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.565 0 O-C-N 121.241 -0.912 . . . . 0.0 109.499 179.971 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.511 ' CE2' ' HD3' ' A' ' 180' ' ' LYS . 71.1 m-85 . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.469 ' HB2' ' HD2' ' A' ' 130' ' ' PRO . 2.6 pp20? -128.13 138.65 33.44 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.325 -0.859 . . . . 0.0 109.464 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.497 ' HA ' ' O ' ' A' ' 148' ' ' VAL . 49.3 Cg_endo -39.0 128.9 1.35 Allowed 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.469 2.112 . . . . 0.0 111.749 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 89.65 10.08 65.66 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.485 ' O ' HG13 ' A' ' 147' ' ' VAL . 84.8 tt0 -104.16 135.15 46.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.341 -1.094 . . . . 0.0 109.458 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.553 ' HG2' HG22 ' A' ' 147' ' ' VAL . 82.9 mtp -71.9 139.94 49.02 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.201 -0.937 . . . . 0.0 109.534 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.668 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -127.03 178.59 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.183 -0.948 . . . . 0.0 109.372 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.668 ' H ' HG12 ' A' ' 134' ' ' VAL . 75.2 ttt-85 -126.56 144.55 50.84 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.274 -0.891 . . . . 0.0 109.549 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.564 HG12 ' HA ' ' A' ' 142' ' ' ALA . 45.0 t -112.15 132.3 61.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.236 -0.915 . . . . 0.0 109.453 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 137' ' ' ASN . . . . . 0.411 ' C ' ' OD1' ' A' ' 137' ' ' ASN . 48.0 p30 -131.83 14.65 4.82 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.233 -0.917 . . . . 0.0 109.474 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 59.1 t0 -142.18 143.15 32.81 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.234 -0.916 . . . . 0.0 109.49 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 79.87 171.2 41.96 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -55.73 -21.96 34.51 Favored 'Trans proline' 0 C--O 1.216 -0.625 0 C-N-CA 122.601 2.201 . . . . 0.0 111.813 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' PHE . . . . . 0.529 ' CZ ' HG11 ' A' ' 171' ' ' VAL . 99.0 m-85 -85.21 5.67 29.2 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.13 -0.981 . . . . 0.0 109.54 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 142' ' ' ALA . . . . . 0.564 ' HA ' HG12 ' A' ' 136' ' ' VAL . . . -69.15 149.01 49.11 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.272 -0.892 . . . . 0.0 109.416 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.493 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 30.3 t0 75.13 28.67 1.01 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.174 -0.954 . . . . 0.0 109.45 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.445 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 90.2 m-85 -135.77 145.0 46.1 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.263 -0.898 . . . . 0.0 109.456 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 74.0 m-20 -97.9 140.22 32.58 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.26 -0.9 . . . . 0.0 109.415 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -153.85 -173.06 22.53 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.792 ' O ' HG13 ' A' ' 160' ' ' VAL . 44.9 t -129.08 152.63 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.248 -1.148 . . . . 0.0 109.418 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.671 HG21 HG22 ' A' ' 151' ' ' VAL . 2.5 p -92.52 107.97 19.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.294 -0.879 . . . . 0.0 109.398 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.476 ' HB2' ' HE3' ' A' ' 159' ' ' LYS . 75.1 mm-40 -70.63 -39.23 73.83 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.224 -0.923 . . . . 0.0 109.365 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.46 ' HB2' ' HE2' ' A' ' 159' ' ' LYS . 92.4 mt-10 -139.41 157.5 45.75 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.239 -0.913 . . . . 0.0 109.393 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.849 HG13 ' CD2' ' A' ' 158' ' ' LEU . 48.5 t -127.29 151.04 33.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.274 -0.891 . . . . 0.0 109.481 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 152' ' ' ASP . . . . . 0.401 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 88.1 m-20 -134.43 87.7 2.38 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.223 -0.923 . . . . 0.0 109.436 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -63.34 -39.45 94.59 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.259 -0.901 . . . . 0.0 109.461 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -62.27 -42.15 99.1 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.18 -0.95 . . . . 0.0 109.506 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.412 ' O ' ' C ' ' A' ' 156' ' ' SER . 43.5 mttp -91.19 5.17 50.14 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.186 -0.946 . . . . 0.0 109.61 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 156' ' ' SER . . . . . 0.517 ' HA ' ' CZ ' ' A' ' 175' ' ' PHE . 0.3 OUTLIER 43.91 51.8 6.8 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.187 -0.945 . . . . 0.0 109.472 -179.943 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 157' ' ' ARG . . . . . 0.469 ' HD2' ' OD1' ' A' ' 174' ' ' ASP . 9.3 tpt180 -145.44 137.14 25.32 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.257 -0.902 . . . . 0.0 109.402 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 158' ' ' LEU . . . . . 0.849 ' CD2' HG13 ' A' ' 151' ' ' VAL . 46.2 mt -108.34 136.2 48.37 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 109.53 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 159' ' ' LYS . . . . . 0.476 ' HE3' ' HB2' ' A' ' 149' ' ' GLU . 14.2 ttpt -95.19 109.2 21.33 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.327 -0.858 . . . . 0.0 109.442 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.792 HG13 ' O ' ' A' ' 147' ' ' VAL . 39.2 t -127.84 142.0 44.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -0.921 . . . . 0.0 109.464 -179.88 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 161' ' ' SER . . . . . 0.486 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 96.1 p -107.0 147.44 29.89 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.191 -0.943 . . . . 0.0 109.504 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 162' ' ' VAL . . . . . . . . . . . . . 26.1 t -119.21 132.05 70.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.31 -0.869 . . . . 0.0 109.565 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 32.0 t . . . . . 0 N--CA 1.489 1.521 0 O-C-N 121.217 -0.927 . . . . 0.0 109.433 179.921 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 39.0 mtm105 . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -72.08 137.29 46.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.208 -0.933 . . . . 0.0 109.497 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 169' ' ' THR . . . . . 0.685 ' O ' HG13 ' A' ' 171' ' ' VAL . 59.3 m -129.82 77.02 77.55 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.244 -0.91 . . . . 0.0 109.44 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.486 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 50.6 Cg_endo -53.19 111.47 0.68 Allowed 'Trans proline' 0 C--O 1.214 -0.687 0 C-N-CA 122.579 2.186 . . . . 0.0 111.807 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.685 HG13 ' O ' ' A' ' 169' ' ' THR . 20.9 m -130.44 155.27 41.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.288 -0.883 . . . . 0.0 109.493 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.75 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.2 mt-10 -104.57 135.81 45.28 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.268 -0.895 . . . . 0.0 109.528 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 173' ' ' LEU . . . . . 0.75 HD23 ' O ' ' A' ' 172' ' ' GLU . 63.0 mt -133.91 148.28 51.2 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.316 -0.865 . . . . 0.0 109.576 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 174' ' ' ASP . . . . . 0.482 ' O ' HG22 ' A' ' 178' ' ' VAL . 91.4 m-20 -68.91 171.16 8.42 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.283 -0.886 . . . . 0.0 109.4 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.548 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 3.6 m-30 -65.29 -47.58 76.13 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.206 -0.934 . . . . 0.0 109.463 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 14.6 m -70.73 -28.03 64.41 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.315 -0.865 . . . . 0.0 109.498 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 177' ' ' GLN . . . . . 0.407 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 91.0 mt-30 -68.07 -20.64 64.97 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.306 -0.871 . . . . 0.0 109.473 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.632 HG11 ' HB2' ' A' ' 173' ' ' LEU . 13.7 m -131.23 160.29 42.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.278 -0.888 . . . . 0.0 109.484 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 179' ' ' GLU . . . . . 0.488 ' O ' ' N ' ' A' ' 135' ' ' ARG . 55.1 mt-10 -128.65 167.54 17.06 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.183 -0.948 . . . . 0.0 109.513 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 180' ' ' LYS . . . . . 0.511 ' HD3' ' CE2' ' A' ' 128' ' ' PHE . 29.0 mmtp -66.36 145.83 55.26 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.275 -0.89 . . . . 0.0 109.497 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.502 0 O-C-N 121.139 -0.975 . . . . 0.0 109.48 179.973 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.505 ' CD2' HD21 ' A' ' 158' ' ' LEU . 69.0 m-85 . . . . . 0 N--CA 1.489 1.513 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.53 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.9 OUTLIER -144.55 157.73 55.14 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.26 -0.9 . . . . 0.0 109.394 179.959 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.53 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.2 Cg_endo -49.51 128.18 20.1 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.625 2.217 . . . . 0.0 111.805 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 96.1 -3.89 64.74 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.463 ' OE1' ' HA ' ' A' ' 128' ' ' PHE . 88.2 mt-10 -92.38 129.88 38.2 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.14 -1.212 . . . . 0.0 109.5 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.492 ' O ' ' HB3' ' A' ' 181' ' ' ALA . 43.5 ttm -77.13 145.7 37.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.237 -0.914 . . . . 0.0 109.353 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.683 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -129.76 178.66 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.198 -0.939 . . . . 0.0 109.404 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.683 ' H ' HG12 ' A' ' 134' ' ' VAL . 58.6 ttt180 -131.61 140.95 49.54 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.308 -0.87 . . . . 0.0 109.426 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.607 HG22 ' CD1' ' A' ' 173' ' ' LEU . 40.6 t -113.21 135.86 51.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.222 -0.923 . . . . 0.0 109.54 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 137' ' ' ASN . . . . . 0.446 ' O ' ' OD1' ' A' ' 138' ' ' ASP . 29.0 p30 -128.8 18.04 6.22 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.273 -0.892 . . . . 0.0 109.537 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.497 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 91.3 m-20 -139.43 164.37 30.03 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.208 -0.932 . . . . 0.0 109.497 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 57.94 172.86 0.32 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -53.26 -21.1 16.32 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.581 2.187 . . . . 0.0 111.777 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 141' ' ' PHE . . . . . 0.559 ' CZ ' HG11 ' A' ' 171' ' ' VAL . 91.8 m-85 -82.18 6.36 16.83 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.216 -0.928 . . . . 0.0 109.458 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 142' ' ' ALA . . . . . 0.423 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -62.62 143.24 57.52 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.278 -0.889 . . . . 0.0 109.488 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.423 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 10.2 m-20 67.06 48.69 1.2 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.257 -0.902 . . . . 0.0 109.413 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.494 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 43.6 m-85 -146.39 129.08 16.16 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.239 -0.913 . . . . 0.0 109.465 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 68.5 m-20 -90.87 138.04 31.9 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.227 -0.921 . . . . 0.0 109.509 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -152.71 177.39 30.44 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.851 ' O ' HG13 ' A' ' 160' ' ' VAL . 38.9 t -118.95 156.52 20.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.273 -1.134 . . . . 0.0 109.447 179.87 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.9 HG11 HG22 ' A' ' 151' ' ' VAL . 50.9 t -89.36 106.84 17.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.161 -0.962 . . . . 0.0 109.574 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -73.58 -31.84 63.81 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.247 -0.908 . . . . 0.0 109.392 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -144.42 148.63 34.87 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.282 -0.886 . . . . 0.0 109.25 179.852 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.9 HG22 HG11 ' A' ' 148' ' ' VAL . 37.1 t -125.55 146.43 31.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.157 -0.964 . . . . 0.0 109.644 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -132.28 87.89 2.48 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.279 -0.888 . . . . 0.0 109.412 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -61.1 -40.41 93.64 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.195 -0.941 . . . . 0.0 109.442 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -62.39 -40.53 96.76 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.21 -0.932 . . . . 0.0 109.51 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -91.52 2.45 56.43 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.217 -0.927 . . . . 0.0 109.649 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 13.6 p 45.21 52.62 8.52 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.154 -0.966 . . . . 0.0 109.394 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 157' ' ' ARG . . . . . 0.639 ' C ' HD12 ' A' ' 158' ' ' LEU . 0.0 OUTLIER -136.67 156.28 48.75 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.202 -0.937 . . . . 0.0 109.543 179.919 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 158' ' ' LEU . . . . . 0.845 HD11 ' CE1' ' A' ' 175' ' ' PHE . 7.4 mp -120.39 123.66 43.61 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.257 -0.902 . . . . 0.0 109.525 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 18.0 tttm -91.01 92.18 8.63 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.25 -0.906 . . . . 0.0 109.378 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.851 HG13 ' O ' ' A' ' 147' ' ' VAL . 21.7 t -116.22 150.27 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.199 -0.938 . . . . 0.0 109.359 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 161' ' ' SER . . . . . 0.467 ' OG ' ' N ' ' A' ' 170' ' ' PRO . 18.3 t -119.74 131.32 55.34 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.311 -0.868 . . . . 0.0 109.431 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 162' ' ' VAL . . . . . 0.494 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 11.7 t -102.16 131.98 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.243 -0.91 . . . . 0.0 109.387 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 40.5 t . . . . . 0 N--CA 1.489 1.515 0 O-C-N 121.273 -0.892 . . . . 0.0 109.43 -179.978 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 70.1 mtm180 . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -68.17 144.53 54.93 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 109.521 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 169' ' ' THR . . . . . 0.781 ' O ' HG13 ' A' ' 171' ' ' VAL . 2.9 m -128.09 73.82 79.34 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.249 -0.907 . . . . 0.0 109.414 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.467 ' N ' ' OG ' ' A' ' 161' ' ' SER . 50.2 Cg_endo -49.09 105.98 0.1 Allowed 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.585 2.19 . . . . 0.0 111.794 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.781 HG13 ' O ' ' A' ' 169' ' ' THR . 19.3 m -133.67 153.94 37.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.295 -0.878 . . . . 0.0 109.359 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.72 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.2 mt-10 -97.23 135.81 38.63 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.259 -0.901 . . . . 0.0 109.489 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 173' ' ' LEU . . . . . 0.72 HD23 ' O ' ' A' ' 172' ' ' GLU . 28.9 mt -124.97 160.06 29.8 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.256 -0.902 . . . . 0.0 109.421 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 174' ' ' ASP . . . . . 0.471 ' HB2' ' HB2' ' A' ' 177' ' ' GLN . 92.7 m-20 -83.54 160.78 21.4 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.184 -0.948 . . . . 0.0 109.521 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.845 ' CE1' HD11 ' A' ' 158' ' ' LEU . 4.5 m-85 -53.67 -49.95 66.86 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.321 -0.862 . . . . 0.0 109.561 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 15.5 m -74.67 -24.36 58.79 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.162 -0.961 . . . . 0.0 109.546 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 177' ' ' GLN . . . . . 0.69 ' NE2' HD22 ' A' ' 173' ' ' LEU . 61.9 tt0 -64.6 -27.21 68.79 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.231 -0.918 . . . . 0.0 109.425 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.66 HG11 HD12 ' A' ' 173' ' ' LEU . 13.7 m -127.97 161.83 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.334 -0.854 . . . . 0.0 109.482 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 179' ' ' GLU . . . . . 0.43 ' N ' ' O ' ' A' ' 135' ' ' ARG . 61.6 mt-10 -118.32 148.19 42.73 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.207 -0.933 . . . . 0.0 109.489 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -66.95 130.91 44.67 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.32 -0.863 . . . . 0.0 109.427 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 181' ' ' ALA . . . . . 0.492 ' HB3' ' O ' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.558 0 O-C-N 121.259 -0.901 . . . . 0.0 109.461 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.416 ' CE1' ' HB2' ' A' ' 180' ' ' LYS . 68.8 m-85 . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.474 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.0 OUTLIER -125.87 153.54 73.52 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.23 -0.919 . . . . 0.0 109.503 179.949 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.474 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 49.4 Cg_endo -47.88 134.59 23.13 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.636 2.224 . . . . 0.0 111.72 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 85.45 3.72 86.47 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 48.9 tp10 -89.9 136.11 33.24 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.168 -1.195 . . . . 0.0 109.474 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.914 ' SD ' HG22 ' A' ' 147' ' ' VAL . 92.9 mmm -74.82 148.55 40.19 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.253 -0.904 . . . . 0.0 109.48 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.836 HG21 HG23 ' A' ' 148' ' ' VAL . 2.5 t -139.06 179.18 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.285 -0.885 . . . . 0.0 109.373 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.686 ' H ' HG12 ' A' ' 134' ' ' VAL . 19.8 ttp85 -137.58 142.41 41.31 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.323 -0.861 . . . . 0.0 109.445 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.46 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 43.8 t -106.45 132.16 54.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.224 -0.923 . . . . 0.0 109.533 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 29.0 p30 -118.48 13.33 13.47 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.337 -0.852 . . . . 0.0 109.425 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.432 ' H ' HG12 ' A' ' 136' ' ' VAL . 51.9 p30 -151.89 169.93 21.07 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.235 -0.916 . . . . 0.0 109.461 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 67.4 168.79 3.94 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -56.71 -18.11 25.45 Favored 'Trans proline' 0 C--O 1.214 -0.702 0 C-N-CA 122.565 2.177 . . . . 0.0 111.848 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' PHE . . . . . 0.726 ' CE2' HG11 ' A' ' 171' ' ' VAL . 92.5 m-85 -88.12 8.1 28.46 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.28 -0.888 . . . . 0.0 109.48 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 142' ' ' ALA . . . . . 0.481 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -61.34 150.68 34.35 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.213 -0.929 . . . . 0.0 109.458 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.448 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 63.2 m-20 62.63 42.4 8.44 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.243 -0.911 . . . . 0.0 109.446 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.481 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 51.3 m-85 -146.9 134.52 21.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.165 -0.959 . . . . 0.0 109.516 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -87.68 141.98 28.18 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.898 . . . . 0.0 109.453 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -149.61 177.89 27.48 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.914 HG22 ' SD ' ' A' ' 133' ' ' MET . 35.6 t -119.92 156.34 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.306 -1.114 . . . . 0.0 109.462 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.836 HG23 HG21 ' A' ' 134' ' ' VAL . 61.3 t -87.54 103.18 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.22 -0.925 . . . . 0.0 109.457 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 75.2 mm-40 -67.63 -38.69 84.23 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.268 -0.895 . . . . 0.0 109.415 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -153.77 150.81 28.88 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.232 -0.918 . . . . 0.0 109.426 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.708 HG13 ' CD2' ' A' ' 158' ' ' LEU . 58.9 t -122.68 154.41 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.269 -0.895 . . . . 0.0 109.475 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -135.12 94.83 3.19 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.301 -0.875 . . . . 0.0 109.459 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 81.1 m-85 -67.32 -42.44 83.65 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.301 -0.874 . . . . 0.0 109.487 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -62.63 -36.67 83.56 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.212 -0.93 . . . . 0.0 109.412 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.47 ' O ' ' HG2' ' A' ' 155' ' ' LYS . 57.0 tttm -95.59 1.4 53.73 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.202 -0.936 . . . . 0.0 109.617 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 41.1 t 46.6 52.4 11.09 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.171 -0.956 . . . . 0.0 109.486 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 7.7 tpt180 -141.28 138.25 33.07 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.256 -0.903 . . . . 0.0 109.417 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 158' ' ' LEU . . . . . 0.708 ' CD2' HG13 ' A' ' 151' ' ' VAL . 55.2 mt -107.25 131.66 53.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.221 -0.924 . . . . 0.0 109.496 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 60.3 tttm -96.52 105.78 17.93 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.874 . . . . 0.0 109.373 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.698 HG13 ' O ' ' A' ' 147' ' ' VAL . 38.6 t -123.36 145.75 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.265 -0.897 . . . . 0.0 109.578 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 161' ' ' SER . . . . . 0.404 ' OG ' ' HA ' ' A' ' 170' ' ' PRO . 11.4 m -118.85 137.01 53.72 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.33 -0.856 . . . . 0.0 109.359 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 162' ' ' VAL . . . . . 0.55 HG21 ' HB3' ' A' ' 141' ' ' PHE . 25.2 t -107.85 133.68 51.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.292 -0.88 . . . . 0.0 109.634 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 33.8 t . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.233 -0.917 . . . . 0.0 109.193 179.82 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 51.1 mtt180 . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -74.29 140.94 45.26 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.194 -0.941 . . . . 0.0 109.568 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 169' ' ' THR . . . . . 0.56 ' O ' HG13 ' A' ' 171' ' ' VAL . 0.2 OUTLIER -127.03 73.99 76.76 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.317 -0.864 . . . . 0.0 109.443 179.953 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.404 ' HA ' ' OG ' ' A' ' 161' ' ' SER . 49.8 Cg_endo -54.17 100.28 0.06 OUTLIER 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.567 2.178 . . . . 0.0 111.81 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.726 HG11 ' CE2' ' A' ' 141' ' ' PHE . 26.9 m -126.96 153.4 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.278 -0.889 . . . . 0.0 109.489 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.778 ' O ' HD23 ' A' ' 173' ' ' LEU . 57.0 mp0 -102.02 134.8 44.66 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.292 -0.88 . . . . 0.0 109.563 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 173' ' ' LEU . . . . . 0.778 HD23 ' O ' ' A' ' 172' ' ' GLU . 53.4 mt -132.95 147.8 52.28 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.245 -0.91 . . . . 0.0 109.455 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 174' ' ' ASP . . . . . 0.414 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 90.7 m-20 -70.89 174.32 6.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.262 -0.899 . . . . 0.0 109.458 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.529 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 3.8 m-30 -65.13 -44.66 87.94 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.212 -0.93 . . . . 0.0 109.457 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 94.8 p -73.73 -28.81 61.9 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.205 -0.935 . . . . 0.0 109.463 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 177' ' ' GLN . . . . . 0.414 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 82.1 mt-30 -63.49 -25.71 68.38 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.283 -0.885 . . . . 0.0 109.49 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.473 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 6.1 m -130.02 160.79 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.266 -0.896 . . . . 0.0 109.485 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 179' ' ' GLU . . . . . 0.478 ' OE1' ' CZ ' ' A' ' 135' ' ' ARG . 79.6 mt-10 -112.14 147.61 35.75 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.278 -0.889 . . . . 0.0 109.465 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 180' ' ' LYS . . . . . 0.416 ' HB2' ' CE1' ' A' ' 128' ' ' PHE . 19.1 tttm -76.02 132.04 39.9 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.286 -0.884 . . . . 0.0 109.465 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.552 0 O-C-N 121.2 -0.937 . . . . 0.0 109.518 -179.957 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 72.8 m-85 . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.508 -0.552 . . . . 0.0 109.508 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.542 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.1 OUTLIER -143.62 156.69 59.72 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.328 -0.858 . . . . 0.0 109.412 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.542 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.4 Cg_endo -47.34 132.19 19.11 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.552 2.168 . . . . 0.0 111.737 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 93.59 0.67 66.74 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -103.68 139.99 38.19 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.234 -1.157 . . . . 0.0 109.435 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 87.7 mtp -83.78 152.69 24.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.317 -0.865 . . . . 0.0 109.491 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.836 ' CG2' HG23 ' A' ' 148' ' ' VAL . 2.5 t -136.82 179.21 3.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.258 -0.901 . . . . 0.0 109.345 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.683 ' H ' HG12 ' A' ' 134' ' ' VAL . 53.0 ttm-85 -135.08 139.02 44.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.232 -0.918 . . . . 0.0 109.456 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.775 HG22 ' CD1' ' A' ' 173' ' ' LEU . 50.0 t -107.1 131.23 57.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.266 -0.896 . . . . 0.0 109.494 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 137' ' ' ASN . . . . . 0.421 ' O ' ' OD1' ' A' ' 138' ' ' ASP . 11.4 p30 -122.54 16.32 10.39 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.279 -0.888 . . . . 0.0 109.43 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.421 ' OD1' ' O ' ' A' ' 137' ' ' ASN . 93.5 m-20 -135.67 160.16 39.39 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.229 -0.919 . . . . 0.0 109.489 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 60.35 173.08 0.82 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -53.53 -20.37 15.95 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.609 2.206 . . . . 0.0 111.803 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' PHE . . . . . 0.571 ' HB3' HG21 ' A' ' 162' ' ' VAL . 99.4 m-85 -80.57 4.07 19.71 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.222 -0.924 . . . . 0.0 109.481 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 142' ' ' ALA . . . . . 0.497 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -63.99 150.84 44.35 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.139 -0.976 . . . . 0.0 109.474 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.444 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 57.9 m-20 62.83 47.53 4.5 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.275 -0.89 . . . . 0.0 109.398 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.497 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 50.2 m-85 -149.34 144.56 26.51 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.308 -0.87 . . . . 0.0 109.493 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 74.4 m-20 -97.9 145.52 26.36 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.27 -0.894 . . . . 0.0 109.497 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -154.21 174.68 32.62 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.559 HG12 ' N ' ' A' ' 148' ' ' VAL . 47.3 t -114.4 165.16 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.223 -1.163 . . . . 0.0 109.386 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.836 HG23 ' CG2' ' A' ' 134' ' ' VAL . 51.0 t -101.57 123.66 54.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.273 -0.892 . . . . 0.0 109.512 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 74.7 mm-40 -99.76 -44.55 6.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.256 -0.903 . . . . 0.0 109.435 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -133.24 155.61 49.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.237 -0.914 . . . . 0.0 109.348 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.52 HG11 ' CZ ' ' A' ' 153' ' ' TYR . 38.7 t -122.79 151.15 26.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.29 -0.881 . . . . 0.0 109.565 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 152' ' ' ASP . . . . . 0.408 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 93.3 m-20 -135.3 78.93 1.76 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.292 -0.88 . . . . 0.0 109.373 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 153' ' ' TYR . . . . . 0.52 ' CZ ' HG11 ' A' ' 151' ' ' VAL . 98.1 m-85 -62.68 -37.3 85.9 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.197 -0.939 . . . . 0.0 109.651 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -64.35 -40.95 96.88 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.277 -0.889 . . . . 0.0 109.593 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.463 ' O ' ' HG3' ' A' ' 157' ' ' ARG . 28.9 mttt -87.1 3.13 47.44 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.211 -0.93 . . . . 0.0 109.627 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 156' ' ' SER . . . . . 0.492 ' HA ' ' CZ ' ' A' ' 175' ' ' PHE . 58.1 m 52.83 52.59 13.63 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.224 -0.922 . . . . 0.0 109.469 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 157' ' ' ARG . . . . . 0.472 ' CG ' ' O ' ' A' ' 156' ' ' SER . 47.0 mtt180 -157.81 155.43 29.72 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.278 -0.889 . . . . 0.0 109.44 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 158' ' ' LEU . . . . . 0.66 HD21 ' CE1' ' A' ' 175' ' ' PHE . 12.0 mt -119.83 137.0 54.26 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.243 -0.911 . . . . 0.0 109.57 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 14.8 tttt -83.63 105.34 14.48 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.302 -0.874 . . . . 0.0 109.308 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.769 HG22 HG22 ' A' ' 148' ' ' VAL . 57.8 t -123.11 145.27 30.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.205 -0.934 . . . . 0.0 109.596 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 14.9 m -111.86 140.85 46.17 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.257 -0.902 . . . . 0.0 109.444 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 162' ' ' VAL . . . . . 0.571 HG21 ' HB3' ' A' ' 141' ' ' PHE . 14.0 t -110.46 133.14 56.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.206 -0.934 . . . . 0.0 109.493 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 60.7 p . . . . . 0 N--CA 1.49 1.534 0 O-C-N 121.191 -0.943 . . . . 0.0 109.435 179.928 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.462 -0.569 . . . . 0.0 109.462 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -72.76 137.23 45.73 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.287 -0.883 . . . . 0.0 109.471 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 169' ' ' THR . . . . . 0.709 ' O ' HG13 ' A' ' 171' ' ' VAL . 18.6 m -129.96 74.18 80.79 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.203 -0.936 . . . . 0.0 109.486 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -51.04 112.72 0.85 Allowed 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.607 2.205 . . . . 0.0 111.73 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.709 HG13 ' O ' ' A' ' 169' ' ' THR . 28.7 m -133.11 153.46 37.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.308 -0.87 . . . . 0.0 109.423 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.675 ' O ' HD23 ' A' ' 173' ' ' LEU . 94.8 mt-10 -95.68 130.28 42.62 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.24 -0.913 . . . . 0.0 109.5 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 173' ' ' LEU . . . . . 0.775 ' CD1' HG22 ' A' ' 136' ' ' VAL . 51.6 mt -128.08 146.4 50.7 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.327 -0.858 . . . . 0.0 109.404 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 57.1 m-20 -67.77 171.06 6.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.268 -0.895 . . . . 0.0 109.451 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.66 ' CE1' HD21 ' A' ' 158' ' ' LEU . 6.2 m-30 -64.64 -49.19 71.99 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.248 -0.908 . . . . 0.0 109.386 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 87.0 p -74.94 -18.64 60.36 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.169 -0.957 . . . . 0.0 109.453 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 177' ' ' GLN . . . . . 0.651 ' NE2' HD22 ' A' ' 173' ' ' LEU . 63.8 tt0 -70.66 -20.85 62.67 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.296 -0.878 . . . . 0.0 109.483 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.556 HG11 ' HB2' ' A' ' 173' ' ' LEU . 4.7 m -130.2 159.2 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.285 -0.885 . . . . 0.0 109.403 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 179' ' ' GLU . . . . . 0.405 ' HB2' ' HB3' ' A' ' 135' ' ' ARG . 73.0 mt-10 -115.6 151.96 33.98 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.189 -0.944 . . . . 0.0 109.525 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 21.1 tttt -75.7 136.42 40.36 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.249 -0.907 . . . . 0.0 109.511 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.516 0 O-C-N 121.292 -0.88 . . . . 0.0 109.527 179.978 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.683 ' CD2' HD21 ' A' ' 158' ' ' LEU . 83.9 m-85 . . . . . 0 N--CA 1.489 1.509 0 CA-C-O 121.246 0.546 . . . . 0.0 109.564 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.434 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.2 OUTLIER -123.02 155.03 64.71 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.287 -0.883 . . . . 0.0 109.464 179.979 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.434 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 49.5 Cg_endo -51.22 128.89 26.78 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.648 2.232 . . . . 0.0 111.815 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 91.52 2.93 69.58 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.433 ' OE2' ' HE3' ' A' ' 180' ' ' LYS . 65.7 tt0 -88.5 141.87 28.18 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.154 -1.204 . . . . 0.0 109.485 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.925 ' SD ' HG22 ' A' ' 147' ' ' VAL . 80.4 mmm -80.33 137.56 36.59 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.208 -0.932 . . . . 0.0 109.556 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.75 HG21 ' CG2' ' A' ' 148' ' ' VAL . 2.5 t -129.22 179.28 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.247 -0.908 . . . . 0.0 109.285 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.685 ' H ' HG12 ' A' ' 134' ' ' VAL . 37.4 ttm180 -137.83 142.6 40.77 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.123 -0.986 . . . . 0.0 109.48 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.47 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 59.3 t -110.95 133.02 57.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.302 -0.874 . . . . 0.0 109.512 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 40.7 p30 -124.75 19.86 8.55 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.176 -0.952 . . . . 0.0 109.384 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.444 ' HB3' ' HG3' ' A' ' 177' ' ' GLN . 55.9 t0 -143.13 153.77 43.23 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.289 -0.882 . . . . 0.0 109.481 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.44 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 69.84 172.07 9.52 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -52.88 -16.9 6.62 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.582 2.188 . . . . 0.0 111.71 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' PHE . . . . . 0.488 ' CD1' HG21 ' A' ' 162' ' ' VAL . 99.5 m-85 -88.15 10.83 18.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.299 -0.876 . . . . 0.0 109.426 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 142' ' ' ALA . . . . . 0.449 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -64.27 145.79 55.42 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.276 -0.89 . . . . 0.0 109.554 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.449 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 50.8 m-20 63.54 46.88 4.02 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.33 -0.856 . . . . 0.0 109.622 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.6 ' HB3' HG13 ' A' ' 162' ' ' VAL . 39.3 m-85 -143.38 140.86 30.68 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.176 -0.952 . . . . 0.0 109.599 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 73.5 m-20 -95.6 142.05 28.38 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.271 -0.893 . . . . 0.0 109.492 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -151.29 173.16 30.76 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.925 HG22 ' SD ' ' A' ' 133' ' ' MET . 22.6 t -117.9 153.04 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.154 -1.204 . . . . 0.0 109.401 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.858 HG22 HG22 ' A' ' 160' ' ' VAL . 57.5 t -88.87 109.67 20.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.234 -0.916 . . . . 0.0 109.521 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -68.13 -40.9 82.37 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.262 -0.899 . . . . 0.0 109.418 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.451 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 95.6 mt-10 -153.93 157.53 39.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.207 -0.933 . . . . 0.0 109.395 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.498 HG21 ' O ' ' A' ' 128' ' ' PHE . 43.9 t -120.99 144.27 30.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.233 -0.917 . . . . 0.0 109.462 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -123.15 95.61 4.67 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.212 -0.93 . . . . 0.0 109.493 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -66.14 -42.24 89.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.183 -0.948 . . . . 0.0 109.51 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 76.2 mm-40 -59.58 -43.37 93.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.29 -0.881 . . . . 0.0 109.427 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 23.7 mttt -87.35 -10.25 52.69 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.29 -0.881 . . . . 0.0 109.495 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 1.6 m 55.62 53.28 9.81 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.23 -0.919 . . . . 0.0 109.432 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 157' ' ' ARG . . . . . 0.573 ' C ' HD12 ' A' ' 158' ' ' LEU . 88.5 mmt-85 -139.47 162.55 34.79 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.277 -0.889 . . . . 0.0 109.512 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 158' ' ' LEU . . . . . 0.748 HD11 ' CE1' ' A' ' 175' ' ' PHE . 7.0 mp -122.55 131.31 53.78 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.278 -0.889 . . . . 0.0 109.542 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 159' ' ' LYS . . . . . 0.451 ' HD2' ' HB2' ' A' ' 150' ' ' GLU . 23.8 mttm -97.14 98.6 10.17 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.198 -0.939 . . . . 0.0 109.233 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.858 HG22 HG22 ' A' ' 148' ' ' VAL . 30.0 t -123.17 145.68 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.236 -0.915 . . . . 0.0 109.662 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 161' ' ' SER . . . . . 0.466 ' CB ' ' HA ' ' A' ' 170' ' ' PRO . 88.1 p -112.71 148.29 35.02 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.277 -0.89 . . . . 0.0 109.333 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 162' ' ' VAL . . . . . 0.6 HG13 ' HB3' ' A' ' 144' ' ' PHE . 18.0 t -113.4 128.32 70.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.215 -0.928 . . . . 0.0 109.626 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 36.5 t . . . . . 0 N--CA 1.489 1.522 0 O-C-N 121.29 -0.881 . . . . 0.0 109.503 179.85 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 72.9 mtm180 . . . . . 0 N--CA 1.489 1.512 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -81.08 134.75 35.71 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.258 -0.901 . . . . 0.0 109.496 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 169' ' ' THR . . . . . 0.717 ' O ' HG13 ' A' ' 171' ' ' VAL . 64.8 m -128.48 77.26 77.5 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.215 -0.928 . . . . 0.0 109.475 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.466 ' HA ' ' CB ' ' A' ' 161' ' ' SER . 48.9 Cg_endo -53.13 107.8 0.22 Allowed 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.631 2.22 . . . . 0.0 111.789 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 1.03 HG23 HD21 ' A' ' 173' ' ' LEU . 19.4 m -127.04 157.68 38.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.27 -0.893 . . . . 0.0 109.463 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.745 ' C ' HD22 ' A' ' 173' ' ' LEU . 95.8 mt-10 -91.05 128.46 36.88 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.311 -0.868 . . . . 0.0 109.503 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 173' ' ' LEU . . . . . 1.03 HD21 HG23 ' A' ' 171' ' ' VAL . 2.2 mm? -122.33 156.08 34.64 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.289 -0.882 . . . . 0.0 109.497 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 174' ' ' ASP . . . . . 0.466 ' HB2' ' HB2' ' A' ' 177' ' ' GLN . 84.5 m-20 -83.34 168.13 16.92 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.217 -0.927 . . . . 0.0 109.596 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.748 ' CE1' HD11 ' A' ' 158' ' ' LEU . 8.2 m-85 -59.49 -49.44 77.77 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.255 -0.903 . . . . 0.0 109.584 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 84.0 p -78.09 -19.36 54.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.2 -0.937 . . . . 0.0 109.653 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 177' ' ' GLN . . . . . 0.6 ' NE2' HD12 ' A' ' 173' ' ' LEU . 64.9 tt0 -67.25 -25.26 65.99 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.116 -0.99 . . . . 0.0 109.483 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.536 HG13 ' HB3' ' A' ' 173' ' ' LEU . 4.5 m -127.08 157.57 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.264 -0.897 . . . . 0.0 109.592 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 179' ' ' GLU . . . . . 0.445 ' N ' ' O ' ' A' ' 135' ' ' ARG . 56.4 mt-10 -111.29 152.74 26.86 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.258 -0.901 . . . . 0.0 109.438 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 180' ' ' LYS . . . . . 0.433 ' HE3' ' OE2' ' A' ' 132' ' ' GLU . 5.4 tttp -72.9 133.02 44.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.228 -0.92 . . . . 0.0 109.481 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 181' ' ' ALA . . . . . 0.418 ' CB ' ' O ' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.547 0 O-C-N 121.249 -0.907 . . . . 0.0 109.514 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.435 ' HA ' ' OE1' ' A' ' 132' ' ' GLU . 56.9 m-85 . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.497 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.1 OUTLIER -145.42 155.44 53.69 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.252 -0.905 . . . . 0.0 109.502 179.933 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.497 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.2 Cg_endo -48.58 128.52 18.3 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.633 2.222 . . . . 0.0 111.828 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 96.25 -9.57 67.41 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.435 ' OE1' ' HA ' ' A' ' 128' ' ' PHE . 92.2 mt-10 -86.95 140.24 29.8 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.155 -1.203 . . . . 0.0 109.496 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.557 ' HG2' HG22 ' A' ' 147' ' ' VAL . 87.9 mtp -84.76 152.25 23.82 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.333 -0.854 . . . . 0.0 109.456 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.692 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -133.45 179.21 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.236 -0.915 . . . . 0.0 109.308 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.692 ' H ' HG12 ' A' ' 134' ' ' VAL . 64.1 mtm180 -138.9 150.31 45.8 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.233 -0.917 . . . . 0.0 109.53 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.531 HG12 ' H ' ' A' ' 138' ' ' ASP . 42.1 t -108.31 135.24 47.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.297 -0.877 . . . . 0.0 109.444 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 36.7 p30 -118.17 14.16 13.91 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.239 -0.913 . . . . 0.0 109.528 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.531 ' H ' HG12 ' A' ' 136' ' ' VAL . 53.7 p30 -157.21 169.95 23.6 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.269 -0.894 . . . . 0.0 109.499 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 69.04 165.55 4.11 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -55.97 -18.61 23.0 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.629 2.219 . . . . 0.0 111.739 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' PHE . . . . . 1.175 ' CD1' HG21 ' A' ' 162' ' ' VAL . 94.1 m-85 -88.74 7.77 32.18 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.291 -0.881 . . . . 0.0 109.523 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 142' ' ' ALA . . . . . 0.497 ' O ' ' CB ' ' A' ' 143' ' ' ASP . . . -67.9 147.98 51.75 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.178 -0.951 . . . . 0.0 109.48 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.497 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 3.9 t70 76.29 27.47 0.86 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.281 -0.887 . . . . 0.0 109.56 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.482 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 96.5 m-85 -135.87 146.55 47.55 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -0.878 . . . . 0.0 109.47 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 75.6 m-20 -103.63 146.98 27.77 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.268 -0.895 . . . . 0.0 109.377 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 146' ' ' GLY . . . . . 0.459 ' HA3' ' O ' ' A' ' 161' ' ' SER . . . -151.24 -173.94 21.63 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.557 HG22 ' HG2' ' A' ' 133' ' ' MET . 48.7 t -123.99 156.68 31.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.302 -1.116 . . . . 0.0 109.487 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.638 HG23 ' CG2' ' A' ' 134' ' ' VAL . 98.7 t -86.59 96.07 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.246 -0.909 . . . . 0.0 109.519 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -68.31 -34.92 77.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.294 -0.879 . . . . 0.0 109.411 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.404 ' O ' ' HB3' ' A' ' 159' ' ' LYS . 95.0 mt-10 -151.11 159.19 44.63 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.202 -0.936 . . . . 0.0 109.479 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.481 HG22 HG11 ' A' ' 148' ' ' VAL . 43.6 t -129.02 148.22 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.459 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -134.2 86.71 2.3 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.242 -0.911 . . . . 0.0 109.476 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -67.34 -36.72 82.0 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.285 -0.884 . . . . 0.0 109.505 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -64.15 -41.45 97.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.202 -0.937 . . . . 0.0 109.442 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.415 ' O ' ' C ' ' A' ' 156' ' ' SER . 42.7 mttp -92.64 9.43 34.82 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.225 -0.922 . . . . 0.0 109.478 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 156' ' ' SER . . . . . 0.415 ' C ' ' O ' ' A' ' 155' ' ' LYS . 8.1 m 43.85 52.76 6.46 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.304 -0.872 . . . . 0.0 109.445 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 157' ' ' ARG . . . . . 0.45 ' CG ' ' HB3' ' A' ' 172' ' ' GLU . 7.7 tpt180 -144.45 140.0 28.68 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.243 -0.911 . . . . 0.0 109.43 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 158' ' ' LEU . . . . . 0.501 HD21 ' CE1' ' A' ' 175' ' ' PHE . 53.7 mt -107.35 134.54 50.26 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.198 -0.939 . . . . 0.0 109.454 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 159' ' ' LYS . . . . . 0.428 ' HD2' ' HG2' ' A' ' 172' ' ' GLU . 13.6 tptt -92.74 95.9 9.83 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.247 -0.908 . . . . 0.0 109.463 179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.523 HG22 HG22 ' A' ' 148' ' ' VAL . 40.9 t -117.7 143.41 28.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.148 -0.97 . . . . 0.0 109.473 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 161' ' ' SER . . . . . 0.527 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 28.4 t -109.21 147.67 32.18 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.246 -0.909 . . . . 0.0 109.469 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 162' ' ' VAL . . . . . 1.175 HG21 ' CD1' ' A' ' 141' ' ' PHE . 21.1 t -88.43 134.39 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.258 -0.901 . . . . 0.0 109.615 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 5.7 m . . . . . 0 N--CA 1.49 1.541 0 O-C-N 121.319 -0.863 . . . . 0.0 109.231 179.765 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 17.3 ttt180 . . . . . 0 N--CA 1.492 1.656 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -67.28 147.57 52.83 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.206 -0.934 . . . . 0.0 109.382 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 169' ' ' THR . . . . . 0.581 HG21 ' CE1' ' A' ' 141' ' ' PHE . 5.3 m -124.58 88.95 52.89 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.221 -0.924 . . . . 0.0 109.541 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.527 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.4 Cg_endo -68.23 107.89 1.65 Allowed 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 122.592 2.194 . . . . 0.0 111.783 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.425 ' O ' ' O ' ' A' ' 160' ' ' VAL . 21.2 m -132.87 160.69 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.302 -0.874 . . . . 0.0 109.45 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.69 ' O ' HD23 ' A' ' 173' ' ' LEU . 97.7 mt-10 -103.97 128.61 51.51 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.266 -0.896 . . . . 0.0 109.508 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 173' ' ' LEU . . . . . 0.69 HD23 ' O ' ' A' ' 172' ' ' GLU . 55.7 mt -129.74 147.32 51.5 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.269 -0.895 . . . . 0.0 109.51 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 174' ' ' ASP . . . . . 0.424 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 88.9 m-20 -67.41 173.13 4.24 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.282 -0.886 . . . . 0.0 109.455 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.53 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.7 m-30 -64.92 -41.46 95.55 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.191 -0.943 . . . . 0.0 109.403 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 19.4 m -75.11 -25.79 58.76 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.233 -0.917 . . . . 0.0 109.433 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 177' ' ' GLN . . . . . 0.424 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 83.2 mt-30 -68.29 -22.67 64.72 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.219 -0.926 . . . . 0.0 109.415 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.532 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 9.0 m -132.99 157.57 43.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.241 -0.912 . . . . 0.0 109.396 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 179' ' ' GLU . . . . . 0.431 ' N ' ' O ' ' A' ' 135' ' ' ARG . 93.4 mt-10 -114.94 150.18 36.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.359 -0.838 . . . . 0.0 109.486 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 18.1 tttm -66.04 140.1 58.24 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.253 -0.904 . . . . 0.0 109.428 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.503 0 O-C-N 121.23 -0.919 . . . . 0.0 109.456 -179.971 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.519 ' O ' HG21 ' A' ' 151' ' ' VAL . 66.0 m-85 . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.502 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.6 OUTLIER -133.38 153.16 80.38 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.236 -0.915 . . . . 0.0 109.476 179.961 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.502 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 49.8 Cg_endo -45.79 132.79 13.77 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.591 2.194 . . . . 0.0 111.762 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 89.57 -1.28 81.42 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.643 ' O ' HG12 ' A' ' 148' ' ' VAL . 49.0 tp10 -94.5 127.98 40.77 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.131 -1.217 . . . . 0.0 109.423 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.726 ' HG2' HG22 ' A' ' 147' ' ' VAL . 81.6 mtp -68.14 153.96 42.67 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.208 -0.932 . . . . 0.0 109.438 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.682 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -138.1 178.82 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.218 -0.927 . . . . 0.0 109.284 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.682 ' H ' HG12 ' A' ' 134' ' ' VAL . 76.3 ttt180 -135.42 148.09 49.19 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.25 -0.906 . . . . 0.0 109.458 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.475 HG12 ' HA ' ' A' ' 142' ' ' ALA . 48.5 t -118.15 126.91 75.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.278 -0.889 . . . . 0.0 109.471 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 137' ' ' ASN . . . . . 0.403 ' O ' ' OD1' ' A' ' 138' ' ' ASP . 26.2 p30 -126.28 12.87 7.66 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.249 -0.907 . . . . 0.0 109.492 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.473 ' HB2' ' OE1' ' A' ' 177' ' ' GLN . 93.5 m-20 -137.78 163.07 32.28 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.21 -0.931 . . . . 0.0 109.506 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 63.86 176.48 4.2 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -58.14 -24.49 66.8 Favored 'Trans proline' 0 C--O 1.216 -0.613 0 C-N-CA 122.597 2.198 . . . . 0.0 111.745 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' PHE . . . . . 0.554 ' CZ ' HG11 ' A' ' 171' ' ' VAL . 98.8 m-85 -82.81 7.87 13.95 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.224 -0.922 . . . . 0.0 109.488 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 142' ' ' ALA . . . . . 0.475 ' HA ' HG12 ' A' ' 136' ' ' VAL . . . -61.03 150.87 32.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.215 -0.928 . . . . 0.0 109.499 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.473 ' N ' ' O ' ' A' ' 136' ' ' VAL . 37.8 m-20 62.66 52.58 2.8 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.271 -0.893 . . . . 0.0 109.579 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.497 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 35.6 m-85 -150.4 132.02 14.88 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.237 -0.914 . . . . 0.0 109.489 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 56.5 m-20 -92.98 138.72 31.23 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.209 -0.932 . . . . 0.0 109.402 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -156.67 -179.65 31.8 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.965 ' O ' HG13 ' A' ' 160' ' ' VAL . 40.9 t -121.48 159.52 23.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.243 -1.151 . . . . 0.0 109.349 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.701 ' HA ' HG22 ' A' ' 160' ' ' VAL . 2.5 p -100.26 115.62 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.281 -0.887 . . . . 0.0 109.519 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 83.3 mt-10 -70.52 -36.59 73.82 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.279 -0.888 . . . . 0.0 109.294 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.473 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 93.7 mt-10 -152.32 162.45 41.15 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.283 -0.886 . . . . 0.0 109.459 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.679 HG22 HG21 ' A' ' 148' ' ' VAL . 48.0 t -132.27 151.75 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.19 -0.944 . . . . 0.0 109.51 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 152' ' ' ASP . . . . . 0.517 ' O ' ' N ' ' A' ' 156' ' ' SER . 84.3 m-20 -125.52 98.58 5.65 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.243 -0.91 . . . . 0.0 109.424 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 87.4 m-85 -66.33 -35.8 81.29 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.219 -0.926 . . . . 0.0 109.572 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -66.94 -45.3 78.24 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.286 -0.883 . . . . 0.0 109.551 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 19.3 mttt -91.07 -8.55 48.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.242 -0.911 . . . . 0.0 109.512 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 156' ' ' SER . . . . . 0.517 ' N ' ' O ' ' A' ' 152' ' ' ASP . 44.3 t 55.75 52.33 11.04 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.548 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 157' ' ' ARG . . . . . 0.67 ' C ' HD12 ' A' ' 158' ' ' LEU . 83.3 mmt-85 -133.2 151.1 51.95 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.896 . . . . 0.0 109.327 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 158' ' ' LEU . . . . . 0.869 HD11 ' CE1' ' A' ' 175' ' ' PHE . 4.3 mp -118.16 137.12 53.19 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.18 -0.95 . . . . 0.0 109.592 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 159' ' ' LYS . . . . . 0.473 ' HD2' ' HB2' ' A' ' 150' ' ' GLU . 34.1 mttt -99.15 90.55 4.63 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.243 -0.911 . . . . 0.0 109.347 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.965 HG13 ' O ' ' A' ' 147' ' ' VAL . 46.5 t -118.52 142.99 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.224 -0.922 . . . . 0.0 109.533 -179.759 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 161' ' ' SER . . . . . 0.435 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 27.0 t -112.53 136.64 51.82 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.245 -0.909 . . . . 0.0 109.395 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 162' ' ' VAL . . . . . 0.497 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 21.5 t -107.47 132.35 55.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.176 -0.953 . . . . 0.0 109.511 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 33.1 t . . . . . 0 N--CA 1.491 1.576 0 O-C-N 121.292 -0.88 . . . . 0.0 109.48 -179.994 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 78.7 mtp180 . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -68.5 140.67 55.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.274 -0.891 . . . . 0.0 109.543 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 169' ' ' THR . . . . . 0.662 ' O ' HG13 ' A' ' 171' ' ' VAL . 8.2 m -128.36 74.44 79.76 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.235 -0.916 . . . . 0.0 109.37 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.435 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.6 Cg_endo -54.24 105.2 0.13 Allowed 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.579 2.186 . . . . 0.0 111.82 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.662 HG13 ' O ' ' A' ' 169' ' ' THR . 19.6 m -128.09 159.37 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.243 -0.911 . . . . 0.0 109.419 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.529 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.9 mt-10 -102.91 130.93 50.13 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.213 -0.929 . . . . 0.0 109.45 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 173' ' ' LEU . . . . . 0.658 HD12 ' CG1' ' A' ' 178' ' ' VAL . 55.1 mt -125.02 160.84 28.07 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.276 -0.89 . . . . 0.0 109.527 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 174' ' ' ASP . . . . . 0.458 ' HB2' ' HG2' ' A' ' 177' ' ' GLN . 90.6 m-20 -82.82 176.78 9.04 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.3 -0.875 . . . . 0.0 109.558 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.869 ' CE1' HD11 ' A' ' 158' ' ' LEU . 3.2 m-85 -66.1 -39.77 90.24 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.333 -0.855 . . . . 0.0 109.613 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 15.4 m -79.81 -26.23 40.58 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.208 -0.933 . . . . 0.0 109.619 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 177' ' ' GLN . . . . . 0.473 ' OE1' ' HB2' ' A' ' 138' ' ' ASP . 96.6 mm-40 -67.08 -30.71 70.83 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.22 -0.925 . . . . 0.0 109.519 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.658 ' CG1' HD12 ' A' ' 173' ' ' LEU . 12.7 m -125.29 158.26 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.249 -0.907 . . . . 0.0 109.386 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 179' ' ' GLU . . . . . 0.511 ' O ' ' N ' ' A' ' 135' ' ' ARG . 70.6 tt0 -120.38 143.09 48.61 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.218 -0.926 . . . . 0.0 109.498 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 23.6 ttmt -59.71 140.15 56.69 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.309 -0.87 . . . . 0.0 109.434 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.527 0 O-C-N 121.174 -0.954 . . . . 0.0 109.452 -179.984 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 92.2 m-85 . . . . . 0 N--CA 1.489 1.477 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.461 ' HB2' ' HD2' ' A' ' 130' ' ' PRO . 16.5 pt-20 -133.01 134.98 25.06 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.921 . . . . 0.0 109.454 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.505 ' HA ' ' O ' ' A' ' 148' ' ' VAL . 49.2 Cg_endo -35.28 131.36 0.24 Allowed 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.517 2.145 . . . . 0.0 111.738 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 131' ' ' GLY . . . . . 0.487 ' C ' ' CG1' ' A' ' 147' ' ' VAL . . . 90.89 -4.48 81.71 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.803 ' O ' HG13 ' A' ' 147' ' ' VAL . 49.2 tp10 -83.58 141.7 31.38 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.125 -1.221 . . . . 0.0 109.548 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.743 ' HG2' HG22 ' A' ' 147' ' ' VAL . 90.5 mtp -80.94 150.11 29.11 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.184 -0.948 . . . . 0.0 109.438 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.679 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -135.65 179.06 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.168 -0.958 . . . . 0.0 109.375 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.679 ' H ' HG12 ' A' ' 134' ' ' VAL . 94.5 mtt180 -132.86 146.52 51.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.318 -0.864 . . . . 0.0 109.467 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 41.4 t -112.53 130.42 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.265 -0.897 . . . . 0.0 109.423 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 54.9 p30 -123.37 19.21 9.75 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.201 -0.937 . . . . 0.0 109.534 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -156.27 151.24 26.26 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.212 -0.93 . . . . 0.0 109.493 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 82.27 164.16 33.97 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -54.19 -23.66 30.54 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.606 2.204 . . . . 0.0 111.779 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 141' ' ' PHE . . . . . 0.474 ' CD1' HG21 ' A' ' 162' ' ' VAL . 98.9 m-85 -86.87 11.05 14.26 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.252 -0.905 . . . . 0.0 109.391 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 142' ' ' ALA . . . . . 0.471 ' O ' ' CB ' ' A' ' 143' ' ' ASP . . . -70.09 151.09 45.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.491 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.471 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 25.0 t0 74.9 28.62 1.09 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.279 -0.888 . . . . 0.0 109.517 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.525 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 92.5 m-85 -135.03 140.3 45.5 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.164 -0.96 . . . . 0.0 109.608 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 21.2 m120 -95.95 141.07 29.81 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.32 -0.862 . . . . 0.0 109.418 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -151.3 -173.42 21.18 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.803 HG13 ' O ' ' A' ' 132' ' ' GLU . 54.8 t -132.01 144.26 37.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.362 -1.081 . . . . 0.0 109.454 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.768 ' CA ' HG22 ' A' ' 160' ' ' VAL . 2.1 p -83.03 106.11 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.281 -0.887 . . . . 0.0 109.443 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 56.5 mp0 -70.2 -46.8 63.83 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.231 -0.918 . . . . 0.0 109.461 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.409 ' HG2' ' N ' ' A' ' 151' ' ' VAL . 83.5 tt0 -131.8 153.24 50.34 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.186 -0.947 . . . . 0.0 109.36 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.608 HG22 HG21 ' A' ' 148' ' ' VAL . 47.9 t -120.18 153.53 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.174 -0.954 . . . . 0.0 109.579 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 152' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 92.2 m-20 -135.76 83.25 2.0 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.306 -0.871 . . . . 0.0 109.339 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 153' ' ' TYR . . . . . 0.463 ' CZ ' HG11 ' A' ' 151' ' ' VAL . 96.7 m-85 -67.03 -34.84 78.59 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.244 -0.91 . . . . 0.0 109.555 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 76.0 mm-40 -62.21 -40.81 97.32 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.202 -0.936 . . . . 0.0 109.562 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.451 ' O ' ' HG2' ' A' ' 155' ' ' LYS . 31.7 tttt -96.88 -4.3 40.44 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.289 -0.882 . . . . 0.0 109.655 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 156' ' ' SER . . . . . 0.435 ' HB2' ' O ' ' A' ' 155' ' ' LYS . 19.8 m 59.9 53.05 4.92 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.195 -0.941 . . . . 0.0 109.46 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 13.5 tpt180 -142.63 138.97 31.07 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.281 -0.887 . . . . 0.0 109.488 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 158' ' ' LEU . . . . . 0.552 ' CD2' HG13 ' A' ' 151' ' ' VAL . 41.9 mt -108.08 134.63 50.68 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.252 -0.905 . . . . 0.0 109.524 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 62.8 tttm -97.28 97.08 8.85 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.225 -0.922 . . . . 0.0 109.418 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.768 HG22 ' CA ' ' A' ' 148' ' ' VAL . 42.9 t -123.27 138.37 53.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.258 -0.901 . . . . 0.0 109.615 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 161' ' ' SER . . . . . 0.432 ' CB ' ' HA ' ' A' ' 170' ' ' PRO . 83.6 p -100.75 155.24 18.02 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.299 -0.876 . . . . 0.0 109.508 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 162' ' ' VAL . . . . . 0.525 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 5.3 t -106.14 129.15 59.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.25 -0.906 . . . . 0.0 109.479 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 55.1 m . . . . . 0 N--CA 1.49 1.564 0 O-C-N 121.286 -0.884 . . . . 0.0 109.383 179.887 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 7.9 mtm180 . . . . . 0 N--CA 1.492 1.665 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -69.39 138.87 53.98 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.221 -0.924 . . . . 0.0 109.384 179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 29.7 m -123.04 87.85 51.0 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.172 -0.955 . . . . 0.0 109.526 -179.801 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.432 ' HA ' ' CB ' ' A' ' 161' ' ' SER . 50.2 Cg_endo -62.74 107.53 0.62 Allowed 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.558 2.172 . . . . 0.0 111.685 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' A' ' 160' ' ' VAL . 18.9 m -129.97 156.92 42.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.278 -0.889 . . . . 0.0 109.567 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.499 ' O ' HD23 ' A' ' 173' ' ' LEU . 94.5 mt-10 -103.97 129.38 51.54 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.281 -0.887 . . . . 0.0 109.371 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 173' ' ' LEU . . . . . 0.547 ' HB2' ' CG1' ' A' ' 178' ' ' VAL . 65.5 mt -126.25 147.89 49.6 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.268 -0.895 . . . . 0.0 109.471 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -68.5 173.35 5.07 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.25 -0.907 . . . . 0.0 109.407 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.492 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.9 m-30 -66.51 -40.24 89.11 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.248 -0.907 . . . . 0.0 109.446 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 14.8 m -75.36 -24.41 57.29 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.231 -0.918 . . . . 0.0 109.406 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -70.32 -28.8 65.45 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.219 -0.926 . . . . 0.0 109.499 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.547 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 4.4 m -127.95 161.08 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.231 -0.918 . . . . 0.0 109.468 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 179' ' ' GLU . . . . . . . . . . . . . 75.0 mm-40 -120.0 148.64 43.31 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.236 -0.915 . . . . 0.0 109.505 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 20.1 tttt -58.95 140.56 55.43 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.188 -0.945 . . . . 0.0 109.485 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 181' ' ' ALA . . . . . 0.477 ' HB2' ' C ' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.491 1.589 0 O-C-N 121.21 -0.932 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.611 ' CD2' HD21 ' A' ' 158' ' ' LEU . 92.0 m-85 . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.486 ' HB2' ' HD2' ' A' ' 130' ' ' PRO . 2.2 pt-20 -142.35 147.31 42.91 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.231 -0.918 . . . . 0.0 109.418 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.486 ' HD2' ' HB2' ' A' ' 129' ' ' GLU . 48.8 Cg_endo -40.95 128.47 2.79 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.436 2.091 . . . . 0.0 111.84 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 100.28 -4.19 56.96 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.642 ' O ' HG13 ' A' ' 147' ' ' VAL . 78.1 mm-40 -93.03 144.32 25.37 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.207 -1.172 . . . . 0.0 109.541 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.895 ' SD ' HG22 ' A' ' 147' ' ' VAL . 77.3 mmm -83.48 143.08 30.47 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.225 -0.922 . . . . 0.0 109.413 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.938 ' CG2' HG23 ' A' ' 148' ' ' VAL . 2.5 t -128.63 178.59 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.225 -0.922 . . . . 0.0 109.362 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.683 ' H ' HG12 ' A' ' 134' ' ' VAL . 40.0 ttt85 -141.88 145.8 35.04 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.343 -0.848 . . . . 0.0 109.405 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.575 HG22 ' CD1' ' A' ' 173' ' ' LEU . 43.5 t -112.48 135.29 52.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.235 -0.915 . . . . 0.0 109.495 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 34.6 p30 -126.67 10.41 7.17 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.279 -0.888 . . . . 0.0 109.411 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.484 ' HB3' ' HG3' ' A' ' 177' ' ' GLN . 49.9 t0 -150.58 159.04 44.78 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.229 -0.919 . . . . 0.0 109.541 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.416 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 77.52 165.33 24.63 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -50.45 -22.33 8.74 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 122.593 2.195 . . . . 0.0 111.721 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 141' ' ' PHE . . . . . 0.915 ' CZ ' HG11 ' A' ' 171' ' ' VAL . 93.9 m-85 -88.61 12.57 14.31 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.207 -0.933 . . . . 0.0 109.485 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 142' ' ' ALA . . . . . 0.451 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -62.83 149.2 44.86 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.339 -0.851 . . . . 0.0 109.529 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.432 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 44.7 m-20 63.28 45.31 5.07 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.472 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.538 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 46.0 m-85 -147.08 126.08 12.83 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.184 -0.947 . . . . 0.0 109.474 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 67.8 m-20 -88.42 145.24 25.89 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.224 -0.923 . . . . 0.0 109.605 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -157.1 177.26 34.06 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.895 HG22 ' SD ' ' A' ' 133' ' ' MET . 22.0 t -114.86 156.69 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.177 -1.19 . . . . 0.0 109.395 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.938 HG23 ' CG2' ' A' ' 134' ' ' VAL . 47.8 t -82.37 104.11 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.248 -0.907 . . . . 0.0 109.498 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.42 ' O ' ' CD ' ' A' ' 150' ' ' GLU . 97.2 mt-10 -69.86 -35.41 74.69 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.282 -0.886 . . . . 0.0 109.36 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.474 ' HB2' ' HD3' ' A' ' 159' ' ' LYS . 76.1 mm-40 -152.81 164.88 36.98 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.322 -0.861 . . . . 0.0 109.41 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.44 HG11 ' CZ ' ' A' ' 153' ' ' TYR . 46.5 t -128.56 143.48 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.267 -0.896 . . . . 0.0 109.424 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 93.8 m-20 -124.91 78.31 1.69 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.19 -0.944 . . . . 0.0 109.542 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 153' ' ' TYR . . . . . 0.44 ' CZ ' HG11 ' A' ' 151' ' ' VAL . 92.9 m-85 -59.87 -42.21 93.24 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.238 -0.914 . . . . 0.0 109.385 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -54.61 -45.08 73.6 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.244 -0.91 . . . . 0.0 109.366 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.412 ' O ' ' HG3' ' A' ' 157' ' ' ARG . 44.2 mttp -86.23 -2.96 58.85 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.264 -0.897 . . . . 0.0 109.515 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 17.1 m 55.68 53.7 9.21 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.183 -0.948 . . . . 0.0 109.358 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 157' ' ' ARG . . . . . 0.412 ' HG3' ' O ' ' A' ' 155' ' ' LYS . 66.9 mtt180 -147.95 162.79 38.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 109.534 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 158' ' ' LEU . . . . . 0.638 ' CD1' ' CE1' ' A' ' 175' ' ' PHE . 6.7 mp -114.02 139.27 49.4 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.331 -0.856 . . . . 0.0 109.428 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 159' ' ' LYS . . . . . 0.474 ' HD3' ' HB2' ' A' ' 150' ' ' GLU . 41.1 tttt -104.56 100.22 9.9 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.158 -0.963 . . . . 0.0 109.312 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.567 HG13 ' O ' ' A' ' 147' ' ' VAL . 39.9 t -119.9 148.52 22.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.207 -0.933 . . . . 0.0 109.549 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 161' ' ' SER . . . . . 0.416 ' CB ' ' HA ' ' A' ' 170' ' ' PRO . 22.7 t -117.95 138.85 51.88 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.245 -0.909 . . . . 0.0 109.333 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 162' ' ' VAL . . . . . 0.538 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 4.4 t -107.19 133.13 52.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.182 -0.949 . . . . 0.0 109.708 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 44.1 t . . . . . 0 N--CA 1.49 1.53 0 O-C-N 121.321 -0.862 . . . . 0.0 109.311 179.838 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 76.1 mtm180 . . . . . 0 N--CA 1.489 1.485 0 N-CA-C 109.441 -0.578 . . . . 0.0 109.441 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -80.12 134.6 36.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.2 -0.938 . . . . 0.0 109.413 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 169' ' ' THR . . . . . 0.726 ' O ' HG13 ' A' ' 171' ' ' VAL . 57.3 m -128.65 73.32 80.92 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.286 -0.884 . . . . 0.0 109.437 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.416 ' HA ' ' CB ' ' A' ' 161' ' ' SER . 49.6 Cg_endo -52.1 108.42 0.25 Allowed 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.69 2.26 . . . . 0.0 111.89 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.915 HG11 ' CZ ' ' A' ' 141' ' ' PHE . 20.5 m -126.04 155.12 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.264 -0.898 . . . . 0.0 109.417 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.451 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.3 mt-10 -90.89 129.99 36.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.213 -0.929 . . . . 0.0 109.553 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 173' ' ' LEU . . . . . 0.575 ' CD1' HG22 ' A' ' 136' ' ' VAL . 61.9 mt -122.02 154.91 36.63 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.234 -0.916 . . . . 0.0 109.49 179.907 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 174' ' ' ASP . . . . . 0.481 ' HB2' ' HB2' ' A' ' 177' ' ' GLN . 85.1 m-20 -83.81 154.95 23.23 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.221 -0.925 . . . . 0.0 109.629 -179.867 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.638 ' CE1' ' CD1' ' A' ' 158' ' ' LEU . 25.4 m-85 -51.14 -50.24 59.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.38 -0.825 . . . . 0.0 109.615 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 72.4 p -74.8 -18.45 60.46 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.223 -0.923 . . . . 0.0 109.594 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 177' ' ' GLN . . . . . 0.484 ' HG3' ' HB3' ' A' ' 138' ' ' ASP . 65.7 tt0 -72.95 -25.15 60.92 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.301 -0.874 . . . . 0.0 109.448 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.509 HG13 ' HB3' ' A' ' 173' ' ' LEU . 5.2 m -125.34 161.81 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.154 -0.966 . . . . 0.0 109.487 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 179' ' ' GLU . . . . . . . . . . . . . 61.1 mt-10 -118.42 148.96 42.01 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.225 -0.922 . . . . 0.0 109.482 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 21.1 tttm -79.79 132.65 36.19 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.34 -0.85 . . . . 0.0 109.449 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.499 0 O-C-N 121.278 -0.889 . . . . 0.0 109.49 179.99 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.547 ' CD2' HD21 ' A' ' 158' ' ' LEU . 75.2 m-85 . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.459 ' O ' ' HG2' ' A' ' 132' ' ' GLU . 0.6 OUTLIER -129.46 150.04 74.5 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.206 -0.934 . . . . 0.0 109.469 -179.99 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.464 ' HA ' ' O ' ' A' ' 148' ' ' VAL . 50.0 Cg_endo -47.27 123.48 7.81 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.67 2.247 . . . . 0.0 111.771 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 99.29 2.17 56.78 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.626 -1.389 . . . . 0.0 109.626 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.459 ' HG2' ' O ' ' A' ' 129' ' ' GLU . 74.9 mm-40 -92.32 141.3 28.71 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.186 -1.185 . . . . 0.0 109.438 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.909 ' SD ' HG22 ' A' ' 147' ' ' VAL . 84.4 mmm -74.18 142.18 45.46 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.234 -0.916 . . . . 0.0 109.468 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.685 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -130.27 178.96 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.248 -0.908 . . . . 0.0 109.347 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.685 ' H ' HG12 ' A' ' 134' ' ' VAL . 45.7 ttt85 -142.44 135.75 28.8 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.333 -0.855 . . . . 0.0 109.429 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.715 HG22 HD12 ' A' ' 173' ' ' LEU . 66.3 t -106.29 133.56 50.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.264 -0.897 . . . . 0.0 109.444 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 11.4 p30 -132.06 22.11 4.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.302 -0.874 . . . . 0.0 109.431 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.498 ' HB3' ' HG3' ' A' ' 177' ' ' GLN . 51.7 t0 -143.23 156.42 44.74 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.243 -0.911 . . . . 0.0 109.447 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.452 ' O ' ' N ' ' A' ' 142' ' ' ALA . . . 62.98 167.17 0.74 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -44.28 -24.86 1.08 Allowed 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.585 2.19 . . . . 0.0 111.795 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' PHE . . . . . 0.45 ' O ' ' HB ' ' A' ' 136' ' ' VAL . 88.0 m-85 -86.57 14.96 6.04 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.255 -0.903 . . . . 0.0 109.468 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 142' ' ' ALA . . . . . 0.518 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -73.67 145.24 45.43 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.285 -0.885 . . . . 0.0 109.501 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.44 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 3.5 m-20 71.05 43.83 0.63 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.318 -0.864 . . . . 0.0 109.526 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.518 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 80.9 m-85 -142.25 139.98 32.12 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.25 -0.906 . . . . 0.0 109.522 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 78.9 m-20 -94.05 138.99 31.52 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.235 -0.916 . . . . 0.0 109.46 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -153.1 179.8 29.23 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.909 HG22 ' SD ' ' A' ' 133' ' ' MET . 22.8 t -124.18 151.38 29.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.256 -1.144 . . . . 0.0 109.449 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.706 HG21 HG22 ' A' ' 151' ' ' VAL . 3.1 p -87.28 95.23 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.219 -0.925 . . . . 0.0 109.552 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -65.75 -36.35 83.33 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.219 -0.925 . . . . 0.0 109.408 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.495 ' HG2' ' N ' ' A' ' 151' ' ' VAL . 84.7 tt0 -142.21 160.36 40.4 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.33 -0.856 . . . . 0.0 109.385 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.706 HG22 HG21 ' A' ' 148' ' ' VAL . 39.8 t -131.37 149.06 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.258 -0.901 . . . . 0.0 109.467 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -131.04 94.64 3.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.24 -0.912 . . . . 0.0 109.501 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -66.69 -32.9 74.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.257 -0.902 . . . . 0.0 109.487 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -61.81 -42.71 99.36 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -0.916 . . . . 0.0 109.368 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 29.9 mttm -90.03 -6.38 55.63 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.258 -0.901 . . . . 0.0 109.471 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 57.48 52.76 8.13 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.23 -0.919 . . . . 0.0 109.475 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 157' ' ' ARG . . . . . 0.649 ' C ' HD12 ' A' ' 158' ' ' LEU . 75.3 mtt180 -147.13 165.83 28.78 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.222 -0.924 . . . . 0.0 109.536 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 158' ' ' LEU . . . . . 1.17 HD11 ' CD1' ' A' ' 175' ' ' PHE . 3.5 mp -116.01 133.94 55.49 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.227 -0.921 . . . . 0.0 109.532 -179.736 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 159' ' ' LYS . . . . . 0.417 ' HD3' ' HB3' ' A' ' 150' ' ' GLU . 80.8 tttt -91.53 85.77 5.83 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.183 -0.948 . . . . 0.0 109.298 179.765 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.777 HG13 ' O ' ' A' ' 147' ' ' VAL . 61.1 t -110.4 144.28 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.264 -0.898 . . . . 0.0 109.603 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 161' ' ' SER . . . . . 0.441 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 60.0 p -107.76 140.51 40.71 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.282 -0.886 . . . . 0.0 109.348 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 162' ' ' VAL . . . . . . . . . . . . . 6.6 t -110.29 131.98 59.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.242 -0.911 . . . . 0.0 109.59 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 32.6 t . . . . . 0 N--CA 1.491 1.582 0 O-C-N 121.233 -0.917 . . . . 0.0 109.42 179.85 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 39.0 ptt180 . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -75.44 143.23 42.77 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.267 -0.895 . . . . 0.0 109.46 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 169' ' ' THR . . . . . 0.855 ' O ' HG13 ' A' ' 171' ' ' VAL . 27.2 m -130.12 70.61 82.23 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.237 -0.914 . . . . 0.0 109.441 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.441 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 50.5 Cg_endo -46.88 108.15 0.15 Allowed 'Trans proline' 0 C--O 1.214 -0.683 0 C-N-CA 122.613 2.209 . . . . 0.0 111.858 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.855 HG13 ' O ' ' A' ' 169' ' ' THR . 21.2 m -133.26 154.28 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.283 -0.886 . . . . 0.0 109.424 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.748 ' O ' HD23 ' A' ' 173' ' ' LEU . 94.5 mt-10 -100.08 136.36 40.1 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.18 -0.95 . . . . 0.0 109.451 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 173' ' ' LEU . . . . . 0.861 HD22 ' NE2' ' A' ' 177' ' ' GLN . 47.7 mt -131.01 152.47 50.29 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.285 -0.884 . . . . 0.0 109.513 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -69.54 156.34 39.05 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.245 -0.909 . . . . 0.0 109.515 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 1.17 ' CD1' HD11 ' A' ' 158' ' ' LEU . 51.0 m-85 -53.08 -44.48 67.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.547 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 82.5 p -75.3 -20.03 59.33 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.159 -0.963 . . . . 0.0 109.587 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 177' ' ' GLN . . . . . 0.861 ' NE2' HD22 ' A' ' 173' ' ' LEU . 50.6 tt0 -72.02 -24.55 61.57 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.283 -0.886 . . . . 0.0 109.503 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.461 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 17.7 m -127.26 163.55 30.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.26 -0.9 . . . . 0.0 109.516 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 179' ' ' GLU . . . . . 0.448 ' HB2' ' HB3' ' A' ' 135' ' ' ARG . 63.6 mm-40 -114.79 151.02 34.5 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.281 -0.887 . . . . 0.0 109.483 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 24.3 tttt -81.18 131.67 35.31 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.255 -0.903 . . . . 0.0 109.508 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 181' ' ' ALA . . . . . 0.559 ' HB3' ' HB2' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.544 0 O-C-N 121.193 -0.942 . . . . 0.0 109.415 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.571 ' CD2' HD11 ' A' ' 158' ' ' LEU . 93.0 m-85 . . . . . 0 N--CA 1.489 1.501 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.457 ' O ' ' HB2' ' A' ' 132' ' ' GLU . 1.8 mm-40 -103.32 139.59 20.25 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.265 -0.897 . . . . 0.0 109.442 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.422 ' HD2' ' HB3' ' A' ' 129' ' ' GLU . 49.3 Cg_endo -43.25 135.82 5.82 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.623 2.215 . . . . 0.0 111.712 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 80.35 6.75 89.1 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.457 ' HB2' ' O ' ' A' ' 129' ' ' GLU . 85.0 tt0 -89.04 128.76 35.74 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.269 -1.136 . . . . 0.0 109.448 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.491 ' O ' ' HB3' ' A' ' 181' ' ' ALA . 42.2 ttm -68.19 144.57 54.9 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.235 -0.916 . . . . 0.0 109.44 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.695 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -131.4 179.15 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.242 -0.911 . . . . 0.0 109.316 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.695 ' H ' HG12 ' A' ' 134' ' ' VAL . 28.4 ttt85 -129.99 135.98 48.9 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.196 -0.94 . . . . 0.0 109.42 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.498 HG22 HG12 ' A' ' 178' ' ' VAL . 60.7 t -107.71 133.87 51.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.213 -0.93 . . . . 0.0 109.498 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 137' ' ' ASN . . . . . 0.412 ' OD1' ' C ' ' A' ' 137' ' ' ASN . 44.0 p30 -132.59 23.39 4.34 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.239 -0.913 . . . . 0.0 109.462 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -142.85 144.08 32.36 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.269 -0.894 . . . . 0.0 109.531 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 75.49 172.85 32.58 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -52.1 -17.17 5.42 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.669 2.246 . . . . 0.0 111.756 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 141' ' ' PHE . . . . . 1.034 ' CD1' HG21 ' A' ' 162' ' ' VAL . 97.0 m-85 -92.68 17.51 10.17 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.28 -0.887 . . . . 0.0 109.495 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 142' ' ' ALA . . . . . 0.553 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -73.33 149.88 42.28 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.324 -0.86 . . . . 0.0 109.498 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.451 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 35.2 m-20 65.14 48.27 2.26 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.205 -0.935 . . . . 0.0 109.527 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.553 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 64.1 m-85 -147.22 146.89 29.96 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.218 -0.926 . . . . 0.0 109.404 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 145' ' ' ASN . . . . . 0.424 ' O ' ' OD1' ' A' ' 145' ' ' ASN . 44.0 p-10 -102.56 151.38 22.39 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.257 -0.902 . . . . 0.0 109.414 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 146' ' ' GLY . . . . . 0.452 ' O ' ' HA ' ' A' ' 133' ' ' MET . . . -164.95 -174.45 34.67 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.892 ' C ' HG13 ' A' ' 160' ' ' VAL . 96.7 t -130.29 150.75 34.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.18 -1.188 . . . . 0.0 109.427 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.78 HG21 HG22 ' A' ' 151' ' ' VAL . 2.1 p -89.61 107.2 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.178 -0.951 . . . . 0.0 109.502 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -70.86 -37.4 73.09 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.182 -0.949 . . . . 0.0 109.396 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -138.64 157.5 46.02 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.355 -0.841 . . . . 0.0 109.338 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.78 HG22 HG21 ' A' ' 148' ' ' VAL . 57.1 t -130.81 149.79 33.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.179 -0.95 . . . . 0.0 109.417 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 152' ' ' ASP . . . . . 0.4 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 95.3 m-20 -136.43 90.17 2.54 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.273 -0.892 . . . . 0.0 109.484 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -67.56 -37.0 82.03 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.233 -0.917 . . . . 0.0 109.495 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -63.6 -42.61 98.24 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.257 -0.902 . . . . 0.0 109.411 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.418 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 58.2 mttt -89.44 -4.64 57.9 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.248 -0.908 . . . . 0.0 109.478 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 58.5 m 55.65 52.73 10.54 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.171 -0.956 . . . . 0.0 109.439 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 157' ' ' ARG . . . . . 0.439 ' HD3' ' OD1' ' A' ' 174' ' ' ASP . 15.6 mmt85 -144.64 141.97 29.77 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.213 -0.93 . . . . 0.0 109.427 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 158' ' ' LEU . . . . . 0.606 ' CD2' HG13 ' A' ' 151' ' ' VAL . 40.1 mt -111.74 132.34 54.71 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -0.901 . . . . 0.0 109.577 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 22.0 tttt -94.9 91.74 6.57 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.23 -0.919 . . . . 0.0 109.277 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.892 HG13 ' C ' ' A' ' 147' ' ' VAL . 33.1 t -117.98 144.55 25.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.281 -0.887 . . . . 0.0 109.466 -179.868 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 161' ' ' SER . . . . . 0.491 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 61.8 m -99.84 148.62 24.23 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.241 -0.912 . . . . 0.0 109.45 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 162' ' ' VAL . . . . . 1.034 HG21 ' CD1' ' A' ' 141' ' ' PHE . 6.2 t -96.53 138.39 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.29 -0.881 . . . . 0.0 109.621 -179.873 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 19.7 m . . . . . 0 N--CA 1.489 1.501 0 O-C-N 121.266 -0.896 . . . . 0.0 109.254 179.737 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 17.8 ttp180 . . . . . 0 N--CA 1.494 1.765 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -61.18 143.67 55.11 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.243 -0.91 . . . . 0.0 109.33 179.78 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 169' ' ' THR . . . . . 0.482 HG22 HG13 ' A' ' 171' ' ' VAL . 36.6 m -126.36 98.57 32.08 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.17 -0.956 . . . . 0.0 109.554 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.491 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 50.3 Cg_endo -70.26 103.89 1.32 Allowed 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.492 2.128 . . . . 0.0 111.707 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.977 HG23 HD21 ' A' ' 173' ' ' LEU . 14.6 m -129.25 161.08 39.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.246 -0.909 . . . . 0.0 109.523 -179.866 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.845 ' C ' HD22 ' A' ' 173' ' ' LEU . 96.5 mt-10 -99.03 129.15 45.29 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.277 -0.889 . . . . 0.0 109.4 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 173' ' ' LEU . . . . . 0.977 HD21 HG23 ' A' ' 171' ' ' VAL . 2.8 mm? -125.41 146.3 49.67 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.192 -0.942 . . . . 0.0 109.529 -179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 174' ' ' ASP . . . . . 0.439 ' OD1' ' HD3' ' A' ' 157' ' ' ARG . 87.4 m-20 -69.35 170.36 10.52 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.228 -0.92 . . . . 0.0 109.489 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.538 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.7 m-30 -65.74 -40.64 92.34 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.269 -0.895 . . . . 0.0 109.47 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 83.0 p -75.51 -28.66 59.23 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.362 -0.836 . . . . 0.0 109.499 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 177' ' ' GLN . . . . . 0.4 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 90.2 mt-30 -65.76 -23.55 66.75 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.293 -0.879 . . . . 0.0 109.435 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.512 HG13 ' HB3' ' A' ' 173' ' ' LEU . 12.3 m -130.23 164.42 33.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.259 -0.901 . . . . 0.0 109.452 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 179' ' ' GLU . . . . . 0.452 ' N ' ' O ' ' A' ' 135' ' ' ARG . 76.3 mt-10 -119.41 142.49 48.16 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.259 -0.901 . . . . 0.0 109.542 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 31.4 ttmt -62.6 134.86 56.97 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.159 -0.963 . . . . 0.0 109.521 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 181' ' ' ALA . . . . . 0.491 ' HB3' ' O ' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.128 -0.982 . . . . 0.0 109.391 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.625 ' CD2' HD21 ' A' ' 158' ' ' LEU . 89.6 m-85 . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 121.333 0.587 . . . . 0.0 109.446 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.487 ' HB3' ' HD2' ' A' ' 130' ' ' PRO . 3.5 mt-10 -139.41 150.04 62.54 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.241 -0.912 . . . . 0.0 109.354 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.487 ' HD2' ' HB3' ' A' ' 129' ' ' GLU . 49.4 Cg_endo -46.33 128.88 12.74 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.418 2.079 . . . . 0.0 111.751 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 93.69 3.61 64.28 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.52 ' O ' HG13 ' A' ' 147' ' ' VAL . 76.7 mm-40 -98.57 138.57 35.57 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.168 -1.196 . . . . 0.0 109.455 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.639 ' HG2' HG22 ' A' ' 147' ' ' VAL . 78.5 mtp -76.12 148.78 37.61 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.23 -0.919 . . . . 0.0 109.468 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.675 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -137.21 179.38 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.26 -0.9 . . . . 0.0 109.375 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.675 ' H ' HG12 ' A' ' 134' ' ' VAL . 43.6 ttt180 -135.7 135.01 39.72 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.104 -0.997 . . . . 0.0 109.503 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.454 ' O ' ' N ' ' A' ' 143' ' ' ASP . 80.3 t -108.73 135.72 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.298 -0.877 . . . . 0.0 109.502 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 31.6 p30 -131.83 18.98 4.62 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.242 -0.911 . . . . 0.0 109.438 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -132.52 144.07 50.17 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.31 -0.869 . . . . 0.0 109.408 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 71.66 175.99 24.57 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -53.22 -19.49 12.51 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.608 2.205 . . . . 0.0 111.779 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 141' ' ' PHE . . . . . 0.434 ' O ' ' HB ' ' A' ' 136' ' ' VAL . 90.5 m-85 -88.61 12.65 14.08 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.279 -0.888 . . . . 0.0 109.415 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 142' ' ' ALA . . . . . 0.448 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -71.96 150.38 44.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.28 -0.888 . . . . 0.0 109.403 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.454 ' N ' ' O ' ' A' ' 136' ' ' VAL . 31.9 m-20 63.49 48.69 3.37 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.169 -0.957 . . . . 0.0 109.449 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.448 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 43.3 m-85 -145.06 143.05 30.24 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.147 -0.971 . . . . 0.0 109.524 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 73.6 m-20 -95.89 145.08 25.67 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.248 -0.908 . . . . 0.0 109.5 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -161.7 -178.42 35.6 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.682 ' O ' HG13 ' A' ' 160' ' ' VAL . 40.6 t -126.1 147.23 30.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.256 -1.143 . . . . 0.0 109.408 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.724 ' HA ' HG22 ' A' ' 160' ' ' VAL . 2.5 p -82.95 99.37 5.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.179 -0.951 . . . . 0.0 109.467 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -66.59 -34.21 77.37 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.245 -0.91 . . . . 0.0 109.391 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.478 ' HB2' ' CD ' ' A' ' 159' ' ' LYS . 75.5 mm-40 -147.0 162.47 38.7 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.27 -0.894 . . . . 0.0 109.386 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.623 HG22 HG21 ' A' ' 148' ' ' VAL . 41.0 t -129.17 146.69 33.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.2 -0.937 . . . . 0.0 109.487 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -127.63 96.48 4.55 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.203 -0.936 . . . . 0.0 109.511 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -66.29 -40.3 89.94 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.305 -0.872 . . . . 0.0 109.475 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -62.37 -42.19 99.21 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.201 -0.937 . . . . 0.0 109.431 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 47.9 mttt -83.93 0.79 46.4 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.278 -0.889 . . . . 0.0 109.548 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 24.3 p 45.62 57.04 5.28 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.216 -0.927 . . . . 0.0 109.465 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 157' ' ' ARG . . . . . 0.616 ' C ' HD12 ' A' ' 158' ' ' LEU . 30.4 mtt180 -155.49 165.5 36.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.277 -0.89 . . . . 0.0 109.516 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 158' ' ' LEU . . . . . 1.165 HD11 ' CD1' ' A' ' 175' ' ' PHE . 4.3 mp -114.34 137.3 51.98 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.241 -0.912 . . . . 0.0 109.453 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 159' ' ' LYS . . . . . 0.478 ' CD ' ' HB2' ' A' ' 150' ' ' GLU . 40.4 tttp -92.97 94.88 9.15 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.184 -0.947 . . . . 0.0 109.339 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.724 HG22 ' HA ' ' A' ' 148' ' ' VAL . 45.1 t -122.04 146.04 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.28 -0.888 . . . . 0.0 109.602 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 29.3 t -111.82 141.64 45.19 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.329 -0.857 . . . . 0.0 109.28 179.868 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 162' ' ' VAL . . . . . . . . . . . . . 12.1 t -113.28 131.09 65.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.132 -0.98 . . . . 0.0 109.563 -179.85 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 35.5 t . . . . . 0 N--CA 1.489 1.511 0 O-C-N 121.291 -0.881 . . . . 0.0 109.403 179.928 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 42.1 mtp-105 . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -71.16 137.76 49.05 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.267 -0.896 . . . . 0.0 109.411 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 169' ' ' THR . . . . . 0.57 ' O ' HG13 ' A' ' 171' ' ' VAL . 1.9 m -133.01 75.96 71.07 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.292 -0.88 . . . . 0.0 109.458 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -56.69 104.2 0.14 Allowed 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.622 2.215 . . . . 0.0 111.836 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 1.012 HG23 HD21 ' A' ' 173' ' ' LEU . 18.2 m -129.34 155.56 41.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.305 -0.872 . . . . 0.0 109.419 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.749 ' C ' HD22 ' A' ' 173' ' ' LEU . 95.5 mt-10 -102.01 129.61 48.35 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.217 -0.927 . . . . 0.0 109.522 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 173' ' ' LEU . . . . . 1.012 HD21 HG23 ' A' ' 171' ' ' VAL . 2.3 mm? -121.54 149.82 42.54 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.269 -0.895 . . . . 0.0 109.39 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 174' ' ' ASP . . . . . 0.483 ' O ' HG22 ' A' ' 178' ' ' VAL . 82.1 m-20 -68.93 157.95 35.62 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.279 -0.888 . . . . 0.0 109.515 179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 1.165 ' CD1' HD11 ' A' ' 158' ' ' LEU . 98.7 m-85 -61.25 -40.79 95.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.293 -0.879 . . . . 0.0 109.334 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 28.6 m -74.98 -19.7 59.98 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.222 -0.923 . . . . 0.0 109.313 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 89.9 mt-30 -82.16 -20.01 38.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.348 -0.845 . . . . 0.0 109.245 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.678 HG11 ' HB2' ' A' ' 173' ' ' LEU . 19.3 m -124.9 161.88 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.396 -0.815 . . . . 0.0 109.264 179.821 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 179' ' ' GLU . . . . . 0.412 ' HB2' ' HB3' ' A' ' 135' ' ' ARG . 61.8 mt-10 -121.31 153.26 37.95 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.133 -0.98 . . . . 0.0 109.695 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 17.8 tttm -74.14 135.52 42.87 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.322 -0.861 . . . . 0.0 109.451 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.309 -0.869 . . . . 0.0 109.494 179.989 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.448 ' O ' HG21 ' A' ' 151' ' ' VAL . 93.5 m-85 . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.487 ' HB2' ' HD2' ' A' ' 130' ' ' PRO . 22.3 pt-20 -142.07 138.75 17.13 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.234 -0.916 . . . . 0.0 109.3 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.509 ' HA ' ' O ' ' A' ' 148' ' ' VAL . 47.7 Cg_endo -35.62 124.11 0.26 Allowed 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.107 1.872 . . . . 0.0 111.721 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 106.25 -0.47 37.83 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.495 ' O ' HG13 ' A' ' 147' ' ' VAL . 75.5 mt-10 -98.21 152.04 19.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.242 -1.152 . . . . 0.0 109.611 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 133' ' ' MET . . . . . 1.013 ' SD ' HG22 ' A' ' 147' ' ' VAL . 68.3 mmm -92.16 148.75 21.92 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.192 -0.943 . . . . 0.0 109.327 179.826 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.674 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -135.99 178.92 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.166 -0.959 . . . . 0.0 109.325 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.674 ' H ' HG12 ' A' ' 134' ' ' VAL . 74.8 mtp85 -134.17 143.96 48.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.179 -0.951 . . . . 0.0 109.343 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.46 ' O ' ' N ' ' A' ' 143' ' ' ASP . 59.0 t -115.43 130.18 70.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.216 -0.927 . . . . 0.0 109.452 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 30.3 p30 -127.89 14.77 6.89 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.298 -0.876 . . . . 0.0 109.482 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.43 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 59.1 t0 -135.82 147.6 48.36 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.292 -0.88 . . . . 0.0 109.475 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.43 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 73.85 172.15 25.31 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -51.35 -21.96 10.98 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.602 2.201 . . . . 0.0 111.69 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 141' ' ' PHE . . . . . 0.728 ' HZ ' HG21 ' A' ' 169' ' ' THR . 98.3 m-85 -85.73 8.94 17.87 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.271 -0.893 . . . . 0.0 109.373 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 142' ' ' ALA . . . . . 0.442 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -64.02 145.27 56.19 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.241 -0.912 . . . . 0.0 109.558 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.46 ' N ' ' O ' ' A' ' 136' ' ' VAL . 31.6 m-20 64.96 46.82 2.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.259 -0.9 . . . . 0.0 109.593 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.427 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 44.9 m-85 -145.46 126.49 14.59 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.246 -0.909 . . . . 0.0 109.535 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 145' ' ' ASN . . . . . 0.462 ' OD1' ' NH2' ' A' ' 135' ' ' ARG . 69.9 m-20 -79.4 137.54 37.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.224 -0.923 . . . . 0.0 109.45 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -149.22 166.78 29.53 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 1.013 HG22 ' SD ' ' A' ' 133' ' ' MET . 15.1 t -108.79 154.87 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.255 -1.144 . . . . 0.0 109.406 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.509 ' O ' ' HA ' ' A' ' 130' ' ' PRO . 1.7 p -96.23 114.93 34.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.323 -0.861 . . . . 0.0 109.356 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.472 ' O ' ' HB3' ' A' ' 130' ' ' PRO . 74.9 mm-40 -75.94 -34.08 59.85 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.3 -0.875 . . . . 0.0 109.315 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.473 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 94.7 mt-10 -158.11 159.15 35.93 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.36 -0.838 . . . . 0.0 109.415 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.493 HG22 HG21 ' A' ' 148' ' ' VAL . 26.3 t -127.59 151.02 33.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.22 -0.925 . . . . 0.0 109.563 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 152' ' ' ASP . . . . . 0.477 ' O ' ' N ' ' A' ' 156' ' ' SER . 83.2 m-20 -120.71 84.46 2.23 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.339 -0.85 . . . . 0.0 109.342 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -57.4 -33.72 68.15 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.234 -0.916 . . . . 0.0 109.502 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -64.75 -41.48 95.88 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.167 -0.958 . . . . 0.0 109.529 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.4 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 29.5 mttt -97.09 -3.77 40.66 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.29 -0.881 . . . . 0.0 109.591 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 156' ' ' SER . . . . . 0.477 ' N ' ' O ' ' A' ' 152' ' ' ASP . 31.8 m 56.95 52.46 9.25 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.194 -0.941 . . . . 0.0 109.543 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 157' ' ' ARG . . . . . 0.587 ' C ' HD12 ' A' ' 158' ' ' LEU . 48.7 mmm-85 -137.06 155.82 49.17 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.258 -0.901 . . . . 0.0 109.355 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 158' ' ' LEU . . . . . 0.881 HD11 ' CD1' ' A' ' 175' ' ' PHE . 5.0 mp -115.87 139.26 50.38 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.201 -0.937 . . . . 0.0 109.643 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 159' ' ' LYS . . . . . 0.473 ' HD2' ' HB2' ' A' ' 150' ' ' GLU . 84.1 mttt -101.45 89.36 3.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.213 -0.929 . . . . 0.0 109.178 179.653 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.923 HG13 ' O ' ' A' ' 147' ' ' VAL . 24.6 t -114.58 148.64 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.268 -0.895 . . . . 0.0 109.875 -179.617 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 161' ' ' SER . . . . . 0.403 ' HB2' ' HA ' ' A' ' 170' ' ' PRO . 43.9 t -119.37 131.17 55.65 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.378 -0.826 . . . . 0.0 109.242 179.769 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 162' ' ' VAL . . . . . 0.424 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 15.5 t -100.53 134.03 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.209 -0.932 . . . . 0.0 109.697 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 37.2 t . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.229 -0.919 . . . . 0.0 109.275 179.777 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 86.3 mtt-85 . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -72.16 141.84 49.09 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.352 -0.842 . . . . 0.0 109.463 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 169' ' ' THR . . . . . 0.885 ' O ' HG13 ' A' ' 171' ' ' VAL . 32.8 m -128.27 68.71 77.3 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.206 -0.934 . . . . 0.0 109.475 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.407 ' HD2' ' HA ' ' A' ' 169' ' ' THR . 49.4 Cg_endo -45.55 106.64 0.09 OUTLIER 'Trans proline' 0 C--O 1.214 -0.694 0 C-N-CA 122.703 2.269 . . . . 0.0 111.768 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.885 HG13 ' O ' ' A' ' 169' ' ' THR . 21.9 m -133.42 156.49 41.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.219 -0.926 . . . . 0.0 109.565 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.637 ' C ' HD22 ' A' ' 173' ' ' LEU . 94.6 mt-10 -105.39 129.97 53.59 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.301 -0.874 . . . . 0.0 109.334 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 173' ' ' LEU . . . . . 0.882 HD21 HG23 ' A' ' 171' ' ' VAL . 1.9 mm? -119.46 157.81 27.5 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.189 -0.945 . . . . 0.0 109.618 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 174' ' ' ASP . . . . . 0.439 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 91.1 m-20 -79.64 157.89 27.17 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.352 -0.843 . . . . 0.0 109.573 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.881 ' CD1' HD11 ' A' ' 158' ' ' LEU . 3.6 m-85 -49.71 -49.39 48.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.305 -0.872 . . . . 0.0 109.785 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 11.2 m -71.15 -24.74 62.32 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.237 -0.914 . . . . 0.0 109.692 -179.754 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 177' ' ' GLN . . . . . 0.439 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 81.7 mt-30 -70.36 -24.72 63.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.218 -0.926 . . . . 0.0 109.722 -179.813 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.511 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 17.5 m -131.06 161.82 40.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.189 -0.945 . . . . 0.0 109.511 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 179' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -120.67 145.46 47.42 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.296 -0.878 . . . . 0.0 109.473 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 30.2 tttm -69.67 134.61 48.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.302 -0.874 . . . . 0.0 109.481 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.495 0 O-C-N 121.163 -0.96 . . . . 0.0 109.485 179.985 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.909 ' O ' HG21 ' A' ' 151' ' ' VAL . 69.1 m-85 . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.464 ' HB3' ' HD2' ' A' ' 130' ' ' PRO . 1.2 mp0 -109.24 138.16 20.4 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.296 -0.878 . . . . 0.0 109.399 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.464 ' HD2' ' HB3' ' A' ' 129' ' ' GLU . 50.6 Cg_endo -39.68 133.99 1.57 Allowed 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.549 2.166 . . . . 0.0 111.765 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 84.69 8.45 82.83 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 45.7 tp10 -102.25 135.04 44.55 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.263 -1.14 . . . . 0.0 109.443 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.553 ' HG2' HG22 ' A' ' 147' ' ' VAL . 76.3 mtp -70.28 148.17 48.83 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.248 -0.908 . . . . 0.0 109.456 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.749 HG13 ' CE2' ' A' ' 128' ' ' PHE . 2.5 t -136.72 179.08 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.26 -0.9 . . . . 0.0 109.353 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.673 ' H ' HG12 ' A' ' 134' ' ' VAL . 70.3 ttt180 -136.51 143.12 43.59 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.263 -0.898 . . . . 0.0 109.43 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.632 HG11 ' HB2' ' A' ' 141' ' ' PHE . 60.3 t -111.16 124.86 68.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.258 -0.902 . . . . 0.0 109.524 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 26.4 p30 -124.77 22.31 8.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -0.905 . . . . 0.0 109.511 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -145.15 140.98 28.35 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.328 -0.858 . . . . 0.0 109.479 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 81.62 -179.82 53.26 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -58.67 -20.18 49.35 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.679 2.252 . . . . 0.0 111.764 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 141' ' ' PHE . . . . . 0.888 ' CZ ' HG11 ' A' ' 171' ' ' VAL . 99.2 m-85 -87.38 10.15 18.33 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.239 -0.913 . . . . 0.0 109.379 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 142' ' ' ALA . . . . . 0.505 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -64.17 152.99 39.21 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.282 -0.886 . . . . 0.0 109.59 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.453 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 58.8 m-20 63.65 42.57 6.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.3 -0.875 . . . . 0.0 109.676 179.746 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.556 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 58.8 m-85 -145.51 152.64 40.08 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.164 -0.96 . . . . 0.0 109.494 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 43.7 p-10 -113.63 167.06 10.92 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.238 -0.914 . . . . 0.0 109.395 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 179.35 -170.45 42.03 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.553 HG22 ' HG2' ' A' ' 133' ' ' MET . 43.0 t -129.11 150.43 34.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.225 -1.162 . . . . 0.0 109.517 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.664 ' HA ' HG22 ' A' ' 160' ' ' VAL . 2.5 p -91.05 113.83 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.203 -0.936 . . . . 0.0 109.497 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.423 ' N ' ' O ' ' A' ' 159' ' ' LYS . 75.8 mm-40 -67.02 -37.1 83.54 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.222 -0.924 . . . . 0.0 109.445 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.406 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 94.9 mt-10 -153.97 163.38 40.15 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.223 -0.923 . . . . 0.0 109.501 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 1.073 HG13 ' CD2' ' A' ' 158' ' ' LEU . 45.7 t -127.27 146.32 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.247 -0.908 . . . . 0.0 109.535 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -133.02 90.88 2.8 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.277 -0.89 . . . . 0.0 109.5 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -62.93 -38.82 92.54 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.214 -0.929 . . . . 0.0 109.502 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -61.25 -41.7 97.35 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.48 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.459 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 60.2 mttm -92.23 -2.25 56.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -0.893 . . . . 0.0 109.601 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 156' ' ' SER . . . . . 0.473 ' HA ' ' CZ ' ' A' ' 175' ' ' PHE . 12.9 m 50.23 52.52 14.59 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.28 -0.887 . . . . 0.0 109.587 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 157' ' ' ARG . . . . . 0.459 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 13.7 mmt85 -146.15 142.77 28.79 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.295 -0.878 . . . . 0.0 109.468 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 158' ' ' LEU . . . . . 1.073 ' CD2' HG13 ' A' ' 151' ' ' VAL . 49.0 mt -116.34 133.19 56.29 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.196 -0.94 . . . . 0.0 109.497 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 159' ' ' LYS . . . . . 0.441 ' O ' ' HA ' ' A' ' 148' ' ' VAL . 65.5 mttm -87.39 100.64 12.88 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.282 -0.886 . . . . 0.0 109.346 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.664 HG22 ' HA ' ' A' ' 148' ' ' VAL . 57.6 t -128.34 138.75 53.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.176 -0.952 . . . . 0.0 109.524 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 161' ' ' SER . . . . . 0.467 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 88.3 p -107.2 148.13 29.28 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.272 -0.893 . . . . 0.0 109.431 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 162' ' ' VAL . . . . . 0.556 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 3.8 t -115.33 130.02 70.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.211 -0.931 . . . . 0.0 109.637 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 33.2 t . . . . . 0 N--CA 1.488 1.454 0 O-C-N 121.221 -0.924 . . . . 0.0 109.153 179.639 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 46.0 tpt85 . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 121.303 0.573 . . . . 0.0 109.546 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -72.76 138.89 46.76 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.206 -0.934 . . . . 0.0 109.477 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 169' ' ' THR . . . . . 0.658 ' O ' HG13 ' A' ' 171' ' ' VAL . 10.1 m -122.53 75.78 44.88 Favored Pre-proline 0 N--CA 1.488 1.465 0 O-C-N 121.128 -0.983 . . . . 0.0 109.484 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.467 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.4 Cg_endo -56.13 110.73 0.61 Allowed 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.572 2.181 . . . . 0.0 111.734 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 1.031 HG23 HD21 ' A' ' 173' ' ' LEU . 16.5 m -129.6 154.87 40.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.26 -0.9 . . . . 0.0 109.502 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.786 ' C ' HD22 ' A' ' 173' ' ' LEU . 95.7 mt-10 -100.69 125.88 47.16 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.222 -0.923 . . . . 0.0 109.459 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 173' ' ' LEU . . . . . 1.031 HD21 HG23 ' A' ' 171' ' ' VAL . 2.6 mm? -122.93 147.18 46.9 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.311 -0.868 . . . . 0.0 109.434 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 174' ' ' ASP . . . . . 0.427 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 90.3 m-20 -65.41 169.14 6.25 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.209 -0.932 . . . . 0.0 109.457 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.565 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.3 m-30 -64.4 -36.83 85.44 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.178 -0.951 . . . . 0.0 109.462 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 86.1 p -80.07 -25.87 39.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.248 -0.907 . . . . 0.0 109.429 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 177' ' ' GLN . . . . . 0.427 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 86.2 mt-30 -66.57 -27.3 67.62 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.189 -0.945 . . . . 0.0 109.422 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.528 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 4.6 m -123.89 156.73 30.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.291 -0.881 . . . . 0.0 109.499 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 179' ' ' GLU . . . . . 0.502 ' O ' ' N ' ' A' ' 135' ' ' ARG . 83.6 tt0 -116.51 156.17 27.37 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.31 -0.869 . . . . 0.0 109.463 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 180' ' ' LYS . . . . . 0.456 ' HG2' ' CE2' ' A' ' 128' ' ' PHE . 54.4 mttt -69.89 142.88 52.93 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.233 -0.917 . . . . 0.0 109.481 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.578 0 O-C-N 121.267 -0.895 . . . . 0.0 109.472 179.999 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.624 ' CE1' HG13 ' A' ' 134' ' ' VAL . 50.8 m-85 . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.534 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.0 OUTLIER -134.57 156.91 78.36 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.312 -0.868 . . . . 0.0 109.454 179.99 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.534 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.2 Cg_endo -48.66 130.31 22.1 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.626 2.217 . . . . 0.0 111.819 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 90.15 10.26 64.48 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -113.42 138.9 49.42 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.243 -1.151 . . . . 0.0 109.51 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.569 ' HG2' HG22 ' A' ' 147' ' ' VAL . 87.1 mtp -79.77 149.25 31.16 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.294 -0.879 . . . . 0.0 109.527 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.687 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -131.93 179.08 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.314 -0.866 . . . . 0.0 109.387 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.687 ' H ' HG12 ' A' ' 134' ' ' VAL . 24.4 tpt180 -130.88 138.92 50.03 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.284 -0.885 . . . . 0.0 109.365 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.491 HG13 HD13 ' A' ' 173' ' ' LEU . 28.7 t -103.98 130.56 54.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.24 -0.912 . . . . 0.0 109.539 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 137' ' ' ASN . . . . . 0.428 ' OD1' ' C ' ' A' ' 137' ' ' ASN . 22.2 p30 -132.03 18.08 4.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.324 -0.86 . . . . 0.0 109.403 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.473 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 59.7 t0 -140.66 148.67 41.19 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.204 -0.935 . . . . 0.0 109.499 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.473 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 73.0 172.85 23.57 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -52.99 -19.83 12.24 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.652 2.235 . . . . 0.0 111.786 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 141' ' ' PHE . . . . . 0.632 ' CD1' HG11 ' A' ' 162' ' ' VAL . 97.9 m-85 -87.43 10.31 17.96 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.183 -0.948 . . . . 0.0 109.444 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 142' ' ' ALA . . . . . 0.499 ' O ' ' CB ' ' A' ' 143' ' ' ASP . . . -66.29 147.77 52.83 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.256 -0.902 . . . . 0.0 109.485 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.499 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 24.9 t0 74.34 28.26 1.37 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.291 -0.881 . . . . 0.0 109.471 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -134.38 153.27 51.99 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.292 -0.88 . . . . 0.0 109.466 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 43.2 p-10 -113.77 165.54 12.45 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.258 -0.901 . . . . 0.0 109.425 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -174.07 -177.1 43.0 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.569 HG22 ' HG2' ' A' ' 133' ' ' MET . 44.2 t -117.27 161.28 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.213 -1.169 . . . . 0.0 109.477 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.847 HG11 HG22 ' A' ' 151' ' ' VAL . 79.4 t -93.4 96.25 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.213 -0.929 . . . . 0.0 109.524 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -66.02 -31.92 73.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.247 -0.908 . . . . 0.0 109.429 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.409 ' O ' ' HB3' ' A' ' 159' ' ' LYS . 84.7 tt0 -148.83 150.25 32.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.286 -0.884 . . . . 0.0 109.415 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.847 HG22 HG11 ' A' ' 148' ' ' VAL . 45.3 t -124.19 149.99 28.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.214 -0.929 . . . . 0.0 109.516 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 152' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 95.2 m-20 -136.48 79.88 1.79 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.216 -0.928 . . . . 0.0 109.502 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 153' ' ' TYR . . . . . 0.507 ' CZ ' HG11 ' A' ' 151' ' ' VAL . 98.9 m-85 -63.64 -37.46 87.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.227 -0.921 . . . . 0.0 109.518 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -59.42 -46.45 88.68 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.185 -0.947 . . . . 0.0 109.528 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.473 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 58.1 mttt -90.72 0.5 57.4 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.268 -0.895 . . . . 0.0 109.548 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 31.1 t 56.06 52.82 9.89 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.196 -0.94 . . . . 0.0 109.485 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 157' ' ' ARG . . . . . 0.473 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 22.9 mmt85 -140.29 140.51 35.72 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.275 -0.891 . . . . 0.0 109.367 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 158' ' ' LEU . . . . . 0.478 HD11 ' CD1' ' A' ' 175' ' ' PHE . 61.5 mt -110.06 129.47 55.68 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.162 -0.962 . . . . 0.0 109.522 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 159' ' ' LYS . . . . . 0.441 ' HG3' ' OE2' ' A' ' 172' ' ' GLU . 29.4 tttp -92.31 104.79 17.1 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.331 -0.856 . . . . 0.0 109.352 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.541 HG13 ' O ' ' A' ' 147' ' ' VAL . 44.4 t -124.64 140.62 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.29 -0.881 . . . . 0.0 109.545 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 161' ' ' SER . . . . . 0.46 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 30.1 t -109.17 137.65 46.74 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.295 -0.878 . . . . 0.0 109.462 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 162' ' ' VAL . . . . . 0.742 HG12 ' HB ' ' A' ' 169' ' ' THR . 9.4 p -104.9 138.86 27.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.185 -0.947 . . . . 0.0 109.636 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 163' ' ' SER . . . . . 0.438 ' HA ' ' O ' ' A' ' 167' ' ' ARG . 5.3 m . . . . . 0 N--CA 1.49 1.568 0 O-C-N 121.215 -0.928 . . . . 0.0 109.461 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 167' ' ' ARG . . . . . 0.438 ' O ' ' HA ' ' A' ' 163' ' ' SER . 62.2 mtt180 . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -98.19 139.12 34.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.232 -0.918 . . . . 0.0 109.497 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 169' ' ' THR . . . . . 0.781 ' O ' HG13 ' A' ' 171' ' ' VAL . 6.0 m -129.81 74.04 80.98 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.287 -0.883 . . . . 0.0 109.453 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.46 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.7 Cg_endo -49.08 109.9 0.31 Allowed 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.603 2.202 . . . . 0.0 111.774 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.781 HG13 ' O ' ' A' ' 169' ' ' THR . 23.6 m -128.96 156.8 41.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.29 -0.881 . . . . 0.0 109.514 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.735 ' O ' HD23 ' A' ' 173' ' ' LEU . 75.7 mm-40 -101.6 130.65 47.97 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.293 -0.88 . . . . 0.0 109.465 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 173' ' ' LEU . . . . . 0.735 HD23 ' O ' ' A' ' 172' ' ' GLU . 51.8 mt -131.28 148.81 52.73 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.245 -0.91 . . . . 0.0 109.419 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -74.91 171.54 13.85 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.213 -0.93 . . . . 0.0 109.447 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.583 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.7 m-30 -64.25 -36.81 85.29 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.318 -0.864 . . . . 0.0 109.439 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 83.4 p -79.58 -26.97 41.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.312 -0.867 . . . . 0.0 109.355 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 67.0 mt-30 -68.86 -19.69 64.25 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.26 -0.9 . . . . 0.0 109.381 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.466 HG11 ' HB2' ' A' ' 173' ' ' LEU . 4.2 m -135.73 154.4 34.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.217 -0.927 . . . . 0.0 109.526 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 179' ' ' GLU . . . . . 0.504 ' O ' ' N ' ' A' ' 135' ' ' ARG . 37.7 mt-10 -120.07 166.53 13.27 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.278 -0.888 . . . . 0.0 109.427 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 180' ' ' LYS . . . . . 0.452 ' HG2' ' CE1' ' A' ' 128' ' ' PHE . 54.9 mttt -71.97 145.83 48.14 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.229 -0.919 . . . . 0.0 109.551 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.521 0 O-C-N 121.285 -0.884 . . . . 0.0 109.498 179.999 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 83.8 m-85 . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.468 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.0 OUTLIER -135.77 153.18 77.11 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.262 -0.899 . . . . 0.0 109.445 -179.968 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.468 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.4 Cg_endo -47.18 133.21 19.06 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.593 2.195 . . . . 0.0 111.793 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 86.51 3.1 84.42 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 50.2 tp10 -88.05 137.57 32.21 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.202 -1.175 . . . . 0.0 109.544 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.497 ' HG2' HG22 ' A' ' 147' ' ' VAL . 77.4 mtp -79.44 149.49 31.57 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.279 -0.888 . . . . 0.0 109.446 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.735 ' CG2' HG23 ' A' ' 148' ' ' VAL . 2.5 t -139.25 179.0 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.266 -0.896 . . . . 0.0 109.318 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.673 ' H ' HG12 ' A' ' 134' ' ' VAL . 18.5 mtp-105 -137.47 142.49 41.54 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.245 -0.91 . . . . 0.0 109.466 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.479 HG22 HG12 ' A' ' 178' ' ' VAL . 43.3 t -111.56 135.2 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.232 -0.917 . . . . 0.0 109.537 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 38.2 p30 -127.08 15.52 7.32 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.54 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.487 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 59.2 t0 -142.06 153.53 44.27 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.28 -0.888 . . . . 0.0 109.462 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.487 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 75.38 171.02 28.86 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -54.93 -18.47 16.73 Favored 'Trans proline' 0 C--O 1.214 -0.705 0 C-N-CA 122.578 2.185 . . . . 0.0 111.792 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 141' ' ' PHE . . . . . 0.699 ' CD1' HG11 ' A' ' 162' ' ' VAL . 90.5 m-85 -92.79 14.92 15.86 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.25 -0.906 . . . . 0.0 109.454 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 142' ' ' ALA . . . . . 0.449 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -66.23 149.51 50.23 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.301 -0.874 . . . . 0.0 109.523 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.449 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 43.7 m-20 64.03 46.85 3.58 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.232 -0.918 . . . . 0.0 109.473 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -140.79 142.01 34.73 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.295 -0.878 . . . . 0.0 109.531 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 73.0 m-20 -100.81 142.4 32.33 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.245 -0.909 . . . . 0.0 109.462 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.54 177.94 34.98 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.613 ' O ' HG13 ' A' ' 160' ' ' VAL . 49.0 t -114.29 164.2 10.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.184 -1.186 . . . . 0.0 109.438 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.735 HG23 ' CG2' ' A' ' 134' ' ' VAL . 98.6 t -93.16 95.54 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.257 -0.902 . . . . 0.0 109.553 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -67.42 -34.52 77.4 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.178 -0.951 . . . . 0.0 109.432 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.502 ' HB2' ' CD ' ' A' ' 159' ' ' LYS . 94.2 mt-10 -151.23 161.49 42.61 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.237 -0.915 . . . . 0.0 109.332 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.506 HG11 ' CZ ' ' A' ' 153' ' ' TYR . 44.1 t -124.25 151.35 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.206 -0.934 . . . . 0.0 109.569 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -125.49 78.3 1.72 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.236 -0.915 . . . . 0.0 109.413 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 153' ' ' TYR . . . . . 0.506 ' CZ ' HG11 ' A' ' 151' ' ' VAL . 83.9 m-85 -63.68 -37.05 85.87 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.338 -0.851 . . . . 0.0 109.569 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -60.74 -42.83 98.15 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.247 -0.908 . . . . 0.0 109.532 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.474 ' O ' ' HG3' ' A' ' 157' ' ' ARG . 45.9 mttp -94.68 3.03 55.56 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.241 -0.912 . . . . 0.0 109.604 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 56.62 51.98 10.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.245 -0.909 . . . . 0.0 109.464 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 157' ' ' ARG . . . . . 0.474 ' HG3' ' O ' ' A' ' 155' ' ' LYS . 58.1 mtt180 -146.29 157.49 43.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.281 -0.887 . . . . 0.0 109.522 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 158' ' ' LEU . . . . . 0.545 HD21 ' CE1' ' A' ' 175' ' ' PHE . 18.2 mt -115.01 135.56 54.09 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.199 -0.938 . . . . 0.0 109.451 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 159' ' ' LYS . . . . . 0.502 ' CD ' ' HB2' ' A' ' 150' ' ' GLU . 31.0 tttp -87.99 105.92 17.78 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.269 -0.894 . . . . 0.0 109.318 179.855 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.613 HG13 ' O ' ' A' ' 147' ' ' VAL . 39.9 t -121.99 143.46 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.228 -0.92 . . . . 0.0 109.636 -179.833 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 93.5 p -110.31 145.24 37.79 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.263 -0.898 . . . . 0.0 109.41 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 162' ' ' VAL . . . . . 0.765 HG12 ' HB ' ' A' ' 169' ' ' THR . 9.8 p -115.93 138.89 44.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.226 -0.921 . . . . 0.0 109.527 -179.899 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 163' ' ' SER . . . . . 0.403 ' HA ' ' O ' ' A' ' 167' ' ' ARG . 37.8 t . . . . . 0 N--CA 1.489 1.511 0 O-C-N 121.256 -0.903 . . . . 0.0 109.408 179.892 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 167' ' ' ARG . . . . . 0.403 ' O ' ' HA ' ' A' ' 163' ' ' SER . 65.7 mtt-85 . . . . . 0 N--CA 1.49 1.525 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -91.43 134.37 34.69 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.265 -0.897 . . . . 0.0 109.54 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 169' ' ' THR . . . . . 0.765 ' HB ' HG12 ' A' ' 162' ' ' VAL . 0.2 OUTLIER -128.3 74.11 79.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.312 -0.867 . . . . 0.0 109.458 -179.963 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -57.6 104.64 0.17 Allowed 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.598 2.198 . . . . 0.0 111.805 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 1.018 HG23 HD21 ' A' ' 173' ' ' LEU . 19.3 m -130.41 155.95 42.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.253 -0.905 . . . . 0.0 109.538 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.737 ' C ' HD22 ' A' ' 173' ' ' LEU . 95.2 mt-10 -104.03 128.94 51.63 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.236 -0.915 . . . . 0.0 109.46 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 173' ' ' LEU . . . . . 1.018 HD21 HG23 ' A' ' 171' ' ' VAL . 2.3 mm? -121.29 145.67 47.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.248 -0.907 . . . . 0.0 109.432 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 64.6 m-20 -65.63 173.48 2.76 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.263 -0.898 . . . . 0.0 109.38 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.545 ' CE1' HD21 ' A' ' 158' ' ' LEU . 4.2 m-30 -66.65 -44.47 81.8 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.252 -0.905 . . . . 0.0 109.471 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 18.7 m -73.09 -23.62 60.55 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.201 -0.937 . . . . 0.0 109.384 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -70.78 -23.8 62.46 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.298 -0.876 . . . . 0.0 109.39 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.555 HG11 ' HB2' ' A' ' 173' ' ' LEU . 6.0 m -131.43 163.42 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.31 -0.869 . . . . 0.0 109.378 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 179' ' ' GLU . . . . . . . . . . . . . 74.3 mm-40 -119.0 145.45 45.83 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.172 -0.955 . . . . 0.0 109.485 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 18.3 tttm -64.87 140.0 58.82 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.202 -0.936 . . . . 0.0 109.463 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.542 0 O-C-N 121.207 -0.933 . . . . 0.0 109.44 -179.942 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.71 ' CE1' HG13 ' A' ' 134' ' ' VAL . 59.4 m-85 . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 129' ' ' GLU . . . . . 0.429 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 3.9 mt-10 -122.77 154.75 63.88 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.245 -0.909 . . . . 0.0 109.353 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.429 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.3 Cg_endo -51.15 129.05 27.15 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.597 2.198 . . . . 0.0 111.804 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 84.44 13.24 73.87 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.422 ' OE1' ' HA ' ' A' ' 128' ' ' PHE . 77.5 tt0 -104.13 133.83 48.4 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.236 -1.155 . . . . 0.0 109.443 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.605 ' HG2' HG22 ' A' ' 147' ' ' VAL . 85.7 mtp -69.36 144.97 53.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.316 -0.865 . . . . 0.0 109.545 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.752 HG21 HG23 ' A' ' 148' ' ' VAL . 2.5 t -133.11 178.87 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.344 -0.847 . . . . 0.0 109.363 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.686 ' H ' HG12 ' A' ' 134' ' ' VAL . 40.9 ttm180 -129.15 136.08 49.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.275 -0.891 . . . . 0.0 109.326 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.462 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 39.5 t -106.34 130.34 58.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.215 -0.928 . . . . 0.0 109.529 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 137' ' ' ASN . . . . . 0.408 ' OD1' ' C ' ' A' ' 137' ' ' ASN . 43.0 p30 -127.61 17.4 6.93 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.282 -0.886 . . . . 0.0 109.443 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.462 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 60.1 t0 -136.98 147.17 46.13 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.306 -0.871 . . . . 0.0 109.468 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.462 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 74.58 173.62 30.93 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -57.2 -17.21 24.74 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.627 2.218 . . . . 0.0 111.883 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 141' ' ' PHE . . . . . 0.732 ' CD1' HG21 ' A' ' 162' ' ' VAL . 99.7 m-85 -90.23 12.68 17.35 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.13 -0.981 . . . . 0.0 109.452 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 142' ' ' ALA . . . . . 0.516 ' O ' ' CB ' ' A' ' 143' ' ' ASP . . . -72.5 147.15 46.3 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.276 -0.89 . . . . 0.0 109.509 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.516 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 24.9 t0 75.74 28.69 0.89 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.272 -0.893 . . . . 0.0 109.529 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.544 ' HB3' HG13 ' A' ' 162' ' ' VAL . 91.8 m-85 -132.26 146.26 51.87 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.155 -0.966 . . . . 0.0 109.514 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -98.5 144.73 27.51 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.245 -0.909 . . . . 0.0 109.442 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -157.52 -178.77 31.89 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.605 HG22 ' HG2' ' A' ' 133' ' ' MET . 28.3 t -124.08 156.36 31.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.227 -1.161 . . . . 0.0 109.408 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.752 HG23 HG21 ' A' ' 134' ' ' VAL . 87.5 t -89.25 100.54 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.206 -0.934 . . . . 0.0 109.388 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -65.47 -38.26 89.26 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.209 -0.932 . . . . 0.0 109.499 179.875 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -145.43 165.71 27.76 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.234 -0.916 . . . . 0.0 109.478 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.488 HG22 HG11 ' A' ' 148' ' ' VAL . 41.2 t -129.45 150.82 34.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.3 -0.875 . . . . 0.0 109.497 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 152' ' ' ASP . . . . . 0.406 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 88.8 m-20 -134.45 83.2 2.02 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.268 -0.895 . . . . 0.0 109.413 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 153' ' ' TYR . . . . . 0.413 ' CZ ' HG11 ' A' ' 151' ' ' VAL . 96.4 m-85 -64.77 -37.95 89.33 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.178 -0.951 . . . . 0.0 109.468 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 154' ' ' GLU . . . . . 0.417 ' OE1' ' HA ' ' A' ' 154' ' ' GLU . 72.8 mm-40 -60.53 -44.65 95.84 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.267 -0.896 . . . . 0.0 109.491 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.479 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 93.4 mttt -90.63 -1.0 57.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.306 -0.871 . . . . 0.0 109.559 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 48.9 m 54.32 53.09 11.41 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.146 -0.971 . . . . 0.0 109.495 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 157' ' ' ARG . . . . . 0.479 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 20.1 mmt85 -144.5 144.82 31.53 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.142 -0.973 . . . . 0.0 109.465 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 158' ' ' LEU . . . . . 0.51 HD21 ' CE1' ' A' ' 175' ' ' PHE . 55.6 mt -111.87 126.14 54.78 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.254 -0.904 . . . . 0.0 109.537 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 60.4 tttt -83.92 105.14 14.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.178 -0.952 . . . . 0.0 109.415 179.786 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.75 HG22 HG22 ' A' ' 148' ' ' VAL . 38.1 t -124.21 141.27 44.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.25 -0.906 . . . . 0.0 109.434 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 161' ' ' SER . . . . . 0.445 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 23.6 t -112.44 134.49 53.95 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.278 -0.889 . . . . 0.0 109.611 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 162' ' ' VAL . . . . . 0.732 HG21 ' CD1' ' A' ' 141' ' ' PHE . 3.7 t -88.84 130.32 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.234 -0.916 . . . . 0.0 109.47 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 59.3 m . . . . . 0 N--CA 1.489 1.525 0 O-C-N 121.228 -0.92 . . . . 0.0 109.387 179.939 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 30.5 ttp180 . . . . . 0 N--CA 1.493 1.717 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -63.16 136.71 57.91 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.243 -0.911 . . . . 0.0 109.292 179.841 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 169' ' ' THR . . . . . 0.582 HG21 ' CZ ' ' A' ' 141' ' ' PHE . 63.0 m -123.36 91.92 49.35 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.192 -0.943 . . . . 0.0 109.662 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.445 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.8 Cg_endo -64.33 109.85 1.26 Allowed 'Trans proline' 0 C--O 1.216 -0.603 0 C-N-CA 122.502 2.134 . . . . 0.0 111.533 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 1.111 HG23 HD21 ' A' ' 173' ' ' LEU . 17.6 m -128.2 158.07 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.194 -0.942 . . . . 0.0 109.69 -179.806 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.681 ' O ' HD13 ' A' ' 173' ' ' LEU . 95.5 mt-10 -100.04 125.07 46.05 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.383 -0.823 . . . . 0.0 109.348 179.843 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 173' ' ' LEU . . . . . 1.111 HD21 HG23 ' A' ' 171' ' ' VAL . 1.7 mm? -120.48 145.63 47.07 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.203 -0.936 . . . . 0.0 109.493 -179.842 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 174' ' ' ASP . . . . . 0.446 ' OD1' ' HD3' ' A' ' 157' ' ' ARG . 88.3 m-20 -68.84 170.81 8.9 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.224 -0.923 . . . . 0.0 109.452 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.577 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.5 m-30 -65.67 -44.21 86.95 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.217 -0.927 . . . . 0.0 109.436 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 11.1 m -76.0 -24.31 55.3 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.151 -0.968 . . . . 0.0 109.422 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 177' ' ' GLN . . . . . 0.427 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 86.5 mt-30 -69.68 -18.81 63.58 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.265 -0.897 . . . . 0.0 109.339 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.612 HG11 ' HB2' ' A' ' 173' ' ' LEU . 4.8 m -132.35 162.85 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.343 -0.848 . . . . 0.0 109.427 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 179' ' ' GLU . . . . . 0.507 ' O ' ' N ' ' A' ' 135' ' ' ARG . 60.7 mt-10 -126.38 161.73 27.18 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.29 -0.881 . . . . 0.0 109.554 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 84.5 mttt -67.36 144.28 55.91 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.204 -0.935 . . . . 0.0 109.447 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.566 0 O-C-N 121.202 -0.937 . . . . 0.0 109.481 179.959 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -118.47 146.97 40.91 Favored Pre-proline 0 N--CA 1.489 1.488 0 O-C-N 121.296 -0.877 . . . . 0.0 109.47 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -48.09 126.63 13.66 Favored 'Trans proline' 0 C--O 1.214 -0.694 0 C-N-CA 122.576 2.184 . . . . 0.0 111.816 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 131' ' ' GLY . . . . . 0.44 ' C ' ' CG1' ' A' ' 147' ' ' VAL . . . 94.59 -5.25 70.04 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.845 ' O ' HG13 ' A' ' 147' ' ' VAL . 80.3 tt0 -79.21 148.42 32.25 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.124 -1.221 . . . . 0.0 109.467 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 133' ' ' MET . . . . . 0.671 ' HG2' HG22 ' A' ' 147' ' ' VAL . 64.1 mtp -82.08 146.49 29.62 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.26 -0.9 . . . . 0.0 109.545 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.673 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -135.92 179.13 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.264 -0.898 . . . . 0.0 109.255 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 135' ' ' ARG . . . . . 0.673 ' H ' HG12 ' A' ' 134' ' ' VAL . 87.8 mtt180 -137.33 146.62 44.8 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.225 -0.922 . . . . 0.0 109.399 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.421 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 39.3 t -117.01 134.73 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.212 -0.93 . . . . 0.0 109.558 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 30.7 p30 -128.45 14.7 6.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.233 -0.917 . . . . 0.0 109.48 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.452 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 57.8 t0 -147.17 153.4 39.83 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.253 -0.904 . . . . 0.0 109.396 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 139' ' ' GLY . . . . . 0.452 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 78.65 172.26 40.91 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -55.28 -19.1 20.41 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.571 2.181 . . . . 0.0 111.78 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 141' ' ' PHE . . . . . 0.766 ' CZ ' HG11 ' A' ' 171' ' ' VAL . 86.3 m-85 -93.0 9.2 36.72 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.214 -0.929 . . . . 0.0 109.536 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 142' ' ' ALA . . . . . 0.446 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -61.79 146.38 49.66 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.217 -0.927 . . . . 0.0 109.562 -179.867 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 143' ' ' ASP . . . . . 0.446 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 18.0 m-20 65.86 47.83 1.97 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.296 -0.878 . . . . 0.0 109.592 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.401 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 43.9 m-85 -146.51 136.14 23.11 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.296 -0.877 . . . . 0.0 109.457 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 71.3 m-20 -94.03 141.02 29.01 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.236 -0.915 . . . . 0.0 109.419 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.14 -177.19 31.0 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 147' ' ' VAL . . . . . 0.845 HG13 ' O ' ' A' ' 132' ' ' GLU . 46.5 t -125.07 148.92 29.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.207 -1.172 . . . . 0.0 109.369 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.589 ' HA ' HG22 ' A' ' 160' ' ' VAL . 2.5 p -85.67 102.2 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.192 -0.942 . . . . 0.0 109.552 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -68.33 -36.41 79.23 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.146 -0.971 . . . . 0.0 109.414 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -140.78 164.29 30.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.189 -0.944 . . . . 0.0 109.471 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 99.8 t -125.67 152.94 33.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.327 -0.858 . . . . 0.0 109.523 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -130.53 88.43 2.63 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.319 -0.863 . . . . 0.0 109.386 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -69.58 -38.55 77.41 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.22 -0.925 . . . . 0.0 109.593 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -60.44 -46.64 89.29 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.213 -0.929 . . . . 0.0 109.45 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 155' ' ' LYS . . . . . 0.444 ' O ' ' HG3' ' A' ' 157' ' ' ARG . 32.0 mttt -89.32 -1.08 57.93 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.244 -0.91 . . . . 0.0 109.611 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 34.0 t 56.46 52.36 10.03 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.196 -0.94 . . . . 0.0 109.467 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 157' ' ' ARG . . . . . 0.444 ' HG3' ' O ' ' A' ' 155' ' ' LYS . 20.5 mtm180 -146.21 157.71 43.84 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.152 -0.967 . . . . 0.0 109.454 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 158' ' ' LEU . . . . . 0.629 HD21 ' CE1' ' A' ' 175' ' ' PHE . 13.9 mt -118.23 131.69 56.35 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.892 . . . . 0.0 109.531 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 20.9 tttp -84.37 106.77 16.23 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.295 -0.878 . . . . 0.0 109.443 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 160' ' ' VAL . . . . . 0.626 HG13 ' O ' ' A' ' 147' ' ' VAL . 47.5 t -124.86 140.72 47.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.162 -0.961 . . . . 0.0 109.56 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 161' ' ' SER . . . . . 0.461 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 23.0 t -104.3 141.88 35.53 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.439 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 162' ' ' VAL . . . . . 0.749 HG12 ' HB ' ' A' ' 169' ' ' THR . 9.4 p -105.53 126.28 60.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.314 -0.867 . . . . 0.0 109.562 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 18.5 t . . . . . 0 N--CA 1.491 1.597 0 O-C-N 121.303 -0.873 . . . . 0.0 109.377 179.875 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 19.1 ttp180 . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -76.33 141.0 41.71 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.294 -0.879 . . . . 0.0 109.454 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 169' ' ' THR . . . . . 0.749 ' HB ' HG12 ' A' ' 162' ' ' VAL . 2.4 m -128.02 76.81 77.36 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.308 -0.87 . . . . 0.0 109.437 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.8 Cg_endo -55.27 106.51 0.19 Allowed 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.604 2.203 . . . . 0.0 111.852 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.766 HG11 ' CZ ' ' A' ' 141' ' ' PHE . 18.9 m -129.61 157.84 42.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.461 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.633 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.5 mt-10 -102.1 128.54 48.53 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.24 -0.913 . . . . 0.0 109.477 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 173' ' ' LEU . . . . . 0.633 HD23 ' O ' ' A' ' 172' ' ' GLU . 42.4 mt -124.86 144.13 50.47 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.29 -0.881 . . . . 0.0 109.513 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 24.6 m-20 -64.57 172.48 2.64 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.191 -0.943 . . . . 0.0 109.527 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 175' ' ' PHE . . . . . 0.629 ' CE1' HD21 ' A' ' 158' ' ' LEU . 4.5 m-30 -67.67 -44.41 77.89 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.166 -0.959 . . . . 0.0 109.501 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 15.0 m -71.33 -23.56 61.95 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.219 -0.925 . . . . 0.0 109.524 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 90.3 mt-30 -72.79 -23.53 60.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.177 -0.952 . . . . 0.0 109.431 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.563 HG11 ' HB2' ' A' ' 173' ' ' LEU . 4.5 m -128.16 161.26 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.253 -0.905 . . . . 0.0 109.401 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 179' ' ' GLU . . . . . 0.472 ' HB2' ' HB2' ' A' ' 135' ' ' ARG . 95.0 mt-10 -116.74 149.97 39.02 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.179 -0.951 . . . . 0.0 109.559 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 180' ' ' LYS . . . . . 0.508 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 33.6 tttm -69.13 137.34 53.31 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.181 -0.949 . . . . 0.0 109.505 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 181' ' ' ALA . . . . . 0.423 ' HB2' ' C ' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.536 0 O-C-N 121.211 -0.931 . . . . 0.0 109.46 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 6.3 ttm180 . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -56.6 145.93 78.51 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.62 2.213 . . . . 0.0 111.749 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 24.0 mttm -91.16 144.14 25.94 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.264 -0.898 . . . . 0.0 109.484 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.449 ' HA ' ' CE2' ' A' ' 128' ' ' PHE . 51.1 p -99.43 12.1 37.31 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.263 -0.898 . . . . 0.0 109.425 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.484 ' O ' ' HE3' ' A' ' 180' ' ' LYS . 64.6 mt -92.74 98.76 11.61 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.24 -0.912 . . . . 0.0 109.446 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.449 ' CE2' ' HA ' ' A' ' 126' ' ' THR . 79.8 m-85 -117.65 146.51 43.63 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.296 -0.878 . . . . 0.0 109.468 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.493 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 1.2 mt-10 -138.65 159.29 68.03 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.202 -0.937 . . . . 0.0 109.457 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.493 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.1 Cg_endo -53.53 129.41 33.68 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.547 2.165 . . . . 0.0 111.82 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 90.47 -1.2 78.82 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.489 ' O ' HG12 ' A' ' 148' ' ' VAL . 77.0 mm-40 -86.45 135.51 33.45 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.168 -1.195 . . . . 0.0 109.475 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.469 ' HA ' ' HA ' ' A' ' 147' ' ' VAL . 44.2 ttm -79.58 146.91 32.32 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.16 -0.963 . . . . 0.0 109.49 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.694 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -131.55 179.24 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.266 -0.896 . . . . 0.0 109.324 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.694 ' H ' HG12 ' A' ' 134' ' ' VAL . 40.4 ttt180 -130.29 138.34 50.43 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.226 -0.921 . . . . 0.0 109.49 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.493 HG22 ' CD1' ' A' ' 173' ' ' LEU . 45.4 t -106.63 132.79 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.271 -0.893 . . . . 0.0 109.451 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 56.1 p30 -135.64 20.44 3.33 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.263 -0.898 . . . . 0.0 109.495 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.422 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 59.0 t0 -140.88 148.17 40.07 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.209 -0.932 . . . . 0.0 109.481 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.422 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 70.23 177.23 20.76 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -55.01 -20.17 22.37 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.562 2.175 . . . . 0.0 111.791 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' PHE . . . . . 0.491 ' HB2' HG11 ' A' ' 136' ' ' VAL . 98.7 m-85 -85.6 6.73 26.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.217 -0.927 . . . . 0.0 109.504 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 142' ' ' ALA . . . . . 0.469 ' O ' ' HB3' ' A' ' 143' ' ' ASP . . . -66.19 148.91 51.13 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.287 -0.883 . . . . 0.0 109.462 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.469 ' HB3' ' O ' ' A' ' 142' ' ' ALA . 35.5 t0 73.06 29.97 1.69 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.222 -0.924 . . . . 0.0 109.51 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.533 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 84.7 m-85 -138.12 151.52 47.86 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.249 -0.907 . . . . 0.0 109.511 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 43.3 p-10 -118.04 164.09 15.63 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.25 -0.906 . . . . 0.0 109.427 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -172.16 -173.73 39.07 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.849 ' O ' HG13 ' A' ' 160' ' ' VAL . 57.9 t -120.29 151.64 23.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.227 -1.161 . . . . 0.0 109.491 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.856 HG21 HG22 ' A' ' 151' ' ' VAL . 2.1 p -94.39 98.85 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.274 -0.892 . . . . 0.0 109.466 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 76.2 mm-40 -69.37 -36.69 77.09 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.215 -0.928 . . . . 0.0 109.425 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -134.44 149.63 50.77 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.261 -0.9 . . . . 0.0 109.464 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.856 HG22 HG21 ' A' ' 148' ' ' VAL . 48.0 t -127.3 150.22 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.233 -0.917 . . . . 0.0 109.477 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 152' ' ' ASP . . . . . 0.416 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 93.5 m-20 -136.2 87.77 2.33 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.261 -0.9 . . . . 0.0 109.466 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -66.31 -37.05 84.5 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.274 -0.891 . . . . 0.0 109.463 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 48.3 tp10 -62.62 -44.28 96.69 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.248 -0.907 . . . . 0.0 109.484 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.48 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 21.5 mttt -88.62 0.61 56.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.289 -0.882 . . . . 0.0 109.602 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 156' ' ' SER . . . . . 0.404 ' O ' ' OG ' ' A' ' 156' ' ' SER . 7.5 p 52.51 51.98 15.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.188 -0.945 . . . . 0.0 109.437 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.48 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 41.0 mmm-85 -145.32 140.46 27.76 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.259 -0.901 . . . . 0.0 109.472 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 158' ' ' LEU . . . . . 0.599 ' CD2' HG13 ' A' ' 151' ' ' VAL . 35.2 mt -108.53 134.28 51.52 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.254 -0.904 . . . . 0.0 109.542 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 15.1 tttp -92.47 93.09 8.39 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.224 -0.923 . . . . 0.0 109.374 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.849 HG13 ' O ' ' A' ' 147' ' ' VAL . 41.4 t -124.13 142.01 42.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.222 -0.923 . . . . 0.0 109.519 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 161' ' ' SER . . . . . 0.512 ' CA ' ' HA ' ' A' ' 170' ' ' PRO . 86.7 p -106.31 147.7 28.87 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.263 -0.898 . . . . 0.0 109.436 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 162' ' ' VAL . . . . . 0.533 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 18.1 t -108.49 132.66 55.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.231 -0.918 . . . . 0.0 109.523 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 71.6 m -72.14 85.23 1.03 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.205 -0.934 . . . . 0.0 109.433 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 1.016 HG22 ' CD2' ' A' ' 165' ' ' PHE . 56.4 mt -108.32 139.89 28.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.265 -0.897 . . . . 0.0 109.485 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 165' ' ' PHE . . . . . 1.016 ' CD2' HG22 ' A' ' 164' ' ' ILE . 93.8 m-85 61.05 17.87 8.41 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.221 -0.925 . . . . 0.0 109.503 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 83.81 5.25 88.2 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 82.0 mtp180 -124.07 144.43 49.87 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.184 -1.186 . . . . 0.0 109.432 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -69.17 142.13 54.39 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.261 -0.9 . . . . 0.0 109.443 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.829 ' O ' HG13 ' A' ' 171' ' ' VAL . 15.4 m -124.37 75.81 61.59 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.271 -0.893 . . . . 0.0 109.475 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.512 ' HA ' ' CA ' ' A' ' 161' ' ' SER . 50.0 Cg_endo -47.95 106.45 0.11 Allowed 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.642 2.228 . . . . 0.0 111.784 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.829 HG13 ' O ' ' A' ' 169' ' ' THR . 21.2 m -128.74 155.12 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.293 -0.879 . . . . 0.0 109.478 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.497 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.0 mt-10 -95.04 123.33 38.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.924 . . . . 0.0 109.458 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 173' ' ' LEU . . . . . 0.554 ' HB3' HG13 ' A' ' 178' ' ' VAL . 67.2 mt -125.98 147.91 49.41 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.231 -0.918 . . . . 0.0 109.477 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 174' ' ' ASP . . . . . 0.422 ' OD1' ' HD2' ' A' ' 157' ' ' ARG . 91.7 m-20 -75.84 164.87 25.78 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.216 -0.927 . . . . 0.0 109.441 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.56 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.3 m-30 -60.69 -41.16 94.57 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.211 -0.931 . . . . 0.0 109.495 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 19.3 m -76.06 -26.28 56.38 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.258 -0.901 . . . . 0.0 109.384 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 177' ' ' GLN . . . . . 0.419 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 87.9 mt-30 -69.04 -25.8 64.65 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.31 -0.869 . . . . 0.0 109.465 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.554 HG13 ' HB3' ' A' ' 173' ' ' LEU . 13.9 m -128.41 158.72 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.242 -0.911 . . . . 0.0 109.434 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 179' ' ' GLU . . . . . 0.434 ' HB2' ' HB3' ' A' ' 135' ' ' ARG . 77.8 mt-10 -113.13 149.24 33.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.232 -0.917 . . . . 0.0 109.49 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 180' ' ' LYS . . . . . 0.484 ' HE3' ' O ' ' A' ' 127' ' ' LEU . 30.6 tttm -69.94 135.79 49.85 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.241 -0.912 . . . . 0.0 109.479 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.587 0 O-C-N 121.266 -0.896 . . . . 0.0 109.454 -179.986 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.402 ' HA ' ' HD2' ' A' ' 124' ' ' PRO . 4.0 tmm_? . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.402 ' HD2' ' HA ' ' A' ' 123' ' ' ARG . 50.8 Cg_endo -60.39 143.15 99.47 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.547 2.165 . . . . 0.0 111.829 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' LYS . . . . . 0.668 ' HB3' HD11 ' A' ' 127' ' ' LEU . 84.4 tttt -126.98 140.27 52.43 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.21 -0.931 . . . . 0.0 109.433 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.557 ' HB ' ' CE2' ' A' ' 128' ' ' PHE . 6.2 p -96.21 95.34 8.05 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.269 -0.895 . . . . 0.0 109.537 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.853 HD12 ' N ' ' A' ' 127' ' ' LEU . 3.7 mp -102.24 86.0 2.75 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.246 -0.909 . . . . 0.0 109.507 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.596 ' CE1' ' HG3' ' A' ' 180' ' ' LYS . 74.5 m-85 -81.71 130.51 35.08 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.17 -0.956 . . . . 0.0 109.464 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.472 ' HB2' ' HG3' ' A' ' 132' ' ' GLU . 28.9 mt-10 -131.55 153.85 81.68 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.252 -0.905 . . . . 0.0 109.508 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -52.96 128.14 27.68 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 122.605 2.203 . . . . 0.0 111.776 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 86.5 10.16 74.15 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.472 ' HG3' ' HB2' ' A' ' 129' ' ' GLU . 72.7 mm-40 -96.13 127.26 41.98 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.304 -1.115 . . . . 0.0 109.432 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 5.8 ttm -63.71 134.71 55.84 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.263 -0.898 . . . . 0.0 109.501 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.678 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -123.5 179.03 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.228 -0.92 . . . . 0.0 109.394 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.678 ' H ' HG12 ' A' ' 134' ' ' VAL . 55.1 ttt-85 -135.95 133.53 37.68 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.264 -0.898 . . . . 0.0 109.288 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.598 HG11 ' HB2' ' A' ' 141' ' ' PHE . 90.7 t -106.03 132.06 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.202 -0.937 . . . . 0.0 109.584 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 137' ' ' ASN . . . . . 0.455 ' HB3' ' NH1' ' A' ' 135' ' ' ARG . 32.3 p30 -130.34 18.8 5.35 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.227 -0.921 . . . . 0.0 109.45 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -134.53 143.77 47.62 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.248 -0.907 . . . . 0.0 109.4 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 72.15 177.16 29.01 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -51.14 -20.95 8.44 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.638 2.225 . . . . 0.0 111.757 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' PHE . . . . . 0.598 ' HB2' HG11 ' A' ' 136' ' ' VAL . 93.8 m-85 -86.94 12.92 10.02 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.896 . . . . 0.0 109.45 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 142' ' ' ALA . . . . . 0.455 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -69.57 143.71 53.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.25 -0.907 . . . . 0.0 109.594 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.45 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 19.3 m-20 65.9 50.52 1.49 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.57 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.465 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 49.9 m-85 -144.11 146.26 32.67 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.238 -0.914 . . . . 0.0 109.455 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -99.64 141.35 32.56 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.266 -0.896 . . . . 0.0 109.548 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.44 -173.85 27.39 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.379 -1.488 . . . . 0.0 109.379 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.809 ' O ' HG13 ' A' ' 160' ' ' VAL . 40.1 t -132.19 152.34 36.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.256 -1.143 . . . . 0.0 109.463 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.664 ' CA ' HG22 ' A' ' 160' ' ' VAL . 2.3 p -95.47 118.09 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.227 -0.921 . . . . 0.0 109.486 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 77.1 mm-40 -73.78 -42.18 61.38 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.331 -0.856 . . . . 0.0 109.364 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.459 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 95.3 mt-10 -147.21 162.56 38.64 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.298 -0.876 . . . . 0.0 109.431 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.983 HG13 ' CD2' ' A' ' 158' ' ' LEU . 49.1 t -129.03 153.2 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.216 -0.927 . . . . 0.0 109.459 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 152' ' ' ASP . . . . . 0.4 ' O ' ' N ' ' A' ' 156' ' ' SER . 91.4 m-20 -128.7 97.37 4.66 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.176 -0.953 . . . . 0.0 109.442 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 90.3 m-85 -66.51 -41.59 88.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.232 -0.917 . . . . 0.0 109.453 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -63.12 -40.41 97.54 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.283 -0.885 . . . . 0.0 109.504 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 82.7 mttt -93.36 -0.66 56.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.246 -0.909 . . . . 0.0 109.592 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' SER . . . . . 0.4 ' N ' ' O ' ' A' ' 152' ' ' ASP . 4.5 m 46.22 52.27 10.54 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.239 -0.913 . . . . 0.0 109.426 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.412 ' CG ' ' HB3' ' A' ' 172' ' ' GLU . 7.4 tpt180 -138.08 140.62 40.09 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.298 -0.876 . . . . 0.0 109.451 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 158' ' ' LEU . . . . . 0.983 ' CD2' HG13 ' A' ' 151' ' ' VAL . 41.1 mt -109.04 137.49 46.87 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.243 -0.911 . . . . 0.0 109.597 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 159' ' ' LYS . . . . . 0.459 ' HD2' ' HB2' ' A' ' 150' ' ' GLU . 21.3 mttp -99.78 96.7 7.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.259 -0.9 . . . . 0.0 109.377 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.809 HG13 ' O ' ' A' ' 147' ' ' VAL . 38.6 t -124.5 139.65 50.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.187 -0.946 . . . . 0.0 109.498 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 60.7 p -108.67 147.98 31.1 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.32 -0.862 . . . . 0.0 109.435 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 162' ' ' VAL . . . . . 0.465 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 4.2 t -117.69 133.01 65.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.158 -0.964 . . . . 0.0 109.472 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 31.0 t -83.73 83.04 8.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.306 -0.871 . . . . 0.0 109.457 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.41 ' O ' ' HB3' ' A' ' 165' ' ' PHE . 44.2 mt -102.58 139.26 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.155 -0.966 . . . . 0.0 109.476 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 165' ' ' PHE . . . . . 0.506 ' O ' ' CD2' ' A' ' 165' ' ' PHE . 60.0 t80 63.65 11.91 6.14 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.289 -0.882 . . . . 0.0 109.515 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 85.81 4.11 85.23 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 72.3 ttt180 -116.63 139.07 50.94 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.214 -1.168 . . . . 0.0 109.448 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -68.03 138.73 56.07 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.279 -0.888 . . . . 0.0 109.491 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.548 ' O ' HG13 ' A' ' 171' ' ' VAL . 1.3 m -125.44 77.91 68.33 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.214 -0.929 . . . . 0.0 109.435 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.402 ' HD2' ' HA ' ' A' ' 169' ' ' THR . 50.0 Cg_endo -53.91 103.66 0.1 OUTLIER 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.668 2.245 . . . . 0.0 111.78 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.873 HG23 HD21 ' A' ' 173' ' ' LEU . 31.4 m -129.8 154.46 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.242 -0.912 . . . . 0.0 109.434 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.879 ' C ' HD22 ' A' ' 173' ' ' LEU . 94.9 mt-10 -108.17 130.18 55.14 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.243 -0.911 . . . . 0.0 109.529 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 173' ' ' LEU . . . . . 0.879 HD22 ' C ' ' A' ' 172' ' ' GLU . 2.5 mm? -126.96 157.59 39.1 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.284 -0.885 . . . . 0.0 109.477 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 174' ' ' ASP . . . . . 0.545 ' O ' HG22 ' A' ' 178' ' ' VAL . 94.2 m-20 -77.04 176.19 8.89 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.261 -0.899 . . . . 0.0 109.394 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.422 ' CE1' HD21 ' A' ' 158' ' ' LEU . 7.3 m-30 -65.87 -43.15 89.19 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.222 -0.924 . . . . 0.0 109.417 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 82.4 p -76.77 -26.04 54.07 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.214 -0.929 . . . . 0.0 109.518 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -68.03 -18.95 64.85 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.264 -0.897 . . . . 0.0 109.538 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.545 HG22 ' O ' ' A' ' 174' ' ' ASP . 27.2 m -138.48 162.13 30.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.232 -0.918 . . . . 0.0 109.51 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 179' ' ' GLU . . . . . 0.512 ' O ' ' N ' ' A' ' 135' ' ' ARG . 35.7 mt-10 -127.38 155.9 42.88 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.24 -0.912 . . . . 0.0 109.476 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 180' ' ' LYS . . . . . 0.596 ' HG3' ' CE1' ' A' ' 128' ' ' PHE . 9.5 mtmt -85.48 143.72 28.38 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.245 -0.91 . . . . 0.0 109.488 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.565 0 O-C-N 121.241 -0.912 . . . . 0.0 109.499 179.971 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.5 ' N ' ' CD ' ' A' ' 124' ' ' PRO . 5.4 mtt85 . . . . . 0 N--CA 1.491 1.607 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.5 ' CD ' ' N ' ' A' ' 123' ' ' ARG . 49.5 Cg_endo -56.06 143.99 81.43 Favored 'Trans proline' 0 C--O 1.216 -0.623 0 C-N-CA 122.516 2.144 . . . . 0.0 111.765 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 125' ' ' LYS . . . . . 0.449 ' O ' ' HG3' ' A' ' 180' ' ' LYS . 96.0 mttt -112.56 143.91 42.93 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.285 -0.885 . . . . 0.0 109.519 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.43 ' HA ' ' HE3' ' A' ' 180' ' ' LYS . 44.8 p -108.49 20.79 18.15 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.221 -0.924 . . . . 0.0 109.402 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 58.4 mt -83.37 99.66 10.19 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.271 -0.893 . . . . 0.0 109.532 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.511 ' CE2' ' HD3' ' A' ' 180' ' ' LYS . 71.1 m-85 -82.4 132.48 35.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.242 -0.911 . . . . 0.0 109.431 -179.867 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.469 ' HB2' ' HD2' ' A' ' 130' ' ' PRO . 2.6 pp20? -128.13 138.65 33.44 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.325 -0.859 . . . . 0.0 109.464 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.497 ' HA ' ' O ' ' A' ' 148' ' ' VAL . 49.3 Cg_endo -39.0 128.9 1.35 Allowed 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.469 2.112 . . . . 0.0 111.749 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 89.65 10.08 65.66 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.485 ' O ' HG13 ' A' ' 147' ' ' VAL . 84.8 tt0 -104.16 135.15 46.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.341 -1.094 . . . . 0.0 109.458 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.553 ' HG2' HG22 ' A' ' 147' ' ' VAL . 82.9 mtp -71.9 139.94 49.02 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.201 -0.937 . . . . 0.0 109.534 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.668 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -127.03 178.59 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.183 -0.948 . . . . 0.0 109.372 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.668 ' H ' HG12 ' A' ' 134' ' ' VAL . 75.2 ttt-85 -126.56 144.55 50.84 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.274 -0.891 . . . . 0.0 109.549 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.564 HG12 ' HA ' ' A' ' 142' ' ' ALA . 45.0 t -112.15 132.3 61.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.236 -0.915 . . . . 0.0 109.453 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 137' ' ' ASN . . . . . 0.411 ' C ' ' OD1' ' A' ' 137' ' ' ASN . 48.0 p30 -131.83 14.65 4.82 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.233 -0.917 . . . . 0.0 109.474 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 59.1 t0 -142.18 143.15 32.81 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.234 -0.916 . . . . 0.0 109.49 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 79.87 171.2 41.96 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -55.73 -21.96 34.51 Favored 'Trans proline' 0 C--O 1.216 -0.625 0 C-N-CA 122.601 2.201 . . . . 0.0 111.813 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' PHE . . . . . 0.529 ' CZ ' HG11 ' A' ' 171' ' ' VAL . 99.0 m-85 -85.21 5.67 29.2 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.13 -0.981 . . . . 0.0 109.54 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 142' ' ' ALA . . . . . 0.564 ' HA ' HG12 ' A' ' 136' ' ' VAL . . . -69.15 149.01 49.11 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.272 -0.892 . . . . 0.0 109.416 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.493 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 30.3 t0 75.13 28.67 1.01 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.174 -0.954 . . . . 0.0 109.45 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.445 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 90.2 m-85 -135.77 145.0 46.1 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.263 -0.898 . . . . 0.0 109.456 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 74.0 m-20 -97.9 140.22 32.58 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.26 -0.9 . . . . 0.0 109.415 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -153.85 -173.06 22.53 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.792 ' O ' HG13 ' A' ' 160' ' ' VAL . 44.9 t -129.08 152.63 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.248 -1.148 . . . . 0.0 109.418 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.671 HG21 HG22 ' A' ' 151' ' ' VAL . 2.5 p -92.52 107.97 19.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.294 -0.879 . . . . 0.0 109.398 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.476 ' HB2' ' HE3' ' A' ' 159' ' ' LYS . 75.1 mm-40 -70.63 -39.23 73.83 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.224 -0.923 . . . . 0.0 109.365 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.46 ' HB2' ' HE2' ' A' ' 159' ' ' LYS . 92.4 mt-10 -139.41 157.5 45.75 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.239 -0.913 . . . . 0.0 109.393 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.849 HG13 ' CD2' ' A' ' 158' ' ' LEU . 48.5 t -127.29 151.04 33.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.274 -0.891 . . . . 0.0 109.481 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 152' ' ' ASP . . . . . 0.401 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 88.1 m-20 -134.43 87.7 2.38 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.223 -0.923 . . . . 0.0 109.436 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -63.34 -39.45 94.59 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.259 -0.901 . . . . 0.0 109.461 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -62.27 -42.15 99.1 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.18 -0.95 . . . . 0.0 109.506 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.412 ' O ' ' C ' ' A' ' 156' ' ' SER . 43.5 mttp -91.19 5.17 50.14 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.186 -0.946 . . . . 0.0 109.61 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 156' ' ' SER . . . . . 0.517 ' HA ' ' CZ ' ' A' ' 175' ' ' PHE . 0.3 OUTLIER 43.91 51.8 6.8 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.187 -0.945 . . . . 0.0 109.472 -179.943 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.469 ' HD2' ' OD1' ' A' ' 174' ' ' ASP . 9.3 tpt180 -145.44 137.14 25.32 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.257 -0.902 . . . . 0.0 109.402 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 158' ' ' LEU . . . . . 0.849 ' CD2' HG13 ' A' ' 151' ' ' VAL . 46.2 mt -108.34 136.2 48.37 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 109.53 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 159' ' ' LYS . . . . . 0.476 ' HE3' ' HB2' ' A' ' 149' ' ' GLU . 14.2 ttpt -95.19 109.2 21.33 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.327 -0.858 . . . . 0.0 109.442 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.792 HG13 ' O ' ' A' ' 147' ' ' VAL . 39.2 t -127.84 142.0 44.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -0.921 . . . . 0.0 109.464 -179.88 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 161' ' ' SER . . . . . 0.486 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 96.1 p -107.0 147.44 29.89 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.191 -0.943 . . . . 0.0 109.504 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 162' ' ' VAL . . . . . . . . . . . . . 26.1 t -119.21 132.05 70.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.31 -0.869 . . . . 0.0 109.565 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 32.0 t -83.31 83.0 8.03 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.217 -0.927 . . . . 0.0 109.433 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.93 HG22 ' CD2' ' A' ' 165' ' ' PHE . 43.9 mt -106.57 142.95 18.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.241 -0.912 . . . . 0.0 109.494 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 165' ' ' PHE . . . . . 0.93 ' CD2' HG22 ' A' ' 164' ' ' ILE . 93.1 m-85 62.38 13.92 6.45 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.272 -0.893 . . . . 0.0 109.5 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 81.59 10.12 84.79 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 39.0 mtm105 -122.85 140.84 52.52 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.225 -1.162 . . . . 0.0 109.453 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -72.08 137.29 46.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.208 -0.933 . . . . 0.0 109.497 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.685 ' O ' HG13 ' A' ' 171' ' ' VAL . 59.3 m -129.82 77.02 77.55 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.244 -0.91 . . . . 0.0 109.44 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.486 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 50.6 Cg_endo -53.19 111.47 0.68 Allowed 'Trans proline' 0 C--O 1.214 -0.687 0 C-N-CA 122.579 2.186 . . . . 0.0 111.807 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.685 HG13 ' O ' ' A' ' 169' ' ' THR . 20.9 m -130.44 155.27 41.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.288 -0.883 . . . . 0.0 109.493 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.75 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.2 mt-10 -104.57 135.81 45.28 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.268 -0.895 . . . . 0.0 109.528 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 173' ' ' LEU . . . . . 0.75 HD23 ' O ' ' A' ' 172' ' ' GLU . 63.0 mt -133.91 148.28 51.2 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.316 -0.865 . . . . 0.0 109.576 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 174' ' ' ASP . . . . . 0.482 ' O ' HG22 ' A' ' 178' ' ' VAL . 91.4 m-20 -68.91 171.16 8.42 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.283 -0.886 . . . . 0.0 109.4 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.548 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 3.6 m-30 -65.29 -47.58 76.13 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.206 -0.934 . . . . 0.0 109.463 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 14.6 m -70.73 -28.03 64.41 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.315 -0.865 . . . . 0.0 109.498 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 177' ' ' GLN . . . . . 0.407 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 91.0 mt-30 -68.07 -20.64 64.97 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.306 -0.871 . . . . 0.0 109.473 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.632 HG11 ' HB2' ' A' ' 173' ' ' LEU . 13.7 m -131.23 160.29 42.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.278 -0.888 . . . . 0.0 109.484 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 179' ' ' GLU . . . . . 0.488 ' O ' ' N ' ' A' ' 135' ' ' ARG . 55.1 mt-10 -128.65 167.54 17.06 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.183 -0.948 . . . . 0.0 109.513 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 180' ' ' LYS . . . . . 0.511 ' HD3' ' CE2' ' A' ' 128' ' ' PHE . 29.0 mmtp -66.36 145.83 55.26 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.275 -0.89 . . . . 0.0 109.497 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.502 0 O-C-N 121.139 -0.975 . . . . 0.0 109.48 179.973 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 55.0 mtm-85 . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -56.36 145.09 80.27 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.578 2.185 . . . . 0.0 111.763 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 12.3 mtpt -90.56 151.27 21.4 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.242 -0.911 . . . . 0.0 109.462 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.486 ' HA ' ' CE2' ' A' ' 128' ' ' PHE . 28.8 p -88.15 15.1 7.95 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.218 -0.926 . . . . 0.0 109.458 -179.911 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 47.5 mt -94.41 92.38 7.12 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.247 -0.908 . . . . 0.0 109.488 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.505 ' CD2' HD21 ' A' ' 158' ' ' LEU . 69.0 m-85 -106.27 141.09 38.19 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.222 -0.923 . . . . 0.0 109.473 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.53 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.9 OUTLIER -144.55 157.73 55.14 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.26 -0.9 . . . . 0.0 109.394 179.959 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.53 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.2 Cg_endo -49.51 128.18 20.1 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.625 2.217 . . . . 0.0 111.805 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 96.1 -3.89 64.74 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.463 ' OE1' ' HA ' ' A' ' 128' ' ' PHE . 88.2 mt-10 -92.38 129.88 38.2 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.14 -1.212 . . . . 0.0 109.5 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.492 ' O ' ' HB3' ' A' ' 181' ' ' ALA . 43.5 ttm -77.13 145.7 37.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.237 -0.914 . . . . 0.0 109.353 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.683 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -129.76 178.66 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.198 -0.939 . . . . 0.0 109.404 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.683 ' H ' HG12 ' A' ' 134' ' ' VAL . 58.6 ttt180 -131.61 140.95 49.54 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.308 -0.87 . . . . 0.0 109.426 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.607 HG22 ' CD1' ' A' ' 173' ' ' LEU . 40.6 t -113.21 135.86 51.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.222 -0.923 . . . . 0.0 109.54 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 137' ' ' ASN . . . . . 0.446 ' O ' ' OD1' ' A' ' 138' ' ' ASP . 29.0 p30 -128.8 18.04 6.22 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.273 -0.892 . . . . 0.0 109.537 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.497 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 91.3 m-20 -139.43 164.37 30.03 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.208 -0.932 . . . . 0.0 109.497 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 57.94 172.86 0.32 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -53.26 -21.1 16.32 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.581 2.187 . . . . 0.0 111.777 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' PHE . . . . . 0.559 ' CZ ' HG11 ' A' ' 171' ' ' VAL . 91.8 m-85 -82.18 6.36 16.83 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.216 -0.928 . . . . 0.0 109.458 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 142' ' ' ALA . . . . . 0.423 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -62.62 143.24 57.52 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.278 -0.889 . . . . 0.0 109.488 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.423 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 10.2 m-20 67.06 48.69 1.2 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.257 -0.902 . . . . 0.0 109.413 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.494 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 43.6 m-85 -146.39 129.08 16.16 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.239 -0.913 . . . . 0.0 109.465 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 68.5 m-20 -90.87 138.04 31.9 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.227 -0.921 . . . . 0.0 109.509 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -152.71 177.39 30.44 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.851 ' O ' HG13 ' A' ' 160' ' ' VAL . 38.9 t -118.95 156.52 20.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.273 -1.134 . . . . 0.0 109.447 179.87 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.9 HG11 HG22 ' A' ' 151' ' ' VAL . 50.9 t -89.36 106.84 17.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.161 -0.962 . . . . 0.0 109.574 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -73.58 -31.84 63.81 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.247 -0.908 . . . . 0.0 109.392 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -144.42 148.63 34.87 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.282 -0.886 . . . . 0.0 109.25 179.852 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.9 HG22 HG11 ' A' ' 148' ' ' VAL . 37.1 t -125.55 146.43 31.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.157 -0.964 . . . . 0.0 109.644 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -132.28 87.89 2.48 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.279 -0.888 . . . . 0.0 109.412 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -61.1 -40.41 93.64 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.195 -0.941 . . . . 0.0 109.442 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -62.39 -40.53 96.76 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.21 -0.932 . . . . 0.0 109.51 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -91.52 2.45 56.43 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.217 -0.927 . . . . 0.0 109.649 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 13.6 p 45.21 52.62 8.52 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.154 -0.966 . . . . 0.0 109.394 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.639 ' C ' HD12 ' A' ' 158' ' ' LEU . 0.0 OUTLIER -136.67 156.28 48.75 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.202 -0.937 . . . . 0.0 109.543 179.919 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 158' ' ' LEU . . . . . 0.845 HD11 ' CE1' ' A' ' 175' ' ' PHE . 7.4 mp -120.39 123.66 43.61 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.257 -0.902 . . . . 0.0 109.525 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 18.0 tttm -91.01 92.18 8.63 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.25 -0.906 . . . . 0.0 109.378 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.851 HG13 ' O ' ' A' ' 147' ' ' VAL . 21.7 t -116.22 150.27 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.199 -0.938 . . . . 0.0 109.359 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 161' ' ' SER . . . . . 0.467 ' OG ' ' N ' ' A' ' 170' ' ' PRO . 18.3 t -119.74 131.32 55.34 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.311 -0.868 . . . . 0.0 109.431 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 162' ' ' VAL . . . . . 0.494 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 11.7 t -102.16 131.98 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.243 -0.91 . . . . 0.0 109.387 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 40.5 t -77.64 81.52 4.08 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.273 -0.892 . . . . 0.0 109.43 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.684 HG22 ' CD1' ' A' ' 165' ' ' PHE . 68.5 mt -100.18 142.18 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.305 -0.872 . . . . 0.0 109.483 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 165' ' ' PHE . . . . . 0.684 ' CD1' HG22 ' A' ' 164' ' ' ILE . 7.7 m-30 64.47 18.09 11.17 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.16 -0.963 . . . . 0.0 109.517 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 81.81 4.23 90.38 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 70.1 mtm180 -124.12 142.17 51.43 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.177 -1.19 . . . . 0.0 109.38 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -68.17 144.53 54.93 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 109.521 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.781 ' O ' HG13 ' A' ' 171' ' ' VAL . 2.9 m -128.09 73.82 79.34 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.249 -0.907 . . . . 0.0 109.414 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.467 ' N ' ' OG ' ' A' ' 161' ' ' SER . 50.2 Cg_endo -49.09 105.98 0.1 Allowed 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.585 2.19 . . . . 0.0 111.794 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.781 HG13 ' O ' ' A' ' 169' ' ' THR . 19.3 m -133.67 153.94 37.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.295 -0.878 . . . . 0.0 109.359 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.72 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.2 mt-10 -97.23 135.81 38.63 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.259 -0.901 . . . . 0.0 109.489 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 173' ' ' LEU . . . . . 0.72 HD23 ' O ' ' A' ' 172' ' ' GLU . 28.9 mt -124.97 160.06 29.8 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.256 -0.902 . . . . 0.0 109.421 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 174' ' ' ASP . . . . . 0.471 ' HB2' ' HB2' ' A' ' 177' ' ' GLN . 92.7 m-20 -83.54 160.78 21.4 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.184 -0.948 . . . . 0.0 109.521 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.845 ' CE1' HD11 ' A' ' 158' ' ' LEU . 4.5 m-85 -53.67 -49.95 66.86 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.321 -0.862 . . . . 0.0 109.561 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 15.5 m -74.67 -24.36 58.79 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.162 -0.961 . . . . 0.0 109.546 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 177' ' ' GLN . . . . . 0.69 ' NE2' HD22 ' A' ' 173' ' ' LEU . 61.9 tt0 -64.6 -27.21 68.79 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.231 -0.918 . . . . 0.0 109.425 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.66 HG11 HD12 ' A' ' 173' ' ' LEU . 13.7 m -127.97 161.83 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.334 -0.854 . . . . 0.0 109.482 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 179' ' ' GLU . . . . . 0.43 ' N ' ' O ' ' A' ' 135' ' ' ARG . 61.6 mt-10 -118.32 148.19 42.73 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.207 -0.933 . . . . 0.0 109.489 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -66.95 130.91 44.67 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.32 -0.863 . . . . 0.0 109.427 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 181' ' ' ALA . . . . . 0.492 ' HB3' ' O ' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.558 0 O-C-N 121.259 -0.901 . . . . 0.0 109.461 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.518 0 CA-C-O 121.248 0.547 . . . . 0.0 109.531 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -56.0 146.04 71.28 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.583 2.189 . . . . 0.0 111.748 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' LYS . . . . . 0.41 ' O ' ' HD2' ' A' ' 180' ' ' LYS . 68.8 mttm -92.28 144.63 25.2 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.27 -0.893 . . . . 0.0 109.485 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 46.6 p -93.26 11.29 28.55 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.316 -0.865 . . . . 0.0 109.435 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 47.8 mt -96.91 95.32 7.76 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.29 -0.881 . . . . 0.0 109.494 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.416 ' CE1' ' HB2' ' A' ' 180' ' ' LYS . 68.8 m-85 -99.48 135.67 40.55 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.299 -0.875 . . . . 0.0 109.463 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.474 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.0 OUTLIER -125.87 153.54 73.52 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.23 -0.919 . . . . 0.0 109.503 179.949 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.474 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 49.4 Cg_endo -47.88 134.59 23.13 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.636 2.224 . . . . 0.0 111.72 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 85.45 3.72 86.47 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 48.9 tp10 -89.9 136.11 33.24 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.168 -1.195 . . . . 0.0 109.474 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.914 ' SD ' HG22 ' A' ' 147' ' ' VAL . 92.9 mmm -74.82 148.55 40.19 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.253 -0.904 . . . . 0.0 109.48 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.836 HG21 HG23 ' A' ' 148' ' ' VAL . 2.5 t -139.06 179.18 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.285 -0.885 . . . . 0.0 109.373 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.686 ' H ' HG12 ' A' ' 134' ' ' VAL . 19.8 ttp85 -137.58 142.41 41.31 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.323 -0.861 . . . . 0.0 109.445 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.46 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 43.8 t -106.45 132.16 54.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.224 -0.923 . . . . 0.0 109.533 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 29.0 p30 -118.48 13.33 13.47 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.337 -0.852 . . . . 0.0 109.425 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.432 ' H ' HG12 ' A' ' 136' ' ' VAL . 51.9 p30 -151.89 169.93 21.07 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.235 -0.916 . . . . 0.0 109.461 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 67.4 168.79 3.94 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -56.71 -18.11 25.45 Favored 'Trans proline' 0 C--O 1.214 -0.702 0 C-N-CA 122.565 2.177 . . . . 0.0 111.848 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' PHE . . . . . 0.726 ' CE2' HG11 ' A' ' 171' ' ' VAL . 92.5 m-85 -88.12 8.1 28.46 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.28 -0.888 . . . . 0.0 109.48 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 142' ' ' ALA . . . . . 0.481 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -61.34 150.68 34.35 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.213 -0.929 . . . . 0.0 109.458 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.448 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 63.2 m-20 62.63 42.4 8.44 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.243 -0.911 . . . . 0.0 109.446 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.481 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 51.3 m-85 -146.9 134.52 21.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.165 -0.959 . . . . 0.0 109.516 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -87.68 141.98 28.18 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.898 . . . . 0.0 109.453 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -149.61 177.89 27.48 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.914 HG22 ' SD ' ' A' ' 133' ' ' MET . 35.6 t -119.92 156.34 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.306 -1.114 . . . . 0.0 109.462 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.836 HG23 HG21 ' A' ' 134' ' ' VAL . 61.3 t -87.54 103.18 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.22 -0.925 . . . . 0.0 109.457 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 75.2 mm-40 -67.63 -38.69 84.23 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.268 -0.895 . . . . 0.0 109.415 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -153.77 150.81 28.88 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.232 -0.918 . . . . 0.0 109.426 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.708 HG13 ' CD2' ' A' ' 158' ' ' LEU . 58.9 t -122.68 154.41 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.269 -0.895 . . . . 0.0 109.475 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -135.12 94.83 3.19 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.301 -0.875 . . . . 0.0 109.459 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 81.1 m-85 -67.32 -42.44 83.65 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.301 -0.874 . . . . 0.0 109.487 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -62.63 -36.67 83.56 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.212 -0.93 . . . . 0.0 109.412 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.47 ' O ' ' HG2' ' A' ' 155' ' ' LYS . 57.0 tttm -95.59 1.4 53.73 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.202 -0.936 . . . . 0.0 109.617 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 41.1 t 46.6 52.4 11.09 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.171 -0.956 . . . . 0.0 109.486 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 7.7 tpt180 -141.28 138.25 33.07 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.256 -0.903 . . . . 0.0 109.417 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 158' ' ' LEU . . . . . 0.708 ' CD2' HG13 ' A' ' 151' ' ' VAL . 55.2 mt -107.25 131.66 53.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.221 -0.924 . . . . 0.0 109.496 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 60.3 tttm -96.52 105.78 17.93 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.874 . . . . 0.0 109.373 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.698 HG13 ' O ' ' A' ' 147' ' ' VAL . 38.6 t -123.36 145.75 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.265 -0.897 . . . . 0.0 109.578 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 161' ' ' SER . . . . . 0.404 ' OG ' ' HA ' ' A' ' 170' ' ' PRO . 11.4 m -118.85 137.01 53.72 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.33 -0.856 . . . . 0.0 109.359 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 162' ' ' VAL . . . . . 0.55 HG21 ' HB3' ' A' ' 141' ' ' PHE . 25.2 t -107.85 133.68 51.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.292 -0.88 . . . . 0.0 109.634 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 33.8 t -87.31 83.49 7.35 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.233 -0.917 . . . . 0.0 109.193 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 1.0 HG22 ' CD2' ' A' ' 165' ' ' PHE . 31.7 mt -105.15 142.24 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.22 -0.925 . . . . 0.0 109.573 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 165' ' ' PHE . . . . . 1.0 ' CD2' HG22 ' A' ' 164' ' ' ILE . 98.5 m-85 60.57 19.8 9.66 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.263 -0.898 . . . . 0.0 109.523 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 76.18 12.39 84.16 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 51.1 mtt180 -121.68 139.54 53.42 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.259 -1.142 . . . . 0.0 109.433 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -74.29 140.94 45.26 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.194 -0.941 . . . . 0.0 109.568 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.56 ' O ' HG13 ' A' ' 171' ' ' VAL . 0.2 OUTLIER -127.03 73.99 76.76 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.317 -0.864 . . . . 0.0 109.443 179.953 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.404 ' HA ' ' OG ' ' A' ' 161' ' ' SER . 49.8 Cg_endo -54.17 100.28 0.06 OUTLIER 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.567 2.178 . . . . 0.0 111.81 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.726 HG11 ' CE2' ' A' ' 141' ' ' PHE . 26.9 m -126.96 153.4 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.278 -0.889 . . . . 0.0 109.489 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.778 ' O ' HD23 ' A' ' 173' ' ' LEU . 57.0 mp0 -102.02 134.8 44.66 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.292 -0.88 . . . . 0.0 109.563 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 173' ' ' LEU . . . . . 0.778 HD23 ' O ' ' A' ' 172' ' ' GLU . 53.4 mt -132.95 147.8 52.28 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.245 -0.91 . . . . 0.0 109.455 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 174' ' ' ASP . . . . . 0.414 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 90.7 m-20 -70.89 174.32 6.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.262 -0.899 . . . . 0.0 109.458 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.529 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 3.8 m-30 -65.13 -44.66 87.94 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.212 -0.93 . . . . 0.0 109.457 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 94.8 p -73.73 -28.81 61.9 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.205 -0.935 . . . . 0.0 109.463 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 177' ' ' GLN . . . . . 0.414 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 82.1 mt-30 -63.49 -25.71 68.38 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.283 -0.885 . . . . 0.0 109.49 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.473 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 6.1 m -130.02 160.79 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.266 -0.896 . . . . 0.0 109.485 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 179' ' ' GLU . . . . . 0.478 ' OE1' ' CZ ' ' A' ' 135' ' ' ARG . 79.6 mt-10 -112.14 147.61 35.75 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.278 -0.889 . . . . 0.0 109.465 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 180' ' ' LYS . . . . . 0.416 ' HB2' ' CE1' ' A' ' 128' ' ' PHE . 19.1 tttm -76.02 132.04 39.9 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.286 -0.884 . . . . 0.0 109.465 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.552 0 O-C-N 121.2 -0.937 . . . . 0.0 109.518 -179.957 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 12.8 mtp180 . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -55.75 146.71 64.8 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.606 2.204 . . . . 0.0 111.764 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' LYS . . . . . 0.456 ' HB2' ' CD ' ' A' ' 180' ' ' LYS . 67.2 mttt -95.18 146.69 24.15 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.889 . . . . 0.0 109.43 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 49.7 p -102.55 16.89 25.07 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -0.907 . . . . 0.0 109.426 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 44.6 mt -94.81 96.36 9.3 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.157 -0.964 . . . . 0.0 109.433 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 72.8 m-85 -98.43 132.51 43.82 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.277 -0.889 . . . . 0.0 109.508 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.542 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.1 OUTLIER -143.62 156.69 59.72 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.328 -0.858 . . . . 0.0 109.412 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.542 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.4 Cg_endo -47.34 132.19 19.11 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.552 2.168 . . . . 0.0 111.737 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 93.59 0.67 66.74 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -103.68 139.99 38.19 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.234 -1.157 . . . . 0.0 109.435 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 87.7 mtp -83.78 152.69 24.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.317 -0.865 . . . . 0.0 109.491 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.836 ' CG2' HG23 ' A' ' 148' ' ' VAL . 2.5 t -136.82 179.21 3.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.258 -0.901 . . . . 0.0 109.345 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.683 ' H ' HG12 ' A' ' 134' ' ' VAL . 53.0 ttm-85 -135.08 139.02 44.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.232 -0.918 . . . . 0.0 109.456 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.775 HG22 ' CD1' ' A' ' 173' ' ' LEU . 50.0 t -107.1 131.23 57.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.266 -0.896 . . . . 0.0 109.494 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 137' ' ' ASN . . . . . 0.421 ' O ' ' OD1' ' A' ' 138' ' ' ASP . 11.4 p30 -122.54 16.32 10.39 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.279 -0.888 . . . . 0.0 109.43 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.421 ' OD1' ' O ' ' A' ' 137' ' ' ASN . 93.5 m-20 -135.67 160.16 39.39 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.229 -0.919 . . . . 0.0 109.489 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 60.35 173.08 0.82 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -53.53 -20.37 15.95 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.609 2.206 . . . . 0.0 111.803 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' PHE . . . . . 0.571 ' HB3' HG21 ' A' ' 162' ' ' VAL . 99.4 m-85 -80.57 4.07 19.71 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.222 -0.924 . . . . 0.0 109.481 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' ALA . . . . . 0.497 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -63.99 150.84 44.35 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.139 -0.976 . . . . 0.0 109.474 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.444 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 57.9 m-20 62.83 47.53 4.5 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.275 -0.89 . . . . 0.0 109.398 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.497 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 50.2 m-85 -149.34 144.56 26.51 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.308 -0.87 . . . . 0.0 109.493 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 74.4 m-20 -97.9 145.52 26.36 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.27 -0.894 . . . . 0.0 109.497 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -154.21 174.68 32.62 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.559 HG12 ' N ' ' A' ' 148' ' ' VAL . 47.3 t -114.4 165.16 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.223 -1.163 . . . . 0.0 109.386 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.836 HG23 ' CG2' ' A' ' 134' ' ' VAL . 51.0 t -101.57 123.66 54.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.273 -0.892 . . . . 0.0 109.512 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 74.7 mm-40 -99.76 -44.55 6.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.256 -0.903 . . . . 0.0 109.435 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -133.24 155.61 49.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.237 -0.914 . . . . 0.0 109.348 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.52 HG11 ' CZ ' ' A' ' 153' ' ' TYR . 38.7 t -122.79 151.15 26.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.29 -0.881 . . . . 0.0 109.565 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 152' ' ' ASP . . . . . 0.408 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 93.3 m-20 -135.3 78.93 1.76 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.292 -0.88 . . . . 0.0 109.373 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 153' ' ' TYR . . . . . 0.52 ' CZ ' HG11 ' A' ' 151' ' ' VAL . 98.1 m-85 -62.68 -37.3 85.9 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.197 -0.939 . . . . 0.0 109.651 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -64.35 -40.95 96.88 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.277 -0.889 . . . . 0.0 109.593 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.463 ' O ' ' HG3' ' A' ' 157' ' ' ARG . 28.9 mttt -87.1 3.13 47.44 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.211 -0.93 . . . . 0.0 109.627 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 156' ' ' SER . . . . . 0.492 ' HA ' ' CZ ' ' A' ' 175' ' ' PHE . 58.1 m 52.83 52.59 13.63 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.224 -0.922 . . . . 0.0 109.469 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.472 ' CG ' ' O ' ' A' ' 156' ' ' SER . 47.0 mtt180 -157.81 155.43 29.72 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.278 -0.889 . . . . 0.0 109.44 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 158' ' ' LEU . . . . . 0.66 HD21 ' CE1' ' A' ' 175' ' ' PHE . 12.0 mt -119.83 137.0 54.26 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.243 -0.911 . . . . 0.0 109.57 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 14.8 tttt -83.63 105.34 14.48 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.302 -0.874 . . . . 0.0 109.308 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.769 HG22 HG22 ' A' ' 148' ' ' VAL . 57.8 t -123.11 145.27 30.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.205 -0.934 . . . . 0.0 109.596 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 14.9 m -111.86 140.85 46.17 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.257 -0.902 . . . . 0.0 109.444 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 162' ' ' VAL . . . . . 0.571 HG21 ' HB3' ' A' ' 141' ' ' PHE . 14.0 t -110.46 133.14 56.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.206 -0.934 . . . . 0.0 109.493 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 60.7 p -83.36 82.56 8.23 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.191 -0.943 . . . . 0.0 109.435 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.536 HG22 ' CD1' ' A' ' 165' ' ' PHE . 54.5 mt -107.23 139.11 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.286 -0.884 . . . . 0.0 109.537 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 165' ' ' PHE . . . . . 0.536 ' CD1' HG22 ' A' ' 164' ' ' ILE . 9.4 m-85 66.2 18.55 10.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.282 -0.886 . . . . 0.0 109.454 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 74.4 12.07 82.22 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -123.85 142.42 51.14 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.207 -1.172 . . . . 0.0 109.462 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -72.76 137.23 45.73 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.287 -0.883 . . . . 0.0 109.471 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.709 ' O ' HG13 ' A' ' 171' ' ' VAL . 18.6 m -129.96 74.18 80.79 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.203 -0.936 . . . . 0.0 109.486 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -51.04 112.72 0.85 Allowed 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.607 2.205 . . . . 0.0 111.73 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.709 HG13 ' O ' ' A' ' 169' ' ' THR . 28.7 m -133.11 153.46 37.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.308 -0.87 . . . . 0.0 109.423 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.675 ' O ' HD23 ' A' ' 173' ' ' LEU . 94.8 mt-10 -95.68 130.28 42.62 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.24 -0.913 . . . . 0.0 109.5 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 173' ' ' LEU . . . . . 0.775 ' CD1' HG22 ' A' ' 136' ' ' VAL . 51.6 mt -128.08 146.4 50.7 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.327 -0.858 . . . . 0.0 109.404 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 57.1 m-20 -67.77 171.06 6.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.268 -0.895 . . . . 0.0 109.451 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.66 ' CE1' HD21 ' A' ' 158' ' ' LEU . 6.2 m-30 -64.64 -49.19 71.99 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.248 -0.908 . . . . 0.0 109.386 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 87.0 p -74.94 -18.64 60.36 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.169 -0.957 . . . . 0.0 109.453 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 177' ' ' GLN . . . . . 0.651 ' NE2' HD22 ' A' ' 173' ' ' LEU . 63.8 tt0 -70.66 -20.85 62.67 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.296 -0.878 . . . . 0.0 109.483 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.556 HG11 ' HB2' ' A' ' 173' ' ' LEU . 4.7 m -130.2 159.2 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.285 -0.885 . . . . 0.0 109.403 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 179' ' ' GLU . . . . . 0.405 ' HB2' ' HB3' ' A' ' 135' ' ' ARG . 73.0 mt-10 -115.6 151.96 33.98 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.189 -0.944 . . . . 0.0 109.525 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 180' ' ' LYS . . . . . 0.456 ' CD ' ' HB2' ' A' ' 125' ' ' LYS . 21.1 tttt -75.7 136.42 40.36 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.249 -0.907 . . . . 0.0 109.511 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.516 0 O-C-N 121.292 -0.88 . . . . 0.0 109.527 179.978 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.522 ' CB ' ' CD ' ' A' ' 124' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 . . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.522 ' CD ' ' CB ' ' A' ' 123' ' ' ARG . 50.2 Cg_endo -55.52 143.86 76.37 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 C-N-CA 122.652 2.235 . . . . 0.0 111.784 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 59.8 mttp -104.53 154.02 20.43 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.297 -0.877 . . . . 0.0 109.478 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 52.1 p -99.63 28.83 4.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.276 -0.89 . . . . 0.0 109.471 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 58.7 mt -92.72 94.66 9.11 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.25 -0.906 . . . . 0.0 109.457 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.683 ' CD2' HD21 ' A' ' 158' ' ' LEU . 83.9 m-85 -91.77 129.78 37.67 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.232 -0.917 . . . . 0.0 109.564 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.434 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.2 OUTLIER -123.02 155.03 64.71 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.287 -0.883 . . . . 0.0 109.464 179.979 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.434 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 49.5 Cg_endo -51.22 128.89 26.78 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.648 2.232 . . . . 0.0 111.815 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 91.52 2.93 69.58 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.433 ' OE2' ' HE3' ' A' ' 180' ' ' LYS . 65.7 tt0 -88.5 141.87 28.18 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.154 -1.204 . . . . 0.0 109.485 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.925 ' SD ' HG22 ' A' ' 147' ' ' VAL . 80.4 mmm -80.33 137.56 36.59 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.208 -0.932 . . . . 0.0 109.556 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.75 HG21 ' CG2' ' A' ' 148' ' ' VAL . 2.5 t -129.22 179.28 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.247 -0.908 . . . . 0.0 109.285 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.685 ' H ' HG12 ' A' ' 134' ' ' VAL . 37.4 ttm180 -137.83 142.6 40.77 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.123 -0.986 . . . . 0.0 109.48 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.47 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 59.3 t -110.95 133.02 57.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.302 -0.874 . . . . 0.0 109.512 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 40.7 p30 -124.75 19.86 8.55 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.176 -0.952 . . . . 0.0 109.384 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.444 ' HB3' ' HG3' ' A' ' 177' ' ' GLN . 55.9 t0 -143.13 153.77 43.23 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.289 -0.882 . . . . 0.0 109.481 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.44 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 69.84 172.07 9.52 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -52.88 -16.9 6.62 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.582 2.188 . . . . 0.0 111.71 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' PHE . . . . . 0.525 ' CD1' HD11 ' A' ' 164' ' ' ILE . 99.5 m-85 -88.15 10.83 18.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.299 -0.876 . . . . 0.0 109.426 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 142' ' ' ALA . . . . . 0.449 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -64.27 145.79 55.42 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.276 -0.89 . . . . 0.0 109.554 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.449 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 50.8 m-20 63.54 46.88 4.02 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.33 -0.856 . . . . 0.0 109.622 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.6 ' HB3' HG13 ' A' ' 162' ' ' VAL . 39.3 m-85 -143.38 140.86 30.68 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.176 -0.952 . . . . 0.0 109.599 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 73.5 m-20 -95.6 142.05 28.38 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.271 -0.893 . . . . 0.0 109.492 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -151.29 173.16 30.76 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.925 HG22 ' SD ' ' A' ' 133' ' ' MET . 22.6 t -117.9 153.04 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.154 -1.204 . . . . 0.0 109.401 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.858 HG22 HG22 ' A' ' 160' ' ' VAL . 57.5 t -88.87 109.67 20.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.234 -0.916 . . . . 0.0 109.521 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -68.13 -40.9 82.37 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.262 -0.899 . . . . 0.0 109.418 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.451 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 95.6 mt-10 -153.93 157.53 39.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.207 -0.933 . . . . 0.0 109.395 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.498 HG21 ' O ' ' A' ' 128' ' ' PHE . 43.9 t -120.99 144.27 30.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.233 -0.917 . . . . 0.0 109.462 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -123.15 95.61 4.67 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.212 -0.93 . . . . 0.0 109.493 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -66.14 -42.24 89.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.183 -0.948 . . . . 0.0 109.51 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 76.2 mm-40 -59.58 -43.37 93.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.29 -0.881 . . . . 0.0 109.427 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 23.7 mttt -87.35 -10.25 52.69 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.29 -0.881 . . . . 0.0 109.495 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 1.6 m 55.62 53.28 9.81 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.23 -0.919 . . . . 0.0 109.432 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.573 ' C ' HD12 ' A' ' 158' ' ' LEU . 88.5 mmt-85 -139.47 162.55 34.79 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.277 -0.889 . . . . 0.0 109.512 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 158' ' ' LEU . . . . . 0.748 HD11 ' CE1' ' A' ' 175' ' ' PHE . 7.0 mp -122.55 131.31 53.78 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.278 -0.889 . . . . 0.0 109.542 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 159' ' ' LYS . . . . . 0.451 ' HD2' ' HB2' ' A' ' 150' ' ' GLU . 23.8 mttm -97.14 98.6 10.17 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.198 -0.939 . . . . 0.0 109.233 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.858 HG22 HG22 ' A' ' 148' ' ' VAL . 30.0 t -123.17 145.68 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.236 -0.915 . . . . 0.0 109.662 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 161' ' ' SER . . . . . 0.466 ' CB ' ' HA ' ' A' ' 170' ' ' PRO . 88.1 p -112.71 148.29 35.02 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.277 -0.89 . . . . 0.0 109.333 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 162' ' ' VAL . . . . . 0.6 HG13 ' HB3' ' A' ' 144' ' ' PHE . 18.0 t -113.4 128.32 70.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.215 -0.928 . . . . 0.0 109.626 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 36.5 t -80.75 80.76 7.16 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.29 -0.881 . . . . 0.0 109.503 179.85 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.525 HD11 ' CD1' ' A' ' 141' ' ' PHE . 57.9 mt -97.3 137.64 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.311 -0.868 . . . . 0.0 109.318 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 165' ' ' PHE . . . . . 0.508 ' O ' ' CD2' ' A' ' 165' ' ' PHE . 46.9 t80 63.87 14.25 8.19 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.215 -0.928 . . . . 0.0 109.363 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 84.72 9.62 80.78 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 72.9 mtm180 -117.83 142.41 47.33 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.24 -1.153 . . . . 0.0 109.403 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -81.08 134.75 35.71 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.258 -0.901 . . . . 0.0 109.496 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.717 ' O ' HG13 ' A' ' 171' ' ' VAL . 64.8 m -128.48 77.26 77.5 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.215 -0.928 . . . . 0.0 109.475 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.466 ' HA ' ' CB ' ' A' ' 161' ' ' SER . 48.9 Cg_endo -53.13 107.8 0.22 Allowed 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.631 2.22 . . . . 0.0 111.789 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 1.03 HG23 HD21 ' A' ' 173' ' ' LEU . 19.4 m -127.04 157.68 38.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.27 -0.893 . . . . 0.0 109.463 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.745 ' C ' HD22 ' A' ' 173' ' ' LEU . 95.8 mt-10 -91.05 128.46 36.88 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.311 -0.868 . . . . 0.0 109.503 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 173' ' ' LEU . . . . . 1.03 HD21 HG23 ' A' ' 171' ' ' VAL . 2.2 mm? -122.33 156.08 34.64 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.289 -0.882 . . . . 0.0 109.497 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 174' ' ' ASP . . . . . 0.466 ' HB2' ' HB2' ' A' ' 177' ' ' GLN . 84.5 m-20 -83.34 168.13 16.92 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.217 -0.927 . . . . 0.0 109.596 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.748 ' CE1' HD11 ' A' ' 158' ' ' LEU . 8.2 m-85 -59.49 -49.44 77.77 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.255 -0.903 . . . . 0.0 109.584 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 84.0 p -78.09 -19.36 54.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.2 -0.937 . . . . 0.0 109.653 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 177' ' ' GLN . . . . . 0.6 ' NE2' HD12 ' A' ' 173' ' ' LEU . 64.9 tt0 -67.25 -25.26 65.99 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.116 -0.99 . . . . 0.0 109.483 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.536 HG13 ' HB3' ' A' ' 173' ' ' LEU . 4.5 m -127.08 157.57 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.264 -0.897 . . . . 0.0 109.592 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 179' ' ' GLU . . . . . 0.445 ' N ' ' O ' ' A' ' 135' ' ' ARG . 56.4 mt-10 -111.29 152.74 26.86 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.258 -0.901 . . . . 0.0 109.438 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 180' ' ' LYS . . . . . 0.433 ' HE3' ' OE2' ' A' ' 132' ' ' GLU . 5.4 tttp -72.9 133.02 44.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.228 -0.92 . . . . 0.0 109.481 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 181' ' ' ALA . . . . . 0.418 ' CB ' ' O ' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.547 0 O-C-N 121.249 -0.907 . . . . 0.0 109.514 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.579 ' CB ' ' CD ' ' A' ' 124' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.579 ' CD ' ' CB ' ' A' ' 123' ' ' ARG . 50.6 Cg_endo -55.91 146.8 66.18 Favored 'Trans proline' 0 C--O 1.213 -0.726 0 C-N-CA 122.621 2.214 . . . . 0.0 111.746 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 91.7 mttt -90.6 146.72 23.83 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.396 -0.815 . . . . 0.0 109.435 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 45.7 p -93.47 12.62 24.39 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.203 -0.936 . . . . 0.0 109.5 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.45 ' O ' ' HE3' ' A' ' 180' ' ' LYS . 44.4 mt -90.99 97.37 11.14 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.239 -0.913 . . . . 0.0 109.518 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.435 ' HA ' ' OE1' ' A' ' 132' ' ' GLU . 56.9 m-85 -109.14 145.49 35.65 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.191 -0.943 . . . . 0.0 109.442 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.497 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.1 OUTLIER -145.42 155.44 53.69 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.252 -0.905 . . . . 0.0 109.502 179.933 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.497 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.2 Cg_endo -48.58 128.52 18.3 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.633 2.222 . . . . 0.0 111.828 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 96.25 -9.57 67.41 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.435 ' OE1' ' HA ' ' A' ' 128' ' ' PHE . 92.2 mt-10 -86.95 140.24 29.8 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.155 -1.203 . . . . 0.0 109.496 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.557 ' HG2' HG22 ' A' ' 147' ' ' VAL . 87.9 mtp -84.76 152.25 23.82 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.333 -0.854 . . . . 0.0 109.456 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.692 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -133.45 179.21 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.236 -0.915 . . . . 0.0 109.308 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.692 ' H ' HG12 ' A' ' 134' ' ' VAL . 64.1 mtm180 -138.9 150.31 45.8 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.233 -0.917 . . . . 0.0 109.53 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.531 HG12 ' H ' ' A' ' 138' ' ' ASP . 42.1 t -108.31 135.24 47.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.297 -0.877 . . . . 0.0 109.444 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 36.7 p30 -118.17 14.16 13.91 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.239 -0.913 . . . . 0.0 109.528 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.531 ' H ' HG12 ' A' ' 136' ' ' VAL . 53.7 p30 -157.21 169.95 23.6 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.269 -0.894 . . . . 0.0 109.499 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 69.04 165.55 4.11 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -55.97 -18.61 23.0 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.629 2.219 . . . . 0.0 111.739 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' PHE . . . . . 1.175 ' CD1' HG21 ' A' ' 162' ' ' VAL . 94.1 m-85 -88.74 7.77 32.18 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.291 -0.881 . . . . 0.0 109.523 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 142' ' ' ALA . . . . . 0.497 ' O ' ' CB ' ' A' ' 143' ' ' ASP . . . -67.9 147.98 51.75 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.178 -0.951 . . . . 0.0 109.48 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.497 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 3.9 t70 76.29 27.47 0.86 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.281 -0.887 . . . . 0.0 109.56 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.482 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 96.5 m-85 -135.87 146.55 47.55 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -0.878 . . . . 0.0 109.47 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 75.6 m-20 -103.63 146.98 27.77 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.268 -0.895 . . . . 0.0 109.377 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' GLY . . . . . 0.459 ' HA3' ' O ' ' A' ' 161' ' ' SER . . . -151.24 -173.94 21.63 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.557 HG22 ' HG2' ' A' ' 133' ' ' MET . 48.7 t -123.99 156.68 31.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.302 -1.116 . . . . 0.0 109.487 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.638 HG23 ' CG2' ' A' ' 134' ' ' VAL . 98.7 t -86.59 96.07 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.246 -0.909 . . . . 0.0 109.519 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -68.31 -34.92 77.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.294 -0.879 . . . . 0.0 109.411 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.404 ' O ' ' HB3' ' A' ' 159' ' ' LYS . 95.0 mt-10 -151.11 159.19 44.63 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.202 -0.936 . . . . 0.0 109.479 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.481 HG22 HG11 ' A' ' 148' ' ' VAL . 43.6 t -129.02 148.22 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.459 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -134.2 86.71 2.3 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.242 -0.911 . . . . 0.0 109.476 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -67.34 -36.72 82.0 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.285 -0.884 . . . . 0.0 109.505 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -64.15 -41.45 97.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.202 -0.937 . . . . 0.0 109.442 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.415 ' O ' ' C ' ' A' ' 156' ' ' SER . 42.7 mttp -92.64 9.43 34.82 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.225 -0.922 . . . . 0.0 109.478 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 156' ' ' SER . . . . . 0.415 ' C ' ' O ' ' A' ' 155' ' ' LYS . 8.1 m 43.85 52.76 6.46 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.304 -0.872 . . . . 0.0 109.445 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.45 ' CG ' ' HB3' ' A' ' 172' ' ' GLU . 7.7 tpt180 -144.45 140.0 28.68 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.243 -0.911 . . . . 0.0 109.43 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 158' ' ' LEU . . . . . 0.501 HD21 ' CE1' ' A' ' 175' ' ' PHE . 53.7 mt -107.35 134.54 50.26 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.198 -0.939 . . . . 0.0 109.454 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 159' ' ' LYS . . . . . 0.428 ' HD2' ' HG2' ' A' ' 172' ' ' GLU . 13.6 tptt -92.74 95.9 9.83 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.247 -0.908 . . . . 0.0 109.463 179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.523 HG22 HG22 ' A' ' 148' ' ' VAL . 40.9 t -117.7 143.41 28.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.148 -0.97 . . . . 0.0 109.473 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 161' ' ' SER . . . . . 0.527 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 28.4 t -109.21 147.67 32.18 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.246 -0.909 . . . . 0.0 109.469 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 162' ' ' VAL . . . . . 1.175 HG21 ' CD1' ' A' ' 141' ' ' PHE . 21.1 t -88.43 134.39 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.258 -0.901 . . . . 0.0 109.615 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 5.7 m -85.97 82.42 8.13 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.319 -0.863 . . . . 0.0 109.231 179.765 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.494 HG22 ' H ' ' A' ' 166' ' ' GLY . 41.3 mt -98.31 139.96 19.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.256 -0.902 . . . . 0.0 109.442 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 71.6 t80 -56.7 -39.18 73.38 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.303 -0.873 . . . . 0.0 109.635 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.505 ' O ' ' HB2' ' A' ' 167' ' ' ARG . . . -63.37 -31.22 80.01 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 167' ' ' ARG . . . . . 0.505 ' HB2' ' O ' ' A' ' 166' ' ' GLY . 17.3 ttt180 165.13 154.22 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.336 -1.096 . . . . 0.0 109.226 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -67.28 147.57 52.83 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.206 -0.934 . . . . 0.0 109.382 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.581 HG21 ' CE1' ' A' ' 141' ' ' PHE . 5.3 m -124.58 88.95 52.89 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.221 -0.924 . . . . 0.0 109.541 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.527 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.4 Cg_endo -68.23 107.89 1.65 Allowed 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 122.592 2.194 . . . . 0.0 111.783 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.425 ' O ' ' O ' ' A' ' 160' ' ' VAL . 21.2 m -132.87 160.69 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.302 -0.874 . . . . 0.0 109.45 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.69 ' O ' HD23 ' A' ' 173' ' ' LEU . 97.7 mt-10 -103.97 128.61 51.51 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.266 -0.896 . . . . 0.0 109.508 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 173' ' ' LEU . . . . . 0.69 HD23 ' O ' ' A' ' 172' ' ' GLU . 55.7 mt -129.74 147.32 51.5 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.269 -0.895 . . . . 0.0 109.51 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 174' ' ' ASP . . . . . 0.424 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 88.9 m-20 -67.41 173.13 4.24 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.282 -0.886 . . . . 0.0 109.455 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.53 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.7 m-30 -64.92 -41.46 95.55 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.191 -0.943 . . . . 0.0 109.403 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 19.4 m -75.11 -25.79 58.76 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.233 -0.917 . . . . 0.0 109.433 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 177' ' ' GLN . . . . . 0.424 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 83.2 mt-30 -68.29 -22.67 64.72 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.219 -0.926 . . . . 0.0 109.415 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.532 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 9.0 m -132.99 157.57 43.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.241 -0.912 . . . . 0.0 109.396 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 179' ' ' GLU . . . . . 0.431 ' N ' ' O ' ' A' ' 135' ' ' ARG . 93.4 mt-10 -114.94 150.18 36.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.359 -0.838 . . . . 0.0 109.486 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 180' ' ' LYS . . . . . 0.45 ' HE3' ' O ' ' A' ' 127' ' ' LEU . 18.1 tttm -66.04 140.1 58.24 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.253 -0.904 . . . . 0.0 109.428 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.503 0 O-C-N 121.23 -0.919 . . . . 0.0 109.456 -179.971 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.489 1.484 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -55.9 144.24 78.73 Favored 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 122.608 2.205 . . . . 0.0 111.766 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' LYS . . . . . 0.527 ' HB2' ' CE ' ' A' ' 180' ' ' LYS . 35.4 mmtp -95.21 151.86 18.86 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.249 -0.907 . . . . 0.0 109.446 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 52.4 p -104.07 18.32 22.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.228 -0.92 . . . . 0.0 109.508 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 63.7 mt -97.12 95.39 7.74 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.246 -0.909 . . . . 0.0 109.461 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.519 ' O ' HG21 ' A' ' 151' ' ' VAL . 66.0 m-85 -103.37 132.58 49.51 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.3 -0.875 . . . . 0.0 109.457 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.502 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.6 OUTLIER -133.38 153.16 80.38 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.236 -0.915 . . . . 0.0 109.476 179.961 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.502 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 49.8 Cg_endo -45.79 132.79 13.77 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.591 2.194 . . . . 0.0 111.762 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 89.57 -1.28 81.42 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.643 ' O ' HG12 ' A' ' 148' ' ' VAL . 49.0 tp10 -94.5 127.98 40.77 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.131 -1.217 . . . . 0.0 109.423 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.726 ' HG2' HG22 ' A' ' 147' ' ' VAL . 81.6 mtp -68.14 153.96 42.67 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.208 -0.932 . . . . 0.0 109.438 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.682 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -138.1 178.82 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.218 -0.927 . . . . 0.0 109.284 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.682 ' H ' HG12 ' A' ' 134' ' ' VAL . 76.3 ttt180 -135.42 148.09 49.19 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.25 -0.906 . . . . 0.0 109.458 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.475 HG12 ' HA ' ' A' ' 142' ' ' ALA . 48.5 t -118.15 126.91 75.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.278 -0.889 . . . . 0.0 109.471 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 137' ' ' ASN . . . . . 0.403 ' O ' ' OD1' ' A' ' 138' ' ' ASP . 26.2 p30 -126.28 12.87 7.66 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.249 -0.907 . . . . 0.0 109.492 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.473 ' HB2' ' OE1' ' A' ' 177' ' ' GLN . 93.5 m-20 -137.78 163.07 32.28 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.21 -0.931 . . . . 0.0 109.506 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 63.86 176.48 4.2 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -58.14 -24.49 66.8 Favored 'Trans proline' 0 C--O 1.216 -0.613 0 C-N-CA 122.597 2.198 . . . . 0.0 111.745 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' PHE . . . . . 0.554 ' CZ ' HG11 ' A' ' 171' ' ' VAL . 98.8 m-85 -82.81 7.87 13.95 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.224 -0.922 . . . . 0.0 109.488 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 142' ' ' ALA . . . . . 0.475 ' HA ' HG12 ' A' ' 136' ' ' VAL . . . -61.03 150.87 32.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.215 -0.928 . . . . 0.0 109.499 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.473 ' N ' ' O ' ' A' ' 136' ' ' VAL . 37.8 m-20 62.66 52.58 2.8 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.271 -0.893 . . . . 0.0 109.579 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.497 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 35.6 m-85 -150.4 132.02 14.88 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.237 -0.914 . . . . 0.0 109.489 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 56.5 m-20 -92.98 138.72 31.23 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.209 -0.932 . . . . 0.0 109.402 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -156.67 -179.65 31.8 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.965 ' O ' HG13 ' A' ' 160' ' ' VAL . 40.9 t -121.48 159.52 23.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.243 -1.151 . . . . 0.0 109.349 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.701 ' HA ' HG22 ' A' ' 160' ' ' VAL . 2.5 p -100.26 115.62 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.281 -0.887 . . . . 0.0 109.519 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 83.3 mt-10 -70.52 -36.59 73.82 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.279 -0.888 . . . . 0.0 109.294 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.473 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 93.7 mt-10 -152.32 162.45 41.15 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.283 -0.886 . . . . 0.0 109.459 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.679 HG22 HG21 ' A' ' 148' ' ' VAL . 48.0 t -132.27 151.75 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.19 -0.944 . . . . 0.0 109.51 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 152' ' ' ASP . . . . . 0.517 ' O ' ' N ' ' A' ' 156' ' ' SER . 84.3 m-20 -125.52 98.58 5.65 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.243 -0.91 . . . . 0.0 109.424 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 87.4 m-85 -66.33 -35.8 81.29 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.219 -0.926 . . . . 0.0 109.572 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -66.94 -45.3 78.24 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.286 -0.883 . . . . 0.0 109.551 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 19.3 mttt -91.07 -8.55 48.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.242 -0.911 . . . . 0.0 109.512 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' SER . . . . . 0.517 ' N ' ' O ' ' A' ' 152' ' ' ASP . 44.3 t 55.75 52.33 11.04 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.548 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.67 ' C ' HD12 ' A' ' 158' ' ' LEU . 83.3 mmt-85 -133.2 151.1 51.95 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.896 . . . . 0.0 109.327 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 158' ' ' LEU . . . . . 0.869 HD11 ' CE1' ' A' ' 175' ' ' PHE . 4.3 mp -118.16 137.12 53.19 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.18 -0.95 . . . . 0.0 109.592 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 159' ' ' LYS . . . . . 0.473 ' HD2' ' HB2' ' A' ' 150' ' ' GLU . 34.1 mttt -99.15 90.55 4.63 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.243 -0.911 . . . . 0.0 109.347 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.965 HG13 ' O ' ' A' ' 147' ' ' VAL . 46.5 t -118.52 142.99 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.224 -0.922 . . . . 0.0 109.533 -179.759 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 161' ' ' SER . . . . . 0.435 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 27.0 t -112.53 136.64 51.82 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.245 -0.909 . . . . 0.0 109.395 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 162' ' ' VAL . . . . . 0.497 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 21.5 t -107.47 132.35 55.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.176 -0.953 . . . . 0.0 109.511 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 33.1 t -78.62 82.42 4.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.292 -0.88 . . . . 0.0 109.48 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.66 HG22 ' CD1' ' A' ' 165' ' ' PHE . 47.0 mt -105.35 141.81 19.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.191 -0.943 . . . . 0.0 109.398 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 165' ' ' PHE . . . . . 0.66 ' CD1' HG22 ' A' ' 164' ' ' ILE . 8.0 m-30 64.88 16.2 10.35 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.289 -0.882 . . . . 0.0 109.429 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 80.08 7.64 88.35 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 78.7 mtp180 -125.43 139.15 53.9 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.275 -1.133 . . . . 0.0 109.455 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -68.5 140.67 55.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.274 -0.891 . . . . 0.0 109.543 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.662 ' O ' HG13 ' A' ' 171' ' ' VAL . 8.2 m -128.36 74.44 79.76 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.235 -0.916 . . . . 0.0 109.37 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.435 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.6 Cg_endo -54.24 105.2 0.13 Allowed 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.579 2.186 . . . . 0.0 111.82 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.662 HG13 ' O ' ' A' ' 169' ' ' THR . 19.6 m -128.09 159.37 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.243 -0.911 . . . . 0.0 109.419 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.529 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.9 mt-10 -102.91 130.93 50.13 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.213 -0.929 . . . . 0.0 109.45 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 173' ' ' LEU . . . . . 0.658 HD12 ' CG1' ' A' ' 178' ' ' VAL . 55.1 mt -125.02 160.84 28.07 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.276 -0.89 . . . . 0.0 109.527 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 174' ' ' ASP . . . . . 0.458 ' HB2' ' HG2' ' A' ' 177' ' ' GLN . 90.6 m-20 -82.82 176.78 9.04 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.3 -0.875 . . . . 0.0 109.558 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.869 ' CE1' HD11 ' A' ' 158' ' ' LEU . 3.2 m-85 -66.1 -39.77 90.24 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.333 -0.855 . . . . 0.0 109.613 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 15.4 m -79.81 -26.23 40.58 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.208 -0.933 . . . . 0.0 109.619 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 177' ' ' GLN . . . . . 0.473 ' OE1' ' HB2' ' A' ' 138' ' ' ASP . 96.6 mm-40 -67.08 -30.71 70.83 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.22 -0.925 . . . . 0.0 109.519 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.658 ' CG1' HD12 ' A' ' 173' ' ' LEU . 12.7 m -125.29 158.26 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.249 -0.907 . . . . 0.0 109.386 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 179' ' ' GLU . . . . . 0.511 ' O ' ' N ' ' A' ' 135' ' ' ARG . 70.6 tt0 -120.38 143.09 48.61 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.218 -0.926 . . . . 0.0 109.498 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 180' ' ' LYS . . . . . 0.527 ' CE ' ' HB2' ' A' ' 125' ' ' LYS . 23.6 ttmt -59.71 140.15 56.69 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.309 -0.87 . . . . 0.0 109.434 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.527 0 O-C-N 121.174 -0.954 . . . . 0.0 109.452 -179.984 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.522 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -55.34 145.82 65.06 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.621 2.214 . . . . 0.0 111.789 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' LYS . . . . . 0.471 ' O ' ' HD2' ' A' ' 180' ' ' LYS . 58.9 mttt -94.7 150.72 19.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.175 -0.953 . . . . 0.0 109.504 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 52.2 p -89.64 9.4 27.1 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.276 -0.89 . . . . 0.0 109.447 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.405 ' O ' ' HE3' ' A' ' 180' ' ' LYS . 49.6 mt -91.46 98.46 11.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.241 -0.912 . . . . 0.0 109.449 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 92.2 m-85 -103.12 136.51 42.79 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.259 -0.901 . . . . 0.0 109.491 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.461 ' HB2' ' HD2' ' A' ' 130' ' ' PRO . 16.5 pt-20 -133.01 134.98 25.06 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.921 . . . . 0.0 109.454 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.505 ' HA ' ' O ' ' A' ' 148' ' ' VAL . 49.2 Cg_endo -35.28 131.36 0.24 Allowed 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.517 2.145 . . . . 0.0 111.738 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 131' ' ' GLY . . . . . 0.487 ' C ' ' CG1' ' A' ' 147' ' ' VAL . . . 90.89 -4.48 81.71 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.803 ' O ' HG13 ' A' ' 147' ' ' VAL . 49.2 tp10 -83.58 141.7 31.38 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.125 -1.221 . . . . 0.0 109.548 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.743 ' HG2' HG22 ' A' ' 147' ' ' VAL . 90.5 mtp -80.94 150.11 29.11 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.184 -0.948 . . . . 0.0 109.438 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.679 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -135.65 179.06 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.168 -0.958 . . . . 0.0 109.375 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.679 ' H ' HG12 ' A' ' 134' ' ' VAL . 94.5 mtt180 -132.86 146.52 51.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.318 -0.864 . . . . 0.0 109.467 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 41.4 t -112.53 130.42 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.265 -0.897 . . . . 0.0 109.423 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 54.9 p30 -123.37 19.21 9.75 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.201 -0.937 . . . . 0.0 109.534 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -156.27 151.24 26.26 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.212 -0.93 . . . . 0.0 109.493 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 82.27 164.16 33.97 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -54.19 -23.66 30.54 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.606 2.204 . . . . 0.0 111.779 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' PHE . . . . . 0.474 ' CD1' HG21 ' A' ' 162' ' ' VAL . 98.9 m-85 -86.87 11.05 14.26 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.252 -0.905 . . . . 0.0 109.391 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 142' ' ' ALA . . . . . 0.471 ' O ' ' CB ' ' A' ' 143' ' ' ASP . . . -70.09 151.09 45.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.491 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.471 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 25.0 t0 74.9 28.62 1.09 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.279 -0.888 . . . . 0.0 109.517 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.525 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 92.5 m-85 -135.03 140.3 45.5 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.164 -0.96 . . . . 0.0 109.608 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 21.2 m120 -95.95 141.07 29.81 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.32 -0.862 . . . . 0.0 109.418 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -151.3 -173.42 21.18 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.803 HG13 ' O ' ' A' ' 132' ' ' GLU . 54.8 t -132.01 144.26 37.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.362 -1.081 . . . . 0.0 109.454 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.768 ' CA ' HG22 ' A' ' 160' ' ' VAL . 2.1 p -83.03 106.11 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.281 -0.887 . . . . 0.0 109.443 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 56.5 mp0 -70.2 -46.8 63.83 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.231 -0.918 . . . . 0.0 109.461 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.409 ' HG2' ' N ' ' A' ' 151' ' ' VAL . 83.5 tt0 -131.8 153.24 50.34 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.186 -0.947 . . . . 0.0 109.36 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.608 HG22 HG21 ' A' ' 148' ' ' VAL . 47.9 t -120.18 153.53 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.174 -0.954 . . . . 0.0 109.579 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 152' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 92.2 m-20 -135.76 83.25 2.0 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.306 -0.871 . . . . 0.0 109.339 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 153' ' ' TYR . . . . . 0.463 ' CZ ' HG11 ' A' ' 151' ' ' VAL . 96.7 m-85 -67.03 -34.84 78.59 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.244 -0.91 . . . . 0.0 109.555 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 76.0 mm-40 -62.21 -40.81 97.32 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.202 -0.936 . . . . 0.0 109.562 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.451 ' O ' ' HG2' ' A' ' 155' ' ' LYS . 31.7 tttt -96.88 -4.3 40.44 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.289 -0.882 . . . . 0.0 109.655 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 156' ' ' SER . . . . . 0.435 ' HB2' ' O ' ' A' ' 155' ' ' LYS . 19.8 m 59.9 53.05 4.92 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.195 -0.941 . . . . 0.0 109.46 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 13.5 tpt180 -142.63 138.97 31.07 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.281 -0.887 . . . . 0.0 109.488 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 158' ' ' LEU . . . . . 0.552 ' CD2' HG13 ' A' ' 151' ' ' VAL . 41.9 mt -108.08 134.63 50.68 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.252 -0.905 . . . . 0.0 109.524 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 62.8 tttm -97.28 97.08 8.85 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.225 -0.922 . . . . 0.0 109.418 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.768 HG22 ' CA ' ' A' ' 148' ' ' VAL . 42.9 t -123.27 138.37 53.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.258 -0.901 . . . . 0.0 109.615 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 161' ' ' SER . . . . . 0.432 ' CB ' ' HA ' ' A' ' 170' ' ' PRO . 83.6 p -100.75 155.24 18.02 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.299 -0.876 . . . . 0.0 109.508 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 162' ' ' VAL . . . . . 0.525 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 5.3 t -106.14 129.15 59.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.25 -0.906 . . . . 0.0 109.479 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 55.1 m -75.78 81.5 2.72 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.286 -0.884 . . . . 0.0 109.383 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.462 HD12 ' OG1' ' A' ' 169' ' ' THR . 75.1 mt -91.45 146.78 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.231 -0.918 . . . . 0.0 109.421 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -55.05 -47.65 74.52 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.248 -0.908 . . . . 0.0 109.75 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.526 ' O ' ' CB ' ' A' ' 167' ' ' ARG . . . -54.54 -34.22 55.14 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.788 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 167' ' ' ARG . . . . . 0.526 ' CB ' ' O ' ' A' ' 166' ' ' GLY . 7.9 mtm180 161.26 167.14 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.315 -1.109 . . . . 0.0 109.423 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -69.39 138.87 53.98 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.221 -0.924 . . . . 0.0 109.384 179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.462 ' OG1' HD12 ' A' ' 164' ' ' ILE . 29.7 m -123.04 87.85 51.0 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.172 -0.955 . . . . 0.0 109.526 -179.801 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.432 ' HA ' ' CB ' ' A' ' 161' ' ' SER . 50.2 Cg_endo -62.74 107.53 0.62 Allowed 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.558 2.172 . . . . 0.0 111.685 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' A' ' 160' ' ' VAL . 18.9 m -129.97 156.92 42.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.278 -0.889 . . . . 0.0 109.567 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.499 ' O ' HD23 ' A' ' 173' ' ' LEU . 94.5 mt-10 -103.97 129.38 51.54 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.281 -0.887 . . . . 0.0 109.371 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 173' ' ' LEU . . . . . 0.547 ' HB2' ' CG1' ' A' ' 178' ' ' VAL . 65.5 mt -126.25 147.89 49.6 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.268 -0.895 . . . . 0.0 109.471 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -68.5 173.35 5.07 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.25 -0.907 . . . . 0.0 109.407 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.492 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.9 m-30 -66.51 -40.24 89.11 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.248 -0.907 . . . . 0.0 109.446 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 14.8 m -75.36 -24.41 57.29 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.231 -0.918 . . . . 0.0 109.406 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -70.32 -28.8 65.45 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.219 -0.926 . . . . 0.0 109.499 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.547 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 4.4 m -127.95 161.08 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.231 -0.918 . . . . 0.0 109.468 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 179' ' ' GLU . . . . . . . . . . . . . 75.0 mm-40 -120.0 148.64 43.31 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.236 -0.915 . . . . 0.0 109.505 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 180' ' ' LYS . . . . . 0.471 ' HD2' ' O ' ' A' ' 125' ' ' LYS . 20.1 tttt -58.95 140.56 55.43 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.188 -0.945 . . . . 0.0 109.485 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 181' ' ' ALA . . . . . 0.477 ' HB2' ' C ' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.491 1.589 0 O-C-N 121.21 -0.932 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.436 ' N ' ' CD ' ' A' ' 124' ' ' PRO . 2.5 ttp85 . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.436 ' CD ' ' N ' ' A' ' 123' ' ' ARG . 49.2 Cg_endo -55.87 142.79 83.63 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.608 2.206 . . . . 0.0 111.847 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 125' ' ' LYS . . . . . 0.462 ' HB2' ' HD3' ' A' ' 180' ' ' LYS . 22.0 mttp -116.87 143.67 45.42 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -0.89 . . . . 0.0 109.497 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 48.7 p -113.41 21.46 15.16 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.224 -0.922 . . . . 0.0 109.478 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 56.2 mt -98.55 95.23 7.15 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.206 -0.934 . . . . 0.0 109.463 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.611 ' CD2' HD21 ' A' ' 158' ' ' LEU . 92.0 m-85 -96.84 131.4 43.62 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.368 -0.833 . . . . 0.0 109.455 179.861 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.486 ' HB2' ' HD2' ' A' ' 130' ' ' PRO . 2.2 pt-20 -142.35 147.31 42.91 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.231 -0.918 . . . . 0.0 109.418 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.486 ' HD2' ' HB2' ' A' ' 129' ' ' GLU . 48.8 Cg_endo -40.95 128.47 2.79 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.436 2.091 . . . . 0.0 111.84 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 100.28 -4.19 56.96 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.642 ' O ' HG13 ' A' ' 147' ' ' VAL . 78.1 mm-40 -93.03 144.32 25.37 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.207 -1.172 . . . . 0.0 109.541 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.895 ' SD ' HG22 ' A' ' 147' ' ' VAL . 77.3 mmm -83.48 143.08 30.47 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.225 -0.922 . . . . 0.0 109.413 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.938 ' CG2' HG23 ' A' ' 148' ' ' VAL . 2.5 t -128.63 178.59 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.225 -0.922 . . . . 0.0 109.362 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.683 ' H ' HG12 ' A' ' 134' ' ' VAL . 40.0 ttt85 -141.88 145.8 35.04 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.343 -0.848 . . . . 0.0 109.405 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.575 HG22 ' CD1' ' A' ' 173' ' ' LEU . 43.5 t -112.48 135.29 52.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.235 -0.915 . . . . 0.0 109.495 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 34.6 p30 -126.67 10.41 7.17 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.279 -0.888 . . . . 0.0 109.411 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.484 ' HB3' ' HG3' ' A' ' 177' ' ' GLN . 49.9 t0 -150.58 159.04 44.78 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.229 -0.919 . . . . 0.0 109.541 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.416 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 77.52 165.33 24.63 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -50.45 -22.33 8.74 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 122.593 2.195 . . . . 0.0 111.721 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 141' ' ' PHE . . . . . 0.915 ' CZ ' HG11 ' A' ' 171' ' ' VAL . 93.9 m-85 -88.61 12.57 14.31 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.207 -0.933 . . . . 0.0 109.485 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 142' ' ' ALA . . . . . 0.451 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -62.83 149.2 44.86 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.339 -0.851 . . . . 0.0 109.529 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.432 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 44.7 m-20 63.28 45.31 5.07 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.472 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.538 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 46.0 m-85 -147.08 126.08 12.83 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.184 -0.947 . . . . 0.0 109.474 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 67.8 m-20 -88.42 145.24 25.89 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.224 -0.923 . . . . 0.0 109.605 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -157.1 177.26 34.06 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.895 HG22 ' SD ' ' A' ' 133' ' ' MET . 22.0 t -114.86 156.69 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.177 -1.19 . . . . 0.0 109.395 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.938 HG23 ' CG2' ' A' ' 134' ' ' VAL . 47.8 t -82.37 104.11 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.248 -0.907 . . . . 0.0 109.498 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.42 ' O ' ' CD ' ' A' ' 150' ' ' GLU . 97.2 mt-10 -69.86 -35.41 74.69 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.282 -0.886 . . . . 0.0 109.36 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.474 ' HB2' ' HD3' ' A' ' 159' ' ' LYS . 76.1 mm-40 -152.81 164.88 36.98 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.322 -0.861 . . . . 0.0 109.41 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.44 HG11 ' CZ ' ' A' ' 153' ' ' TYR . 46.5 t -128.56 143.48 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.267 -0.896 . . . . 0.0 109.424 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 93.8 m-20 -124.91 78.31 1.69 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.19 -0.944 . . . . 0.0 109.542 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 153' ' ' TYR . . . . . 0.44 ' CZ ' HG11 ' A' ' 151' ' ' VAL . 92.9 m-85 -59.87 -42.21 93.24 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.238 -0.914 . . . . 0.0 109.385 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -54.61 -45.08 73.6 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.244 -0.91 . . . . 0.0 109.366 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.412 ' O ' ' HG3' ' A' ' 157' ' ' ARG . 44.2 mttp -86.23 -2.96 58.85 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.264 -0.897 . . . . 0.0 109.515 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 17.1 m 55.68 53.7 9.21 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.183 -0.948 . . . . 0.0 109.358 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.412 ' HG3' ' O ' ' A' ' 155' ' ' LYS . 66.9 mtt180 -147.95 162.79 38.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 109.534 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 158' ' ' LEU . . . . . 0.638 ' CD1' ' CE1' ' A' ' 175' ' ' PHE . 6.7 mp -114.02 139.27 49.4 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.331 -0.856 . . . . 0.0 109.428 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 159' ' ' LYS . . . . . 0.474 ' HD3' ' HB2' ' A' ' 150' ' ' GLU . 41.1 tttt -104.56 100.22 9.9 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.158 -0.963 . . . . 0.0 109.312 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.567 HG13 ' O ' ' A' ' 147' ' ' VAL . 39.9 t -119.9 148.52 22.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.207 -0.933 . . . . 0.0 109.549 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 161' ' ' SER . . . . . 0.416 ' CB ' ' HA ' ' A' ' 170' ' ' PRO . 22.7 t -117.95 138.85 51.88 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.245 -0.909 . . . . 0.0 109.333 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 162' ' ' VAL . . . . . 0.538 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 4.4 t -107.19 133.13 52.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.182 -0.949 . . . . 0.0 109.708 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 44.1 t -82.93 81.84 8.45 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.321 -0.862 . . . . 0.0 109.311 179.838 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.997 HG22 ' CD2' ' A' ' 165' ' ' PHE . 59.5 mt -97.19 134.91 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.142 -0.974 . . . . 0.0 109.469 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 165' ' ' PHE . . . . . 0.997 ' CD2' HG22 ' A' ' 164' ' ' ILE . 79.4 m-85 62.14 27.69 16.67 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.296 -0.878 . . . . 0.0 109.474 -179.903 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 70.13 13.09 69.63 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.792 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 76.1 mtm180 -119.35 141.1 49.33 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.252 -1.146 . . . . 0.0 109.441 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -80.12 134.6 36.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.2 -0.938 . . . . 0.0 109.413 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.726 ' O ' HG13 ' A' ' 171' ' ' VAL . 57.3 m -128.65 73.32 80.92 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.286 -0.884 . . . . 0.0 109.437 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.416 ' HA ' ' CB ' ' A' ' 161' ' ' SER . 49.6 Cg_endo -52.1 108.42 0.25 Allowed 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.69 2.26 . . . . 0.0 111.89 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.915 HG11 ' CZ ' ' A' ' 141' ' ' PHE . 20.5 m -126.04 155.12 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.264 -0.898 . . . . 0.0 109.417 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.451 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.3 mt-10 -90.89 129.99 36.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.213 -0.929 . . . . 0.0 109.553 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 173' ' ' LEU . . . . . 0.575 ' CD1' HG22 ' A' ' 136' ' ' VAL . 61.9 mt -122.02 154.91 36.63 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.234 -0.916 . . . . 0.0 109.49 179.907 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 174' ' ' ASP . . . . . 0.481 ' HB2' ' HB2' ' A' ' 177' ' ' GLN . 85.1 m-20 -83.81 154.95 23.23 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.221 -0.925 . . . . 0.0 109.629 -179.867 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.638 ' CE1' ' CD1' ' A' ' 158' ' ' LEU . 25.4 m-85 -51.14 -50.24 59.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.38 -0.825 . . . . 0.0 109.615 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 72.4 p -74.8 -18.45 60.46 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.223 -0.923 . . . . 0.0 109.594 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 177' ' ' GLN . . . . . 0.484 ' HG3' ' HB3' ' A' ' 138' ' ' ASP . 65.7 tt0 -72.95 -25.15 60.92 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.301 -0.874 . . . . 0.0 109.448 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.509 HG13 ' HB3' ' A' ' 173' ' ' LEU . 5.2 m -125.34 161.81 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.154 -0.966 . . . . 0.0 109.487 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 179' ' ' GLU . . . . . . . . . . . . . 61.1 mt-10 -118.42 148.96 42.01 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.225 -0.922 . . . . 0.0 109.482 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 180' ' ' LYS . . . . . 0.462 ' HD3' ' HB2' ' A' ' 125' ' ' LYS . 21.1 tttm -79.79 132.65 36.19 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.34 -0.85 . . . . 0.0 109.449 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.499 0 O-C-N 121.278 -0.889 . . . . 0.0 109.49 179.99 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.402 ' HD3' ' HD2' ' A' ' 124' ' ' PRO . 9.5 mmt180 . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.402 ' HD2' ' HD3' ' A' ' 123' ' ' ARG . 50.0 Cg_endo -54.47 147.33 48.1 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.606 2.204 . . . . 0.0 111.819 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 49.6 mttp -101.54 140.63 35.56 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.139 -0.976 . . . . 0.0 109.553 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 47.6 p -113.58 26.59 10.26 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.242 -0.911 . . . . 0.0 109.438 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 66.4 mt -95.01 91.98 6.63 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.254 -0.903 . . . . 0.0 109.431 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.547 ' CD2' HD21 ' A' ' 158' ' ' LEU . 75.2 m-85 -79.13 131.61 36.29 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.295 -0.878 . . . . 0.0 109.386 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.459 ' O ' ' HG2' ' A' ' 132' ' ' GLU . 0.6 OUTLIER -129.46 150.04 74.5 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.206 -0.934 . . . . 0.0 109.469 -179.99 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.464 ' HA ' ' O ' ' A' ' 148' ' ' VAL . 50.0 Cg_endo -47.27 123.48 7.81 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.67 2.247 . . . . 0.0 111.771 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 99.29 2.17 56.78 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.626 -1.389 . . . . 0.0 109.626 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.459 ' HG2' ' O ' ' A' ' 129' ' ' GLU . 74.9 mm-40 -92.32 141.3 28.71 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.186 -1.185 . . . . 0.0 109.438 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.909 ' SD ' HG22 ' A' ' 147' ' ' VAL . 84.4 mmm -74.18 142.18 45.46 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.234 -0.916 . . . . 0.0 109.468 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.685 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -130.27 178.96 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.248 -0.908 . . . . 0.0 109.347 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.685 ' H ' HG12 ' A' ' 134' ' ' VAL . 45.7 ttt85 -142.44 135.75 28.8 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.333 -0.855 . . . . 0.0 109.429 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.715 HG22 HD12 ' A' ' 173' ' ' LEU . 66.3 t -106.29 133.56 50.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.264 -0.897 . . . . 0.0 109.444 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 11.4 p30 -132.06 22.11 4.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.302 -0.874 . . . . 0.0 109.431 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.498 ' HB3' ' HG3' ' A' ' 177' ' ' GLN . 51.7 t0 -143.23 156.42 44.74 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.243 -0.911 . . . . 0.0 109.447 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.452 ' O ' ' N ' ' A' ' 142' ' ' ALA . . . 62.98 167.17 0.74 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -44.28 -24.86 1.08 Allowed 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.585 2.19 . . . . 0.0 111.795 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' PHE . . . . . 0.523 ' CE1' HD12 ' A' ' 164' ' ' ILE . 88.0 m-85 -86.57 14.96 6.04 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.255 -0.903 . . . . 0.0 109.468 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 142' ' ' ALA . . . . . 0.518 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -73.67 145.24 45.43 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.285 -0.885 . . . . 0.0 109.501 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.44 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 3.5 m-20 71.05 43.83 0.63 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.318 -0.864 . . . . 0.0 109.526 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.518 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 80.9 m-85 -142.25 139.98 32.12 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.25 -0.906 . . . . 0.0 109.522 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 78.9 m-20 -94.05 138.99 31.52 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.235 -0.916 . . . . 0.0 109.46 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -153.1 179.8 29.23 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.909 HG22 ' SD ' ' A' ' 133' ' ' MET . 22.8 t -124.18 151.38 29.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.256 -1.144 . . . . 0.0 109.449 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.706 HG21 HG22 ' A' ' 151' ' ' VAL . 3.1 p -87.28 95.23 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.219 -0.925 . . . . 0.0 109.552 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -65.75 -36.35 83.33 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.219 -0.925 . . . . 0.0 109.408 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.495 ' HG2' ' N ' ' A' ' 151' ' ' VAL . 84.7 tt0 -142.21 160.36 40.4 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.33 -0.856 . . . . 0.0 109.385 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.706 HG22 HG21 ' A' ' 148' ' ' VAL . 39.8 t -131.37 149.06 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.258 -0.901 . . . . 0.0 109.467 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -131.04 94.64 3.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.24 -0.912 . . . . 0.0 109.501 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -66.69 -32.9 74.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.257 -0.902 . . . . 0.0 109.487 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -61.81 -42.71 99.36 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -0.916 . . . . 0.0 109.368 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 29.9 mttm -90.03 -6.38 55.63 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.258 -0.901 . . . . 0.0 109.471 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 57.48 52.76 8.13 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.23 -0.919 . . . . 0.0 109.475 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.649 ' C ' HD12 ' A' ' 158' ' ' LEU . 75.3 mtt180 -147.13 165.83 28.78 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.222 -0.924 . . . . 0.0 109.536 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 158' ' ' LEU . . . . . 1.17 HD11 ' CD1' ' A' ' 175' ' ' PHE . 3.5 mp -116.01 133.94 55.49 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.227 -0.921 . . . . 0.0 109.532 -179.736 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 159' ' ' LYS . . . . . 0.417 ' HD3' ' HB3' ' A' ' 150' ' ' GLU . 80.8 tttt -91.53 85.77 5.83 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.183 -0.948 . . . . 0.0 109.298 179.765 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.777 HG13 ' O ' ' A' ' 147' ' ' VAL . 61.1 t -110.4 144.28 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.264 -0.898 . . . . 0.0 109.603 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 161' ' ' SER . . . . . 0.441 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 60.0 p -107.76 140.51 40.71 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.282 -0.886 . . . . 0.0 109.348 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 162' ' ' VAL . . . . . . . . . . . . . 6.6 t -110.29 131.98 59.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.242 -0.911 . . . . 0.0 109.59 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 32.6 t -78.63 82.12 4.9 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.233 -0.917 . . . . 0.0 109.42 179.85 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.652 HG22 ' CD2' ' A' ' 165' ' ' PHE . 68.9 mt -112.59 146.87 16.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.26 -0.9 . . . . 0.0 109.535 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 165' ' ' PHE . . . . . 0.652 ' CD2' HG22 ' A' ' 164' ' ' ILE . 28.2 m-85 68.84 13.73 8.87 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.246 -0.909 . . . . 0.0 109.408 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 80.09 22.71 62.76 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 167' ' ' ARG . . . . . 0.457 ' HG2' ' O ' ' A' ' 164' ' ' ILE . 39.0 ptt180 -148.44 155.42 41.18 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.245 -1.15 . . . . 0.0 109.413 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -75.44 143.23 42.77 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.267 -0.895 . . . . 0.0 109.46 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.855 ' O ' HG13 ' A' ' 171' ' ' VAL . 27.2 m -130.12 70.61 82.23 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.237 -0.914 . . . . 0.0 109.441 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.441 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 50.5 Cg_endo -46.88 108.15 0.15 Allowed 'Trans proline' 0 C--O 1.214 -0.683 0 C-N-CA 122.613 2.209 . . . . 0.0 111.858 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.855 HG13 ' O ' ' A' ' 169' ' ' THR . 21.2 m -133.26 154.28 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.283 -0.886 . . . . 0.0 109.424 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.748 ' O ' HD23 ' A' ' 173' ' ' LEU . 94.5 mt-10 -100.08 136.36 40.1 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.18 -0.95 . . . . 0.0 109.451 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 173' ' ' LEU . . . . . 0.861 HD22 ' NE2' ' A' ' 177' ' ' GLN . 47.7 mt -131.01 152.47 50.29 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.285 -0.884 . . . . 0.0 109.513 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -69.54 156.34 39.05 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.245 -0.909 . . . . 0.0 109.515 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 1.17 ' CD1' HD11 ' A' ' 158' ' ' LEU . 51.0 m-85 -53.08 -44.48 67.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.547 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 82.5 p -75.3 -20.03 59.33 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.159 -0.963 . . . . 0.0 109.587 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 177' ' ' GLN . . . . . 0.861 ' NE2' HD22 ' A' ' 173' ' ' LEU . 50.6 tt0 -72.02 -24.55 61.57 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.283 -0.886 . . . . 0.0 109.503 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.461 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 17.7 m -127.26 163.55 30.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.26 -0.9 . . . . 0.0 109.516 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 179' ' ' GLU . . . . . 0.448 ' HB2' ' HB3' ' A' ' 135' ' ' ARG . 63.6 mm-40 -114.79 151.02 34.5 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.281 -0.887 . . . . 0.0 109.483 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 24.3 tttt -81.18 131.67 35.31 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.255 -0.903 . . . . 0.0 109.508 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 181' ' ' ALA . . . . . 0.559 ' HB3' ' HB2' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.544 0 O-C-N 121.193 -0.942 . . . . 0.0 109.415 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -55.62 151.1 40.46 Favored 'Trans proline' 0 C--O 1.214 -0.707 0 C-N-CA 122.642 2.228 . . . . 0.0 111.732 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' LYS . . . . . 0.808 ' HB3' HD23 ' A' ' 127' ' ' LEU . 71.2 mttt -82.34 142.17 32.25 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.265 -0.897 . . . . 0.0 109.397 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.526 ' O ' ' CD2' ' A' ' 128' ' ' PHE . 72.9 p -104.02 15.87 27.55 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.316 -0.865 . . . . 0.0 109.49 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.808 HD23 ' HB3' ' A' ' 125' ' ' LYS . 1.3 pp -74.91 99.66 3.88 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.239 -0.913 . . . . 0.0 109.426 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.571 ' CD2' HD11 ' A' ' 158' ' ' LEU . 93.0 m-85 -102.53 129.1 48.97 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.163 -0.96 . . . . 0.0 109.423 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.457 ' O ' ' HB2' ' A' ' 132' ' ' GLU . 1.8 mm-40 -103.32 139.59 20.25 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.265 -0.897 . . . . 0.0 109.442 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.422 ' HD2' ' HB3' ' A' ' 129' ' ' GLU . 49.3 Cg_endo -43.25 135.82 5.82 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.623 2.215 . . . . 0.0 111.712 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 80.35 6.75 89.1 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.457 ' HB2' ' O ' ' A' ' 129' ' ' GLU . 85.0 tt0 -89.04 128.76 35.74 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.269 -1.136 . . . . 0.0 109.448 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.491 ' O ' ' HB3' ' A' ' 181' ' ' ALA . 42.2 ttm -68.19 144.57 54.9 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.235 -0.916 . . . . 0.0 109.44 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.695 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -131.4 179.15 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.242 -0.911 . . . . 0.0 109.316 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.695 ' H ' HG12 ' A' ' 134' ' ' VAL . 28.4 ttt85 -129.99 135.98 48.9 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.196 -0.94 . . . . 0.0 109.42 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.498 HG22 HG12 ' A' ' 178' ' ' VAL . 60.7 t -107.71 133.87 51.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.213 -0.93 . . . . 0.0 109.498 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 137' ' ' ASN . . . . . 0.412 ' OD1' ' C ' ' A' ' 137' ' ' ASN . 44.0 p30 -132.59 23.39 4.34 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.239 -0.913 . . . . 0.0 109.462 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -142.85 144.08 32.36 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.269 -0.894 . . . . 0.0 109.531 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 75.49 172.85 32.58 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -52.1 -17.17 5.42 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.669 2.246 . . . . 0.0 111.756 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 141' ' ' PHE . . . . . 1.034 ' CD1' HG21 ' A' ' 162' ' ' VAL . 97.0 m-85 -92.68 17.51 10.17 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.28 -0.887 . . . . 0.0 109.495 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 142' ' ' ALA . . . . . 0.553 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -73.33 149.88 42.28 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.324 -0.86 . . . . 0.0 109.498 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.451 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 35.2 m-20 65.14 48.27 2.26 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.205 -0.935 . . . . 0.0 109.527 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.553 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 64.1 m-85 -147.22 146.89 29.96 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.218 -0.926 . . . . 0.0 109.404 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 145' ' ' ASN . . . . . 0.424 ' O ' ' OD1' ' A' ' 145' ' ' ASN . 44.0 p-10 -102.56 151.38 22.39 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.257 -0.902 . . . . 0.0 109.414 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 146' ' ' GLY . . . . . 0.452 ' O ' ' HA ' ' A' ' 133' ' ' MET . . . -164.95 -174.45 34.67 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.892 ' C ' HG13 ' A' ' 160' ' ' VAL . 96.7 t -130.29 150.75 34.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.18 -1.188 . . . . 0.0 109.427 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.78 HG21 HG22 ' A' ' 151' ' ' VAL . 2.1 p -89.61 107.2 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.178 -0.951 . . . . 0.0 109.502 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -70.86 -37.4 73.09 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.182 -0.949 . . . . 0.0 109.396 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -138.64 157.5 46.02 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.355 -0.841 . . . . 0.0 109.338 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.78 HG22 HG21 ' A' ' 148' ' ' VAL . 57.1 t -130.81 149.79 33.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.179 -0.95 . . . . 0.0 109.417 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 152' ' ' ASP . . . . . 0.4 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 95.3 m-20 -136.43 90.17 2.54 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.273 -0.892 . . . . 0.0 109.484 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -67.56 -37.0 82.03 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.233 -0.917 . . . . 0.0 109.495 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -63.6 -42.61 98.24 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.257 -0.902 . . . . 0.0 109.411 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.418 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 58.2 mttt -89.44 -4.64 57.9 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.248 -0.908 . . . . 0.0 109.478 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 58.5 m 55.65 52.73 10.54 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.171 -0.956 . . . . 0.0 109.439 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.439 ' HD3' ' OD1' ' A' ' 174' ' ' ASP . 15.6 mmt85 -144.64 141.97 29.77 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.213 -0.93 . . . . 0.0 109.427 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 158' ' ' LEU . . . . . 0.606 ' CD2' HG13 ' A' ' 151' ' ' VAL . 40.1 mt -111.74 132.34 54.71 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -0.901 . . . . 0.0 109.577 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 22.0 tttt -94.9 91.74 6.57 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.23 -0.919 . . . . 0.0 109.277 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.892 HG13 ' C ' ' A' ' 147' ' ' VAL . 33.1 t -117.98 144.55 25.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.281 -0.887 . . . . 0.0 109.466 -179.868 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 161' ' ' SER . . . . . 0.491 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 61.8 m -99.84 148.62 24.23 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.241 -0.912 . . . . 0.0 109.45 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 162' ' ' VAL . . . . . 1.034 HG21 ' CD1' ' A' ' 141' ' ' PHE . 6.2 t -96.53 138.39 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.29 -0.881 . . . . 0.0 109.621 -179.873 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 19.7 m -86.58 83.39 7.63 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.266 -0.896 . . . . 0.0 109.254 179.737 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 43.8 mt -98.96 139.28 21.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.254 -0.904 . . . . 0.0 109.537 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -53.79 -41.5 67.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.35 -0.844 . . . . 0.0 109.743 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.526 ' O ' ' CB ' ' A' ' 167' ' ' ARG . . . -60.61 -34.01 84.4 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.646 -1.381 . . . . 0.0 109.646 -179.741 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 167' ' ' ARG . . . . . 0.526 ' CB ' ' O ' ' A' ' 166' ' ' GLY . 17.8 ttp180 161.78 148.49 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.461 -1.023 . . . . 0.0 109.151 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -61.18 143.67 55.11 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.243 -0.91 . . . . 0.0 109.33 179.78 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.482 HG22 HG13 ' A' ' 171' ' ' VAL . 36.6 m -126.36 98.57 32.08 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.17 -0.956 . . . . 0.0 109.554 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.491 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 50.3 Cg_endo -70.26 103.89 1.32 Allowed 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.492 2.128 . . . . 0.0 111.707 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.977 HG23 HD21 ' A' ' 173' ' ' LEU . 14.6 m -129.25 161.08 39.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.246 -0.909 . . . . 0.0 109.523 -179.866 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.845 ' C ' HD22 ' A' ' 173' ' ' LEU . 96.5 mt-10 -99.03 129.15 45.29 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.277 -0.889 . . . . 0.0 109.4 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 173' ' ' LEU . . . . . 0.977 HD21 HG23 ' A' ' 171' ' ' VAL . 2.8 mm? -125.41 146.3 49.67 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.192 -0.942 . . . . 0.0 109.529 -179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 174' ' ' ASP . . . . . 0.439 ' OD1' ' HD3' ' A' ' 157' ' ' ARG . 87.4 m-20 -69.35 170.36 10.52 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.228 -0.92 . . . . 0.0 109.489 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.538 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.7 m-30 -65.74 -40.64 92.34 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.269 -0.895 . . . . 0.0 109.47 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 83.0 p -75.51 -28.66 59.23 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.362 -0.836 . . . . 0.0 109.499 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 177' ' ' GLN . . . . . 0.4 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 90.2 mt-30 -65.76 -23.55 66.75 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.293 -0.879 . . . . 0.0 109.435 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.512 HG13 ' HB3' ' A' ' 173' ' ' LEU . 12.3 m -130.23 164.42 33.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.259 -0.901 . . . . 0.0 109.452 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 179' ' ' GLU . . . . . 0.452 ' N ' ' O ' ' A' ' 135' ' ' ARG . 76.3 mt-10 -119.41 142.49 48.16 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.259 -0.901 . . . . 0.0 109.542 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 180' ' ' LYS . . . . . 0.412 ' NZ ' ' HG ' ' A' ' 127' ' ' LEU . 31.4 ttmt -62.6 134.86 56.97 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.159 -0.963 . . . . 0.0 109.521 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 181' ' ' ALA . . . . . 0.491 ' HB3' ' O ' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.128 -0.982 . . . . 0.0 109.391 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 4.5 mmt180 . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -58.32 143.01 97.93 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.576 2.184 . . . . 0.0 111.76 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 11.1 mtmt -102.12 150.4 23.3 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.3 -0.875 . . . . 0.0 109.514 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 61.8 p -92.62 14.2 17.7 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.289 -0.882 . . . . 0.0 109.466 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.478 ' O ' ' HE3' ' A' ' 180' ' ' LYS . 47.6 mt -89.81 97.67 11.32 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.208 -0.933 . . . . 0.0 109.529 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.625 ' CD2' HD21 ' A' ' 158' ' ' LEU . 89.6 m-85 -106.5 134.43 49.65 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.33 -0.856 . . . . 0.0 109.446 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.487 ' HB3' ' HD2' ' A' ' 130' ' ' PRO . 3.5 mt-10 -139.41 150.04 62.54 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.241 -0.912 . . . . 0.0 109.354 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.487 ' HD2' ' HB3' ' A' ' 129' ' ' GLU . 49.4 Cg_endo -46.33 128.88 12.74 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.418 2.079 . . . . 0.0 111.751 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 93.69 3.61 64.28 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.52 ' O ' HG13 ' A' ' 147' ' ' VAL . 76.7 mm-40 -98.57 138.57 35.57 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.168 -1.196 . . . . 0.0 109.455 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.639 ' HG2' HG22 ' A' ' 147' ' ' VAL . 78.5 mtp -76.12 148.78 37.61 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.23 -0.919 . . . . 0.0 109.468 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.675 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -137.21 179.38 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.26 -0.9 . . . . 0.0 109.375 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.675 ' H ' HG12 ' A' ' 134' ' ' VAL . 43.6 ttt180 -135.7 135.01 39.72 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.104 -0.997 . . . . 0.0 109.503 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.454 ' O ' ' N ' ' A' ' 143' ' ' ASP . 80.3 t -108.73 135.72 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.298 -0.877 . . . . 0.0 109.502 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 31.6 p30 -131.83 18.98 4.62 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.242 -0.911 . . . . 0.0 109.438 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -132.52 144.07 50.17 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.31 -0.869 . . . . 0.0 109.408 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 71.66 175.99 24.57 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -53.22 -19.49 12.51 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.608 2.205 . . . . 0.0 111.779 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 141' ' ' PHE . . . . . 0.434 ' O ' ' HB ' ' A' ' 136' ' ' VAL . 90.5 m-85 -88.61 12.65 14.08 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.279 -0.888 . . . . 0.0 109.415 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 142' ' ' ALA . . . . . 0.448 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -71.96 150.38 44.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.28 -0.888 . . . . 0.0 109.403 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.454 ' N ' ' O ' ' A' ' 136' ' ' VAL . 31.9 m-20 63.49 48.69 3.37 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.169 -0.957 . . . . 0.0 109.449 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.448 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 43.3 m-85 -145.06 143.05 30.24 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.147 -0.971 . . . . 0.0 109.524 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 73.6 m-20 -95.89 145.08 25.67 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.248 -0.908 . . . . 0.0 109.5 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -161.7 -178.42 35.6 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.682 ' O ' HG13 ' A' ' 160' ' ' VAL . 40.6 t -126.1 147.23 30.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.256 -1.143 . . . . 0.0 109.408 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.724 ' HA ' HG22 ' A' ' 160' ' ' VAL . 2.5 p -82.95 99.37 5.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.179 -0.951 . . . . 0.0 109.467 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -66.59 -34.21 77.37 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.245 -0.91 . . . . 0.0 109.391 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.478 ' HB2' ' CD ' ' A' ' 159' ' ' LYS . 75.5 mm-40 -147.0 162.47 38.7 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.27 -0.894 . . . . 0.0 109.386 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.623 HG22 HG21 ' A' ' 148' ' ' VAL . 41.0 t -129.17 146.69 33.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.2 -0.937 . . . . 0.0 109.487 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -127.63 96.48 4.55 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.203 -0.936 . . . . 0.0 109.511 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -66.29 -40.3 89.94 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.305 -0.872 . . . . 0.0 109.475 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -62.37 -42.19 99.21 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.201 -0.937 . . . . 0.0 109.431 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 47.9 mttt -83.93 0.79 46.4 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.278 -0.889 . . . . 0.0 109.548 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 24.3 p 45.62 57.04 5.28 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.216 -0.927 . . . . 0.0 109.465 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.616 ' C ' HD12 ' A' ' 158' ' ' LEU . 30.4 mtt180 -155.49 165.5 36.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.277 -0.89 . . . . 0.0 109.516 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 158' ' ' LEU . . . . . 1.165 HD11 ' CD1' ' A' ' 175' ' ' PHE . 4.3 mp -114.34 137.3 51.98 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.241 -0.912 . . . . 0.0 109.453 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 159' ' ' LYS . . . . . 0.478 ' CD ' ' HB2' ' A' ' 150' ' ' GLU . 40.4 tttp -92.97 94.88 9.15 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.184 -0.947 . . . . 0.0 109.339 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.724 HG22 ' HA ' ' A' ' 148' ' ' VAL . 45.1 t -122.04 146.04 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.28 -0.888 . . . . 0.0 109.602 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 29.3 t -111.82 141.64 45.19 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.329 -0.857 . . . . 0.0 109.28 179.868 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 162' ' ' VAL . . . . . . . . . . . . . 12.1 t -113.28 131.09 65.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.132 -0.98 . . . . 0.0 109.563 -179.85 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 35.5 t -83.24 81.53 8.66 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.291 -0.881 . . . . 0.0 109.403 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.426 ' O ' ' HB3' ' A' ' 165' ' ' PHE . 45.2 mt -102.27 139.03 24.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.288 -0.882 . . . . 0.0 109.321 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 165' ' ' PHE . . . . . 0.522 ' O ' ' CD2' ' A' ' 165' ' ' PHE . 45.7 t80 65.42 12.11 7.88 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.281 -0.887 . . . . 0.0 109.404 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 80.75 11.56 83.81 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 42.1 mtp-105 -120.2 138.25 53.73 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.239 -1.154 . . . . 0.0 109.443 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -71.16 137.76 49.05 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.267 -0.896 . . . . 0.0 109.411 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.57 ' O ' HG13 ' A' ' 171' ' ' VAL . 1.9 m -133.01 75.96 71.07 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.292 -0.88 . . . . 0.0 109.458 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -56.69 104.2 0.14 Allowed 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.622 2.215 . . . . 0.0 111.836 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 1.012 HG23 HD21 ' A' ' 173' ' ' LEU . 18.2 m -129.34 155.56 41.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.305 -0.872 . . . . 0.0 109.419 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.749 ' C ' HD22 ' A' ' 173' ' ' LEU . 95.5 mt-10 -102.01 129.61 48.35 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.217 -0.927 . . . . 0.0 109.522 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 173' ' ' LEU . . . . . 1.012 HD21 HG23 ' A' ' 171' ' ' VAL . 2.3 mm? -121.54 149.82 42.54 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.269 -0.895 . . . . 0.0 109.39 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 174' ' ' ASP . . . . . 0.483 ' O ' HG22 ' A' ' 178' ' ' VAL . 82.1 m-20 -68.93 157.95 35.62 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.279 -0.888 . . . . 0.0 109.515 179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 1.165 ' CD1' HD11 ' A' ' 158' ' ' LEU . 98.7 m-85 -61.25 -40.79 95.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.293 -0.879 . . . . 0.0 109.334 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 28.6 m -74.98 -19.7 59.98 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.222 -0.923 . . . . 0.0 109.313 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 89.9 mt-30 -82.16 -20.01 38.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.348 -0.845 . . . . 0.0 109.245 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.678 HG11 ' HB2' ' A' ' 173' ' ' LEU . 19.3 m -124.9 161.88 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.396 -0.815 . . . . 0.0 109.264 179.821 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 179' ' ' GLU . . . . . 0.412 ' HB2' ' HB3' ' A' ' 135' ' ' ARG . 61.8 mt-10 -121.31 153.26 37.95 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.133 -0.98 . . . . 0.0 109.695 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 180' ' ' LYS . . . . . 0.478 ' HE3' ' O ' ' A' ' 127' ' ' LEU . 17.8 tttm -74.14 135.52 42.87 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.322 -0.861 . . . . 0.0 109.451 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.309 -0.869 . . . . 0.0 109.494 179.989 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 6.8 mmt85 . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -56.35 148.64 60.46 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.587 2.191 . . . . 0.0 111.738 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 33.9 tptt -83.41 133.66 34.92 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.237 -0.915 . . . . 0.0 109.529 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.79 HG23 ' CE2' ' A' ' 128' ' ' PHE . 95.0 m -73.25 125.44 27.78 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.256 -0.903 . . . . 0.0 109.444 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.691 HD23 ' O ' ' A' ' 126' ' ' THR . 48.3 mt -140.5 81.57 1.81 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.162 -0.961 . . . . 0.0 109.695 -179.825 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.79 ' CE2' HG23 ' A' ' 126' ' ' THR . 93.5 m-85 -101.55 120.92 41.05 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.313 -0.867 . . . . 0.0 109.352 179.73 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.487 ' HB2' ' HD2' ' A' ' 130' ' ' PRO . 22.3 pt-20 -142.07 138.75 17.13 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.234 -0.916 . . . . 0.0 109.3 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.509 ' HA ' ' O ' ' A' ' 148' ' ' VAL . 47.7 Cg_endo -35.62 124.11 0.26 Allowed 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.107 1.872 . . . . 0.0 111.721 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 106.25 -0.47 37.83 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.495 ' O ' HG13 ' A' ' 147' ' ' VAL . 75.5 mt-10 -98.21 152.04 19.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.242 -1.152 . . . . 0.0 109.611 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 133' ' ' MET . . . . . 1.013 ' SD ' HG22 ' A' ' 147' ' ' VAL . 68.3 mmm -92.16 148.75 21.92 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.192 -0.943 . . . . 0.0 109.327 179.826 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.674 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -135.99 178.92 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.166 -0.959 . . . . 0.0 109.325 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.674 ' H ' HG12 ' A' ' 134' ' ' VAL . 74.8 mtp85 -134.17 143.96 48.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.179 -0.951 . . . . 0.0 109.343 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.46 ' O ' ' N ' ' A' ' 143' ' ' ASP . 59.0 t -115.43 130.18 70.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.216 -0.927 . . . . 0.0 109.452 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 30.3 p30 -127.89 14.77 6.89 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.298 -0.876 . . . . 0.0 109.482 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.43 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 59.1 t0 -135.82 147.6 48.36 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.292 -0.88 . . . . 0.0 109.475 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.43 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 73.85 172.15 25.31 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -51.35 -21.96 10.98 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.602 2.201 . . . . 0.0 111.69 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 141' ' ' PHE . . . . . 0.728 ' HZ ' HG21 ' A' ' 169' ' ' THR . 98.3 m-85 -85.73 8.94 17.87 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.271 -0.893 . . . . 0.0 109.373 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 142' ' ' ALA . . . . . 0.442 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -64.02 145.27 56.19 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.241 -0.912 . . . . 0.0 109.558 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.46 ' N ' ' O ' ' A' ' 136' ' ' VAL . 31.6 m-20 64.96 46.82 2.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.259 -0.9 . . . . 0.0 109.593 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.427 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 44.9 m-85 -145.46 126.49 14.59 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.246 -0.909 . . . . 0.0 109.535 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 145' ' ' ASN . . . . . 0.462 ' OD1' ' NH2' ' A' ' 135' ' ' ARG . 69.9 m-20 -79.4 137.54 37.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.224 -0.923 . . . . 0.0 109.45 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -149.22 166.78 29.53 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 1.013 HG22 ' SD ' ' A' ' 133' ' ' MET . 15.1 t -108.79 154.87 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.255 -1.144 . . . . 0.0 109.406 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.509 ' O ' ' HA ' ' A' ' 130' ' ' PRO . 1.7 p -96.23 114.93 34.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.323 -0.861 . . . . 0.0 109.356 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.472 ' O ' ' HB3' ' A' ' 130' ' ' PRO . 74.9 mm-40 -75.94 -34.08 59.85 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.3 -0.875 . . . . 0.0 109.315 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.473 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 94.7 mt-10 -158.11 159.15 35.93 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.36 -0.838 . . . . 0.0 109.415 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.493 HG22 HG21 ' A' ' 148' ' ' VAL . 26.3 t -127.59 151.02 33.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.22 -0.925 . . . . 0.0 109.563 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 152' ' ' ASP . . . . . 0.477 ' O ' ' N ' ' A' ' 156' ' ' SER . 83.2 m-20 -120.71 84.46 2.23 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.339 -0.85 . . . . 0.0 109.342 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -57.4 -33.72 68.15 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.234 -0.916 . . . . 0.0 109.502 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -64.75 -41.48 95.88 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.167 -0.958 . . . . 0.0 109.529 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.4 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 29.5 mttt -97.09 -3.77 40.66 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.29 -0.881 . . . . 0.0 109.591 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 156' ' ' SER . . . . . 0.477 ' N ' ' O ' ' A' ' 152' ' ' ASP . 31.8 m 56.95 52.46 9.25 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.194 -0.941 . . . . 0.0 109.543 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.587 ' C ' HD12 ' A' ' 158' ' ' LEU . 48.7 mmm-85 -137.06 155.82 49.17 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.258 -0.901 . . . . 0.0 109.355 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 158' ' ' LEU . . . . . 0.881 HD11 ' CD1' ' A' ' 175' ' ' PHE . 5.0 mp -115.87 139.26 50.38 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.201 -0.937 . . . . 0.0 109.643 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 159' ' ' LYS . . . . . 0.473 ' HD2' ' HB2' ' A' ' 150' ' ' GLU . 84.1 mttt -101.45 89.36 3.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.213 -0.929 . . . . 0.0 109.178 179.653 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.923 HG13 ' O ' ' A' ' 147' ' ' VAL . 24.6 t -114.58 148.64 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.268 -0.895 . . . . 0.0 109.875 -179.617 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 161' ' ' SER . . . . . 0.403 ' HB2' ' HA ' ' A' ' 170' ' ' PRO . 43.9 t -119.37 131.17 55.65 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.378 -0.826 . . . . 0.0 109.242 179.769 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 162' ' ' VAL . . . . . 0.424 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 15.5 t -100.53 134.03 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.209 -0.932 . . . . 0.0 109.697 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 37.2 t -84.53 82.49 8.39 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.229 -0.919 . . . . 0.0 109.275 179.777 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.409 HG21 HD13 ' A' ' 164' ' ' ILE . 37.5 mt -101.86 141.71 17.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.203 -0.936 . . . . 0.0 109.526 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 165' ' ' PHE . . . . . 0.512 ' O ' ' CD2' ' A' ' 165' ' ' PHE . 54.4 t80 63.3 14.04 7.5 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.293 -0.879 . . . . 0.0 109.365 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 83.2 4.06 89.9 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 86.3 mtt-85 -117.85 139.13 51.55 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -1.149 . . . . 0.0 109.422 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -72.16 141.84 49.09 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.352 -0.842 . . . . 0.0 109.463 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.885 ' O ' HG13 ' A' ' 171' ' ' VAL . 32.8 m -128.27 68.71 77.3 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.206 -0.934 . . . . 0.0 109.475 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.407 ' HD2' ' HA ' ' A' ' 169' ' ' THR . 49.4 Cg_endo -45.55 106.64 0.09 OUTLIER 'Trans proline' 0 C--O 1.214 -0.694 0 C-N-CA 122.703 2.269 . . . . 0.0 111.768 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.885 HG13 ' O ' ' A' ' 169' ' ' THR . 21.9 m -133.42 156.49 41.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.219 -0.926 . . . . 0.0 109.565 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.637 ' C ' HD22 ' A' ' 173' ' ' LEU . 94.6 mt-10 -105.39 129.97 53.59 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.301 -0.874 . . . . 0.0 109.334 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 173' ' ' LEU . . . . . 0.882 HD21 HG23 ' A' ' 171' ' ' VAL . 1.9 mm? -119.46 157.81 27.5 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.189 -0.945 . . . . 0.0 109.618 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 174' ' ' ASP . . . . . 0.439 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 91.1 m-20 -79.64 157.89 27.17 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.352 -0.843 . . . . 0.0 109.573 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.881 ' CD1' HD11 ' A' ' 158' ' ' LEU . 3.6 m-85 -49.71 -49.39 48.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.305 -0.872 . . . . 0.0 109.785 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 11.2 m -71.15 -24.74 62.32 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.237 -0.914 . . . . 0.0 109.692 -179.754 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 177' ' ' GLN . . . . . 0.439 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 81.7 mt-30 -70.36 -24.72 63.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.218 -0.926 . . . . 0.0 109.722 -179.813 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.511 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 17.5 m -131.06 161.82 40.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.189 -0.945 . . . . 0.0 109.511 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 179' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -120.67 145.46 47.42 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.296 -0.878 . . . . 0.0 109.473 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 180' ' ' LYS . . . . . 0.461 ' HE3' ' O ' ' A' ' 127' ' ' LEU . 30.2 tttm -69.67 134.61 48.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.302 -0.874 . . . . 0.0 109.481 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.495 0 O-C-N 121.163 -0.96 . . . . 0.0 109.485 179.985 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.561 ' CB ' ' CD ' ' A' ' 124' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 . . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.561 ' CD ' ' CB ' ' A' ' 123' ' ' ARG . 51.1 Cg_endo -54.42 150.34 34.46 Favored 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 122.626 2.217 . . . . 0.0 111.862 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 125' ' ' LYS . . . . . 0.452 ' O ' ' HE3' ' A' ' 180' ' ' LYS . 11.4 pttt -131.35 156.69 45.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.285 -0.884 . . . . 0.0 109.483 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.403 ' HA ' ' HE3' ' A' ' 180' ' ' LYS . 63.2 p -114.22 30.72 7.09 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.321 -0.862 . . . . 0.0 109.485 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 56.2 mt -80.63 99.45 8.15 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.183 -0.948 . . . . 0.0 109.554 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.909 ' O ' HG21 ' A' ' 151' ' ' VAL . 69.1 m-85 -86.34 132.29 34.0 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.324 -0.86 . . . . 0.0 109.453 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.464 ' HB3' ' HD2' ' A' ' 130' ' ' PRO . 1.2 mp0 -109.24 138.16 20.4 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.296 -0.878 . . . . 0.0 109.399 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.464 ' HD2' ' HB3' ' A' ' 129' ' ' GLU . 50.6 Cg_endo -39.68 133.99 1.57 Allowed 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.549 2.166 . . . . 0.0 111.765 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 84.69 8.45 82.83 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 45.7 tp10 -102.25 135.04 44.55 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.263 -1.14 . . . . 0.0 109.443 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.553 ' HG2' HG22 ' A' ' 147' ' ' VAL . 76.3 mtp -70.28 148.17 48.83 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.248 -0.908 . . . . 0.0 109.456 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.749 HG13 ' CE2' ' A' ' 128' ' ' PHE . 2.5 t -136.72 179.08 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.26 -0.9 . . . . 0.0 109.353 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.673 ' H ' HG12 ' A' ' 134' ' ' VAL . 70.3 ttt180 -136.51 143.12 43.59 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.263 -0.898 . . . . 0.0 109.43 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.632 HG11 ' HB2' ' A' ' 141' ' ' PHE . 60.3 t -111.16 124.86 68.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.258 -0.902 . . . . 0.0 109.524 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 26.4 p30 -124.77 22.31 8.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -0.905 . . . . 0.0 109.511 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -145.15 140.98 28.35 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.328 -0.858 . . . . 0.0 109.479 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 81.62 -179.82 53.26 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -58.67 -20.18 49.35 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.679 2.252 . . . . 0.0 111.764 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 141' ' ' PHE . . . . . 0.888 ' CZ ' HG11 ' A' ' 171' ' ' VAL . 99.2 m-85 -87.38 10.15 18.33 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.239 -0.913 . . . . 0.0 109.379 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 142' ' ' ALA . . . . . 0.505 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -64.17 152.99 39.21 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.282 -0.886 . . . . 0.0 109.59 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.453 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 58.8 m-20 63.65 42.57 6.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.3 -0.875 . . . . 0.0 109.676 179.746 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.556 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 58.8 m-85 -145.51 152.64 40.08 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.164 -0.96 . . . . 0.0 109.494 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 43.7 p-10 -113.63 167.06 10.92 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.238 -0.914 . . . . 0.0 109.395 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 179.35 -170.45 42.03 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.553 HG22 ' HG2' ' A' ' 133' ' ' MET . 43.0 t -129.11 150.43 34.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.225 -1.162 . . . . 0.0 109.517 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.664 ' HA ' HG22 ' A' ' 160' ' ' VAL . 2.5 p -91.05 113.83 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.203 -0.936 . . . . 0.0 109.497 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.423 ' N ' ' O ' ' A' ' 159' ' ' LYS . 75.8 mm-40 -67.02 -37.1 83.54 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.222 -0.924 . . . . 0.0 109.445 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.406 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 94.9 mt-10 -153.97 163.38 40.15 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.223 -0.923 . . . . 0.0 109.501 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 1.073 HG13 ' CD2' ' A' ' 158' ' ' LEU . 45.7 t -127.27 146.32 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.247 -0.908 . . . . 0.0 109.535 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -133.02 90.88 2.8 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.277 -0.89 . . . . 0.0 109.5 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -62.93 -38.82 92.54 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.214 -0.929 . . . . 0.0 109.502 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -61.25 -41.7 97.35 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.48 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.459 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 60.2 mttm -92.23 -2.25 56.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -0.893 . . . . 0.0 109.601 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 156' ' ' SER . . . . . 0.473 ' HA ' ' CZ ' ' A' ' 175' ' ' PHE . 12.9 m 50.23 52.52 14.59 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.28 -0.887 . . . . 0.0 109.587 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.459 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 13.7 mmt85 -146.15 142.77 28.79 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.295 -0.878 . . . . 0.0 109.468 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 158' ' ' LEU . . . . . 1.073 ' CD2' HG13 ' A' ' 151' ' ' VAL . 49.0 mt -116.34 133.19 56.29 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.196 -0.94 . . . . 0.0 109.497 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 159' ' ' LYS . . . . . 0.441 ' O ' ' HA ' ' A' ' 148' ' ' VAL . 65.5 mttm -87.39 100.64 12.88 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.282 -0.886 . . . . 0.0 109.346 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.664 HG22 ' HA ' ' A' ' 148' ' ' VAL . 57.6 t -128.34 138.75 53.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.176 -0.952 . . . . 0.0 109.524 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 161' ' ' SER . . . . . 0.467 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 88.3 p -107.2 148.13 29.28 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.272 -0.893 . . . . 0.0 109.431 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 162' ' ' VAL . . . . . 0.556 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 3.8 t -115.33 130.02 70.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.211 -0.931 . . . . 0.0 109.637 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 33.2 t -75.58 90.59 2.78 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.221 -0.924 . . . . 0.0 109.153 179.639 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.93 HG22 ' CD2' ' A' ' 165' ' ' PHE . 38.2 mt -106.53 137.35 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.307 -0.871 . . . . 0.0 109.42 -179.735 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 165' ' ' PHE . . . . . 0.93 ' CD2' HG22 ' A' ' 164' ' ' ILE . 91.1 m-85 48.46 -126.2 1.92 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.276 -0.89 . . . . 0.0 109.15 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -119.34 31.46 5.42 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 46.0 tpt85 -145.0 132.98 21.3 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.089 -1.242 . . . . 0.0 109.546 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -72.76 138.89 46.76 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.206 -0.934 . . . . 0.0 109.477 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.658 ' O ' HG13 ' A' ' 171' ' ' VAL . 10.1 m -122.53 75.78 44.88 Favored Pre-proline 0 N--CA 1.488 1.465 0 O-C-N 121.128 -0.983 . . . . 0.0 109.484 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.467 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.4 Cg_endo -56.13 110.73 0.61 Allowed 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.572 2.181 . . . . 0.0 111.734 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 1.031 HG23 HD21 ' A' ' 173' ' ' LEU . 16.5 m -129.6 154.87 40.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.26 -0.9 . . . . 0.0 109.502 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.786 ' C ' HD22 ' A' ' 173' ' ' LEU . 95.7 mt-10 -100.69 125.88 47.16 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.222 -0.923 . . . . 0.0 109.459 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 173' ' ' LEU . . . . . 1.031 HD21 HG23 ' A' ' 171' ' ' VAL . 2.6 mm? -122.93 147.18 46.9 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.311 -0.868 . . . . 0.0 109.434 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 174' ' ' ASP . . . . . 0.427 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 90.3 m-20 -65.41 169.14 6.25 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.209 -0.932 . . . . 0.0 109.457 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.565 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.3 m-30 -64.4 -36.83 85.44 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.178 -0.951 . . . . 0.0 109.462 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 86.1 p -80.07 -25.87 39.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.248 -0.907 . . . . 0.0 109.429 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 177' ' ' GLN . . . . . 0.427 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 86.2 mt-30 -66.57 -27.3 67.62 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.189 -0.945 . . . . 0.0 109.422 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.528 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 4.6 m -123.89 156.73 30.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.291 -0.881 . . . . 0.0 109.499 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 179' ' ' GLU . . . . . 0.502 ' O ' ' N ' ' A' ' 135' ' ' ARG . 83.6 tt0 -116.51 156.17 27.37 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.31 -0.869 . . . . 0.0 109.463 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 180' ' ' LYS . . . . . 0.456 ' HG2' ' CE2' ' A' ' 128' ' ' PHE . 54.4 mttt -69.89 142.88 52.93 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.233 -0.917 . . . . 0.0 109.481 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.578 0 O-C-N 121.267 -0.895 . . . . 0.0 109.472 179.999 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 1.4 mmt85 . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -56.48 144.93 82.35 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.575 2.183 . . . . 0.0 111.789 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' LYS . . . . . 0.469 ' O ' ' HG ' ' A' ' 127' ' ' LEU . 53.9 mttp -97.8 25.88 5.56 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.211 -0.931 . . . . 0.0 109.42 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 61.2 p 48.17 23.3 0.51 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.34 -0.85 . . . . 0.0 109.631 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.469 ' HG ' ' O ' ' A' ' 125' ' ' LYS . 26.2 mt -94.5 99.75 11.86 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.232 -0.917 . . . . 0.0 109.496 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.624 ' CE1' HG13 ' A' ' 134' ' ' VAL . 50.8 m-85 -92.43 138.31 31.63 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.256 -0.903 . . . . 0.0 109.489 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.534 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.0 OUTLIER -134.57 156.91 78.36 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.312 -0.868 . . . . 0.0 109.454 179.99 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.534 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.2 Cg_endo -48.66 130.31 22.1 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.626 2.217 . . . . 0.0 111.819 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 90.15 10.26 64.48 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -113.42 138.9 49.42 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.243 -1.151 . . . . 0.0 109.51 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.569 ' HG2' HG22 ' A' ' 147' ' ' VAL . 87.1 mtp -79.77 149.25 31.16 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.294 -0.879 . . . . 0.0 109.527 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.687 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -131.93 179.08 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.314 -0.866 . . . . 0.0 109.387 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.687 ' H ' HG12 ' A' ' 134' ' ' VAL . 24.4 tpt180 -130.88 138.92 50.03 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.284 -0.885 . . . . 0.0 109.365 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.491 HG13 HD13 ' A' ' 173' ' ' LEU . 28.7 t -103.98 130.56 54.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.24 -0.912 . . . . 0.0 109.539 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 137' ' ' ASN . . . . . 0.428 ' OD1' ' C ' ' A' ' 137' ' ' ASN . 22.2 p30 -132.03 18.08 4.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.324 -0.86 . . . . 0.0 109.403 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.473 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 59.7 t0 -140.66 148.67 41.19 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.204 -0.935 . . . . 0.0 109.499 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.473 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 73.0 172.85 23.57 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -52.99 -19.83 12.24 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.652 2.235 . . . . 0.0 111.786 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 141' ' ' PHE . . . . . 0.632 ' CD1' HG11 ' A' ' 162' ' ' VAL . 97.9 m-85 -87.43 10.31 17.96 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.183 -0.948 . . . . 0.0 109.444 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 142' ' ' ALA . . . . . 0.499 ' O ' ' CB ' ' A' ' 143' ' ' ASP . . . -66.29 147.77 52.83 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.256 -0.902 . . . . 0.0 109.485 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.499 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 24.9 t0 74.34 28.26 1.37 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.291 -0.881 . . . . 0.0 109.471 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -134.38 153.27 51.99 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.292 -0.88 . . . . 0.0 109.466 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 43.2 p-10 -113.77 165.54 12.45 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.258 -0.901 . . . . 0.0 109.425 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -174.07 -177.1 43.0 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.569 HG22 ' HG2' ' A' ' 133' ' ' MET . 44.2 t -117.27 161.28 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.213 -1.169 . . . . 0.0 109.477 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.847 HG11 HG22 ' A' ' 151' ' ' VAL . 79.4 t -93.4 96.25 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.213 -0.929 . . . . 0.0 109.524 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -66.02 -31.92 73.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.247 -0.908 . . . . 0.0 109.429 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.409 ' O ' ' HB3' ' A' ' 159' ' ' LYS . 84.7 tt0 -148.83 150.25 32.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.286 -0.884 . . . . 0.0 109.415 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.847 HG22 HG11 ' A' ' 148' ' ' VAL . 45.3 t -124.19 149.99 28.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.214 -0.929 . . . . 0.0 109.516 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 152' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 95.2 m-20 -136.48 79.88 1.79 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.216 -0.928 . . . . 0.0 109.502 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 153' ' ' TYR . . . . . 0.507 ' CZ ' HG11 ' A' ' 151' ' ' VAL . 98.9 m-85 -63.64 -37.46 87.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.227 -0.921 . . . . 0.0 109.518 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -59.42 -46.45 88.68 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.185 -0.947 . . . . 0.0 109.528 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.473 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 58.1 mttt -90.72 0.5 57.4 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.268 -0.895 . . . . 0.0 109.548 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 31.1 t 56.06 52.82 9.89 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.196 -0.94 . . . . 0.0 109.485 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.473 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 22.9 mmt85 -140.29 140.51 35.72 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.275 -0.891 . . . . 0.0 109.367 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 158' ' ' LEU . . . . . 0.478 HD11 ' CD1' ' A' ' 175' ' ' PHE . 61.5 mt -110.06 129.47 55.68 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.162 -0.962 . . . . 0.0 109.522 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 159' ' ' LYS . . . . . 0.441 ' HG3' ' OE2' ' A' ' 172' ' ' GLU . 29.4 tttp -92.31 104.79 17.1 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.331 -0.856 . . . . 0.0 109.352 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.541 HG13 ' O ' ' A' ' 147' ' ' VAL . 44.4 t -124.64 140.62 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.29 -0.881 . . . . 0.0 109.545 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 161' ' ' SER . . . . . 0.46 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 30.1 t -109.17 137.65 46.74 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.295 -0.878 . . . . 0.0 109.462 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 162' ' ' VAL . . . . . 0.742 HG12 ' HB ' ' A' ' 169' ' ' THR . 9.4 p -104.9 138.86 27.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.185 -0.947 . . . . 0.0 109.636 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 163' ' ' SER . . . . . 0.438 ' HA ' ' O ' ' A' ' 167' ' ' ARG . 5.3 m -102.7 95.2 6.05 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.215 -0.928 . . . . 0.0 109.461 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 1.06 HG22 ' CD2' ' A' ' 165' ' ' PHE . 37.4 mt -114.52 134.77 56.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.226 -0.921 . . . . 0.0 109.545 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 165' ' ' PHE . . . . . 1.06 ' CD2' HG22 ' A' ' 164' ' ' ILE . 94.3 m-85 59.4 23.97 12.54 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.271 -0.893 . . . . 0.0 109.485 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 78.64 14.3 82.24 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 167' ' ' ARG . . . . . 0.438 ' O ' ' HA ' ' A' ' 163' ' ' SER . 62.2 mtt180 -117.95 148.34 42.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.197 -1.178 . . . . 0.0 109.516 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -98.19 139.12 34.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.232 -0.918 . . . . 0.0 109.497 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.781 ' O ' HG13 ' A' ' 171' ' ' VAL . 6.0 m -129.81 74.04 80.98 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.287 -0.883 . . . . 0.0 109.453 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.46 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.7 Cg_endo -49.08 109.9 0.31 Allowed 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.603 2.202 . . . . 0.0 111.774 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.781 HG13 ' O ' ' A' ' 169' ' ' THR . 23.6 m -128.96 156.8 41.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.29 -0.881 . . . . 0.0 109.514 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.735 ' O ' HD23 ' A' ' 173' ' ' LEU . 75.7 mm-40 -101.6 130.65 47.97 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.293 -0.88 . . . . 0.0 109.465 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 173' ' ' LEU . . . . . 0.735 HD23 ' O ' ' A' ' 172' ' ' GLU . 51.8 mt -131.28 148.81 52.73 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.245 -0.91 . . . . 0.0 109.419 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -74.91 171.54 13.85 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.213 -0.93 . . . . 0.0 109.447 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.583 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.7 m-30 -64.25 -36.81 85.29 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.318 -0.864 . . . . 0.0 109.439 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 83.4 p -79.58 -26.97 41.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.312 -0.867 . . . . 0.0 109.355 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 67.0 mt-30 -68.86 -19.69 64.25 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.26 -0.9 . . . . 0.0 109.381 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.466 HG11 ' HB2' ' A' ' 173' ' ' LEU . 4.2 m -135.73 154.4 34.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.217 -0.927 . . . . 0.0 109.526 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 179' ' ' GLU . . . . . 0.504 ' O ' ' N ' ' A' ' 135' ' ' ARG . 37.7 mt-10 -120.07 166.53 13.27 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.278 -0.888 . . . . 0.0 109.427 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 180' ' ' LYS . . . . . 0.452 ' HG2' ' CE1' ' A' ' 128' ' ' PHE . 54.9 mttt -71.97 145.83 48.14 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.229 -0.919 . . . . 0.0 109.551 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.521 0 O-C-N 121.285 -0.884 . . . . 0.0 109.498 179.999 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -56.13 148.69 57.96 Favored 'Trans proline' 0 C--O 1.214 -0.689 0 C-N-CA 122.596 2.197 . . . . 0.0 111.717 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 23.6 mttm -85.56 148.73 25.79 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.249 -0.907 . . . . 0.0 109.536 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.405 ' HA ' ' CE2' ' A' ' 128' ' ' PHE . 69.3 p -98.08 15.87 22.9 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.268 -0.895 . . . . 0.0 109.482 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.456 ' O ' ' HE3' ' A' ' 180' ' ' LYS . 52.5 mt -88.11 98.26 11.44 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.235 -0.915 . . . . 0.0 109.456 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.405 ' CE2' ' HA ' ' A' ' 126' ' ' THR . 83.8 m-85 -109.2 139.83 43.61 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.17 -0.956 . . . . 0.0 109.482 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.468 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.0 OUTLIER -135.77 153.18 77.11 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.262 -0.899 . . . . 0.0 109.445 -179.968 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.468 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.4 Cg_endo -47.18 133.21 19.06 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.593 2.195 . . . . 0.0 111.793 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 86.51 3.1 84.42 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 50.2 tp10 -88.05 137.57 32.21 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.202 -1.175 . . . . 0.0 109.544 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.497 ' HG2' HG22 ' A' ' 147' ' ' VAL . 77.4 mtp -79.44 149.49 31.57 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.279 -0.888 . . . . 0.0 109.446 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.735 ' CG2' HG23 ' A' ' 148' ' ' VAL . 2.5 t -139.25 179.0 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.266 -0.896 . . . . 0.0 109.318 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.673 ' H ' HG12 ' A' ' 134' ' ' VAL . 18.5 mtp-105 -137.47 142.49 41.54 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.245 -0.91 . . . . 0.0 109.466 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.479 HG22 HG12 ' A' ' 178' ' ' VAL . 43.3 t -111.56 135.2 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.232 -0.917 . . . . 0.0 109.537 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 38.2 p30 -127.08 15.52 7.32 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.54 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.487 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 59.2 t0 -142.06 153.53 44.27 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.28 -0.888 . . . . 0.0 109.462 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.487 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 75.38 171.02 28.86 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -54.93 -18.47 16.73 Favored 'Trans proline' 0 C--O 1.214 -0.705 0 C-N-CA 122.578 2.185 . . . . 0.0 111.792 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 141' ' ' PHE . . . . . 0.699 ' CD1' HG11 ' A' ' 162' ' ' VAL . 90.5 m-85 -92.79 14.92 15.86 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.25 -0.906 . . . . 0.0 109.454 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 142' ' ' ALA . . . . . 0.449 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -66.23 149.51 50.23 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.301 -0.874 . . . . 0.0 109.523 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.449 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 43.7 m-20 64.03 46.85 3.58 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.232 -0.918 . . . . 0.0 109.473 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -140.79 142.01 34.73 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.295 -0.878 . . . . 0.0 109.531 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 73.0 m-20 -100.81 142.4 32.33 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.245 -0.909 . . . . 0.0 109.462 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.54 177.94 34.98 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.613 ' O ' HG13 ' A' ' 160' ' ' VAL . 49.0 t -114.29 164.2 10.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.184 -1.186 . . . . 0.0 109.438 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.735 HG23 ' CG2' ' A' ' 134' ' ' VAL . 98.6 t -93.16 95.54 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.257 -0.902 . . . . 0.0 109.553 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -67.42 -34.52 77.4 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.178 -0.951 . . . . 0.0 109.432 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.502 ' HB2' ' CD ' ' A' ' 159' ' ' LYS . 94.2 mt-10 -151.23 161.49 42.61 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.237 -0.915 . . . . 0.0 109.332 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.506 HG11 ' CZ ' ' A' ' 153' ' ' TYR . 44.1 t -124.25 151.35 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.206 -0.934 . . . . 0.0 109.569 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -125.49 78.3 1.72 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.236 -0.915 . . . . 0.0 109.413 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 153' ' ' TYR . . . . . 0.506 ' CZ ' HG11 ' A' ' 151' ' ' VAL . 83.9 m-85 -63.68 -37.05 85.87 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.338 -0.851 . . . . 0.0 109.569 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -60.74 -42.83 98.15 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.247 -0.908 . . . . 0.0 109.532 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.474 ' O ' ' HG3' ' A' ' 157' ' ' ARG . 45.9 mttp -94.68 3.03 55.56 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.241 -0.912 . . . . 0.0 109.604 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 56.62 51.98 10.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.245 -0.909 . . . . 0.0 109.464 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.474 ' HG3' ' O ' ' A' ' 155' ' ' LYS . 58.1 mtt180 -146.29 157.49 43.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.281 -0.887 . . . . 0.0 109.522 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 158' ' ' LEU . . . . . 0.545 HD21 ' CE1' ' A' ' 175' ' ' PHE . 18.2 mt -115.01 135.56 54.09 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.199 -0.938 . . . . 0.0 109.451 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 159' ' ' LYS . . . . . 0.502 ' CD ' ' HB2' ' A' ' 150' ' ' GLU . 31.0 tttp -87.99 105.92 17.78 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.269 -0.894 . . . . 0.0 109.318 179.855 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.613 HG13 ' O ' ' A' ' 147' ' ' VAL . 39.9 t -121.99 143.46 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.228 -0.92 . . . . 0.0 109.636 -179.833 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 93.5 p -110.31 145.24 37.79 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.263 -0.898 . . . . 0.0 109.41 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 162' ' ' VAL . . . . . 0.765 HG12 ' HB ' ' A' ' 169' ' ' THR . 9.8 p -115.93 138.89 44.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.226 -0.921 . . . . 0.0 109.527 -179.899 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 163' ' ' SER . . . . . 0.403 ' HA ' ' O ' ' A' ' 167' ' ' ARG . 37.8 t -102.82 97.55 7.68 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.256 -0.903 . . . . 0.0 109.408 179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 29.9 mt -116.04 135.88 54.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.28 -0.887 . . . . 0.0 109.498 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 9.0 m-30 57.91 28.12 15.65 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.211 -0.931 . . . . 0.0 109.494 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 72.03 21.19 79.2 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 167' ' ' ARG . . . . . 0.403 ' O ' ' HA ' ' A' ' 163' ' ' SER . 65.7 mtt-85 -119.18 143.79 47.04 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.279 -1.13 . . . . 0.0 109.463 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -91.43 134.37 34.69 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.265 -0.897 . . . . 0.0 109.54 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.765 ' HB ' HG12 ' A' ' 162' ' ' VAL . 0.2 OUTLIER -128.3 74.11 79.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.312 -0.867 . . . . 0.0 109.458 -179.963 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -57.6 104.64 0.17 Allowed 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.598 2.198 . . . . 0.0 111.805 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 1.018 HG23 HD21 ' A' ' 173' ' ' LEU . 19.3 m -130.41 155.95 42.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.253 -0.905 . . . . 0.0 109.538 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.737 ' C ' HD22 ' A' ' 173' ' ' LEU . 95.2 mt-10 -104.03 128.94 51.63 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.236 -0.915 . . . . 0.0 109.46 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 173' ' ' LEU . . . . . 1.018 HD21 HG23 ' A' ' 171' ' ' VAL . 2.3 mm? -121.29 145.67 47.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.248 -0.907 . . . . 0.0 109.432 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 64.6 m-20 -65.63 173.48 2.76 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.263 -0.898 . . . . 0.0 109.38 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.545 ' CE1' HD21 ' A' ' 158' ' ' LEU . 4.2 m-30 -66.65 -44.47 81.8 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.252 -0.905 . . . . 0.0 109.471 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 18.7 m -73.09 -23.62 60.55 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.201 -0.937 . . . . 0.0 109.384 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -70.78 -23.8 62.46 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.298 -0.876 . . . . 0.0 109.39 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.555 HG11 ' HB2' ' A' ' 173' ' ' LEU . 6.0 m -131.43 163.42 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.31 -0.869 . . . . 0.0 109.378 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 179' ' ' GLU . . . . . . . . . . . . . 74.3 mm-40 -119.0 145.45 45.83 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.172 -0.955 . . . . 0.0 109.485 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 180' ' ' LYS . . . . . 0.456 ' HE3' ' O ' ' A' ' 127' ' ' LEU . 18.3 tttm -64.87 140.0 58.82 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.202 -0.936 . . . . 0.0 109.463 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.542 0 O-C-N 121.207 -0.933 . . . . 0.0 109.44 -179.942 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.418 ' HA ' ' HD2' ' A' ' 124' ' ' PRO . 7.1 ttt180 . . . . . 0 N--CA 1.489 1.519 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.418 ' HD2' ' HA ' ' A' ' 123' ' ' ARG . 50.8 Cg_endo -50.67 143.23 29.47 Favored 'Trans proline' 0 C--O 1.216 -0.596 0 C-N-CA 122.441 2.094 . . . . 0.0 111.787 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 125' ' ' LYS . . . . . 0.527 ' CB ' ' HG ' ' A' ' 127' ' ' LEU . 20.8 mttt -99.5 20.01 14.63 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.186 -0.946 . . . . 0.0 109.527 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 126' ' ' THR . . . . . 0.425 HG22 ' CE2' ' A' ' 128' ' ' PHE . 0.0 OUTLIER 40.16 33.1 0.14 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.665 -0.647 . . . . 0.0 109.829 179.795 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.527 ' HG ' ' CB ' ' A' ' 125' ' ' LYS . 39.4 mt -89.62 100.23 13.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.236 -0.915 . . . . 0.0 109.658 -179.88 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.71 ' CE1' HG13 ' A' ' 134' ' ' VAL . 59.4 m-85 -93.98 140.63 29.47 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.296 -0.877 . . . . 0.0 109.424 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 129' ' ' GLU . . . . . 0.429 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 3.9 mt-10 -122.77 154.75 63.88 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.245 -0.909 . . . . 0.0 109.353 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.429 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.3 Cg_endo -51.15 129.05 27.15 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.597 2.198 . . . . 0.0 111.804 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 84.44 13.24 73.87 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.422 ' OE1' ' HA ' ' A' ' 128' ' ' PHE . 77.5 tt0 -104.13 133.83 48.4 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.236 -1.155 . . . . 0.0 109.443 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.605 ' HG2' HG22 ' A' ' 147' ' ' VAL . 85.7 mtp -69.36 144.97 53.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.316 -0.865 . . . . 0.0 109.545 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.752 HG21 HG23 ' A' ' 148' ' ' VAL . 2.5 t -133.11 178.87 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.344 -0.847 . . . . 0.0 109.363 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.686 ' H ' HG12 ' A' ' 134' ' ' VAL . 40.9 ttm180 -129.15 136.08 49.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.275 -0.891 . . . . 0.0 109.326 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.462 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 39.5 t -106.34 130.34 58.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.215 -0.928 . . . . 0.0 109.529 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 137' ' ' ASN . . . . . 0.408 ' OD1' ' C ' ' A' ' 137' ' ' ASN . 43.0 p30 -127.61 17.4 6.93 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.282 -0.886 . . . . 0.0 109.443 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.462 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 60.1 t0 -136.98 147.17 46.13 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.306 -0.871 . . . . 0.0 109.468 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.462 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 74.58 173.62 30.93 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -57.2 -17.21 24.74 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.627 2.218 . . . . 0.0 111.883 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 141' ' ' PHE . . . . . 0.732 ' CD1' HG21 ' A' ' 162' ' ' VAL . 99.7 m-85 -90.23 12.68 17.35 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.13 -0.981 . . . . 0.0 109.452 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 142' ' ' ALA . . . . . 0.516 ' O ' ' CB ' ' A' ' 143' ' ' ASP . . . -72.5 147.15 46.3 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.276 -0.89 . . . . 0.0 109.509 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.516 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 24.9 t0 75.74 28.69 0.89 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.272 -0.893 . . . . 0.0 109.529 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.544 ' HB3' HG13 ' A' ' 162' ' ' VAL . 91.8 m-85 -132.26 146.26 51.87 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.155 -0.966 . . . . 0.0 109.514 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -98.5 144.73 27.51 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.245 -0.909 . . . . 0.0 109.442 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -157.52 -178.77 31.89 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.605 HG22 ' HG2' ' A' ' 133' ' ' MET . 28.3 t -124.08 156.36 31.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.227 -1.161 . . . . 0.0 109.408 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.752 HG23 HG21 ' A' ' 134' ' ' VAL . 87.5 t -89.25 100.54 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.206 -0.934 . . . . 0.0 109.388 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -65.47 -38.26 89.26 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.209 -0.932 . . . . 0.0 109.499 179.875 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -145.43 165.71 27.76 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.234 -0.916 . . . . 0.0 109.478 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.488 HG22 HG11 ' A' ' 148' ' ' VAL . 41.2 t -129.45 150.82 34.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.3 -0.875 . . . . 0.0 109.497 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 152' ' ' ASP . . . . . 0.406 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 88.8 m-20 -134.45 83.2 2.02 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.268 -0.895 . . . . 0.0 109.413 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 153' ' ' TYR . . . . . 0.413 ' CZ ' HG11 ' A' ' 151' ' ' VAL . 96.4 m-85 -64.77 -37.95 89.33 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.178 -0.951 . . . . 0.0 109.468 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 154' ' ' GLU . . . . . 0.417 ' OE1' ' HA ' ' A' ' 154' ' ' GLU . 72.8 mm-40 -60.53 -44.65 95.84 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.267 -0.896 . . . . 0.0 109.491 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.479 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 93.4 mttt -90.63 -1.0 57.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.306 -0.871 . . . . 0.0 109.559 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 48.9 m 54.32 53.09 11.41 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.146 -0.971 . . . . 0.0 109.495 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.479 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 20.1 mmt85 -144.5 144.82 31.53 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.142 -0.973 . . . . 0.0 109.465 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 158' ' ' LEU . . . . . 0.51 HD21 ' CE1' ' A' ' 175' ' ' PHE . 55.6 mt -111.87 126.14 54.78 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.254 -0.904 . . . . 0.0 109.537 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 60.4 tttt -83.92 105.14 14.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.178 -0.952 . . . . 0.0 109.415 179.786 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.75 HG22 HG22 ' A' ' 148' ' ' VAL . 38.1 t -124.21 141.27 44.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.25 -0.906 . . . . 0.0 109.434 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 161' ' ' SER . . . . . 0.445 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 23.6 t -112.44 134.49 53.95 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.278 -0.889 . . . . 0.0 109.611 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 162' ' ' VAL . . . . . 0.732 HG21 ' CD1' ' A' ' 141' ' ' PHE . 3.7 t -88.84 130.32 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.234 -0.916 . . . . 0.0 109.47 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 59.3 m -81.15 82.11 7.16 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.228 -0.92 . . . . 0.0 109.387 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 54.8 mt -96.1 139.46 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.278 -0.889 . . . . 0.0 109.453 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 20.6 m-85 -51.87 -44.8 63.84 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.298 -0.876 . . . . 0.0 109.665 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 166' ' ' GLY . . . . . 0.533 ' O ' ' CB ' ' A' ' 167' ' ' ARG . . . -53.96 -35.61 54.09 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.656 -1.377 . . . . 0.0 109.656 -179.684 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 167' ' ' ARG . . . . . 0.533 ' CB ' ' O ' ' A' ' 166' ' ' GLY . 30.5 ttp180 160.48 146.86 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.376 -1.073 . . . . 0.0 109.006 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -63.16 136.71 57.91 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.243 -0.911 . . . . 0.0 109.292 179.841 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.582 HG21 ' CZ ' ' A' ' 141' ' ' PHE . 63.0 m -123.36 91.92 49.35 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.192 -0.943 . . . . 0.0 109.662 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.445 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.8 Cg_endo -64.33 109.85 1.26 Allowed 'Trans proline' 0 C--O 1.216 -0.603 0 C-N-CA 122.502 2.134 . . . . 0.0 111.533 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 1.111 HG23 HD21 ' A' ' 173' ' ' LEU . 17.6 m -128.2 158.07 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.194 -0.942 . . . . 0.0 109.69 -179.806 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.681 ' O ' HD13 ' A' ' 173' ' ' LEU . 95.5 mt-10 -100.04 125.07 46.05 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.383 -0.823 . . . . 0.0 109.348 179.843 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 173' ' ' LEU . . . . . 1.111 HD21 HG23 ' A' ' 171' ' ' VAL . 1.7 mm? -120.48 145.63 47.07 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.203 -0.936 . . . . 0.0 109.493 -179.842 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 174' ' ' ASP . . . . . 0.446 ' OD1' ' HD3' ' A' ' 157' ' ' ARG . 88.3 m-20 -68.84 170.81 8.9 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.224 -0.923 . . . . 0.0 109.452 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.577 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.5 m-30 -65.67 -44.21 86.95 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.217 -0.927 . . . . 0.0 109.436 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 11.1 m -76.0 -24.31 55.3 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.151 -0.968 . . . . 0.0 109.422 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 177' ' ' GLN . . . . . 0.427 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 86.5 mt-30 -69.68 -18.81 63.58 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.265 -0.897 . . . . 0.0 109.339 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.612 HG11 ' HB2' ' A' ' 173' ' ' LEU . 4.8 m -132.35 162.85 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.343 -0.848 . . . . 0.0 109.427 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 179' ' ' GLU . . . . . 0.507 ' O ' ' N ' ' A' ' 135' ' ' ARG . 60.7 mt-10 -126.38 161.73 27.18 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.29 -0.881 . . . . 0.0 109.554 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 84.5 mttt -67.36 144.28 55.91 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.204 -0.935 . . . . 0.0 109.447 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.566 0 O-C-N 121.202 -0.937 . . . . 0.0 109.481 179.959 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.513 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -53.48 147.0 39.71 Favored 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.527 2.151 . . . . 0.0 111.827 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' LYS . . . . . 0.444 ' O ' ' HD2' ' A' ' 180' ' ' LYS . 23.3 mttm -94.66 149.68 21.0 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.225 -0.922 . . . . 0.0 109.464 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 42.6 p -107.74 26.44 10.3 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.226 -0.921 . . . . 0.0 109.457 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 60.0 mt -101.2 95.53 6.6 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.278 -0.889 . . . . 0.0 109.518 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -99.17 128.3 45.28 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.218 -0.927 . . . . 0.0 109.449 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -118.47 146.97 40.91 Favored Pre-proline 0 N--CA 1.489 1.488 0 O-C-N 121.296 -0.877 . . . . 0.0 109.47 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -48.09 126.63 13.66 Favored 'Trans proline' 0 C--O 1.214 -0.694 0 C-N-CA 122.576 2.184 . . . . 0.0 111.816 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' GLY . . . . . 0.44 ' C ' ' CG1' ' A' ' 147' ' ' VAL . . . 94.59 -5.25 70.04 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.845 ' O ' HG13 ' A' ' 147' ' ' VAL . 80.3 tt0 -79.21 148.42 32.25 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.124 -1.221 . . . . 0.0 109.467 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 133' ' ' MET . . . . . 0.671 ' HG2' HG22 ' A' ' 147' ' ' VAL . 64.1 mtp -82.08 146.49 29.62 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.26 -0.9 . . . . 0.0 109.545 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.673 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -135.92 179.13 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.264 -0.898 . . . . 0.0 109.255 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 135' ' ' ARG . . . . . 0.673 ' H ' HG12 ' A' ' 134' ' ' VAL . 87.8 mtt180 -137.33 146.62 44.8 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.225 -0.922 . . . . 0.0 109.399 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.421 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 39.3 t -117.01 134.73 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.212 -0.93 . . . . 0.0 109.558 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 30.7 p30 -128.45 14.7 6.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.233 -0.917 . . . . 0.0 109.48 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.452 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 57.8 t0 -147.17 153.4 39.83 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.253 -0.904 . . . . 0.0 109.396 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 139' ' ' GLY . . . . . 0.452 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 78.65 172.26 40.91 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -55.28 -19.1 20.41 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.571 2.181 . . . . 0.0 111.78 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 141' ' ' PHE . . . . . 0.766 ' CZ ' HG11 ' A' ' 171' ' ' VAL . 86.3 m-85 -93.0 9.2 36.72 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.214 -0.929 . . . . 0.0 109.536 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 142' ' ' ALA . . . . . 0.446 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -61.79 146.38 49.66 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.217 -0.927 . . . . 0.0 109.562 -179.867 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 143' ' ' ASP . . . . . 0.446 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 18.0 m-20 65.86 47.83 1.97 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.296 -0.878 . . . . 0.0 109.592 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.401 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 43.9 m-85 -146.51 136.14 23.11 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.296 -0.877 . . . . 0.0 109.457 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 71.3 m-20 -94.03 141.02 29.01 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.236 -0.915 . . . . 0.0 109.419 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.14 -177.19 31.0 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 147' ' ' VAL . . . . . 0.845 HG13 ' O ' ' A' ' 132' ' ' GLU . 46.5 t -125.07 148.92 29.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.207 -1.172 . . . . 0.0 109.369 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.589 ' HA ' HG22 ' A' ' 160' ' ' VAL . 2.5 p -85.67 102.2 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.192 -0.942 . . . . 0.0 109.552 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -68.33 -36.41 79.23 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.146 -0.971 . . . . 0.0 109.414 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -140.78 164.29 30.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.189 -0.944 . . . . 0.0 109.471 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 99.8 t -125.67 152.94 33.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.327 -0.858 . . . . 0.0 109.523 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -130.53 88.43 2.63 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.319 -0.863 . . . . 0.0 109.386 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -69.58 -38.55 77.41 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.22 -0.925 . . . . 0.0 109.593 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -60.44 -46.64 89.29 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.213 -0.929 . . . . 0.0 109.45 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 155' ' ' LYS . . . . . 0.444 ' O ' ' HG3' ' A' ' 157' ' ' ARG . 32.0 mttt -89.32 -1.08 57.93 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.244 -0.91 . . . . 0.0 109.611 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 34.0 t 56.46 52.36 10.03 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.196 -0.94 . . . . 0.0 109.467 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 157' ' ' ARG . . . . . 0.444 ' HG3' ' O ' ' A' ' 155' ' ' LYS . 20.5 mtm180 -146.21 157.71 43.84 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.152 -0.967 . . . . 0.0 109.454 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 158' ' ' LEU . . . . . 0.629 HD21 ' CE1' ' A' ' 175' ' ' PHE . 13.9 mt -118.23 131.69 56.35 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.892 . . . . 0.0 109.531 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 20.9 tttp -84.37 106.77 16.23 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.295 -0.878 . . . . 0.0 109.443 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 160' ' ' VAL . . . . . 0.626 HG13 ' O ' ' A' ' 147' ' ' VAL . 47.5 t -124.86 140.72 47.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.162 -0.961 . . . . 0.0 109.56 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 161' ' ' SER . . . . . 0.461 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 23.0 t -104.3 141.88 35.53 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.439 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 162' ' ' VAL . . . . . 0.849 HG22 HG23 ' A' ' 164' ' ' ILE . 9.4 p -105.53 126.28 60.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.314 -0.867 . . . . 0.0 109.562 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 18.5 t -91.05 85.14 5.84 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.303 -0.873 . . . . 0.0 109.377 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 164' ' ' ILE . . . . . 0.849 HG23 HG22 ' A' ' 162' ' ' VAL . 7.3 pt -130.22 158.07 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.241 -0.912 . . . . 0.0 109.564 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 7.7 m-30 61.74 13.54 5.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.225 -0.922 . . . . 0.0 109.429 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 75.59 11.34 84.48 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 19.1 ttp180 -132.12 135.67 46.57 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.245 -1.15 . . . . 0.0 109.454 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -76.33 141.0 41.71 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.294 -0.879 . . . . 0.0 109.454 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.749 ' HB ' HG12 ' A' ' 162' ' ' VAL . 2.4 m -128.02 76.81 77.36 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.308 -0.87 . . . . 0.0 109.437 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.8 Cg_endo -55.27 106.51 0.19 Allowed 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.604 2.203 . . . . 0.0 111.852 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.766 HG11 ' CZ ' ' A' ' 141' ' ' PHE . 18.9 m -129.61 157.84 42.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.461 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.633 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.5 mt-10 -102.1 128.54 48.53 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.24 -0.913 . . . . 0.0 109.477 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 173' ' ' LEU . . . . . 0.633 HD23 ' O ' ' A' ' 172' ' ' GLU . 42.4 mt -124.86 144.13 50.47 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.29 -0.881 . . . . 0.0 109.513 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 24.6 m-20 -64.57 172.48 2.64 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.191 -0.943 . . . . 0.0 109.527 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 175' ' ' PHE . . . . . 0.629 ' CE1' HD21 ' A' ' 158' ' ' LEU . 4.5 m-30 -67.67 -44.41 77.89 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.166 -0.959 . . . . 0.0 109.501 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 15.0 m -71.33 -23.56 61.95 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.219 -0.925 . . . . 0.0 109.524 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 90.3 mt-30 -72.79 -23.53 60.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.177 -0.952 . . . . 0.0 109.431 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.563 HG11 ' HB2' ' A' ' 173' ' ' LEU . 4.5 m -128.16 161.26 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.253 -0.905 . . . . 0.0 109.401 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 179' ' ' GLU . . . . . 0.472 ' HB2' ' HB2' ' A' ' 135' ' ' ARG . 95.0 mt-10 -116.74 149.97 39.02 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.179 -0.951 . . . . 0.0 109.559 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 180' ' ' LYS . . . . . 0.508 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 33.6 tttm -69.13 137.34 53.31 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.181 -0.949 . . . . 0.0 109.505 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 181' ' ' ALA . . . . . 0.423 ' HB2' ' C ' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.536 0 O-C-N 121.211 -0.931 . . . . 0.0 109.46 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 . . . . . 0 N--CA 1.489 1.514 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.493 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 1.2 mt-10 -138.65 159.29 68.03 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.202 -0.937 . . . . 0.0 109.457 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.493 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.1 Cg_endo -53.53 129.41 33.68 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.547 2.165 . . . . 0.0 111.82 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 90.47 -1.2 78.82 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.489 ' O ' HG12 ' A' ' 148' ' ' VAL . 77.0 mm-40 -86.45 135.51 33.45 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.168 -1.195 . . . . 0.0 109.475 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.469 ' HA ' ' HA ' ' A' ' 147' ' ' VAL . 44.2 ttm -79.58 146.91 32.32 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.16 -0.963 . . . . 0.0 109.49 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.694 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -131.55 179.24 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.266 -0.896 . . . . 0.0 109.324 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.694 ' H ' HG12 ' A' ' 134' ' ' VAL . 40.4 ttt180 -130.29 138.34 50.43 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.226 -0.921 . . . . 0.0 109.49 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.493 HG22 ' CD1' ' A' ' 173' ' ' LEU . 45.4 t -106.63 132.79 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.271 -0.893 . . . . 0.0 109.451 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 56.1 p30 -135.64 20.44 3.33 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.263 -0.898 . . . . 0.0 109.495 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.422 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 59.0 t0 -140.88 148.17 40.07 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.209 -0.932 . . . . 0.0 109.481 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.422 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 70.23 177.23 20.76 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -55.01 -20.17 22.37 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.562 2.175 . . . . 0.0 111.791 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . 0.491 ' HB2' HG11 ' A' ' 136' ' ' VAL . 98.7 m-85 -85.6 6.73 26.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.217 -0.927 . . . . 0.0 109.504 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' ALA . . . . . 0.469 ' O ' ' HB3' ' A' ' 143' ' ' ASP . . . -66.19 148.91 51.13 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.287 -0.883 . . . . 0.0 109.462 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.469 ' HB3' ' O ' ' A' ' 142' ' ' ALA . 35.5 t0 73.06 29.97 1.69 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.222 -0.924 . . . . 0.0 109.51 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.533 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 84.7 m-85 -138.12 151.52 47.86 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.249 -0.907 . . . . 0.0 109.511 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 43.3 p-10 -118.04 164.09 15.63 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.25 -0.906 . . . . 0.0 109.427 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -172.16 -173.73 39.07 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.849 ' O ' HG13 ' A' ' 160' ' ' VAL . 57.9 t -120.29 151.64 23.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.227 -1.161 . . . . 0.0 109.491 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.856 HG21 HG22 ' A' ' 151' ' ' VAL . 2.1 p -94.39 98.85 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.274 -0.892 . . . . 0.0 109.466 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 76.2 mm-40 -69.37 -36.69 77.09 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.215 -0.928 . . . . 0.0 109.425 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -134.44 149.63 50.77 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.261 -0.9 . . . . 0.0 109.464 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.856 HG22 HG21 ' A' ' 148' ' ' VAL . 48.0 t -127.3 150.22 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.233 -0.917 . . . . 0.0 109.477 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' ASP . . . . . 0.416 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 93.5 m-20 -136.2 87.77 2.33 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.261 -0.9 . . . . 0.0 109.466 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -66.31 -37.05 84.5 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.274 -0.891 . . . . 0.0 109.463 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 48.3 tp10 -62.62 -44.28 96.69 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.248 -0.907 . . . . 0.0 109.484 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.48 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 21.5 mttt -88.62 0.61 56.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.289 -0.882 . . . . 0.0 109.602 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . 0.404 ' O ' ' OG ' ' A' ' 156' ' ' SER . 7.5 p 52.51 51.98 15.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.188 -0.945 . . . . 0.0 109.437 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' ARG . . . . . 0.48 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 41.0 mmm-85 -145.32 140.46 27.76 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.259 -0.901 . . . . 0.0 109.472 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' LEU . . . . . 0.599 ' CD2' HG13 ' A' ' 151' ' ' VAL . 35.2 mt -108.53 134.28 51.52 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.254 -0.904 . . . . 0.0 109.542 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 15.1 tttp -92.47 93.09 8.39 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.224 -0.923 . . . . 0.0 109.374 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.849 HG13 ' O ' ' A' ' 147' ' ' VAL . 41.4 t -124.13 142.01 42.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.222 -0.923 . . . . 0.0 109.519 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . 0.512 ' CA ' ' HA ' ' A' ' 170' ' ' PRO . 86.7 p -106.31 147.7 28.87 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.263 -0.898 . . . . 0.0 109.436 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' VAL . . . . . 0.533 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 18.1 t -108.49 132.66 55.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.231 -0.918 . . . . 0.0 109.523 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 71.6 m . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.205 -0.934 . . . . 0.0 109.433 179.988 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 82.0 mtp180 . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -69.17 142.13 54.39 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.261 -0.9 . . . . 0.0 109.443 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . 0.829 ' O ' HG13 ' A' ' 171' ' ' VAL . 15.4 m -124.37 75.81 61.59 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.271 -0.893 . . . . 0.0 109.475 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.512 ' HA ' ' CA ' ' A' ' 161' ' ' SER . 50.0 Cg_endo -47.95 106.45 0.11 Allowed 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.642 2.228 . . . . 0.0 111.784 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.829 HG13 ' O ' ' A' ' 169' ' ' THR . 21.2 m -128.74 155.12 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.293 -0.879 . . . . 0.0 109.478 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.497 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.0 mt-10 -95.04 123.33 38.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.924 . . . . 0.0 109.458 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . 0.554 ' HB3' HG13 ' A' ' 178' ' ' VAL . 67.2 mt -125.98 147.91 49.41 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.231 -0.918 . . . . 0.0 109.477 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 174' ' ' ASP . . . . . 0.422 ' OD1' ' HD2' ' A' ' 157' ' ' ARG . 91.7 m-20 -75.84 164.87 25.78 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.216 -0.927 . . . . 0.0 109.441 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.56 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.3 m-30 -60.69 -41.16 94.57 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.211 -0.931 . . . . 0.0 109.495 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 19.3 m -76.06 -26.28 56.38 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.258 -0.901 . . . . 0.0 109.384 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 177' ' ' GLN . . . . . 0.419 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 87.9 mt-30 -69.04 -25.8 64.65 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.31 -0.869 . . . . 0.0 109.465 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.554 HG13 ' HB3' ' A' ' 173' ' ' LEU . 13.9 m -128.41 158.72 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.242 -0.911 . . . . 0.0 109.434 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 179' ' ' GLU . . . . . 0.434 ' HB2' ' HB3' ' A' ' 135' ' ' ARG . 77.8 mt-10 -113.13 149.24 33.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.232 -0.917 . . . . 0.0 109.49 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 30.6 tttm -69.94 135.79 49.85 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.241 -0.912 . . . . 0.0 109.479 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.587 0 O-C-N 121.266 -0.896 . . . . 0.0 109.454 -179.986 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.596 ' CE1' ' HG3' ' A' ' 180' ' ' LYS . 74.5 m-85 . . . . . 0 N--CA 1.49 1.525 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.472 ' HB2' ' HG3' ' A' ' 132' ' ' GLU . 28.9 mt-10 -131.55 153.85 81.68 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.252 -0.905 . . . . 0.0 109.508 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -52.96 128.14 27.68 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 122.605 2.203 . . . . 0.0 111.776 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 86.5 10.16 74.15 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.472 ' HG3' ' HB2' ' A' ' 129' ' ' GLU . 72.7 mm-40 -96.13 127.26 41.98 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.304 -1.115 . . . . 0.0 109.432 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 5.8 ttm -63.71 134.71 55.84 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.263 -0.898 . . . . 0.0 109.501 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.678 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -123.5 179.03 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.228 -0.92 . . . . 0.0 109.394 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.678 ' H ' HG12 ' A' ' 134' ' ' VAL . 55.1 ttt-85 -135.95 133.53 37.68 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.264 -0.898 . . . . 0.0 109.288 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.598 HG11 ' HB2' ' A' ' 141' ' ' PHE . 90.7 t -106.03 132.06 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.202 -0.937 . . . . 0.0 109.584 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . 0.455 ' HB3' ' NH1' ' A' ' 135' ' ' ARG . 32.3 p30 -130.34 18.8 5.35 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.227 -0.921 . . . . 0.0 109.45 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -134.53 143.77 47.62 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.248 -0.907 . . . . 0.0 109.4 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 72.15 177.16 29.01 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -51.14 -20.95 8.44 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.638 2.225 . . . . 0.0 111.757 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . 0.598 ' HB2' HG11 ' A' ' 136' ' ' VAL . 93.8 m-85 -86.94 12.92 10.02 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.896 . . . . 0.0 109.45 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' ALA . . . . . 0.455 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -69.57 143.71 53.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.25 -0.907 . . . . 0.0 109.594 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.45 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 19.3 m-20 65.9 50.52 1.49 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.57 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.465 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 49.9 m-85 -144.11 146.26 32.67 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.238 -0.914 . . . . 0.0 109.455 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -99.64 141.35 32.56 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.266 -0.896 . . . . 0.0 109.548 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.44 -173.85 27.39 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.379 -1.488 . . . . 0.0 109.379 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.809 ' O ' HG13 ' A' ' 160' ' ' VAL . 40.1 t -132.19 152.34 36.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.256 -1.143 . . . . 0.0 109.463 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.664 ' CA ' HG22 ' A' ' 160' ' ' VAL . 2.3 p -95.47 118.09 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.227 -0.921 . . . . 0.0 109.486 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 77.1 mm-40 -73.78 -42.18 61.38 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.331 -0.856 . . . . 0.0 109.364 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.459 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 95.3 mt-10 -147.21 162.56 38.64 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.298 -0.876 . . . . 0.0 109.431 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.983 HG13 ' CD2' ' A' ' 158' ' ' LEU . 49.1 t -129.03 153.2 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.216 -0.927 . . . . 0.0 109.459 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' ASP . . . . . 0.4 ' O ' ' N ' ' A' ' 156' ' ' SER . 91.4 m-20 -128.7 97.37 4.66 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.176 -0.953 . . . . 0.0 109.442 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 90.3 m-85 -66.51 -41.59 88.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.232 -0.917 . . . . 0.0 109.453 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -63.12 -40.41 97.54 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.283 -0.885 . . . . 0.0 109.504 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 82.7 mttt -93.36 -0.66 56.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.246 -0.909 . . . . 0.0 109.592 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . 0.4 ' N ' ' O ' ' A' ' 152' ' ' ASP . 4.5 m 46.22 52.27 10.54 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.239 -0.913 . . . . 0.0 109.426 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' ARG . . . . . 0.412 ' CG ' ' HB3' ' A' ' 172' ' ' GLU . 7.4 tpt180 -138.08 140.62 40.09 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.298 -0.876 . . . . 0.0 109.451 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' LEU . . . . . 0.983 ' CD2' HG13 ' A' ' 151' ' ' VAL . 41.1 mt -109.04 137.49 46.87 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.243 -0.911 . . . . 0.0 109.597 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . 0.459 ' HD2' ' HB2' ' A' ' 150' ' ' GLU . 21.3 mttp -99.78 96.7 7.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.259 -0.9 . . . . 0.0 109.377 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.809 HG13 ' O ' ' A' ' 147' ' ' VAL . 38.6 t -124.5 139.65 50.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.187 -0.946 . . . . 0.0 109.498 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 60.7 p -108.67 147.98 31.1 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.32 -0.862 . . . . 0.0 109.435 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' VAL . . . . . 0.465 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 4.2 t -117.69 133.01 65.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.158 -0.964 . . . . 0.0 109.472 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 31.0 t . . . . . 0 N--CA 1.49 1.564 0 O-C-N 121.306 -0.871 . . . . 0.0 109.457 -179.998 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 72.3 ttt180 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -68.03 138.73 56.07 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.279 -0.888 . . . . 0.0 109.491 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . 0.548 ' O ' HG13 ' A' ' 171' ' ' VAL . 1.3 m -125.44 77.91 68.33 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.214 -0.929 . . . . 0.0 109.435 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.402 ' HD2' ' HA ' ' A' ' 169' ' ' THR . 50.0 Cg_endo -53.91 103.66 0.1 OUTLIER 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.668 2.245 . . . . 0.0 111.78 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.873 HG23 HD21 ' A' ' 173' ' ' LEU . 31.4 m -129.8 154.46 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.242 -0.912 . . . . 0.0 109.434 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.879 ' C ' HD22 ' A' ' 173' ' ' LEU . 94.9 mt-10 -108.17 130.18 55.14 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.243 -0.911 . . . . 0.0 109.529 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . 0.879 HD22 ' C ' ' A' ' 172' ' ' GLU . 2.5 mm? -126.96 157.59 39.1 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.284 -0.885 . . . . 0.0 109.477 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 174' ' ' ASP . . . . . 0.545 ' O ' HG22 ' A' ' 178' ' ' VAL . 94.2 m-20 -77.04 176.19 8.89 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.261 -0.899 . . . . 0.0 109.394 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.422 ' CE1' HD21 ' A' ' 158' ' ' LEU . 7.3 m-30 -65.87 -43.15 89.19 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.222 -0.924 . . . . 0.0 109.417 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 82.4 p -76.77 -26.04 54.07 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.214 -0.929 . . . . 0.0 109.518 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -68.03 -18.95 64.85 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.264 -0.897 . . . . 0.0 109.538 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.545 HG22 ' O ' ' A' ' 174' ' ' ASP . 27.2 m -138.48 162.13 30.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.232 -0.918 . . . . 0.0 109.51 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 179' ' ' GLU . . . . . 0.512 ' O ' ' N ' ' A' ' 135' ' ' ARG . 35.7 mt-10 -127.38 155.9 42.88 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.24 -0.912 . . . . 0.0 109.476 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 180' ' ' LYS . . . . . 0.596 ' HG3' ' CE1' ' A' ' 128' ' ' PHE . 9.5 mtmt -85.48 143.72 28.38 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.245 -0.91 . . . . 0.0 109.488 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.565 0 O-C-N 121.241 -0.912 . . . . 0.0 109.499 179.971 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.511 ' CE2' ' HD3' ' A' ' 180' ' ' LYS . 71.1 m-85 . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.469 ' HB2' ' HD2' ' A' ' 130' ' ' PRO . 2.6 pp20? -128.13 138.65 33.44 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.325 -0.859 . . . . 0.0 109.464 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.497 ' HA ' ' O ' ' A' ' 148' ' ' VAL . 49.3 Cg_endo -39.0 128.9 1.35 Allowed 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.469 2.112 . . . . 0.0 111.749 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 89.65 10.08 65.66 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.485 ' O ' HG13 ' A' ' 147' ' ' VAL . 84.8 tt0 -104.16 135.15 46.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.341 -1.094 . . . . 0.0 109.458 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.553 ' HG2' HG22 ' A' ' 147' ' ' VAL . 82.9 mtp -71.9 139.94 49.02 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.201 -0.937 . . . . 0.0 109.534 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.668 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -127.03 178.59 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.183 -0.948 . . . . 0.0 109.372 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.668 ' H ' HG12 ' A' ' 134' ' ' VAL . 75.2 ttt-85 -126.56 144.55 50.84 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.274 -0.891 . . . . 0.0 109.549 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.564 HG12 ' HA ' ' A' ' 142' ' ' ALA . 45.0 t -112.15 132.3 61.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.236 -0.915 . . . . 0.0 109.453 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . 0.411 ' C ' ' OD1' ' A' ' 137' ' ' ASN . 48.0 p30 -131.83 14.65 4.82 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.233 -0.917 . . . . 0.0 109.474 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 59.1 t0 -142.18 143.15 32.81 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.234 -0.916 . . . . 0.0 109.49 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 79.87 171.2 41.96 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -55.73 -21.96 34.51 Favored 'Trans proline' 0 C--O 1.216 -0.625 0 C-N-CA 122.601 2.201 . . . . 0.0 111.813 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . 0.529 ' CZ ' HG11 ' A' ' 171' ' ' VAL . 99.0 m-85 -85.21 5.67 29.2 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.13 -0.981 . . . . 0.0 109.54 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' ALA . . . . . 0.564 ' HA ' HG12 ' A' ' 136' ' ' VAL . . . -69.15 149.01 49.11 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.272 -0.892 . . . . 0.0 109.416 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.493 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 30.3 t0 75.13 28.67 1.01 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.174 -0.954 . . . . 0.0 109.45 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.445 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 90.2 m-85 -135.77 145.0 46.1 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.263 -0.898 . . . . 0.0 109.456 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 74.0 m-20 -97.9 140.22 32.58 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.26 -0.9 . . . . 0.0 109.415 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -153.85 -173.06 22.53 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.792 ' O ' HG13 ' A' ' 160' ' ' VAL . 44.9 t -129.08 152.63 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.248 -1.148 . . . . 0.0 109.418 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.671 HG21 HG22 ' A' ' 151' ' ' VAL . 2.5 p -92.52 107.97 19.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.294 -0.879 . . . . 0.0 109.398 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.476 ' HB2' ' HE3' ' A' ' 159' ' ' LYS . 75.1 mm-40 -70.63 -39.23 73.83 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.224 -0.923 . . . . 0.0 109.365 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.46 ' HB2' ' HE2' ' A' ' 159' ' ' LYS . 92.4 mt-10 -139.41 157.5 45.75 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.239 -0.913 . . . . 0.0 109.393 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.849 HG13 ' CD2' ' A' ' 158' ' ' LEU . 48.5 t -127.29 151.04 33.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.274 -0.891 . . . . 0.0 109.481 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' ASP . . . . . 0.401 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 88.1 m-20 -134.43 87.7 2.38 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.223 -0.923 . . . . 0.0 109.436 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -63.34 -39.45 94.59 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.259 -0.901 . . . . 0.0 109.461 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -62.27 -42.15 99.1 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.18 -0.95 . . . . 0.0 109.506 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.412 ' O ' ' C ' ' A' ' 156' ' ' SER . 43.5 mttp -91.19 5.17 50.14 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.186 -0.946 . . . . 0.0 109.61 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . 0.517 ' HA ' ' CZ ' ' A' ' 175' ' ' PHE . 0.3 OUTLIER 43.91 51.8 6.8 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.187 -0.945 . . . . 0.0 109.472 -179.943 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' ARG . . . . . 0.469 ' HD2' ' OD1' ' A' ' 174' ' ' ASP . 9.3 tpt180 -145.44 137.14 25.32 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.257 -0.902 . . . . 0.0 109.402 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' LEU . . . . . 0.849 ' CD2' HG13 ' A' ' 151' ' ' VAL . 46.2 mt -108.34 136.2 48.37 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 109.53 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . 0.476 ' HE3' ' HB2' ' A' ' 149' ' ' GLU . 14.2 ttpt -95.19 109.2 21.33 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.327 -0.858 . . . . 0.0 109.442 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.792 HG13 ' O ' ' A' ' 147' ' ' VAL . 39.2 t -127.84 142.0 44.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -0.921 . . . . 0.0 109.464 -179.88 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . 0.486 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 96.1 p -107.0 147.44 29.89 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.191 -0.943 . . . . 0.0 109.504 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' VAL . . . . . . . . . . . . . 26.1 t -119.21 132.05 70.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.31 -0.869 . . . . 0.0 109.565 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 32.0 t . . . . . 0 N--CA 1.489 1.521 0 O-C-N 121.217 -0.927 . . . . 0.0 109.433 179.921 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 39.0 mtm105 . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -72.08 137.29 46.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.208 -0.933 . . . . 0.0 109.497 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . 0.685 ' O ' HG13 ' A' ' 171' ' ' VAL . 59.3 m -129.82 77.02 77.55 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.244 -0.91 . . . . 0.0 109.44 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.486 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 50.6 Cg_endo -53.19 111.47 0.68 Allowed 'Trans proline' 0 C--O 1.214 -0.687 0 C-N-CA 122.579 2.186 . . . . 0.0 111.807 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.685 HG13 ' O ' ' A' ' 169' ' ' THR . 20.9 m -130.44 155.27 41.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.288 -0.883 . . . . 0.0 109.493 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.75 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.2 mt-10 -104.57 135.81 45.28 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.268 -0.895 . . . . 0.0 109.528 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . 0.75 HD23 ' O ' ' A' ' 172' ' ' GLU . 63.0 mt -133.91 148.28 51.2 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.316 -0.865 . . . . 0.0 109.576 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 174' ' ' ASP . . . . . 0.482 ' O ' HG22 ' A' ' 178' ' ' VAL . 91.4 m-20 -68.91 171.16 8.42 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.283 -0.886 . . . . 0.0 109.4 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.548 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 3.6 m-30 -65.29 -47.58 76.13 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.206 -0.934 . . . . 0.0 109.463 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 14.6 m -70.73 -28.03 64.41 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.315 -0.865 . . . . 0.0 109.498 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 177' ' ' GLN . . . . . 0.407 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 91.0 mt-30 -68.07 -20.64 64.97 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.306 -0.871 . . . . 0.0 109.473 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.632 HG11 ' HB2' ' A' ' 173' ' ' LEU . 13.7 m -131.23 160.29 42.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.278 -0.888 . . . . 0.0 109.484 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 179' ' ' GLU . . . . . 0.488 ' O ' ' N ' ' A' ' 135' ' ' ARG . 55.1 mt-10 -128.65 167.54 17.06 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.183 -0.948 . . . . 0.0 109.513 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 180' ' ' LYS . . . . . 0.511 ' HD3' ' CE2' ' A' ' 128' ' ' PHE . 29.0 mmtp -66.36 145.83 55.26 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.275 -0.89 . . . . 0.0 109.497 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.502 0 O-C-N 121.139 -0.975 . . . . 0.0 109.48 179.973 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.505 ' CD2' HD21 ' A' ' 158' ' ' LEU . 69.0 m-85 . . . . . 0 N--CA 1.489 1.513 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.53 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.9 OUTLIER -144.55 157.73 55.14 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.26 -0.9 . . . . 0.0 109.394 179.959 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.53 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.2 Cg_endo -49.51 128.18 20.1 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.625 2.217 . . . . 0.0 111.805 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 96.1 -3.89 64.74 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.463 ' OE1' ' HA ' ' A' ' 128' ' ' PHE . 88.2 mt-10 -92.38 129.88 38.2 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.14 -1.212 . . . . 0.0 109.5 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.492 ' O ' ' HB3' ' A' ' 181' ' ' ALA . 43.5 ttm -77.13 145.7 37.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.237 -0.914 . . . . 0.0 109.353 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.683 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -129.76 178.66 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.198 -0.939 . . . . 0.0 109.404 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.683 ' H ' HG12 ' A' ' 134' ' ' VAL . 58.6 ttt180 -131.61 140.95 49.54 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.308 -0.87 . . . . 0.0 109.426 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.607 HG22 ' CD1' ' A' ' 173' ' ' LEU . 40.6 t -113.21 135.86 51.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.222 -0.923 . . . . 0.0 109.54 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . 0.446 ' O ' ' OD1' ' A' ' 138' ' ' ASP . 29.0 p30 -128.8 18.04 6.22 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.273 -0.892 . . . . 0.0 109.537 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.497 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 91.3 m-20 -139.43 164.37 30.03 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.208 -0.932 . . . . 0.0 109.497 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 57.94 172.86 0.32 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -53.26 -21.1 16.32 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.581 2.187 . . . . 0.0 111.777 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . 0.559 ' CZ ' HG11 ' A' ' 171' ' ' VAL . 91.8 m-85 -82.18 6.36 16.83 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.216 -0.928 . . . . 0.0 109.458 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' ALA . . . . . 0.423 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -62.62 143.24 57.52 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.278 -0.889 . . . . 0.0 109.488 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.423 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 10.2 m-20 67.06 48.69 1.2 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.257 -0.902 . . . . 0.0 109.413 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.494 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 43.6 m-85 -146.39 129.08 16.16 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.239 -0.913 . . . . 0.0 109.465 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 68.5 m-20 -90.87 138.04 31.9 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.227 -0.921 . . . . 0.0 109.509 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -152.71 177.39 30.44 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.851 ' O ' HG13 ' A' ' 160' ' ' VAL . 38.9 t -118.95 156.52 20.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.273 -1.134 . . . . 0.0 109.447 179.87 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.9 HG11 HG22 ' A' ' 151' ' ' VAL . 50.9 t -89.36 106.84 17.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.161 -0.962 . . . . 0.0 109.574 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -73.58 -31.84 63.81 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.247 -0.908 . . . . 0.0 109.392 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -144.42 148.63 34.87 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.282 -0.886 . . . . 0.0 109.25 179.852 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.9 HG22 HG11 ' A' ' 148' ' ' VAL . 37.1 t -125.55 146.43 31.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.157 -0.964 . . . . 0.0 109.644 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -132.28 87.89 2.48 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.279 -0.888 . . . . 0.0 109.412 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -61.1 -40.41 93.64 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.195 -0.941 . . . . 0.0 109.442 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -62.39 -40.53 96.76 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.21 -0.932 . . . . 0.0 109.51 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -91.52 2.45 56.43 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.217 -0.927 . . . . 0.0 109.649 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 13.6 p 45.21 52.62 8.52 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.154 -0.966 . . . . 0.0 109.394 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' ARG . . . . . 0.639 ' C ' HD12 ' A' ' 158' ' ' LEU . 0.0 OUTLIER -136.67 156.28 48.75 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.202 -0.937 . . . . 0.0 109.543 179.919 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' LEU . . . . . 0.845 HD11 ' CE1' ' A' ' 175' ' ' PHE . 7.4 mp -120.39 123.66 43.61 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.257 -0.902 . . . . 0.0 109.525 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 18.0 tttm -91.01 92.18 8.63 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.25 -0.906 . . . . 0.0 109.378 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.851 HG13 ' O ' ' A' ' 147' ' ' VAL . 21.7 t -116.22 150.27 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.199 -0.938 . . . . 0.0 109.359 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . 0.467 ' OG ' ' N ' ' A' ' 170' ' ' PRO . 18.3 t -119.74 131.32 55.34 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.311 -0.868 . . . . 0.0 109.431 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' VAL . . . . . 0.494 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 11.7 t -102.16 131.98 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.243 -0.91 . . . . 0.0 109.387 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 40.5 t . . . . . 0 N--CA 1.489 1.515 0 O-C-N 121.273 -0.892 . . . . 0.0 109.43 -179.978 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 70.1 mtm180 . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -68.17 144.53 54.93 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 109.521 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . 0.781 ' O ' HG13 ' A' ' 171' ' ' VAL . 2.9 m -128.09 73.82 79.34 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.249 -0.907 . . . . 0.0 109.414 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.467 ' N ' ' OG ' ' A' ' 161' ' ' SER . 50.2 Cg_endo -49.09 105.98 0.1 Allowed 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.585 2.19 . . . . 0.0 111.794 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.781 HG13 ' O ' ' A' ' 169' ' ' THR . 19.3 m -133.67 153.94 37.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.295 -0.878 . . . . 0.0 109.359 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.72 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.2 mt-10 -97.23 135.81 38.63 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.259 -0.901 . . . . 0.0 109.489 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . 0.72 HD23 ' O ' ' A' ' 172' ' ' GLU . 28.9 mt -124.97 160.06 29.8 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.256 -0.902 . . . . 0.0 109.421 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 174' ' ' ASP . . . . . 0.471 ' HB2' ' HB2' ' A' ' 177' ' ' GLN . 92.7 m-20 -83.54 160.78 21.4 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.184 -0.948 . . . . 0.0 109.521 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.845 ' CE1' HD11 ' A' ' 158' ' ' LEU . 4.5 m-85 -53.67 -49.95 66.86 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.321 -0.862 . . . . 0.0 109.561 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 15.5 m -74.67 -24.36 58.79 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.162 -0.961 . . . . 0.0 109.546 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 177' ' ' GLN . . . . . 0.69 ' NE2' HD22 ' A' ' 173' ' ' LEU . 61.9 tt0 -64.6 -27.21 68.79 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.231 -0.918 . . . . 0.0 109.425 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.66 HG11 HD12 ' A' ' 173' ' ' LEU . 13.7 m -127.97 161.83 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.334 -0.854 . . . . 0.0 109.482 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 179' ' ' GLU . . . . . 0.43 ' N ' ' O ' ' A' ' 135' ' ' ARG . 61.6 mt-10 -118.32 148.19 42.73 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.207 -0.933 . . . . 0.0 109.489 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -66.95 130.91 44.67 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.32 -0.863 . . . . 0.0 109.427 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . 0.492 ' HB3' ' O ' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.558 0 O-C-N 121.259 -0.901 . . . . 0.0 109.461 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.416 ' CE1' ' HB2' ' A' ' 180' ' ' LYS . 68.8 m-85 . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.474 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.0 OUTLIER -125.87 153.54 73.52 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.23 -0.919 . . . . 0.0 109.503 179.949 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.474 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 49.4 Cg_endo -47.88 134.59 23.13 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.636 2.224 . . . . 0.0 111.72 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 85.45 3.72 86.47 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 48.9 tp10 -89.9 136.11 33.24 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.168 -1.195 . . . . 0.0 109.474 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.914 ' SD ' HG22 ' A' ' 147' ' ' VAL . 92.9 mmm -74.82 148.55 40.19 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.253 -0.904 . . . . 0.0 109.48 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.836 HG21 HG23 ' A' ' 148' ' ' VAL . 2.5 t -139.06 179.18 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.285 -0.885 . . . . 0.0 109.373 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.686 ' H ' HG12 ' A' ' 134' ' ' VAL . 19.8 ttp85 -137.58 142.41 41.31 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.323 -0.861 . . . . 0.0 109.445 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.46 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 43.8 t -106.45 132.16 54.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.224 -0.923 . . . . 0.0 109.533 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 29.0 p30 -118.48 13.33 13.47 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.337 -0.852 . . . . 0.0 109.425 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.432 ' H ' HG12 ' A' ' 136' ' ' VAL . 51.9 p30 -151.89 169.93 21.07 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.235 -0.916 . . . . 0.0 109.461 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 67.4 168.79 3.94 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -56.71 -18.11 25.45 Favored 'Trans proline' 0 C--O 1.214 -0.702 0 C-N-CA 122.565 2.177 . . . . 0.0 111.848 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . 0.726 ' CE2' HG11 ' A' ' 171' ' ' VAL . 92.5 m-85 -88.12 8.1 28.46 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.28 -0.888 . . . . 0.0 109.48 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' ALA . . . . . 0.481 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -61.34 150.68 34.35 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.213 -0.929 . . . . 0.0 109.458 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.448 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 63.2 m-20 62.63 42.4 8.44 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.243 -0.911 . . . . 0.0 109.446 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.481 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 51.3 m-85 -146.9 134.52 21.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.165 -0.959 . . . . 0.0 109.516 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -87.68 141.98 28.18 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.898 . . . . 0.0 109.453 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -149.61 177.89 27.48 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.914 HG22 ' SD ' ' A' ' 133' ' ' MET . 35.6 t -119.92 156.34 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.306 -1.114 . . . . 0.0 109.462 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.836 HG23 HG21 ' A' ' 134' ' ' VAL . 61.3 t -87.54 103.18 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.22 -0.925 . . . . 0.0 109.457 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 75.2 mm-40 -67.63 -38.69 84.23 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.268 -0.895 . . . . 0.0 109.415 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -153.77 150.81 28.88 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.232 -0.918 . . . . 0.0 109.426 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.708 HG13 ' CD2' ' A' ' 158' ' ' LEU . 58.9 t -122.68 154.41 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.269 -0.895 . . . . 0.0 109.475 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -135.12 94.83 3.19 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.301 -0.875 . . . . 0.0 109.459 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 81.1 m-85 -67.32 -42.44 83.65 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.301 -0.874 . . . . 0.0 109.487 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -62.63 -36.67 83.56 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.212 -0.93 . . . . 0.0 109.412 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.47 ' O ' ' HG2' ' A' ' 155' ' ' LYS . 57.0 tttm -95.59 1.4 53.73 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.202 -0.936 . . . . 0.0 109.617 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 41.1 t 46.6 52.4 11.09 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.171 -0.956 . . . . 0.0 109.486 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 7.7 tpt180 -141.28 138.25 33.07 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.256 -0.903 . . . . 0.0 109.417 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' LEU . . . . . 0.708 ' CD2' HG13 ' A' ' 151' ' ' VAL . 55.2 mt -107.25 131.66 53.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.221 -0.924 . . . . 0.0 109.496 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 60.3 tttm -96.52 105.78 17.93 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.874 . . . . 0.0 109.373 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.698 HG13 ' O ' ' A' ' 147' ' ' VAL . 38.6 t -123.36 145.75 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.265 -0.897 . . . . 0.0 109.578 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . 0.404 ' OG ' ' HA ' ' A' ' 170' ' ' PRO . 11.4 m -118.85 137.01 53.72 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.33 -0.856 . . . . 0.0 109.359 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' VAL . . . . . 0.55 HG21 ' HB3' ' A' ' 141' ' ' PHE . 25.2 t -107.85 133.68 51.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.292 -0.88 . . . . 0.0 109.634 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 33.8 t . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.233 -0.917 . . . . 0.0 109.193 179.82 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 51.1 mtt180 . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -74.29 140.94 45.26 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.194 -0.941 . . . . 0.0 109.568 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . 0.56 ' O ' HG13 ' A' ' 171' ' ' VAL . 0.2 OUTLIER -127.03 73.99 76.76 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.317 -0.864 . . . . 0.0 109.443 179.953 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.404 ' HA ' ' OG ' ' A' ' 161' ' ' SER . 49.8 Cg_endo -54.17 100.28 0.06 OUTLIER 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.567 2.178 . . . . 0.0 111.81 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.726 HG11 ' CE2' ' A' ' 141' ' ' PHE . 26.9 m -126.96 153.4 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.278 -0.889 . . . . 0.0 109.489 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.778 ' O ' HD23 ' A' ' 173' ' ' LEU . 57.0 mp0 -102.02 134.8 44.66 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.292 -0.88 . . . . 0.0 109.563 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . 0.778 HD23 ' O ' ' A' ' 172' ' ' GLU . 53.4 mt -132.95 147.8 52.28 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.245 -0.91 . . . . 0.0 109.455 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 174' ' ' ASP . . . . . 0.414 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 90.7 m-20 -70.89 174.32 6.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.262 -0.899 . . . . 0.0 109.458 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.529 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 3.8 m-30 -65.13 -44.66 87.94 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.212 -0.93 . . . . 0.0 109.457 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 94.8 p -73.73 -28.81 61.9 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.205 -0.935 . . . . 0.0 109.463 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 177' ' ' GLN . . . . . 0.414 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 82.1 mt-30 -63.49 -25.71 68.38 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.283 -0.885 . . . . 0.0 109.49 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.473 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 6.1 m -130.02 160.79 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.266 -0.896 . . . . 0.0 109.485 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 179' ' ' GLU . . . . . 0.478 ' OE1' ' CZ ' ' A' ' 135' ' ' ARG . 79.6 mt-10 -112.14 147.61 35.75 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.278 -0.889 . . . . 0.0 109.465 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 180' ' ' LYS . . . . . 0.416 ' HB2' ' CE1' ' A' ' 128' ' ' PHE . 19.1 tttm -76.02 132.04 39.9 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.286 -0.884 . . . . 0.0 109.465 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.552 0 O-C-N 121.2 -0.937 . . . . 0.0 109.518 -179.957 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 72.8 m-85 . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.508 -0.552 . . . . 0.0 109.508 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.542 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.1 OUTLIER -143.62 156.69 59.72 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.328 -0.858 . . . . 0.0 109.412 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.542 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.4 Cg_endo -47.34 132.19 19.11 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.552 2.168 . . . . 0.0 111.737 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 93.59 0.67 66.74 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -103.68 139.99 38.19 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.234 -1.157 . . . . 0.0 109.435 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 87.7 mtp -83.78 152.69 24.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.317 -0.865 . . . . 0.0 109.491 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.836 ' CG2' HG23 ' A' ' 148' ' ' VAL . 2.5 t -136.82 179.21 3.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.258 -0.901 . . . . 0.0 109.345 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.683 ' H ' HG12 ' A' ' 134' ' ' VAL . 53.0 ttm-85 -135.08 139.02 44.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.232 -0.918 . . . . 0.0 109.456 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.775 HG22 ' CD1' ' A' ' 173' ' ' LEU . 50.0 t -107.1 131.23 57.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.266 -0.896 . . . . 0.0 109.494 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . 0.421 ' O ' ' OD1' ' A' ' 138' ' ' ASP . 11.4 p30 -122.54 16.32 10.39 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.279 -0.888 . . . . 0.0 109.43 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.421 ' OD1' ' O ' ' A' ' 137' ' ' ASN . 93.5 m-20 -135.67 160.16 39.39 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.229 -0.919 . . . . 0.0 109.489 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 60.35 173.08 0.82 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -53.53 -20.37 15.95 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.609 2.206 . . . . 0.0 111.803 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . 0.571 ' HB3' HG21 ' A' ' 162' ' ' VAL . 99.4 m-85 -80.57 4.07 19.71 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.222 -0.924 . . . . 0.0 109.481 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' ALA . . . . . 0.497 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -63.99 150.84 44.35 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.139 -0.976 . . . . 0.0 109.474 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.444 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 57.9 m-20 62.83 47.53 4.5 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.275 -0.89 . . . . 0.0 109.398 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.497 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 50.2 m-85 -149.34 144.56 26.51 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.308 -0.87 . . . . 0.0 109.493 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 19.8 m120 -97.9 145.52 26.36 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.27 -0.894 . . . . 0.0 109.497 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -154.21 174.68 32.62 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.559 HG12 ' N ' ' A' ' 148' ' ' VAL . 47.3 t -114.4 165.16 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.223 -1.163 . . . . 0.0 109.386 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.836 HG23 ' CG2' ' A' ' 134' ' ' VAL . 51.0 t -101.57 123.66 54.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.273 -0.892 . . . . 0.0 109.512 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 74.7 mm-40 -99.76 -44.55 6.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.256 -0.903 . . . . 0.0 109.435 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -133.24 155.61 49.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.237 -0.914 . . . . 0.0 109.348 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.52 HG11 ' CZ ' ' A' ' 153' ' ' TYR . 38.7 t -122.79 151.15 26.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.29 -0.881 . . . . 0.0 109.565 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' ASP . . . . . 0.408 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 93.3 m-20 -135.3 78.93 1.76 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.292 -0.88 . . . . 0.0 109.373 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' TYR . . . . . 0.52 ' CZ ' HG11 ' A' ' 151' ' ' VAL . 98.1 m-85 -62.68 -37.3 85.9 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.197 -0.939 . . . . 0.0 109.651 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -64.35 -40.95 96.88 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.277 -0.889 . . . . 0.0 109.593 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.463 ' O ' ' HG3' ' A' ' 157' ' ' ARG . 28.9 mttt -87.1 3.13 47.44 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.211 -0.93 . . . . 0.0 109.627 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . 0.492 ' HA ' ' CZ ' ' A' ' 175' ' ' PHE . 58.1 m 52.83 52.59 13.63 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.224 -0.922 . . . . 0.0 109.469 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' ARG . . . . . 0.472 ' CG ' ' O ' ' A' ' 156' ' ' SER . 47.0 mtt180 -157.81 155.43 29.72 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.278 -0.889 . . . . 0.0 109.44 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' LEU . . . . . 0.66 HD21 ' CE1' ' A' ' 175' ' ' PHE . 12.0 mt -119.83 137.0 54.26 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.243 -0.911 . . . . 0.0 109.57 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 14.8 tttt -83.63 105.34 14.48 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.302 -0.874 . . . . 0.0 109.308 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.769 HG22 HG22 ' A' ' 148' ' ' VAL . 57.8 t -123.11 145.27 30.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.205 -0.934 . . . . 0.0 109.596 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 14.9 m -111.86 140.85 46.17 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.257 -0.902 . . . . 0.0 109.444 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' VAL . . . . . 0.571 HG21 ' HB3' ' A' ' 141' ' ' PHE . 14.0 t -110.46 133.14 56.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.206 -0.934 . . . . 0.0 109.493 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 60.7 p . . . . . 0 N--CA 1.49 1.534 0 O-C-N 121.191 -0.943 . . . . 0.0 109.435 179.928 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.462 -0.569 . . . . 0.0 109.462 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -72.76 137.23 45.73 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.287 -0.883 . . . . 0.0 109.471 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . 0.709 ' O ' HG13 ' A' ' 171' ' ' VAL . 18.6 m -129.96 74.18 80.79 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.203 -0.936 . . . . 0.0 109.486 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -51.04 112.72 0.85 Allowed 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.607 2.205 . . . . 0.0 111.73 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.709 HG13 ' O ' ' A' ' 169' ' ' THR . 28.7 m -133.11 153.46 37.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.308 -0.87 . . . . 0.0 109.423 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.675 ' O ' HD23 ' A' ' 173' ' ' LEU . 94.8 mt-10 -95.68 130.28 42.62 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.24 -0.913 . . . . 0.0 109.5 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . 0.775 ' CD1' HG22 ' A' ' 136' ' ' VAL . 51.6 mt -128.08 146.4 50.7 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.327 -0.858 . . . . 0.0 109.404 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 57.1 m-20 -67.77 171.06 6.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.268 -0.895 . . . . 0.0 109.451 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.66 ' CE1' HD21 ' A' ' 158' ' ' LEU . 6.2 m-30 -64.64 -49.19 71.99 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.248 -0.908 . . . . 0.0 109.386 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 87.0 p -74.94 -18.64 60.36 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.169 -0.957 . . . . 0.0 109.453 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 177' ' ' GLN . . . . . 0.651 ' NE2' HD22 ' A' ' 173' ' ' LEU . 63.8 tt0 -70.66 -20.85 62.67 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.296 -0.878 . . . . 0.0 109.483 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.556 HG11 ' HB2' ' A' ' 173' ' ' LEU . 4.7 m -130.2 159.2 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.285 -0.885 . . . . 0.0 109.403 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 179' ' ' GLU . . . . . 0.405 ' HB2' ' HB3' ' A' ' 135' ' ' ARG . 73.0 mt-10 -115.6 151.96 33.98 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.189 -0.944 . . . . 0.0 109.525 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 21.1 tttt -75.7 136.42 40.36 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.249 -0.907 . . . . 0.0 109.511 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.516 0 O-C-N 121.292 -0.88 . . . . 0.0 109.527 179.978 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.683 ' CD2' HD21 ' A' ' 158' ' ' LEU . 83.9 m-85 . . . . . 0 N--CA 1.489 1.509 0 CA-C-O 121.246 0.546 . . . . 0.0 109.564 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.434 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.2 OUTLIER -123.02 155.03 64.71 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.287 -0.883 . . . . 0.0 109.464 179.979 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.434 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 49.5 Cg_endo -51.22 128.89 26.78 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.648 2.232 . . . . 0.0 111.815 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 91.52 2.93 69.58 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.433 ' OE2' ' HE3' ' A' ' 180' ' ' LYS . 65.7 tt0 -88.5 141.87 28.18 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.154 -1.204 . . . . 0.0 109.485 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.925 ' SD ' HG22 ' A' ' 147' ' ' VAL . 80.4 mmm -80.33 137.56 36.59 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.208 -0.932 . . . . 0.0 109.556 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.75 HG21 ' CG2' ' A' ' 148' ' ' VAL . 2.5 t -129.22 179.28 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.247 -0.908 . . . . 0.0 109.285 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.685 ' H ' HG12 ' A' ' 134' ' ' VAL . 37.4 ttm180 -137.83 142.6 40.77 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.123 -0.986 . . . . 0.0 109.48 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.47 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 59.3 t -110.95 133.02 57.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.302 -0.874 . . . . 0.0 109.512 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 40.7 p30 -124.75 19.86 8.55 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.176 -0.952 . . . . 0.0 109.384 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.444 ' HB3' ' HG3' ' A' ' 177' ' ' GLN . 55.9 t0 -143.13 153.77 43.23 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.289 -0.882 . . . . 0.0 109.481 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.44 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 69.84 172.07 9.52 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -52.88 -16.9 6.62 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.582 2.188 . . . . 0.0 111.71 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . 0.488 ' CD1' HG21 ' A' ' 162' ' ' VAL . 99.5 m-85 -88.15 10.83 18.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.299 -0.876 . . . . 0.0 109.426 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' ALA . . . . . 0.449 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -64.27 145.79 55.42 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.276 -0.89 . . . . 0.0 109.554 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.449 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 50.8 m-20 63.54 46.88 4.02 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.33 -0.856 . . . . 0.0 109.622 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.6 ' HB3' HG13 ' A' ' 162' ' ' VAL . 39.3 m-85 -143.38 140.86 30.68 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.176 -0.952 . . . . 0.0 109.599 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 73.5 m-20 -95.6 142.05 28.38 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.271 -0.893 . . . . 0.0 109.492 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -151.29 173.16 30.76 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.925 HG22 ' SD ' ' A' ' 133' ' ' MET . 22.6 t -117.9 153.04 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.154 -1.204 . . . . 0.0 109.401 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.858 HG22 HG22 ' A' ' 160' ' ' VAL . 57.5 t -88.87 109.67 20.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.234 -0.916 . . . . 0.0 109.521 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -68.13 -40.9 82.37 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.262 -0.899 . . . . 0.0 109.418 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.451 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 95.6 mt-10 -153.93 157.53 39.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.207 -0.933 . . . . 0.0 109.395 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.498 HG21 ' O ' ' A' ' 128' ' ' PHE . 43.9 t -120.99 144.27 30.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.233 -0.917 . . . . 0.0 109.462 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -123.15 95.61 4.67 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.212 -0.93 . . . . 0.0 109.493 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -66.14 -42.24 89.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.183 -0.948 . . . . 0.0 109.51 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 76.2 mm-40 -59.58 -43.37 93.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.29 -0.881 . . . . 0.0 109.427 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 23.7 mttt -87.35 -10.25 52.69 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.29 -0.881 . . . . 0.0 109.495 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 1.6 m 55.62 53.28 9.81 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.23 -0.919 . . . . 0.0 109.432 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' ARG . . . . . 0.573 ' C ' HD12 ' A' ' 158' ' ' LEU . 88.5 mmt-85 -139.47 162.55 34.79 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.277 -0.889 . . . . 0.0 109.512 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' LEU . . . . . 0.748 HD11 ' CE1' ' A' ' 175' ' ' PHE . 7.0 mp -122.55 131.31 53.78 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.278 -0.889 . . . . 0.0 109.542 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . 0.451 ' HD2' ' HB2' ' A' ' 150' ' ' GLU . 23.8 mttm -97.14 98.6 10.17 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.198 -0.939 . . . . 0.0 109.233 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.858 HG22 HG22 ' A' ' 148' ' ' VAL . 30.0 t -123.17 145.68 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.236 -0.915 . . . . 0.0 109.662 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . 0.466 ' CB ' ' HA ' ' A' ' 170' ' ' PRO . 88.1 p -112.71 148.29 35.02 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.277 -0.89 . . . . 0.0 109.333 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' VAL . . . . . 0.6 HG13 ' HB3' ' A' ' 144' ' ' PHE . 18.0 t -113.4 128.32 70.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.215 -0.928 . . . . 0.0 109.626 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 36.5 t . . . . . 0 N--CA 1.489 1.522 0 O-C-N 121.29 -0.881 . . . . 0.0 109.503 179.85 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 72.9 mtm180 . . . . . 0 N--CA 1.489 1.512 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -81.08 134.75 35.71 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.258 -0.901 . . . . 0.0 109.496 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . 0.717 ' O ' HG13 ' A' ' 171' ' ' VAL . 64.8 m -128.48 77.26 77.5 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.215 -0.928 . . . . 0.0 109.475 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.466 ' HA ' ' CB ' ' A' ' 161' ' ' SER . 48.9 Cg_endo -53.13 107.8 0.22 Allowed 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.631 2.22 . . . . 0.0 111.789 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 1.03 HG23 HD21 ' A' ' 173' ' ' LEU . 19.4 m -127.04 157.68 38.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.27 -0.893 . . . . 0.0 109.463 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.745 ' C ' HD22 ' A' ' 173' ' ' LEU . 95.8 mt-10 -91.05 128.46 36.88 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.311 -0.868 . . . . 0.0 109.503 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . 1.03 HD21 HG23 ' A' ' 171' ' ' VAL . 2.2 mm? -122.33 156.08 34.64 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.289 -0.882 . . . . 0.0 109.497 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 174' ' ' ASP . . . . . 0.466 ' HB2' ' HB2' ' A' ' 177' ' ' GLN . 84.5 m-20 -83.34 168.13 16.92 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.217 -0.927 . . . . 0.0 109.596 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.748 ' CE1' HD11 ' A' ' 158' ' ' LEU . 8.2 m-85 -59.49 -49.44 77.77 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.255 -0.903 . . . . 0.0 109.584 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 84.0 p -78.09 -19.36 54.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.2 -0.937 . . . . 0.0 109.653 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 177' ' ' GLN . . . . . 0.6 ' NE2' HD12 ' A' ' 173' ' ' LEU . 64.9 tt0 -67.25 -25.26 65.99 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.116 -0.99 . . . . 0.0 109.483 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.536 HG13 ' HB3' ' A' ' 173' ' ' LEU . 4.5 m -127.08 157.57 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.264 -0.897 . . . . 0.0 109.592 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 179' ' ' GLU . . . . . 0.445 ' N ' ' O ' ' A' ' 135' ' ' ARG . 56.4 mt-10 -111.29 152.74 26.86 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.258 -0.901 . . . . 0.0 109.438 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 180' ' ' LYS . . . . . 0.433 ' HE3' ' OE2' ' A' ' 132' ' ' GLU . 5.4 tttp -72.9 133.02 44.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.228 -0.92 . . . . 0.0 109.481 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . 0.418 ' CB ' ' O ' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.547 0 O-C-N 121.249 -0.907 . . . . 0.0 109.514 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.435 ' HA ' ' OE1' ' A' ' 132' ' ' GLU . 56.9 m-85 . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.497 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.1 OUTLIER -145.42 155.44 53.69 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.252 -0.905 . . . . 0.0 109.502 179.933 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.497 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.2 Cg_endo -48.58 128.52 18.3 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.633 2.222 . . . . 0.0 111.828 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 96.25 -9.57 67.41 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.435 ' OE1' ' HA ' ' A' ' 128' ' ' PHE . 92.2 mt-10 -86.95 140.24 29.8 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.155 -1.203 . . . . 0.0 109.496 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.557 ' HG2' HG22 ' A' ' 147' ' ' VAL . 87.9 mtp -84.76 152.25 23.82 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.333 -0.854 . . . . 0.0 109.456 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.692 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -133.45 179.21 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.236 -0.915 . . . . 0.0 109.308 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.692 ' H ' HG12 ' A' ' 134' ' ' VAL . 64.1 mtm180 -138.9 150.31 45.8 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.233 -0.917 . . . . 0.0 109.53 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.531 HG12 ' H ' ' A' ' 138' ' ' ASP . 42.1 t -108.31 135.24 47.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.297 -0.877 . . . . 0.0 109.444 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 36.7 p30 -118.17 14.16 13.91 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.239 -0.913 . . . . 0.0 109.528 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.531 ' H ' HG12 ' A' ' 136' ' ' VAL . 53.7 p30 -157.21 169.95 23.6 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.269 -0.894 . . . . 0.0 109.499 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 69.04 165.55 4.11 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -55.97 -18.61 23.0 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.629 2.219 . . . . 0.0 111.739 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . 1.175 ' CD1' HG21 ' A' ' 162' ' ' VAL . 94.1 m-85 -88.74 7.77 32.18 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.291 -0.881 . . . . 0.0 109.523 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' ALA . . . . . 0.497 ' O ' ' CB ' ' A' ' 143' ' ' ASP . . . -67.9 147.98 51.75 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.178 -0.951 . . . . 0.0 109.48 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.497 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 3.9 t70 76.29 27.47 0.86 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.281 -0.887 . . . . 0.0 109.56 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.482 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 96.5 m-85 -135.87 146.55 47.55 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -0.878 . . . . 0.0 109.47 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 75.6 m-20 -103.63 146.98 27.77 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.268 -0.895 . . . . 0.0 109.377 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . 0.459 ' HA3' ' O ' ' A' ' 161' ' ' SER . . . -151.24 -173.94 21.63 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.557 HG22 ' HG2' ' A' ' 133' ' ' MET . 48.7 t -123.99 156.68 31.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.302 -1.116 . . . . 0.0 109.487 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.638 HG23 ' CG2' ' A' ' 134' ' ' VAL . 98.7 t -86.59 96.07 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.246 -0.909 . . . . 0.0 109.519 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -68.31 -34.92 77.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.294 -0.879 . . . . 0.0 109.411 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.404 ' O ' ' HB3' ' A' ' 159' ' ' LYS . 95.0 mt-10 -151.11 159.19 44.63 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.202 -0.936 . . . . 0.0 109.479 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.481 HG22 HG11 ' A' ' 148' ' ' VAL . 43.6 t -129.02 148.22 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.459 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -134.2 86.71 2.3 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.242 -0.911 . . . . 0.0 109.476 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -67.34 -36.72 82.0 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.285 -0.884 . . . . 0.0 109.505 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -64.15 -41.45 97.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.202 -0.937 . . . . 0.0 109.442 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.415 ' O ' ' C ' ' A' ' 156' ' ' SER . 42.7 mttp -92.64 9.43 34.82 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.225 -0.922 . . . . 0.0 109.478 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . 0.415 ' C ' ' O ' ' A' ' 155' ' ' LYS . 8.1 m 43.85 52.76 6.46 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.304 -0.872 . . . . 0.0 109.445 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' ARG . . . . . 0.45 ' CG ' ' HB3' ' A' ' 172' ' ' GLU . 7.7 tpt180 -144.45 140.0 28.68 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.243 -0.911 . . . . 0.0 109.43 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' LEU . . . . . 0.501 HD21 ' CE1' ' A' ' 175' ' ' PHE . 53.7 mt -107.35 134.54 50.26 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.198 -0.939 . . . . 0.0 109.454 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . 0.428 ' HD2' ' HG2' ' A' ' 172' ' ' GLU . 13.6 tptt -92.74 95.9 9.83 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.247 -0.908 . . . . 0.0 109.463 179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.523 HG22 HG22 ' A' ' 148' ' ' VAL . 40.9 t -117.7 143.41 28.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.148 -0.97 . . . . 0.0 109.473 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . 0.527 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 28.4 t -109.21 147.67 32.18 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.246 -0.909 . . . . 0.0 109.469 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' VAL . . . . . 1.175 HG21 ' CD1' ' A' ' 141' ' ' PHE . 21.1 t -88.43 134.39 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.258 -0.901 . . . . 0.0 109.615 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 5.7 m . . . . . 0 N--CA 1.49 1.541 0 O-C-N 121.319 -0.863 . . . . 0.0 109.231 179.765 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 17.3 ttt180 . . . . . 0 N--CA 1.492 1.656 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -67.28 147.57 52.83 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.206 -0.934 . . . . 0.0 109.382 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . 0.581 HG21 ' CE1' ' A' ' 141' ' ' PHE . 5.3 m -124.58 88.95 52.89 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.221 -0.924 . . . . 0.0 109.541 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.527 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.4 Cg_endo -68.23 107.89 1.65 Allowed 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 122.592 2.194 . . . . 0.0 111.783 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.425 ' O ' ' O ' ' A' ' 160' ' ' VAL . 21.2 m -132.87 160.69 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.302 -0.874 . . . . 0.0 109.45 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.69 ' O ' HD23 ' A' ' 173' ' ' LEU . 97.7 mt-10 -103.97 128.61 51.51 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.266 -0.896 . . . . 0.0 109.508 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . 0.69 HD23 ' O ' ' A' ' 172' ' ' GLU . 55.7 mt -129.74 147.32 51.5 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.269 -0.895 . . . . 0.0 109.51 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 174' ' ' ASP . . . . . 0.424 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 88.9 m-20 -67.41 173.13 4.24 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.282 -0.886 . . . . 0.0 109.455 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.53 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.7 m-30 -64.92 -41.46 95.55 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.191 -0.943 . . . . 0.0 109.403 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 19.4 m -75.11 -25.79 58.76 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.233 -0.917 . . . . 0.0 109.433 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 177' ' ' GLN . . . . . 0.424 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 83.2 mt-30 -68.29 -22.67 64.72 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.219 -0.926 . . . . 0.0 109.415 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.532 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 9.0 m -132.99 157.57 43.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.241 -0.912 . . . . 0.0 109.396 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 179' ' ' GLU . . . . . 0.431 ' N ' ' O ' ' A' ' 135' ' ' ARG . 93.4 mt-10 -114.94 150.18 36.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.359 -0.838 . . . . 0.0 109.486 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 18.1 tttm -66.04 140.1 58.24 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.253 -0.904 . . . . 0.0 109.428 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.503 0 O-C-N 121.23 -0.919 . . . . 0.0 109.456 -179.971 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.519 ' O ' HG21 ' A' ' 151' ' ' VAL . 66.0 m-85 . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.502 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.6 OUTLIER -133.38 153.16 80.38 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.236 -0.915 . . . . 0.0 109.476 179.961 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.502 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 49.8 Cg_endo -45.79 132.79 13.77 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.591 2.194 . . . . 0.0 111.762 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 89.57 -1.28 81.42 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.643 ' O ' HG12 ' A' ' 148' ' ' VAL . 49.0 tp10 -94.5 127.98 40.77 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.131 -1.217 . . . . 0.0 109.423 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.726 ' HG2' HG22 ' A' ' 147' ' ' VAL . 81.6 mtp -68.14 153.96 42.67 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.208 -0.932 . . . . 0.0 109.438 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.682 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -138.1 178.82 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.218 -0.927 . . . . 0.0 109.284 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.682 ' H ' HG12 ' A' ' 134' ' ' VAL . 76.3 ttt180 -135.42 148.09 49.19 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.25 -0.906 . . . . 0.0 109.458 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.475 HG12 ' HA ' ' A' ' 142' ' ' ALA . 48.5 t -118.15 126.91 75.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.278 -0.889 . . . . 0.0 109.471 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . 0.403 ' O ' ' OD1' ' A' ' 138' ' ' ASP . 26.2 p30 -126.28 12.87 7.66 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.249 -0.907 . . . . 0.0 109.492 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.473 ' HB2' ' OE1' ' A' ' 177' ' ' GLN . 93.5 m-20 -137.78 163.07 32.28 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.21 -0.931 . . . . 0.0 109.506 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 63.86 176.48 4.2 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -58.14 -24.49 66.8 Favored 'Trans proline' 0 C--O 1.216 -0.613 0 C-N-CA 122.597 2.198 . . . . 0.0 111.745 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . 0.554 ' CZ ' HG11 ' A' ' 171' ' ' VAL . 98.8 m-85 -82.81 7.87 13.95 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.224 -0.922 . . . . 0.0 109.488 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' ALA . . . . . 0.475 ' HA ' HG12 ' A' ' 136' ' ' VAL . . . -61.03 150.87 32.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.215 -0.928 . . . . 0.0 109.499 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.473 ' N ' ' O ' ' A' ' 136' ' ' VAL . 37.8 m-20 62.66 52.58 2.8 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.271 -0.893 . . . . 0.0 109.579 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.497 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 35.6 m-85 -150.4 132.02 14.88 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.237 -0.914 . . . . 0.0 109.489 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 56.5 m-20 -92.98 138.72 31.23 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.209 -0.932 . . . . 0.0 109.402 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -156.67 -179.65 31.8 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.965 ' O ' HG13 ' A' ' 160' ' ' VAL . 40.9 t -121.48 159.52 23.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.243 -1.151 . . . . 0.0 109.349 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.701 ' HA ' HG22 ' A' ' 160' ' ' VAL . 2.5 p -100.26 115.62 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.281 -0.887 . . . . 0.0 109.519 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 83.3 mt-10 -70.52 -36.59 73.82 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.279 -0.888 . . . . 0.0 109.294 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.473 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 93.7 mt-10 -152.32 162.45 41.15 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.283 -0.886 . . . . 0.0 109.459 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.679 HG22 HG21 ' A' ' 148' ' ' VAL . 48.0 t -132.27 151.75 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.19 -0.944 . . . . 0.0 109.51 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' ASP . . . . . 0.517 ' O ' ' N ' ' A' ' 156' ' ' SER . 84.3 m-20 -125.52 98.58 5.65 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.243 -0.91 . . . . 0.0 109.424 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 87.4 m-85 -66.33 -35.8 81.29 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.219 -0.926 . . . . 0.0 109.572 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -66.94 -45.3 78.24 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.286 -0.883 . . . . 0.0 109.551 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 19.3 mttt -91.07 -8.55 48.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.242 -0.911 . . . . 0.0 109.512 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . 0.517 ' N ' ' O ' ' A' ' 152' ' ' ASP . 44.3 t 55.75 52.33 11.04 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.548 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' ARG . . . . . 0.67 ' C ' HD12 ' A' ' 158' ' ' LEU . 83.3 mmt-85 -133.2 151.1 51.95 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.896 . . . . 0.0 109.327 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' LEU . . . . . 0.869 HD11 ' CE1' ' A' ' 175' ' ' PHE . 4.3 mp -118.16 137.12 53.19 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.18 -0.95 . . . . 0.0 109.592 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . 0.473 ' HD2' ' HB2' ' A' ' 150' ' ' GLU . 34.1 mttt -99.15 90.55 4.63 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.243 -0.911 . . . . 0.0 109.347 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.965 HG13 ' O ' ' A' ' 147' ' ' VAL . 46.5 t -118.52 142.99 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.224 -0.922 . . . . 0.0 109.533 -179.759 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . 0.435 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 27.0 t -112.53 136.64 51.82 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.245 -0.909 . . . . 0.0 109.395 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' VAL . . . . . 0.497 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 21.5 t -107.47 132.35 55.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.176 -0.953 . . . . 0.0 109.511 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 33.1 t . . . . . 0 N--CA 1.491 1.576 0 O-C-N 121.292 -0.88 . . . . 0.0 109.48 -179.994 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 78.7 mtp180 . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -68.5 140.67 55.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.274 -0.891 . . . . 0.0 109.543 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . 0.662 ' O ' HG13 ' A' ' 171' ' ' VAL . 8.2 m -128.36 74.44 79.76 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.235 -0.916 . . . . 0.0 109.37 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.435 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.6 Cg_endo -54.24 105.2 0.13 Allowed 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.579 2.186 . . . . 0.0 111.82 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.662 HG13 ' O ' ' A' ' 169' ' ' THR . 19.6 m -128.09 159.37 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.243 -0.911 . . . . 0.0 109.419 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.529 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.9 mt-10 -102.91 130.93 50.13 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.213 -0.929 . . . . 0.0 109.45 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . 0.658 HD12 ' CG1' ' A' ' 178' ' ' VAL . 55.1 mt -125.02 160.84 28.07 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.276 -0.89 . . . . 0.0 109.527 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 174' ' ' ASP . . . . . 0.458 ' HB2' ' HG2' ' A' ' 177' ' ' GLN . 90.6 m-20 -82.82 176.78 9.04 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.3 -0.875 . . . . 0.0 109.558 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.869 ' CE1' HD11 ' A' ' 158' ' ' LEU . 3.2 m-85 -66.1 -39.77 90.24 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.333 -0.855 . . . . 0.0 109.613 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 15.4 m -79.81 -26.23 40.58 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.208 -0.933 . . . . 0.0 109.619 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 177' ' ' GLN . . . . . 0.473 ' OE1' ' HB2' ' A' ' 138' ' ' ASP . 96.6 mm-40 -67.08 -30.71 70.83 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.22 -0.925 . . . . 0.0 109.519 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.658 ' CG1' HD12 ' A' ' 173' ' ' LEU . 12.7 m -125.29 158.26 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.249 -0.907 . . . . 0.0 109.386 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 179' ' ' GLU . . . . . 0.511 ' O ' ' N ' ' A' ' 135' ' ' ARG . 70.6 tt0 -120.38 143.09 48.61 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.218 -0.926 . . . . 0.0 109.498 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 23.6 ttmt -59.71 140.15 56.69 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.309 -0.87 . . . . 0.0 109.434 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.527 0 O-C-N 121.174 -0.954 . . . . 0.0 109.452 -179.984 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 92.2 m-85 . . . . . 0 N--CA 1.489 1.477 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.461 ' HB2' ' HD2' ' A' ' 130' ' ' PRO . 16.5 pt-20 -133.01 134.98 25.06 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.921 . . . . 0.0 109.454 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.505 ' HA ' ' O ' ' A' ' 148' ' ' VAL . 49.2 Cg_endo -35.28 131.36 0.24 Allowed 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.517 2.145 . . . . 0.0 111.738 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . 0.487 ' C ' ' CG1' ' A' ' 147' ' ' VAL . . . 90.89 -4.48 81.71 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.803 ' O ' HG13 ' A' ' 147' ' ' VAL . 49.2 tp10 -83.58 141.7 31.38 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.125 -1.221 . . . . 0.0 109.548 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.743 ' HG2' HG22 ' A' ' 147' ' ' VAL . 90.5 mtp -80.94 150.11 29.11 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.184 -0.948 . . . . 0.0 109.438 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.679 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -135.65 179.06 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.168 -0.958 . . . . 0.0 109.375 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.679 ' H ' HG12 ' A' ' 134' ' ' VAL . 94.5 mtt180 -132.86 146.52 51.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.318 -0.864 . . . . 0.0 109.467 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 41.4 t -112.53 130.42 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.265 -0.897 . . . . 0.0 109.423 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 54.9 p30 -123.37 19.21 9.75 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.201 -0.937 . . . . 0.0 109.534 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -156.27 151.24 26.26 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.212 -0.93 . . . . 0.0 109.493 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 82.27 164.16 33.97 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -54.19 -23.66 30.54 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.606 2.204 . . . . 0.0 111.779 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . 0.474 ' CD1' HG21 ' A' ' 162' ' ' VAL . 98.9 m-85 -86.87 11.05 14.26 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.252 -0.905 . . . . 0.0 109.391 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' ALA . . . . . 0.471 ' O ' ' CB ' ' A' ' 143' ' ' ASP . . . -70.09 151.09 45.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.491 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.471 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 25.0 t0 74.9 28.62 1.09 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.279 -0.888 . . . . 0.0 109.517 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.525 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 92.5 m-85 -135.03 140.3 45.5 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.164 -0.96 . . . . 0.0 109.608 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 21.2 m120 -95.95 141.07 29.81 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.32 -0.862 . . . . 0.0 109.418 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -151.3 -173.42 21.18 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.803 HG13 ' O ' ' A' ' 132' ' ' GLU . 54.8 t -132.01 144.26 37.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.362 -1.081 . . . . 0.0 109.454 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.768 ' CA ' HG22 ' A' ' 160' ' ' VAL . 2.1 p -83.03 106.11 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.281 -0.887 . . . . 0.0 109.443 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 56.5 mp0 -70.2 -46.8 63.83 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.231 -0.918 . . . . 0.0 109.461 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.409 ' HG2' ' N ' ' A' ' 151' ' ' VAL . 83.5 tt0 -131.8 153.24 50.34 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.186 -0.947 . . . . 0.0 109.36 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.608 HG22 HG21 ' A' ' 148' ' ' VAL . 47.9 t -120.18 153.53 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.174 -0.954 . . . . 0.0 109.579 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 92.2 m-20 -135.76 83.25 2.0 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.306 -0.871 . . . . 0.0 109.339 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' TYR . . . . . 0.463 ' CZ ' HG11 ' A' ' 151' ' ' VAL . 96.7 m-85 -67.03 -34.84 78.59 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.244 -0.91 . . . . 0.0 109.555 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 76.0 mm-40 -62.21 -40.81 97.32 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.202 -0.936 . . . . 0.0 109.562 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.451 ' O ' ' HG2' ' A' ' 155' ' ' LYS . 31.7 tttt -96.88 -4.3 40.44 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.289 -0.882 . . . . 0.0 109.655 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . 0.435 ' HB2' ' O ' ' A' ' 155' ' ' LYS . 19.8 m 59.9 53.05 4.92 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.195 -0.941 . . . . 0.0 109.46 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 13.5 tpt180 -142.63 138.97 31.07 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.281 -0.887 . . . . 0.0 109.488 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' LEU . . . . . 0.552 ' CD2' HG13 ' A' ' 151' ' ' VAL . 41.9 mt -108.08 134.63 50.68 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.252 -0.905 . . . . 0.0 109.524 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 62.8 tttm -97.28 97.08 8.85 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.225 -0.922 . . . . 0.0 109.418 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.768 HG22 ' CA ' ' A' ' 148' ' ' VAL . 42.9 t -123.27 138.37 53.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.258 -0.901 . . . . 0.0 109.615 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . 0.432 ' CB ' ' HA ' ' A' ' 170' ' ' PRO . 83.6 p -100.75 155.24 18.02 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.299 -0.876 . . . . 0.0 109.508 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' VAL . . . . . 0.525 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 5.3 t -106.14 129.15 59.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.25 -0.906 . . . . 0.0 109.479 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 55.1 m . . . . . 0 N--CA 1.49 1.564 0 O-C-N 121.286 -0.884 . . . . 0.0 109.383 179.887 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 7.9 mtm180 . . . . . 0 N--CA 1.492 1.665 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -69.39 138.87 53.98 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.221 -0.924 . . . . 0.0 109.384 179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 29.7 m -123.04 87.85 51.0 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.172 -0.955 . . . . 0.0 109.526 -179.801 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.432 ' HA ' ' CB ' ' A' ' 161' ' ' SER . 50.2 Cg_endo -62.74 107.53 0.62 Allowed 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.558 2.172 . . . . 0.0 111.685 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' A' ' 160' ' ' VAL . 18.9 m -129.97 156.92 42.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.278 -0.889 . . . . 0.0 109.567 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.499 ' O ' HD23 ' A' ' 173' ' ' LEU . 94.5 mt-10 -103.97 129.38 51.54 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.281 -0.887 . . . . 0.0 109.371 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . 0.547 ' HB2' ' CG1' ' A' ' 178' ' ' VAL . 65.5 mt -126.25 147.89 49.6 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.268 -0.895 . . . . 0.0 109.471 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -68.5 173.35 5.07 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.25 -0.907 . . . . 0.0 109.407 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.492 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.9 m-30 -66.51 -40.24 89.11 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.248 -0.907 . . . . 0.0 109.446 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 14.8 m -75.36 -24.41 57.29 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.231 -0.918 . . . . 0.0 109.406 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -70.32 -28.8 65.45 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.219 -0.926 . . . . 0.0 109.499 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.547 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 4.4 m -127.95 161.08 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.231 -0.918 . . . . 0.0 109.468 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 179' ' ' GLU . . . . . . . . . . . . . 75.0 mm-40 -120.0 148.64 43.31 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.236 -0.915 . . . . 0.0 109.505 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 20.1 tttt -58.95 140.56 55.43 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.188 -0.945 . . . . 0.0 109.485 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . 0.477 ' HB2' ' C ' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.491 1.589 0 O-C-N 121.21 -0.932 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.611 ' CD2' HD21 ' A' ' 158' ' ' LEU . 92.0 m-85 . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.486 ' HB2' ' HD2' ' A' ' 130' ' ' PRO . 2.2 pt-20 -142.35 147.31 42.91 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.231 -0.918 . . . . 0.0 109.418 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.486 ' HD2' ' HB2' ' A' ' 129' ' ' GLU . 48.8 Cg_endo -40.95 128.47 2.79 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.436 2.091 . . . . 0.0 111.84 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 100.28 -4.19 56.96 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.642 ' O ' HG13 ' A' ' 147' ' ' VAL . 78.1 mm-40 -93.03 144.32 25.37 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.207 -1.172 . . . . 0.0 109.541 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.895 ' SD ' HG22 ' A' ' 147' ' ' VAL . 77.3 mmm -83.48 143.08 30.47 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.225 -0.922 . . . . 0.0 109.413 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.938 ' CG2' HG23 ' A' ' 148' ' ' VAL . 2.5 t -128.63 178.59 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.225 -0.922 . . . . 0.0 109.362 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.683 ' H ' HG12 ' A' ' 134' ' ' VAL . 40.0 ttt85 -141.88 145.8 35.04 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.343 -0.848 . . . . 0.0 109.405 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.575 HG22 ' CD1' ' A' ' 173' ' ' LEU . 43.5 t -112.48 135.29 52.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.235 -0.915 . . . . 0.0 109.495 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 34.6 p30 -126.67 10.41 7.17 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.279 -0.888 . . . . 0.0 109.411 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.484 ' HB3' ' HG3' ' A' ' 177' ' ' GLN . 49.9 t0 -150.58 159.04 44.78 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.229 -0.919 . . . . 0.0 109.541 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.416 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 77.52 165.33 24.63 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -50.45 -22.33 8.74 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 122.593 2.195 . . . . 0.0 111.721 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . 0.915 ' CZ ' HG11 ' A' ' 171' ' ' VAL . 93.9 m-85 -88.61 12.57 14.31 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.207 -0.933 . . . . 0.0 109.485 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' ALA . . . . . 0.451 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -62.83 149.2 44.86 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.339 -0.851 . . . . 0.0 109.529 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.432 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 44.7 m-20 63.28 45.31 5.07 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.472 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.538 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 46.0 m-85 -147.08 126.08 12.83 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.184 -0.947 . . . . 0.0 109.474 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 67.8 m-20 -88.42 145.24 25.89 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.224 -0.923 . . . . 0.0 109.605 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -157.1 177.26 34.06 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.895 HG22 ' SD ' ' A' ' 133' ' ' MET . 22.0 t -114.86 156.69 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.177 -1.19 . . . . 0.0 109.395 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.938 HG23 ' CG2' ' A' ' 134' ' ' VAL . 47.8 t -82.37 104.11 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.248 -0.907 . . . . 0.0 109.498 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.42 ' O ' ' CD ' ' A' ' 150' ' ' GLU . 97.2 mt-10 -69.86 -35.41 74.69 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.282 -0.886 . . . . 0.0 109.36 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.474 ' HB2' ' HD3' ' A' ' 159' ' ' LYS . 76.1 mm-40 -152.81 164.88 36.98 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.322 -0.861 . . . . 0.0 109.41 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.44 HG11 ' CZ ' ' A' ' 153' ' ' TYR . 46.5 t -128.56 143.48 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.267 -0.896 . . . . 0.0 109.424 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 93.8 m-20 -124.91 78.31 1.69 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.19 -0.944 . . . . 0.0 109.542 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' TYR . . . . . 0.44 ' CZ ' HG11 ' A' ' 151' ' ' VAL . 92.9 m-85 -59.87 -42.21 93.24 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.238 -0.914 . . . . 0.0 109.385 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -54.61 -45.08 73.6 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.244 -0.91 . . . . 0.0 109.366 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.412 ' O ' ' HG3' ' A' ' 157' ' ' ARG . 44.2 mttp -86.23 -2.96 58.85 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.264 -0.897 . . . . 0.0 109.515 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 17.1 m 55.68 53.7 9.21 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.183 -0.948 . . . . 0.0 109.358 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' ARG . . . . . 0.412 ' HG3' ' O ' ' A' ' 155' ' ' LYS . 66.9 mtt180 -147.95 162.79 38.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 109.534 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' LEU . . . . . 0.638 ' CD1' ' CE1' ' A' ' 175' ' ' PHE . 6.7 mp -114.02 139.27 49.4 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.331 -0.856 . . . . 0.0 109.428 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . 0.474 ' HD3' ' HB2' ' A' ' 150' ' ' GLU . 41.1 tttt -104.56 100.22 9.9 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.158 -0.963 . . . . 0.0 109.312 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.567 HG13 ' O ' ' A' ' 147' ' ' VAL . 39.9 t -119.9 148.52 22.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.207 -0.933 . . . . 0.0 109.549 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . 0.416 ' CB ' ' HA ' ' A' ' 170' ' ' PRO . 22.7 t -117.95 138.85 51.88 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.245 -0.909 . . . . 0.0 109.333 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 162' ' ' VAL . . . . . 0.538 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 4.4 t -107.19 133.13 52.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.182 -0.949 . . . . 0.0 109.708 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 44.1 t . . . . . 0 N--CA 1.49 1.53 0 O-C-N 121.321 -0.862 . . . . 0.0 109.311 179.838 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 76.1 mtm180 . . . . . 0 N--CA 1.489 1.485 0 N-CA-C 109.441 -0.578 . . . . 0.0 109.441 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -80.12 134.6 36.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.2 -0.938 . . . . 0.0 109.413 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . 0.726 ' O ' HG13 ' A' ' 171' ' ' VAL . 57.3 m -128.65 73.32 80.92 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.286 -0.884 . . . . 0.0 109.437 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.416 ' HA ' ' CB ' ' A' ' 161' ' ' SER . 49.6 Cg_endo -52.1 108.42 0.25 Allowed 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.69 2.26 . . . . 0.0 111.89 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.915 HG11 ' CZ ' ' A' ' 141' ' ' PHE . 20.5 m -126.04 155.12 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.264 -0.898 . . . . 0.0 109.417 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.451 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.3 mt-10 -90.89 129.99 36.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.213 -0.929 . . . . 0.0 109.553 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . 0.575 ' CD1' HG22 ' A' ' 136' ' ' VAL . 61.9 mt -122.02 154.91 36.63 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.234 -0.916 . . . . 0.0 109.49 179.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 174' ' ' ASP . . . . . 0.481 ' HB2' ' HB2' ' A' ' 177' ' ' GLN . 85.1 m-20 -83.81 154.95 23.23 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.221 -0.925 . . . . 0.0 109.629 -179.867 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.638 ' CE1' ' CD1' ' A' ' 158' ' ' LEU . 25.4 m-85 -51.14 -50.24 59.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.38 -0.825 . . . . 0.0 109.615 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 72.4 p -74.8 -18.45 60.46 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.223 -0.923 . . . . 0.0 109.594 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 177' ' ' GLN . . . . . 0.484 ' HG3' ' HB3' ' A' ' 138' ' ' ASP . 65.7 tt0 -72.95 -25.15 60.92 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.301 -0.874 . . . . 0.0 109.448 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.509 HG13 ' HB3' ' A' ' 173' ' ' LEU . 5.2 m -125.34 161.81 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.154 -0.966 . . . . 0.0 109.487 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 179' ' ' GLU . . . . . . . . . . . . . 61.1 mt-10 -118.42 148.96 42.01 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.225 -0.922 . . . . 0.0 109.482 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 21.1 tttm -79.79 132.65 36.19 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.34 -0.85 . . . . 0.0 109.449 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.499 0 O-C-N 121.278 -0.889 . . . . 0.0 109.49 179.99 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.547 ' CD2' HD21 ' A' ' 158' ' ' LEU . 75.2 m-85 . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.459 ' O ' ' HG2' ' A' ' 132' ' ' GLU . 0.6 OUTLIER -129.46 150.04 74.5 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.206 -0.934 . . . . 0.0 109.469 -179.99 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.464 ' HA ' ' O ' ' A' ' 148' ' ' VAL . 50.0 Cg_endo -47.27 123.48 7.81 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.67 2.247 . . . . 0.0 111.771 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 99.29 2.17 56.78 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.626 -1.389 . . . . 0.0 109.626 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.459 ' HG2' ' O ' ' A' ' 129' ' ' GLU . 74.9 mm-40 -92.32 141.3 28.71 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.186 -1.185 . . . . 0.0 109.438 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.909 ' SD ' HG22 ' A' ' 147' ' ' VAL . 84.4 mmm -74.18 142.18 45.46 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.234 -0.916 . . . . 0.0 109.468 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.685 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -130.27 178.96 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.248 -0.908 . . . . 0.0 109.347 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.685 ' H ' HG12 ' A' ' 134' ' ' VAL . 45.7 ttt85 -142.44 135.75 28.8 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.333 -0.855 . . . . 0.0 109.429 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.715 HG22 HD12 ' A' ' 173' ' ' LEU . 66.3 t -106.29 133.56 50.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.264 -0.897 . . . . 0.0 109.444 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 11.4 p30 -132.06 22.11 4.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.302 -0.874 . . . . 0.0 109.431 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.498 ' HB3' ' HG3' ' A' ' 177' ' ' GLN . 51.7 t0 -143.23 156.42 44.74 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.243 -0.911 . . . . 0.0 109.447 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.452 ' O ' ' N ' ' A' ' 142' ' ' ALA . . . 62.98 167.17 0.74 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -44.28 -24.86 1.08 Allowed 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.585 2.19 . . . . 0.0 111.795 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . 0.45 ' O ' ' HB ' ' A' ' 136' ' ' VAL . 88.0 m-85 -86.57 14.96 6.04 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.255 -0.903 . . . . 0.0 109.468 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' ALA . . . . . 0.518 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -73.67 145.24 45.43 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.285 -0.885 . . . . 0.0 109.501 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.44 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 3.5 m-20 71.05 43.83 0.63 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.318 -0.864 . . . . 0.0 109.526 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.518 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 80.9 m-85 -142.25 139.98 32.12 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.25 -0.906 . . . . 0.0 109.522 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 78.9 m-20 -94.05 138.99 31.52 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.235 -0.916 . . . . 0.0 109.46 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -153.1 179.8 29.23 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.909 HG22 ' SD ' ' A' ' 133' ' ' MET . 22.8 t -124.18 151.38 29.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.256 -1.144 . . . . 0.0 109.449 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.706 HG21 HG22 ' A' ' 151' ' ' VAL . 3.1 p -87.28 95.23 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.219 -0.925 . . . . 0.0 109.552 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -65.75 -36.35 83.33 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.219 -0.925 . . . . 0.0 109.408 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.495 ' HG2' ' N ' ' A' ' 151' ' ' VAL . 84.7 tt0 -142.21 160.36 40.4 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.33 -0.856 . . . . 0.0 109.385 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.706 HG22 HG21 ' A' ' 148' ' ' VAL . 39.8 t -131.37 149.06 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.258 -0.901 . . . . 0.0 109.467 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -131.04 94.64 3.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.24 -0.912 . . . . 0.0 109.501 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -66.69 -32.9 74.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.257 -0.902 . . . . 0.0 109.487 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -61.81 -42.71 99.36 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -0.916 . . . . 0.0 109.368 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 29.9 mttm -90.03 -6.38 55.63 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.258 -0.901 . . . . 0.0 109.471 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 57.48 52.76 8.13 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.23 -0.919 . . . . 0.0 109.475 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' ARG . . . . . 0.649 ' C ' HD12 ' A' ' 158' ' ' LEU . 75.3 mtt180 -147.13 165.83 28.78 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.222 -0.924 . . . . 0.0 109.536 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' LEU . . . . . 1.17 HD11 ' CD1' ' A' ' 175' ' ' PHE . 3.5 mp -116.01 133.94 55.49 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.227 -0.921 . . . . 0.0 109.532 -179.736 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . 0.417 ' HD3' ' HB3' ' A' ' 150' ' ' GLU . 80.8 tttt -91.53 85.77 5.83 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.183 -0.948 . . . . 0.0 109.298 179.765 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.777 HG13 ' O ' ' A' ' 147' ' ' VAL . 61.1 t -110.4 144.28 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.264 -0.898 . . . . 0.0 109.603 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . 0.441 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 60.0 p -107.76 140.51 40.71 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.282 -0.886 . . . . 0.0 109.348 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 162' ' ' VAL . . . . . . . . . . . . . 6.6 t -110.29 131.98 59.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.242 -0.911 . . . . 0.0 109.59 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 32.6 t . . . . . 0 N--CA 1.491 1.582 0 O-C-N 121.233 -0.917 . . . . 0.0 109.42 179.85 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 39.0 ptt180 . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -75.44 143.23 42.77 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.267 -0.895 . . . . 0.0 109.46 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . 0.855 ' O ' HG13 ' A' ' 171' ' ' VAL . 27.2 m -130.12 70.61 82.23 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.237 -0.914 . . . . 0.0 109.441 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.441 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 50.5 Cg_endo -46.88 108.15 0.15 Allowed 'Trans proline' 0 C--O 1.214 -0.683 0 C-N-CA 122.613 2.209 . . . . 0.0 111.858 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.855 HG13 ' O ' ' A' ' 169' ' ' THR . 21.2 m -133.26 154.28 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.283 -0.886 . . . . 0.0 109.424 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.748 ' O ' HD23 ' A' ' 173' ' ' LEU . 94.5 mt-10 -100.08 136.36 40.1 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.18 -0.95 . . . . 0.0 109.451 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . 0.861 HD22 ' NE2' ' A' ' 177' ' ' GLN . 47.7 mt -131.01 152.47 50.29 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.285 -0.884 . . . . 0.0 109.513 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -69.54 156.34 39.05 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.245 -0.909 . . . . 0.0 109.515 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 1.17 ' CD1' HD11 ' A' ' 158' ' ' LEU . 51.0 m-85 -53.08 -44.48 67.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.547 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 82.5 p -75.3 -20.03 59.33 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.159 -0.963 . . . . 0.0 109.587 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 177' ' ' GLN . . . . . 0.861 ' NE2' HD22 ' A' ' 173' ' ' LEU . 50.6 tt0 -72.02 -24.55 61.57 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.283 -0.886 . . . . 0.0 109.503 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.461 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 17.7 m -127.26 163.55 30.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.26 -0.9 . . . . 0.0 109.516 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 179' ' ' GLU . . . . . 0.448 ' HB2' ' HB3' ' A' ' 135' ' ' ARG . 63.6 mm-40 -114.79 151.02 34.5 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.281 -0.887 . . . . 0.0 109.483 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 24.3 tttt -81.18 131.67 35.31 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.255 -0.903 . . . . 0.0 109.508 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . 0.559 ' HB3' ' HB2' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.544 0 O-C-N 121.193 -0.942 . . . . 0.0 109.415 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.571 ' CD2' HD11 ' A' ' 158' ' ' LEU . 93.0 m-85 . . . . . 0 N--CA 1.489 1.501 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.457 ' O ' ' HB2' ' A' ' 132' ' ' GLU . 1.8 mm-40 -103.32 139.59 20.25 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.265 -0.897 . . . . 0.0 109.442 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.422 ' HD2' ' HB3' ' A' ' 129' ' ' GLU . 49.3 Cg_endo -43.25 135.82 5.82 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.623 2.215 . . . . 0.0 111.712 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 80.35 6.75 89.1 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.457 ' HB2' ' O ' ' A' ' 129' ' ' GLU . 85.0 tt0 -89.04 128.76 35.74 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.269 -1.136 . . . . 0.0 109.448 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.491 ' O ' ' HB3' ' A' ' 181' ' ' ALA . 42.2 ttm -68.19 144.57 54.9 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.235 -0.916 . . . . 0.0 109.44 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.695 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -131.4 179.15 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.242 -0.911 . . . . 0.0 109.316 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.695 ' H ' HG12 ' A' ' 134' ' ' VAL . 28.4 ttt85 -129.99 135.98 48.9 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.196 -0.94 . . . . 0.0 109.42 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.498 HG22 HG12 ' A' ' 178' ' ' VAL . 60.7 t -107.71 133.87 51.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.213 -0.93 . . . . 0.0 109.498 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . 0.412 ' OD1' ' C ' ' A' ' 137' ' ' ASN . 44.0 p30 -132.59 23.39 4.34 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.239 -0.913 . . . . 0.0 109.462 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -142.85 144.08 32.36 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.269 -0.894 . . . . 0.0 109.531 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 75.49 172.85 32.58 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -52.1 -17.17 5.42 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.669 2.246 . . . . 0.0 111.756 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . 1.034 ' CD1' HG21 ' A' ' 162' ' ' VAL . 97.0 m-85 -92.68 17.51 10.17 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.28 -0.887 . . . . 0.0 109.495 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' ALA . . . . . 0.553 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -73.33 149.88 42.28 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.324 -0.86 . . . . 0.0 109.498 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.451 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 35.2 m-20 65.14 48.27 2.26 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.205 -0.935 . . . . 0.0 109.527 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.553 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 64.1 m-85 -147.22 146.89 29.96 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.218 -0.926 . . . . 0.0 109.404 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . 0.424 ' O ' ' OD1' ' A' ' 145' ' ' ASN . 44.0 p-10 -102.56 151.38 22.39 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.257 -0.902 . . . . 0.0 109.414 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . 0.452 ' O ' ' HA ' ' A' ' 133' ' ' MET . . . -164.95 -174.45 34.67 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.892 ' C ' HG13 ' A' ' 160' ' ' VAL . 96.7 t -130.29 150.75 34.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.18 -1.188 . . . . 0.0 109.427 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.78 HG21 HG22 ' A' ' 151' ' ' VAL . 2.1 p -89.61 107.2 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.178 -0.951 . . . . 0.0 109.502 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -70.86 -37.4 73.09 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.182 -0.949 . . . . 0.0 109.396 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -138.64 157.5 46.02 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.355 -0.841 . . . . 0.0 109.338 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.78 HG22 HG21 ' A' ' 148' ' ' VAL . 57.1 t -130.81 149.79 33.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.179 -0.95 . . . . 0.0 109.417 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' ASP . . . . . 0.4 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 95.3 m-20 -136.43 90.17 2.54 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.273 -0.892 . . . . 0.0 109.484 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -67.56 -37.0 82.03 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.233 -0.917 . . . . 0.0 109.495 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -63.6 -42.61 98.24 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.257 -0.902 . . . . 0.0 109.411 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.418 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 58.2 mttt -89.44 -4.64 57.9 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.248 -0.908 . . . . 0.0 109.478 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 58.5 m 55.65 52.73 10.54 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.171 -0.956 . . . . 0.0 109.439 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' ARG . . . . . 0.439 ' HD3' ' OD1' ' A' ' 174' ' ' ASP . 15.6 mmt85 -144.64 141.97 29.77 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.213 -0.93 . . . . 0.0 109.427 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' LEU . . . . . 0.606 ' CD2' HG13 ' A' ' 151' ' ' VAL . 40.1 mt -111.74 132.34 54.71 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -0.901 . . . . 0.0 109.577 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 22.0 tttt -94.9 91.74 6.57 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.23 -0.919 . . . . 0.0 109.277 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.892 HG13 ' C ' ' A' ' 147' ' ' VAL . 33.1 t -117.98 144.55 25.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.281 -0.887 . . . . 0.0 109.466 -179.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . 0.491 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 61.8 m -99.84 148.62 24.23 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.241 -0.912 . . . . 0.0 109.45 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 162' ' ' VAL . . . . . 1.034 HG21 ' CD1' ' A' ' 141' ' ' PHE . 6.2 t -96.53 138.39 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.29 -0.881 . . . . 0.0 109.621 -179.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 19.7 m . . . . . 0 N--CA 1.489 1.501 0 O-C-N 121.266 -0.896 . . . . 0.0 109.254 179.737 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 17.8 ttp180 . . . . . 0 N--CA 1.494 1.765 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -61.18 143.67 55.11 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.243 -0.91 . . . . 0.0 109.33 179.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . 0.482 HG22 HG13 ' A' ' 171' ' ' VAL . 36.6 m -126.36 98.57 32.08 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.17 -0.956 . . . . 0.0 109.554 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.491 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 50.3 Cg_endo -70.26 103.89 1.32 Allowed 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.492 2.128 . . . . 0.0 111.707 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.977 HG23 HD21 ' A' ' 173' ' ' LEU . 14.6 m -129.25 161.08 39.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.246 -0.909 . . . . 0.0 109.523 -179.866 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.845 ' C ' HD22 ' A' ' 173' ' ' LEU . 96.5 mt-10 -99.03 129.15 45.29 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.277 -0.889 . . . . 0.0 109.4 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . 0.977 HD21 HG23 ' A' ' 171' ' ' VAL . 2.8 mm? -125.41 146.3 49.67 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.192 -0.942 . . . . 0.0 109.529 -179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 174' ' ' ASP . . . . . 0.439 ' OD1' ' HD3' ' A' ' 157' ' ' ARG . 87.4 m-20 -69.35 170.36 10.52 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.228 -0.92 . . . . 0.0 109.489 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.538 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.7 m-30 -65.74 -40.64 92.34 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.269 -0.895 . . . . 0.0 109.47 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 83.0 p -75.51 -28.66 59.23 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.362 -0.836 . . . . 0.0 109.499 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 177' ' ' GLN . . . . . 0.4 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 90.2 mt-30 -65.76 -23.55 66.75 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.293 -0.879 . . . . 0.0 109.435 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.512 HG13 ' HB3' ' A' ' 173' ' ' LEU . 12.3 m -130.23 164.42 33.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.259 -0.901 . . . . 0.0 109.452 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 179' ' ' GLU . . . . . 0.452 ' N ' ' O ' ' A' ' 135' ' ' ARG . 76.3 mt-10 -119.41 142.49 48.16 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.259 -0.901 . . . . 0.0 109.542 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 31.4 ttmt -62.6 134.86 56.97 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.159 -0.963 . . . . 0.0 109.521 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . 0.491 ' HB3' ' O ' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.128 -0.982 . . . . 0.0 109.391 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.625 ' CD2' HD21 ' A' ' 158' ' ' LEU . 89.6 m-85 . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 121.333 0.587 . . . . 0.0 109.446 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.487 ' HB3' ' HD2' ' A' ' 130' ' ' PRO . 3.5 mt-10 -139.41 150.04 62.54 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.241 -0.912 . . . . 0.0 109.354 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.487 ' HD2' ' HB3' ' A' ' 129' ' ' GLU . 49.4 Cg_endo -46.33 128.88 12.74 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.418 2.079 . . . . 0.0 111.751 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 93.69 3.61 64.28 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.52 ' O ' HG13 ' A' ' 147' ' ' VAL . 76.7 mm-40 -98.57 138.57 35.57 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.168 -1.196 . . . . 0.0 109.455 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.639 ' HG2' HG22 ' A' ' 147' ' ' VAL . 78.5 mtp -76.12 148.78 37.61 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.23 -0.919 . . . . 0.0 109.468 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.675 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -137.21 179.38 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.26 -0.9 . . . . 0.0 109.375 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.675 ' H ' HG12 ' A' ' 134' ' ' VAL . 43.6 ttt180 -135.7 135.01 39.72 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.104 -0.997 . . . . 0.0 109.503 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.454 ' O ' ' N ' ' A' ' 143' ' ' ASP . 80.3 t -108.73 135.72 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.298 -0.877 . . . . 0.0 109.502 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 31.6 p30 -131.83 18.98 4.62 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.242 -0.911 . . . . 0.0 109.438 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -132.52 144.07 50.17 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.31 -0.869 . . . . 0.0 109.408 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 71.66 175.99 24.57 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -53.22 -19.49 12.51 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.608 2.205 . . . . 0.0 111.779 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . 0.434 ' O ' ' HB ' ' A' ' 136' ' ' VAL . 90.5 m-85 -88.61 12.65 14.08 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.279 -0.888 . . . . 0.0 109.415 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' ALA . . . . . 0.448 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -71.96 150.38 44.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.28 -0.888 . . . . 0.0 109.403 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.454 ' N ' ' O ' ' A' ' 136' ' ' VAL . 31.9 m-20 63.49 48.69 3.37 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.169 -0.957 . . . . 0.0 109.449 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.448 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 43.3 m-85 -145.06 143.05 30.24 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.147 -0.971 . . . . 0.0 109.524 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 73.6 m-20 -95.89 145.08 25.67 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.248 -0.908 . . . . 0.0 109.5 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -161.7 -178.42 35.6 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.682 ' O ' HG13 ' A' ' 160' ' ' VAL . 40.6 t -126.1 147.23 30.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.256 -1.143 . . . . 0.0 109.408 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.724 ' HA ' HG22 ' A' ' 160' ' ' VAL . 2.5 p -82.95 99.37 5.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.179 -0.951 . . . . 0.0 109.467 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -66.59 -34.21 77.37 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.245 -0.91 . . . . 0.0 109.391 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.478 ' HB2' ' CD ' ' A' ' 159' ' ' LYS . 75.5 mm-40 -147.0 162.47 38.7 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.27 -0.894 . . . . 0.0 109.386 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.623 HG22 HG21 ' A' ' 148' ' ' VAL . 41.0 t -129.17 146.69 33.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.2 -0.937 . . . . 0.0 109.487 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -127.63 96.48 4.55 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.203 -0.936 . . . . 0.0 109.511 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -66.29 -40.3 89.94 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.305 -0.872 . . . . 0.0 109.475 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -62.37 -42.19 99.21 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.201 -0.937 . . . . 0.0 109.431 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 47.9 mttt -83.93 0.79 46.4 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.278 -0.889 . . . . 0.0 109.548 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 24.3 p 45.62 57.04 5.28 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.216 -0.927 . . . . 0.0 109.465 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' ARG . . . . . 0.616 ' C ' HD12 ' A' ' 158' ' ' LEU . 30.4 mtt180 -155.49 165.5 36.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.277 -0.89 . . . . 0.0 109.516 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' LEU . . . . . 1.165 HD11 ' CD1' ' A' ' 175' ' ' PHE . 4.3 mp -114.34 137.3 51.98 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.241 -0.912 . . . . 0.0 109.453 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . 0.478 ' CD ' ' HB2' ' A' ' 150' ' ' GLU . 40.4 tttp -92.97 94.88 9.15 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.184 -0.947 . . . . 0.0 109.339 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.724 HG22 ' HA ' ' A' ' 148' ' ' VAL . 45.1 t -122.04 146.04 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.28 -0.888 . . . . 0.0 109.602 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 29.3 t -111.82 141.64 45.19 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.329 -0.857 . . . . 0.0 109.28 179.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 162' ' ' VAL . . . . . . . . . . . . . 12.1 t -113.28 131.09 65.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.132 -0.98 . . . . 0.0 109.563 -179.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 35.5 t . . . . . 0 N--CA 1.489 1.511 0 O-C-N 121.291 -0.881 . . . . 0.0 109.403 179.928 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 42.1 mtp-105 . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -71.16 137.76 49.05 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.267 -0.896 . . . . 0.0 109.411 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . 0.57 ' O ' HG13 ' A' ' 171' ' ' VAL . 1.9 m -133.01 75.96 71.07 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.292 -0.88 . . . . 0.0 109.458 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -56.69 104.2 0.14 Allowed 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.622 2.215 . . . . 0.0 111.836 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 1.012 HG23 HD21 ' A' ' 173' ' ' LEU . 18.2 m -129.34 155.56 41.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.305 -0.872 . . . . 0.0 109.419 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.749 ' C ' HD22 ' A' ' 173' ' ' LEU . 95.5 mt-10 -102.01 129.61 48.35 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.217 -0.927 . . . . 0.0 109.522 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . 1.012 HD21 HG23 ' A' ' 171' ' ' VAL . 2.3 mm? -121.54 149.82 42.54 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.269 -0.895 . . . . 0.0 109.39 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 174' ' ' ASP . . . . . 0.483 ' O ' HG22 ' A' ' 178' ' ' VAL . 82.1 m-20 -68.93 157.95 35.62 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.279 -0.888 . . . . 0.0 109.515 179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 1.165 ' CD1' HD11 ' A' ' 158' ' ' LEU . 98.7 m-85 -61.25 -40.79 95.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.293 -0.879 . . . . 0.0 109.334 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 28.6 m -74.98 -19.7 59.98 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.222 -0.923 . . . . 0.0 109.313 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 89.9 mt-30 -82.16 -20.01 38.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.348 -0.845 . . . . 0.0 109.245 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.678 HG11 ' HB2' ' A' ' 173' ' ' LEU . 19.3 m -124.9 161.88 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.396 -0.815 . . . . 0.0 109.264 179.821 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 179' ' ' GLU . . . . . 0.412 ' HB2' ' HB3' ' A' ' 135' ' ' ARG . 61.8 mt-10 -121.31 153.26 37.95 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.133 -0.98 . . . . 0.0 109.695 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 17.8 tttm -74.14 135.52 42.87 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.322 -0.861 . . . . 0.0 109.451 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.309 -0.869 . . . . 0.0 109.494 179.989 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.448 ' O ' HG21 ' A' ' 151' ' ' VAL . 93.5 m-85 . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.487 ' HB2' ' HD2' ' A' ' 130' ' ' PRO . 22.3 pt-20 -142.07 138.75 17.13 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.234 -0.916 . . . . 0.0 109.3 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.509 ' HA ' ' O ' ' A' ' 148' ' ' VAL . 47.7 Cg_endo -35.62 124.11 0.26 Allowed 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.107 1.872 . . . . 0.0 111.721 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 106.25 -0.47 37.83 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.495 ' O ' HG13 ' A' ' 147' ' ' VAL . 75.5 mt-10 -98.21 152.04 19.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.242 -1.152 . . . . 0.0 109.611 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 1.013 ' SD ' HG22 ' A' ' 147' ' ' VAL . 68.3 mmm -92.16 148.75 21.92 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.192 -0.943 . . . . 0.0 109.327 179.826 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.674 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -135.99 178.92 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.166 -0.959 . . . . 0.0 109.325 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.674 ' H ' HG12 ' A' ' 134' ' ' VAL . 74.8 mtp85 -134.17 143.96 48.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.179 -0.951 . . . . 0.0 109.343 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.46 ' O ' ' N ' ' A' ' 143' ' ' ASP . 59.0 t -115.43 130.18 70.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.216 -0.927 . . . . 0.0 109.452 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 30.3 p30 -127.89 14.77 6.89 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.298 -0.876 . . . . 0.0 109.482 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.43 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 59.1 t0 -135.82 147.6 48.36 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.292 -0.88 . . . . 0.0 109.475 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.43 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 73.85 172.15 25.31 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -51.35 -21.96 10.98 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.602 2.201 . . . . 0.0 111.69 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . 0.728 ' HZ ' HG21 ' A' ' 169' ' ' THR . 98.3 m-85 -85.73 8.94 17.87 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.271 -0.893 . . . . 0.0 109.373 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' ALA . . . . . 0.442 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -64.02 145.27 56.19 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.241 -0.912 . . . . 0.0 109.558 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.46 ' N ' ' O ' ' A' ' 136' ' ' VAL . 31.6 m-20 64.96 46.82 2.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.259 -0.9 . . . . 0.0 109.593 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.427 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 44.9 m-85 -145.46 126.49 14.59 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.246 -0.909 . . . . 0.0 109.535 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . 0.462 ' OD1' ' NH2' ' A' ' 135' ' ' ARG . 69.9 m-20 -79.4 137.54 37.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.224 -0.923 . . . . 0.0 109.45 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -149.22 166.78 29.53 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 1.013 HG22 ' SD ' ' A' ' 133' ' ' MET . 15.1 t -108.79 154.87 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.255 -1.144 . . . . 0.0 109.406 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.509 ' O ' ' HA ' ' A' ' 130' ' ' PRO . 1.7 p -96.23 114.93 34.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.323 -0.861 . . . . 0.0 109.356 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.472 ' O ' ' HB3' ' A' ' 130' ' ' PRO . 74.9 mm-40 -75.94 -34.08 59.85 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.3 -0.875 . . . . 0.0 109.315 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.473 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 94.7 mt-10 -158.11 159.15 35.93 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.36 -0.838 . . . . 0.0 109.415 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.493 HG22 HG21 ' A' ' 148' ' ' VAL . 26.3 t -127.59 151.02 33.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.22 -0.925 . . . . 0.0 109.563 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' ASP . . . . . 0.477 ' O ' ' N ' ' A' ' 156' ' ' SER . 83.2 m-20 -120.71 84.46 2.23 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.339 -0.85 . . . . 0.0 109.342 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -57.4 -33.72 68.15 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.234 -0.916 . . . . 0.0 109.502 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -64.75 -41.48 95.88 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.167 -0.958 . . . . 0.0 109.529 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.4 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 29.5 mttt -97.09 -3.77 40.66 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.29 -0.881 . . . . 0.0 109.591 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . 0.477 ' N ' ' O ' ' A' ' 152' ' ' ASP . 31.8 m 56.95 52.46 9.25 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.194 -0.941 . . . . 0.0 109.543 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' ARG . . . . . 0.587 ' C ' HD12 ' A' ' 158' ' ' LEU . 48.7 mmm-85 -137.06 155.82 49.17 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.258 -0.901 . . . . 0.0 109.355 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' LEU . . . . . 0.881 HD11 ' CD1' ' A' ' 175' ' ' PHE . 5.0 mp -115.87 139.26 50.38 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.201 -0.937 . . . . 0.0 109.643 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . 0.473 ' HD2' ' HB2' ' A' ' 150' ' ' GLU . 84.1 mttt -101.45 89.36 3.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.213 -0.929 . . . . 0.0 109.178 179.653 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.923 HG13 ' O ' ' A' ' 147' ' ' VAL . 24.6 t -114.58 148.64 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.268 -0.895 . . . . 0.0 109.875 -179.617 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . 0.403 ' HB2' ' HA ' ' A' ' 170' ' ' PRO . 43.9 t -119.37 131.17 55.65 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.378 -0.826 . . . . 0.0 109.242 179.769 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 162' ' ' VAL . . . . . 0.424 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 15.5 t -100.53 134.03 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.209 -0.932 . . . . 0.0 109.697 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 37.2 t . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.229 -0.919 . . . . 0.0 109.275 179.777 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 86.3 mtt-85 . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -72.16 141.84 49.09 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.352 -0.842 . . . . 0.0 109.463 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . 0.885 ' O ' HG13 ' A' ' 171' ' ' VAL . 32.8 m -128.27 68.71 77.3 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.206 -0.934 . . . . 0.0 109.475 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.407 ' HD2' ' HA ' ' A' ' 169' ' ' THR . 49.4 Cg_endo -45.55 106.64 0.09 OUTLIER 'Trans proline' 0 C--O 1.214 -0.694 0 C-N-CA 122.703 2.269 . . . . 0.0 111.768 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.885 HG13 ' O ' ' A' ' 169' ' ' THR . 21.9 m -133.42 156.49 41.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.219 -0.926 . . . . 0.0 109.565 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.637 ' C ' HD22 ' A' ' 173' ' ' LEU . 94.6 mt-10 -105.39 129.97 53.59 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.301 -0.874 . . . . 0.0 109.334 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . 0.882 HD21 HG23 ' A' ' 171' ' ' VAL . 1.9 mm? -119.46 157.81 27.5 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.189 -0.945 . . . . 0.0 109.618 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 174' ' ' ASP . . . . . 0.439 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 91.1 m-20 -79.64 157.89 27.17 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.352 -0.843 . . . . 0.0 109.573 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.881 ' CD1' HD11 ' A' ' 158' ' ' LEU . 3.6 m-85 -49.71 -49.39 48.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.305 -0.872 . . . . 0.0 109.785 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 11.2 m -71.15 -24.74 62.32 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.237 -0.914 . . . . 0.0 109.692 -179.754 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 177' ' ' GLN . . . . . 0.439 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 81.7 mt-30 -70.36 -24.72 63.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.218 -0.926 . . . . 0.0 109.722 -179.813 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.511 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 17.5 m -131.06 161.82 40.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.189 -0.945 . . . . 0.0 109.511 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 179' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -120.67 145.46 47.42 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.296 -0.878 . . . . 0.0 109.473 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 30.2 tttm -69.67 134.61 48.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.302 -0.874 . . . . 0.0 109.481 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.495 0 O-C-N 121.163 -0.96 . . . . 0.0 109.485 179.985 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.909 ' O ' HG21 ' A' ' 151' ' ' VAL . 69.1 m-85 . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.464 ' HB3' ' HD2' ' A' ' 130' ' ' PRO . 1.2 mp0 -109.24 138.16 20.4 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.296 -0.878 . . . . 0.0 109.399 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.464 ' HD2' ' HB3' ' A' ' 129' ' ' GLU . 50.6 Cg_endo -39.68 133.99 1.57 Allowed 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.549 2.166 . . . . 0.0 111.765 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 84.69 8.45 82.83 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 45.7 tp10 -102.25 135.04 44.55 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.263 -1.14 . . . . 0.0 109.443 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.553 ' HG2' HG22 ' A' ' 147' ' ' VAL . 76.3 mtp -70.28 148.17 48.83 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.248 -0.908 . . . . 0.0 109.456 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.749 HG13 ' CE2' ' A' ' 128' ' ' PHE . 2.5 t -136.72 179.08 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.26 -0.9 . . . . 0.0 109.353 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.673 ' H ' HG12 ' A' ' 134' ' ' VAL . 70.3 ttt180 -136.51 143.12 43.59 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.263 -0.898 . . . . 0.0 109.43 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.632 HG11 ' HB2' ' A' ' 141' ' ' PHE . 60.3 t -111.16 124.86 68.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.258 -0.902 . . . . 0.0 109.524 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 26.4 p30 -124.77 22.31 8.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -0.905 . . . . 0.0 109.511 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -145.15 140.98 28.35 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.328 -0.858 . . . . 0.0 109.479 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 81.62 -179.82 53.26 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -58.67 -20.18 49.35 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.679 2.252 . . . . 0.0 111.764 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . 0.888 ' CZ ' HG11 ' A' ' 171' ' ' VAL . 99.2 m-85 -87.38 10.15 18.33 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.239 -0.913 . . . . 0.0 109.379 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' ALA . . . . . 0.505 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -64.17 152.99 39.21 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.282 -0.886 . . . . 0.0 109.59 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.453 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 58.8 m-20 63.65 42.57 6.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.3 -0.875 . . . . 0.0 109.676 179.746 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.556 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 58.8 m-85 -145.51 152.64 40.08 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.164 -0.96 . . . . 0.0 109.494 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 43.7 p-10 -113.63 167.06 10.92 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.238 -0.914 . . . . 0.0 109.395 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 179.35 -170.45 42.03 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.553 HG22 ' HG2' ' A' ' 133' ' ' MET . 43.0 t -129.11 150.43 34.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.225 -1.162 . . . . 0.0 109.517 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.664 ' HA ' HG22 ' A' ' 160' ' ' VAL . 2.5 p -91.05 113.83 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.203 -0.936 . . . . 0.0 109.497 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.423 ' N ' ' O ' ' A' ' 159' ' ' LYS . 75.8 mm-40 -67.02 -37.1 83.54 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.222 -0.924 . . . . 0.0 109.445 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.406 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 94.9 mt-10 -153.97 163.38 40.15 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.223 -0.923 . . . . 0.0 109.501 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 1.073 HG13 ' CD2' ' A' ' 158' ' ' LEU . 45.7 t -127.27 146.32 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.247 -0.908 . . . . 0.0 109.535 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -133.02 90.88 2.8 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.277 -0.89 . . . . 0.0 109.5 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -62.93 -38.82 92.54 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.214 -0.929 . . . . 0.0 109.502 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -61.25 -41.7 97.35 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.48 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.459 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 60.2 mttm -92.23 -2.25 56.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -0.893 . . . . 0.0 109.601 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . 0.473 ' HA ' ' CZ ' ' A' ' 175' ' ' PHE . 12.9 m 50.23 52.52 14.59 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.28 -0.887 . . . . 0.0 109.587 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' ARG . . . . . 0.459 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 13.7 mmt85 -146.15 142.77 28.79 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.295 -0.878 . . . . 0.0 109.468 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' LEU . . . . . 1.073 ' CD2' HG13 ' A' ' 151' ' ' VAL . 49.0 mt -116.34 133.19 56.29 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.196 -0.94 . . . . 0.0 109.497 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . 0.441 ' O ' ' HA ' ' A' ' 148' ' ' VAL . 65.5 mttm -87.39 100.64 12.88 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.282 -0.886 . . . . 0.0 109.346 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.664 HG22 ' HA ' ' A' ' 148' ' ' VAL . 57.6 t -128.34 138.75 53.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.176 -0.952 . . . . 0.0 109.524 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . 0.467 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 88.3 p -107.2 148.13 29.28 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.272 -0.893 . . . . 0.0 109.431 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 162' ' ' VAL . . . . . 0.556 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 3.8 t -115.33 130.02 70.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.211 -0.931 . . . . 0.0 109.637 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 33.2 t . . . . . 0 N--CA 1.488 1.454 0 O-C-N 121.221 -0.924 . . . . 0.0 109.153 179.639 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 46.0 tpt85 . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 121.303 0.573 . . . . 0.0 109.546 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -72.76 138.89 46.76 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.206 -0.934 . . . . 0.0 109.477 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . 0.658 ' O ' HG13 ' A' ' 171' ' ' VAL . 10.1 m -122.53 75.78 44.88 Favored Pre-proline 0 N--CA 1.488 1.465 0 O-C-N 121.128 -0.983 . . . . 0.0 109.484 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.467 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.4 Cg_endo -56.13 110.73 0.61 Allowed 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.572 2.181 . . . . 0.0 111.734 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 1.031 HG23 HD21 ' A' ' 173' ' ' LEU . 16.5 m -129.6 154.87 40.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.26 -0.9 . . . . 0.0 109.502 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.786 ' C ' HD22 ' A' ' 173' ' ' LEU . 95.7 mt-10 -100.69 125.88 47.16 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.222 -0.923 . . . . 0.0 109.459 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . 1.031 HD21 HG23 ' A' ' 171' ' ' VAL . 2.6 mm? -122.93 147.18 46.9 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.311 -0.868 . . . . 0.0 109.434 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 174' ' ' ASP . . . . . 0.427 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 90.3 m-20 -65.41 169.14 6.25 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.209 -0.932 . . . . 0.0 109.457 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.565 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.3 m-30 -64.4 -36.83 85.44 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.178 -0.951 . . . . 0.0 109.462 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 86.1 p -80.07 -25.87 39.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.248 -0.907 . . . . 0.0 109.429 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 177' ' ' GLN . . . . . 0.427 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 86.2 mt-30 -66.57 -27.3 67.62 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.189 -0.945 . . . . 0.0 109.422 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.528 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 4.6 m -123.89 156.73 30.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.291 -0.881 . . . . 0.0 109.499 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 179' ' ' GLU . . . . . 0.502 ' O ' ' N ' ' A' ' 135' ' ' ARG . 83.6 tt0 -116.51 156.17 27.37 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.31 -0.869 . . . . 0.0 109.463 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 180' ' ' LYS . . . . . 0.456 ' HG2' ' CE2' ' A' ' 128' ' ' PHE . 54.4 mttt -69.89 142.88 52.93 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.233 -0.917 . . . . 0.0 109.481 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.578 0 O-C-N 121.267 -0.895 . . . . 0.0 109.472 179.999 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.624 ' CE1' HG13 ' A' ' 134' ' ' VAL . 50.8 m-85 . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.534 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.0 OUTLIER -134.57 156.91 78.36 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.312 -0.868 . . . . 0.0 109.454 179.99 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.534 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.2 Cg_endo -48.66 130.31 22.1 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.626 2.217 . . . . 0.0 111.819 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 90.15 10.26 64.48 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -113.42 138.9 49.42 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.243 -1.151 . . . . 0.0 109.51 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.569 ' HG2' HG22 ' A' ' 147' ' ' VAL . 87.1 mtp -79.77 149.25 31.16 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.294 -0.879 . . . . 0.0 109.527 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.687 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -131.93 179.08 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.314 -0.866 . . . . 0.0 109.387 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.687 ' H ' HG12 ' A' ' 134' ' ' VAL . 24.4 tpt180 -130.88 138.92 50.03 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.284 -0.885 . . . . 0.0 109.365 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.491 HG13 HD13 ' A' ' 173' ' ' LEU . 28.7 t -103.98 130.56 54.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.24 -0.912 . . . . 0.0 109.539 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . 0.428 ' OD1' ' C ' ' A' ' 137' ' ' ASN . 22.2 p30 -132.03 18.08 4.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.324 -0.86 . . . . 0.0 109.403 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.473 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 59.7 t0 -140.66 148.67 41.19 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.204 -0.935 . . . . 0.0 109.499 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.473 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 73.0 172.85 23.57 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -52.99 -19.83 12.24 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.652 2.235 . . . . 0.0 111.786 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . 0.632 ' CD1' HG11 ' A' ' 162' ' ' VAL . 97.9 m-85 -87.43 10.31 17.96 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.183 -0.948 . . . . 0.0 109.444 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' ALA . . . . . 0.499 ' O ' ' CB ' ' A' ' 143' ' ' ASP . . . -66.29 147.77 52.83 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.256 -0.902 . . . . 0.0 109.485 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.499 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 24.9 t0 74.34 28.26 1.37 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.291 -0.881 . . . . 0.0 109.471 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -134.38 153.27 51.99 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.292 -0.88 . . . . 0.0 109.466 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 43.2 p-10 -113.77 165.54 12.45 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.258 -0.901 . . . . 0.0 109.425 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -174.07 -177.1 43.0 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.569 HG22 ' HG2' ' A' ' 133' ' ' MET . 44.2 t -117.27 161.28 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.213 -1.169 . . . . 0.0 109.477 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.847 HG11 HG22 ' A' ' 151' ' ' VAL . 79.4 t -93.4 96.25 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.213 -0.929 . . . . 0.0 109.524 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -66.02 -31.92 73.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.247 -0.908 . . . . 0.0 109.429 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.409 ' O ' ' HB3' ' A' ' 159' ' ' LYS . 84.7 tt0 -148.83 150.25 32.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.286 -0.884 . . . . 0.0 109.415 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.847 HG22 HG11 ' A' ' 148' ' ' VAL . 45.3 t -124.19 149.99 28.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.214 -0.929 . . . . 0.0 109.516 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 95.2 m-20 -136.48 79.88 1.79 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.216 -0.928 . . . . 0.0 109.502 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' TYR . . . . . 0.507 ' CZ ' HG11 ' A' ' 151' ' ' VAL . 98.9 m-85 -63.64 -37.46 87.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.227 -0.921 . . . . 0.0 109.518 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -59.42 -46.45 88.68 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.185 -0.947 . . . . 0.0 109.528 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.473 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 58.1 mttt -90.72 0.5 57.4 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.268 -0.895 . . . . 0.0 109.548 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 31.1 t 56.06 52.82 9.89 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.196 -0.94 . . . . 0.0 109.485 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' ARG . . . . . 0.473 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 22.9 mmt85 -140.29 140.51 35.72 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.275 -0.891 . . . . 0.0 109.367 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' LEU . . . . . 0.478 HD11 ' CD1' ' A' ' 175' ' ' PHE . 61.5 mt -110.06 129.47 55.68 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.162 -0.962 . . . . 0.0 109.522 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . 0.441 ' HG3' ' OE2' ' A' ' 172' ' ' GLU . 29.4 tttp -92.31 104.79 17.1 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.331 -0.856 . . . . 0.0 109.352 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.541 HG13 ' O ' ' A' ' 147' ' ' VAL . 44.4 t -124.64 140.62 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.29 -0.881 . . . . 0.0 109.545 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . 0.46 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 30.1 t -109.17 137.65 46.74 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.295 -0.878 . . . . 0.0 109.462 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 162' ' ' VAL . . . . . 0.742 HG12 ' HB ' ' A' ' 169' ' ' THR . 9.4 p -104.9 138.86 27.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.185 -0.947 . . . . 0.0 109.636 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . 0.438 ' HA ' ' O ' ' A' ' 167' ' ' ARG . 5.3 m . . . . . 0 N--CA 1.49 1.568 0 O-C-N 121.215 -0.928 . . . . 0.0 109.461 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 167' ' ' ARG . . . . . 0.438 ' O ' ' HA ' ' A' ' 163' ' ' SER . 62.2 mtt180 . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -98.19 139.12 34.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.232 -0.918 . . . . 0.0 109.497 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . 0.781 ' O ' HG13 ' A' ' 171' ' ' VAL . 6.0 m -129.81 74.04 80.98 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.287 -0.883 . . . . 0.0 109.453 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.46 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.7 Cg_endo -49.08 109.9 0.31 Allowed 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.603 2.202 . . . . 0.0 111.774 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.781 HG13 ' O ' ' A' ' 169' ' ' THR . 23.6 m -128.96 156.8 41.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.29 -0.881 . . . . 0.0 109.514 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.735 ' O ' HD23 ' A' ' 173' ' ' LEU . 75.7 mm-40 -101.6 130.65 47.97 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.293 -0.88 . . . . 0.0 109.465 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . 0.735 HD23 ' O ' ' A' ' 172' ' ' GLU . 51.8 mt -131.28 148.81 52.73 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.245 -0.91 . . . . 0.0 109.419 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -74.91 171.54 13.85 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.213 -0.93 . . . . 0.0 109.447 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.583 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.7 m-30 -64.25 -36.81 85.29 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.318 -0.864 . . . . 0.0 109.439 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 83.4 p -79.58 -26.97 41.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.312 -0.867 . . . . 0.0 109.355 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 23.6 mt-30 -68.86 -19.69 64.25 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.26 -0.9 . . . . 0.0 109.381 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.466 HG11 ' HB2' ' A' ' 173' ' ' LEU . 4.2 m -135.73 154.4 34.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.217 -0.927 . . . . 0.0 109.526 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 179' ' ' GLU . . . . . 0.504 ' O ' ' N ' ' A' ' 135' ' ' ARG . 37.7 mt-10 -120.07 166.53 13.27 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.278 -0.888 . . . . 0.0 109.427 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 180' ' ' LYS . . . . . 0.452 ' HG2' ' CE1' ' A' ' 128' ' ' PHE . 54.9 mttt -71.97 145.83 48.14 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.229 -0.919 . . . . 0.0 109.551 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.521 0 O-C-N 121.285 -0.884 . . . . 0.0 109.498 179.999 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 83.8 m-85 . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.468 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.0 OUTLIER -135.77 153.18 77.11 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.262 -0.899 . . . . 0.0 109.445 -179.968 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.468 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.4 Cg_endo -47.18 133.21 19.06 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.593 2.195 . . . . 0.0 111.793 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 86.51 3.1 84.42 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 50.2 tp10 -88.05 137.57 32.21 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.202 -1.175 . . . . 0.0 109.544 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.497 ' HG2' HG22 ' A' ' 147' ' ' VAL . 77.4 mtp -79.44 149.49 31.57 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.279 -0.888 . . . . 0.0 109.446 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.735 ' CG2' HG23 ' A' ' 148' ' ' VAL . 2.5 t -139.25 179.0 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.266 -0.896 . . . . 0.0 109.318 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.673 ' H ' HG12 ' A' ' 134' ' ' VAL . 18.5 mtp-105 -137.47 142.49 41.54 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.245 -0.91 . . . . 0.0 109.466 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.479 HG22 HG12 ' A' ' 178' ' ' VAL . 43.3 t -111.56 135.2 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.232 -0.917 . . . . 0.0 109.537 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 38.2 p30 -127.08 15.52 7.32 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.54 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.487 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 59.2 t0 -142.06 153.53 44.27 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.28 -0.888 . . . . 0.0 109.462 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.487 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 75.38 171.02 28.86 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -54.93 -18.47 16.73 Favored 'Trans proline' 0 C--O 1.214 -0.705 0 C-N-CA 122.578 2.185 . . . . 0.0 111.792 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . 0.699 ' CD1' HG11 ' A' ' 162' ' ' VAL . 90.5 m-85 -92.79 14.92 15.86 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.25 -0.906 . . . . 0.0 109.454 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' ALA . . . . . 0.449 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -66.23 149.51 50.23 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.301 -0.874 . . . . 0.0 109.523 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.449 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 43.7 m-20 64.03 46.85 3.58 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.232 -0.918 . . . . 0.0 109.473 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -140.79 142.01 34.73 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.295 -0.878 . . . . 0.0 109.531 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 73.0 m-20 -100.81 142.4 32.33 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.245 -0.909 . . . . 0.0 109.462 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.54 177.94 34.98 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.613 ' O ' HG13 ' A' ' 160' ' ' VAL . 49.0 t -114.29 164.2 10.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.184 -1.186 . . . . 0.0 109.438 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.735 HG23 ' CG2' ' A' ' 134' ' ' VAL . 98.6 t -93.16 95.54 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.257 -0.902 . . . . 0.0 109.553 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -67.42 -34.52 77.4 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.178 -0.951 . . . . 0.0 109.432 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.502 ' HB2' ' CD ' ' A' ' 159' ' ' LYS . 94.2 mt-10 -151.23 161.49 42.61 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.237 -0.915 . . . . 0.0 109.332 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.506 HG11 ' CZ ' ' A' ' 153' ' ' TYR . 44.1 t -124.25 151.35 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.206 -0.934 . . . . 0.0 109.569 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -125.49 78.3 1.72 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.236 -0.915 . . . . 0.0 109.413 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' TYR . . . . . 0.506 ' CZ ' HG11 ' A' ' 151' ' ' VAL . 83.9 m-85 -63.68 -37.05 85.87 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.338 -0.851 . . . . 0.0 109.569 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -60.74 -42.83 98.15 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.247 -0.908 . . . . 0.0 109.532 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.474 ' O ' ' HG3' ' A' ' 157' ' ' ARG . 45.9 mttp -94.68 3.03 55.56 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.241 -0.912 . . . . 0.0 109.604 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 56.62 51.98 10.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.245 -0.909 . . . . 0.0 109.464 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' ARG . . . . . 0.474 ' HG3' ' O ' ' A' ' 155' ' ' LYS . 58.1 mtt180 -146.29 157.49 43.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.281 -0.887 . . . . 0.0 109.522 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' LEU . . . . . 0.545 HD21 ' CE1' ' A' ' 175' ' ' PHE . 18.2 mt -115.01 135.56 54.09 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.199 -0.938 . . . . 0.0 109.451 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . 0.502 ' CD ' ' HB2' ' A' ' 150' ' ' GLU . 31.0 tttp -87.99 105.92 17.78 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.269 -0.894 . . . . 0.0 109.318 179.855 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.613 HG13 ' O ' ' A' ' 147' ' ' VAL . 39.9 t -121.99 143.46 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.228 -0.92 . . . . 0.0 109.636 -179.833 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 93.5 p -110.31 145.24 37.79 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.263 -0.898 . . . . 0.0 109.41 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 162' ' ' VAL . . . . . 0.765 HG12 ' HB ' ' A' ' 169' ' ' THR . 9.8 p -115.93 138.89 44.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.226 -0.921 . . . . 0.0 109.527 -179.899 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . 0.403 ' HA ' ' O ' ' A' ' 167' ' ' ARG . 37.8 t . . . . . 0 N--CA 1.489 1.511 0 O-C-N 121.256 -0.903 . . . . 0.0 109.408 179.892 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 167' ' ' ARG . . . . . 0.403 ' O ' ' HA ' ' A' ' 163' ' ' SER . 65.7 mtt-85 . . . . . 0 N--CA 1.49 1.525 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -91.43 134.37 34.69 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.265 -0.897 . . . . 0.0 109.54 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . 0.765 ' HB ' HG12 ' A' ' 162' ' ' VAL . 0.2 OUTLIER -128.3 74.11 79.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.312 -0.867 . . . . 0.0 109.458 -179.963 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -57.6 104.64 0.17 Allowed 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.598 2.198 . . . . 0.0 111.805 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 1.018 HG23 HD21 ' A' ' 173' ' ' LEU . 19.3 m -130.41 155.95 42.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.253 -0.905 . . . . 0.0 109.538 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.737 ' C ' HD22 ' A' ' 173' ' ' LEU . 95.2 mt-10 -104.03 128.94 51.63 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.236 -0.915 . . . . 0.0 109.46 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . 1.018 HD21 HG23 ' A' ' 171' ' ' VAL . 2.3 mm? -121.29 145.67 47.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.248 -0.907 . . . . 0.0 109.432 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 64.6 m-20 -65.63 173.48 2.76 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.263 -0.898 . . . . 0.0 109.38 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.545 ' CE1' HD21 ' A' ' 158' ' ' LEU . 4.2 m-30 -66.65 -44.47 81.8 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.252 -0.905 . . . . 0.0 109.471 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 18.7 m -73.09 -23.62 60.55 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.201 -0.937 . . . . 0.0 109.384 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -70.78 -23.8 62.46 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.298 -0.876 . . . . 0.0 109.39 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.555 HG11 ' HB2' ' A' ' 173' ' ' LEU . 6.0 m -131.43 163.42 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.31 -0.869 . . . . 0.0 109.378 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 179' ' ' GLU . . . . . . . . . . . . . 74.3 mm-40 -119.0 145.45 45.83 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.172 -0.955 . . . . 0.0 109.485 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 18.3 tttm -64.87 140.0 58.82 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.202 -0.936 . . . . 0.0 109.463 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.542 0 O-C-N 121.207 -0.933 . . . . 0.0 109.44 -179.942 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.71 ' CE1' HG13 ' A' ' 134' ' ' VAL . 59.4 m-85 . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . 0.429 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 3.9 mt-10 -122.77 154.75 63.88 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.245 -0.909 . . . . 0.0 109.353 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.429 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.3 Cg_endo -51.15 129.05 27.15 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.597 2.198 . . . . 0.0 111.804 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 84.44 13.24 73.87 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.422 ' OE1' ' HA ' ' A' ' 128' ' ' PHE . 77.5 tt0 -104.13 133.83 48.4 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.236 -1.155 . . . . 0.0 109.443 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.605 ' HG2' HG22 ' A' ' 147' ' ' VAL . 85.7 mtp -69.36 144.97 53.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.316 -0.865 . . . . 0.0 109.545 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.752 HG21 HG23 ' A' ' 148' ' ' VAL . 2.5 t -133.11 178.87 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.344 -0.847 . . . . 0.0 109.363 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.686 ' H ' HG12 ' A' ' 134' ' ' VAL . 40.9 ttm180 -129.15 136.08 49.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.275 -0.891 . . . . 0.0 109.326 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.462 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 39.5 t -106.34 130.34 58.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.215 -0.928 . . . . 0.0 109.529 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . 0.408 ' OD1' ' C ' ' A' ' 137' ' ' ASN . 43.0 p30 -127.61 17.4 6.93 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.282 -0.886 . . . . 0.0 109.443 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.462 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 60.1 t0 -136.98 147.17 46.13 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.306 -0.871 . . . . 0.0 109.468 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.462 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 74.58 173.62 30.93 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -57.2 -17.21 24.74 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.627 2.218 . . . . 0.0 111.883 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . 0.732 ' CD1' HG21 ' A' ' 162' ' ' VAL . 99.7 m-85 -90.23 12.68 17.35 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.13 -0.981 . . . . 0.0 109.452 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' ALA . . . . . 0.516 ' O ' ' CB ' ' A' ' 143' ' ' ASP . . . -72.5 147.15 46.3 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.276 -0.89 . . . . 0.0 109.509 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.516 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 24.9 t0 75.74 28.69 0.89 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.272 -0.893 . . . . 0.0 109.529 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.544 ' HB3' HG13 ' A' ' 162' ' ' VAL . 91.8 m-85 -132.26 146.26 51.87 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.155 -0.966 . . . . 0.0 109.514 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -98.5 144.73 27.51 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.245 -0.909 . . . . 0.0 109.442 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -157.52 -178.77 31.89 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.605 HG22 ' HG2' ' A' ' 133' ' ' MET . 28.3 t -124.08 156.36 31.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.227 -1.161 . . . . 0.0 109.408 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.752 HG23 HG21 ' A' ' 134' ' ' VAL . 87.5 t -89.25 100.54 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.206 -0.934 . . . . 0.0 109.388 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -65.47 -38.26 89.26 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.209 -0.932 . . . . 0.0 109.499 179.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -145.43 165.71 27.76 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.234 -0.916 . . . . 0.0 109.478 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.488 HG22 HG11 ' A' ' 148' ' ' VAL . 41.2 t -129.45 150.82 34.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.3 -0.875 . . . . 0.0 109.497 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' ASP . . . . . 0.406 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 88.8 m-20 -134.45 83.2 2.02 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.268 -0.895 . . . . 0.0 109.413 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' TYR . . . . . 0.413 ' CZ ' HG11 ' A' ' 151' ' ' VAL . 96.4 m-85 -64.77 -37.95 89.33 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.178 -0.951 . . . . 0.0 109.468 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . 0.417 ' OE1' ' HA ' ' A' ' 154' ' ' GLU . 72.8 mm-40 -60.53 -44.65 95.84 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.267 -0.896 . . . . 0.0 109.491 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.479 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 93.4 mttt -90.63 -1.0 57.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.306 -0.871 . . . . 0.0 109.559 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 48.9 m 54.32 53.09 11.41 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.146 -0.971 . . . . 0.0 109.495 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' ARG . . . . . 0.479 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 20.1 mmt85 -144.5 144.82 31.53 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.142 -0.973 . . . . 0.0 109.465 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' LEU . . . . . 0.51 HD21 ' CE1' ' A' ' 175' ' ' PHE . 55.6 mt -111.87 126.14 54.78 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.254 -0.904 . . . . 0.0 109.537 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 60.4 tttt -83.92 105.14 14.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.178 -0.952 . . . . 0.0 109.415 179.786 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.75 HG22 HG22 ' A' ' 148' ' ' VAL . 38.1 t -124.21 141.27 44.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.25 -0.906 . . . . 0.0 109.434 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . 0.445 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 23.6 t -112.44 134.49 53.95 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.278 -0.889 . . . . 0.0 109.611 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 162' ' ' VAL . . . . . 0.732 HG21 ' CD1' ' A' ' 141' ' ' PHE . 3.7 t -88.84 130.32 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.234 -0.916 . . . . 0.0 109.47 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 59.3 m . . . . . 0 N--CA 1.489 1.525 0 O-C-N 121.228 -0.92 . . . . 0.0 109.387 179.939 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 30.5 ttp180 . . . . . 0 N--CA 1.493 1.717 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -63.16 136.71 57.91 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.243 -0.911 . . . . 0.0 109.292 179.841 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . 0.582 HG21 ' CZ ' ' A' ' 141' ' ' PHE . 63.0 m -123.36 91.92 49.35 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.192 -0.943 . . . . 0.0 109.662 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.445 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.8 Cg_endo -64.33 109.85 1.26 Allowed 'Trans proline' 0 C--O 1.216 -0.603 0 C-N-CA 122.502 2.134 . . . . 0.0 111.533 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 1.111 HG23 HD21 ' A' ' 173' ' ' LEU . 17.6 m -128.2 158.07 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.194 -0.942 . . . . 0.0 109.69 -179.806 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.681 ' O ' HD13 ' A' ' 173' ' ' LEU . 95.5 mt-10 -100.04 125.07 46.05 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.383 -0.823 . . . . 0.0 109.348 179.843 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . 1.111 HD21 HG23 ' A' ' 171' ' ' VAL . 1.7 mm? -120.48 145.63 47.07 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.203 -0.936 . . . . 0.0 109.493 -179.842 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 174' ' ' ASP . . . . . 0.446 ' OD1' ' HD3' ' A' ' 157' ' ' ARG . 88.3 m-20 -68.84 170.81 8.9 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.224 -0.923 . . . . 0.0 109.452 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.577 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.5 m-30 -65.67 -44.21 86.95 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.217 -0.927 . . . . 0.0 109.436 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 11.1 m -76.0 -24.31 55.3 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.151 -0.968 . . . . 0.0 109.422 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 177' ' ' GLN . . . . . 0.427 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 86.5 mt-30 -69.68 -18.81 63.58 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.265 -0.897 . . . . 0.0 109.339 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.612 HG11 ' HB2' ' A' ' 173' ' ' LEU . 4.8 m -132.35 162.85 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.343 -0.848 . . . . 0.0 109.427 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 179' ' ' GLU . . . . . 0.507 ' O ' ' N ' ' A' ' 135' ' ' ARG . 60.7 mt-10 -126.38 161.73 27.18 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.29 -0.881 . . . . 0.0 109.554 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 84.5 mttt -67.36 144.28 55.91 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.204 -0.935 . . . . 0.0 109.447 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.566 0 O-C-N 121.202 -0.937 . . . . 0.0 109.481 179.959 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -118.47 146.97 40.91 Favored Pre-proline 0 N--CA 1.489 1.488 0 O-C-N 121.296 -0.877 . . . . 0.0 109.47 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -48.09 126.63 13.66 Favored 'Trans proline' 0 C--O 1.214 -0.694 0 C-N-CA 122.576 2.184 . . . . 0.0 111.816 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . 0.44 ' C ' ' CG1' ' A' ' 147' ' ' VAL . . . 94.59 -5.25 70.04 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.845 ' O ' HG13 ' A' ' 147' ' ' VAL . 80.3 tt0 -79.21 148.42 32.25 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.124 -1.221 . . . . 0.0 109.467 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' MET . . . . . 0.671 ' HG2' HG22 ' A' ' 147' ' ' VAL . 64.1 mtp -82.08 146.49 29.62 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.26 -0.9 . . . . 0.0 109.545 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.673 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -135.92 179.13 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.264 -0.898 . . . . 0.0 109.255 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' ARG . . . . . 0.673 ' H ' HG12 ' A' ' 134' ' ' VAL . 87.8 mtt180 -137.33 146.62 44.8 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.225 -0.922 . . . . 0.0 109.399 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.421 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 39.3 t -117.01 134.73 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.212 -0.93 . . . . 0.0 109.558 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 30.7 p30 -128.45 14.7 6.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.233 -0.917 . . . . 0.0 109.48 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.452 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 57.8 t0 -147.17 153.4 39.83 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.253 -0.904 . . . . 0.0 109.396 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . 0.452 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 78.65 172.26 40.91 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -55.28 -19.1 20.41 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.571 2.181 . . . . 0.0 111.78 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . 0.766 ' CZ ' HG11 ' A' ' 171' ' ' VAL . 86.3 m-85 -93.0 9.2 36.72 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.214 -0.929 . . . . 0.0 109.536 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' ALA . . . . . 0.446 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -61.79 146.38 49.66 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.217 -0.927 . . . . 0.0 109.562 -179.867 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' ASP . . . . . 0.446 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 18.0 m-20 65.86 47.83 1.97 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.296 -0.878 . . . . 0.0 109.592 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.401 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 43.9 m-85 -146.51 136.14 23.11 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.296 -0.877 . . . . 0.0 109.457 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 71.3 m-20 -94.03 141.02 29.01 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.236 -0.915 . . . . 0.0 109.419 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.14 -177.19 31.0 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' VAL . . . . . 0.845 HG13 ' O ' ' A' ' 132' ' ' GLU . 46.5 t -125.07 148.92 29.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.207 -1.172 . . . . 0.0 109.369 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.589 ' HA ' HG22 ' A' ' 160' ' ' VAL . 2.5 p -85.67 102.2 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.192 -0.942 . . . . 0.0 109.552 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -68.33 -36.41 79.23 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.146 -0.971 . . . . 0.0 109.414 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -140.78 164.29 30.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.189 -0.944 . . . . 0.0 109.471 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 99.8 t -125.67 152.94 33.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.327 -0.858 . . . . 0.0 109.523 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -130.53 88.43 2.63 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.319 -0.863 . . . . 0.0 109.386 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -69.58 -38.55 77.41 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.22 -0.925 . . . . 0.0 109.593 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -60.44 -46.64 89.29 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.213 -0.929 . . . . 0.0 109.45 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' LYS . . . . . 0.444 ' O ' ' HG3' ' A' ' 157' ' ' ARG . 32.0 mttt -89.32 -1.08 57.93 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.244 -0.91 . . . . 0.0 109.611 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 34.0 t 56.46 52.36 10.03 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.196 -0.94 . . . . 0.0 109.467 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' ARG . . . . . 0.444 ' HG3' ' O ' ' A' ' 155' ' ' LYS . 20.5 mtm180 -146.21 157.71 43.84 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.152 -0.967 . . . . 0.0 109.454 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' LEU . . . . . 0.629 HD21 ' CE1' ' A' ' 175' ' ' PHE . 13.9 mt -118.23 131.69 56.35 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.892 . . . . 0.0 109.531 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 20.9 tttp -84.37 106.77 16.23 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.295 -0.878 . . . . 0.0 109.443 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 160' ' ' VAL . . . . . 0.626 HG13 ' O ' ' A' ' 147' ' ' VAL . 47.5 t -124.86 140.72 47.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.162 -0.961 . . . . 0.0 109.56 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 161' ' ' SER . . . . . 0.461 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 23.0 t -104.3 141.88 35.53 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.439 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 162' ' ' VAL . . . . . 0.749 HG12 ' HB ' ' A' ' 169' ' ' THR . 9.4 p -105.53 126.28 60.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.314 -0.867 . . . . 0.0 109.562 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 18.5 t . . . . . 0 N--CA 1.491 1.597 0 O-C-N 121.303 -0.873 . . . . 0.0 109.377 179.875 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 19.1 ttp180 . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -76.33 141.0 41.71 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.294 -0.879 . . . . 0.0 109.454 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . 0.749 ' HB ' HG12 ' A' ' 162' ' ' VAL . 2.4 m -128.02 76.81 77.36 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.308 -0.87 . . . . 0.0 109.437 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.8 Cg_endo -55.27 106.51 0.19 Allowed 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.604 2.203 . . . . 0.0 111.852 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.766 HG11 ' CZ ' ' A' ' 141' ' ' PHE . 18.9 m -129.61 157.84 42.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.461 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.633 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.5 mt-10 -102.1 128.54 48.53 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.24 -0.913 . . . . 0.0 109.477 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 173' ' ' LEU . . . . . 0.633 HD23 ' O ' ' A' ' 172' ' ' GLU . 42.4 mt -124.86 144.13 50.47 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.29 -0.881 . . . . 0.0 109.513 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 24.6 m-20 -64.57 172.48 2.64 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.191 -0.943 . . . . 0.0 109.527 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 175' ' ' PHE . . . . . 0.629 ' CE1' HD21 ' A' ' 158' ' ' LEU . 4.5 m-30 -67.67 -44.41 77.89 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.166 -0.959 . . . . 0.0 109.501 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 15.0 m -71.33 -23.56 61.95 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.219 -0.925 . . . . 0.0 109.524 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 90.3 mt-30 -72.79 -23.53 60.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.177 -0.952 . . . . 0.0 109.431 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.563 HG11 ' HB2' ' A' ' 173' ' ' LEU . 4.5 m -128.16 161.26 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.253 -0.905 . . . . 0.0 109.401 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 179' ' ' GLU . . . . . 0.472 ' HB2' ' HB2' ' A' ' 135' ' ' ARG . 95.0 mt-10 -116.74 149.97 39.02 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.179 -0.951 . . . . 0.0 109.559 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 180' ' ' LYS . . . . . 0.508 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 33.6 tttm -69.13 137.34 53.31 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.181 -0.949 . . . . 0.0 109.505 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 181' ' ' ALA . . . . . 0.423 ' HB2' ' C ' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.536 0 O-C-N 121.211 -0.931 . . . . 0.0 109.46 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 6.3 ttm180 . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -56.6 145.93 78.51 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.62 2.213 . . . . 0.0 111.749 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 24.0 mttm -91.16 144.14 25.94 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.264 -0.898 . . . . 0.0 109.484 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.449 ' HA ' ' CE2' ' A' ' 128' ' ' PHE . 51.1 p -99.43 12.1 37.31 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.263 -0.898 . . . . 0.0 109.425 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.484 ' O ' ' HE3' ' A' ' 180' ' ' LYS . 64.6 mt -92.74 98.76 11.61 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.24 -0.912 . . . . 0.0 109.446 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.449 ' CE2' ' HA ' ' A' ' 126' ' ' THR . 79.8 m-85 -117.65 146.51 43.63 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.296 -0.878 . . . . 0.0 109.468 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.493 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 1.2 mt-10 -138.65 159.29 68.03 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.202 -0.937 . . . . 0.0 109.457 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.493 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.1 Cg_endo -53.53 129.41 33.68 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.547 2.165 . . . . 0.0 111.82 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 90.47 -1.2 78.82 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.489 ' O ' HG12 ' A' ' 148' ' ' VAL . 77.0 mm-40 -86.45 135.51 33.45 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.168 -1.195 . . . . 0.0 109.475 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.469 ' HA ' ' HA ' ' A' ' 147' ' ' VAL . 44.2 ttm -79.58 146.91 32.32 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.16 -0.963 . . . . 0.0 109.49 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.694 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -131.55 179.24 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.266 -0.896 . . . . 0.0 109.324 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.694 ' H ' HG12 ' A' ' 134' ' ' VAL . 40.4 ttt180 -130.29 138.34 50.43 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.226 -0.921 . . . . 0.0 109.49 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.493 HG22 ' CD1' ' A' ' 173' ' ' LEU . 45.4 t -106.63 132.79 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.271 -0.893 . . . . 0.0 109.451 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 56.1 p30 -135.64 20.44 3.33 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.263 -0.898 . . . . 0.0 109.495 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.422 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 59.0 t0 -140.88 148.17 40.07 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.209 -0.932 . . . . 0.0 109.481 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.422 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 70.23 177.23 20.76 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -55.01 -20.17 22.37 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.562 2.175 . . . . 0.0 111.791 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . 0.491 ' HB2' HG11 ' A' ' 136' ' ' VAL . 98.7 m-85 -85.6 6.73 26.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.217 -0.927 . . . . 0.0 109.504 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' ALA . . . . . 0.469 ' O ' ' HB3' ' A' ' 143' ' ' ASP . . . -66.19 148.91 51.13 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.287 -0.883 . . . . 0.0 109.462 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.469 ' HB3' ' O ' ' A' ' 142' ' ' ALA . 35.5 t0 73.06 29.97 1.69 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.222 -0.924 . . . . 0.0 109.51 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.533 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 84.7 m-85 -138.12 151.52 47.86 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.249 -0.907 . . . . 0.0 109.511 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 43.3 p-10 -118.04 164.09 15.63 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.25 -0.906 . . . . 0.0 109.427 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -172.16 -173.73 39.07 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.849 ' O ' HG13 ' A' ' 160' ' ' VAL . 57.9 t -120.29 151.64 23.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.227 -1.161 . . . . 0.0 109.491 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.856 HG21 HG22 ' A' ' 151' ' ' VAL . 2.1 p -94.39 98.85 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.274 -0.892 . . . . 0.0 109.466 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 76.2 mm-40 -69.37 -36.69 77.09 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.215 -0.928 . . . . 0.0 109.425 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -134.44 149.63 50.77 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.261 -0.9 . . . . 0.0 109.464 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.856 HG22 HG21 ' A' ' 148' ' ' VAL . 48.0 t -127.3 150.22 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.233 -0.917 . . . . 0.0 109.477 -179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' ASP . . . . . 0.416 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 93.5 m-20 -136.2 87.77 2.33 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.261 -0.9 . . . . 0.0 109.466 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -66.31 -37.05 84.5 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.274 -0.891 . . . . 0.0 109.463 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 48.3 tp10 -62.62 -44.28 96.69 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.248 -0.907 . . . . 0.0 109.484 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.48 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 21.5 mttt -88.62 0.61 56.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.289 -0.882 . . . . 0.0 109.602 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . 0.404 ' O ' ' OG ' ' A' ' 156' ' ' SER . 7.5 p 52.51 51.98 15.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.188 -0.945 . . . . 0.0 109.437 -179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.48 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 41.0 mmm-85 -145.32 140.46 27.76 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.259 -0.901 . . . . 0.0 109.472 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' LEU . . . . . 0.599 ' CD2' HG13 ' A' ' 151' ' ' VAL . 35.2 mt -108.53 134.28 51.52 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.254 -0.904 . . . . 0.0 109.542 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 15.1 tttp -92.47 93.09 8.39 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.224 -0.923 . . . . 0.0 109.374 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.849 HG13 ' O ' ' A' ' 147' ' ' VAL . 41.4 t -124.13 142.01 42.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.222 -0.923 . . . . 0.0 109.519 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . 0.512 ' CA ' ' HA ' ' A' ' 170' ' ' PRO . 86.7 p -106.31 147.7 28.87 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.263 -0.898 . . . . 0.0 109.436 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' VAL . . . . . 0.533 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 18.1 t -108.49 132.66 55.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.231 -0.918 . . . . 0.0 109.523 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 71.6 m -72.14 85.23 1.03 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.205 -0.934 . . . . 0.0 109.433 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 1.016 HG22 ' CD2' ' A' ' 165' ' ' PHE . 56.4 mt -108.32 139.89 28.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.265 -0.897 . . . . 0.0 109.485 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . 1.016 ' CD2' HG22 ' A' ' 164' ' ' ILE . 93.8 m-85 61.05 17.87 8.41 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.221 -0.925 . . . . 0.0 109.503 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 83.81 5.25 88.2 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 82.0 mtp180 -124.07 144.43 49.87 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.184 -1.186 . . . . 0.0 109.432 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -69.17 142.13 54.39 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.261 -0.9 . . . . 0.0 109.443 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.829 ' O ' HG13 ' A' ' 171' ' ' VAL . 15.4 m -124.37 75.81 61.59 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.271 -0.893 . . . . 0.0 109.475 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.512 ' HA ' ' CA ' ' A' ' 161' ' ' SER . 50.0 Cg_endo -47.95 106.45 0.11 Allowed 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.642 2.228 . . . . 0.0 111.784 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.829 HG13 ' O ' ' A' ' 169' ' ' THR . 21.2 m -128.74 155.12 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.293 -0.879 . . . . 0.0 109.478 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.497 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.0 mt-10 -95.04 123.33 38.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.222 -0.924 . . . . 0.0 109.458 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . 0.554 ' HB3' HG13 ' A' ' 178' ' ' VAL . 67.2 mt -125.98 147.91 49.41 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.231 -0.918 . . . . 0.0 109.477 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' ASP . . . . . 0.422 ' OD1' ' HD2' ' A' ' 157' ' ' ARG . 91.7 m-20 -75.84 164.87 25.78 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.216 -0.927 . . . . 0.0 109.441 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.56 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.3 m-30 -60.69 -41.16 94.57 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.211 -0.931 . . . . 0.0 109.495 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 19.3 m -76.06 -26.28 56.38 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.258 -0.901 . . . . 0.0 109.384 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' GLN . . . . . 0.419 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 87.9 mt-30 -69.04 -25.8 64.65 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.31 -0.869 . . . . 0.0 109.465 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.554 HG13 ' HB3' ' A' ' 173' ' ' LEU . 13.9 m -128.41 158.72 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.242 -0.911 . . . . 0.0 109.434 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 179' ' ' GLU . . . . . 0.434 ' HB2' ' HB3' ' A' ' 135' ' ' ARG . 77.8 mt-10 -113.13 149.24 33.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.232 -0.917 . . . . 0.0 109.49 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 180' ' ' LYS . . . . . 0.484 ' HE3' ' O ' ' A' ' 127' ' ' LEU . 30.6 tttm -69.94 135.79 49.85 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.241 -0.912 . . . . 0.0 109.479 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.587 0 O-C-N 121.266 -0.896 . . . . 0.0 109.454 -179.986 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.402 ' HA ' ' HD2' ' A' ' 124' ' ' PRO . 4.0 tmm_? . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.402 ' HD2' ' HA ' ' A' ' 123' ' ' ARG . 50.8 Cg_endo -60.39 143.15 99.47 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.547 2.165 . . . . 0.0 111.829 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . 0.668 ' HB3' HD11 ' A' ' 127' ' ' LEU . 84.4 tttt -126.98 140.27 52.43 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.21 -0.931 . . . . 0.0 109.433 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.557 ' HB ' ' CE2' ' A' ' 128' ' ' PHE . 6.2 p -96.21 95.34 8.05 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.269 -0.895 . . . . 0.0 109.537 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.853 HD12 ' N ' ' A' ' 127' ' ' LEU . 3.7 mp -102.24 86.0 2.75 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.246 -0.909 . . . . 0.0 109.507 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.596 ' CE1' ' HG3' ' A' ' 180' ' ' LYS . 74.5 m-85 -81.71 130.51 35.08 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.17 -0.956 . . . . 0.0 109.464 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.472 ' HB2' ' HG3' ' A' ' 132' ' ' GLU . 28.9 mt-10 -131.55 153.85 81.68 Favored Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.252 -0.905 . . . . 0.0 109.508 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -52.96 128.14 27.68 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 122.605 2.203 . . . . 0.0 111.776 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 86.5 10.16 74.15 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.472 ' HG3' ' HB2' ' A' ' 129' ' ' GLU . 72.7 mm-40 -96.13 127.26 41.98 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.304 -1.115 . . . . 0.0 109.432 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 5.8 ttm -63.71 134.71 55.84 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.263 -0.898 . . . . 0.0 109.501 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.678 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -123.5 179.03 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.228 -0.92 . . . . 0.0 109.394 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.678 ' H ' HG12 ' A' ' 134' ' ' VAL . 55.1 ttt-85 -135.95 133.53 37.68 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.264 -0.898 . . . . 0.0 109.288 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.598 HG11 ' HB2' ' A' ' 141' ' ' PHE . 90.7 t -106.03 132.06 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.202 -0.937 . . . . 0.0 109.584 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . 0.455 ' HB3' ' NH1' ' A' ' 135' ' ' ARG . 32.3 p30 -130.34 18.8 5.35 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.227 -0.921 . . . . 0.0 109.45 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -134.53 143.77 47.62 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.248 -0.907 . . . . 0.0 109.4 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 72.15 177.16 29.01 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -51.14 -20.95 8.44 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.638 2.225 . . . . 0.0 111.757 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . 0.598 ' HB2' HG11 ' A' ' 136' ' ' VAL . 93.8 m-85 -86.94 12.92 10.02 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.267 -0.896 . . . . 0.0 109.45 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' ALA . . . . . 0.455 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -69.57 143.71 53.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.25 -0.907 . . . . 0.0 109.594 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.45 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 19.3 m-20 65.9 50.52 1.49 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.57 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.465 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 49.9 m-85 -144.11 146.26 32.67 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.238 -0.914 . . . . 0.0 109.455 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -99.64 141.35 32.56 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.266 -0.896 . . . . 0.0 109.548 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.44 -173.85 27.39 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.379 -1.488 . . . . 0.0 109.379 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.809 ' O ' HG13 ' A' ' 160' ' ' VAL . 40.1 t -132.19 152.34 36.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.256 -1.143 . . . . 0.0 109.463 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.664 ' CA ' HG22 ' A' ' 160' ' ' VAL . 2.3 p -95.47 118.09 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.227 -0.921 . . . . 0.0 109.486 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 77.1 mm-40 -73.78 -42.18 61.38 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.331 -0.856 . . . . 0.0 109.364 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.459 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 95.3 mt-10 -147.21 162.56 38.64 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.298 -0.876 . . . . 0.0 109.431 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.983 HG13 ' CD2' ' A' ' 158' ' ' LEU . 49.1 t -129.03 153.2 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.216 -0.927 . . . . 0.0 109.459 179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' ASP . . . . . 0.4 ' O ' ' N ' ' A' ' 156' ' ' SER . 91.4 m-20 -128.7 97.37 4.66 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.176 -0.953 . . . . 0.0 109.442 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 90.3 m-85 -66.51 -41.59 88.6 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.232 -0.917 . . . . 0.0 109.453 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -63.12 -40.41 97.54 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.283 -0.885 . . . . 0.0 109.504 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 82.7 mttt -93.36 -0.66 56.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.246 -0.909 . . . . 0.0 109.592 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . 0.4 ' N ' ' O ' ' A' ' 152' ' ' ASP . 4.5 m 46.22 52.27 10.54 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.239 -0.913 . . . . 0.0 109.426 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.412 ' CG ' ' HB3' ' A' ' 172' ' ' GLU . 7.4 tpt180 -138.08 140.62 40.09 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.298 -0.876 . . . . 0.0 109.451 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' LEU . . . . . 0.983 ' CD2' HG13 ' A' ' 151' ' ' VAL . 41.1 mt -109.04 137.49 46.87 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.243 -0.911 . . . . 0.0 109.597 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . 0.459 ' HD2' ' HB2' ' A' ' 150' ' ' GLU . 21.3 mttp -99.78 96.7 7.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.259 -0.9 . . . . 0.0 109.377 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.809 HG13 ' O ' ' A' ' 147' ' ' VAL . 38.6 t -124.5 139.65 50.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.187 -0.946 . . . . 0.0 109.498 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 60.7 p -108.67 147.98 31.1 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.32 -0.862 . . . . 0.0 109.435 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' VAL . . . . . 0.465 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 4.2 t -117.69 133.01 65.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.158 -0.964 . . . . 0.0 109.472 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 31.0 t -83.73 83.04 8.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.306 -0.871 . . . . 0.0 109.457 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.41 ' O ' ' HB3' ' A' ' 165' ' ' PHE . 44.2 mt -102.58 139.26 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.155 -0.966 . . . . 0.0 109.476 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . 0.506 ' O ' ' CD2' ' A' ' 165' ' ' PHE . 60.0 t80 63.65 11.91 6.14 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.289 -0.882 . . . . 0.0 109.515 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 85.81 4.11 85.23 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 72.3 ttt180 -116.63 139.07 50.94 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.214 -1.168 . . . . 0.0 109.448 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -68.03 138.73 56.07 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.279 -0.888 . . . . 0.0 109.491 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.548 ' O ' HG13 ' A' ' 171' ' ' VAL . 1.3 m -125.44 77.91 68.33 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.214 -0.929 . . . . 0.0 109.435 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.402 ' HD2' ' HA ' ' A' ' 169' ' ' THR . 50.0 Cg_endo -53.91 103.66 0.1 OUTLIER 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.668 2.245 . . . . 0.0 111.78 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.873 HG23 HD21 ' A' ' 173' ' ' LEU . 31.4 m -129.8 154.46 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.242 -0.912 . . . . 0.0 109.434 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.879 ' C ' HD22 ' A' ' 173' ' ' LEU . 94.9 mt-10 -108.17 130.18 55.14 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.243 -0.911 . . . . 0.0 109.529 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . 0.879 HD22 ' C ' ' A' ' 172' ' ' GLU . 2.5 mm? -126.96 157.59 39.1 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.284 -0.885 . . . . 0.0 109.477 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' ASP . . . . . 0.545 ' O ' HG22 ' A' ' 178' ' ' VAL . 94.2 m-20 -77.04 176.19 8.89 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.261 -0.899 . . . . 0.0 109.394 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.422 ' CE1' HD21 ' A' ' 158' ' ' LEU . 7.3 m-30 -65.87 -43.15 89.19 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.222 -0.924 . . . . 0.0 109.417 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 82.4 p -76.77 -26.04 54.07 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.214 -0.929 . . . . 0.0 109.518 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -68.03 -18.95 64.85 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.264 -0.897 . . . . 0.0 109.538 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.545 HG22 ' O ' ' A' ' 174' ' ' ASP . 27.2 m -138.48 162.13 30.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.232 -0.918 . . . . 0.0 109.51 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 179' ' ' GLU . . . . . 0.512 ' O ' ' N ' ' A' ' 135' ' ' ARG . 35.7 mt-10 -127.38 155.9 42.88 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.24 -0.912 . . . . 0.0 109.476 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 180' ' ' LYS . . . . . 0.596 ' HG3' ' CE1' ' A' ' 128' ' ' PHE . 9.5 mtmt -85.48 143.72 28.38 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.245 -0.91 . . . . 0.0 109.488 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.565 0 O-C-N 121.241 -0.912 . . . . 0.0 109.499 179.971 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.5 ' N ' ' CD ' ' A' ' 124' ' ' PRO . 5.4 mtt85 . . . . . 0 N--CA 1.491 1.607 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.5 ' CD ' ' N ' ' A' ' 123' ' ' ARG . 49.5 Cg_endo -56.06 143.99 81.43 Favored 'Trans proline' 0 C--O 1.216 -0.623 0 C-N-CA 122.516 2.144 . . . . 0.0 111.765 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . 0.449 ' O ' ' HG3' ' A' ' 180' ' ' LYS . 96.0 mttt -112.56 143.91 42.93 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.285 -0.885 . . . . 0.0 109.519 -179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.43 ' HA ' ' HE3' ' A' ' 180' ' ' LYS . 44.8 p -108.49 20.79 18.15 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.221 -0.924 . . . . 0.0 109.402 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 58.4 mt -83.37 99.66 10.19 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.271 -0.893 . . . . 0.0 109.532 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.511 ' CE2' ' HD3' ' A' ' 180' ' ' LYS . 71.1 m-85 -82.4 132.48 35.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.242 -0.911 . . . . 0.0 109.431 -179.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.469 ' HB2' ' HD2' ' A' ' 130' ' ' PRO . 2.6 pp20? -128.13 138.65 33.44 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.325 -0.859 . . . . 0.0 109.464 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.497 ' HA ' ' O ' ' A' ' 148' ' ' VAL . 49.3 Cg_endo -39.0 128.9 1.35 Allowed 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.469 2.112 . . . . 0.0 111.749 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 89.65 10.08 65.66 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.485 ' O ' HG13 ' A' ' 147' ' ' VAL . 84.8 tt0 -104.16 135.15 46.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.341 -1.094 . . . . 0.0 109.458 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.553 ' HG2' HG22 ' A' ' 147' ' ' VAL . 82.9 mtp -71.9 139.94 49.02 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.201 -0.937 . . . . 0.0 109.534 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.668 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -127.03 178.59 4.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.183 -0.948 . . . . 0.0 109.372 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.668 ' H ' HG12 ' A' ' 134' ' ' VAL . 75.2 ttt-85 -126.56 144.55 50.84 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.274 -0.891 . . . . 0.0 109.549 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.564 HG12 ' HA ' ' A' ' 142' ' ' ALA . 45.0 t -112.15 132.3 61.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.236 -0.915 . . . . 0.0 109.453 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . 0.411 ' C ' ' OD1' ' A' ' 137' ' ' ASN . 48.0 p30 -131.83 14.65 4.82 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.233 -0.917 . . . . 0.0 109.474 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 59.1 t0 -142.18 143.15 32.81 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.234 -0.916 . . . . 0.0 109.49 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 79.87 171.2 41.96 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -55.73 -21.96 34.51 Favored 'Trans proline' 0 C--O 1.216 -0.625 0 C-N-CA 122.601 2.201 . . . . 0.0 111.813 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . 0.529 ' CZ ' HG11 ' A' ' 171' ' ' VAL . 99.0 m-85 -85.21 5.67 29.2 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.13 -0.981 . . . . 0.0 109.54 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' ALA . . . . . 0.564 ' HA ' HG12 ' A' ' 136' ' ' VAL . . . -69.15 149.01 49.11 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.272 -0.892 . . . . 0.0 109.416 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.493 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 30.3 t0 75.13 28.67 1.01 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.174 -0.954 . . . . 0.0 109.45 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.445 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 90.2 m-85 -135.77 145.0 46.1 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.263 -0.898 . . . . 0.0 109.456 -179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 74.0 m-20 -97.9 140.22 32.58 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.26 -0.9 . . . . 0.0 109.415 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -153.85 -173.06 22.53 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.792 ' O ' HG13 ' A' ' 160' ' ' VAL . 44.9 t -129.08 152.63 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.248 -1.148 . . . . 0.0 109.418 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.671 HG21 HG22 ' A' ' 151' ' ' VAL . 2.5 p -92.52 107.97 19.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.294 -0.879 . . . . 0.0 109.398 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.476 ' HB2' ' HE3' ' A' ' 159' ' ' LYS . 75.1 mm-40 -70.63 -39.23 73.83 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.224 -0.923 . . . . 0.0 109.365 179.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.46 ' HB2' ' HE2' ' A' ' 159' ' ' LYS . 92.4 mt-10 -139.41 157.5 45.75 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.239 -0.913 . . . . 0.0 109.393 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.849 HG13 ' CD2' ' A' ' 158' ' ' LEU . 48.5 t -127.29 151.04 33.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.274 -0.891 . . . . 0.0 109.481 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' ASP . . . . . 0.401 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 88.1 m-20 -134.43 87.7 2.38 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.223 -0.923 . . . . 0.0 109.436 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -63.34 -39.45 94.59 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.259 -0.901 . . . . 0.0 109.461 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -62.27 -42.15 99.1 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.18 -0.95 . . . . 0.0 109.506 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.412 ' O ' ' C ' ' A' ' 156' ' ' SER . 43.5 mttp -91.19 5.17 50.14 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.186 -0.946 . . . . 0.0 109.61 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . 0.517 ' HA ' ' CZ ' ' A' ' 175' ' ' PHE . 0.3 OUTLIER 43.91 51.8 6.8 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.187 -0.945 . . . . 0.0 109.472 -179.943 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.469 ' HD2' ' OD1' ' A' ' 174' ' ' ASP . 9.3 tpt180 -145.44 137.14 25.32 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.257 -0.902 . . . . 0.0 109.402 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' LEU . . . . . 0.849 ' CD2' HG13 ' A' ' 151' ' ' VAL . 46.2 mt -108.34 136.2 48.37 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 109.53 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . 0.476 ' HE3' ' HB2' ' A' ' 149' ' ' GLU . 14.2 ttpt -95.19 109.2 21.33 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.327 -0.858 . . . . 0.0 109.442 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.792 HG13 ' O ' ' A' ' 147' ' ' VAL . 39.2 t -127.84 142.0 44.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.226 -0.921 . . . . 0.0 109.464 -179.88 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . 0.486 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 96.1 p -107.0 147.44 29.89 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.191 -0.943 . . . . 0.0 109.504 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' VAL . . . . . . . . . . . . . 26.1 t -119.21 132.05 70.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.31 -0.869 . . . . 0.0 109.565 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 32.0 t -83.31 83.0 8.03 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.217 -0.927 . . . . 0.0 109.433 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.93 HG22 ' CD2' ' A' ' 165' ' ' PHE . 43.9 mt -106.57 142.95 18.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.241 -0.912 . . . . 0.0 109.494 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . 0.93 ' CD2' HG22 ' A' ' 164' ' ' ILE . 93.1 m-85 62.38 13.92 6.45 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.272 -0.893 . . . . 0.0 109.5 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 81.59 10.12 84.79 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 39.0 mtm105 -122.85 140.84 52.52 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.225 -1.162 . . . . 0.0 109.453 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -72.08 137.29 46.99 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.208 -0.933 . . . . 0.0 109.497 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.685 ' O ' HG13 ' A' ' 171' ' ' VAL . 59.3 m -129.82 77.02 77.55 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.244 -0.91 . . . . 0.0 109.44 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.486 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 50.6 Cg_endo -53.19 111.47 0.68 Allowed 'Trans proline' 0 C--O 1.214 -0.687 0 C-N-CA 122.579 2.186 . . . . 0.0 111.807 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.685 HG13 ' O ' ' A' ' 169' ' ' THR . 20.9 m -130.44 155.27 41.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.288 -0.883 . . . . 0.0 109.493 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.75 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.2 mt-10 -104.57 135.81 45.28 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.268 -0.895 . . . . 0.0 109.528 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . 0.75 HD23 ' O ' ' A' ' 172' ' ' GLU . 63.0 mt -133.91 148.28 51.2 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.316 -0.865 . . . . 0.0 109.576 -179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' ASP . . . . . 0.482 ' O ' HG22 ' A' ' 178' ' ' VAL . 91.4 m-20 -68.91 171.16 8.42 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.283 -0.886 . . . . 0.0 109.4 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.548 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 3.6 m-30 -65.29 -47.58 76.13 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.206 -0.934 . . . . 0.0 109.463 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 14.6 m -70.73 -28.03 64.41 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.315 -0.865 . . . . 0.0 109.498 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 177' ' ' GLN . . . . . 0.407 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 91.0 mt-30 -68.07 -20.64 64.97 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.306 -0.871 . . . . 0.0 109.473 -179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.632 HG11 ' HB2' ' A' ' 173' ' ' LEU . 13.7 m -131.23 160.29 42.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.278 -0.888 . . . . 0.0 109.484 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 179' ' ' GLU . . . . . 0.488 ' O ' ' N ' ' A' ' 135' ' ' ARG . 55.1 mt-10 -128.65 167.54 17.06 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.183 -0.948 . . . . 0.0 109.513 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 180' ' ' LYS . . . . . 0.511 ' HD3' ' CE2' ' A' ' 128' ' ' PHE . 29.0 mmtp -66.36 145.83 55.26 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.275 -0.89 . . . . 0.0 109.497 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.502 0 O-C-N 121.139 -0.975 . . . . 0.0 109.48 179.973 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 55.0 mtm-85 . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -56.36 145.09 80.27 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.578 2.185 . . . . 0.0 111.763 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 12.3 mtpt -90.56 151.27 21.4 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.242 -0.911 . . . . 0.0 109.462 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.486 ' HA ' ' CE2' ' A' ' 128' ' ' PHE . 28.8 p -88.15 15.1 7.95 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.218 -0.926 . . . . 0.0 109.458 -179.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 47.5 mt -94.41 92.38 7.12 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.247 -0.908 . . . . 0.0 109.488 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.505 ' CD2' HD21 ' A' ' 158' ' ' LEU . 69.0 m-85 -106.27 141.09 38.19 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.222 -0.923 . . . . 0.0 109.473 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.53 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.9 OUTLIER -144.55 157.73 55.14 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.26 -0.9 . . . . 0.0 109.394 179.959 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.53 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.2 Cg_endo -49.51 128.18 20.1 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.625 2.217 . . . . 0.0 111.805 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 96.1 -3.89 64.74 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.463 ' OE1' ' HA ' ' A' ' 128' ' ' PHE . 88.2 mt-10 -92.38 129.88 38.2 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.14 -1.212 . . . . 0.0 109.5 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.492 ' O ' ' HB3' ' A' ' 181' ' ' ALA . 43.5 ttm -77.13 145.7 37.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.237 -0.914 . . . . 0.0 109.353 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.683 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -129.76 178.66 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.198 -0.939 . . . . 0.0 109.404 -179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.683 ' H ' HG12 ' A' ' 134' ' ' VAL . 58.6 ttt180 -131.61 140.95 49.54 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.308 -0.87 . . . . 0.0 109.426 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.607 HG22 ' CD1' ' A' ' 173' ' ' LEU . 40.6 t -113.21 135.86 51.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.222 -0.923 . . . . 0.0 109.54 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . 0.446 ' O ' ' OD1' ' A' ' 138' ' ' ASP . 29.0 p30 -128.8 18.04 6.22 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.273 -0.892 . . . . 0.0 109.537 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.497 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 91.3 m-20 -139.43 164.37 30.03 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.208 -0.932 . . . . 0.0 109.497 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 57.94 172.86 0.32 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -53.26 -21.1 16.32 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.581 2.187 . . . . 0.0 111.777 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . 0.559 ' CZ ' HG11 ' A' ' 171' ' ' VAL . 91.8 m-85 -82.18 6.36 16.83 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.216 -0.928 . . . . 0.0 109.458 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' ALA . . . . . 0.423 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -62.62 143.24 57.52 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.278 -0.889 . . . . 0.0 109.488 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.423 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 10.2 m-20 67.06 48.69 1.2 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.257 -0.902 . . . . 0.0 109.413 -179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.494 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 43.6 m-85 -146.39 129.08 16.16 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.239 -0.913 . . . . 0.0 109.465 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 68.5 m-20 -90.87 138.04 31.9 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.227 -0.921 . . . . 0.0 109.509 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -152.71 177.39 30.44 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.851 ' O ' HG13 ' A' ' 160' ' ' VAL . 38.9 t -118.95 156.52 20.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.273 -1.134 . . . . 0.0 109.447 179.87 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.9 HG11 HG22 ' A' ' 151' ' ' VAL . 50.9 t -89.36 106.84 17.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.161 -0.962 . . . . 0.0 109.574 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -73.58 -31.84 63.81 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.247 -0.908 . . . . 0.0 109.392 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -144.42 148.63 34.87 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.282 -0.886 . . . . 0.0 109.25 179.852 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.9 HG22 HG11 ' A' ' 148' ' ' VAL . 37.1 t -125.55 146.43 31.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.157 -0.964 . . . . 0.0 109.644 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -132.28 87.89 2.48 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.279 -0.888 . . . . 0.0 109.412 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -61.1 -40.41 93.64 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.195 -0.941 . . . . 0.0 109.442 -179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -62.39 -40.53 96.76 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.21 -0.932 . . . . 0.0 109.51 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -91.52 2.45 56.43 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.217 -0.927 . . . . 0.0 109.649 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 13.6 p 45.21 52.62 8.52 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.154 -0.966 . . . . 0.0 109.394 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.639 ' C ' HD12 ' A' ' 158' ' ' LEU . 0.0 OUTLIER -136.67 156.28 48.75 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.202 -0.937 . . . . 0.0 109.543 179.919 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' LEU . . . . . 0.845 HD11 ' CE1' ' A' ' 175' ' ' PHE . 7.4 mp -120.39 123.66 43.61 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.257 -0.902 . . . . 0.0 109.525 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 18.0 tttm -91.01 92.18 8.63 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.25 -0.906 . . . . 0.0 109.378 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.851 HG13 ' O ' ' A' ' 147' ' ' VAL . 21.7 t -116.22 150.27 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.199 -0.938 . . . . 0.0 109.359 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . 0.467 ' OG ' ' N ' ' A' ' 170' ' ' PRO . 18.3 t -119.74 131.32 55.34 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.311 -0.868 . . . . 0.0 109.431 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' VAL . . . . . 0.494 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 11.7 t -102.16 131.98 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.243 -0.91 . . . . 0.0 109.387 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 40.5 t -77.64 81.52 4.08 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.273 -0.892 . . . . 0.0 109.43 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.684 HG22 ' CD1' ' A' ' 165' ' ' PHE . 68.5 mt -100.18 142.18 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.305 -0.872 . . . . 0.0 109.483 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . 0.684 ' CD1' HG22 ' A' ' 164' ' ' ILE . 7.7 m-30 64.47 18.09 11.17 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.16 -0.963 . . . . 0.0 109.517 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 81.81 4.23 90.38 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 70.1 mtm180 -124.12 142.17 51.43 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.177 -1.19 . . . . 0.0 109.38 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -68.17 144.53 54.93 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 109.521 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.781 ' O ' HG13 ' A' ' 171' ' ' VAL . 2.9 m -128.09 73.82 79.34 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.249 -0.907 . . . . 0.0 109.414 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.467 ' N ' ' OG ' ' A' ' 161' ' ' SER . 50.2 Cg_endo -49.09 105.98 0.1 Allowed 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.585 2.19 . . . . 0.0 111.794 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.781 HG13 ' O ' ' A' ' 169' ' ' THR . 19.3 m -133.67 153.94 37.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.295 -0.878 . . . . 0.0 109.359 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.72 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.2 mt-10 -97.23 135.81 38.63 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.259 -0.901 . . . . 0.0 109.489 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . 0.72 HD23 ' O ' ' A' ' 172' ' ' GLU . 28.9 mt -124.97 160.06 29.8 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.256 -0.902 . . . . 0.0 109.421 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' ASP . . . . . 0.471 ' HB2' ' HB2' ' A' ' 177' ' ' GLN . 92.7 m-20 -83.54 160.78 21.4 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.184 -0.948 . . . . 0.0 109.521 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.845 ' CE1' HD11 ' A' ' 158' ' ' LEU . 4.5 m-85 -53.67 -49.95 66.86 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.321 -0.862 . . . . 0.0 109.561 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 15.5 m -74.67 -24.36 58.79 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.162 -0.961 . . . . 0.0 109.546 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 177' ' ' GLN . . . . . 0.69 ' NE2' HD22 ' A' ' 173' ' ' LEU . 61.9 tt0 -64.6 -27.21 68.79 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.231 -0.918 . . . . 0.0 109.425 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.66 HG11 HD12 ' A' ' 173' ' ' LEU . 13.7 m -127.97 161.83 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.334 -0.854 . . . . 0.0 109.482 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 179' ' ' GLU . . . . . 0.43 ' N ' ' O ' ' A' ' 135' ' ' ARG . 61.6 mt-10 -118.32 148.19 42.73 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.207 -0.933 . . . . 0.0 109.489 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 18.8 tttt -66.95 130.91 44.67 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.32 -0.863 . . . . 0.0 109.427 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . 0.492 ' HB3' ' O ' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.558 0 O-C-N 121.259 -0.901 . . . . 0.0 109.461 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.518 0 CA-C-O 121.248 0.547 . . . . 0.0 109.531 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -56.0 146.04 71.28 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.583 2.189 . . . . 0.0 111.748 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . 0.41 ' O ' ' HD2' ' A' ' 180' ' ' LYS . 68.8 mttm -92.28 144.63 25.2 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.27 -0.893 . . . . 0.0 109.485 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 46.6 p -93.26 11.29 28.55 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.316 -0.865 . . . . 0.0 109.435 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 47.8 mt -96.91 95.32 7.76 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.29 -0.881 . . . . 0.0 109.494 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.416 ' CE1' ' HB2' ' A' ' 180' ' ' LYS . 68.8 m-85 -99.48 135.67 40.55 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.299 -0.875 . . . . 0.0 109.463 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.474 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.0 OUTLIER -125.87 153.54 73.52 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.23 -0.919 . . . . 0.0 109.503 179.949 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.474 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 49.4 Cg_endo -47.88 134.59 23.13 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.636 2.224 . . . . 0.0 111.72 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 85.45 3.72 86.47 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 48.9 tp10 -89.9 136.11 33.24 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.168 -1.195 . . . . 0.0 109.474 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.914 ' SD ' HG22 ' A' ' 147' ' ' VAL . 92.9 mmm -74.82 148.55 40.19 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.253 -0.904 . . . . 0.0 109.48 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.836 HG21 HG23 ' A' ' 148' ' ' VAL . 2.5 t -139.06 179.18 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.285 -0.885 . . . . 0.0 109.373 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.686 ' H ' HG12 ' A' ' 134' ' ' VAL . 19.8 ttp85 -137.58 142.41 41.31 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.323 -0.861 . . . . 0.0 109.445 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.46 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 43.8 t -106.45 132.16 54.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.224 -0.923 . . . . 0.0 109.533 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 29.0 p30 -118.48 13.33 13.47 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.337 -0.852 . . . . 0.0 109.425 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.432 ' H ' HG12 ' A' ' 136' ' ' VAL . 51.9 p30 -151.89 169.93 21.07 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.235 -0.916 . . . . 0.0 109.461 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 67.4 168.79 3.94 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -56.71 -18.11 25.45 Favored 'Trans proline' 0 C--O 1.214 -0.702 0 C-N-CA 122.565 2.177 . . . . 0.0 111.848 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . 0.726 ' CE2' HG11 ' A' ' 171' ' ' VAL . 92.5 m-85 -88.12 8.1 28.46 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.28 -0.888 . . . . 0.0 109.48 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' ALA . . . . . 0.481 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -61.34 150.68 34.35 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.213 -0.929 . . . . 0.0 109.458 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.448 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 63.2 m-20 62.63 42.4 8.44 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.243 -0.911 . . . . 0.0 109.446 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.481 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 51.3 m-85 -146.9 134.52 21.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.165 -0.959 . . . . 0.0 109.516 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -87.68 141.98 28.18 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.264 -0.898 . . . . 0.0 109.453 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -149.61 177.89 27.48 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.914 HG22 ' SD ' ' A' ' 133' ' ' MET . 35.6 t -119.92 156.34 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.306 -1.114 . . . . 0.0 109.462 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.836 HG23 HG21 ' A' ' 134' ' ' VAL . 61.3 t -87.54 103.18 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.22 -0.925 . . . . 0.0 109.457 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 75.2 mm-40 -67.63 -38.69 84.23 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.268 -0.895 . . . . 0.0 109.415 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -153.77 150.81 28.88 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.232 -0.918 . . . . 0.0 109.426 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.708 HG13 ' CD2' ' A' ' 158' ' ' LEU . 58.9 t -122.68 154.41 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.269 -0.895 . . . . 0.0 109.475 -179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -135.12 94.83 3.19 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.301 -0.875 . . . . 0.0 109.459 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 81.1 m-85 -67.32 -42.44 83.65 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.301 -0.874 . . . . 0.0 109.487 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -62.63 -36.67 83.56 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.212 -0.93 . . . . 0.0 109.412 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.47 ' O ' ' HG2' ' A' ' 155' ' ' LYS . 57.0 tttm -95.59 1.4 53.73 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.202 -0.936 . . . . 0.0 109.617 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 41.1 t 46.6 52.4 11.09 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.171 -0.956 . . . . 0.0 109.486 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 7.7 tpt180 -141.28 138.25 33.07 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.256 -0.903 . . . . 0.0 109.417 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' LEU . . . . . 0.708 ' CD2' HG13 ' A' ' 151' ' ' VAL . 55.2 mt -107.25 131.66 53.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.221 -0.924 . . . . 0.0 109.496 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 60.3 tttm -96.52 105.78 17.93 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.874 . . . . 0.0 109.373 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.698 HG13 ' O ' ' A' ' 147' ' ' VAL . 38.6 t -123.36 145.75 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.265 -0.897 . . . . 0.0 109.578 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . 0.404 ' OG ' ' HA ' ' A' ' 170' ' ' PRO . 11.4 m -118.85 137.01 53.72 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.33 -0.856 . . . . 0.0 109.359 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' VAL . . . . . 0.55 HG21 ' HB3' ' A' ' 141' ' ' PHE . 25.2 t -107.85 133.68 51.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.292 -0.88 . . . . 0.0 109.634 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 33.8 t -87.31 83.49 7.35 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.233 -0.917 . . . . 0.0 109.193 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 1.0 HG22 ' CD2' ' A' ' 165' ' ' PHE . 31.7 mt -105.15 142.24 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.22 -0.925 . . . . 0.0 109.573 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . 1.0 ' CD2' HG22 ' A' ' 164' ' ' ILE . 98.5 m-85 60.57 19.8 9.66 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.263 -0.898 . . . . 0.0 109.523 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 76.18 12.39 84.16 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 51.1 mtt180 -121.68 139.54 53.42 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.259 -1.142 . . . . 0.0 109.433 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -74.29 140.94 45.26 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.194 -0.941 . . . . 0.0 109.568 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.56 ' O ' HG13 ' A' ' 171' ' ' VAL . 0.2 OUTLIER -127.03 73.99 76.76 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 121.317 -0.864 . . . . 0.0 109.443 179.953 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.404 ' HA ' ' OG ' ' A' ' 161' ' ' SER . 49.8 Cg_endo -54.17 100.28 0.06 OUTLIER 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.567 2.178 . . . . 0.0 111.81 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.726 HG11 ' CE2' ' A' ' 141' ' ' PHE . 26.9 m -126.96 153.4 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.278 -0.889 . . . . 0.0 109.489 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.778 ' O ' HD23 ' A' ' 173' ' ' LEU . 57.0 mp0 -102.02 134.8 44.66 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.292 -0.88 . . . . 0.0 109.563 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . 0.778 HD23 ' O ' ' A' ' 172' ' ' GLU . 53.4 mt -132.95 147.8 52.28 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.245 -0.91 . . . . 0.0 109.455 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' ASP . . . . . 0.414 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 90.7 m-20 -70.89 174.32 6.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.262 -0.899 . . . . 0.0 109.458 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.529 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 3.8 m-30 -65.13 -44.66 87.94 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.212 -0.93 . . . . 0.0 109.457 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 94.8 p -73.73 -28.81 61.9 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.205 -0.935 . . . . 0.0 109.463 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 177' ' ' GLN . . . . . 0.414 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 82.1 mt-30 -63.49 -25.71 68.38 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.283 -0.885 . . . . 0.0 109.49 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.473 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 6.1 m -130.02 160.79 40.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.266 -0.896 . . . . 0.0 109.485 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 179' ' ' GLU . . . . . 0.478 ' OE1' ' CZ ' ' A' ' 135' ' ' ARG . 79.6 mt-10 -112.14 147.61 35.75 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.278 -0.889 . . . . 0.0 109.465 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 180' ' ' LYS . . . . . 0.416 ' HB2' ' CE1' ' A' ' 128' ' ' PHE . 19.1 tttm -76.02 132.04 39.9 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.286 -0.884 . . . . 0.0 109.465 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.552 0 O-C-N 121.2 -0.937 . . . . 0.0 109.518 -179.957 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 12.8 mtp180 . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -55.75 146.71 64.8 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.606 2.204 . . . . 0.0 111.764 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . 0.456 ' HB2' ' CD ' ' A' ' 180' ' ' LYS . 67.2 mttt -95.18 146.69 24.15 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.889 . . . . 0.0 109.43 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 49.7 p -102.55 16.89 25.07 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -0.907 . . . . 0.0 109.426 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 44.6 mt -94.81 96.36 9.3 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.157 -0.964 . . . . 0.0 109.433 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 72.8 m-85 -98.43 132.51 43.82 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.277 -0.889 . . . . 0.0 109.508 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.542 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.1 OUTLIER -143.62 156.69 59.72 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.328 -0.858 . . . . 0.0 109.412 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.542 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.4 Cg_endo -47.34 132.19 19.11 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.552 2.168 . . . . 0.0 111.737 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 93.59 0.67 66.74 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -103.68 139.99 38.19 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.234 -1.157 . . . . 0.0 109.435 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . . . . . . . . . 87.7 mtp -83.78 152.69 24.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.317 -0.865 . . . . 0.0 109.491 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.836 ' CG2' HG23 ' A' ' 148' ' ' VAL . 2.5 t -136.82 179.21 3.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.258 -0.901 . . . . 0.0 109.345 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.683 ' H ' HG12 ' A' ' 134' ' ' VAL . 53.0 ttm-85 -135.08 139.02 44.39 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.232 -0.918 . . . . 0.0 109.456 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.775 HG22 ' CD1' ' A' ' 173' ' ' LEU . 50.0 t -107.1 131.23 57.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.266 -0.896 . . . . 0.0 109.494 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . 0.421 ' O ' ' OD1' ' A' ' 138' ' ' ASP . 11.4 p30 -122.54 16.32 10.39 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.279 -0.888 . . . . 0.0 109.43 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.421 ' OD1' ' O ' ' A' ' 137' ' ' ASN . 93.5 m-20 -135.67 160.16 39.39 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.229 -0.919 . . . . 0.0 109.489 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 60.35 173.08 0.82 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -53.53 -20.37 15.95 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.609 2.206 . . . . 0.0 111.803 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . 0.571 ' HB3' HG21 ' A' ' 162' ' ' VAL . 99.4 m-85 -80.57 4.07 19.71 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.222 -0.924 . . . . 0.0 109.481 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' ALA . . . . . 0.497 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -63.99 150.84 44.35 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.139 -0.976 . . . . 0.0 109.474 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.444 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 57.9 m-20 62.83 47.53 4.5 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.275 -0.89 . . . . 0.0 109.398 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.497 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 50.2 m-85 -149.34 144.56 26.51 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.308 -0.87 . . . . 0.0 109.493 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 19.8 m120 -97.9 145.52 26.36 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.27 -0.894 . . . . 0.0 109.497 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -154.21 174.68 32.62 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.559 HG12 ' N ' ' A' ' 148' ' ' VAL . 47.3 t -114.4 165.16 9.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.223 -1.163 . . . . 0.0 109.386 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.836 HG23 ' CG2' ' A' ' 134' ' ' VAL . 51.0 t -101.57 123.66 54.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.273 -0.892 . . . . 0.0 109.512 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 74.7 mm-40 -99.76 -44.55 6.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.256 -0.903 . . . . 0.0 109.435 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -133.24 155.61 49.04 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.237 -0.914 . . . . 0.0 109.348 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.52 HG11 ' CZ ' ' A' ' 153' ' ' TYR . 38.7 t -122.79 151.15 26.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.29 -0.881 . . . . 0.0 109.565 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' ASP . . . . . 0.408 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 93.3 m-20 -135.3 78.93 1.76 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.292 -0.88 . . . . 0.0 109.373 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' TYR . . . . . 0.52 ' CZ ' HG11 ' A' ' 151' ' ' VAL . 98.1 m-85 -62.68 -37.3 85.9 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.197 -0.939 . . . . 0.0 109.651 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -64.35 -40.95 96.88 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.277 -0.889 . . . . 0.0 109.593 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.463 ' O ' ' HG3' ' A' ' 157' ' ' ARG . 28.9 mttt -87.1 3.13 47.44 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.211 -0.93 . . . . 0.0 109.627 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . 0.492 ' HA ' ' CZ ' ' A' ' 175' ' ' PHE . 58.1 m 52.83 52.59 13.63 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.224 -0.922 . . . . 0.0 109.469 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.472 ' CG ' ' O ' ' A' ' 156' ' ' SER . 47.0 mtt180 -157.81 155.43 29.72 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.278 -0.889 . . . . 0.0 109.44 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' LEU . . . . . 0.66 HD21 ' CE1' ' A' ' 175' ' ' PHE . 12.0 mt -119.83 137.0 54.26 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.243 -0.911 . . . . 0.0 109.57 -179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 14.8 tttt -83.63 105.34 14.48 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.302 -0.874 . . . . 0.0 109.308 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.769 HG22 HG22 ' A' ' 148' ' ' VAL . 57.8 t -123.11 145.27 30.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.205 -0.934 . . . . 0.0 109.596 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 14.9 m -111.86 140.85 46.17 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.257 -0.902 . . . . 0.0 109.444 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' VAL . . . . . 0.571 HG21 ' HB3' ' A' ' 141' ' ' PHE . 14.0 t -110.46 133.14 56.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.206 -0.934 . . . . 0.0 109.493 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 60.7 p -83.36 82.56 8.23 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.191 -0.943 . . . . 0.0 109.435 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.536 HG22 ' CD1' ' A' ' 165' ' ' PHE . 54.5 mt -107.23 139.11 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.286 -0.884 . . . . 0.0 109.537 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . 0.536 ' CD1' HG22 ' A' ' 164' ' ' ILE . 9.4 m-85 66.2 18.55 10.98 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.282 -0.886 . . . . 0.0 109.454 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 74.4 12.07 82.22 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -123.85 142.42 51.14 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.207 -1.172 . . . . 0.0 109.462 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -72.76 137.23 45.73 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.287 -0.883 . . . . 0.0 109.471 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.709 ' O ' HG13 ' A' ' 171' ' ' VAL . 18.6 m -129.96 74.18 80.79 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.203 -0.936 . . . . 0.0 109.486 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -51.04 112.72 0.85 Allowed 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.607 2.205 . . . . 0.0 111.73 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.709 HG13 ' O ' ' A' ' 169' ' ' THR . 28.7 m -133.11 153.46 37.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.308 -0.87 . . . . 0.0 109.423 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.675 ' O ' HD23 ' A' ' 173' ' ' LEU . 94.8 mt-10 -95.68 130.28 42.62 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.24 -0.913 . . . . 0.0 109.5 -179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . 0.775 ' CD1' HG22 ' A' ' 136' ' ' VAL . 51.6 mt -128.08 146.4 50.7 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.327 -0.858 . . . . 0.0 109.404 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 57.1 m-20 -67.77 171.06 6.94 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.268 -0.895 . . . . 0.0 109.451 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.66 ' CE1' HD21 ' A' ' 158' ' ' LEU . 6.2 m-30 -64.64 -49.19 71.99 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.248 -0.908 . . . . 0.0 109.386 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 87.0 p -74.94 -18.64 60.36 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.169 -0.957 . . . . 0.0 109.453 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 177' ' ' GLN . . . . . 0.651 ' NE2' HD22 ' A' ' 173' ' ' LEU . 63.8 tt0 -70.66 -20.85 62.67 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.296 -0.878 . . . . 0.0 109.483 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.556 HG11 ' HB2' ' A' ' 173' ' ' LEU . 4.7 m -130.2 159.2 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.285 -0.885 . . . . 0.0 109.403 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 179' ' ' GLU . . . . . 0.405 ' HB2' ' HB3' ' A' ' 135' ' ' ARG . 73.0 mt-10 -115.6 151.96 33.98 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.189 -0.944 . . . . 0.0 109.525 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 180' ' ' LYS . . . . . 0.456 ' CD ' ' HB2' ' A' ' 125' ' ' LYS . 21.1 tttt -75.7 136.42 40.36 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.249 -0.907 . . . . 0.0 109.511 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.516 0 O-C-N 121.292 -0.88 . . . . 0.0 109.527 179.978 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.522 ' CB ' ' CD ' ' A' ' 124' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.522 ' CD ' ' CB ' ' A' ' 123' ' ' ARG . 50.2 Cg_endo -55.52 143.86 76.37 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 C-N-CA 122.652 2.235 . . . . 0.0 111.784 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 59.8 mttp -104.53 154.02 20.43 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.297 -0.877 . . . . 0.0 109.478 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 52.1 p -99.63 28.83 4.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.276 -0.89 . . . . 0.0 109.471 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 58.7 mt -92.72 94.66 9.11 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.25 -0.906 . . . . 0.0 109.457 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.683 ' CD2' HD21 ' A' ' 158' ' ' LEU . 83.9 m-85 -91.77 129.78 37.67 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.232 -0.917 . . . . 0.0 109.564 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.434 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.2 OUTLIER -123.02 155.03 64.71 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.287 -0.883 . . . . 0.0 109.464 179.979 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.434 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 49.5 Cg_endo -51.22 128.89 26.78 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.648 2.232 . . . . 0.0 111.815 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 91.52 2.93 69.58 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.433 ' OE2' ' HE3' ' A' ' 180' ' ' LYS . 65.7 tt0 -88.5 141.87 28.18 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.154 -1.204 . . . . 0.0 109.485 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.925 ' SD ' HG22 ' A' ' 147' ' ' VAL . 80.4 mmm -80.33 137.56 36.59 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.208 -0.932 . . . . 0.0 109.556 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.75 HG21 ' CG2' ' A' ' 148' ' ' VAL . 2.5 t -129.22 179.28 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.247 -0.908 . . . . 0.0 109.285 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.685 ' H ' HG12 ' A' ' 134' ' ' VAL . 37.4 ttm180 -137.83 142.6 40.77 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.123 -0.986 . . . . 0.0 109.48 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.47 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 59.3 t -110.95 133.02 57.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.302 -0.874 . . . . 0.0 109.512 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 40.7 p30 -124.75 19.86 8.55 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.176 -0.952 . . . . 0.0 109.384 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.444 ' HB3' ' HG3' ' A' ' 177' ' ' GLN . 55.9 t0 -143.13 153.77 43.23 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.289 -0.882 . . . . 0.0 109.481 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.44 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 69.84 172.07 9.52 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -52.88 -16.9 6.62 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.582 2.188 . . . . 0.0 111.71 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . 0.525 ' CD1' HD11 ' A' ' 164' ' ' ILE . 99.5 m-85 -88.15 10.83 18.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.299 -0.876 . . . . 0.0 109.426 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' ALA . . . . . 0.449 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -64.27 145.79 55.42 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.276 -0.89 . . . . 0.0 109.554 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.449 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 50.8 m-20 63.54 46.88 4.02 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.33 -0.856 . . . . 0.0 109.622 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.6 ' HB3' HG13 ' A' ' 162' ' ' VAL . 39.3 m-85 -143.38 140.86 30.68 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.176 -0.952 . . . . 0.0 109.599 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 73.5 m-20 -95.6 142.05 28.38 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.271 -0.893 . . . . 0.0 109.492 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -151.29 173.16 30.76 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.925 HG22 ' SD ' ' A' ' 133' ' ' MET . 22.6 t -117.9 153.04 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.154 -1.204 . . . . 0.0 109.401 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.858 HG22 HG22 ' A' ' 160' ' ' VAL . 57.5 t -88.87 109.67 20.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.234 -0.916 . . . . 0.0 109.521 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -68.13 -40.9 82.37 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.262 -0.899 . . . . 0.0 109.418 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.451 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 95.6 mt-10 -153.93 157.53 39.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.207 -0.933 . . . . 0.0 109.395 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.498 HG21 ' O ' ' A' ' 128' ' ' PHE . 43.9 t -120.99 144.27 30.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.233 -0.917 . . . . 0.0 109.462 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -123.15 95.61 4.67 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.212 -0.93 . . . . 0.0 109.493 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -66.14 -42.24 89.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.183 -0.948 . . . . 0.0 109.51 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 76.2 mm-40 -59.58 -43.37 93.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.29 -0.881 . . . . 0.0 109.427 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 23.7 mttt -87.35 -10.25 52.69 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.29 -0.881 . . . . 0.0 109.495 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 1.6 m 55.62 53.28 9.81 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.23 -0.919 . . . . 0.0 109.432 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.573 ' C ' HD12 ' A' ' 158' ' ' LEU . 88.5 mmt-85 -139.47 162.55 34.79 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.277 -0.889 . . . . 0.0 109.512 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' LEU . . . . . 0.748 HD11 ' CE1' ' A' ' 175' ' ' PHE . 7.0 mp -122.55 131.31 53.78 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.278 -0.889 . . . . 0.0 109.542 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . 0.451 ' HD2' ' HB2' ' A' ' 150' ' ' GLU . 23.8 mttm -97.14 98.6 10.17 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.198 -0.939 . . . . 0.0 109.233 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.858 HG22 HG22 ' A' ' 148' ' ' VAL . 30.0 t -123.17 145.68 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.236 -0.915 . . . . 0.0 109.662 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . 0.466 ' CB ' ' HA ' ' A' ' 170' ' ' PRO . 88.1 p -112.71 148.29 35.02 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.277 -0.89 . . . . 0.0 109.333 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' VAL . . . . . 0.6 HG13 ' HB3' ' A' ' 144' ' ' PHE . 18.0 t -113.4 128.32 70.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.215 -0.928 . . . . 0.0 109.626 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 36.5 t -80.75 80.76 7.16 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.29 -0.881 . . . . 0.0 109.503 179.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.525 HD11 ' CD1' ' A' ' 141' ' ' PHE . 57.9 mt -97.3 137.64 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.311 -0.868 . . . . 0.0 109.318 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . 0.508 ' O ' ' CD2' ' A' ' 165' ' ' PHE . 46.9 t80 63.87 14.25 8.19 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.215 -0.928 . . . . 0.0 109.363 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 84.72 9.62 80.78 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 72.9 mtm180 -117.83 142.41 47.33 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.24 -1.153 . . . . 0.0 109.403 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -81.08 134.75 35.71 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.258 -0.901 . . . . 0.0 109.496 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.717 ' O ' HG13 ' A' ' 171' ' ' VAL . 64.8 m -128.48 77.26 77.5 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.215 -0.928 . . . . 0.0 109.475 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.466 ' HA ' ' CB ' ' A' ' 161' ' ' SER . 48.9 Cg_endo -53.13 107.8 0.22 Allowed 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.631 2.22 . . . . 0.0 111.789 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 1.03 HG23 HD21 ' A' ' 173' ' ' LEU . 19.4 m -127.04 157.68 38.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.27 -0.893 . . . . 0.0 109.463 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.745 ' C ' HD22 ' A' ' 173' ' ' LEU . 95.8 mt-10 -91.05 128.46 36.88 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.311 -0.868 . . . . 0.0 109.503 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . 1.03 HD21 HG23 ' A' ' 171' ' ' VAL . 2.2 mm? -122.33 156.08 34.64 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.289 -0.882 . . . . 0.0 109.497 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' ASP . . . . . 0.466 ' HB2' ' HB2' ' A' ' 177' ' ' GLN . 84.5 m-20 -83.34 168.13 16.92 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.217 -0.927 . . . . 0.0 109.596 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.748 ' CE1' HD11 ' A' ' 158' ' ' LEU . 8.2 m-85 -59.49 -49.44 77.77 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.255 -0.903 . . . . 0.0 109.584 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 84.0 p -78.09 -19.36 54.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.2 -0.937 . . . . 0.0 109.653 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 177' ' ' GLN . . . . . 0.6 ' NE2' HD12 ' A' ' 173' ' ' LEU . 64.9 tt0 -67.25 -25.26 65.99 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.116 -0.99 . . . . 0.0 109.483 -179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.536 HG13 ' HB3' ' A' ' 173' ' ' LEU . 4.5 m -127.08 157.57 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.264 -0.897 . . . . 0.0 109.592 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 179' ' ' GLU . . . . . 0.445 ' N ' ' O ' ' A' ' 135' ' ' ARG . 56.4 mt-10 -111.29 152.74 26.86 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.258 -0.901 . . . . 0.0 109.438 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 180' ' ' LYS . . . . . 0.433 ' HE3' ' OE2' ' A' ' 132' ' ' GLU . 5.4 tttp -72.9 133.02 44.21 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.228 -0.92 . . . . 0.0 109.481 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . 0.418 ' CB ' ' O ' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.547 0 O-C-N 121.249 -0.907 . . . . 0.0 109.514 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.579 ' CB ' ' CD ' ' A' ' 124' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.579 ' CD ' ' CB ' ' A' ' 123' ' ' ARG . 50.6 Cg_endo -55.91 146.8 66.18 Favored 'Trans proline' 0 C--O 1.213 -0.726 0 C-N-CA 122.621 2.214 . . . . 0.0 111.746 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 91.7 mttt -90.6 146.72 23.83 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.396 -0.815 . . . . 0.0 109.435 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 45.7 p -93.47 12.62 24.39 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.203 -0.936 . . . . 0.0 109.5 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.45 ' O ' ' HE3' ' A' ' 180' ' ' LYS . 44.4 mt -90.99 97.37 11.14 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.239 -0.913 . . . . 0.0 109.518 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.435 ' HA ' ' OE1' ' A' ' 132' ' ' GLU . 56.9 m-85 -109.14 145.49 35.65 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.191 -0.943 . . . . 0.0 109.442 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.497 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.1 OUTLIER -145.42 155.44 53.69 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.252 -0.905 . . . . 0.0 109.502 179.933 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.497 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.2 Cg_endo -48.58 128.52 18.3 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.633 2.222 . . . . 0.0 111.828 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 96.25 -9.57 67.41 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.435 ' OE1' ' HA ' ' A' ' 128' ' ' PHE . 92.2 mt-10 -86.95 140.24 29.8 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.155 -1.203 . . . . 0.0 109.496 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.557 ' HG2' HG22 ' A' ' 147' ' ' VAL . 87.9 mtp -84.76 152.25 23.82 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.333 -0.854 . . . . 0.0 109.456 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.692 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -133.45 179.21 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.236 -0.915 . . . . 0.0 109.308 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.692 ' H ' HG12 ' A' ' 134' ' ' VAL . 64.1 mtm180 -138.9 150.31 45.8 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.233 -0.917 . . . . 0.0 109.53 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.531 HG12 ' H ' ' A' ' 138' ' ' ASP . 42.1 t -108.31 135.24 47.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.297 -0.877 . . . . 0.0 109.444 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 36.7 p30 -118.17 14.16 13.91 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.239 -0.913 . . . . 0.0 109.528 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.531 ' H ' HG12 ' A' ' 136' ' ' VAL . 53.7 p30 -157.21 169.95 23.6 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.269 -0.894 . . . . 0.0 109.499 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 69.04 165.55 4.11 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -55.97 -18.61 23.0 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.629 2.219 . . . . 0.0 111.739 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . 1.175 ' CD1' HG21 ' A' ' 162' ' ' VAL . 94.1 m-85 -88.74 7.77 32.18 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.291 -0.881 . . . . 0.0 109.523 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' ALA . . . . . 0.497 ' O ' ' CB ' ' A' ' 143' ' ' ASP . . . -67.9 147.98 51.75 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.178 -0.951 . . . . 0.0 109.48 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.497 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 3.9 t70 76.29 27.47 0.86 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.281 -0.887 . . . . 0.0 109.56 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.482 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 96.5 m-85 -135.87 146.55 47.55 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.295 -0.878 . . . . 0.0 109.47 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 75.6 m-20 -103.63 146.98 27.77 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.268 -0.895 . . . . 0.0 109.377 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . 0.459 ' HA3' ' O ' ' A' ' 161' ' ' SER . . . -151.24 -173.94 21.63 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.557 HG22 ' HG2' ' A' ' 133' ' ' MET . 48.7 t -123.99 156.68 31.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.302 -1.116 . . . . 0.0 109.487 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.638 HG23 ' CG2' ' A' ' 134' ' ' VAL . 98.7 t -86.59 96.07 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.246 -0.909 . . . . 0.0 109.519 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -68.31 -34.92 77.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.294 -0.879 . . . . 0.0 109.411 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.404 ' O ' ' HB3' ' A' ' 159' ' ' LYS . 95.0 mt-10 -151.11 159.19 44.63 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.202 -0.936 . . . . 0.0 109.479 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.481 HG22 HG11 ' A' ' 148' ' ' VAL . 43.6 t -129.02 148.22 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.459 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -134.2 86.71 2.3 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.242 -0.911 . . . . 0.0 109.476 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -67.34 -36.72 82.0 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.285 -0.884 . . . . 0.0 109.505 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -64.15 -41.45 97.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.202 -0.937 . . . . 0.0 109.442 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.415 ' O ' ' C ' ' A' ' 156' ' ' SER . 42.7 mttp -92.64 9.43 34.82 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.225 -0.922 . . . . 0.0 109.478 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . 0.415 ' C ' ' O ' ' A' ' 155' ' ' LYS . 8.1 m 43.85 52.76 6.46 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.304 -0.872 . . . . 0.0 109.445 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.45 ' CG ' ' HB3' ' A' ' 172' ' ' GLU . 7.7 tpt180 -144.45 140.0 28.68 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.243 -0.911 . . . . 0.0 109.43 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' LEU . . . . . 0.501 HD21 ' CE1' ' A' ' 175' ' ' PHE . 53.7 mt -107.35 134.54 50.26 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.198 -0.939 . . . . 0.0 109.454 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . 0.428 ' HD2' ' HG2' ' A' ' 172' ' ' GLU . 13.6 tptt -92.74 95.9 9.83 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.247 -0.908 . . . . 0.0 109.463 179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.523 HG22 HG22 ' A' ' 148' ' ' VAL . 40.9 t -117.7 143.41 28.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.148 -0.97 . . . . 0.0 109.473 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . 0.527 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 28.4 t -109.21 147.67 32.18 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.246 -0.909 . . . . 0.0 109.469 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' VAL . . . . . 1.175 HG21 ' CD1' ' A' ' 141' ' ' PHE . 21.1 t -88.43 134.39 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.258 -0.901 . . . . 0.0 109.615 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 5.7 m -85.97 82.42 8.13 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.319 -0.863 . . . . 0.0 109.231 179.765 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.494 HG22 ' H ' ' A' ' 166' ' ' GLY . 41.3 mt -98.31 139.96 19.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.256 -0.902 . . . . 0.0 109.442 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 71.6 t80 -56.7 -39.18 73.38 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.303 -0.873 . . . . 0.0 109.635 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.505 ' O ' ' HB2' ' A' ' 167' ' ' ARG . . . -63.37 -31.22 80.01 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' ARG . . . . . 0.505 ' HB2' ' O ' ' A' ' 166' ' ' GLY . 17.3 ttt180 165.13 154.22 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.336 -1.096 . . . . 0.0 109.226 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -67.28 147.57 52.83 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.206 -0.934 . . . . 0.0 109.382 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.581 HG21 ' CE1' ' A' ' 141' ' ' PHE . 5.3 m -124.58 88.95 52.89 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.221 -0.924 . . . . 0.0 109.541 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.527 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.4 Cg_endo -68.23 107.89 1.65 Allowed 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 122.592 2.194 . . . . 0.0 111.783 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.425 ' O ' ' O ' ' A' ' 160' ' ' VAL . 21.2 m -132.87 160.69 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.302 -0.874 . . . . 0.0 109.45 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.69 ' O ' HD23 ' A' ' 173' ' ' LEU . 97.7 mt-10 -103.97 128.61 51.51 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.266 -0.896 . . . . 0.0 109.508 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . 0.69 HD23 ' O ' ' A' ' 172' ' ' GLU . 55.7 mt -129.74 147.32 51.5 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.269 -0.895 . . . . 0.0 109.51 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' ASP . . . . . 0.424 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 88.9 m-20 -67.41 173.13 4.24 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.282 -0.886 . . . . 0.0 109.455 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.53 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.7 m-30 -64.92 -41.46 95.55 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.191 -0.943 . . . . 0.0 109.403 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 19.4 m -75.11 -25.79 58.76 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.233 -0.917 . . . . 0.0 109.433 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 177' ' ' GLN . . . . . 0.424 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 83.2 mt-30 -68.29 -22.67 64.72 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.219 -0.926 . . . . 0.0 109.415 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.532 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 9.0 m -132.99 157.57 43.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.241 -0.912 . . . . 0.0 109.396 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 179' ' ' GLU . . . . . 0.431 ' N ' ' O ' ' A' ' 135' ' ' ARG . 93.4 mt-10 -114.94 150.18 36.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.359 -0.838 . . . . 0.0 109.486 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 180' ' ' LYS . . . . . 0.45 ' HE3' ' O ' ' A' ' 127' ' ' LEU . 18.1 tttm -66.04 140.1 58.24 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.253 -0.904 . . . . 0.0 109.428 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.503 0 O-C-N 121.23 -0.919 . . . . 0.0 109.456 -179.971 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.489 1.484 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -55.9 144.24 78.73 Favored 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 122.608 2.205 . . . . 0.0 111.766 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . 0.527 ' HB2' ' CE ' ' A' ' 180' ' ' LYS . 35.4 mmtp -95.21 151.86 18.86 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.249 -0.907 . . . . 0.0 109.446 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 52.4 p -104.07 18.32 22.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.228 -0.92 . . . . 0.0 109.508 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 63.7 mt -97.12 95.39 7.74 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.246 -0.909 . . . . 0.0 109.461 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.519 ' O ' HG21 ' A' ' 151' ' ' VAL . 66.0 m-85 -103.37 132.58 49.51 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.3 -0.875 . . . . 0.0 109.457 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.502 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.6 OUTLIER -133.38 153.16 80.38 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.236 -0.915 . . . . 0.0 109.476 179.961 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.502 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 49.8 Cg_endo -45.79 132.79 13.77 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.591 2.194 . . . . 0.0 111.762 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 89.57 -1.28 81.42 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.643 ' O ' HG12 ' A' ' 148' ' ' VAL . 49.0 tp10 -94.5 127.98 40.77 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.131 -1.217 . . . . 0.0 109.423 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.726 ' HG2' HG22 ' A' ' 147' ' ' VAL . 81.6 mtp -68.14 153.96 42.67 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.208 -0.932 . . . . 0.0 109.438 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.682 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -138.1 178.82 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.218 -0.927 . . . . 0.0 109.284 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.682 ' H ' HG12 ' A' ' 134' ' ' VAL . 76.3 ttt180 -135.42 148.09 49.19 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.25 -0.906 . . . . 0.0 109.458 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.475 HG12 ' HA ' ' A' ' 142' ' ' ALA . 48.5 t -118.15 126.91 75.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.278 -0.889 . . . . 0.0 109.471 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . 0.403 ' O ' ' OD1' ' A' ' 138' ' ' ASP . 26.2 p30 -126.28 12.87 7.66 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.249 -0.907 . . . . 0.0 109.492 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.473 ' HB2' ' OE1' ' A' ' 177' ' ' GLN . 93.5 m-20 -137.78 163.07 32.28 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.21 -0.931 . . . . 0.0 109.506 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 63.86 176.48 4.2 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -58.14 -24.49 66.8 Favored 'Trans proline' 0 C--O 1.216 -0.613 0 C-N-CA 122.597 2.198 . . . . 0.0 111.745 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . 0.554 ' CZ ' HG11 ' A' ' 171' ' ' VAL . 98.8 m-85 -82.81 7.87 13.95 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.224 -0.922 . . . . 0.0 109.488 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' ALA . . . . . 0.475 ' HA ' HG12 ' A' ' 136' ' ' VAL . . . -61.03 150.87 32.33 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.215 -0.928 . . . . 0.0 109.499 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.473 ' N ' ' O ' ' A' ' 136' ' ' VAL . 37.8 m-20 62.66 52.58 2.8 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.271 -0.893 . . . . 0.0 109.579 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.497 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 35.6 m-85 -150.4 132.02 14.88 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.237 -0.914 . . . . 0.0 109.489 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 56.5 m-20 -92.98 138.72 31.23 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.209 -0.932 . . . . 0.0 109.402 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -156.67 -179.65 31.8 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.965 ' O ' HG13 ' A' ' 160' ' ' VAL . 40.9 t -121.48 159.52 23.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.243 -1.151 . . . . 0.0 109.349 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.701 ' HA ' HG22 ' A' ' 160' ' ' VAL . 2.5 p -100.26 115.62 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.281 -0.887 . . . . 0.0 109.519 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 83.3 mt-10 -70.52 -36.59 73.82 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.279 -0.888 . . . . 0.0 109.294 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.473 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 93.7 mt-10 -152.32 162.45 41.15 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.283 -0.886 . . . . 0.0 109.459 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.679 HG22 HG21 ' A' ' 148' ' ' VAL . 48.0 t -132.27 151.75 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.19 -0.944 . . . . 0.0 109.51 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' ASP . . . . . 0.517 ' O ' ' N ' ' A' ' 156' ' ' SER . 84.3 m-20 -125.52 98.58 5.65 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.243 -0.91 . . . . 0.0 109.424 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 87.4 m-85 -66.33 -35.8 81.29 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.219 -0.926 . . . . 0.0 109.572 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -66.94 -45.3 78.24 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.286 -0.883 . . . . 0.0 109.551 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 19.3 mttt -91.07 -8.55 48.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.242 -0.911 . . . . 0.0 109.512 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . 0.517 ' N ' ' O ' ' A' ' 152' ' ' ASP . 44.3 t 55.75 52.33 11.04 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.548 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.67 ' C ' HD12 ' A' ' 158' ' ' LEU . 83.3 mmt-85 -133.2 151.1 51.95 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.896 . . . . 0.0 109.327 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' LEU . . . . . 0.869 HD11 ' CE1' ' A' ' 175' ' ' PHE . 4.3 mp -118.16 137.12 53.19 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.18 -0.95 . . . . 0.0 109.592 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . 0.473 ' HD2' ' HB2' ' A' ' 150' ' ' GLU . 34.1 mttt -99.15 90.55 4.63 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.243 -0.911 . . . . 0.0 109.347 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.965 HG13 ' O ' ' A' ' 147' ' ' VAL . 46.5 t -118.52 142.99 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.224 -0.922 . . . . 0.0 109.533 -179.759 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . 0.435 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 27.0 t -112.53 136.64 51.82 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.245 -0.909 . . . . 0.0 109.395 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' VAL . . . . . 0.497 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 21.5 t -107.47 132.35 55.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.176 -0.953 . . . . 0.0 109.511 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 33.1 t -78.62 82.42 4.86 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.292 -0.88 . . . . 0.0 109.48 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.66 HG22 ' CD1' ' A' ' 165' ' ' PHE . 47.0 mt -105.35 141.81 19.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.191 -0.943 . . . . 0.0 109.398 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . 0.66 ' CD1' HG22 ' A' ' 164' ' ' ILE . 8.0 m-30 64.88 16.2 10.35 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.289 -0.882 . . . . 0.0 109.429 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 80.08 7.64 88.35 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 78.7 mtp180 -125.43 139.15 53.9 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.275 -1.133 . . . . 0.0 109.455 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -68.5 140.67 55.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.274 -0.891 . . . . 0.0 109.543 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.662 ' O ' HG13 ' A' ' 171' ' ' VAL . 8.2 m -128.36 74.44 79.76 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.235 -0.916 . . . . 0.0 109.37 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.435 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.6 Cg_endo -54.24 105.2 0.13 Allowed 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.579 2.186 . . . . 0.0 111.82 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.662 HG13 ' O ' ' A' ' 169' ' ' THR . 19.6 m -128.09 159.37 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.243 -0.911 . . . . 0.0 109.419 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.529 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.9 mt-10 -102.91 130.93 50.13 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.213 -0.929 . . . . 0.0 109.45 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . 0.658 HD12 ' CG1' ' A' ' 178' ' ' VAL . 55.1 mt -125.02 160.84 28.07 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.276 -0.89 . . . . 0.0 109.527 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' ASP . . . . . 0.458 ' HB2' ' HG2' ' A' ' 177' ' ' GLN . 90.6 m-20 -82.82 176.78 9.04 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.3 -0.875 . . . . 0.0 109.558 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.869 ' CE1' HD11 ' A' ' 158' ' ' LEU . 3.2 m-85 -66.1 -39.77 90.24 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.333 -0.855 . . . . 0.0 109.613 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 15.4 m -79.81 -26.23 40.58 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.208 -0.933 . . . . 0.0 109.619 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 177' ' ' GLN . . . . . 0.473 ' OE1' ' HB2' ' A' ' 138' ' ' ASP . 96.6 mm-40 -67.08 -30.71 70.83 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.22 -0.925 . . . . 0.0 109.519 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.658 ' CG1' HD12 ' A' ' 173' ' ' LEU . 12.7 m -125.29 158.26 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.249 -0.907 . . . . 0.0 109.386 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 179' ' ' GLU . . . . . 0.511 ' O ' ' N ' ' A' ' 135' ' ' ARG . 70.6 tt0 -120.38 143.09 48.61 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.218 -0.926 . . . . 0.0 109.498 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 180' ' ' LYS . . . . . 0.527 ' CE ' ' HB2' ' A' ' 125' ' ' LYS . 23.6 ttmt -59.71 140.15 56.69 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.309 -0.87 . . . . 0.0 109.434 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.527 0 O-C-N 121.174 -0.954 . . . . 0.0 109.452 -179.984 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.522 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -55.34 145.82 65.06 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.621 2.214 . . . . 0.0 111.789 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . 0.471 ' O ' ' HD2' ' A' ' 180' ' ' LYS . 58.9 mttt -94.7 150.72 19.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.175 -0.953 . . . . 0.0 109.504 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 52.2 p -89.64 9.4 27.1 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.276 -0.89 . . . . 0.0 109.447 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.405 ' O ' ' HE3' ' A' ' 180' ' ' LYS . 49.6 mt -91.46 98.46 11.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.241 -0.912 . . . . 0.0 109.449 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 92.2 m-85 -103.12 136.51 42.79 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.259 -0.901 . . . . 0.0 109.491 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.461 ' HB2' ' HD2' ' A' ' 130' ' ' PRO . 16.5 pt-20 -133.01 134.98 25.06 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.921 . . . . 0.0 109.454 -179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.505 ' HA ' ' O ' ' A' ' 148' ' ' VAL . 49.2 Cg_endo -35.28 131.36 0.24 Allowed 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.517 2.145 . . . . 0.0 111.738 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . 0.487 ' C ' ' CG1' ' A' ' 147' ' ' VAL . . . 90.89 -4.48 81.71 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.803 ' O ' HG13 ' A' ' 147' ' ' VAL . 49.2 tp10 -83.58 141.7 31.38 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.125 -1.221 . . . . 0.0 109.548 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.743 ' HG2' HG22 ' A' ' 147' ' ' VAL . 90.5 mtp -80.94 150.11 29.11 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.184 -0.948 . . . . 0.0 109.438 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.679 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -135.65 179.06 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.168 -0.958 . . . . 0.0 109.375 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.679 ' H ' HG12 ' A' ' 134' ' ' VAL . 94.5 mtt180 -132.86 146.52 51.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.318 -0.864 . . . . 0.0 109.467 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 41.4 t -112.53 130.42 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.265 -0.897 . . . . 0.0 109.423 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 54.9 p30 -123.37 19.21 9.75 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.201 -0.937 . . . . 0.0 109.534 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -156.27 151.24 26.26 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.212 -0.93 . . . . 0.0 109.493 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 82.27 164.16 33.97 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -54.19 -23.66 30.54 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.606 2.204 . . . . 0.0 111.779 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . 0.474 ' CD1' HG21 ' A' ' 162' ' ' VAL . 98.9 m-85 -86.87 11.05 14.26 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.252 -0.905 . . . . 0.0 109.391 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' ALA . . . . . 0.471 ' O ' ' CB ' ' A' ' 143' ' ' ASP . . . -70.09 151.09 45.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.891 . . . . 0.0 109.491 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.471 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 25.0 t0 74.9 28.62 1.09 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.279 -0.888 . . . . 0.0 109.517 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.525 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 92.5 m-85 -135.03 140.3 45.5 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.164 -0.96 . . . . 0.0 109.608 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 21.2 m120 -95.95 141.07 29.81 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.32 -0.862 . . . . 0.0 109.418 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -151.3 -173.42 21.18 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.803 HG13 ' O ' ' A' ' 132' ' ' GLU . 54.8 t -132.01 144.26 37.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.362 -1.081 . . . . 0.0 109.454 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.768 ' CA ' HG22 ' A' ' 160' ' ' VAL . 2.1 p -83.03 106.11 13.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.281 -0.887 . . . . 0.0 109.443 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 56.5 mp0 -70.2 -46.8 63.83 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.231 -0.918 . . . . 0.0 109.461 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.409 ' HG2' ' N ' ' A' ' 151' ' ' VAL . 83.5 tt0 -131.8 153.24 50.34 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.186 -0.947 . . . . 0.0 109.36 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.608 HG22 HG21 ' A' ' 148' ' ' VAL . 47.9 t -120.18 153.53 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.174 -0.954 . . . . 0.0 109.579 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 92.2 m-20 -135.76 83.25 2.0 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.306 -0.871 . . . . 0.0 109.339 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' TYR . . . . . 0.463 ' CZ ' HG11 ' A' ' 151' ' ' VAL . 96.7 m-85 -67.03 -34.84 78.59 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.244 -0.91 . . . . 0.0 109.555 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 76.0 mm-40 -62.21 -40.81 97.32 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.202 -0.936 . . . . 0.0 109.562 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.451 ' O ' ' HG2' ' A' ' 155' ' ' LYS . 31.7 tttt -96.88 -4.3 40.44 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.289 -0.882 . . . . 0.0 109.655 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . 0.435 ' HB2' ' O ' ' A' ' 155' ' ' LYS . 19.8 m 59.9 53.05 4.92 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.195 -0.941 . . . . 0.0 109.46 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . . . . . . . . . 13.5 tpt180 -142.63 138.97 31.07 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.281 -0.887 . . . . 0.0 109.488 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' LEU . . . . . 0.552 ' CD2' HG13 ' A' ' 151' ' ' VAL . 41.9 mt -108.08 134.63 50.68 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.252 -0.905 . . . . 0.0 109.524 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 62.8 tttm -97.28 97.08 8.85 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.225 -0.922 . . . . 0.0 109.418 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.768 HG22 ' CA ' ' A' ' 148' ' ' VAL . 42.9 t -123.27 138.37 53.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.258 -0.901 . . . . 0.0 109.615 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . 0.432 ' CB ' ' HA ' ' A' ' 170' ' ' PRO . 83.6 p -100.75 155.24 18.02 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.299 -0.876 . . . . 0.0 109.508 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' VAL . . . . . 0.525 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 5.3 t -106.14 129.15 59.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.25 -0.906 . . . . 0.0 109.479 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 55.1 m -75.78 81.5 2.72 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.286 -0.884 . . . . 0.0 109.383 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.462 HD12 ' OG1' ' A' ' 169' ' ' THR . 75.1 mt -91.45 146.78 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.231 -0.918 . . . . 0.0 109.421 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -55.05 -47.65 74.52 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.248 -0.908 . . . . 0.0 109.75 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.526 ' O ' ' CB ' ' A' ' 167' ' ' ARG . . . -54.54 -34.22 55.14 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.788 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' ARG . . . . . 0.526 ' CB ' ' O ' ' A' ' 166' ' ' GLY . 7.9 mtm180 161.26 167.14 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.315 -1.109 . . . . 0.0 109.423 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -69.39 138.87 53.98 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.221 -0.924 . . . . 0.0 109.384 179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.462 ' OG1' HD12 ' A' ' 164' ' ' ILE . 29.7 m -123.04 87.85 51.0 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.172 -0.955 . . . . 0.0 109.526 -179.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.432 ' HA ' ' CB ' ' A' ' 161' ' ' SER . 50.2 Cg_endo -62.74 107.53 0.62 Allowed 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.558 2.172 . . . . 0.0 111.685 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' A' ' 160' ' ' VAL . 18.9 m -129.97 156.92 42.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.278 -0.889 . . . . 0.0 109.567 -179.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.499 ' O ' HD23 ' A' ' 173' ' ' LEU . 94.5 mt-10 -103.97 129.38 51.54 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.281 -0.887 . . . . 0.0 109.371 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . 0.547 ' HB2' ' CG1' ' A' ' 178' ' ' VAL . 65.5 mt -126.25 147.89 49.6 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.268 -0.895 . . . . 0.0 109.471 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -68.5 173.35 5.07 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.25 -0.907 . . . . 0.0 109.407 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.492 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.9 m-30 -66.51 -40.24 89.11 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.248 -0.907 . . . . 0.0 109.446 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 14.8 m -75.36 -24.41 57.29 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.231 -0.918 . . . . 0.0 109.406 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -70.32 -28.8 65.45 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.219 -0.926 . . . . 0.0 109.499 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.547 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 4.4 m -127.95 161.08 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.231 -0.918 . . . . 0.0 109.468 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 179' ' ' GLU . . . . . . . . . . . . . 75.0 mm-40 -120.0 148.64 43.31 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.236 -0.915 . . . . 0.0 109.505 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 180' ' ' LYS . . . . . 0.471 ' HD2' ' O ' ' A' ' 125' ' ' LYS . 20.1 tttt -58.95 140.56 55.43 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.188 -0.945 . . . . 0.0 109.485 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . 0.477 ' HB2' ' C ' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.491 1.589 0 O-C-N 121.21 -0.932 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.436 ' N ' ' CD ' ' A' ' 124' ' ' PRO . 2.5 ttp85 . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.436 ' CD ' ' N ' ' A' ' 123' ' ' ARG . 49.2 Cg_endo -55.87 142.79 83.63 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.608 2.206 . . . . 0.0 111.847 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . 0.462 ' HB2' ' HD3' ' A' ' 180' ' ' LYS . 22.0 mttp -116.87 143.67 45.42 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.277 -0.89 . . . . 0.0 109.497 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 48.7 p -113.41 21.46 15.16 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.224 -0.922 . . . . 0.0 109.478 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 56.2 mt -98.55 95.23 7.15 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.206 -0.934 . . . . 0.0 109.463 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.611 ' CD2' HD21 ' A' ' 158' ' ' LEU . 92.0 m-85 -96.84 131.4 43.62 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.368 -0.833 . . . . 0.0 109.455 179.861 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.486 ' HB2' ' HD2' ' A' ' 130' ' ' PRO . 2.2 pt-20 -142.35 147.31 42.91 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.231 -0.918 . . . . 0.0 109.418 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.486 ' HD2' ' HB2' ' A' ' 129' ' ' GLU . 48.8 Cg_endo -40.95 128.47 2.79 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.436 2.091 . . . . 0.0 111.84 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 100.28 -4.19 56.96 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.642 ' O ' HG13 ' A' ' 147' ' ' VAL . 78.1 mm-40 -93.03 144.32 25.37 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.207 -1.172 . . . . 0.0 109.541 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.895 ' SD ' HG22 ' A' ' 147' ' ' VAL . 77.3 mmm -83.48 143.08 30.47 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.225 -0.922 . . . . 0.0 109.413 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.938 ' CG2' HG23 ' A' ' 148' ' ' VAL . 2.5 t -128.63 178.59 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.225 -0.922 . . . . 0.0 109.362 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.683 ' H ' HG12 ' A' ' 134' ' ' VAL . 40.0 ttt85 -141.88 145.8 35.04 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.343 -0.848 . . . . 0.0 109.405 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.575 HG22 ' CD1' ' A' ' 173' ' ' LEU . 43.5 t -112.48 135.29 52.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.235 -0.915 . . . . 0.0 109.495 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 34.6 p30 -126.67 10.41 7.17 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.279 -0.888 . . . . 0.0 109.411 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.484 ' HB3' ' HG3' ' A' ' 177' ' ' GLN . 49.9 t0 -150.58 159.04 44.78 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.229 -0.919 . . . . 0.0 109.541 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.416 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 77.52 165.33 24.63 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -50.45 -22.33 8.74 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 122.593 2.195 . . . . 0.0 111.721 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . 0.915 ' CZ ' HG11 ' A' ' 171' ' ' VAL . 93.9 m-85 -88.61 12.57 14.31 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.207 -0.933 . . . . 0.0 109.485 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' ALA . . . . . 0.451 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -62.83 149.2 44.86 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.339 -0.851 . . . . 0.0 109.529 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.432 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 44.7 m-20 63.28 45.31 5.07 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.26 -0.9 . . . . 0.0 109.472 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.538 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 46.0 m-85 -147.08 126.08 12.83 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.184 -0.947 . . . . 0.0 109.474 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 67.8 m-20 -88.42 145.24 25.89 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.224 -0.923 . . . . 0.0 109.605 -179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -157.1 177.26 34.06 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.895 HG22 ' SD ' ' A' ' 133' ' ' MET . 22.0 t -114.86 156.69 15.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.177 -1.19 . . . . 0.0 109.395 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.938 HG23 ' CG2' ' A' ' 134' ' ' VAL . 47.8 t -82.37 104.11 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.248 -0.907 . . . . 0.0 109.498 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.42 ' O ' ' CD ' ' A' ' 150' ' ' GLU . 97.2 mt-10 -69.86 -35.41 74.69 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.282 -0.886 . . . . 0.0 109.36 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.474 ' HB2' ' HD3' ' A' ' 159' ' ' LYS . 76.1 mm-40 -152.81 164.88 36.98 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.322 -0.861 . . . . 0.0 109.41 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.44 HG11 ' CZ ' ' A' ' 153' ' ' TYR . 46.5 t -128.56 143.48 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.267 -0.896 . . . . 0.0 109.424 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 93.8 m-20 -124.91 78.31 1.69 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.19 -0.944 . . . . 0.0 109.542 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' TYR . . . . . 0.44 ' CZ ' HG11 ' A' ' 151' ' ' VAL . 92.9 m-85 -59.87 -42.21 93.24 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.238 -0.914 . . . . 0.0 109.385 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -54.61 -45.08 73.6 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.244 -0.91 . . . . 0.0 109.366 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.412 ' O ' ' HG3' ' A' ' 157' ' ' ARG . 44.2 mttp -86.23 -2.96 58.85 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.264 -0.897 . . . . 0.0 109.515 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 17.1 m 55.68 53.7 9.21 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.183 -0.948 . . . . 0.0 109.358 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.412 ' HG3' ' O ' ' A' ' 155' ' ' LYS . 66.9 mtt180 -147.95 162.79 38.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 109.534 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' LEU . . . . . 0.638 ' CD1' ' CE1' ' A' ' 175' ' ' PHE . 6.7 mp -114.02 139.27 49.4 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.331 -0.856 . . . . 0.0 109.428 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . 0.474 ' HD3' ' HB2' ' A' ' 150' ' ' GLU . 41.1 tttt -104.56 100.22 9.9 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.158 -0.963 . . . . 0.0 109.312 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.567 HG13 ' O ' ' A' ' 147' ' ' VAL . 39.9 t -119.9 148.52 22.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.207 -0.933 . . . . 0.0 109.549 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . 0.416 ' CB ' ' HA ' ' A' ' 170' ' ' PRO . 22.7 t -117.95 138.85 51.88 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.245 -0.909 . . . . 0.0 109.333 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' VAL . . . . . 0.538 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 4.4 t -107.19 133.13 52.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.182 -0.949 . . . . 0.0 109.708 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 44.1 t -82.93 81.84 8.45 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.321 -0.862 . . . . 0.0 109.311 179.838 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.997 HG22 ' CD2' ' A' ' 165' ' ' PHE . 59.5 mt -97.19 134.91 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.142 -0.974 . . . . 0.0 109.469 -179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . 0.997 ' CD2' HG22 ' A' ' 164' ' ' ILE . 79.4 m-85 62.14 27.69 16.67 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.296 -0.878 . . . . 0.0 109.474 -179.903 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 70.13 13.09 69.63 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.792 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 76.1 mtm180 -119.35 141.1 49.33 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.252 -1.146 . . . . 0.0 109.441 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -80.12 134.6 36.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.2 -0.938 . . . . 0.0 109.413 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.726 ' O ' HG13 ' A' ' 171' ' ' VAL . 57.3 m -128.65 73.32 80.92 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 121.286 -0.884 . . . . 0.0 109.437 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.416 ' HA ' ' CB ' ' A' ' 161' ' ' SER . 49.6 Cg_endo -52.1 108.42 0.25 Allowed 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.69 2.26 . . . . 0.0 111.89 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.915 HG11 ' CZ ' ' A' ' 141' ' ' PHE . 20.5 m -126.04 155.12 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.264 -0.898 . . . . 0.0 109.417 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.451 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.3 mt-10 -90.89 129.99 36.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.213 -0.929 . . . . 0.0 109.553 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . 0.575 ' CD1' HG22 ' A' ' 136' ' ' VAL . 61.9 mt -122.02 154.91 36.63 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.234 -0.916 . . . . 0.0 109.49 179.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 174' ' ' ASP . . . . . 0.481 ' HB2' ' HB2' ' A' ' 177' ' ' GLN . 85.1 m-20 -83.81 154.95 23.23 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.221 -0.925 . . . . 0.0 109.629 -179.867 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.638 ' CE1' ' CD1' ' A' ' 158' ' ' LEU . 25.4 m-85 -51.14 -50.24 59.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.38 -0.825 . . . . 0.0 109.615 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 72.4 p -74.8 -18.45 60.46 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.223 -0.923 . . . . 0.0 109.594 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 177' ' ' GLN . . . . . 0.484 ' HG3' ' HB3' ' A' ' 138' ' ' ASP . 65.7 tt0 -72.95 -25.15 60.92 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.301 -0.874 . . . . 0.0 109.448 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.509 HG13 ' HB3' ' A' ' 173' ' ' LEU . 5.2 m -125.34 161.81 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.154 -0.966 . . . . 0.0 109.487 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 179' ' ' GLU . . . . . . . . . . . . . 61.1 mt-10 -118.42 148.96 42.01 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.225 -0.922 . . . . 0.0 109.482 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 180' ' ' LYS . . . . . 0.462 ' HD3' ' HB2' ' A' ' 125' ' ' LYS . 21.1 tttm -79.79 132.65 36.19 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.34 -0.85 . . . . 0.0 109.449 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.499 0 O-C-N 121.278 -0.889 . . . . 0.0 109.49 179.99 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.402 ' HD3' ' HD2' ' A' ' 124' ' ' PRO . 9.5 mmt180 . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.402 ' HD2' ' HD3' ' A' ' 123' ' ' ARG . 50.0 Cg_endo -54.47 147.33 48.1 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.606 2.204 . . . . 0.0 111.819 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 49.6 mttp -101.54 140.63 35.56 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.139 -0.976 . . . . 0.0 109.553 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 47.6 p -113.58 26.59 10.26 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.242 -0.911 . . . . 0.0 109.438 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 66.4 mt -95.01 91.98 6.63 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.254 -0.903 . . . . 0.0 109.431 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.547 ' CD2' HD21 ' A' ' 158' ' ' LEU . 75.2 m-85 -79.13 131.61 36.29 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.295 -0.878 . . . . 0.0 109.386 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.459 ' O ' ' HG2' ' A' ' 132' ' ' GLU . 0.6 OUTLIER -129.46 150.04 74.5 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.206 -0.934 . . . . 0.0 109.469 -179.99 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.464 ' HA ' ' O ' ' A' ' 148' ' ' VAL . 50.0 Cg_endo -47.27 123.48 7.81 Favored 'Trans proline' 0 C--O 1.215 -0.632 0 C-N-CA 122.67 2.247 . . . . 0.0 111.771 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 99.29 2.17 56.78 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.626 -1.389 . . . . 0.0 109.626 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.459 ' HG2' ' O ' ' A' ' 129' ' ' GLU . 74.9 mm-40 -92.32 141.3 28.71 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.186 -1.185 . . . . 0.0 109.438 179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.909 ' SD ' HG22 ' A' ' 147' ' ' VAL . 84.4 mmm -74.18 142.18 45.46 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.234 -0.916 . . . . 0.0 109.468 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.685 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -130.27 178.96 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.248 -0.908 . . . . 0.0 109.347 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.685 ' H ' HG12 ' A' ' 134' ' ' VAL . 45.7 ttt85 -142.44 135.75 28.8 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.333 -0.855 . . . . 0.0 109.429 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.715 HG22 HD12 ' A' ' 173' ' ' LEU . 66.3 t -106.29 133.56 50.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.264 -0.897 . . . . 0.0 109.444 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 11.4 p30 -132.06 22.11 4.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.302 -0.874 . . . . 0.0 109.431 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.498 ' HB3' ' HG3' ' A' ' 177' ' ' GLN . 51.7 t0 -143.23 156.42 44.74 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.243 -0.911 . . . . 0.0 109.447 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.452 ' O ' ' N ' ' A' ' 142' ' ' ALA . . . 62.98 167.17 0.74 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -44.28 -24.86 1.08 Allowed 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.585 2.19 . . . . 0.0 111.795 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . 0.523 ' CE1' HD12 ' A' ' 164' ' ' ILE . 88.0 m-85 -86.57 14.96 6.04 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.255 -0.903 . . . . 0.0 109.468 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' ALA . . . . . 0.518 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -73.67 145.24 45.43 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.285 -0.885 . . . . 0.0 109.501 -179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.44 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 3.5 m-20 71.05 43.83 0.63 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.318 -0.864 . . . . 0.0 109.526 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.518 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 80.9 m-85 -142.25 139.98 32.12 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.25 -0.906 . . . . 0.0 109.522 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 78.9 m-20 -94.05 138.99 31.52 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.235 -0.916 . . . . 0.0 109.46 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -153.1 179.8 29.23 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.909 HG22 ' SD ' ' A' ' 133' ' ' MET . 22.8 t -124.18 151.38 29.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.256 -1.144 . . . . 0.0 109.449 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.706 HG21 HG22 ' A' ' 151' ' ' VAL . 3.1 p -87.28 95.23 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.219 -0.925 . . . . 0.0 109.552 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -65.75 -36.35 83.33 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.219 -0.925 . . . . 0.0 109.408 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.495 ' HG2' ' N ' ' A' ' 151' ' ' VAL . 84.7 tt0 -142.21 160.36 40.4 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.33 -0.856 . . . . 0.0 109.385 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.706 HG22 HG21 ' A' ' 148' ' ' VAL . 39.8 t -131.37 149.06 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.258 -0.901 . . . . 0.0 109.467 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -131.04 94.64 3.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.24 -0.912 . . . . 0.0 109.501 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -66.69 -32.9 74.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.257 -0.902 . . . . 0.0 109.487 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -61.81 -42.71 99.36 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.235 -0.916 . . . . 0.0 109.368 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 29.9 mttm -90.03 -6.38 55.63 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.258 -0.901 . . . . 0.0 109.471 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 57.48 52.76 8.13 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.23 -0.919 . . . . 0.0 109.475 179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.649 ' C ' HD12 ' A' ' 158' ' ' LEU . 75.3 mtt180 -147.13 165.83 28.78 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.222 -0.924 . . . . 0.0 109.536 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' LEU . . . . . 1.17 HD11 ' CD1' ' A' ' 175' ' ' PHE . 3.5 mp -116.01 133.94 55.49 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.227 -0.921 . . . . 0.0 109.532 -179.736 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . 0.417 ' HD3' ' HB3' ' A' ' 150' ' ' GLU . 80.8 tttt -91.53 85.77 5.83 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.183 -0.948 . . . . 0.0 109.298 179.765 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.777 HG13 ' O ' ' A' ' 147' ' ' VAL . 61.1 t -110.4 144.28 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.264 -0.898 . . . . 0.0 109.603 -179.832 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . 0.441 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 60.0 p -107.76 140.51 40.71 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.282 -0.886 . . . . 0.0 109.348 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' VAL . . . . . . . . . . . . . 6.6 t -110.29 131.98 59.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.242 -0.911 . . . . 0.0 109.59 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 32.6 t -78.63 82.12 4.9 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.233 -0.917 . . . . 0.0 109.42 179.85 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.652 HG22 ' CD2' ' A' ' 165' ' ' PHE . 68.9 mt -112.59 146.87 16.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.26 -0.9 . . . . 0.0 109.535 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . 0.652 ' CD2' HG22 ' A' ' 164' ' ' ILE . 28.2 m-85 68.84 13.73 8.87 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.246 -0.909 . . . . 0.0 109.408 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 80.09 22.71 62.76 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 167' ' ' ARG . . . . . 0.457 ' HG2' ' O ' ' A' ' 164' ' ' ILE . 39.0 ptt180 -148.44 155.42 41.18 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.245 -1.15 . . . . 0.0 109.413 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -75.44 143.23 42.77 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.267 -0.895 . . . . 0.0 109.46 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.855 ' O ' HG13 ' A' ' 171' ' ' VAL . 27.2 m -130.12 70.61 82.23 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.237 -0.914 . . . . 0.0 109.441 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.441 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 50.5 Cg_endo -46.88 108.15 0.15 Allowed 'Trans proline' 0 C--O 1.214 -0.683 0 C-N-CA 122.613 2.209 . . . . 0.0 111.858 179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.855 HG13 ' O ' ' A' ' 169' ' ' THR . 21.2 m -133.26 154.28 38.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.283 -0.886 . . . . 0.0 109.424 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.748 ' O ' HD23 ' A' ' 173' ' ' LEU . 94.5 mt-10 -100.08 136.36 40.1 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.18 -0.95 . . . . 0.0 109.451 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . 0.861 HD22 ' NE2' ' A' ' 177' ' ' GLN . 47.7 mt -131.01 152.47 50.29 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.285 -0.884 . . . . 0.0 109.513 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -69.54 156.34 39.05 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.245 -0.909 . . . . 0.0 109.515 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 1.17 ' CD1' HD11 ' A' ' 158' ' ' LEU . 51.0 m-85 -53.08 -44.48 67.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 109.547 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 82.5 p -75.3 -20.03 59.33 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.159 -0.963 . . . . 0.0 109.587 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 177' ' ' GLN . . . . . 0.861 ' NE2' HD22 ' A' ' 173' ' ' LEU . 50.6 tt0 -72.02 -24.55 61.57 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.283 -0.886 . . . . 0.0 109.503 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.461 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 17.7 m -127.26 163.55 30.05 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.26 -0.9 . . . . 0.0 109.516 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 179' ' ' GLU . . . . . 0.448 ' HB2' ' HB3' ' A' ' 135' ' ' ARG . 63.6 mm-40 -114.79 151.02 34.5 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.281 -0.887 . . . . 0.0 109.483 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 24.3 tttt -81.18 131.67 35.31 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.255 -0.903 . . . . 0.0 109.508 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . 0.559 ' HB3' ' HB2' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.544 0 O-C-N 121.193 -0.942 . . . . 0.0 109.415 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -55.62 151.1 40.46 Favored 'Trans proline' 0 C--O 1.214 -0.707 0 C-N-CA 122.642 2.228 . . . . 0.0 111.732 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . 0.808 ' HB3' HD23 ' A' ' 127' ' ' LEU . 71.2 mttt -82.34 142.17 32.25 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.265 -0.897 . . . . 0.0 109.397 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.526 ' O ' ' CD2' ' A' ' 128' ' ' PHE . 72.9 p -104.02 15.87 27.55 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.316 -0.865 . . . . 0.0 109.49 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.808 HD23 ' HB3' ' A' ' 125' ' ' LYS . 1.3 pp -74.91 99.66 3.88 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.239 -0.913 . . . . 0.0 109.426 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.571 ' CD2' HD11 ' A' ' 158' ' ' LEU . 93.0 m-85 -102.53 129.1 48.97 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.163 -0.96 . . . . 0.0 109.423 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.457 ' O ' ' HB2' ' A' ' 132' ' ' GLU . 1.8 mm-40 -103.32 139.59 20.25 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.265 -0.897 . . . . 0.0 109.442 179.929 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.422 ' HD2' ' HB3' ' A' ' 129' ' ' GLU . 49.3 Cg_endo -43.25 135.82 5.82 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.623 2.215 . . . . 0.0 111.712 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 80.35 6.75 89.1 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.457 ' HB2' ' O ' ' A' ' 129' ' ' GLU . 85.0 tt0 -89.04 128.76 35.74 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.269 -1.136 . . . . 0.0 109.448 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.491 ' O ' ' HB3' ' A' ' 181' ' ' ALA . 42.2 ttm -68.19 144.57 54.9 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.235 -0.916 . . . . 0.0 109.44 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.695 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -131.4 179.15 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.242 -0.911 . . . . 0.0 109.316 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.695 ' H ' HG12 ' A' ' 134' ' ' VAL . 28.4 ttt85 -129.99 135.98 48.9 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.196 -0.94 . . . . 0.0 109.42 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.498 HG22 HG12 ' A' ' 178' ' ' VAL . 60.7 t -107.71 133.87 51.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.213 -0.93 . . . . 0.0 109.498 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . 0.412 ' OD1' ' C ' ' A' ' 137' ' ' ASN . 44.0 p30 -132.59 23.39 4.34 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.239 -0.913 . . . . 0.0 109.462 179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -142.85 144.08 32.36 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.269 -0.894 . . . . 0.0 109.531 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 75.49 172.85 32.58 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -52.1 -17.17 5.42 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.669 2.246 . . . . 0.0 111.756 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . 1.034 ' CD1' HG21 ' A' ' 162' ' ' VAL . 97.0 m-85 -92.68 17.51 10.17 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.28 -0.887 . . . . 0.0 109.495 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' ALA . . . . . 0.553 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -73.33 149.88 42.28 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.324 -0.86 . . . . 0.0 109.498 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.451 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 35.2 m-20 65.14 48.27 2.26 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.205 -0.935 . . . . 0.0 109.527 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.553 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 64.1 m-85 -147.22 146.89 29.96 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.218 -0.926 . . . . 0.0 109.404 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . 0.424 ' O ' ' OD1' ' A' ' 145' ' ' ASN . 44.0 p-10 -102.56 151.38 22.39 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.257 -0.902 . . . . 0.0 109.414 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . 0.452 ' O ' ' HA ' ' A' ' 133' ' ' MET . . . -164.95 -174.45 34.67 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.892 ' C ' HG13 ' A' ' 160' ' ' VAL . 96.7 t -130.29 150.75 34.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.18 -1.188 . . . . 0.0 109.427 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.78 HG21 HG22 ' A' ' 151' ' ' VAL . 2.1 p -89.61 107.2 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.178 -0.951 . . . . 0.0 109.502 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -70.86 -37.4 73.09 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.182 -0.949 . . . . 0.0 109.396 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -138.64 157.5 46.02 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.355 -0.841 . . . . 0.0 109.338 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.78 HG22 HG21 ' A' ' 148' ' ' VAL . 57.1 t -130.81 149.79 33.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.179 -0.95 . . . . 0.0 109.417 -179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' ASP . . . . . 0.4 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 95.3 m-20 -136.43 90.17 2.54 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.273 -0.892 . . . . 0.0 109.484 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -67.56 -37.0 82.03 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.233 -0.917 . . . . 0.0 109.495 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -63.6 -42.61 98.24 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.257 -0.902 . . . . 0.0 109.411 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.418 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 58.2 mttt -89.44 -4.64 57.9 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.248 -0.908 . . . . 0.0 109.478 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 58.5 m 55.65 52.73 10.54 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.171 -0.956 . . . . 0.0 109.439 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.439 ' HD3' ' OD1' ' A' ' 174' ' ' ASP . 15.6 mmt85 -144.64 141.97 29.77 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.213 -0.93 . . . . 0.0 109.427 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' LEU . . . . . 0.606 ' CD2' HG13 ' A' ' 151' ' ' VAL . 40.1 mt -111.74 132.34 54.71 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -0.901 . . . . 0.0 109.577 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 22.0 tttt -94.9 91.74 6.57 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.23 -0.919 . . . . 0.0 109.277 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.892 HG13 ' C ' ' A' ' 147' ' ' VAL . 33.1 t -117.98 144.55 25.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.281 -0.887 . . . . 0.0 109.466 -179.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . 0.491 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 61.8 m -99.84 148.62 24.23 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.241 -0.912 . . . . 0.0 109.45 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' VAL . . . . . 1.034 HG21 ' CD1' ' A' ' 141' ' ' PHE . 6.2 t -96.53 138.39 21.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.29 -0.881 . . . . 0.0 109.621 -179.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 19.7 m -86.58 83.39 7.63 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.266 -0.896 . . . . 0.0 109.254 179.737 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 43.8 mt -98.96 139.28 21.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.254 -0.904 . . . . 0.0 109.537 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -53.79 -41.5 67.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.35 -0.844 . . . . 0.0 109.743 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.526 ' O ' ' CB ' ' A' ' 167' ' ' ARG . . . -60.61 -34.01 84.4 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.646 -1.381 . . . . 0.0 109.646 -179.741 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 167' ' ' ARG . . . . . 0.526 ' CB ' ' O ' ' A' ' 166' ' ' GLY . 17.8 ttp180 161.78 148.49 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.461 -1.023 . . . . 0.0 109.151 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -61.18 143.67 55.11 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.243 -0.91 . . . . 0.0 109.33 179.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.482 HG22 HG13 ' A' ' 171' ' ' VAL . 36.6 m -126.36 98.57 32.08 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.17 -0.956 . . . . 0.0 109.554 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.491 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 50.3 Cg_endo -70.26 103.89 1.32 Allowed 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.492 2.128 . . . . 0.0 111.707 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.977 HG23 HD21 ' A' ' 173' ' ' LEU . 14.6 m -129.25 161.08 39.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.246 -0.909 . . . . 0.0 109.523 -179.866 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.845 ' C ' HD22 ' A' ' 173' ' ' LEU . 96.5 mt-10 -99.03 129.15 45.29 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.277 -0.889 . . . . 0.0 109.4 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . 0.977 HD21 HG23 ' A' ' 171' ' ' VAL . 2.8 mm? -125.41 146.3 49.67 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.192 -0.942 . . . . 0.0 109.529 -179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 174' ' ' ASP . . . . . 0.439 ' OD1' ' HD3' ' A' ' 157' ' ' ARG . 87.4 m-20 -69.35 170.36 10.52 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.228 -0.92 . . . . 0.0 109.489 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.538 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.7 m-30 -65.74 -40.64 92.34 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.269 -0.895 . . . . 0.0 109.47 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 83.0 p -75.51 -28.66 59.23 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.362 -0.836 . . . . 0.0 109.499 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 177' ' ' GLN . . . . . 0.4 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 90.2 mt-30 -65.76 -23.55 66.75 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.293 -0.879 . . . . 0.0 109.435 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.512 HG13 ' HB3' ' A' ' 173' ' ' LEU . 12.3 m -130.23 164.42 33.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.259 -0.901 . . . . 0.0 109.452 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 179' ' ' GLU . . . . . 0.452 ' N ' ' O ' ' A' ' 135' ' ' ARG . 76.3 mt-10 -119.41 142.49 48.16 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.259 -0.901 . . . . 0.0 109.542 -179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 180' ' ' LYS . . . . . 0.412 ' NZ ' ' HG ' ' A' ' 127' ' ' LEU . 31.4 ttmt -62.6 134.86 56.97 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.159 -0.963 . . . . 0.0 109.521 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . 0.491 ' HB3' ' O ' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.128 -0.982 . . . . 0.0 109.391 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 4.5 mmt180 . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -58.32 143.01 97.93 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.576 2.184 . . . . 0.0 111.76 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 11.1 mtmt -102.12 150.4 23.3 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.3 -0.875 . . . . 0.0 109.514 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 61.8 p -92.62 14.2 17.7 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.289 -0.882 . . . . 0.0 109.466 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.478 ' O ' ' HE3' ' A' ' 180' ' ' LYS . 47.6 mt -89.81 97.67 11.32 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.208 -0.933 . . . . 0.0 109.529 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.625 ' CD2' HD21 ' A' ' 158' ' ' LEU . 89.6 m-85 -106.5 134.43 49.65 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.33 -0.856 . . . . 0.0 109.446 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.487 ' HB3' ' HD2' ' A' ' 130' ' ' PRO . 3.5 mt-10 -139.41 150.04 62.54 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.241 -0.912 . . . . 0.0 109.354 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.487 ' HD2' ' HB3' ' A' ' 129' ' ' GLU . 49.4 Cg_endo -46.33 128.88 12.74 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.418 2.079 . . . . 0.0 111.751 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 93.69 3.61 64.28 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.52 ' O ' HG13 ' A' ' 147' ' ' VAL . 76.7 mm-40 -98.57 138.57 35.57 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.168 -1.196 . . . . 0.0 109.455 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.639 ' HG2' HG22 ' A' ' 147' ' ' VAL . 78.5 mtp -76.12 148.78 37.61 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.23 -0.919 . . . . 0.0 109.468 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.675 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -137.21 179.38 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.26 -0.9 . . . . 0.0 109.375 179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.675 ' H ' HG12 ' A' ' 134' ' ' VAL . 43.6 ttt180 -135.7 135.01 39.72 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.104 -0.997 . . . . 0.0 109.503 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.454 ' O ' ' N ' ' A' ' 143' ' ' ASP . 80.3 t -108.73 135.72 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.298 -0.877 . . . . 0.0 109.502 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 31.6 p30 -131.83 18.98 4.62 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.242 -0.911 . . . . 0.0 109.438 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 60.1 t0 -132.52 144.07 50.17 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.31 -0.869 . . . . 0.0 109.408 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 71.66 175.99 24.57 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -53.22 -19.49 12.51 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 122.608 2.205 . . . . 0.0 111.779 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . 0.434 ' O ' ' HB ' ' A' ' 136' ' ' VAL . 90.5 m-85 -88.61 12.65 14.08 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.279 -0.888 . . . . 0.0 109.415 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' ALA . . . . . 0.448 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -71.96 150.38 44.16 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.28 -0.888 . . . . 0.0 109.403 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.454 ' N ' ' O ' ' A' ' 136' ' ' VAL . 31.9 m-20 63.49 48.69 3.37 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.169 -0.957 . . . . 0.0 109.449 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.448 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 43.3 m-85 -145.06 143.05 30.24 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.147 -0.971 . . . . 0.0 109.524 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 73.6 m-20 -95.89 145.08 25.67 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.248 -0.908 . . . . 0.0 109.5 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -161.7 -178.42 35.6 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.682 ' O ' HG13 ' A' ' 160' ' ' VAL . 40.6 t -126.1 147.23 30.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.256 -1.143 . . . . 0.0 109.408 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.724 ' HA ' HG22 ' A' ' 160' ' ' VAL . 2.5 p -82.95 99.37 5.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.179 -0.951 . . . . 0.0 109.467 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -66.59 -34.21 77.37 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.245 -0.91 . . . . 0.0 109.391 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.478 ' HB2' ' CD ' ' A' ' 159' ' ' LYS . 75.5 mm-40 -147.0 162.47 38.7 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.27 -0.894 . . . . 0.0 109.386 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.623 HG22 HG21 ' A' ' 148' ' ' VAL . 41.0 t -129.17 146.69 33.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.2 -0.937 . . . . 0.0 109.487 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -127.63 96.48 4.55 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.203 -0.936 . . . . 0.0 109.511 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -66.29 -40.3 89.94 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.305 -0.872 . . . . 0.0 109.475 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -62.37 -42.19 99.21 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.201 -0.937 . . . . 0.0 109.431 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . . . . . . . . . 47.9 mttt -83.93 0.79 46.4 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.278 -0.889 . . . . 0.0 109.548 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 24.3 p 45.62 57.04 5.28 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.216 -0.927 . . . . 0.0 109.465 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.616 ' C ' HD12 ' A' ' 158' ' ' LEU . 30.4 mtt180 -155.49 165.5 36.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.277 -0.89 . . . . 0.0 109.516 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' LEU . . . . . 1.165 HD11 ' CD1' ' A' ' 175' ' ' PHE . 4.3 mp -114.34 137.3 51.98 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.241 -0.912 . . . . 0.0 109.453 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . 0.478 ' CD ' ' HB2' ' A' ' 150' ' ' GLU . 40.4 tttp -92.97 94.88 9.15 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.184 -0.947 . . . . 0.0 109.339 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.724 HG22 ' HA ' ' A' ' 148' ' ' VAL . 45.1 t -122.04 146.04 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.28 -0.888 . . . . 0.0 109.602 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 29.3 t -111.82 141.64 45.19 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.329 -0.857 . . . . 0.0 109.28 179.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' VAL . . . . . . . . . . . . . 12.1 t -113.28 131.09 65.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.132 -0.98 . . . . 0.0 109.563 -179.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 35.5 t -83.24 81.53 8.66 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.291 -0.881 . . . . 0.0 109.403 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.426 ' O ' ' HB3' ' A' ' 165' ' ' PHE . 45.2 mt -102.27 139.03 24.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.288 -0.882 . . . . 0.0 109.321 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . 0.522 ' O ' ' CD2' ' A' ' 165' ' ' PHE . 45.7 t80 65.42 12.11 7.88 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.281 -0.887 . . . . 0.0 109.404 -179.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 80.75 11.56 83.81 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.393 -1.483 . . . . 0.0 109.393 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 42.1 mtp-105 -120.2 138.25 53.73 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.239 -1.154 . . . . 0.0 109.443 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -71.16 137.76 49.05 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.267 -0.896 . . . . 0.0 109.411 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.57 ' O ' HG13 ' A' ' 171' ' ' VAL . 1.9 m -133.01 75.96 71.07 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.292 -0.88 . . . . 0.0 109.458 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -56.69 104.2 0.14 Allowed 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.622 2.215 . . . . 0.0 111.836 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 1.012 HG23 HD21 ' A' ' 173' ' ' LEU . 18.2 m -129.34 155.56 41.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.305 -0.872 . . . . 0.0 109.419 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.749 ' C ' HD22 ' A' ' 173' ' ' LEU . 95.5 mt-10 -102.01 129.61 48.35 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.217 -0.927 . . . . 0.0 109.522 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . 1.012 HD21 HG23 ' A' ' 171' ' ' VAL . 2.3 mm? -121.54 149.82 42.54 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.269 -0.895 . . . . 0.0 109.39 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 174' ' ' ASP . . . . . 0.483 ' O ' HG22 ' A' ' 178' ' ' VAL . 82.1 m-20 -68.93 157.95 35.62 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.279 -0.888 . . . . 0.0 109.515 179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 1.165 ' CD1' HD11 ' A' ' 158' ' ' LEU . 98.7 m-85 -61.25 -40.79 95.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.293 -0.879 . . . . 0.0 109.334 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 28.6 m -74.98 -19.7 59.98 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.222 -0.923 . . . . 0.0 109.313 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 89.9 mt-30 -82.16 -20.01 38.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.348 -0.845 . . . . 0.0 109.245 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.678 HG11 ' HB2' ' A' ' 173' ' ' LEU . 19.3 m -124.9 161.88 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.396 -0.815 . . . . 0.0 109.264 179.821 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 179' ' ' GLU . . . . . 0.412 ' HB2' ' HB3' ' A' ' 135' ' ' ARG . 61.8 mt-10 -121.31 153.26 37.95 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.133 -0.98 . . . . 0.0 109.695 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 180' ' ' LYS . . . . . 0.478 ' HE3' ' O ' ' A' ' 127' ' ' LEU . 17.8 tttm -74.14 135.52 42.87 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.322 -0.861 . . . . 0.0 109.451 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.309 -0.869 . . . . 0.0 109.494 179.989 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 6.8 mmt85 . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -56.35 148.64 60.46 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.587 2.191 . . . . 0.0 111.738 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 33.9 tptt -83.41 133.66 34.92 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.237 -0.915 . . . . 0.0 109.529 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.79 HG23 ' CE2' ' A' ' 128' ' ' PHE . 95.0 m -73.25 125.44 27.78 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.256 -0.903 . . . . 0.0 109.444 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.691 HD23 ' O ' ' A' ' 126' ' ' THR . 48.3 mt -140.5 81.57 1.81 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.162 -0.961 . . . . 0.0 109.695 -179.825 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.79 ' CE2' HG23 ' A' ' 126' ' ' THR . 93.5 m-85 -101.55 120.92 41.05 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.313 -0.867 . . . . 0.0 109.352 179.73 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.487 ' HB2' ' HD2' ' A' ' 130' ' ' PRO . 22.3 pt-20 -142.07 138.75 17.13 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.234 -0.916 . . . . 0.0 109.3 -179.842 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.509 ' HA ' ' O ' ' A' ' 148' ' ' VAL . 47.7 Cg_endo -35.62 124.11 0.26 Allowed 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.107 1.872 . . . . 0.0 111.721 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 106.25 -0.47 37.83 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.495 ' O ' HG13 ' A' ' 147' ' ' VAL . 75.5 mt-10 -98.21 152.04 19.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.242 -1.152 . . . . 0.0 109.611 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 1.013 ' SD ' HG22 ' A' ' 147' ' ' VAL . 68.3 mmm -92.16 148.75 21.92 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.192 -0.943 . . . . 0.0 109.327 179.826 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.674 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -135.99 178.92 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.166 -0.959 . . . . 0.0 109.325 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.674 ' H ' HG12 ' A' ' 134' ' ' VAL . 74.8 mtp85 -134.17 143.96 48.2 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.179 -0.951 . . . . 0.0 109.343 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.46 ' O ' ' N ' ' A' ' 143' ' ' ASP . 59.0 t -115.43 130.18 70.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.216 -0.927 . . . . 0.0 109.452 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 30.3 p30 -127.89 14.77 6.89 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.298 -0.876 . . . . 0.0 109.482 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.43 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 59.1 t0 -135.82 147.6 48.36 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.292 -0.88 . . . . 0.0 109.475 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.43 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 73.85 172.15 25.31 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -51.35 -21.96 10.98 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.602 2.201 . . . . 0.0 111.69 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . 0.728 ' HZ ' HG21 ' A' ' 169' ' ' THR . 98.3 m-85 -85.73 8.94 17.87 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.271 -0.893 . . . . 0.0 109.373 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' ALA . . . . . 0.442 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -64.02 145.27 56.19 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.241 -0.912 . . . . 0.0 109.558 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.46 ' N ' ' O ' ' A' ' 136' ' ' VAL . 31.6 m-20 64.96 46.82 2.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.259 -0.9 . . . . 0.0 109.593 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.427 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 44.9 m-85 -145.46 126.49 14.59 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.246 -0.909 . . . . 0.0 109.535 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . 0.462 ' OD1' ' NH2' ' A' ' 135' ' ' ARG . 69.9 m-20 -79.4 137.54 37.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.224 -0.923 . . . . 0.0 109.45 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -149.22 166.78 29.53 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 1.013 HG22 ' SD ' ' A' ' 133' ' ' MET . 15.1 t -108.79 154.87 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.255 -1.144 . . . . 0.0 109.406 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.509 ' O ' ' HA ' ' A' ' 130' ' ' PRO . 1.7 p -96.23 114.93 34.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.323 -0.861 . . . . 0.0 109.356 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.472 ' O ' ' HB3' ' A' ' 130' ' ' PRO . 74.9 mm-40 -75.94 -34.08 59.85 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.3 -0.875 . . . . 0.0 109.315 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.473 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 94.7 mt-10 -158.11 159.15 35.93 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.36 -0.838 . . . . 0.0 109.415 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.493 HG22 HG21 ' A' ' 148' ' ' VAL . 26.3 t -127.59 151.02 33.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.22 -0.925 . . . . 0.0 109.563 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' ASP . . . . . 0.477 ' O ' ' N ' ' A' ' 156' ' ' SER . 83.2 m-20 -120.71 84.46 2.23 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.339 -0.85 . . . . 0.0 109.342 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 68.1 m-85 -57.4 -33.72 68.15 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.234 -0.916 . . . . 0.0 109.502 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -64.75 -41.48 95.88 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.167 -0.958 . . . . 0.0 109.529 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.4 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 29.5 mttt -97.09 -3.77 40.66 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.29 -0.881 . . . . 0.0 109.591 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . 0.477 ' N ' ' O ' ' A' ' 152' ' ' ASP . 31.8 m 56.95 52.46 9.25 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.194 -0.941 . . . . 0.0 109.543 179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.587 ' C ' HD12 ' A' ' 158' ' ' LEU . 48.7 mmm-85 -137.06 155.82 49.17 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.258 -0.901 . . . . 0.0 109.355 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' LEU . . . . . 0.881 HD11 ' CD1' ' A' ' 175' ' ' PHE . 5.0 mp -115.87 139.26 50.38 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.201 -0.937 . . . . 0.0 109.643 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . 0.473 ' HD2' ' HB2' ' A' ' 150' ' ' GLU . 84.1 mttt -101.45 89.36 3.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.213 -0.929 . . . . 0.0 109.178 179.653 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.923 HG13 ' O ' ' A' ' 147' ' ' VAL . 24.6 t -114.58 148.64 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.268 -0.895 . . . . 0.0 109.875 -179.617 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . 0.403 ' HB2' ' HA ' ' A' ' 170' ' ' PRO . 43.9 t -119.37 131.17 55.65 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.378 -0.826 . . . . 0.0 109.242 179.769 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' VAL . . . . . 0.424 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 15.5 t -100.53 134.03 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.209 -0.932 . . . . 0.0 109.697 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 37.2 t -84.53 82.49 8.39 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.229 -0.919 . . . . 0.0 109.275 179.777 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.409 HG21 HD13 ' A' ' 164' ' ' ILE . 37.5 mt -101.86 141.71 17.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.203 -0.936 . . . . 0.0 109.526 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . 0.512 ' O ' ' CD2' ' A' ' 165' ' ' PHE . 54.4 t80 63.3 14.04 7.5 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.293 -0.879 . . . . 0.0 109.365 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 83.2 4.06 89.9 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 86.3 mtt-85 -117.85 139.13 51.55 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -1.149 . . . . 0.0 109.422 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -72.16 141.84 49.09 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.352 -0.842 . . . . 0.0 109.463 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.885 ' O ' HG13 ' A' ' 171' ' ' VAL . 32.8 m -128.27 68.71 77.3 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.206 -0.934 . . . . 0.0 109.475 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.407 ' HD2' ' HA ' ' A' ' 169' ' ' THR . 49.4 Cg_endo -45.55 106.64 0.09 OUTLIER 'Trans proline' 0 C--O 1.214 -0.694 0 C-N-CA 122.703 2.269 . . . . 0.0 111.768 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.885 HG13 ' O ' ' A' ' 169' ' ' THR . 21.9 m -133.42 156.49 41.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.219 -0.926 . . . . 0.0 109.565 179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.637 ' C ' HD22 ' A' ' 173' ' ' LEU . 94.6 mt-10 -105.39 129.97 53.59 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.301 -0.874 . . . . 0.0 109.334 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . 0.882 HD21 HG23 ' A' ' 171' ' ' VAL . 1.9 mm? -119.46 157.81 27.5 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.189 -0.945 . . . . 0.0 109.618 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 174' ' ' ASP . . . . . 0.439 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 91.1 m-20 -79.64 157.89 27.17 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.352 -0.843 . . . . 0.0 109.573 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.881 ' CD1' HD11 ' A' ' 158' ' ' LEU . 3.6 m-85 -49.71 -49.39 48.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.305 -0.872 . . . . 0.0 109.785 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 11.2 m -71.15 -24.74 62.32 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.237 -0.914 . . . . 0.0 109.692 -179.754 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 177' ' ' GLN . . . . . 0.439 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 81.7 mt-30 -70.36 -24.72 63.02 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.218 -0.926 . . . . 0.0 109.722 -179.813 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.511 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 17.5 m -131.06 161.82 40.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.189 -0.945 . . . . 0.0 109.511 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 179' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -120.67 145.46 47.42 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.296 -0.878 . . . . 0.0 109.473 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 180' ' ' LYS . . . . . 0.461 ' HE3' ' O ' ' A' ' 127' ' ' LEU . 30.2 tttm -69.67 134.61 48.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.302 -0.874 . . . . 0.0 109.481 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.495 0 O-C-N 121.163 -0.96 . . . . 0.0 109.485 179.985 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.561 ' CB ' ' CD ' ' A' ' 124' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.561 ' CD ' ' CB ' ' A' ' 123' ' ' ARG . 51.1 Cg_endo -54.42 150.34 34.46 Favored 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 122.626 2.217 . . . . 0.0 111.862 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . 0.452 ' O ' ' HE3' ' A' ' 180' ' ' LYS . 11.4 pttt -131.35 156.69 45.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.285 -0.884 . . . . 0.0 109.483 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.403 ' HA ' ' HE3' ' A' ' 180' ' ' LYS . 63.2 p -114.22 30.72 7.09 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.321 -0.862 . . . . 0.0 109.485 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 56.2 mt -80.63 99.45 8.15 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.183 -0.948 . . . . 0.0 109.554 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.909 ' O ' HG21 ' A' ' 151' ' ' VAL . 69.1 m-85 -86.34 132.29 34.0 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.324 -0.86 . . . . 0.0 109.453 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.464 ' HB3' ' HD2' ' A' ' 130' ' ' PRO . 1.2 mp0 -109.24 138.16 20.4 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.296 -0.878 . . . . 0.0 109.399 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.464 ' HD2' ' HB3' ' A' ' 129' ' ' GLU . 50.6 Cg_endo -39.68 133.99 1.57 Allowed 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.549 2.166 . . . . 0.0 111.765 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 84.69 8.45 82.83 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 45.7 tp10 -102.25 135.04 44.55 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.263 -1.14 . . . . 0.0 109.443 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.553 ' HG2' HG22 ' A' ' 147' ' ' VAL . 76.3 mtp -70.28 148.17 48.83 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.248 -0.908 . . . . 0.0 109.456 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.749 HG13 ' CE2' ' A' ' 128' ' ' PHE . 2.5 t -136.72 179.08 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.26 -0.9 . . . . 0.0 109.353 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.673 ' H ' HG12 ' A' ' 134' ' ' VAL . 70.3 ttt180 -136.51 143.12 43.59 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.263 -0.898 . . . . 0.0 109.43 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.632 HG11 ' HB2' ' A' ' 141' ' ' PHE . 60.3 t -111.16 124.86 68.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.258 -0.902 . . . . 0.0 109.524 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 26.4 p30 -124.77 22.31 8.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -0.905 . . . . 0.0 109.511 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -145.15 140.98 28.35 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.328 -0.858 . . . . 0.0 109.479 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 81.62 -179.82 53.26 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -58.67 -20.18 49.35 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.679 2.252 . . . . 0.0 111.764 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . 0.888 ' CZ ' HG11 ' A' ' 171' ' ' VAL . 99.2 m-85 -87.38 10.15 18.33 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.239 -0.913 . . . . 0.0 109.379 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' ALA . . . . . 0.505 ' O ' ' CD2' ' A' ' 144' ' ' PHE . . . -64.17 152.99 39.21 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.282 -0.886 . . . . 0.0 109.59 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.453 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 58.8 m-20 63.65 42.57 6.27 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.3 -0.875 . . . . 0.0 109.676 179.746 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.556 ' HB3' ' CG1' ' A' ' 162' ' ' VAL . 58.8 m-85 -145.51 152.64 40.08 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.164 -0.96 . . . . 0.0 109.494 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 43.7 p-10 -113.63 167.06 10.92 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.238 -0.914 . . . . 0.0 109.395 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 179.35 -170.45 42.03 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.553 HG22 ' HG2' ' A' ' 133' ' ' MET . 43.0 t -129.11 150.43 34.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.225 -1.162 . . . . 0.0 109.517 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.664 ' HA ' HG22 ' A' ' 160' ' ' VAL . 2.5 p -91.05 113.83 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.203 -0.936 . . . . 0.0 109.497 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.423 ' N ' ' O ' ' A' ' 159' ' ' LYS . 75.8 mm-40 -67.02 -37.1 83.54 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.222 -0.924 . . . . 0.0 109.445 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.406 ' HB2' ' HD2' ' A' ' 159' ' ' LYS . 94.9 mt-10 -153.97 163.38 40.15 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.223 -0.923 . . . . 0.0 109.501 179.913 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 1.073 HG13 ' CD2' ' A' ' 158' ' ' LEU . 45.7 t -127.27 146.32 33.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.247 -0.908 . . . . 0.0 109.535 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -133.02 90.88 2.8 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.277 -0.89 . . . . 0.0 109.5 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -62.93 -38.82 92.54 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.214 -0.929 . . . . 0.0 109.502 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -61.25 -41.7 97.35 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.48 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.459 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 60.2 mttm -92.23 -2.25 56.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.272 -0.893 . . . . 0.0 109.601 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . 0.473 ' HA ' ' CZ ' ' A' ' 175' ' ' PHE . 12.9 m 50.23 52.52 14.59 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.28 -0.887 . . . . 0.0 109.587 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.459 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 13.7 mmt85 -146.15 142.77 28.79 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.295 -0.878 . . . . 0.0 109.468 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' LEU . . . . . 1.073 ' CD2' HG13 ' A' ' 151' ' ' VAL . 49.0 mt -116.34 133.19 56.29 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.196 -0.94 . . . . 0.0 109.497 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . 0.441 ' O ' ' HA ' ' A' ' 148' ' ' VAL . 65.5 mttm -87.39 100.64 12.88 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.282 -0.886 . . . . 0.0 109.346 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.664 HG22 ' HA ' ' A' ' 148' ' ' VAL . 57.6 t -128.34 138.75 53.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.176 -0.952 . . . . 0.0 109.524 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . 0.467 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 88.3 p -107.2 148.13 29.28 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.272 -0.893 . . . . 0.0 109.431 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' VAL . . . . . 0.556 ' CG1' ' HB3' ' A' ' 144' ' ' PHE . 3.8 t -115.33 130.02 70.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.211 -0.931 . . . . 0.0 109.637 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 33.2 t -75.58 90.59 2.78 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.221 -0.924 . . . . 0.0 109.153 179.639 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.93 HG22 ' CD2' ' A' ' 165' ' ' PHE . 38.2 mt -106.53 137.35 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.307 -0.871 . . . . 0.0 109.42 -179.735 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . 0.93 ' CD2' HG22 ' A' ' 164' ' ' ILE . 91.1 m-85 48.46 -126.2 1.92 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.276 -0.89 . . . . 0.0 109.15 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . -119.34 31.46 5.42 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 46.0 tpt85 -145.0 132.98 21.3 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.089 -1.242 . . . . 0.0 109.546 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -72.76 138.89 46.76 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.206 -0.934 . . . . 0.0 109.477 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.658 ' O ' HG13 ' A' ' 171' ' ' VAL . 10.1 m -122.53 75.78 44.88 Favored Pre-proline 0 N--CA 1.488 1.465 0 O-C-N 121.128 -0.983 . . . . 0.0 109.484 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.467 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.4 Cg_endo -56.13 110.73 0.61 Allowed 'Trans proline' 0 C--O 1.216 -0.62 0 C-N-CA 122.572 2.181 . . . . 0.0 111.734 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 1.031 HG23 HD21 ' A' ' 173' ' ' LEU . 16.5 m -129.6 154.87 40.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.26 -0.9 . . . . 0.0 109.502 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.786 ' C ' HD22 ' A' ' 173' ' ' LEU . 95.7 mt-10 -100.69 125.88 47.16 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.222 -0.923 . . . . 0.0 109.459 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . 1.031 HD21 HG23 ' A' ' 171' ' ' VAL . 2.6 mm? -122.93 147.18 46.9 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.311 -0.868 . . . . 0.0 109.434 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 174' ' ' ASP . . . . . 0.427 ' HB2' ' HG3' ' A' ' 177' ' ' GLN . 90.3 m-20 -65.41 169.14 6.25 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.209 -0.932 . . . . 0.0 109.457 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.565 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.3 m-30 -64.4 -36.83 85.44 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.178 -0.951 . . . . 0.0 109.462 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 86.1 p -80.07 -25.87 39.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.248 -0.907 . . . . 0.0 109.429 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 177' ' ' GLN . . . . . 0.427 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 86.2 mt-30 -66.57 -27.3 67.62 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.189 -0.945 . . . . 0.0 109.422 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.528 ' CG1' ' HB2' ' A' ' 173' ' ' LEU . 4.6 m -123.89 156.73 30.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.291 -0.881 . . . . 0.0 109.499 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 179' ' ' GLU . . . . . 0.502 ' O ' ' N ' ' A' ' 135' ' ' ARG . 83.6 tt0 -116.51 156.17 27.37 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.31 -0.869 . . . . 0.0 109.463 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 180' ' ' LYS . . . . . 0.456 ' HG2' ' CE2' ' A' ' 128' ' ' PHE . 54.4 mttt -69.89 142.88 52.93 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.233 -0.917 . . . . 0.0 109.481 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.578 0 O-C-N 121.267 -0.895 . . . . 0.0 109.472 179.999 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 1.4 mmt85 . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -56.48 144.93 82.35 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.575 2.183 . . . . 0.0 111.789 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . 0.469 ' O ' ' HG ' ' A' ' 127' ' ' LEU . 53.9 mttp -97.8 25.88 5.56 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.211 -0.931 . . . . 0.0 109.42 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 61.2 p 48.17 23.3 0.51 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.34 -0.85 . . . . 0.0 109.631 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.469 ' HG ' ' O ' ' A' ' 125' ' ' LYS . 26.2 mt -94.5 99.75 11.86 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.232 -0.917 . . . . 0.0 109.496 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.624 ' CE1' HG13 ' A' ' 134' ' ' VAL . 50.8 m-85 -92.43 138.31 31.63 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.256 -0.903 . . . . 0.0 109.489 179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.534 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.0 OUTLIER -134.57 156.91 78.36 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.312 -0.868 . . . . 0.0 109.454 179.99 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.534 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.2 Cg_endo -48.66 130.31 22.1 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.626 2.217 . . . . 0.0 111.819 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 90.15 10.26 64.48 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -113.42 138.9 49.42 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.243 -1.151 . . . . 0.0 109.51 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.569 ' HG2' HG22 ' A' ' 147' ' ' VAL . 87.1 mtp -79.77 149.25 31.16 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.294 -0.879 . . . . 0.0 109.527 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.687 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -131.93 179.08 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.314 -0.866 . . . . 0.0 109.387 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.687 ' H ' HG12 ' A' ' 134' ' ' VAL . 24.4 tpt180 -130.88 138.92 50.03 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.284 -0.885 . . . . 0.0 109.365 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.491 HG13 HD13 ' A' ' 173' ' ' LEU . 28.7 t -103.98 130.56 54.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.24 -0.912 . . . . 0.0 109.539 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . 0.428 ' OD1' ' C ' ' A' ' 137' ' ' ASN . 22.2 p30 -132.03 18.08 4.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.324 -0.86 . . . . 0.0 109.403 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.473 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 59.7 t0 -140.66 148.67 41.19 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.204 -0.935 . . . . 0.0 109.499 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.473 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 73.0 172.85 23.57 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -52.99 -19.83 12.24 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.652 2.235 . . . . 0.0 111.786 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . 0.632 ' CD1' HG11 ' A' ' 162' ' ' VAL . 97.9 m-85 -87.43 10.31 17.96 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.183 -0.948 . . . . 0.0 109.444 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' ALA . . . . . 0.499 ' O ' ' CB ' ' A' ' 143' ' ' ASP . . . -66.29 147.77 52.83 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.256 -0.902 . . . . 0.0 109.485 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.499 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 24.9 t0 74.34 28.26 1.37 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.291 -0.881 . . . . 0.0 109.471 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -134.38 153.27 51.99 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.292 -0.88 . . . . 0.0 109.466 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 43.2 p-10 -113.77 165.54 12.45 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.258 -0.901 . . . . 0.0 109.425 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -174.07 -177.1 43.0 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.569 HG22 ' HG2' ' A' ' 133' ' ' MET . 44.2 t -117.27 161.28 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.213 -1.169 . . . . 0.0 109.477 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.847 HG11 HG22 ' A' ' 151' ' ' VAL . 79.4 t -93.4 96.25 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.213 -0.929 . . . . 0.0 109.524 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -66.02 -31.92 73.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.247 -0.908 . . . . 0.0 109.429 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.409 ' O ' ' HB3' ' A' ' 159' ' ' LYS . 84.7 tt0 -148.83 150.25 32.69 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.286 -0.884 . . . . 0.0 109.415 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.847 HG22 HG11 ' A' ' 148' ' ' VAL . 45.3 t -124.19 149.99 28.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.214 -0.929 . . . . 0.0 109.516 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 95.2 m-20 -136.48 79.88 1.79 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.216 -0.928 . . . . 0.0 109.502 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' TYR . . . . . 0.507 ' CZ ' HG11 ' A' ' 151' ' ' VAL . 98.9 m-85 -63.64 -37.46 87.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.227 -0.921 . . . . 0.0 109.518 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -59.42 -46.45 88.68 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.185 -0.947 . . . . 0.0 109.528 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.473 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 58.1 mttt -90.72 0.5 57.4 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.268 -0.895 . . . . 0.0 109.548 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 31.1 t 56.06 52.82 9.89 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.196 -0.94 . . . . 0.0 109.485 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.473 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 22.9 mmt85 -140.29 140.51 35.72 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.275 -0.891 . . . . 0.0 109.367 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' LEU . . . . . 0.478 HD11 ' CD1' ' A' ' 175' ' ' PHE . 61.5 mt -110.06 129.47 55.68 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.162 -0.962 . . . . 0.0 109.522 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . 0.441 ' HG3' ' OE2' ' A' ' 172' ' ' GLU . 29.4 tttp -92.31 104.79 17.1 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.331 -0.856 . . . . 0.0 109.352 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.541 HG13 ' O ' ' A' ' 147' ' ' VAL . 44.4 t -124.64 140.62 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.29 -0.881 . . . . 0.0 109.545 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . 0.46 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 30.1 t -109.17 137.65 46.74 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.295 -0.878 . . . . 0.0 109.462 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' VAL . . . . . 0.742 HG12 ' HB ' ' A' ' 169' ' ' THR . 9.4 p -104.9 138.86 27.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.185 -0.947 . . . . 0.0 109.636 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . 0.438 ' HA ' ' O ' ' A' ' 167' ' ' ARG . 5.3 m -102.7 95.2 6.05 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.215 -0.928 . . . . 0.0 109.461 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 1.06 HG22 ' CD2' ' A' ' 165' ' ' PHE . 37.4 mt -114.52 134.77 56.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.226 -0.921 . . . . 0.0 109.545 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . 1.06 ' CD2' HG22 ' A' ' 164' ' ' ILE . 94.3 m-85 59.4 23.97 12.54 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.271 -0.893 . . . . 0.0 109.485 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 78.64 14.3 82.24 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 167' ' ' ARG . . . . . 0.438 ' O ' ' HA ' ' A' ' 163' ' ' SER . 62.2 mtt180 -117.95 148.34 42.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.197 -1.178 . . . . 0.0 109.516 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -98.19 139.12 34.47 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.232 -0.918 . . . . 0.0 109.497 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.781 ' O ' HG13 ' A' ' 171' ' ' VAL . 6.0 m -129.81 74.04 80.98 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.287 -0.883 . . . . 0.0 109.453 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.46 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.7 Cg_endo -49.08 109.9 0.31 Allowed 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.603 2.202 . . . . 0.0 111.774 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.781 HG13 ' O ' ' A' ' 169' ' ' THR . 23.6 m -128.96 156.8 41.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.29 -0.881 . . . . 0.0 109.514 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.735 ' O ' HD23 ' A' ' 173' ' ' LEU . 75.7 mm-40 -101.6 130.65 47.97 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.293 -0.88 . . . . 0.0 109.465 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . 0.735 HD23 ' O ' ' A' ' 172' ' ' GLU . 51.8 mt -131.28 148.81 52.73 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.245 -0.91 . . . . 0.0 109.419 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -74.91 171.54 13.85 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.213 -0.93 . . . . 0.0 109.447 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.583 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.7 m-30 -64.25 -36.81 85.29 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.318 -0.864 . . . . 0.0 109.439 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 83.4 p -79.58 -26.97 41.18 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.312 -0.867 . . . . 0.0 109.355 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 23.6 mt-30 -68.86 -19.69 64.25 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.26 -0.9 . . . . 0.0 109.381 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.466 HG11 ' HB2' ' A' ' 173' ' ' LEU . 4.2 m -135.73 154.4 34.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.217 -0.927 . . . . 0.0 109.526 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 179' ' ' GLU . . . . . 0.504 ' O ' ' N ' ' A' ' 135' ' ' ARG . 37.7 mt-10 -120.07 166.53 13.27 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.278 -0.888 . . . . 0.0 109.427 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 180' ' ' LYS . . . . . 0.452 ' HG2' ' CE1' ' A' ' 128' ' ' PHE . 54.9 mttt -71.97 145.83 48.14 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.229 -0.919 . . . . 0.0 109.551 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.521 0 O-C-N 121.285 -0.884 . . . . 0.0 109.498 179.999 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -56.13 148.69 57.96 Favored 'Trans proline' 0 C--O 1.214 -0.689 0 C-N-CA 122.596 2.197 . . . . 0.0 111.717 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 23.6 mttm -85.56 148.73 25.79 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.249 -0.907 . . . . 0.0 109.536 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.405 ' HA ' ' CE2' ' A' ' 128' ' ' PHE . 69.3 p -98.08 15.87 22.9 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.268 -0.895 . . . . 0.0 109.482 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.456 ' O ' ' HE3' ' A' ' 180' ' ' LYS . 52.5 mt -88.11 98.26 11.44 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.235 -0.915 . . . . 0.0 109.456 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.405 ' CE2' ' HA ' ' A' ' 126' ' ' THR . 83.8 m-85 -109.2 139.83 43.61 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.17 -0.956 . . . . 0.0 109.482 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.468 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 0.0 OUTLIER -135.77 153.18 77.11 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.262 -0.899 . . . . 0.0 109.445 -179.968 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.468 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.4 Cg_endo -47.18 133.21 19.06 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.593 2.195 . . . . 0.0 111.793 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 86.51 3.1 84.42 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 50.2 tp10 -88.05 137.57 32.21 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.202 -1.175 . . . . 0.0 109.544 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.497 ' HG2' HG22 ' A' ' 147' ' ' VAL . 77.4 mtp -79.44 149.49 31.57 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.279 -0.888 . . . . 0.0 109.446 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.735 ' CG2' HG23 ' A' ' 148' ' ' VAL . 2.5 t -139.25 179.0 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.266 -0.896 . . . . 0.0 109.318 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.673 ' H ' HG12 ' A' ' 134' ' ' VAL . 18.5 mtp-105 -137.47 142.49 41.54 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.245 -0.91 . . . . 0.0 109.466 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.479 HG22 HG12 ' A' ' 178' ' ' VAL . 43.3 t -111.56 135.2 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.232 -0.917 . . . . 0.0 109.537 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 38.2 p30 -127.08 15.52 7.32 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.274 -0.891 . . . . 0.0 109.54 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.487 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 59.2 t0 -142.06 153.53 44.27 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.28 -0.888 . . . . 0.0 109.462 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.487 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 75.38 171.02 28.86 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -54.93 -18.47 16.73 Favored 'Trans proline' 0 C--O 1.214 -0.705 0 C-N-CA 122.578 2.185 . . . . 0.0 111.792 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . 0.699 ' CD1' HG11 ' A' ' 162' ' ' VAL . 90.5 m-85 -92.79 14.92 15.86 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.25 -0.906 . . . . 0.0 109.454 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' ALA . . . . . 0.449 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -66.23 149.51 50.23 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.301 -0.874 . . . . 0.0 109.523 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.449 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 43.7 m-20 64.03 46.85 3.58 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.232 -0.918 . . . . 0.0 109.473 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -140.79 142.01 34.73 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.295 -0.878 . . . . 0.0 109.531 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 73.0 m-20 -100.81 142.4 32.33 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.245 -0.909 . . . . 0.0 109.462 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.54 177.94 34.98 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.613 ' O ' HG13 ' A' ' 160' ' ' VAL . 49.0 t -114.29 164.2 10.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.184 -1.186 . . . . 0.0 109.438 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.735 HG23 ' CG2' ' A' ' 134' ' ' VAL . 98.6 t -93.16 95.54 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.257 -0.902 . . . . 0.0 109.553 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 75.1 mm-40 -67.42 -34.52 77.4 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.178 -0.951 . . . . 0.0 109.432 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.502 ' HB2' ' CD ' ' A' ' 159' ' ' LYS . 94.2 mt-10 -151.23 161.49 42.61 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.237 -0.915 . . . . 0.0 109.332 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.506 HG11 ' CZ ' ' A' ' 153' ' ' TYR . 44.1 t -124.25 151.35 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.206 -0.934 . . . . 0.0 109.569 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -125.49 78.3 1.72 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.236 -0.915 . . . . 0.0 109.413 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' TYR . . . . . 0.506 ' CZ ' HG11 ' A' ' 151' ' ' VAL . 83.9 m-85 -63.68 -37.05 85.87 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.338 -0.851 . . . . 0.0 109.569 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -60.74 -42.83 98.15 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.247 -0.908 . . . . 0.0 109.532 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.474 ' O ' ' HG3' ' A' ' 157' ' ' ARG . 45.9 mttp -94.68 3.03 55.56 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.241 -0.912 . . . . 0.0 109.604 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 56.62 51.98 10.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.245 -0.909 . . . . 0.0 109.464 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.474 ' HG3' ' O ' ' A' ' 155' ' ' LYS . 58.1 mtt180 -146.29 157.49 43.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.281 -0.887 . . . . 0.0 109.522 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' LEU . . . . . 0.545 HD21 ' CE1' ' A' ' 175' ' ' PHE . 18.2 mt -115.01 135.56 54.09 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.199 -0.938 . . . . 0.0 109.451 -179.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . 0.502 ' CD ' ' HB2' ' A' ' 150' ' ' GLU . 31.0 tttp -87.99 105.92 17.78 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.269 -0.894 . . . . 0.0 109.318 179.855 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.613 HG13 ' O ' ' A' ' 147' ' ' VAL . 39.9 t -121.99 143.46 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.228 -0.92 . . . . 0.0 109.636 -179.833 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . . . . . . . . . 93.5 p -110.31 145.24 37.79 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.263 -0.898 . . . . 0.0 109.41 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' VAL . . . . . 0.765 HG12 ' HB ' ' A' ' 169' ' ' THR . 9.8 p -115.93 138.89 44.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.226 -0.921 . . . . 0.0 109.527 -179.899 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . 0.403 ' HA ' ' O ' ' A' ' 167' ' ' ARG . 37.8 t -102.82 97.55 7.68 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.256 -0.903 . . . . 0.0 109.408 179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 29.9 mt -116.04 135.88 54.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.28 -0.887 . . . . 0.0 109.498 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 9.0 m-30 57.91 28.12 15.65 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.211 -0.931 . . . . 0.0 109.494 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 72.03 21.19 79.2 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 167' ' ' ARG . . . . . 0.403 ' O ' ' HA ' ' A' ' 163' ' ' SER . 65.7 mtt-85 -119.18 143.79 47.04 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.279 -1.13 . . . . 0.0 109.463 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -91.43 134.37 34.69 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.265 -0.897 . . . . 0.0 109.54 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.765 ' HB ' HG12 ' A' ' 162' ' ' VAL . 0.2 OUTLIER -128.3 74.11 79.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.312 -0.867 . . . . 0.0 109.458 -179.963 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -57.6 104.64 0.17 Allowed 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.598 2.198 . . . . 0.0 111.805 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 1.018 HG23 HD21 ' A' ' 173' ' ' LEU . 19.3 m -130.41 155.95 42.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.253 -0.905 . . . . 0.0 109.538 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.737 ' C ' HD22 ' A' ' 173' ' ' LEU . 95.2 mt-10 -104.03 128.94 51.63 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.236 -0.915 . . . . 0.0 109.46 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . 1.018 HD21 HG23 ' A' ' 171' ' ' VAL . 2.3 mm? -121.29 145.67 47.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.248 -0.907 . . . . 0.0 109.432 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 64.6 m-20 -65.63 173.48 2.76 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.263 -0.898 . . . . 0.0 109.38 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.545 ' CE1' HD21 ' A' ' 158' ' ' LEU . 4.2 m-30 -66.65 -44.47 81.8 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.252 -0.905 . . . . 0.0 109.471 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 18.7 m -73.09 -23.62 60.55 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.201 -0.937 . . . . 0.0 109.384 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -70.78 -23.8 62.46 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.298 -0.876 . . . . 0.0 109.39 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.555 HG11 ' HB2' ' A' ' 173' ' ' LEU . 6.0 m -131.43 163.42 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.31 -0.869 . . . . 0.0 109.378 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 179' ' ' GLU . . . . . . . . . . . . . 74.3 mm-40 -119.0 145.45 45.83 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.172 -0.955 . . . . 0.0 109.485 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 180' ' ' LYS . . . . . 0.456 ' HE3' ' O ' ' A' ' 127' ' ' LEU . 18.3 tttm -64.87 140.0 58.82 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.202 -0.936 . . . . 0.0 109.463 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.542 0 O-C-N 121.207 -0.933 . . . . 0.0 109.44 -179.942 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.418 ' HA ' ' HD2' ' A' ' 124' ' ' PRO . 7.1 ttt180 . . . . . 0 N--CA 1.489 1.519 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.418 ' HD2' ' HA ' ' A' ' 123' ' ' ARG . 50.8 Cg_endo -50.67 143.23 29.47 Favored 'Trans proline' 0 C--O 1.216 -0.596 0 C-N-CA 122.441 2.094 . . . . 0.0 111.787 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . 0.527 ' CB ' ' HG ' ' A' ' 127' ' ' LEU . 20.8 mttt -99.5 20.01 14.63 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.186 -0.946 . . . . 0.0 109.527 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . 0.425 HG22 ' CE2' ' A' ' 128' ' ' PHE . 0.0 OUTLIER 40.16 33.1 0.14 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.665 -0.647 . . . . 0.0 109.829 179.795 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.527 ' HG ' ' CB ' ' A' ' 125' ' ' LYS . 39.4 mt -89.62 100.23 13.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.236 -0.915 . . . . 0.0 109.658 -179.88 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.71 ' CE1' HG13 ' A' ' 134' ' ' VAL . 59.4 m-85 -93.98 140.63 29.47 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.296 -0.877 . . . . 0.0 109.424 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . 0.429 ' CB ' ' HD2' ' A' ' 130' ' ' PRO . 3.9 mt-10 -122.77 154.75 63.88 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.245 -0.909 . . . . 0.0 109.353 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.429 ' HD2' ' CB ' ' A' ' 129' ' ' GLU . 50.3 Cg_endo -51.15 129.05 27.15 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.597 2.198 . . . . 0.0 111.804 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 84.44 13.24 73.87 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.422 ' OE1' ' HA ' ' A' ' 128' ' ' PHE . 77.5 tt0 -104.13 133.83 48.4 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.236 -1.155 . . . . 0.0 109.443 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.605 ' HG2' HG22 ' A' ' 147' ' ' VAL . 85.7 mtp -69.36 144.97 53.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.316 -0.865 . . . . 0.0 109.545 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.752 HG21 HG23 ' A' ' 148' ' ' VAL . 2.5 t -133.11 178.87 5.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.344 -0.847 . . . . 0.0 109.363 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.686 ' H ' HG12 ' A' ' 134' ' ' VAL . 40.9 ttm180 -129.15 136.08 49.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.275 -0.891 . . . . 0.0 109.326 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.462 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 39.5 t -106.34 130.34 58.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.215 -0.928 . . . . 0.0 109.529 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . 0.408 ' OD1' ' C ' ' A' ' 137' ' ' ASN . 43.0 p30 -127.61 17.4 6.93 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.282 -0.886 . . . . 0.0 109.443 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.462 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 60.1 t0 -136.98 147.17 46.13 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.306 -0.871 . . . . 0.0 109.468 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.462 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 74.58 173.62 30.93 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -57.2 -17.21 24.74 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.627 2.218 . . . . 0.0 111.883 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . 0.732 ' CD1' HG21 ' A' ' 162' ' ' VAL . 99.7 m-85 -90.23 12.68 17.35 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.13 -0.981 . . . . 0.0 109.452 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' ALA . . . . . 0.516 ' O ' ' CB ' ' A' ' 143' ' ' ASP . . . -72.5 147.15 46.3 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.276 -0.89 . . . . 0.0 109.509 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.516 ' CB ' ' O ' ' A' ' 142' ' ' ALA . 24.9 t0 75.74 28.69 0.89 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.272 -0.893 . . . . 0.0 109.529 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.544 ' HB3' HG13 ' A' ' 162' ' ' VAL . 91.8 m-85 -132.26 146.26 51.87 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.155 -0.966 . . . . 0.0 109.514 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -98.5 144.73 27.51 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.245 -0.909 . . . . 0.0 109.442 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -157.52 -178.77 31.89 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.605 HG22 ' HG2' ' A' ' 133' ' ' MET . 28.3 t -124.08 156.36 31.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.227 -1.161 . . . . 0.0 109.408 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.752 HG23 HG21 ' A' ' 134' ' ' VAL . 87.5 t -89.25 100.54 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.206 -0.934 . . . . 0.0 109.388 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -65.47 -38.26 89.26 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.209 -0.932 . . . . 0.0 109.499 179.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -145.43 165.71 27.76 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.234 -0.916 . . . . 0.0 109.478 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.488 HG22 HG11 ' A' ' 148' ' ' VAL . 41.2 t -129.45 150.82 34.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.3 -0.875 . . . . 0.0 109.497 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' ASP . . . . . 0.406 ' OD1' ' O ' ' A' ' 151' ' ' VAL . 88.8 m-20 -134.45 83.2 2.02 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.268 -0.895 . . . . 0.0 109.413 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' TYR . . . . . 0.413 ' CZ ' HG11 ' A' ' 151' ' ' VAL . 96.4 m-85 -64.77 -37.95 89.33 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.178 -0.951 . . . . 0.0 109.468 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . 0.417 ' OE1' ' HA ' ' A' ' 154' ' ' GLU . 72.8 mm-40 -60.53 -44.65 95.84 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.267 -0.896 . . . . 0.0 109.491 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.479 ' O ' ' HG2' ' A' ' 157' ' ' ARG . 93.4 mttt -90.63 -1.0 57.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.306 -0.871 . . . . 0.0 109.559 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 48.9 m 54.32 53.09 11.41 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.146 -0.971 . . . . 0.0 109.495 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.479 ' HG2' ' O ' ' A' ' 155' ' ' LYS . 20.1 mmt85 -144.5 144.82 31.53 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.142 -0.973 . . . . 0.0 109.465 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' LEU . . . . . 0.51 HD21 ' CE1' ' A' ' 175' ' ' PHE . 55.6 mt -111.87 126.14 54.78 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.254 -0.904 . . . . 0.0 109.537 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 60.4 tttt -83.92 105.14 14.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.178 -0.952 . . . . 0.0 109.415 179.786 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.75 HG22 HG22 ' A' ' 148' ' ' VAL . 38.1 t -124.21 141.27 44.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.25 -0.906 . . . . 0.0 109.434 -179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . 0.445 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 23.6 t -112.44 134.49 53.95 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.278 -0.889 . . . . 0.0 109.611 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' VAL . . . . . 0.732 HG21 ' CD1' ' A' ' 141' ' ' PHE . 3.7 t -88.84 130.32 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.234 -0.916 . . . . 0.0 109.47 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 59.3 m -81.15 82.11 7.16 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.228 -0.92 . . . . 0.0 109.387 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . . . . . . . . . 54.8 mt -96.1 139.46 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.278 -0.889 . . . . 0.0 109.453 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 20.6 m-85 -51.87 -44.8 63.84 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.298 -0.876 . . . . 0.0 109.665 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . 0.533 ' O ' ' CB ' ' A' ' 167' ' ' ARG . . . -53.96 -35.61 54.09 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.656 -1.377 . . . . 0.0 109.656 -179.684 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 167' ' ' ARG . . . . . 0.533 ' CB ' ' O ' ' A' ' 166' ' ' GLY . 30.5 ttp180 160.48 146.86 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.376 -1.073 . . . . 0.0 109.006 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -63.16 136.71 57.91 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.243 -0.911 . . . . 0.0 109.292 179.841 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.582 HG21 ' CZ ' ' A' ' 141' ' ' PHE . 63.0 m -123.36 91.92 49.35 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.192 -0.943 . . . . 0.0 109.662 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.445 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.8 Cg_endo -64.33 109.85 1.26 Allowed 'Trans proline' 0 C--O 1.216 -0.603 0 C-N-CA 122.502 2.134 . . . . 0.0 111.533 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 1.111 HG23 HD21 ' A' ' 173' ' ' LEU . 17.6 m -128.2 158.07 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.194 -0.942 . . . . 0.0 109.69 -179.806 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.681 ' O ' HD13 ' A' ' 173' ' ' LEU . 95.5 mt-10 -100.04 125.07 46.05 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.383 -0.823 . . . . 0.0 109.348 179.843 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . 1.111 HD21 HG23 ' A' ' 171' ' ' VAL . 1.7 mm? -120.48 145.63 47.07 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.203 -0.936 . . . . 0.0 109.493 -179.842 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 174' ' ' ASP . . . . . 0.446 ' OD1' ' HD3' ' A' ' 157' ' ' ARG . 88.3 m-20 -68.84 170.81 8.9 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.224 -0.923 . . . . 0.0 109.452 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.577 ' CD1' ' N ' ' A' ' 175' ' ' PHE . 2.5 m-30 -65.67 -44.21 86.95 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.217 -0.927 . . . . 0.0 109.436 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 11.1 m -76.0 -24.31 55.3 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.151 -0.968 . . . . 0.0 109.422 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 177' ' ' GLN . . . . . 0.427 ' HG3' ' HB2' ' A' ' 174' ' ' ASP . 86.5 mt-30 -69.68 -18.81 63.58 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.265 -0.897 . . . . 0.0 109.339 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.612 HG11 ' HB2' ' A' ' 173' ' ' LEU . 4.8 m -132.35 162.85 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.343 -0.848 . . . . 0.0 109.427 179.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 179' ' ' GLU . . . . . 0.507 ' O ' ' N ' ' A' ' 135' ' ' ARG . 60.7 mt-10 -126.38 161.73 27.18 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.29 -0.881 . . . . 0.0 109.554 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 180' ' ' LYS . . . . . . . . . . . . . 84.5 mttt -67.36 144.28 55.91 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.204 -0.935 . . . . 0.0 109.447 179.863 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.566 0 O-C-N 121.202 -0.937 . . . . 0.0 109.481 179.959 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.513 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -53.48 147.0 39.71 Favored 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.527 2.151 . . . . 0.0 111.827 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . 0.444 ' O ' ' HD2' ' A' ' 180' ' ' LYS . 23.3 mttm -94.66 149.68 21.0 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.225 -0.922 . . . . 0.0 109.464 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 42.6 p -107.74 26.44 10.3 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.226 -0.921 . . . . 0.0 109.457 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 60.0 mt -101.2 95.53 6.6 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.278 -0.889 . . . . 0.0 109.518 179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -99.17 128.3 45.28 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.218 -0.927 . . . . 0.0 109.449 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -118.47 146.97 40.91 Favored Pre-proline 0 N--CA 1.489 1.488 0 O-C-N 121.296 -0.877 . . . . 0.0 109.47 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -48.09 126.63 13.66 Favored 'Trans proline' 0 C--O 1.214 -0.694 0 C-N-CA 122.576 2.184 . . . . 0.0 111.816 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . 0.44 ' C ' ' CG1' ' A' ' 147' ' ' VAL . . . 94.59 -5.25 70.04 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.845 ' O ' HG13 ' A' ' 147' ' ' VAL . 80.3 tt0 -79.21 148.42 32.25 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.124 -1.221 . . . . 0.0 109.467 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' MET . . . . . 0.671 ' HG2' HG22 ' A' ' 147' ' ' VAL . 64.1 mtp -82.08 146.49 29.62 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.26 -0.9 . . . . 0.0 109.545 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.673 HG12 ' H ' ' A' ' 135' ' ' ARG . 2.5 t -135.92 179.13 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.264 -0.898 . . . . 0.0 109.255 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' ARG . . . . . 0.673 ' H ' HG12 ' A' ' 134' ' ' VAL . 87.8 mtt180 -137.33 146.62 44.8 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.225 -0.922 . . . . 0.0 109.399 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.421 ' HB ' ' O ' ' A' ' 141' ' ' PHE . 39.3 t -117.01 134.73 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.212 -0.93 . . . . 0.0 109.558 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' ASN . . . . . . . . . . . . . 30.7 p30 -128.45 14.7 6.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.233 -0.917 . . . . 0.0 109.48 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.452 ' OD1' ' N ' ' A' ' 139' ' ' GLY . 57.8 t0 -147.17 153.4 39.83 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.253 -0.904 . . . . 0.0 109.396 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . 0.452 ' N ' ' OD1' ' A' ' 138' ' ' ASP . . . 78.65 172.26 40.91 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -55.28 -19.1 20.41 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.571 2.181 . . . . 0.0 111.78 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . 0.766 ' CZ ' HG11 ' A' ' 171' ' ' VAL . 86.3 m-85 -93.0 9.2 36.72 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.214 -0.929 . . . . 0.0 109.536 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' ALA . . . . . 0.446 ' O ' ' HB2' ' A' ' 143' ' ' ASP . . . -61.79 146.38 49.66 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.217 -0.927 . . . . 0.0 109.562 -179.867 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' ASP . . . . . 0.446 ' HB2' ' O ' ' A' ' 142' ' ' ALA . 18.0 m-20 65.86 47.83 1.97 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.296 -0.878 . . . . 0.0 109.592 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.401 ' CD2' ' O ' ' A' ' 142' ' ' ALA . 43.9 m-85 -146.51 136.14 23.11 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.296 -0.877 . . . . 0.0 109.457 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' ASN . . . . . . . . . . . . . 71.3 m-20 -94.03 141.02 29.01 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.236 -0.915 . . . . 0.0 109.419 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -158.14 -177.19 31.0 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 -179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' VAL . . . . . 0.845 HG13 ' O ' ' A' ' 132' ' ' GLU . 46.5 t -125.07 148.92 29.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.207 -1.172 . . . . 0.0 109.369 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.589 ' HA ' HG22 ' A' ' 160' ' ' VAL . 2.5 p -85.67 102.2 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.192 -0.942 . . . . 0.0 109.552 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -68.33 -36.41 79.23 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.146 -0.971 . . . . 0.0 109.414 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -140.78 164.29 30.63 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.189 -0.944 . . . . 0.0 109.471 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 99.8 t -125.67 152.94 33.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.327 -0.858 . . . . 0.0 109.523 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -130.53 88.43 2.63 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.319 -0.863 . . . . 0.0 109.386 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -69.58 -38.55 77.41 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.22 -0.925 . . . . 0.0 109.593 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -60.44 -46.64 89.29 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.213 -0.929 . . . . 0.0 109.45 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' LYS . . . . . 0.444 ' O ' ' HG3' ' A' ' 157' ' ' ARG . 32.0 mttt -89.32 -1.08 57.93 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.244 -0.91 . . . . 0.0 109.611 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' SER . . . . . . . . . . . . . 34.0 t 56.46 52.36 10.03 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.196 -0.94 . . . . 0.0 109.467 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' ARG . . . . . 0.444 ' HG3' ' O ' ' A' ' 155' ' ' LYS . 20.5 mtm180 -146.21 157.71 43.84 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.152 -0.967 . . . . 0.0 109.454 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' LEU . . . . . 0.629 HD21 ' CE1' ' A' ' 175' ' ' PHE . 13.9 mt -118.23 131.69 56.35 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.274 -0.892 . . . . 0.0 109.531 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 20.9 tttp -84.37 106.77 16.23 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.295 -0.878 . . . . 0.0 109.443 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' VAL . . . . . 0.626 HG13 ' O ' ' A' ' 147' ' ' VAL . 47.5 t -124.86 140.72 47.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.162 -0.961 . . . . 0.0 109.56 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' SER . . . . . 0.461 ' HA ' ' HA ' ' A' ' 170' ' ' PRO . 23.0 t -104.3 141.88 35.53 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.439 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' VAL . . . . . 0.849 HG22 HG23 ' A' ' 164' ' ' ILE . 9.4 p -105.53 126.28 60.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.314 -0.867 . . . . 0.0 109.562 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 163' ' ' SER . . . . . . . . . . . . . 18.5 t -91.05 85.14 5.84 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.303 -0.873 . . . . 0.0 109.377 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 164' ' ' ILE . . . . . 0.849 HG23 HG22 ' A' ' 162' ' ' VAL . 7.3 pt -130.22 158.07 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.241 -0.912 . . . . 0.0 109.564 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 165' ' ' PHE . . . . . . . . . . . . . 7.7 m-30 61.74 13.54 5.46 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.225 -0.922 . . . . 0.0 109.429 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 166' ' ' GLY . . . . . . . . . . . . . . . 75.59 11.34 84.48 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 167' ' ' ARG . . . . . . . . . . . . . 19.1 ttp180 -132.12 135.67 46.57 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.245 -1.15 . . . . 0.0 109.454 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 168' ' ' ALA . . . . . . . . . . . . . . . -76.33 141.0 41.71 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.294 -0.879 . . . . 0.0 109.454 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.749 ' HB ' HG12 ' A' ' 162' ' ' VAL . 2.4 m -128.02 76.81 77.36 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.308 -0.87 . . . . 0.0 109.437 179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 161' ' ' SER . 49.8 Cg_endo -55.27 106.51 0.19 Allowed 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 122.604 2.203 . . . . 0.0 111.852 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.766 HG11 ' CZ ' ' A' ' 141' ' ' PHE . 18.9 m -129.61 157.84 42.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.461 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.633 ' O ' HD23 ' A' ' 173' ' ' LEU . 95.5 mt-10 -102.1 128.54 48.53 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.24 -0.913 . . . . 0.0 109.477 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 173' ' ' LEU . . . . . 0.633 HD23 ' O ' ' A' ' 172' ' ' GLU . 42.4 mt -124.86 144.13 50.47 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.29 -0.881 . . . . 0.0 109.513 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 174' ' ' ASP . . . . . . . . . . . . . 24.6 m-20 -64.57 172.48 2.64 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.191 -0.943 . . . . 0.0 109.527 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 175' ' ' PHE . . . . . 0.629 ' CE1' HD21 ' A' ' 158' ' ' LEU . 4.5 m-30 -67.67 -44.41 77.89 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.166 -0.959 . . . . 0.0 109.501 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 15.0 m -71.33 -23.56 61.95 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.219 -0.925 . . . . 0.0 109.524 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 177' ' ' GLN . . . . . . . . . . . . . 90.3 mt-30 -72.79 -23.53 60.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.177 -0.952 . . . . 0.0 109.431 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.563 HG11 ' HB2' ' A' ' 173' ' ' LEU . 4.5 m -128.16 161.26 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.253 -0.905 . . . . 0.0 109.401 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 179' ' ' GLU . . . . . 0.472 ' HB2' ' HB2' ' A' ' 135' ' ' ARG . 95.0 mt-10 -116.74 149.97 39.02 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.179 -0.951 . . . . 0.0 109.559 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 180' ' ' LYS . . . . . 0.508 ' NZ ' ' OE2' ' A' ' 132' ' ' GLU . 33.6 tttm -69.13 137.34 53.31 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.181 -0.949 . . . . 0.0 109.505 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . 0.423 ' HB2' ' C ' ' A' ' 133' ' ' MET . . . . . . . . 0 N--CA 1.49 1.536 0 O-C-N 121.211 -0.931 . . . . 0.0 109.46 -179.972 . . . . . . . . 1 1 . 1 stop_ save_